<SEC-DOCUMENT>0001828185-24-000075.txt : 20240808
<SEC-HEADER>0001828185-24-000075.hdr.sgml : 20240808
<ACCEPTANCE-DATETIME>20240808080945
ACCESSION NUMBER:		0001828185-24-000075
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240808
DATE AS OF CHANGE:		20240808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Barinthus Biotherapeutics plc.
		CENTRAL INDEX KEY:			0001828185
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40367
		FILM NUMBER:		241186183

	BUSINESS ADDRESS:	
		STREET 1:		UNIT 6-10, ZEUS BUILDING
		STREET 2:		RUTHERFORD AVENUE, HARWELL
		CITY:			DIDCOT
		STATE:			X0
		ZIP:			OX11 0DF
		BUSINESS PHONE:		44 (0) 1865 818808

	MAIL ADDRESS:	
		STREET 1:		UNIT 6-10, ZEUS BUILDING
		STREET 2:		RUTHERFORD AVENUE, HARWELL
		CITY:			DIDCOT
		STATE:			X0
		ZIP:			OX11 0DF

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vaccitech plc
		DATE OF NAME CHANGE:	20210407

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vaccitech Ltd
		DATE OF NAME CHANGE:	20201014
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>brns-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a110c5a-492b-47ac-b990-632b9a151dae,g:0cb2830b-fcfe-4af5-8a4f-fdc83046615c,d:f929189504494c2da09ff9dfd66b833d-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:brns="http://www.barinthusbio.com/20240630" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>brns-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001828185</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-30">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-31">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-32">00-0000000</ix:nonNumeric><ix:nonNumeric contextRef="c-16" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-213">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-17" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-214">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-18" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-215">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="c-19" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-216">http://fasb.org/us-gaap/2024#LicenseMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="brns-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="gbpPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>brns:segment</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>brns:vote</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-20</xbrli:startDate><xbrli:endDate>2023-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-21</xbrli:startDate><xbrli:endDate>2021-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-06</xbrli:startDate><xbrli:endDate>2023-11-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">brns:AvideaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-03</xbrli:startDate><xbrli:endDate>2021-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-14</xbrli:startDate><xbrli:endDate>2022-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001828185</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-109 f-110 f-111 f-112" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-1" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-235 f-261 f-289 f-300 f-311 f-337 f-356" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-2" order="2"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="f-403 f-404" linkRole="http://www.xbrl.org/2003/role/link" toRefs="fn-3" order="3"/></ix:resources></ix:header></div><div id="if929189504494c2da09ff9dfd66b833d_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">AND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">EXCHANGE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">20549</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mark</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">One</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;QUARTERLY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REPORT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PURSUANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">THE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXCHANGE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">quarterly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June 30, 2024</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;TRANSITION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REPORT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PURSUANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECTION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">THE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EXCHANGE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ACT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">transition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">from ________to ________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">File</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40367</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">BARINTHUS BIOTHERAPEUTICS PLC</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exact</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Specified</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">its</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Charter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-7">England and Wales</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">Unit 6-10, Zeus Building</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-9">Rutherford Avenue</ix:nonNumeric>, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Harwell, Didcot</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-11">United Kingdom</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">OX11 0DF</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">telephone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">number</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">including</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">area</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">+44 (0)</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">1865 818 808</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">registered</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">pursuant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">b</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:40.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Title of each class</span></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-15">American Depositary Shares</ix:nonNumeric>*</span></div></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-16">BRNS</ix:nonNumeric></span></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-18">Ordinary shares, nominal value &#163;0.000025 per share</ix:nonNumeric>**</span></div></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Not for trading, but only in connection with the listing of American Depositary Shares on The Nasdaq Global Market. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Smaller reporting company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">x</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-25">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;1, 2024, the registrant had <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-26">39,414,722</ix:nonFraction> ordinary shares, nominal value &#163;0.000025 per share, outstanding.</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_13">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_82">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_82">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_118">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_118">Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_118">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_121">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_121">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_121">31</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_124">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_124">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_127">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_127">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_130">Item 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_130">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_130">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_133">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_133">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_136">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_136">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_136">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_139">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_139">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_139">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_142">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_142">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_142">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.84pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_145">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_145">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_145">34</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_148">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_148">35</a></span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own the registered trademark BARINTHUS in the United Kingdom, and we have filed applications at the UK Intellectual Property Office and other intellectual properties to register trademarks for BARINTHUS, SNAP-TI, SNAP-CI and a design logo globally. We also own various trademark registrations and applications, and unregistered trademarks, including the registered trademark VACCITECH, and trademarks relating to the technologies acquired as part of our acquisition of Avidea Technologies, Inc. in December 2021 including the registered trademarks TRAPD, SNAPVAX and SYNTHOLYTIC. All other trade names, trademarks and service marks of other companies appearing in this Quarterly Report on Form 10-Q, or this Quarterly Report, are the property of their respective holders. Solely for convenience, the trademarks and trade names in this Quarterly Report may be referred to without the &#174; and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may use our website, our X (formerly known as Twitter) account at @Barinthusbio and our LinkedIn account at linkedin.com/company/barinthus-bio to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.barinthusbio.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website, our X (formerly known as Twitter) posts and our LinkedIn posts are not incorporated into, and does not form a part of, this Quarterly Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - &#8239;FINANCIAL INFORMATION</span></div><div id="if929189504494c2da09ff9dfd66b833d_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Condensed Consolidated Financial Statements (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Page</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_19">F</a>-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_22">F</a>-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_22">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_25">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_25">F</a>-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_28">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_28">F</a>-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_31">F</a>-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#if929189504494c2da09ff9dfd66b833d_31">5</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.030%"><tr><td style="width:1.0%"/><td style="width:71.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.884%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of<br/>December 31,<br/>2023</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-33">117,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-34">142,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development incentives receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="brns:ResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-35">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:ResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-36">4,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">9,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">9,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">131,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">156,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-41">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-42">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-43">10,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-44">11,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-45">23,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-46">25,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right of use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-47">7,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-48">7,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="f-49">886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="f-50">882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-51">186,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-52">214,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">2,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span id="i4186dd2e824f42a19660d0fcc5ec3e8b_16-0-1-1-48097"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">10,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">9,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeCurrent" scale="3" id="f-57">839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeCurrent" format="ixt:fixed-zero" scale="3" id="f-58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">1,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">15,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">12,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liability - non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">10,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">11,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">1,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred tax liability, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="brns:DeferredTaxLiabilityNet" scale="3" id="f-69">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:DeferredTaxLiabilityNet" scale="3" id="f-70">574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-71">29,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">27,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 15)</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-73"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-74"/></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Ordinary shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-75"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-76">0.000025</ix:nonFraction></ix:nonFraction> nominal value; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-78"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-79">39,184,338</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding (December&#160;31, 2023: authorized, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-80"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-81"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-82">38,643,540</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-83">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-84">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:0.05pt;padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred A shares, &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-7" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-85"><ix:nonFraction unitRef="gbpPerShare" contextRef="c-8" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-86">1</ix:nonFraction></ix:nonFraction> nominal value; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="brns:DeferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="brns:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="brns:DeferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-89">63,443</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares authorized, issued and outstanding (December&#160;31, 2023: authorized, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="brns:DeferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-90"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="brns:DeferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-91"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="brns:DeferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-92">63,443</ix:nonFraction></ix:nonFraction></ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="brns:DeferredStockValueIssued" scale="3" id="f-93">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="brns:DeferredStockValueIssued" scale="3" id="f-94">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-95">390,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-96">386,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-97">209,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-98">176,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss &#8211; foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-99">24,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-100">23,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-101">156,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-102">186,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-103">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="f-104">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-105">156,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-106">186,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-107">186,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-108">214,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:9pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-1</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.188%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-110">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-112">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.68pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="f-113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-114">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-116">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.52pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-117">11,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">13,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-119">22,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-120">23,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.52pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">7,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">13,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-123">13,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">25,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-125">18,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-126">26,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-127">35,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-128">48,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherOperatingIncome" scale="3" id="f-129">577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="3" id="f-130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingIncome" scale="3" id="f-131">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherOperatingIncome" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">18,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">26,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">35,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">47,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income/(expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.52pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-137">635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-138">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-139">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-140">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.52pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-141">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-142">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-143">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-144">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.52pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development incentives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" scale="3" id="f-145">693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" scale="3" id="f-146">559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-147">1,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="brns:ResearchAndDevelopmentIncentiveIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-148">1,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.52pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-149">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-150">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-151">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-152">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">2,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">4,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-157">16,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-158">24,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-159">32,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-160">43,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-161">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-162">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-163">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-164">1,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">16,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">23,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-167">32,463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-168">42,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.08pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-169">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-170">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-171">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-172">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-173">16,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">23,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">32,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-176">41,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average ordinary shares outstanding, basic </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-177">39,041,111</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-178">38,407,672</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-179">38,907,296</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-180">38,211,625</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-181">39,041,111</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-182">38,407,672</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183">38,907,296</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-184">38,211,625</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders, basic</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-185">0.43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-186">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-187">0.83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-188">1.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders, diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-189">0.43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-190">0.62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-191">0.83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-192">1.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-193">16,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-194">23,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-195">32,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-196">42,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-197">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-198">5,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-199">1,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-200">10,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-201">16,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-202">18,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-203">33,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-204">31,863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-205">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-206">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-207">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="f-208">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-209">16,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-210">18,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-211">33,837</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-212">31,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><ix:footnote id="fn-1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Includes <span style="-sec-ix-hidden:f-213"><span style="-sec-ix-hidden:f-214"><span style="-sec-ix-hidden:f-215"><span style="-sec-ix-hidden:f-216">license revenue</span></span></span></span> from related parties for the three and six months ended June&#160;30, 2024 of <ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-217"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-218">nil</ix:nonFraction></ix:nonFraction> and for the three and six months ended June&#160;30, 2023 of $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-219">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-220">0.8</ix:nonFraction> million, respectively.</span></ix:footnote></div><div style="margin-top:12pt;text-indent:9pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-2</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS, EXCEPT NUMBER OF SHARES)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.888%"><tr><td style="width:1.0%"/><td style="width:22.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.602%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.767%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.019%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.384%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="63" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Three and Six months ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Ordinary&#160;Shares</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Deferred A Shares</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional Paid-in-Capital</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Non-Controlling Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">Balance, January 1, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-221">38,643,540</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-222">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-223">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-224">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-225">386,602</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-226">176,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-227">23,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-228">186,784</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-229">211</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-230">186,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-231">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-232">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-233">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Issue of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-234">309,416</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-235">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-236">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-237">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-238">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-239">1,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-240">1,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-241">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-242">1,577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-243">15,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-244">15,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-245">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-246">15,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">Balance, March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-247">38,952,956</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-248">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-249">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-250">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-251">388,720</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-252">192,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-253">24,895</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-254">171,833</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-255">183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-256">172,016</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-257">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-258">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-259">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Issue of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-260">231,382</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-261">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-262">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-263">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-264">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-265">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-266">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-267">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-268">16,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-269">16,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-270">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-271">16,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">Balance, June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-272">39,184,338</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-273">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-274">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-275">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-276">390,273</ix:nonFraction></span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-277">209,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-278">24,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-279">156,618</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-280">172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-281">156,790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.026%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="90" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:114%">Three and Six months ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Ordinary&#160;Shares</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Deferred A Shares</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Deferred B Shares</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Deferred C Shares</span></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional Paid-in-Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Non-Controlling Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">Balance, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-282">37,683,531</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-283">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-284">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-285">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-286">570,987</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-287">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-288">27,828,231</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-289">0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-290">379,504</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-291">103,243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-292">33,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-293">242,896</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-294">305</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-295">243,201</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-296">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-297">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-298">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Issue of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-299">673,494</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-300">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-301">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-302">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-303">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-304">4,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-305">4,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-306">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-307">4,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Cancellation of deferred shares</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="brns:SharesCancelledDuringPeriodSharesDeferredShares" format="ixt:num-dot-decimal" scale="0" id="f-308">570,987</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="brns:SharesCancelledDuringPeriodValueDeferredShares" scale="3" id="f-309">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="brns:SharesCancelledDuringPeriodSharesDeferredShares" format="ixt:num-dot-decimal" scale="0" id="f-310">27,828,231</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="brns:SharesCancelledDuringPeriodValueDeferredShares" scale="3" id="f-311">0</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="brns:SharesCancelledDuringPeriodValueDeferredShares" scale="3" id="f-312">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="brns:SharesCancelledDuringPeriodValueDeferredShares" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="brns:SharesCancelledDuringPeriodValueDeferredShares" format="ixt:fixed-zero" scale="3" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-315">18,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-316">18,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-317">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-318">18,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">Balance, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-319">38,357,025</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-320">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-321">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-322">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-323">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-77" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-325">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-326">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-327">383,523</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-328">121,423</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-329">28,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-330">233,301</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-331">268</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-332">233,569</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-333">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-334">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-335">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Issue of ordinary shares, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-336">167,034</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-337">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-338">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-339">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-340">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-341">5,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-342">5,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-343">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-344">5,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-345">23,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-346">23,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-347">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-348">23,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">Balance, June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-349">38,524,059</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-350">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-351">63,443</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-352">86</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-353">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-355">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-356">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-357">385,636</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-358">145,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-359">23,289</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-360">217,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-361">253</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-362">217,462</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><ix:footnote id="fn-2" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Indicates amount less than one thousand</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-3</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(IN THOUSANDS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.773%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-363">32,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-4.5pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-364">42,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Adjustments to reconcile net (loss)/income to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-4.5pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Share based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-365">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-366">4,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-367">2,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 14.5pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-368">2,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Non-cash lease expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:NonCashLeaseExpenses" scale="3" id="f-369">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="brns:NonCashLeaseExpenses" scale="3" id="f-370">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Unrealized foreign exchange (gain)/loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-371">583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 14.5pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="f-372">7,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Change in contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-373">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-374">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Non cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:NonCashInterestExpenseOnConvertibleLoanNotes" scale="3" id="f-375">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 14.5pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="brns:NonCashInterestExpenseOnConvertibleLoanNotes" scale="3" id="f-376">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-377">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 14.5pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-378">1,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts receivable (including related parties)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-380">5,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-381">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-382">3,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Research and development incentives receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" scale="3" id="f-383">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-384">1,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-385">967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-386">1,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-387">1,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-388">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Deferred income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="f-389">839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-391">819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-394">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net cash used in operating activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-395">23,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt;text-indent:-4.5pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-396">20,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-4.5pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-397">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-398">5,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net cash used in investing activities</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-399">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-4.5pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-400">5,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from issue of ordinary shares, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-401">861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-402">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Issue of shares from the exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-403">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="f-404">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-4.5pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="f-406">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net cash provided by financing activities</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-407">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-4.5pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-408">1,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Effect of exchange rates on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="f-409">849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-410">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-411">24,316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-412">21,355</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-413">142,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-414">194,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-415">117,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-416">173,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Purchases of property and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-4.5pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-418">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Asset retirement obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:AssetRetirementObligations" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="brns:AssetRetirementObligations" scale="3" id="f-420">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Changes to right-of-use asset resulting from lease reassessment event</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" format="ixt:fixed-zero" scale="3" id="f-421">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 8.2pt;text-indent:-7.2pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" scale="3" id="f-422">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><ix:footnote id="fn-3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Indicates amounts less than one thousand</span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-4</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"> </span></div><div id="if929189504494c2da09ff9dfd66b833d_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-423" continuedAt="f-423-1" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-423-1" continuedAt="f-423-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barinthus Biotherapeutics plc is a public limited company incorporated pursuant to the laws of England and Wales in March 2021. Barinthus Biotherapeutics plc and its direct and indirect subsidiaries, Barinthus Biotherapeutics (UK) Limited, Barinthus Australia Pty Limited, Vaccitech Oncology Limited (&#8220;VOLT&#8221;), Barinthus Biotherapeutics North America, Inc., Barinthus Biotherapeutics Switzerland GmbH and Barinthus Biotherapeutics S.R.L., are collectively referred to as the &#8220;Company&#8221; or &#8220;Barinthus Bio.&#8221; The Company is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. The Company is headquartered in Harwell, Oxfordshire, United Kingdom. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in an environment of rapid technological change and substantial competition from pharmaceutical and biotechnology companies. The Company is subject to risks common to companies in the biopharmaceutical industry in a similar stage of its life cycle including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its immunotherapeutic product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of any of its products that are approved, and protection of proprietary technology. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. If the Company does not successfully commercialize any of its products or mitigate any of these other risks, it will be unable to generate revenue or achieve profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain notes or other information that are normally required by GAAP have been omitted if they substantially duplicate the disclosures contained in the Company&#8217;s annual audited consolidated financial statements. Accordingly, the unaudited condensed consolidated financial statements should be read in connection with the Company&#8217;s audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2023. The condensed consolidated balance sheet as of December&#160;31, 2023, was derived from the audited financial statements but does not contain all of the footnote disclosures from the annual financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had cash, cash equivalents and restricted cash of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-424">117.8</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="f-425">209.0</ix:nonFraction> million, and the Company expects to incur losses for the foreseeable future. The Company expects that its cash, cash equivalents and restricted cash will be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. The Company expects to seek additional funding through equity financing, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#8217;s stockholders. If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><ix:continuation id="f-423-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Condensed Consolidated Financial Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Balance Sheets as of June&#160;30, 2024, and December&#160;31, 2023, the Condensed Consolidated Statements of Operations and Comprehensive Loss, Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity and the Condensed Consolidated Statements of Cash Flows for the three and six months ended June&#160;30, 2024 and 2023 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the Securities Exchange Commission (the &#8220;Annual Report&#8221;) on March 20, 2024. In our opinion, the unaudited condensed consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of June&#160;30, 2024, our results of operations for the three and six months ended June&#160;30, 2024, and 2023, and our cash flows for the six months ended June&#160;30, 2024, and 2023. The results of operations for the three and six months ended June&#160;30, 2024, are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2024, or any other interim periods.</span></div></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-426" continuedAt="f-426-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-426-1" continuedAt="f-426-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Annual Report, except as discussed below related to newly adopted accounting pronouncements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-427" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-428" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker ("CODM"), the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts and approves the Company's consolidated operating budget. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-429">one</ix:nonFraction> operating segment, the research and development of vaccines and immunotherapies. The chief operating decision maker uses net loss to monitor budget versus actual results and decide how to use the Company's resources. As the Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-430">one</ix:nonFraction> operating segment, all required financial segment information can be found in these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-431" escape="true"><ix:continuation id="f-426-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our current operations.</span></div></ix:continuation></ix:nonNumeric><div id="if929189504494c2da09ff9dfd66b833d_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyDisclosureTextBlock" id="f-432" continuedAt="f-432-1" escape="true">Foreign Currency Translation in General and Administrative Expenses</ix:nonNumeric></span></div><ix:continuation id="f-432-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate, net foreign exchange gain or loss recognized in general and administrative expenses for the three and six months ended June&#160;30, 2024, was a loss of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-433">0.1</ix:nonFraction> million and gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-434">1.1</ix:nonFraction> million, respectively (three and six months ended June&#160;30, 2023: $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-435">4.2</ix:nonFraction> million loss and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-436">7.7</ix:nonFraction> million loss, respectively).</span></div></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-437" continuedAt="f-437-1" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-437-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-438" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended  June&#160;30, 2024, and 2023 (in thousands, except number of shares):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-439">16,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-440">23,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-441">32,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-442">42,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-443">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-444">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-445">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-446">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-447">16,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-448">23,802</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-449">32,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-450">41,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average ordinary shares outstanding, basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-451">39,041,111</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-452">38,407,672</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-453">38,907,296</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-454">38,211,625</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-455">39,041,111</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-456">38,407,672</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-457">38,907,296</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-458">38,211,625</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders, basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-459">0.43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-460">0.62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-461">0.83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-462">1.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders, diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-463">0.43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-464">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-465">0.83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-466">1.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. As of June&#160;30, 2024, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-467">7,779,884</ix:nonFraction> potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect (June&#160;30, 2023: <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-468">6,781,099</ix:nonFraction>).</span></div></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div id="if929189504494c2da09ff9dfd66b833d_46"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-469" continuedAt="f-469-1" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="f-469-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2024, the Company&#8217;s additions to property and equipment, net were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="f-470">0.5</ix:nonFraction> million which primarily related to an increase in lab equipment in the Company's U.K. office (six months ended June&#160;30, 2023: $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="f-471">6.4</ix:nonFraction> million, primarily related to an increase in leasehold improvements from the Company&#8217;s U.S. office in Germantown, Maryland).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and six months ended June&#160;30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-472">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-473">1.3</ix:nonFraction> million, respectively (June&#160;30, 2023: three and six months $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-474">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-475">0.9</ix:nonFraction> million, respectively).</span></div></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-476" continuedAt="f-476-1" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="f-476-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount of amortizable intangible assets, consisting of acquired developed technology, was $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-477">31.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-478">31.6</ix:nonFraction>&#160;million as of June&#160;30, 2024 and December&#160;31 2023, respectively, and accumulated amortization was $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-479">8.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-480">6.5</ix:nonFraction>&#160;million as of June&#160;30, 2024 and December&#160;31, 2023, respectively. The amortization expense for the three and six months ended June&#160;30, 2024 was $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-481">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-482">1.6</ix:nonFraction>&#160;million, respectively (three and six months ended June&#160;30, 2023: $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-483">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-484">1.6</ix:nonFraction>&#160;million, respectively). The estimated annual amortization expense is $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSix" format="ixt:num-dot-decimal" scale="6" id="f-485"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="f-486"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="f-487"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" format="ixt:num-dot-decimal" scale="6" id="f-488"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="f-489"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="brns:FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-490"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-491"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-492">3.2</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million for the years 2024 through to 2031.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2024, the Company announced plans to prioritize its pipeline to focus on the development of VTP-300 for chronic Hepatitis B virus infection and VTP-1000 in celiac disease. Given this change in Company focus, management identified circumstances that could indicate that the carrying amount of the Company's intangible assets may not be recoverable. Therefore, the Company performed both a qualitative and quantitative assessment as of June&#160;30, 2024 and determined that the carrying amount of the Company's intangible assets are recoverable.</span></div></ix:continuation><div><span><br/></span></div><div id="if929189504494c2da09ff9dfd66b833d_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock" id="f-494" continuedAt="f-494-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="f-493" continuedAt="f-493-1" escape="true">Prepaid Expenses and Other Current Assets (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-494-1"><ix:continuation id="f-493-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepayments and accrued income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-495">7,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-496">5,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-497">1,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-498">3,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-499">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-500">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.64pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-501">9,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-502">9,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" id="f-504" continuedAt="f-504-1" escape="true"><ix:nonNumeric contextRef="c-1" name="brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="f-503" continuedAt="f-503-1" escape="true">Accrued Expenses and Other Current Liabilities (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-504-1" continuedAt="f-504-2"><ix:continuation id="f-503-1" continuedAt="f-503-2"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="brns:AccruedManufacturingAndClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-505">5,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:AccruedManufacturingAndClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-506">4,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-507">1,232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedBonusesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-508">2,412</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="f-509">985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="f-510">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-511">1,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="f-512">942</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-513">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-514">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-515">10,278</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-516">9,212</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt"><ix:continuation id="f-504-2" continuedAt="f-504-3"><ix:continuation id="f-503-2" continuedAt="f-503-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Included in Accrued other as of June 30, 2024 is a provision of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-517">0.8</ix:nonFraction> million for severance costs for the reduction in workforce following the Company&#8217;s announcement in June 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to prioritize its pipelin</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-504-3"><ix:continuation id="f-503-3">e. Of this expense, $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-518">0.7</ix:nonFraction>&#160;million is included in research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-519">0.1</ix:nonFraction>&#160;million is included in general and administrative expenses in the statements of operations and comprehensive loss.</ix:continuation></ix:continuation> </span></div><div style="margin-top:12pt"><span><br/></span></div><div id="if929189504494c2da09ff9dfd66b833d_58"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9.    <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherOperatingIncomeAndExpenseTextBlock" id="f-520" continuedAt="f-520-1" escape="true">Grant Income</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-520-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) Funding Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2023, Barinthus Biotherapeutics (UK) Limited (the &#8220;Company&#8221;), the Chancellors, Masters and Scholars of the University of Oxford (&#8220;Oxford,&#8221; together with the Company, the &#8220;Partners&#8221;) and the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) entered into a Funding Agreement (the &#8220;Funding Agreement&#8221;) pursuant to which CEPI will provide funding of up to $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="brns:FundingAmountMaximum" scale="6" id="f-521">34.8</ix:nonFraction> million to the Company to advance the development of VTP-500, the Company&#8217;s vaccine candidate against Middle East Respiratory Syndrome (&#8220;MERS,&#8221; and such development activities, the &#8220;Project&#8221;). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Funding Agreement, the Company has agreed to pay CEPI on a country-by-country basis increasing mid-single digit percentage royalties of net sales and net income with respect to future cash sales of VTP-500, less certain deductions, for a period starting on December 20, 2023 (&#8220;Effective Date&#8221;) and ending the later of: (i) the expiration of the last valid patent claim included in intellectual property developed under the Project covering VTP-500 in such country, (ii) the expiration of Regulatory Exclusivity (as defined in the Funding Agreement) for VTP-500 in such country, and (iii) the tenth (<ix:nonNumeric contextRef="c-105" name="brns:RoyaltyPaymentTermMaximum" format="ixt-sec:duryear" id="f-522">10</ix:nonNumeric>th) anniversary of the first commercial sale of VTP-500 (the &#8220;Royalty Term&#8221;). The Company shall also pay CEPI a mid-double-digit percentage of net revenue earned on VTP-500 until CEPI has received payments from the Company under the Funding Agreement equaling the total amount of funding paid by CEPI to the Company and a low double-digit percentage of such net revenue thereafter. Sales for the benefit of end users in specified low and middle income countries (&#8220;LMICs&#8221;) and upper and middle income countries (&#8220;UMICs&#8221;) are excluded from the calculations of net sales and net revenue. Sales of the product for the benefit of end users in LMICs and UMICs are subject to tiered discounted pricing requirements under the Funding Agreement. The Company is further required to pay a low to mid-double-digit percentage of any proceeds earned on any priority review voucher related to VTP-500 during the Royalty Period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months period ended June&#160;30, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:DeferredIncomeAddition" scale="6" id="f-523">1.6</ix:nonFraction> million proceeds have been received and $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="us-gaap:DeferredIncomeRevenueRecognized" scale="6" id="f-524">0.8</ix:nonFraction> million income has been recognized in relation to this contract. This is presented as other operating income in the condensed consolidated statements of operations and comprehensive loss. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Funding Agreement cash payments are restricted as to the use and management of the funds. The remaining unused amounts of the Funding Agreement cash payments of $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-525">0.8</ix:nonFraction> million as of June&#160;30, 2024 are reflected in Cash, cash equivalents and restricted cash in the condensed consolidated balance sheets until expenditures contemplated in the Funding Agreement are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Deferred income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income primarily relates to payments received from CEPI in advance of the eligible research and development expenses being incurred and are disclosed as deferred income separately in the condensed consolidated balance sheets. Deferred income is released to the condensed consolidated statements of operations and comprehensive loss in the period in which such research and development activities are actually performed in a manner that satisfies the conditions of the Funding Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredIncomeTableTextBlock" id="f-526" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in deferred income during the three and six months ended June&#160;30, 2024 and 2023, are as follows (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-527">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:fixed-zero" scale="3" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:fixed-zero" scale="3" id="f-529">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredIncomeAddition" format="ixt:fixed-zero" scale="3" id="f-531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredIncomeAddition" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeAddition" format="ixt:num-dot-decimal" scale="3" id="f-533">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredIncomeAddition" format="ixt:fixed-zero" scale="3" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income recognized related to the Funding Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredIncomeRevenueRecognized" scale="3" id="f-535">577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredIncomeRevenueRecognized" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeRevenueRecognized" scale="3" id="f-537">782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredIncomeRevenueRecognized" format="ixt:fixed-zero" scale="3" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="brns:DeferredIncomeForeignExchangeTranslationGainLoss" scale="3" id="f-539">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="brns:DeferredIncomeForeignExchangeTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="f-540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="brns:DeferredIncomeForeignExchangeTranslationGainLoss" scale="3" id="f-541">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="brns:DeferredIncomeForeignExchangeTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncome" scale="3" id="f-543">839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:fixed-zero" scale="3" id="f-544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncome" scale="3" id="f-545">839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:DeferredIncome" format="ixt:fixed-zero" scale="3" id="f-546">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-9</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-547" continuedAt="f-547-1" escape="true">Ordinary Shares</ix:nonNumeric></span></div><ix:continuation id="f-547-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All ordinary shares rank pari passu as a single class. The following is a summary of the rights and privileges of the holders of ordinary shares as of June&#160;30, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidation preference: in the event of the liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to holders of the ordinary shares shall be distributed amongst all holders of the ordinary shares in proportion to the number of shares held irrespective of the amount paid or credited as paid on any share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends: The Company may, subject to the provisions of the Companies Act 2006 and our Articles, by ordinary resolution from time to time declare dividends to be paid to shareholders not exceeding the amount recommended by the Company&#8217;s board of directors. Subject to the provisions of the Companies Act 2006, in so far as, in the board of directors&#8217; opinions, the Company&#8217;s profits justify such payments, the board of directors may pay interim dividends on the Company&#8217;s ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Voting Rights: Each holder of ordinary shares has the right to receive notice of, and to vote at, the Company&#8217;s general meetings. Each holder of ordinary shares who is present (in person or by proxy) at a general meeting on a show of hands has <ix:nonFraction unitRef="vote" contextRef="c-5" decimals="INF" name="brns:CommonStockNumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="f-548">one</ix:nonFraction> vote and, on a poll, every such holder who is present (in person or by proxy) has <ix:nonFraction unitRef="vote" contextRef="c-5" decimals="INF" name="brns:CommonStockNumberOfVotesPerShare" format="ixt-sec:numwordsen" id="f-549">one</ix:nonFraction> vote in respect of each share of which they are the holder.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preemption rights: Pursuant to section 561 of the Companies Act 2006, shareholders are granted preemptive rights when new shares are issued for cash. However, it is possible for our Articles, or shareholders at a general meeting representing at least <ix:nonFraction unitRef="number" contextRef="c-5" decimals="2" name="brns:PercentageOfSharesNecessaryToExercisePreemptiveRights" scale="-2" id="f-550">75</ix:nonFraction>% of our ordinary shares present (in person or by proxy) and eligible to vote at that general meeting, to disapply these preemptive rights by passing a special resolution. Such a disapplication of preemption rights may be for a maximum period of up to <ix:nonNumeric contextRef="c-1" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-551">five years</ix:nonNumeric> from the date on which the shareholder resolution was passed. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at least every <ix:nonNumeric contextRef="c-108" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-552">five years</ix:nonNumeric>) to remain effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;21, 2021, our shareholders approved the disapplication of preemptive rights for a period of <ix:nonNumeric contextRef="c-109" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-553">five years</ix:nonNumeric> from the date of approval by way of a special resolution of our shareholders. This included the disapplication of preemption rights in relation to the allotment of our ordinary shares in connection with the IPO. This disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at least every <ix:nonNumeric contextRef="c-109" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-554">five years</ix:nonNumeric>) to remain effective, but may be sought more frequently for additional <ix:nonNumeric contextRef="c-109" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-555">five-year</ix:nonNumeric> terms (or any shorter period).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;6, 2023, we held a general meeting where our shareholders approved resolutions granting our board of directors or any duly authorized committee of the board of directors the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from pre-emption rights. Pursuant to such approval, our board of directors was authorized to allot shares up to an aggregate nominal amount of &#163;<ix:nonFraction unitRef="gbp" contextRef="c-110" decimals="0" name="brns:MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" format="ixt:num-dot-decimal" scale="0" id="f-556">1,928</ix:nonFraction> free from statutory pre-emption rights. The granting of this authority and the corresponding disapplication of preemptive rights was in addition to all subsisting authorities. This disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at least every <ix:nonNumeric contextRef="c-111" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-557">five years</ix:nonNumeric>) to remain effective, but may be sought more frequently for additional <ix:nonNumeric contextRef="c-111" name="brns:PeriodOfPreemptiveRightsToBeExercised" format="ixt-sec:durwordsen" id="f-558">five-year</ix:nonNumeric> terms (or any shorter period).</span></div></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="brns:StockholdersEquityDeferredSharesDisclosureTextBlock" id="f-559" continuedAt="f-559-1" escape="true">Deferred Shares</ix:nonNumeric></span></div><ix:continuation id="f-559-1" continuedAt="f-559-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All deferred shares rank pari passu as a single class. The deferred shares do not have rights to dividends or to any other right of participation in the profits of the Company. On a return of assets on liquidation, the deferred shares shall confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst the shareholders (subject to the rights of any new class of shares with preferred rights) the amount credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares of the amounts paid up or credited as paid up on such shares and the sum of &#163;<ix:nonFraction unitRef="gbp" contextRef="c-8" decimals="-5" name="brns:OrdinarySharesLiquidationPreference" format="ixt:num-dot-decimal" scale="6" id="f-560">1.0</ix:nonFraction>&#160;million in respect of each ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;29, 2023, all deferred B shares (nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-112" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-561">0.01</ix:nonFraction> each) and deferred C shares (nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-113" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-562">0.00000736245954692556</ix:nonFraction> each) previously in issue were transferred back to the Company and subsequently cancelled. These deferred shares had previously been issued to certain pre-IPO shareholders in connection with the implementation of certain stages of the Company&#8217;s pre-IPO share capital reorganization. The Company received shareholder approval on </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><ix:continuation id="f-559-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 21, 2021 (pursuant to the shareholder resolutions passed on that date) in order to effect the transfer back and cancellation of the deferred shares for nil consideration in accordance with sections 659 and 662 of the Companies Act 2006.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s deferred A shares with a nominal value of &#163;<ix:nonFraction unitRef="gbpPerShare" contextRef="c-114" decimals="INF" name="brns:DeferredStockParOrStatedValuePerShare" scale="0" id="f-563">1.00</ix:nonFraction> each remain in issue for the purposes of satisfying the minimum share capital requirements for a public limited company as prescribed by the Companies Act 2006.</span></div></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-564" continuedAt="f-564-1" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="f-564-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash, cash equivalents and restricted cash, accounts receivable, accounts payable, certain accrued expenses, and contingent consideration. The carrying amounts of cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued expenses approximated their respective fair value due to the short-term nature and maturity of these instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had a contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="f-565">1.9</ix:nonFraction>&#160;million related to the acquisition of Avidea Technologies, Inc. The fair value of the contingent consideration is a Level 3 valuation with the significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Significant judgment is employed in determining the appropriateness of certain of these inputs.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-566" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes to our financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-567">1,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-568">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-569">1,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-570">1,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value recognized in net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-571">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-572">354</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-573">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-574">316</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" scale="3" id="f-575">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" scale="3" id="f-576">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" sign="-" name="brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" scale="3" id="f-577">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" scale="3" id="f-578">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-579">1,888</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-580">2,117</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-581">1,888</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-582">2,117</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillDisclosureTextBlock" id="f-583" continuedAt="f-583-1" escape="true">Goodwill</ix:nonNumeric></span></div><ix:continuation id="f-583-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified qualitative indicators of impairment due to a sustained decline in the price of the Company&#8217;s American Depositary Shares, whereby the market capitalization continues to be below the value of the net assets of the Company, and the plans announced in June 2024 to prioritize its pipeline to focus on the development of VTP-300 for chronic Hepatitis B virus infection and VTP-1000 in celiac disease. Therefore, the Company performed both an interim qualitative and quantitative assessment as of June&#160;30, 2024 to determine whether it was more likely than not that the fair value of the reporting unit is less than its carrying amount. Based on this assessment, management determined it is not more likely than not that the fair value of the reporting unit is less than its carrying amount and hence <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt-sec:numwordsen" id="f-584"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt-sec:numwordsen" id="f-585">no</ix:nonFraction></ix:nonFraction> impairment loss has been recognized.</span></div></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-586" continuedAt="f-586-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-586-1" continuedAt="f-586-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six month period ended June&#160;30, 2024, in accordance with the terms of the Annual Increase of the Barinthus Biotherapeutics plc Award Plan 2021 (the &#8220;Plan&#8221;), the total number of ordinary shares available for issuance under the Plan increased by <ix:nonFraction unitRef="number" contextRef="c-126" decimals="2" name="brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" scale="-2" id="f-587">4</ix:nonFraction>% of the Company&#8217;s issued and outstanding ordinary shares as of January 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2024, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-588">1,951,377</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options to employees and directors with a weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-589">2.71</ix:nonFraction> and a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-590">3.41</ix:nonFraction> per share (June&#160;30, 2023: granted <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-591">2,142,905</ix:nonFraction> options, weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-592">2.00</ix:nonFraction> and a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-593">2.51</ix:nonFraction> per share). For the six months ended June&#160;30, 2024, <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-594">229,430</ix:nonFraction> options (June&#160;30, 2023: <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-595">217,860</ix:nonFraction>) were forfeited.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><ix:continuation id="f-586-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-596" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued to employees was estimated at the date of grant using the Black-Scholes model with the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-597">108.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-598">97.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-127" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-599">6.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-128" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-600">6.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-601">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-602">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-603">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-605">7,779,884</ix:nonFraction> options with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-606">6.19</ix:nonFraction> were outstanding. As of June&#160;30, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-607">5.4</ix:nonFraction>&#160;million unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-129" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-608">1.9</ix:nonNumeric> years. As of June&#160;30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-609">6,781,099</ix:nonFraction> options with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-99" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-610">9.51</ix:nonFraction> were outstanding. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-611" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share based compensation expense is classified in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-612">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-613">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-614">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-615">2,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-616">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-617">963</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-618">1,593</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-619">2,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-620">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-621">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-622">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-623">4,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-624" continuedAt="f-624-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-624-1" continuedAt="f-624-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a number of licensing agreements, most of which are with related parties. These agreements serve to provide the Company with the right to develop and exploit the counterparties&#8217; intellectual property for certain medical indications. As part of execution of these arrangements, the Company paid certain upfront fees, which have been expensed as incurred because the developing technology has not yet reached technical feasibility, the lack of alternative use, and the lack of proof of potential value. The agreements cover a variety of fields, including influenza, cancer, human papillomavirus infection, (&#8220;HPV&#8221;), hepatitis B virus (&#8220;HBV&#8221;) and MERS. The Company&#8217;s obligations for future payments under these arrangements are dependent on its ability to develop promising drug candidates, the potential market for these candidates and potential competing products, and the payment mechanisms in place in countries where the Company retains the right to sell. Each agreement provides for specific milestone payments, typically triggered by achievement of certain testing phases in human candidates, and future royalties ranging from <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" scale="-2" id="f-625">1</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" scale="-2" id="f-626">5</ix:nonFraction>% for direct sales of a covered product to <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" scale="-2" id="f-627">3</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" scale="-2" id="f-628">7</ix:nonFraction>% of net payments received for allowable sublicenses of technology developed by the Company. The obligation to make these payments is contingent upon the Company&#8217;s ability to develop candidates for submission for phased testing and approvals, and for the development of markets for the products developed by the Company. The Company has not made or accrued any material payments under these license agreements during the six month periods ended June&#160;30, 2024 and 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain laboratory and office space under operating leases, which are described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Harwell Science and Innovation Campus, Oxfordshire</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;3, 2021, the Company entered into a lease agreement for the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="c-138" decimals="-3" name="brns:NumberOfSquareFeetUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-629">31,000</ix:nonFraction> square feet in Harwell, Oxfordshire which expires in September 2031. The property is the Company&#8217;s corporate headquarters. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date, being the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company has provided the lessor with a refundable security deposit of $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="f-630">0.7</ix:nonFraction>&#160;million which is included in Other assets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><ix:continuation id="f-624-2" continuedAt="f-624-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Germantown, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;14, 2022, the Company entered into a lease agreement for the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="c-140" decimals="-2" name="brns:NumberOfSquareFeetUnderLeaseAgreement" format="ixt:num-dot-decimal" scale="0" id="f-631">19,700</ix:nonFraction> square feet in Germantown, Maryland. The site houses the Company&#8217;s state-of-the-art wet laboratory in the United States of America. The lease expires on February 28, 2034, with the Company having a single right to extend for an additional <ix:nonNumeric contextRef="c-140" name="brns:LesseeOperatingLeaseExtendedTerm" format="ixt-sec:durwordsen" id="f-632">five years</ix:nonNumeric> on the same terms and conditions other than for the base rent. The Company had a rent-free period up to February 29, 2024, and was entitled to up to $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="6" id="f-633">3.5</ix:nonFraction>&#160;million for leasehold improvements to the premises desired by the Company. The Company has provided the lessor with a refundable security deposit of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="6" id="f-634">0.2</ix:nonFraction>&#160;million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a right-of-use asset and a lease liability on the effective date of the lease term. <ix:nonNumeric contextRef="c-1" name="brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" id="f-635" continuedAt="f-635-1" escape="true">The Company&#8217;s right-of-use asset and lease liability are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-635-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-636">7,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-637">7,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, current</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-638">1,916</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-639">1,785</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-640">10,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-641">11,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.711%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-642">819</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-643">442</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-644">8.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-99" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-645">9.25</ix:nonNumeric></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-646">7.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-647">7.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-648" escape="true"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term lease costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="f-649">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-650">151</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="3" id="f-651">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="f-652">303</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-653">358</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-654">316</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-655">717</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-656">595</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-657">358</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-658">467</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-659">717</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-660">898</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-661" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of June&#160;30, 2024, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.424%"><tr><td style="width:1.0%"/><td style="width:82.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.893%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Remainder of 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-662">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-663">1,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-664">1,952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-665">1,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-666">2,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="brns:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-667">7,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-668">16,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-669">4,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-670">12,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BARINTHUS BIOTHERAPEUTICS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(UNAUDITED)</span></div></div><ix:continuation id="f-624-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. However, from time to time, we could be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div></ix:continuation><div id="if929189504494c2da09ff9dfd66b833d_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-671" continuedAt="f-671-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-671-1" continuedAt="f-671-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2024, the Company incurred expenses of $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-672">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-673">0.5</ix:nonFraction> million, respectively (three and six months ended June&#160;30, 2023: $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-674">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="f-675">0.4</ix:nonFraction> million, respectively) from Oxford University Innovation Limited which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford. </span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-671-2">During the three and six months ended June&#160;30, 2024, the Company recognized license revenue of <ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-676"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-677">nil</ix:nonFraction></ix:nonFraction> (three and six months ended June&#160;30, 2023: $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-678">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-679">0.8</ix:nonFraction> million, respectively), from Oxford University Innovation Limited.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-14</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes appearing elsewhere in this unaudited Quarterly Report on Form 10-Q and our audited financial statements and related notes thereto for the year ended December 31, 2023 included in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on March 20, 2024. Some of the information contained in this discussion and analysis or set forth elsewhere in this report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, uncertainties, and assumptions. Factors that might cause future results to differ materially from those projected in the forward-looking statements include, but are not limited to, those set forth in our Annual Report on Form 10-K and in other filings with the SEC.</span></div><div id="if929189504494c2da09ff9dfd66b833d_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. Helping patients and their families is the guiding principle at the heart of Barinthus Bio. We stand apart through our focused pipeline, built around proprietary platform technologies; viral vector-based, consisting of ChAdOx and MVA; and synthetic, consisting of SNAP-Tolerance Immunotherapy, or SNAP-TI. These platforms are enabling us to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells and guide them towards a healthy balance. Our immunotherapeutic candidates are designed to work by increasing disease-specific CD8+ T cell activity in the case of chronic infectious diseases, or by dampening CD4+ and CD8+ T cells, and increasing regulatory T cells in autoimmunity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Following our strategic pipeline update in June 2024, we are prioritizing a pipeline of two key product candidates in infectious disease and autoimmunity that harness our proprietary viral vector and synthetic platform technologies. These include: VTP-300, a Phase 2 immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA; and VTP-1000, our first preclinical autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have two other programs in infectious disease and cancer: VTP-200, a Phase 2 nonsurgical product candidate for persistent high-risk HPV; and VTP-850, a second-generation Phase 2 immunotherapeutic candidate designed to treat recurrent prostate cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alongside these proprietary programs, we have partnerships in place to advance three additional prophylactic and therapeutic product candidates including VTP-500 for Middle East Respiratory Syndrome, or MERS, VTP-400 for Zoster and VTP-600 for multiple cancer indications including Non-Small Cell Lung Cancer, or NSCLC, and Squamous Esophageal Cancer. We also co-invented a COVID-19 vaccine with the University of Oxford, which was exclusively licensed worldwide to AstraZeneca. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our proven scientific expertise, diverse portfolio and focus on product candidate development uniquely positions us to navigate towards delivering treatments for patients with chronic infectious diseases and autoimmune-disorders that have a significant impact on their every day lives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2022, we filed a Registration Statement on Form S-3, as amended, or the Shelf, with the Securities and Exchange Commission in relation to the registration and potential future issuance of ordinary shares, including ordinary shares represented by American Depositary Shares, or ADSs, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million. The Shelf was declared effective on August 17, 2022. We also simultaneously entered into a sales agreement with Jefferies LLC, as sales agent, providing for the offering, issuance and sale by us of up to an aggregate of $75.0 million of our ordinary shares represented by ADSs from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. As of June&#160;30, 2024, we have sold 1,530,515 ordinary shares represented by ADSs under the sales agreement, amounting to net proceeds of $3.8 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred net losses each year since inception through to December 31, 2021. For the year ended December 31, 2022, we generated net income of $5.3 million, primarily as a result of revenues arising from AstraZeneca sales of Vaxzevria and our agreement with OUI. For the year ended December 31, 2023, we generated a net loss of $73.4 million. For the three and six months ended June&#160;30, 2024, we incurred a net loss of $17.0 million and $32.5 million, respectively. As of June&#160;30, 2024, we had an accumulated deficit of $209.0 million and we do not currently expect positive cash flows from operations in the foreseeable future. We expect to incur net operating losses for at least the next several years as we advance our product candidates through clinical development, seek regulatory approval, prepare for approval, and in some cases proceed to commercialization of our product candidates, as well as continue our research and development efforts and invest to establish a commercial manufacturing facility, as and when appropriate. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate, or know the nature, timing and estimated costs of all of the efforts that will be necessary to complete the development of any of our product candidates that we develop through our programs. We are also unable to predict when, if ever, material net cash inflows will commence from sales of product candidates we develop, if at all. This is due to the numerous risks and uncertainties associated with developing product candidates to approval and commercialization, including the uncertainty of:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of investigational new drug applications, or INDs, for our planned clinical trials or future clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful and timely enrollment and completion of clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data from our clinical program supporting approvable and commercially acceptable risk/benefit profiles for our product candidates in the intended populations;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and maintenance of necessary regulatory and marketing approvals from applicable regulatory authorities, in the light of the commercial environment then existent;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability and successful procurement of raw materials required to manufacture our products for clinical trials, scale-up of our manufacturing processes and formulation of our product candidates for later stages of development and commercial production;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing either our own manufacturing capabilities or satisfactory agreements with third-party manufacturers for clinical supply for later stages of development and commercial manufacturing;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into collaborations where appropriate to further the development of our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining intellectual property and trade secret protection or regulatory exclusivity for our product candidates as well as qualifying for, maintaining, enforcing and defending such intellectual property rights and claims;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully launching or assisting with the launch of commercial sales of our product candidates following approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of each product&#8217;s benefits and uses by patients, the medical community and third-party payors following approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse events experienced with our product candidates in development;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining a continued acceptable safety profile of the&#8201;product candidates following approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors if necessary or desirable; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate, in either direction. Furthermore, our operating plans may change in the future owing to research outcomes or other opportunities, and we may need additional funds to meet operational needs and capital requirements associated with such altered operating plans. Unless and until we can generate a substantial amount of revenue from our product candidates, if approved, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. Based on our research and development plans, we expect that our existing cash, cash equivalents and restricted cash and other financial resources, will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2026. These estimates are based on assumptions that may prove to be wrong, and we could use our available capital resources more quickly than we expect. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we raise additional funds through collaborations, strategic alliances, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="if929189504494c2da09ff9dfd66b833d_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:12pt;text-align:center"><img src="brns-20240630_g1.jpg" alt="Q2 2024 10Q Pipeline.jpg" style="height:364px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These are estimated timelines only and our pipeline may be subject to change.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VTP-300: Hepatitis B</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, we announced updated data from two ongoing clinical trials in people with chronic hepatitis B, or CHB, at the European Association for the Study of the Liver, or EASL, Congress 2024. The presentations included updated interim data from the Phase 2b clinical trial (HBV003), as well as new interim data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in partnership with Arbutus Biopharma, both in people with CHB receiving ongoing standard of care nucleos(t)ide analogue, or NUC, therapy.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interim HBV003 data: VTP-300 and Low-dose Nivolumab</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim data from the HBV003 trial showed that nearly 20% of participants across the groups had undetectable HBsAg and this was maintained for &#8805;16 weeks in the two cases who have reached that timepoint. 76% of participants were eligible for NUC discontinuation and 71% of those who did discontinue remained off NUCs at time of data cutoff on April 15, 2024. 67% of participants across all groups assessed for NUC discontinuation had HBsAg &lt;10 IU/mL at Week 24 or later. Robust T cell responses were observed to all VTP-300 encoded antigens. There were no Serious Adverse Events, or SAEs, Grade 3 or 4 Adverse Events, or AEs, related to treatment. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interim IM-PROVE II data: imdusiran and VTP-300</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interim data from the IM-PROVE II clinical trial showed that at week 72, 20% of participants had undetectable HBsAg in the VTP-300 treatment group compared to none in the placebo group. 84% of participants in the VTP-300 treatment group were eligible for NUC discontinuation and 88% of those who did discontinue remained off NUCs, compared to the placebo group showing 52% of participants eligible for NUC discontinuation and 80% remaining off NUCs at time of data cutoff on April 12, 2024. Robust reductions of HBsAg were observed during the imdusiran lead-in period with 95% of participants achieving HBsAg &lt;100 IU/mL before undergoing dosing in the VTP-300 treatment or placebo groups at week 24, with a statistically significant difference (p&lt;0.05) in HBsAg levels between the VTP-300 treatment and placebo groups recorded at week 72. Treatment with imdusiran and VTP-300 was generally well-tolerated, with no SAEs or treatment discontinuations reported. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A further data update on both trials showing more participants progressed through more time points, as well as preliminary results from IM-PROVE II, is expected in the fourth quarter of 2024.  </span></div><div id="if929189504494c2da09ff9dfd66b833d_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Israel and Gaza Conflict and Ukraine Crisis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In respect of the international conflict in Israel and Gaza and situation in Ukraine, we have no operations or suppliers based in Israel or Gaza, or in Ukraine, Belarus or Russia, and as a result, as of the date of this Quarterly Report on Form 10-Q, we believe the impact on our business, operations and financial condition will be minimal.</span></div><div id="if929189504494c2da09ff9dfd66b833d_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Global Economic Conditions and Inflationary Pressures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Instability in global economic conditions and geopolitical matters, as well as volatility in financial markets, could have a material adverse effect on our results of operations and financial condition. These inflationary pressures and volatile interest rates in the United States, the United Kingdom and elsewhere have given rise to increasing concerns that the U.S., U.K. and other economies are now in, or may enter, economic recession. Sustained inflationary pressures, volatile interest rates, an economic recession or continued or intensified disruptions in the global financial markets could adversely affect our future financing capability or ability to access the capital markets. Additionally, we may incur future increases in operating costs due to additional inflationary increases.</span></div><div id="if929189504494c2da09ff9dfd66b833d_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Operating Results</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from direct product sales and do not expect to do so in the near future, if at all. Most of our revenue to date has been derived from the OUI License Agreement Amendment with OUI relating to Vaxzevria.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into the OUI License Agreement Amendment with OUI in respect of our rights to use the ChAdOx1 technology in COVID-19 vaccines to facilitate the license of those rights by OUI to AstraZeneca. Under this agreement, we are entitled to receive from OUI a share of payments, including royalties and milestones, received by OUI from AstraZeneca in respect of this vaccine. In March 2022, we were notified by OUI of the commencement of revenue relating to commercial sales of Vaxzevria. Our revenue for the three and six months ended June&#160;30, 2024 was nil (three and six months ended June&#160;30, 2023: $0.3 million and $0.8 million, respectively), representing the amounts we have been notified of as due by OUI to date and an estimate of future receipts, constrained to the extent that it is probable that a significant reversal of revenue would not occur. In May 2024, AstraZeneca announced its planned withdrawal of Vaxzevria as demand had declined, and therefore we do not expect to receive any future revenue relating to commercial sales of Vaxzevria. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses since inception have consisted of research and development costs and general and administrative costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have focused significant resources on our research and development activities, including establishing and building on our adenovirus platform, further enhancing our in-licensed ChAdOx1, ChAdOx2 and MVA vectors, developing a new next-generation adenoviral vector, acquiring new technology platforms including SNAP, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conducting preclinical studies, developing various manufacturing processes, initiating the clinical trials for VTP-200, VTP-300, VTP-600 and VTP-850 and readying VTP-500, and VTP-1000 for clinical trials. Research and development activities account for a large portion of our operating expenses, and we expect research and development expenses to increase in the future. Research and development costs are expensed as incurred. These costs include:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">salaries, benefits, and other related costs, including share-based compensation, for personnel engaged in research and development functions;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred in connection with the development of our programs including preclinical studies and clinical trials of our product candidates, under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations, or CROs;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing drug products for use in preclinical development and clinical trials, including agreements with third parties, such as contract manufacturing organizations, consultants and contractors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory costs; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative expenses consist primarily of personnel-related expenses, including share-based compensation, in our executive, finance, business development and other administrative functions. Other general and administrative expenses include consulting fees and professional service fees for auditing, tax and legal services, rent expenses related to our offices, depreciation, foreign exchange gains and losses on our cash balances, other central non-research costs and changes in the fair value of contingent consideration. When determining the fair value of contingent consideration, significant judgment is used to determine the probability of success of achievement of the technology and clinical milestones and the date of the expected milestone. We expect our general and administrative expenses to continue to increase in the future as we expand our operating activities in both the United Kingdom and United States and potentially prepare for manufacturing and/or commercialization of our current and future product candidates. These costs will increase if our headcount rises to allow full support for our operations as a public company, including increased expenses related to legal, accounting, regulatory and tax-related services associated with maintaining compliance with requirements of the Nasdaq Global Market and the Securities and Exchange Commission, directors&#8217; and officers&#8217; liability insurance premiums and investor relations activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Operating Income </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating incomes include the CEPI Funding Agreement pursuant to which CEPI will provide funding to us to advance the development of VTP-500, our vaccine candidate against MERS. When there is reasonable assurance that we will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, grant income is recognized as other operating income on a gross basis in the condensed consolidated statements of operations and comprehensive loss on a systematic basis over the periods in which we recognize expenses for the related costs for which the grants are intended to compensate. Payments received in advance of incurring reimbursable expenses are recorded as deferred income. Any remaining unused amounts of the cash payments received on the balance sheets will be disclosed as restricted cash in the notes of the condensed consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income/(Expense)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income results primarily from the interest earned on our short-term cash deposits and cash balances held by Barinthus Biotherapeutics (UK) Limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense results primarily from the asset retirement obligation discounted over the length of the relevant lease.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development incentives contain payments receivable from the United Kingdom government related to corporation tax relief on research and development projects in the United Kingdom. We account for such relief received as other income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We benefit from the United Kingdom research and development tax credit regime, being the Small and Medium-sized Enterprises R&amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to us by third parties, the Research and Development Expenditure Credit program, or RDEC Program.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until March 2023 under the SME program, we were able to surrender some of our trading losses that arise from qualifying research and development activities for a cash rebate of up to 33.4% of such qualifying research and development expenditure. Qualifying expenditures largely comprise employment costs for research staff, consumables, outsourced contract research organization costs and utilities costs incurred as part of research projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.7%. A large portion of costs relating to research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From April 2023, under the SME Program, the enhanced rate of deduction has decreased from 230% to 186%, the SME credit rate has been reduced from 14.5% to 10% (except for R&amp;D intensive SMEs, which will benefit from a credit rate of 14.5%), and our SME cash rebate has been reduced from an effective rate of 33.4% to 18.6% (or 27.0% for R&amp;D intensive SMEs) and from 21.7% to 12.1% for subcontractors. We are assessing if we can claim under the loss-making R&amp;D Intensive Scheme for SMEs, which will provide benefits consistent with those claimed under the previous SME Program.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to continue to claim research and development tax credits under the SME program in the future because we may no longer qualify as a small or medium-sized company. In addition, the EU State Aid cap limits the total aid claimable in respect of a given project to &#8364;7.5 million which may impact our ability to claim R&amp;D tax credits in future. Further, the U.K. Finance Act of 2021 introduced a cap on payable credit claims under the SME Program in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total Pay As You Earn, or PAYE, and National Insurance Contributions, or NICs, liability, subject to an exception which prevents the cap from applying. That exception requires us to create, take steps to create or manage intellectual property, as well as having qualifying research and development expenditure in respect of connected parties, which does not exceed 15% of the total claimed. If such an exception does not apply, this could restrict the amount of payable credit that we claim.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unsurrendered UK losses may be carried forward indefinitely to be offset against future taxable profits, subject to numerous utilization criteria and restrictions. The amount that can be offset each year is limited to &#163;5.0 million plus an incremental 50% of UK taxable profits.</span></div><div id="if929189504494c2da09ff9dfd66b833d_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis of financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue, income and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to fair value of contingent consideration and impairment of goodwill and intangible assets. Management bases its estimates on historical experience and on various other market specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements and understanding and evaluating our reported financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying amounts may not be recoverable. We have elected to assess goodwill for impairment by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis of determining whether it is necessary to perform the quantitative goodwill impairment test. We have one reporting unit. Accordingly, our review of goodwill impairment indicators is performed at the entity-wide level. This requires us to assess and make judgments regarding a variety of factors, including clinical data results, business plans, anticipated future cash flows, economic projections and other market data. Because there are inherent uncertainties involved in these factors, significant differences between these estimates and actual results could result in future impairment charges and could materially impact our future financial results. The goodwill of $12.2 million recognized as of June&#160;30, 2024 related to the acquisition of Avidea on December 10, 2021. The Company identified qualitative indicators of impairment due to a sustained decline in the price of the Company&#8217;s ADSs, whereby the market capitalization continues to be below the value of the net assets of the Company, and the plans announced in June 2024 to prioritize its pipeline to focus on the development of VTP-300 for chronic Hepatitis B virus infection and VTP-1000 in celiac disease. Therefore, the Company performed both an interim qualitative and quantitative assessment as of June&#160;30, 2024 to determine whether it was more likely than not that the fair value of the reporting unit is less than its carrying amount. Based on this assessment, management determined it is not more likely than not that the fair value of the reporting unit is less than its carrying amount and hence no impairment loss related to goodwill has been recognized related to goodwill for the three and six months ended June&#160;30, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to be held and used, including property and equipment, intangible assets and operating lease right-of-use assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable. Evaluation of recoverability is first based on an estimate of undiscounted future cash flows resulting from the use of the asset or asset group and its eventual disposition. In the event such cash flows are not expected to be sufficient to recover the carrying amount of the asset or asset group, the assets are written down to their estimated fair values. In June 2024, the Company announced plans to prioritize its pipeline to focus on the development of VTP-300 for chronic Hepatitis B virus infection and VTP-1000 in celiac disease. Given this change in Company focus, management identified circumstances that could indicate that the carrying amount of the Company's intangible assets may not be recoverable. Therefore, the Company performed both a qualitative and quantitative assessment as of June&#160;30, 2024 and determined that the carrying amount of the Company's intangible assets are recoverable, hence no impairment loss related to intangible assets has been recorded during the three and six months ended  June&#160;30, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize a contingent consideration liability related to the acquisition of Avidea. The liability is remeasured to fair value at each reporting date until the contingency is resolved. The fair value of the contingent consideration is a Level 3 valuation determined using significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Changes in fair value are recognized in general and administrative expenses in the condensed consolidated statement of operations and comprehensive loss. Avidea&#8217;s stockholders may be entitled to receive an aggregate of up to $40.0 million in additional payments, payable in a combination of cash and ADSs, upon the achievement of certain milestones. This contingent consideration is included within the purchase price and is recognized at its fair value on the acquisition date, and subsequently remeasured to fair value at each reporting date until the contingency is resolved. Changes in fair value are recognized in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. The fair value of contingent consideration is based on the probability of pursuit of the activity associated with the milestone, the probability of success of the achievement of the milestone, the expected date of milestone achievement and applying the relevant discount rate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and 2023</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the significant components of our results of operations (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">License revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">334&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(334)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,927)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(7,808)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(18,286)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(26,337)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">693&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income tax</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16,950)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24,960)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,010&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16,943)</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,824)</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Includes license revenue from related parties for the three months ended June&#160;30, 2024 of nil and for the three months ended June&#160;30, 2023 of $0.3 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the three months ended June&#160;30, 2024 and 2023 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Direct research and development expenses by program:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-200 HPV</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,454)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-300 HBV</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(723)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-500 MERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">304&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">304&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-600 NSCLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-850 Prostate cancer</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">242&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">172&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-1000 Celiac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">3 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other and earlier stage programs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">908&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">701&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total direct research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,438&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,634&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,196)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indirect research and development expenses:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Personnel-related (including share-based compensation)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility related</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">202&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other indirect costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total indirect research and development expenses</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,224&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,909&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,315&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,543&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,881)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">The development of VTP-500 is funded pursuant to an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">The VTP-600 NSCLC Phase 1/2a trial is sponsored by Cancer Research UK.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses related to VTP-1100 HPV Cancer were presented together with VTP-1000 Celiac in the prior period comparative, because our SNAP product candidates were both preclinical. Expenses related to VTP-1100 HPV Cancer are now included in "Other and earlier stage programs," because we are deferring the planned IND application for VTP-1100 in HPV cancer and we are preparing to initiate the clinical trial for VTP-1000 Celiac.</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses for the three months ended June&#160;30, 2024 and 2023 were $11.7 million and $13.5 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct expenses for the three months ended June&#160;30, 2024 and 2023 were $6.4 million and $9.6 million, respectively, and consisted of outside services, consultants, laboratory materials, clinical trials, manufacturing of clinical trial materials, as well as costs for external preclinical services and sample testing. Of the $3.2 million decrease, $1.5 million pertains to a reduction in clinical trial and manufacturing development costs for the VTP-200 HPV program following the completion of the Phase 1b/2 APOLLO (HPV001) clinical trial in the first quarter of 2024 and $1.6 million pertains to the reduction in pre-clinical studies related to the SNAP platform following the IND acceptance for VTP-1000 in celiac disease, and the deprioritization of VTP-1100 for HPV cancer announced earlier in 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indirect research and development expenses for the three months ended June&#160;30, 2024 and 2023 were $5.2 million and $3.9 million, respectively. The increase of $1.3 million relates primarily to an increase in headcount and the provision for severance costs primarily in the United Kingdom following the Company&#8217;s announcement in June 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to prioritize its pipeline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and reduce the size of the workforce. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the three months ended June&#160;30, 2024 and 2023 were $7.2 million and $13.1 million, respectively. The decrease of $5.9 million relates primarily to a decrease of $4.1 million in the net loss on foreign exchange, a $0.6 million decrease in professional costs due to a reduction in activity compared to the prior period, a decrease in insurance costs of $0.6 million due to a reduction in insurance premiums and a decrease in personnel expenses, including share-based payment charges of $0.2 million, primarily due to a reduction in non-cash share-based payment charges.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2024 and 2023, other operating income was $0.6 million and nil, respectively, resulting from the funding provided by CEPI under the Funding Agreement, dated December 20, 2023, entered into by and among us, the Chancellors, Masters and Scholars of the University of Oxford and the CEPI for the development of VTP-500 through Phase 2 clinical trials for the prevention of MERS. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2024 and 2023, interest income was $0.6 million and $0.5 million, respectively, resulting from the interest earned on our short-term cash deposits held by Barinthus Biotherapeutics (UK) Limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2024 and 2023 research and development incentives were $0.7 million and $0.6 million, respectively. Such research and development incentives relate to corporation tax relief on research and development projects incentive programs in the United Kingdom. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax benefit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June&#160;30, 2024 and 2023, the tax benefit was $0.01 million and $1.1 million respectively, which primarily relates to movements in deferred tax.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the six months ended June 30, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and 2023</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the significant components of our results of operations (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">License Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">802&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(802)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(570)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48,623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12,641)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(35,200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(47,821)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income/(expense)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other income, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss before income tax</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(32,507)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(43,699)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,192&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(32,463)</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(42,047)</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Includes license revenue from related parties for the six months ended June&#160;30, 2024 of nil and for the six months ended June&#160;30, 2023 of $0.8 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses for the six months ended June&#160;30, 2024 and 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Direct research and development expenses by program:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-200 HPV</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,636&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,539)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-300 HBV</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(928)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-500 MERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-600 NSCLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-850 Prostate cancer</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">592&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">457&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">VTP-1000 Celiac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">3 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other and earlier stage programs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">712&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total direct research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,277&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15,432&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(3,155)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Indirect research and development expenses:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Personnel-related (including share-based compensation)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Facility related</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">732&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other indirect costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total indirect research and development expenses</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,510&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,925&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,585&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22,787&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(570)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">The development of VTP-500 is funded pursuant to an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">The VTP-600 NSCLC Phase 1/2a trial is sponsored by Cancer Research UK.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses related to VTP-1100 HPV Cancer were presented together with VTP-1000 Celiac in the prior period comparative, because our SNAP product candidates were both preclinical. Expenses related to VTP-1100 HPV Cancer are now included in "Other and earlier stage programs," because we are deferring the planned IND application for VTP-1100 in HPV cancer and we are preparing to initiate the clinical trial for VTP-1000 Celiac.</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses for the six months ended June&#160;30, 2024 and 2023 were $22.8 million and $23.4 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct expenses for the six months ended June&#160;30, 2024 and 2023 were $12.3 million and $15.4 million, respectively, and consisted of outside services, consultants, laboratory materials, clinical trials, manufacturing of clinical trial materials, as well as costs for external preclinical services and sample testing. Of the $3.2 million decrease, $1.5 million pertains to a reduction in clinical trial and manufacturing development costs for the VTP-200 HPV program following the completion of the Phase 1b/2 APOLLO (HPV001) clinical trial in 2024 and $1.8 million pertains to the reduction in pre-clinical studies related to the SNAP platform following the IND acceptance for VTP-1000 in celiac disease, and the deprioritization of VTP-1100 for HPV cancer announced earlier in 2024. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indirect research and development expenses for the six months ended June&#160;30, 2024 and 2023 were $10.5 million and $7.9 million, respectively. Of the $2.6 million increase, $2.1 million relates to an increase in headcount and the provision for severance costs across our locations in the United Kingdom and United States following the Company&#8217;s announcement in June 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to prioritize its pipeline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reduce the size of the workforce.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the six months ended June&#160;30, 2024 and 2023 were $13.2 million and $25.3 million, respectively. The decrease of $12.1 million relates primarily to a gain of $1.1 million on foreign exchange for the six months ended June&#160;30, 2024, compared to a loss of $7.7 million for the six months ended June&#160;30, 2023, a decrease in personnel expenses, including share-based payment charges of $1.1 million, primarily due to a reduction in non-cash share-based payment charges, a decrease in insurance costs of $1.4 million due to a reduction in insurance premiums, a decrease of $0.4 million in professional costs due to reduced activity compared to the prior period and a decrease of $0.3 million in facility related costs due to the relocation to our new U.S. laboratory in June 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Operating Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2024 and 2023, other operating income was $0.8 million and nil, respectively, resulting from the funding provided by CEPI under the Funding Agreement, dated December 20, 2023, entered into by and among us, the Chancellors, Masters and Scholars of the University of Oxford and the CEPI for the development of VTP-500 through Phase 2 clinical trials for the prevention of MERS. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2024 and 2023, interest income was $1.4 million and $2.1 million, respectively, resulting from the interest earned on our short-term cash deposits held by Barinthus Biotherapeutics (UK) Limited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2024 and 2023 research and development incentives were $1.3 million and $1.7 million, respectively. Such research and development incentives relate to corporation tax relief on research and development projects incentive programs in the United Kingdom. The decrease of $0.4 million is due to reduced expenses eligible for the research and development corporation tax relief, as well as a decrease in the enhanced rate of deduction and credit rate under the scheme, effective from April 2023. We are assessing if we can claim under the loss-making R&amp;D Intensive Scheme for SMEs, which will provide benefits consistent with those claimed under the previous SME Program.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax benefit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2024 and 2023, the tax benefit was $0.04 million and $1.7 million respectively, which primarily relates to movements in deferred tax.</span></div><div id="if929189504494c2da09ff9dfd66b833d_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have funded our operations primarily through private and public placements of our ordinary and preferred shares as well as from grants and research incentives, various agreements with public funding agencies, the issuance of convertible loan notes, and most recently from upfront, royalty and milestone payments from OUI in connection with the OUI License Agreement Amendment. Through June&#160;30, 2024, we received gross proceeds of approximately $328.8 million from the issuance of our ordinary and preferred shares and convertible loan notes. As of June&#160;30, 2024, we had cash, cash equivalents and restricted cash of $117.8 million. Recent financing and corporate milestones include the following:</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Between July 2020 and November 2020, we raised gross proceeds of $41.2 million from the issuance of convertible loan notes;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2021, we raised gross proceeds of $125.2 million from the issuance of our series B shares;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2021, we raised gross proceeds of $110.5 million from the initial public offering of our ordinary shares on NASDAQ;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Between April 2022 and June 2023, we received $44.5 million of cash from OUI for the commercial sales of Vaxzevria;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Between December 2022 and June 2024, we raised net proceeds of $3.8 million from the issuance of shares represented by ADSs through &#8220;at-the-market&#8221; offerings under the sales agreement with Jefferies LLC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 9, 2022, we filed the Shelf, with the Securities and Exchange Commission in relation to the registration and potential future issuance of ordinary shares, including ordinary shares represented by ADSs, debt securities, warrants and/or units of any combination thereof in the aggregate amount of up to $200.0 million. The Shelf was declared effective on August 17, 2022. We also simultaneously entered into a sales agreement with Jefferies LLC, as sales agent, providing for the offering, issuance and sale by us of up to an aggregate of $75.0 million of our ordinary shares represented by ADSs from time to time in &#8220;at-the-market&#8221; offerings under the Shelf. As of June&#160;30, 2024, we have sold 1,530,515 ordinary shares represented by ADSs under the sales agreement amounting to net proceeds of $3.8 million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect positive cash flows from operations in the foreseeable future, if at all. In most periods, we have incurred operating losses as a result of ongoing efforts to develop our immunotherapy platforms and our product candidates, including conducting ongoing research and development, preclinical studies, clinical trials, providing general and administrative support for these operations and developing our intellectual property portfolio. We expect to continue to incur net negative cash flows from operations for at least the next few years as we progress clinical development, seek regulatory approval, prepare for and, if approved, proceed to manufacture and commercialization of our most advanced product candidates. Operating profits may arise earlier if programs are licensed or sold to third parties before final approval, but this cannot be guaranteed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the primary sources and uses of cash (in thousands) for each period presented:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,828)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(20,131)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(500)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5,530)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.2pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Effect of exchange rates on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(849)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,589&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net decrease in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24,316)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(21,355)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2024, net cash used in operating activities was $23.8 million, primarily resulting from our net loss of $32.5 million adjusted by share based compensation of $2.8 million, depreciation and amortization of $2.9 million, non-cash lease expenses of $0.7 million, unrealized foreign exchange gain of $0.6 million and changes in our operating assets and liabilities, net, of $2.7 million primarily related to a $2.1 million increase in accounts payable and accrued expenses, a $0.8 million increase in deferred revenue, and a $0.8 million decrease in operating lease liabilities.</span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended June&#160;30, 2023, net cash used in operating activities was $20.1 million, primarily resulting from our net loss of $42.0 million adjusted by share based compensation of $4.2 million, depreciation and amortization of $2.5 million, non-cash lease expense of $0.6 million, foreign exchange gain of $7.1 million, contingent consideration adjustment of $0.3 million, deferred tax benefit of $1.7 million and changes in our operating assets and liabilities, net of $8.9 million primarily related to the receipt of lease incentives for Barinthus NA and OUI receivable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2024 and 2023, cash used in investing activities was $0.5 million and $5.5 million, respectively. These amounts resulted primarily from capital expenditures related to leasehold improvements on our new office and laboratory facilities  in Germantown, Maryland, United States, that we relocated to in June 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the six months ended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June&#160;30, 2024 and 2023, cash provided by financing activities was $0.9 million and $1.7 million, respectively. These amounts primarily related to net proceeds received from the issuance of ordinary shares through the &#8220;at-the-market&#8221; sales agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effect of exchange rates on cash, cash equivalents and restricted cash</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2024 and 2023, the effect of foreign exchange on cash, cash equivalents and restricted cash was a loss of $0.8 million and a gain of $2.6 million respectively, primarily as a result of fluctuations between the United States dollar and pound sterling exchange rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have devoted substantially all of our resources to organizing and staffing our company, business planning, raising capital, undertaking preclinical studies and conducting clinical trials of our product candidates. As a result, we have </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred losses in each year since our inception in 2016, through to December 31, 2021. We were profitable in 2022, however we have negative operating cash flows for the period ended June&#160;30, 2024. As of June&#160;30, 2024, we had an accumulated deficit of $209.0 million. We expect to continue to incur significant losses and negative cash flows from operations for the foreseeable future. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pursue the clinical and preclinical development of our current product candidates;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use our technologies to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing authorizations for product candidates that successfully complete clinical trials, if any;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract, hire and retain additional clinical, regulatory, quality control and other scientific personnel;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish our manufacturing capabilities through third parties or by ourselves and scale-up manufacturing to provide adequate supply for clinical trials and commercialization, including any manufacturing finishing and logistics personnel;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operational, financial and management systems and increase personnel appropriately, including personnel to support our manufacturing and commercialization efforts and our operations as a public company;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand, enforce, and protect our intellectual property portfolio as appropriate;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish sales, marketing, medical affairs and distribution teams and infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other companies, product candidates and technologies; and</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting and other expenses in operating our business, including office expansion and the additional costs associated with operating as a public company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditure to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other factors that may adversely affect our business. The size of our future net losses will depend on the rate of future growth of our expenses combined with our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital unless and until eliminated by revenue growth.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require substantial additional financing in the future to meet any such unanticipated factors and a failure to obtain this necessary capital could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our foundation, we have invested a significant portion of our efforts and financial resources in research and development activities for our viral vector platform (ChAdOx and MVA), acquisition of additional complementary platforms such as SNAP-TI, development of new technologies in house, and our product candidates derived from these technologies. Preclinical studies and especially clinical trials and additional research and development activities will require substantial funds to complete. We believe that we will continue to expend substantial resources for the foreseeable future in connection with the development of our current product candidates and programs as well as any future product candidates we may elect to pursue, as well as the gradual gaining of control over our required manufacturing capabilities and other corporate functions. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals, and potentially in-house manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise as outlined above. Because the outcome of any preclinical study or clinical trial is uncertain and the rate of change of third-party costs is also unpredictable, we cannot reasonably estimate now the actual amounts which will be necessary to complete the development and commercialization of our current or future product candidates successfully.</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements may depend on many factors, including:</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of researching and developing our current and future product candidates and programs, and of conducting preclinical studies and clinical trials;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we may pursue, and of other indications for our current product candidates that we may pursue;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the stability, scale and yield of future manufacturing processes as we scale-up production and formulation of our product candidates either internally or externally for later stages of development and commercialization;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of success achieved and the costs involved in obtaining regulatory and marketing approvals and developing our ability to establish license or sale transactions and/or sales and marketing capabilities, if any, for our current and future product candidates if clinical trials and approval processes are successful;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaborations with CEPI, Oxford University, Arbutus, CanSino, CRUK and the Ludwig Institute and any future collaboration partners;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations, strategic licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost to the company of commercialization activities for our current and future product candidates that we may take on, whether alone or with a collaborator;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent and other intellectual property claims, including litigation costs and the outcome of such litigation;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of sales of, or royalties or other income from, our future products, if any; and</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence and success or otherwise of competing oncology and infectious disease therapies and other market developments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate, in either direction. Furthermore, our operating plans may change in the future owing to research outcomes or other opportunities, and we may need additional funds to meet operational needs and capital requirements associated with such altered operating plans. Unless and until we can generate a substantial amount of revenue from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our research and development plans, we expect that our existing cash, cash equivalents and restricted cash and other financial resources, will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2026. These estimates are based on assumptions that may prove to be wrong, and we could use our available capital resources more quickly than we expect.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease, Purchase, and Other Obligations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operating lease obligations related to our property, plant and equipment. The obligations related to both short- and long-term lease arrangements are set forth in Note 15 &#8220;Commitment and Contingencies&#8221; to our condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with CROs and other third parties for clinical trials and preclinical research studies and testing. These contracts are generally cancellable by us upon prior notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancellable obligations of our service providers, up to the date of cancellation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contingent payment obligations that we may incur upon achievement of clinical, regulatory and commercial milestones, as applicable, or royalty payments that we may be required to make under our licenses; however, the amount, timing and likelihood of such payments are not known as of June&#160;30, 2024.</span></div><div id="if929189504494c2da09ff9dfd66b833d_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012, as amended, or the JOBS Act. As an emerging growth company, we may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of the closing of our IPO, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our ADSs held by non-affiliates exceeded $700.0 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></div><div id="if929189504494c2da09ff9dfd66b833d_115"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements.</span></div><div id="if929189504494c2da09ff9dfd66b833d_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosure About Market Risk.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency and Currency Translation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the risk of fluctuations in foreign currency exchange rates, specifically with respect to the euro, pound sterling, Swiss franc and Australian dollar. Our reporting currency is the United States dollar, and the functional currency of Barinthus Biotherapeutics plc and its consolidated subsidiaries, Barinthus Biotherapeutics (UK) Limited and Vaccitech Oncology Limited, is the pound sterling. The functional currency of our wholly owned foreign subsidiary, Barinthus Biotherapeutics North America, Inc. is the United States dollar. The functional currency of our wholly owned foreign subsidiary, Barinthus Australia Pty, is the Australian dollar. The functional currency of our wholly owned foreign subsidiary, Barinthus Biotherapeutics S.R.L, is the euro. The functional currency of our wholly owned foreign subsidiary, Barinthus Biotherapeutics Switzerland GmbH, is the Swiss franc. Our cash, cash equivalents and restricted cash as of June&#160;30, 2024 consisted primarily of cash balances held by Barinthus Biotherapeutics (UK) Limited in United States dollars.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are translated into United States dollars at the exchange rate in effect on the balance sheet date. Revenue and expenses are translated at the average exchange rate in effect during the period. Translation adjustments are included in the condensed consolidated Balance Sheets as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in operating expenses, net in the condensed consolidated Statements of Operations and Comprehensive Loss as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant operating costs in the U.K. and face exposure to changes in the exchange ratio of the United States dollar and the pound sterling arising from expenses and payables at our U.K. operations that are settled in pound sterling. For the six months ended June 30, 2024, an average 10% weakening in the United States dollar relative to the pound sterling would have resulted in a material change to our current and projected expenses denominated in pound sterling. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently exposed significantly to market risk related to changes in interest rates, as we have no significant interest-bearing liabilities. We had cash, cash equivalents and restricted cash of $117.8 million as of June&#160;30, 2024, which were primarily held as account balances with banks in the United Kingdom, United States and Australia. A hypothetical 10% relative change in interest rates during any of the periods presented would not have had a material impact on our condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule&#8239;13a-15(e) and 15d-15(e) under the Exchange Act) as of June&#160;30, 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The term &#8220;disclosure controls and procedures&#8221; means controls and other procedures of a company that are designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that the information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our evaluation, our management, with the participation of our principal executive officer and principal financial officer, has concluded that, as of such date, our disclosure controls and procedures were effective. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three and six months ended June&#160;30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="if929189504494c2da09ff9dfd66b833d_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of June&#160;30, 2024, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="if929189504494c2da09ff9dfd66b833d_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors previously disclosed in our most recent Annual Report on Form 10-K as filed with the SEC on March 20, 2024.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report contains express or implied forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this Quarterly Report are based upon information available to our management as of the date of this Quarterly Report and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost and timing of our product development activities and clinical trials;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, scope or likelihood of regulatory filings and approvals, including timing of Investigational New Drug Application, or IND and Biological License Application filings for our current and future product candidates, and final U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, or other foreign regulatory authority approvals relating to our current and future product candidates;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop and advance our current and future product candidates and programs into, and successfully complete, clinical trials;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish future or maintain current collaborations or strategic relationships;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our current and future product candidates;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any expectations surrounding the payments we could potentially receive pursuant to our collaborations and license agreements;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain, defend and enforce our intellectual property protection for our product candidates, and the scope of such protection;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our manufacturing, commercialization and marketing capabilities and strategy;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future agreements with third parties in connection with the commercialization of our product candidates, if approved, and any other approved products;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and foreign countries;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive companies, technologies and our industry and the success of competing therapies that are or may become available;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain key scientific or management personnel;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain funding for our operations, including funding necessary to complete further development and commercialization of our product candidates;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates of our annual total addressable markets, future revenue, expenses, capital requirements and needs for additional financing;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations about market trends;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to anticipate and overcome challenges posed to the conduct of our business in the event of a global pandemic or similar event;</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global economic and political developments on our business, including rising or sustained high inflation and capital market disruptions, the conflict in Ukraine, the conflict in Israel and Gaza, disruptions in the banking industry, economic sanctions and economic slowdowns or recessions that may result from such developments; and</span></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You should read this Quarterly Report and the documents that we reference in this Quarterly Report with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements in this Quarterly Report by these cautionary statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Unless the context otherwise requires, reference in this Quarterly Report to the terms &#8220;Barinthus Bio,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar designations refer to Barinthus Biotherapeutics plc and, where appropriate, our wholly-owned subsidiaries. As used herein, all references before November 7, 2023 to (i) Barinthus Biotherapeutics plc shall refer to Vaccitech plc, (ii) Barinthus Biotherapeutics (UK) Limited shall refer to Vaccitech (UK) Limited, (iii) Barinthus Biotherapeutics North America, Inc., or Barinthus Bio NA shall refer to Vaccitech North America, Inc., (iv) Barinthus Biotherapeutics Switzerland GmbH shall refer to Vaccitech Switzerland GmbH (v) Barinthus Biotherapeutics S.R.L. shall refer to Vaccitech Italia S.R.L. and (vi) Barinthus Biotherapeutics Pty Limited shall refer to Vaccitech Australia Pty Limited, after which the name change described herein shall have taken effect.</span></div><div id="if929189504494c2da09ff9dfd66b833d_133"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is information regarding shares of equity securities sold, and options granted, by us during the three and six months ended June&#160;30, 2024 that were not registered under the Securities Act.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Equity Securities</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from Initial Public Offering</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2021, we completed our initial public offering, or the IPO, of 6,500,000 ADSs at a price of $17.00 per ADS for an aggregate offering price of approximately $110.5 million. Morgan Stanley &amp; Co., Jefferies LLC, Barclays Capital Inc., William Blair &amp; Company, L.L.C. and H.C. Wainwright &amp; Co., LLC served as the underwriters of the IPO. The offer and sale of all of the ADSs in the offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-255158), which became effective on April 29, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received aggregate net proceeds from the offering of approximately $102.8 million, after deducting underwriting discounts and commissions, as well as other offering expenses. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in our planned use of the net proceeds from the IPO as described in the final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act.</span></div><div id="if929189504494c2da09ff9dfd66b833d_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;&#160;&#160;Defaults Upon Senior Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div id="if929189504494c2da09ff9dfd66b833d_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div id="if929189504494c2da09ff9dfd66b833d_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160;&#160;&#160;Other Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rule 10b5-1 Trading Plans</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) <ix:nonNumeric contextRef="c-13" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-680"><ix:nonNumeric contextRef="c-13" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-681">adopted</ix:nonNumeric></ix:nonNumeric>, modified, or <ix:nonNumeric contextRef="c-13" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-682"><ix:nonNumeric contextRef="c-13" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-683">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the fiscal quarter ended June&#160;30, 2024.</span></div><div id="if929189504494c2da09ff9dfd66b833d_145"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1828185/000110465921063872/tm2115595d1_ex3-1.htm">Articles of Association of the Registrant (Incorporated herein by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K (File No. 001-40367) filed with the Securities and Exchange Commission on May 10, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="brns-20240630xexx311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="brns-20240630xexx312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="brns-20240630xexx321.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Data File (formatted in as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed herewith.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="if929189504494c2da09ff9dfd66b833d_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#if929189504494c2da09ff9dfd66b833d_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">BARINTHUS BIOTHERAPEUTICS PLC</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: August&#160;8, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ William Enright</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">William Enright</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: August&#160;8, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Gemma Brown</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Gemma Brown</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>brns-20240630xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i6de19cf86d4843ffa891d507918da8ab_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AND 15d-14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, William Enright, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Barinthus Biotherapeutics plc&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; August&#160;8, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58; William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>brns-20240630xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1f10c41524cc4092af6a2103d87da3a3_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AND 15d-14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Gemma Brown, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Barinthus Biotherapeutics plc&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; August&#160;8, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Gemma Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58; Gemma Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>brns-20240630xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic1fa9b9fdf4044faa1c64fbd3841b2b1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO</font></div><div style="padding-left:5.4pt;padding-right:5.4pt;text-align:center;text-indent:-10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18U</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> SECTION 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Barinthus Biotherapeutics plc (the &#8220;Company&#8221;) on Form 10-Q for the period ending June&#160;30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to the best of his or her knowledge that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; August&#160;8, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58; William Enright</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58; August&#160;8, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Gemma Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Name&#58; Gemma Brown</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>brns-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a110c5a-492b-47ac-b990-632b9a151dae,g:0cb2830b-fcfe-4af5-8a4f-fdc83046615c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:brns="http://www.barinthusbio.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.barinthusbio.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="brns-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.barinthusbio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical">
        <link:definition>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>9952157 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ForeignCurrencyTranslationinGeneralandAdministrativeExpenses" roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses">
        <link:definition>9952159 - Disclosure - Foreign Currency Translation in General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.barinthusbio.com/role/NetLossPerShare">
        <link:definition>9952160 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNet">
        <link:definition>9952161 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNet">
        <link:definition>9952162 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssets">
        <link:definition>9952163 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>9952164 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantIncome" roleURI="http://www.barinthusbio.com/role/GrantIncome">
        <link:definition>9952165 - Disclosure - Grant Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinaryShares" roleURI="http://www.barinthusbio.com/role/OrdinaryShares">
        <link:definition>9952166 - Disclosure - Ordinary Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredShares" roleURI="http://www.barinthusbio.com/role/DeferredShares">
        <link:definition>9952167 - Disclosure - Deferred Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.barinthusbio.com/role/FairValue">
        <link:definition>9952168 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.barinthusbio.com/role/Goodwill">
        <link:definition>9952169 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensation">
        <link:definition>9952170 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingencies">
        <link:definition>9952171 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactions">
        <link:definition>9952172 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.barinthusbio.com/role/NetLossPerShareTables">
        <link:definition>9954472 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>9954473 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>9954474 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantIncomeTables" roleURI="http://www.barinthusbio.com/role/GrantIncomeTables">
        <link:definition>9954475 - Disclosure - Grant Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.barinthusbio.com/role/FairValueTables">
        <link:definition>9954476 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationTables">
        <link:definition>9954477 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesTables">
        <link:definition>9954478 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>9954479 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9954480 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails" roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails">
        <link:definition>9954481 - Disclosure - Foreign Currency Translation in General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareComputationDetails" roleURI="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails">
        <link:definition>9954482 - Disclosure - Net Loss Per Share - Computation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails">
        <link:definition>9954483 - Disclosure - Net Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetDetails">
        <link:definition>9954484 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetDetails" roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails">
        <link:definition>9954485 - Disclosure - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9954486 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>9954487 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantIncomeAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails">
        <link:definition>9954488 - Disclosure - Grant Income - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GrantIncomeChangesindeferredincomeDetails" roleURI="http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails">
        <link:definition>9954489 - Disclosure - Grant Income - Changes in deferred income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrdinarySharesDetails" roleURI="http://www.barinthusbio.com/role/OrdinarySharesDetails">
        <link:definition>9954490 - Disclosure - Ordinary Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredSharesDetails" roleURI="http://www.barinthusbio.com/role/DeferredSharesDetails">
        <link:definition>9954491 - Disclosure - Deferred Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueAdditionalinformationDetails" roleURI="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails">
        <link:definition>9954492 - Disclosure - Fair Value - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details" roleURI="http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details">
        <link:definition>9954493 - Disclosure - Fair Value - Change in Financial Instruments Classified within Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.barinthusbio.com/role/GoodwillDetails">
        <link:definition>9954494 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails">
        <link:definition>9954495 - Disclosure - Share-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedaverageassumptionsDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails">
        <link:definition>9954496 - Disclosure - Share-Based Compensation - Weighted-average assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSharebasedcompensationexpenseDetails" roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails">
        <link:definition>9954497 - Disclosure - Share-Based Compensation - Share based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>9954498 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails">
        <link:definition>9954499 - Disclosure - Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseCostDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails">
        <link:definition>9954500 - Disclosure - Commitments and Contingencies - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails">
        <link:definition>9954501 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1">
        <link:definition>9954501 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9954502 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="brns_DeferredShares.Member" abstract="true" name="DeferredShares.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentIncentivesReceivable" abstract="false" name="ResearchAndDevelopmentIncentivesReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredTaxLiabilityNet" abstract="false" name="DeferredTaxLiabilityNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredStockValueIssued" abstract="false" name="DeferredStockValueIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredStockParOrStatedValuePerShare" abstract="false" name="DeferredStockParOrStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="brns_DeferredStockSharesAuthorized" abstract="false" name="DeferredStockSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_DeferredStockSharesIssued" abstract="false" name="DeferredStockSharesIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_DeferredStockSharesOutstanding" abstract="false" name="DeferredStockSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_ResearchAndDevelopmentIncentiveIncomeExpense" abstract="false" name="ResearchAndDevelopmentIncentiveIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_DeferredBSharesMember" abstract="true" name="DeferredBSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_DeferredCSharesMember" abstract="true" name="DeferredCSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_DeferredSharesMember" abstract="true" name="DeferredSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_SharesCancelledDuringPeriodSharesDeferredShares" abstract="false" name="SharesCancelledDuringPeriodSharesDeferredShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="brns_SharesCancelledDuringPeriodValueDeferredShares" abstract="false" name="SharesCancelledDuringPeriodValueDeferredShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_NonCashLeaseExpenses" abstract="false" name="NonCashLeaseExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_NonCashInterestExpenseOnConvertibleLoanNotes" abstract="false" name="NonCashInterestExpenseOnConvertibleLoanNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" abstract="false" name="IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AssetRetirementObligations" abstract="false" name="AssetRetirementObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" abstract="false" name="ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" abstract="false" name="PrepaidExpenseAndOtherAssetsCurrentTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" abstract="false" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_StockholdersEquityDeferredSharesDisclosureTextBlock" abstract="false" name="StockholdersEquityDeferredSharesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" abstract="false" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" abstract="false" name="LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AccruedExpensesAndOtherLiabilitiesCurrentTable" abstract="true" name="AccruedExpensesAndOtherLiabilitiesCurrentTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems" abstract="true" name="AccruedExpensesAndOtherLiabilitiesCurrentLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_AccruedManufacturingAndClinicalExpensesCurrent" abstract="false" name="AccruedManufacturingAndClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_CoalitionForEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionForEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_FundingAmountMaximum" abstract="false" name="FundingAmountMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_RoyaltyPaymentTermMaximum" abstract="false" name="RoyaltyPaymentTermMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_DeferredIncomeForeignExchangeTranslationGainLoss" abstract="false" name="DeferredIncomeForeignExchangeTranslationGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_CommonStockNumberOfVotesPerShare" abstract="false" name="CommonStockNumberOfVotesPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" abstract="false" name="PercentageOfSharesNecessaryToExercisePreemptiveRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_PeriodOfPreemptiveRightsToBeExercised" abstract="false" name="PeriodOfPreemptiveRightsToBeExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" abstract="false" name="MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_OrdinarySharesLiquidationPreference" abstract="false" name="OrdinarySharesLiquidationPreference" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_AvideaMember" abstract="true" name="AvideaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_ContingentConsiderationLiabilityMember" abstract="true" name="ContingentConsiderationLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" abstract="true" name="BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" abstract="true" name="RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" abstract="false" name="ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_EnterpriseManagementIncentiveShareOptionSchemeMember" abstract="true" name="EnterpriseManagementIncentiveShareOptionSchemeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_InLicenseAgreementsMember" abstract="true" name="InLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_OxfordshireMember" abstract="true" name="OxfordshireMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" abstract="false" name="PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" abstract="false" name="PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="brns_NumberOfSquareFeetUnderLeaseAgreement" abstract="false" name="NumberOfSquareFeetUnderLeaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="brns_LesseeOperatingLeaseExtendedTerm" abstract="false" name="LesseeOperatingLeaseExtendedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="brns_OtherInformationLesseeAbstract" abstract="true" name="OtherInformationLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="brns_OxfordUniversityInnovationLimitedMember" abstract="true" name="OxfordUniversityInnovationLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="brns_ExpensesMember" abstract="true" name="ExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>brns-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a110c5a-492b-47ac-b990-632b9a151dae,g:0cb2830b-fcfe-4af5-8a4f-fdc83046615c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_29329882-d114-4583-83d9-ff972c587d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_15f538e2-ba99-483d-b423-dffb53fb6215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29329882-d114-4583-83d9-ff972c587d5a" xlink:to="loc_us-gaap_Goodwill_15f538e2-ba99-483d-b423-dffb53fb6215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_09de8dcf-2253-421d-93cd-bb190b37dc69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29329882-d114-4583-83d9-ff972c587d5a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_09de8dcf-2253-421d-93cd-bb190b37dc69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4c0019d5-7a32-4bce-851a-be23d47cbc33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29329882-d114-4583-83d9-ff972c587d5a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4c0019d5-7a32-4bce-851a-be23d47cbc33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e7f7697f-5d8f-418d-a55e-2e017b156a15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29329882-d114-4583-83d9-ff972c587d5a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e7f7697f-5d8f-418d-a55e-2e017b156a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_82cc93a9-4db5-442c-8153-125350d1e0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29329882-d114-4583-83d9-ff972c587d5a" xlink:to="loc_us-gaap_OtherAssets_82cc93a9-4db5-442c-8153-125350d1e0e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_478e761a-05d0-493d-aaa0-d632dadb4d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29329882-d114-4583-83d9-ff972c587d5a" xlink:to="loc_us-gaap_AssetsCurrent_478e761a-05d0-493d-aaa0-d632dadb4d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa5500f0-c13a-4bb4-ab4e-38328cf6bf39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_64e9db6e-5743-4882-953e-075a76efc41a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa5500f0-c13a-4bb4-ab4e-38328cf6bf39" xlink:to="loc_us-gaap_MinorityInterest_64e9db6e-5743-4882-953e-075a76efc41a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_76ee7060-e52f-4621-8c30-d81302dc77aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa5500f0-c13a-4bb4-ab4e-38328cf6bf39" xlink:to="loc_us-gaap_StockholdersEquity_76ee7060-e52f-4621-8c30-d81302dc77aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_436622e2-75c0-467d-80bd-36070f2f0b17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_36521fcd-fe6b-4321-bdd2-6f4dd6b7d23f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_436622e2-75c0-467d-80bd-36070f2f0b17" xlink:to="loc_us-gaap_CommonStockValue_36521fcd-fe6b-4321-bdd2-6f4dd6b7d23f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued_1d75256c-38f5-4f79-a9d3-d962597b9e57" xlink:href="brns-20240630.xsd#brns_DeferredStockValueIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_436622e2-75c0-467d-80bd-36070f2f0b17" xlink:to="loc_brns_DeferredStockValueIssued_1d75256c-38f5-4f79-a9d3-d962597b9e57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fd95a63c-a6c0-4ade-ae3a-31dbb1ba1581" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_436622e2-75c0-467d-80bd-36070f2f0b17" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fd95a63c-a6c0-4ade-ae3a-31dbb1ba1581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0effb877-8fa6-4e10-a64d-001cc85fe34b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_436622e2-75c0-467d-80bd-36070f2f0b17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0effb877-8fa6-4e10-a64d-001cc85fe34b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_f084dcc7-8060-4879-9adb-f0ccbb63c7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_436622e2-75c0-467d-80bd-36070f2f0b17" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_f084dcc7-8060-4879-9adb-f0ccbb63c7b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b98f4176-8f4b-4daf-9aa2-237a3e2b58c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f947cbdd-0651-43d0-9b7c-02c22dee7fee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b98f4176-8f4b-4daf-9aa2-237a3e2b58c0" xlink:to="loc_us-gaap_AccountsPayableCurrent_f947cbdd-0651-43d0-9b7c-02c22dee7fee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7bdff6ba-f0f4-471a-b890-401fee481302" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b98f4176-8f4b-4daf-9aa2-237a3e2b58c0" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7bdff6ba-f0f4-471a-b890-401fee481302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeCurrent_c6194268-90f5-4cc2-b509-3d4fac201b02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b98f4176-8f4b-4daf-9aa2-237a3e2b58c0" xlink:to="loc_us-gaap_DeferredIncomeCurrent_c6194268-90f5-4cc2-b509-3d4fac201b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_da0129f3-2735-42d1-afe4-35fc8be006b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b98f4176-8f4b-4daf-9aa2-237a3e2b58c0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_da0129f3-2735-42d1-afe4-35fc8be006b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_56fb0fdc-935e-405e-a03b-8fd2d2948e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e240b4b4-9b85-47bb-8812-0820b5ca499f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_56fb0fdc-935e-405e-a03b-8fd2d2948e7d" xlink:to="loc_us-gaap_Liabilities_e240b4b4-9b85-47bb-8812-0820b5ca499f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3d5ac15f-081a-4881-9581-f701c22cd715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_56fb0fdc-935e-405e-a03b-8fd2d2948e7d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3d5ac15f-081a-4881-9581-f701c22cd715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7721054a-bca7-4b6d-a2a0-e57254b92101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_56fb0fdc-935e-405e-a03b-8fd2d2948e7d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7721054a-bca7-4b6d-a2a0-e57254b92101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_95a98b87-af52-4c53-b882-25a8f63825ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a49d8c8a-3a44-4437-a8f5-b42c7bb1488d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_95a98b87-af52-4c53-b882-25a8f63825ea" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a49d8c8a-3a44-4437-a8f5-b42c7bb1488d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable_0efcc672-bbf1-409d-8001-7a51bfcf9a38" xlink:href="brns-20240630.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_95a98b87-af52-4c53-b882-25a8f63825ea" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesReceivable_0efcc672-bbf1-409d-8001-7a51bfcf9a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_85754806-f82b-413f-9de6-fd3cd3d6d055" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_95a98b87-af52-4c53-b882-25a8f63825ea" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_85754806-f82b-413f-9de6-fd3cd3d6d055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a5543080-aea7-4237-bde0-eb647ee645d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a80e54e9-cb32-4cea-aa18-53c060a08975" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a5543080-aea7-4237-bde0-eb647ee645d6" xlink:to="loc_us-gaap_LiabilitiesCurrent_a80e54e9-cb32-4cea-aa18-53c060a08975" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_11cf5306-a0ff-49c5-9c14-4bfed73b4710" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a5543080-aea7-4237-bde0-eb647ee645d6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_11cf5306-a0ff-49c5-9c14-4bfed73b4710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5ce1cea9-1fde-4518-a13f-fe5809ae0bda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a5543080-aea7-4237-bde0-eb647ee645d6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5ce1cea9-1fde-4518-a13f-fe5809ae0bda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxLiabilityNet_dc19c490-0413-4729-93b9-1630655995ba" xlink:href="brns-20240630.xsd#brns_DeferredTaxLiabilityNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a5543080-aea7-4237-bde0-eb647ee645d6" xlink:to="loc_brns_DeferredTaxLiabilityNet_dc19c490-0413-4729-93b9-1630655995ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_06293292-be91-4c6b-88f2-626be70d3425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a5543080-aea7-4237-bde0-eb647ee645d6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_06293292-be91-4c6b-88f2-626be70d3425" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eeae40e7-c5d9-44ad-a7a0-7910a7972b27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_699fd421-6bf7-4994-9efc-97a117fd4873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eeae40e7-c5d9-44ad-a7a0-7910a7972b27" xlink:to="loc_us-gaap_ProfitLoss_699fd421-6bf7-4994-9efc-97a117fd4873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b0cf6780-8453-4595-ae5a-a67999101315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_eeae40e7-c5d9-44ad-a7a0-7910a7972b27" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b0cf6780-8453-4595-ae5a-a67999101315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_eba1aed4-57ef-4eec-8675-5de51308bb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7aa54134-07ca-49c3-b695-00a12563a594" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_eba1aed4-57ef-4eec-8675-5de51308bb2d" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7aa54134-07ca-49c3-b695-00a12563a594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_0f3cd51b-9b4c-4749-b02a-4f608b8db8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_eba1aed4-57ef-4eec-8675-5de51308bb2d" xlink:to="loc_us-gaap_InterestExpenseNonoperating_0f3cd51b-9b4c-4749-b02a-4f608b8db8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_08d4caad-fc79-4b92-a86b-ad9033d5bd1c" xlink:href="brns-20240630.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_eba1aed4-57ef-4eec-8675-5de51308bb2d" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_08d4caad-fc79-4b92-a86b-ad9033d5bd1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f5a660fc-c742-40d0-9e59-a6cb032949cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_eba1aed4-57ef-4eec-8675-5de51308bb2d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f5a660fc-c742-40d0-9e59-a6cb032949cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7aa532a5-dca0-42a9-ab11-a2fe71fdf1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_93ae6a82-a50e-48cd-8411-b91d28878ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7aa532a5-dca0-42a9-ab11-a2fe71fdf1cc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_93ae6a82-a50e-48cd-8411-b91d28878ccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2bee48c3-003d-43e2-8815-a8fb77bd7071" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7aa532a5-dca0-42a9-ab11-a2fe71fdf1cc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2bee48c3-003d-43e2-8815-a8fb77bd7071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5c81029e-baac-4f2c-a833-4ff4e3713011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_efdc6f4e-a90a-4e8b-9aec-903d5e165634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5c81029e-baac-4f2c-a833-4ff4e3713011" xlink:to="loc_us-gaap_OperatingIncomeLoss_efdc6f4e-a90a-4e8b-9aec-903d5e165634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_68e65d6b-5c4f-4f72-bbf5-343edc205da7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5c81029e-baac-4f2c-a833-4ff4e3713011" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_68e65d6b-5c4f-4f72-bbf5-343edc205da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2dbdc43f-e149-4431-a22b-3f7e3a6b395b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_41a419c2-6ce4-4b88-a71e-6b7840be0521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2dbdc43f-e149-4431-a22b-3f7e3a6b395b" xlink:to="loc_us-gaap_ProfitLoss_41a419c2-6ce4-4b88-a71e-6b7840be0521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9bb94e6b-d6d3-41ca-a01a-076c3a45d69f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2dbdc43f-e149-4431-a22b-3f7e3a6b395b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9bb94e6b-d6d3-41ca-a01a-076c3a45d69f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6e0a861a-8282-493a-9239-4c292fe5f6db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45639e6b-ec68-43c3-821f-208a94155477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6e0a861a-8282-493a-9239-4c292fe5f6db" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_45639e6b-ec68-43c3-821f-208a94155477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a2b46eae-4ae8-432b-b403-53c2135f82e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6e0a861a-8282-493a-9239-4c292fe5f6db" xlink:to="loc_us-gaap_OperatingExpenses_a2b46eae-4ae8-432b-b403-53c2135f82e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_9a7df190-4c55-4d43-abc4-5cd6c1bbb355" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6e0a861a-8282-493a-9239-4c292fe5f6db" xlink:to="loc_us-gaap_OtherOperatingIncome_9a7df190-4c55-4d43-abc4-5cd6c1bbb355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dc1fd14b-aee4-427e-8ef5-8b33489f2030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf9ef065-e6c7-445f-94d7-a974986bb3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dc1fd14b-aee4-427e-8ef5-8b33489f2030" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cf9ef065-e6c7-445f-94d7-a974986bb3c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_49cf28d9-c031-4db6-a427-58158c8d5b03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_dc1fd14b-aee4-427e-8ef5-8b33489f2030" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_49cf28d9-c031-4db6-a427-58158c8d5b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ff9e8726-5a3b-4a63-9bd1-f902a93749f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b11fb4e1-5de6-4b41-973b-9297ccbd9720" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ff9e8726-5a3b-4a63-9bd1-f902a93749f6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b11fb4e1-5de6-4b41-973b-9297ccbd9720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_79b58cbe-1e3c-4acb-98ca-0b65266ed249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ff9e8726-5a3b-4a63-9bd1-f902a93749f6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_79b58cbe-1e3c-4acb-98ca-0b65266ed249" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c2f24c3d-409e-41ea-b2b3-1efd1b55b32c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_ProfitLoss_c2f24c3d-409e-41ea-b2b3-1efd1b55b32c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4583e5e3-8399-4597-bed8-0271654a1230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_ShareBasedCompensation_4583e5e3-8399-4597-bed8-0271654a1230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_93280fd4-4bb2-4234-8f8c-ea728933dc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_93280fd4-4bb2-4234-8f8c-ea728933dc6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashLeaseExpenses_70219bad-911d-42fa-858d-28c142d21dd3" xlink:href="brns-20240630.xsd#brns_NonCashLeaseExpenses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_brns_NonCashLeaseExpenses_70219bad-911d-42fa-858d-28c142d21dd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_07c8f4b9-7043-477f-8034-492012ee1825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_07c8f4b9-7043-477f-8034-492012ee1825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a301e4d8-64ed-4974-899a-aa0ed49a1639" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a301e4d8-64ed-4974-899a-aa0ed49a1639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_4ac54260-6b15-4686-ab27-5a7bef492bfb" xlink:href="brns-20240630.xsd#brns_NonCashInterestExpenseOnConvertibleLoanNotes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_4ac54260-6b15-4686-ab27-5a7bef492bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_26b9bf66-ec9f-46f2-92d6-12748fc62aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_26b9bf66-ec9f-46f2-92d6-12748fc62aaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c00d48d6-0d02-4381-9319-4c710f59ebc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c00d48d6-0d02-4381-9319-4c710f59ebc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6f1a149a-c2d9-484e-8919-b606b12156eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6f1a149a-c2d9-484e-8919-b606b12156eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_7b266a7f-33bd-482f-84bf-9b6c9d01d232" xlink:href="brns-20240630.xsd#brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_7b266a7f-33bd-482f-84bf-9b6c9d01d232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_91cdca62-898c-4688-92c9-986c20582af6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_91cdca62-898c-4688-92c9-986c20582af6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_10727ab1-0383-4587-8d24-1d62c6bb2a44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_10727ab1-0383-4587-8d24-1d62c6bb2a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_daa1c06e-bc95-4baf-91ba-4ae1ee465b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_daa1c06e-bc95-4baf-91ba-4ae1ee465b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b3149d54-6fd0-46bf-91ed-68eb4f9f5191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b3149d54-6fd0-46bf-91ed-68eb4f9f5191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3b4237e8-1e95-4c1d-a56e-cf381ae50368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d108b536-ce27-4faa-bf22-13b4fd726b53" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3b4237e8-1e95-4c1d-a56e-cf381ae50368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e8024eb-4a19-4222-9f89-5dddaa1bac18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1ffda566-4a38-4071-8477-5e19a20a669d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e8024eb-4a19-4222-9f89-5dddaa1bac18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1ffda566-4a38-4071-8477-5e19a20a669d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8eb0bd02-e284-4c56-ab23-4272cfef66ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e8024eb-4a19-4222-9f89-5dddaa1bac18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_8eb0bd02-e284-4c56-ab23-4272cfef66ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7bfb9bed-9d86-4514-851e-ac71a0efd1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4e8024eb-4a19-4222-9f89-5dddaa1bac18" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7bfb9bed-9d86-4514-851e-ac71a0efd1e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bb191741-8a4c-4cee-8aeb-5d154d4cfa85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55a3a010-ec0d-45bf-b787-b5dc539c0c39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bb191741-8a4c-4cee-8aeb-5d154d4cfa85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55a3a010-ec0d-45bf-b787-b5dc539c0c39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1884990-c9f0-4e9c-b297-b812214af0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bb191741-8a4c-4cee-8aeb-5d154d4cfa85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1884990-c9f0-4e9c-b297-b812214af0dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_370b653b-5628-44da-8d4c-ccc42835ed79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bb191741-8a4c-4cee-8aeb-5d154d4cfa85" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_370b653b-5628-44da-8d4c-ccc42835ed79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_27485a35-f9d4-47b6-b15e-e8419547db27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bb191741-8a4c-4cee-8aeb-5d154d4cfa85" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_27485a35-f9d4-47b6-b15e-e8419547db27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a1b1e72-0aaa-4ec9-a074-0c81a8abd959" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0267f7e9-a571-437c-bc73-dcbfa2a626f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a1b1e72-0aaa-4ec9-a074-0c81a8abd959" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0267f7e9-a571-437c-bc73-dcbfa2a626f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#NetLossPerShareComputationDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2f4e4c5b-6282-4160-b628-5bfe97e5156a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a3286a46-ee1d-40e6-910b-cdc62454e0be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2f4e4c5b-6282-4160-b628-5bfe97e5156a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a3286a46-ee1d-40e6-910b-cdc62454e0be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_11bea4ef-c08f-4d76-88dc-616e49aa7a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_f9aa1e8c-d7a4-4be1-ab72-3b3ffc52c93c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_11bea4ef-c08f-4d76-88dc-616e49aa7a6b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_f9aa1e8c-d7a4-4be1-ab72-3b3ffc52c93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_1eb470e8-3659-4146-ab80-50a9f7d2107c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_11bea4ef-c08f-4d76-88dc-616e49aa7a6b" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_1eb470e8-3659-4146-ab80-50a9f7d2107c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_871f858a-a30f-4af3-b037-2dc33c8f862f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_11bea4ef-c08f-4d76-88dc-616e49aa7a6b" xlink:to="loc_us-gaap_OtherAssetsCurrent_871f858a-a30f-4af3-b037-2dc33c8f862f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_fea1bdb0-fa80-4cd1-aea1-7fa8568158b8" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_82943b75-b032-4357-8a39-3ea8a02430a7" xlink:href="brns-20240630.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_fea1bdb0-fa80-4cd1-aea1-7fa8568158b8" xlink:to="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_82943b75-b032-4357-8a39-3ea8a02430a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_babb423b-c6c1-401c-8296-fb17ff18c248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_fea1bdb0-fa80-4cd1-aea1-7fa8568158b8" xlink:to="loc_us-gaap_AccruedBonusesCurrent_babb423b-c6c1-401c-8296-fb17ff18c248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_58a98ab2-401f-426f-81ab-faec39bd3e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_fea1bdb0-fa80-4cd1-aea1-7fa8568158b8" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_58a98ab2-401f-426f-81ab-faec39bd3e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f2f269f5-ea4c-43be-9e56-5a7111daabdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_fea1bdb0-fa80-4cd1-aea1-7fa8568158b8" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f2f269f5-ea4c-43be-9e56-5a7111daabdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_34eb02b4-b354-47ee-85ed-821a037fe840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_fea1bdb0-fa80-4cd1-aea1-7fa8568158b8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_34eb02b4-b354-47ee-85ed-821a037fe840" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingenciesLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_fb5427ca-0b34-4f56-868f-b77e411cb29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_7340d067-20fa-483a-9c81-2e2431a9e47c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_fb5427ca-0b34-4f56-868f-b77e411cb29e" xlink:to="loc_us-gaap_ShortTermLeaseCost_7340d067-20fa-483a-9c81-2e2431a9e47c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_60089832-79f4-4f35-acee-002ad1861a82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_fb5427ca-0b34-4f56-868f-b77e411cb29e" xlink:to="loc_us-gaap_OperatingLeaseCost_60089832-79f4-4f35-acee-002ad1861a82" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199cf383-4351-4770-8cd5-a8a0edd65cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fc477889-8d6e-4384-8767-c6b275098db0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199cf383-4351-4770-8cd5-a8a0edd65cd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_fc477889-8d6e-4384-8767-c6b275098db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ff6c1a20-d3bc-478f-b582-792829f46722" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199cf383-4351-4770-8cd5-a8a0edd65cd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ff6c1a20-d3bc-478f-b582-792829f46722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_23adc612-41f5-4736-bc49-af044d467e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199cf383-4351-4770-8cd5-a8a0edd65cd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_23adc612-41f5-4736-bc49-af044d467e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_38db64f6-59a1-4e4a-9f1c-522684daef2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199cf383-4351-4770-8cd5-a8a0edd65cd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_38db64f6-59a1-4e4a-9f1c-522684daef2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1994b69a-79ab-453f-a5d3-5b50abe5ce05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199cf383-4351-4770-8cd5-a8a0edd65cd4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1994b69a-79ab-453f-a5d3-5b50abe5ce05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_ab7dc812-d5b6-43be-8593-c8a47414eda8" xlink:href="brns-20240630.xsd#brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_199cf383-4351-4770-8cd5-a8a0edd65cd4" xlink:to="loc_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_ab7dc812-d5b6-43be-8593-c8a47414eda8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69da8c4c-72cf-4e79-a66f-12bdec6ffb36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_588ff88e-217a-4bc0-83db-f80703b95631" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69da8c4c-72cf-4e79-a66f-12bdec6ffb36" xlink:to="loc_us-gaap_OperatingLeaseLiability_588ff88e-217a-4bc0-83db-f80703b95631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f57008d0-2515-4f9b-9a16-ff0b7455d489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69da8c4c-72cf-4e79-a66f-12bdec6ffb36" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f57008d0-2515-4f9b-9a16-ff0b7455d489" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>brns-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a110c5a-492b-47ac-b990-632b9a151dae,g:0cb2830b-fcfe-4af5-8a4f-fdc83046615c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Cover" xlink:type="simple" xlink:href="brns-20240630.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_52330848-cbf6-4c6a-ae2c-153b00695506" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentInformationTable_52330848-cbf6-4c6a-ae2c-153b00695506" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9f1abdc3-7be4-4b67-8690-79902abe58fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_52330848-cbf6-4c6a-ae2c-153b00695506" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9f1abdc3-7be4-4b67-8690-79902abe58fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9f1abdc3-7be4-4b67-8690-79902abe58fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9f1abdc3-7be4-4b67-8690-79902abe58fe" xlink:to="loc_us-gaap_ClassOfStockDomain_9f1abdc3-7be4-4b67-8690-79902abe58fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a48e3ba5-6a1b-485a-8870-1cab30962789" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9f1abdc3-7be4-4b67-8690-79902abe58fe" xlink:to="loc_us-gaap_ClassOfStockDomain_a48e3ba5-6a1b-485a-8870-1cab30962789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_65407f8d-3c9a-4b00-a9fd-a127629617ee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a48e3ba5-6a1b-485a-8870-1cab30962789" xlink:to="loc_dei_AdrMember_65407f8d-3c9a-4b00-a9fd-a127629617ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_32ee464e-3b26-4d31-be59-248187fd3e99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a48e3ba5-6a1b-485a-8870-1cab30962789" xlink:to="loc_us-gaap_CommonStockMember_32ee464e-3b26-4d31-be59-248187fd3e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4e9f7730-243f-4b94-80f7-03411658b58c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentType_4e9f7730-243f-4b94-80f7-03411658b58c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_12ae607d-6dd4-4196-aabe-5ee445d3dfa8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentQuarterlyReport_12ae607d-6dd4-4196-aabe-5ee445d3dfa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_125957fd-907e-4f6f-8b8d-ed342833eadc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentPeriodEndDate_125957fd-907e-4f6f-8b8d-ed342833eadc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_421aac56-7088-4f32-8183-2b93f004a148" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentTransitionReport_421aac56-7088-4f32-8183-2b93f004a148" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_56f28415-f18c-466a-a04d-0507aab8182d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityFileNumber_56f28415-f18c-466a-a04d-0507aab8182d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b6be9baf-36d9-4a05-b3c8-8635f7573001" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityRegistrantName_b6be9baf-36d9-4a05-b3c8-8635f7573001" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_23beb38d-99cc-4005-bcb7-f7310ce824c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_23beb38d-99cc-4005-bcb7-f7310ce824c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_97724349-826c-4ad2-b719-8dd91fdaaded" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityTaxIdentificationNumber_97724349-826c-4ad2-b719-8dd91fdaaded" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8efa304c-1daa-4f71-98cf-35701eb6aed1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressAddressLine1_8efa304c-1daa-4f71-98cf-35701eb6aed1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_85ad6d74-33f9-4adc-9743-c7753af14293" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressAddressLine2_85ad6d74-33f9-4adc-9743-c7753af14293" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9dff33f1-9c76-4245-9b88-a89be1fc5f8f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressCityOrTown_9dff33f1-9c76-4245-9b88-a89be1fc5f8f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_586a8cae-192c-4529-96b4-18b626f96629" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressCountry_586a8cae-192c-4529-96b4-18b626f96629" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_28715ff2-bd00-4384-be7e-9872a92304fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressPostalZipCode_28715ff2-bd00-4384-be7e-9872a92304fa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4fde6150-c444-4fb1-9525-82890b573a00" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_CityAreaCode_4fde6150-c444-4fb1-9525-82890b573a00" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d84920c9-7fb9-4458-befa-e3c09aa5a0c2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_LocalPhoneNumber_d84920c9-7fb9-4458-befa-e3c09aa5a0c2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_472dee30-98c7-4ca4-b768-e54f6359f3b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_Security12bTitle_472dee30-98c7-4ca4-b768-e54f6359f3b6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9245712b-2621-4dfd-864e-c74c32cd35d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_TradingSymbol_9245712b-2621-4dfd-864e-c74c32cd35d7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d5bc9c99-da74-457c-ad94-f8f419ba837c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_SecurityExchangeName_d5bc9c99-da74-457c-ad94-f8f419ba837c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8442ae56-1155-43a9-90b8-50b4185a61d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityCurrentReportingStatus_8442ae56-1155-43a9-90b8-50b4185a61d7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ff56c988-b9e7-49fe-b08d-020e99e094a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityInteractiveDataCurrent_ff56c988-b9e7-49fe-b08d-020e99e094a5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4c2a4f05-8b96-4a46-a24d-c1be838cddc6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityFilerCategory_4c2a4f05-8b96-4a46-a24d-c1be838cddc6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_78f38569-c2e1-428f-85c4-e607fa376efc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntitySmallBusiness_78f38569-c2e1-428f-85c4-e607fa376efc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ffd1288b-7672-43e5-9cd0-61c06b4b4a5e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityEmergingGrowthCompany_ffd1288b-7672-43e5-9cd0-61c06b4b4a5e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_17abc3ca-c8b1-4133-b8d4-c7328bc1959e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityExTransitionPeriod_17abc3ca-c8b1-4133-b8d4-c7328bc1959e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7344db34-ac44-4f27-8ab7-153be7c41ff8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityShellCompany_7344db34-ac44-4f27-8ab7-153be7c41ff8" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_970a3410-b5ea-4a15-8f06-9ae50472c14a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_970a3410-b5ea-4a15-8f06-9ae50472c14a" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3c820f4a-fba8-4470-914b-e95a5996c6af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityCentralIndexKey_3c820f4a-fba8-4470-914b-e95a5996c6af" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_61beef97-37cc-4d31-a71a-7ac3d0037d84" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentFiscalYearFocus_61beef97-37cc-4d31-a71a-7ac3d0037d84" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_755b78b9-14c5-4513-a36a-5d84136a901a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_755b78b9-14c5-4513-a36a-5d84136a901a" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_465e7f5f-0372-4400-9198-028ddc0fd6b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_AmendmentFlag_465e7f5f-0372-4400-9198-028ddc0fd6b4" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_39c58080-14e1-4475-9dcd-ab8a379dd8e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_CurrentFiscalYearEndDate_39c58080-14e1-4475-9dcd-ab8a379dd8e1" xlink:type="arc" order="30"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cfb1788c-dbe0-4302-a3c5-8ab5293530f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_StatementTable_cfb1788c-dbe0-4302-a3c5-8ab5293530f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d03583b5-dcb8-4307-92b5-b623f418a5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cfb1788c-dbe0-4302-a3c5-8ab5293530f2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d03583b5-dcb8-4307-92b5-b623f418a5d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d03583b5-dcb8-4307-92b5-b623f418a5d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d03583b5-dcb8-4307-92b5-b623f418a5d0" xlink:to="loc_us-gaap_ClassOfStockDomain_d03583b5-dcb8-4307-92b5-b623f418a5d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4fc3a7ea-c4e9-43c7-9ffd-6d0b5dfaa03b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d03583b5-dcb8-4307-92b5-b623f418a5d0" xlink:to="loc_us-gaap_ClassOfStockDomain_4fc3a7ea-c4e9-43c7-9ffd-6d0b5dfaa03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_1993b68b-ca9b-4a3f-888c-ffd49bebfa8d" xlink:href="brns-20240630.xsd#brns_DeferredShares.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4fc3a7ea-c4e9-43c7-9ffd-6d0b5dfaa03b" xlink:to="loc_brns_DeferredShares.Member_1993b68b-ca9b-4a3f-888c-ffd49bebfa8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b1f781e-89e7-41b4-a612-d99c21634b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b1f781e-89e7-41b4-a612-d99c21634b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable_0f8a4404-0328-4de2-9621-4c6e2a95c9e7" xlink:href="brns-20240630.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesReceivable_0f8a4404-0328-4de2-9621-4c6e2a95c9e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_45af7ab7-c428-4398-9e61-810dedbf41d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_45af7ab7-c428-4398-9e61-810dedbf41d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0523fed6-f6fa-41c9-9d1d-91864cf9fb15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:to="loc_us-gaap_AssetsCurrent_0523fed6-f6fa-41c9-9d1d-91864cf9fb15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_df404b17-33a8-48fb-8f26-d343ee01dce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_Goodwill_df404b17-33a8-48fb-8f26-d343ee01dce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_42a6f96b-58e4-4bf0-9fd9-67b98eca4b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_42a6f96b-58e4-4bf0-9fd9-67b98eca4b1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcc374d7-cc77-445c-9c2e-100b322eda5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcc374d7-cc77-445c-9c2e-100b322eda5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1b2fa41f-a0ab-4e51-8f6e-fbe2c23c3972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1b2fa41f-a0ab-4e51-8f6e-fbe2c23c3972" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_d8a00f86-35a1-49fa-b4a1-af883e5c0d66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_OtherAssets_d8a00f86-35a1-49fa-b4a1-af883e5c0d66" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_56d41286-93c8-467e-a745-42871136e638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_Assets_56d41286-93c8-467e-a745-42871136e638" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_22bf3da9-cc33-471d-8d1d-03952243197a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_us-gaap_AccountsPayableCurrent_22bf3da9-cc33-471d-8d1d-03952243197a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_20115426-dc4e-4f9a-82dc-d6362bba3a10" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_20115426-dc4e-4f9a-82dc-d6362bba3a10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeCurrent_b58a7bc6-9742-4f0e-bffd-b156aeadcc89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_us-gaap_DeferredIncomeCurrent_b58a7bc6-9742-4f0e-bffd-b156aeadcc89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2e4bc69d-883b-49eb-9220-04ad95aa9c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2e4bc69d-883b-49eb-9220-04ad95aa9c66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5b18c3dc-8047-4fd5-9456-9ee7f973b27a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_us-gaap_LiabilitiesCurrent_5b18c3dc-8047-4fd5-9456-9ee7f973b27a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c76ff814-89d6-4bc5-9ee7-ba8dc30e9660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c76ff814-89d6-4bc5-9ee7-ba8dc30e9660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8d7f82d2-d764-4030-a6e2-840e821ea6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8d7f82d2-d764-4030-a6e2-840e821ea6ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9af7d17d-4575-4594-a294-954bd7baddcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9af7d17d-4575-4594-a294-954bd7baddcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxLiabilityNet_3f67aecb-5cf7-4ebc-858e-55ef8228bf2b" xlink:href="brns-20240630.xsd#brns_DeferredTaxLiabilityNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_brns_DeferredTaxLiabilityNet_3f67aecb-5cf7-4ebc-858e-55ef8228bf2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_18ba6881-73ec-48fd-9187-a0ce133c4976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_Liabilities_18ba6881-73ec-48fd-9187-a0ce133c4976" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fefeb65c-8e92-4f3b-bca1-1156e61421a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fefeb65c-8e92-4f3b-bca1-1156e61421a7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2e566c49-4afc-4fc7-a315-59e2001229df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_CommonStockValue_2e566c49-4afc-4fc7-a315-59e2001229df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued_9ee3f7ea-fffb-4f94-8c49-7adacc7a4465" xlink:href="brns-20240630.xsd#brns_DeferredStockValueIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_brns_DeferredStockValueIssued_9ee3f7ea-fffb-4f94-8c49-7adacc7a4465" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cec70129-683c-4a3b-a32b-407e0177b7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cec70129-683c-4a3b-a32b-407e0177b7f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a4a90916-9d6d-4aa5-b67f-528e34e6c692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a4a90916-9d6d-4aa5-b67f-528e34e6c692" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_a254ed7e-e03c-4d76-97c4-d06329942d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_a254ed7e-e03c-4d76-97c4-d06329942d63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_64983883-b366-42d3-9b15-cba7e0ddc2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_StockholdersEquity_64983883-b366-42d3-9b15-cba7e0ddc2cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_95d964bc-e549-4595-b0d4-32759a6b1866" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_MinorityInterest_95d964bc-e549-4595-b0d4-32759a6b1866" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7a095eb-a4e0-4754-bef8-c3f787654ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7a095eb-a4e0-4754-bef8-c3f787654ee0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8c3a76b-f341-4daf-8559-8945f8f3a1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8c3a76b-f341-4daf-8559-8945f8f3a1b7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cbafcb8a-0dcb-4d94-985f-c5148cc2d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_us-gaap_StatementTable_cbafcb8a-0dcb-4d94-985f-c5148cc2d3f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_941b28b1-e19c-481a-9626-c726154e13bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cbafcb8a-0dcb-4d94-985f-c5148cc2d3f2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_941b28b1-e19c-481a-9626-c726154e13bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_941b28b1-e19c-481a-9626-c726154e13bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_941b28b1-e19c-481a-9626-c726154e13bb" xlink:to="loc_us-gaap_ClassOfStockDomain_941b28b1-e19c-481a-9626-c726154e13bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_14b2233b-c314-4c3b-a0e4-bab6f272ba06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_941b28b1-e19c-481a-9626-c726154e13bb" xlink:to="loc_us-gaap_ClassOfStockDomain_14b2233b-c314-4c3b-a0e4-bab6f272ba06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_685bafff-89ab-40f5-b076-7d9cb6044f21" xlink:href="brns-20240630.xsd#brns_DeferredShares.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_14b2233b-c314-4c3b-a0e4-bab6f272ba06" xlink:to="loc_brns_DeferredShares.Member_685bafff-89ab-40f5-b076-7d9cb6044f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c76b56d8-7a17-4012-9c4d-08e458df44e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c76b56d8-7a17-4012-9c4d-08e458df44e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_467926fe-4535-448e-89d8-ccf4d140e947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_467926fe-4535-448e-89d8-ccf4d140e947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_324151c9-51b5-4c62-b562-2651ee36868d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_us-gaap_CommonStockSharesIssued_324151c9-51b5-4c62-b562-2651ee36868d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4885989d-dde5-4bca-9c6c-9f88eab5fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4885989d-dde5-4bca-9c6c-9f88eab5fa35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_7a2ef4f5-ec95-4394-a4b1-190c7031a1c5" xlink:href="brns-20240630.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_7a2ef4f5-ec95-4394-a4b1-190c7031a1c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesAuthorized_c52476b2-cb1f-4316-b28d-c86f2263ee63" xlink:href="brns-20240630.xsd#brns_DeferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_brns_DeferredStockSharesAuthorized_c52476b2-cb1f-4316-b28d-c86f2263ee63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesIssued_37b737a2-a00e-4c61-be7c-e483bc11909d" xlink:href="brns-20240630.xsd#brns_DeferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_brns_DeferredStockSharesIssued_37b737a2-a00e-4c61-be7c-e483bc11909d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesOutstanding_92e0b5bd-3abe-4fd2-8d72-dcc57f452882" xlink:href="brns-20240630.xsd#brns_DeferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_brns_DeferredStockSharesOutstanding_92e0b5bd-3abe-4fd2-8d72-dcc57f452882" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac517253-76f1-4e54-85e4-0f30dd0c0bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_StatementTable_ac517253-76f1-4e54-85e4-0f30dd0c0bf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_567cc87f-d0f3-4ef1-a70e-7f6ddc2341f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ac517253-76f1-4e54-85e4-0f30dd0c0bf3" xlink:to="loc_srt_ProductOrServiceAxis_567cc87f-d0f3-4ef1-a70e-7f6ddc2341f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_567cc87f-d0f3-4ef1-a70e-7f6ddc2341f7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_567cc87f-d0f3-4ef1-a70e-7f6ddc2341f7" xlink:to="loc_srt_ProductsAndServicesDomain_567cc87f-d0f3-4ef1-a70e-7f6ddc2341f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_044d88cb-1a8c-4e95-b9e2-1094a5906c65" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_567cc87f-d0f3-4ef1-a70e-7f6ddc2341f7" xlink:to="loc_srt_ProductsAndServicesDomain_044d88cb-1a8c-4e95-b9e2-1094a5906c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_0cbbd7b2-d2da-472b-b344-1ff54925e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_044d88cb-1a8c-4e95-b9e2-1094a5906c65" xlink:to="loc_us-gaap_LicenseMember_0cbbd7b2-d2da-472b-b344-1ff54925e0f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e7a06fe-03f5-4fda-9616-fd751774c479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e7a06fe-03f5-4fda-9616-fd751774c479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e11906b3-02ba-403e-87a3-dfbfe42dd45f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e11906b3-02ba-403e-87a3-dfbfe42dd45f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d7db0c66-f54f-48af-8cf6-017fae8bf7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d7db0c66-f54f-48af-8cf6-017fae8bf7f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_09699cc3-f7a8-437b-a36e-0842031faa24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:to="loc_us-gaap_OperatingExpenses_09699cc3-f7a8-437b-a36e-0842031faa24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_6c7dd215-f74b-4c83-933c-fb2117ad74d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OtherOperatingIncome_6c7dd215-f74b-4c83-933c-fb2117ad74d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cdecdd81-0a39-4b78-a797-d9cb58e11e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OperatingIncomeLoss_cdecdd81-0a39-4b78-a797-d9cb58e11e53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f4d8b799-78b1-4c46-9c45-6201256c74d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f4d8b799-78b1-4c46-9c45-6201256c74d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_83029919-b3a9-48b0-a69f-a0496a56fefa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_us-gaap_InterestExpenseNonoperating_83029919-b3a9-48b0-a69f-a0496a56fefa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_1d5bf584-7f3f-48e4-9193-b3272feccfb9" xlink:href="brns-20240630.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_1d5bf584-7f3f-48e4-9193-b3272feccfb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_99135549-4276-4739-9fcd-8c8fbaa975c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_99135549-4276-4739-9fcd-8c8fbaa975c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bc7c3116-86a4-408f-bda1-363e8b538a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bc7c3116-86a4-408f-bda1-363e8b538a4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a93b1b2-f72d-4097-bac5-c1b5c05d7d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a93b1b2-f72d-4097-bac5-c1b5c05d7d7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a38443b7-1764-4216-b832-e94382a5ae72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a38443b7-1764-4216-b832-e94382a5ae72" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_59cf3e4a-3f66-470a-9d51-efe0ca30d935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_ProfitLoss_59cf3e4a-3f66-470a-9d51-efe0ca30d935" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7ae8f89f-3ef4-41ad-a43d-fa8e25a7d247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7ae8f89f-3ef4-41ad-a43d-fa8e25a7d247" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6bab2f70-922c-48af-9145-b6ab6adc6a11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_NetIncomeLoss_6bab2f70-922c-48af-9145-b6ab6adc6a11" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ba8f2955-c89b-41b8-a781-003d712adf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ba8f2955-c89b-41b8-a781-003d712adf9b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_afebce46-269b-4c07-9b84-20da79691fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_afebce46-269b-4c07-9b84-20da79691fc5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_76a2db34-2100-49ab-ac40-e7e4845b08e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_EarningsPerShareBasic_76a2db34-2100-49ab-ac40-e7e4845b08e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f1b9f471-324d-434e-8c7c-3508512c5478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f1b9f471-324d-434e-8c7c-3508512c5478" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_03aad9fa-f1dd-41ef-8876-1cf5c200baa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d1e3548d-a2da-4eb5-b4a6-a6d730b8fd66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d1e3548d-a2da-4eb5-b4a6-a6d730b8fd66" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_07cba6f8-0bf1-4f55-a522-bf233fc9e894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_07cba6f8-0bf1-4f55-a522-bf233fc9e894" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_62c8883d-7fd5-4778-9eb1-0c49d539c4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_62c8883d-7fd5-4778-9eb1-0c49d539c4c5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9b777b82-3a1f-4607-96e2-78f911f69c22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9b777b82-3a1f-4607-96e2-78f911f69c22" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_82d12f9c-4fc9-4e49-ba67-edc12c074d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b7691485-8db1-4ea8-a7e3-c3c3ffee9892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_82d12f9c-4fc9-4e49-ba67-edc12c074d73" xlink:to="loc_us-gaap_StatementTable_b7691485-8db1-4ea8-a7e3-c3c3ffee9892" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90417485-7433-4308-b0fa-a1a4ad48bd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b7691485-8db1-4ea8-a7e3-c3c3ffee9892" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90417485-7433-4308-b0fa-a1a4ad48bd9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_90417485-7433-4308-b0fa-a1a4ad48bd9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90417485-7433-4308-b0fa-a1a4ad48bd9b" xlink:to="loc_us-gaap_RelatedPartyDomain_90417485-7433-4308-b0fa-a1a4ad48bd9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4b3252ad-5a9b-42c1-aaf2-1def359eea04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90417485-7433-4308-b0fa-a1a4ad48bd9b" xlink:to="loc_us-gaap_RelatedPartyDomain_4b3252ad-5a9b-42c1-aaf2-1def359eea04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_cd65ff9d-a91b-478a-9882-a96fc6bf0a95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4b3252ad-5a9b-42c1-aaf2-1def359eea04" xlink:to="loc_us-gaap_RelatedPartyMember_cd65ff9d-a91b-478a-9882-a96fc6bf0a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e81298a-6995-434b-a611-6be5a95e19ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82d12f9c-4fc9-4e49-ba67-edc12c074d73" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e81298a-6995-434b-a611-6be5a95e19ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_8691c125-8ebc-46bc-9135-ca098bdd52ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82d12f9c-4fc9-4e49-ba67-edc12c074d73" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_8691c125-8ebc-46bc-9135-ca098bdd52ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d98e313-6b57-4968-80ad-0648342bcbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_846e0cb6-d57c-4237-a481-bb39b44f0a20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7d98e313-6b57-4968-80ad-0648342bcbd0" xlink:to="loc_us-gaap_StatementTable_846e0cb6-d57c-4237-a481-bb39b44f0a20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eb5b4a7e-16da-449a-b95b-939777814c97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_846e0cb6-d57c-4237-a481-bb39b44f0a20" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eb5b4a7e-16da-449a-b95b-939777814c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eb5b4a7e-16da-449a-b95b-939777814c97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eb5b4a7e-16da-449a-b95b-939777814c97" xlink:to="loc_us-gaap_ClassOfStockDomain_eb5b4a7e-16da-449a-b95b-939777814c97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eb5b4a7e-16da-449a-b95b-939777814c97" xlink:to="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_d5931e27-69d8-478e-b2f4-eebd8e10c676" xlink:href="brns-20240630.xsd#brns_DeferredShares.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:to="loc_brns_DeferredShares.Member_d5931e27-69d8-478e-b2f4-eebd8e10c676" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_24166455-e373-4222-969a-4d8c4987f212" xlink:href="brns-20240630.xsd#brns_DeferredBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:to="loc_brns_DeferredBSharesMember_24166455-e373-4222-969a-4d8c4987f212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_b20101ea-2f6d-4bbe-8d0e-312535fe9e1d" xlink:href="brns-20240630.xsd#brns_DeferredCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:to="loc_brns_DeferredCSharesMember_b20101ea-2f6d-4bbe-8d0e-312535fe9e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7f4d71c5-e627-4f1d-86b8-bf0bc1ae85ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_846e0cb6-d57c-4237-a481-bb39b44f0a20" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7f4d71c5-e627-4f1d-86b8-bf0bc1ae85ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7f4d71c5-e627-4f1d-86b8-bf0bc1ae85ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7f4d71c5-e627-4f1d-86b8-bf0bc1ae85ee" xlink:to="loc_us-gaap_EquityComponentDomain_7f4d71c5-e627-4f1d-86b8-bf0bc1ae85ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a845f29d-1c44-40e2-8a91-b4e143a28556" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7f4d71c5-e627-4f1d-86b8-bf0bc1ae85ee" xlink:to="loc_us-gaap_EquityComponentDomain_a845f29d-1c44-40e2-8a91-b4e143a28556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a845f29d-1c44-40e2-8a91-b4e143a28556" xlink:to="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_955fafab-f612-4a09-bb97-ce3bff2e3aff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_us-gaap_CommonStockMember_955fafab-f612-4a09-bb97-ce3bff2e3aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredSharesMember_f880827e-ae9b-4f10-a0f6-8cd49582797d" xlink:href="brns-20240630.xsd#brns_DeferredSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_brns_DeferredSharesMember_f880827e-ae9b-4f10-a0f6-8cd49582797d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_18975b46-5a54-4ff8-b11f-e5aa57088574" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_18975b46-5a54-4ff8-b11f-e5aa57088574" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_069f10fa-fd21-4f4d-9946-0fb563807c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_us-gaap_RetainedEarningsMember_069f10fa-fd21-4f4d-9946-0fb563807c02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_500b0a64-1fed-405b-873b-0b1e4e4309c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_500b0a64-1fed-405b-873b-0b1e4e4309c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_59753492-9c7e-4228-82fb-4dc50665b41e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a845f29d-1c44-40e2-8a91-b4e143a28556" xlink:to="loc_us-gaap_NoncontrollingInterestMember_59753492-9c7e-4228-82fb-4dc50665b41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d98e313-6b57-4968-80ad-0648342bcbd0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a446c068-3578-4df0-94e4-336fd69703c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_SharesIssued_a446c068-3578-4df0-94e4-336fd69703c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a2229ca-ca6f-45b9-b497-1a22783676d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a2229ca-ca6f-45b9-b497-1a22783676d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8935513e-04cf-4b6c-83f4-5f8d71bff4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8935513e-04cf-4b6c-83f4-5f8d71bff4ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12c63735-c98f-4288-a2f6-9eadcd9aa5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12c63735-c98f-4288-a2f6-9eadcd9aa5ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9c3f9953-86a4-4d37-bd30-055983887a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9c3f9953-86a4-4d37-bd30-055983887a64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_71815e5f-d844-4e91-866c-86cac319c723" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_71815e5f-d844-4e91-866c-86cac319c723" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares_1565db52-f6cf-4180-bb85-84a7ffdfa38a" xlink:href="brns-20240630.xsd#brns_SharesCancelledDuringPeriodSharesDeferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares_1565db52-f6cf-4180-bb85-84a7ffdfa38a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodValueDeferredShares_59fe6e69-c311-4b37-bc43-97689e44dd52" xlink:href="brns-20240630.xsd#brns_SharesCancelledDuringPeriodValueDeferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_brns_SharesCancelledDuringPeriodValueDeferredShares_59fe6e69-c311-4b37-bc43-97689e44dd52" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_39d08004-db69-4d8a-b13f-941673edbff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_ProfitLoss_39d08004-db69-4d8a-b13f-941673edbff4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_d510f664-bd44-4a10-9e78-1a6865df436f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa749a56-74d5-4feb-ac2e-c398aa193f75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#IntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e61ae6b6-496b-4f37-83cb-53416e4b68db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e61ae6b6-496b-4f37-83cb-53416e4b68db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51d557c5-5be3-460a-87db-9e46cca4b08c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e61ae6b6-496b-4f37-83cb-53416e4b68db" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51d557c5-5be3-460a-87db-9e46cca4b08c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51d557c5-5be3-460a-87db-9e46cca4b08c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51d557c5-5be3-460a-87db-9e46cca4b08c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51d557c5-5be3-460a-87db-9e46cca4b08c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44cc9653-1d04-4c7b-b3d9-f647adf9f4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51d557c5-5be3-460a-87db-9e46cca4b08c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44cc9653-1d04-4c7b-b3d9-f647adf9f4f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_87ab2d53-0ce7-40d0-90f9-7cabeca0bd04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44cc9653-1d04-4c7b-b3d9-f647adf9f4f2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_87ab2d53-0ce7-40d0-90f9-7cabeca0bd04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b3ef8aa-6f41-4237-ba4b-6a94a32b3de6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b3ef8aa-6f41-4237-ba4b-6a94a32b3de6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6afc870f-b19e-4b3e-9f50-db3f05a6e104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6afc870f-b19e-4b3e-9f50-db3f05a6e104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d05c84a9-8f34-49ff-a655-04447b13954f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d05c84a9-8f34-49ff-a655-04447b13954f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear_d39ba6bd-feea-4549-b8c6-5d8893d5091b" xlink:href="brns-20240630.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear_d39ba6bd-feea-4549-b8c6-5d8893d5091b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f16f9710-d399-4ed2-aa5d-05e19d556422" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f16f9710-d399-4ed2-aa5d-05e19d556422" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_32096439-16f8-4e89-a848-19f17b04aa20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_32096439-16f8-4e89-a848-19f17b04aa20" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_51c9d013-a2aa-4365-8210-37049fd70f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_51c9d013-a2aa-4365-8210-37049fd70f7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4d0fc820-06d0-4f87-8707-2252901d901c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4d0fc820-06d0-4f87-8707-2252901d901c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_bc918373-116f-4aa8-bc91-eb78426c5127" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_bc918373-116f-4aa8-bc91-eb78426c5127" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_f0c96cee-594e-4885-acee-9a0c4d8ca442" xlink:href="brns-20240630.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_f0c96cee-594e-4885-acee-9a0c4d8ca442" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_8ba455e2-779c-415c-8f40-defaceb46dce" xlink:href="brns-20240630.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_8ba455e2-779c-415c-8f40-defaceb46dce" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:href="brns-20240630.xsd#brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_5ed05b27-8eae-41ce-bdd5-fcd1042dbf24" xlink:href="brns-20240630.xsd#brns_AccruedExpensesAndOtherLiabilitiesCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_5ed05b27-8eae-41ce-bdd5-fcd1042dbf24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13bdfe34-80d9-4b87-81e2-cfe1e665f855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_5ed05b27-8eae-41ce-bdd5-fcd1042dbf24" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13bdfe34-80d9-4b87-81e2-cfe1e665f855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_13bdfe34-80d9-4b87-81e2-cfe1e665f855_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13bdfe34-80d9-4b87-81e2-cfe1e665f855" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_13bdfe34-80d9-4b87-81e2-cfe1e665f855_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c316575-cabb-4e8d-af0b-b60f1fce256b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13bdfe34-80d9-4b87-81e2-cfe1e665f855" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c316575-cabb-4e8d-af0b-b60f1fce256b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e185021-bab9-403a-bd27-243c16516a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c316575-cabb-4e8d-af0b-b60f1fce256b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e185021-bab9-403a-bd27-243c16516a55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_909a3838-8364-4a33-a7bc-5a54f496130d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c316575-cabb-4e8d-af0b-b60f1fce256b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_909a3838-8364-4a33-a7bc-5a54f496130d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_7f99d8e4-88e6-4c9a-9dc7-c4bb57101d5a" xlink:href="brns-20240630.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_7f99d8e4-88e6-4c9a-9dc7-c4bb57101d5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_731c8e6a-372f-49ea-bcb7-ecaf725c0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_AccruedBonusesCurrent_731c8e6a-372f-49ea-bcb7-ecaf725c0f8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1e97d5ed-ab75-48be-86a1-ca1de146a5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1e97d5ed-ab75-48be-86a1-ca1de146a5c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_33a13b11-2f4b-4666-976d-29328c547635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_33a13b11-2f4b-4666-976d-29328c547635" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a8da95aa-2224-4dca-9a56-5ecbc6860acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a8da95aa-2224-4dca-9a56-5ecbc6860acd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_53af2032-6a3f-4f90-9c57-35114e94c967" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_53af2032-6a3f-4f90-9c57-35114e94c967" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_386b0688-45ef-41f2-a3cb-00084c2f3d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_SeveranceCosts1_386b0688-45ef-41f2-a3cb-00084c2f3d9d" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#GrantIncomeAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTable_ddef7941-7033-409a-8db6-6b18d10eb02a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_us-gaap_DeferredIncomeTable_ddef7941-7033-409a-8db6-6b18d10eb02a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e007b9b6-10bb-40e9-a749-0643f9e1e54f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredIncomeTable_ddef7941-7033-409a-8db6-6b18d10eb02a" xlink:to="loc_srt_CounterpartyNameAxis_e007b9b6-10bb-40e9-a749-0643f9e1e54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e007b9b6-10bb-40e9-a749-0643f9e1e54f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e007b9b6-10bb-40e9-a749-0643f9e1e54f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e007b9b6-10bb-40e9-a749-0643f9e1e54f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26e6b8a3-81d8-4b34-a8be-7115ac2ef442" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e007b9b6-10bb-40e9-a749-0643f9e1e54f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26e6b8a3-81d8-4b34-a8be-7115ac2ef442" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember_983f0927-2bd5-4a24-bed5-0e0f5504e1e8" xlink:href="brns-20240630.xsd#brns_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26e6b8a3-81d8-4b34-a8be-7115ac2ef442" xlink:to="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember_983f0927-2bd5-4a24-bed5-0e0f5504e1e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FundingAmountMaximum_0dfca00a-fefa-4d99-8140-f07e7b5c9114" xlink:href="brns-20240630.xsd#brns_FundingAmountMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_brns_FundingAmountMaximum_0dfca00a-fefa-4d99-8140-f07e7b5c9114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RoyaltyPaymentTermMaximum_6e8ef5f8-35d1-4ed2-b283-2b061fa620a4" xlink:href="brns-20240630.xsd#brns_RoyaltyPaymentTermMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_brns_RoyaltyPaymentTermMaximum_6e8ef5f8-35d1-4ed2-b283-2b061fa620a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeAddition_8ea91c18-e12e-42d2-8b86-15aac36c6fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeAddition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_us-gaap_DeferredIncomeAddition_8ea91c18-e12e-42d2-8b86-15aac36c6fb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRevenueRecognized_6e115014-70d5-47f1-8277-47e91bdbe035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_us-gaap_DeferredIncomeRevenueRecognized_6e115014-70d5-47f1-8277-47e91bdbe035" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_02f55677-d1d3-4415-b160-5c96eb724253" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_us-gaap_RestrictedCashCurrent_02f55677-d1d3-4415-b160-5c96eb724253" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#OrdinarySharesDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dd30dbdf-416f-40ae-8707-6b93bf7ceaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dd30dbdf-416f-40ae-8707-6b93bf7ceaa8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e85b4823-3ec3-4b60-8b13-447fb1c2d90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dd30dbdf-416f-40ae-8707-6b93bf7ceaa8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e85b4823-3ec3-4b60-8b13-447fb1c2d90c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e85b4823-3ec3-4b60-8b13-447fb1c2d90c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e85b4823-3ec3-4b60-8b13-447fb1c2d90c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e85b4823-3ec3-4b60-8b13-447fb1c2d90c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b921b9f-e721-4b5e-a8c0-0510c159dd27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e85b4823-3ec3-4b60-8b13-447fb1c2d90c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b921b9f-e721-4b5e-a8c0-0510c159dd27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4dcd056e-a058-4a45-a03f-ee71cc899f65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b921b9f-e721-4b5e-a8c0-0510c159dd27" xlink:to="loc_us-gaap_IPOMember_4dcd056e-a058-4a45-a03f-ee71cc899f65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CommonStockNumberOfVotesPerShare_fe42d4bb-cf96-4e7a-aba5-b8e675268c2d" xlink:href="brns-20240630.xsd#brns_CommonStockNumberOfVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:to="loc_brns_CommonStockNumberOfVotesPerShare_fe42d4bb-cf96-4e7a-aba5-b8e675268c2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_dcd80425-77a8-4cf1-8b46-e8eae8914eb2" xlink:href="brns-20240630.xsd#brns_PercentageOfSharesNecessaryToExercisePreemptiveRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:to="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_dcd80425-77a8-4cf1-8b46-e8eae8914eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PeriodOfPreemptiveRightsToBeExercised_35fabaf4-ca29-42e2-9880-871745f715c9" xlink:href="brns-20240630.xsd#brns_PeriodOfPreemptiveRightsToBeExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:to="loc_brns_PeriodOfPreemptiveRightsToBeExercised_35fabaf4-ca29-42e2-9880-871745f715c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_9beebca6-a682-41df-b406-66eccfdf32da" xlink:href="brns-20240630.xsd#brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:to="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_9beebca6-a682-41df-b406-66eccfdf32da" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/DeferredSharesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#DeferredSharesDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/DeferredSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_50928cbf-e5a8-4c42-b595-7d4db35f8b49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_76759be3-6ab4-4106-9589-199654baa0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_50928cbf-e5a8-4c42-b595-7d4db35f8b49" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_76759be3-6ab4-4106-9589-199654baa0ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_06144e98-e26d-4608-b065-026ac420593b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_76759be3-6ab4-4106-9589-199654baa0ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_06144e98-e26d-4608-b065-026ac420593b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_06144e98-e26d-4608-b065-026ac420593b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_06144e98-e26d-4608-b065-026ac420593b" xlink:to="loc_us-gaap_ClassOfStockDomain_06144e98-e26d-4608-b065-026ac420593b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_06144e98-e26d-4608-b065-026ac420593b" xlink:to="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_bb51de3b-c13c-4668-8918-66994d989f40" xlink:href="brns-20240630.xsd#brns_DeferredShares.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:to="loc_brns_DeferredShares.Member_bb51de3b-c13c-4668-8918-66994d989f40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_da58e1f7-51df-4ba4-b4dd-21e98ed6397e" xlink:href="brns-20240630.xsd#brns_DeferredBSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:to="loc_brns_DeferredBSharesMember_da58e1f7-51df-4ba4-b4dd-21e98ed6397e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_47058bcd-e5a0-459d-a6e8-fb55f2388e24" xlink:href="brns-20240630.xsd#brns_DeferredCSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:to="loc_brns_DeferredCSharesMember_47058bcd-e5a0-459d-a6e8-fb55f2388e24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OrdinarySharesLiquidationPreference_b11b36de-18e4-498c-add7-056b96205477" xlink:href="brns-20240630.xsd#brns_OrdinarySharesLiquidationPreference"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_50928cbf-e5a8-4c42-b595-7d4db35f8b49" xlink:to="loc_brns_OrdinarySharesLiquidationPreference_b11b36de-18e4-498c-add7-056b96205477" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_01dc4e18-5d20-46b9-9e12-9f9d78c76ba7" xlink:href="brns-20240630.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_50928cbf-e5a8-4c42-b595-7d4db35f8b49" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_01dc4e18-5d20-46b9-9e12-9f9d78c76ba7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#FairValueAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d0ec80e2-259e-4ff1-b2ac-406466340bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1e863cb5-92eb-4e4a-8e7a-b657e642afd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d0ec80e2-259e-4ff1-b2ac-406466340bfa" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1e863cb5-92eb-4e4a-8e7a-b657e642afd5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ee34b8c3-b0e9-421a-bb83-682138416d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1e863cb5-92eb-4e4a-8e7a-b657e642afd5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ee34b8c3-b0e9-421a-bb83-682138416d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee34b8c3-b0e9-421a-bb83-682138416d73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee34b8c3-b0e9-421a-bb83-682138416d73" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee34b8c3-b0e9-421a-bb83-682138416d73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44c399ff-2f26-4c41-a2e0-809f38fd7a39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee34b8c3-b0e9-421a-bb83-682138416d73" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44c399ff-2f26-4c41-a2e0-809f38fd7a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AvideaMember_3aed2550-7cd6-4ab8-a4cb-3364582a4553" xlink:href="brns-20240630.xsd#brns_AvideaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44c399ff-2f26-4c41-a2e0-809f38fd7a39" xlink:to="loc_brns_AvideaMember_3aed2550-7cd6-4ab8-a4cb-3364582a4553" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cad13dcf-9c24-4c97-808d-63b0f7be35d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d0ec80e2-259e-4ff1-b2ac-406466340bfa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cad13dcf-9c24-4c97-808d-63b0f7be35d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details" xlink:type="simple" xlink:href="brns-20240630.xsd#FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5af8d2eb-b360-41cb-bad4-ba7a6415add8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_eefb4874-b1e6-4e17-bee3-5817fb6c4c92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5af8d2eb-b360-41cb-bad4-ba7a6415add8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_eefb4874-b1e6-4e17-bee3-5817fb6c4c92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_aa85cf48-bf68-437a-8806-f1c913461547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_eefb4874-b1e6-4e17-bee3-5817fb6c4c92" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_aa85cf48-bf68-437a-8806-f1c913461547" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_aa85cf48-bf68-437a-8806-f1c913461547_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_aa85cf48-bf68-437a-8806-f1c913461547" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_aa85cf48-bf68-437a-8806-f1c913461547_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c7a72d47-8cd1-45f2-ae29-c7fc64c293fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_aa85cf48-bf68-437a-8806-f1c913461547" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c7a72d47-8cd1-45f2-ae29-c7fc64c293fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContingentConsiderationLiabilityMember_fa6b3c4c-cf9f-423e-a4d8-3c677cf55a8d" xlink:href="brns-20240630.xsd#brns_ContingentConsiderationLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c7a72d47-8cd1-45f2-ae29-c7fc64c293fd" xlink:to="loc_brns_ContingentConsiderationLiabilityMember_fa6b3c4c-cf9f-423e-a4d8-3c677cf55a8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5af8d2eb-b360-41cb-bad4-ba7a6415add8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f1e087d2-d6ef-4450-92b7-2316b5703fca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f1e087d2-d6ef-4450-92b7-2316b5703fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7e8405f8-17d9-44eb-8480-dd9cc06e9a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7e8405f8-17d9-44eb-8480-dd9cc06e9a28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_0cfdbb2c-d27a-43a7-8bae-945bc5363a63" xlink:href="brns-20240630.xsd#brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:to="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_0cfdbb2c-d27a-43a7-8bae-945bc5363a63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3e73e0ca-ec7b-4ad9-8be5-653197555a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0a9b4e5-e254-477e-b7f1-9835dfd17bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0a9b4e5-e254-477e-b7f1-9835dfd17bdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ee5430e1-fcca-4c9b-b077-25c2be9888d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0a9b4e5-e254-477e-b7f1-9835dfd17bdd" xlink:to="loc_us-gaap_PlanNameAxis_ee5430e1-fcca-4c9b-b077-25c2be9888d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ee5430e1-fcca-4c9b-b077-25c2be9888d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ee5430e1-fcca-4c9b-b077-25c2be9888d9" xlink:to="loc_us-gaap_PlanNameDomain_ee5430e1-fcca-4c9b-b077-25c2be9888d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3d1ff46e-145e-442d-9509-4fa20735bcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ee5430e1-fcca-4c9b-b077-25c2be9888d9" xlink:to="loc_us-gaap_PlanNameDomain_3d1ff46e-145e-442d-9509-4fa20735bcb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_3b326c4e-04e5-44de-aee3-11a4f6e3824d" xlink:href="brns-20240630.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3d1ff46e-145e-442d-9509-4fa20735bcb2" xlink:to="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_3b326c4e-04e5-44de-aee3-11a4f6e3824d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d43c87b-69b9-4b08-9bff-d056da266c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0a9b4e5-e254-477e-b7f1-9835dfd17bdd" xlink:to="loc_us-gaap_AwardTypeAxis_5d43c87b-69b9-4b08-9bff-d056da266c85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d43c87b-69b9-4b08-9bff-d056da266c85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5d43c87b-69b9-4b08-9bff-d056da266c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d43c87b-69b9-4b08-9bff-d056da266c85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7c1f9b-243d-4660-9a21-57394ad8bb97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5d43c87b-69b9-4b08-9bff-d056da266c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7c1f9b-243d-4660-9a21-57394ad8bb97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_819b1e24-094e-433f-aeea-9fdddb3efd4c" xlink:href="brns-20240630.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7c1f9b-243d-4660-9a21-57394ad8bb97" xlink:to="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_819b1e24-094e-433f-aeea-9fdddb3efd4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b0ae9e84-e046-4e9f-a11b-0d2795734097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7c1f9b-243d-4660-9a21-57394ad8bb97" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b0ae9e84-e046-4e9f-a11b-0d2795734097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_f6f8e7fe-78a0-4a9c-b303-88f48ef95d4b" xlink:href="brns-20240630.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_f6f8e7fe-78a0-4a9c-b303-88f48ef95d4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ebca8223-b395-449b-a72f-d41bb0b1c315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ebca8223-b395-449b-a72f-d41bb0b1c315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b7070ac0-5df9-4211-9972-a04c11a184c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b7070ac0-5df9-4211-9972-a04c11a184c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14221a07-87d4-4387-bad1-2faa55da5792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14221a07-87d4-4387-bad1-2faa55da5792" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_33db028a-f67c-4764-908d-4343cbbf4658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_33db028a-f67c-4764-908d-4343cbbf4658" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dccb659d-6a2c-40d5-a393-5e66dcf31c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dccb659d-6a2c-40d5-a393-5e66dcf31c3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4acf6ab0-6132-4322-8169-d12c123ffae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4acf6ab0-6132-4322-8169-d12c123ffae2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_72cee304-f335-41af-82a5-c3fbfa3c23a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_72cee304-f335-41af-82a5-c3fbfa3c23a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d5426039-1b2c-4499-9d80-ad18e3110ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d5426039-1b2c-4499-9d80-ad18e3110ef8" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#ShareBasedCompensationWeightedaverageassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c787fc09-329d-40b5-8a44-e4dbabd4bd98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c787fc09-329d-40b5-8a44-e4dbabd4bd98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f5f0e011-94ef-4f12-b24a-448e087dc9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c787fc09-329d-40b5-8a44-e4dbabd4bd98" xlink:to="loc_us-gaap_PlanNameAxis_f5f0e011-94ef-4f12-b24a-448e087dc9fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f5f0e011-94ef-4f12-b24a-448e087dc9fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f5f0e011-94ef-4f12-b24a-448e087dc9fe" xlink:to="loc_us-gaap_PlanNameDomain_f5f0e011-94ef-4f12-b24a-448e087dc9fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cda0eb92-3fc8-4322-b6cf-26cf4e40b3af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f5f0e011-94ef-4f12-b24a-448e087dc9fe" xlink:to="loc_us-gaap_PlanNameDomain_cda0eb92-3fc8-4322-b6cf-26cf4e40b3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_9b4460a3-851b-4622-97c8-18597dc80b13" xlink:href="brns-20240630.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cda0eb92-3fc8-4322-b6cf-26cf4e40b3af" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_9b4460a3-851b-4622-97c8-18597dc80b13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_39b9d4aa-354b-4c4b-9c84-d7d02fd764af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_39b9d4aa-354b-4c4b-9c84-d7d02fd764af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c7636273-5c3d-4727-806a-2c2b27bf9ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c7636273-5c3d-4727-806a-2c2b27bf9ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_222ca206-5a99-4a91-ba60-c9627ac27f90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_222ca206-5a99-4a91-ba60-c9627ac27f90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f3a3d31a-48e1-4314-a906-d42400172a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f3a3d31a-48e1-4314-a906-d42400172a0c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#ShareBasedCompensationSharebasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75976122-4189-470a-8009-eb9edd67f4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8862c929-651f-4a5c-a358-4b313755b390" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75976122-4189-470a-8009-eb9edd67f4ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8862c929-651f-4a5c-a358-4b313755b390" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_303c8d45-2944-49e0-b7eb-c73b36d0a12d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8862c929-651f-4a5c-a358-4b313755b390" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_303c8d45-2944-49e0-b7eb-c73b36d0a12d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_303c8d45-2944-49e0-b7eb-c73b36d0a12d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_303c8d45-2944-49e0-b7eb-c73b36d0a12d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_303c8d45-2944-49e0-b7eb-c73b36d0a12d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f469a60-4afa-41fb-8a4b-d29d1e670998" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_303c8d45-2944-49e0-b7eb-c73b36d0a12d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f469a60-4afa-41fb-8a4b-d29d1e670998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60a3816f-6673-4f1a-b7fe-433b3ee269cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f469a60-4afa-41fb-8a4b-d29d1e670998" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60a3816f-6673-4f1a-b7fe-433b3ee269cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_caeb5819-43db-414b-b840-ac13a010f234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f469a60-4afa-41fb-8a4b-d29d1e670998" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_caeb5819-43db-414b-b840-ac13a010f234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_289d82da-5454-459a-98d3-233a5b40cdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75976122-4189-470a-8009-eb9edd67f4ca" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_289d82da-5454-459a-98d3-233a5b40cdd5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44a810dc-70a9-4b35-9d88-cb7277fc79d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44a810dc-70a9-4b35-9d88-cb7277fc79d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44a810dc-70a9-4b35-9d88-cb7277fc79d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44a810dc-70a9-4b35-9d88-cb7277fc79d1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44a810dc-70a9-4b35-9d88-cb7277fc79d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f81c26fe-3274-425c-8169-e4e3e38f4dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44a810dc-70a9-4b35-9d88-cb7277fc79d1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f81c26fe-3274-425c-8169-e4e3e38f4dd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_InLicenseAgreementsMember_aa63cd64-d6b9-4093-9987-b38d09ed512d" xlink:href="brns-20240630.xsd#brns_InLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f81c26fe-3274-425c-8169-e4e3e38f4dd8" xlink:to="loc_brns_InLicenseAgreementsMember_aa63cd64-d6b9-4093-9987-b38d09ed512d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_535d9205-a9b1-435d-80f1-d929ce5485d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:to="loc_srt_RangeAxis_535d9205-a9b1-435d-80f1-d929ce5485d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_535d9205-a9b1-435d-80f1-d929ce5485d3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_535d9205-a9b1-435d-80f1-d929ce5485d3" xlink:to="loc_srt_RangeMember_535d9205-a9b1-435d-80f1-d929ce5485d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cfefda7a-deec-4e74-bbac-8ea7b7d195e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_535d9205-a9b1-435d-80f1-d929ce5485d3" xlink:to="loc_srt_RangeMember_cfefda7a-deec-4e74-bbac-8ea7b7d195e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_80d33971-4ed2-466b-9ee1-496677365c55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cfefda7a-deec-4e74-bbac-8ea7b7d195e7" xlink:to="loc_srt_MinimumMember_80d33971-4ed2-466b-9ee1-496677365c55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8a8b1209-7674-4d59-92e7-d850af03bf71" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cfefda7a-deec-4e74-bbac-8ea7b7d195e7" xlink:to="loc_srt_MaximumMember_8a8b1209-7674-4d59-92e7-d850af03bf71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d0c0522c-0b5a-4f97-adb2-05e10085dc5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:to="loc_srt_StatementGeographicalAxis_d0c0522c-0b5a-4f97-adb2-05e10085dc5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d0c0522c-0b5a-4f97-adb2-05e10085dc5c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d0c0522c-0b5a-4f97-adb2-05e10085dc5c" xlink:to="loc_srt_SegmentGeographicalDomain_d0c0522c-0b5a-4f97-adb2-05e10085dc5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_70f9d2cc-5013-4c68-ba86-47aa2a15881d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d0c0522c-0b5a-4f97-adb2-05e10085dc5c" xlink:to="loc_srt_SegmentGeographicalDomain_70f9d2cc-5013-4c68-ba86-47aa2a15881d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordshireMember_7fd1c66e-bb38-4a69-855d-4769ac5da91a" xlink:href="brns-20240630.xsd#brns_OxfordshireMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_70f9d2cc-5013-4c68-ba86-47aa2a15881d" xlink:to="loc_brns_OxfordshireMember_7fd1c66e-bb38-4a69-855d-4769ac5da91a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_c09e5faf-478f-4870-afa4-20c87f87bec7" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_70f9d2cc-5013-4c68-ba86-47aa2a15881d" xlink:to="loc_stpr_MD_c09e5faf-478f-4870-afa4-20c87f87bec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_5bf9b250-2f31-4f52-a7af-d8e9bf195171" xlink:href="brns-20240630.xsd#brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_5bf9b250-2f31-4f52-a7af-d8e9bf195171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_5087f0d0-6249-493a-b399-84a87db924bd" xlink:href="brns-20240630.xsd#brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_5087f0d0-6249-493a-b399-84a87db924bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_0c58328d-e535-44b2-bfb7-7a0a720ae893" xlink:href="brns-20240630.xsd#brns_NumberOfSquareFeetUnderLeaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_0c58328d-e535-44b2-bfb7-7a0a720ae893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_6971f328-efeb-4fbd-8367-3699d24768d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_us-gaap_SecurityDeposit_6971f328-efeb-4fbd-8367-3699d24768d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseExtendedTerm_8952c6ad-0873-4c65-bf09-132c6c90c7c2" xlink:href="brns-20240630.xsd#brns_LesseeOperatingLeaseExtendedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_brns_LesseeOperatingLeaseExtendedTerm_8952c6ad-0873-4c65-bf09-132c6c90c7c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_becc52bf-0a55-4436-a7d3-34f8ef96a2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_becc52bf-0a55-4436-a7d3-34f8ef96a2ac" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1358f1be-b284-4466-af4c-7b418e72febc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1358f1be-b284-4466-af4c-7b418e72febc" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2dfc7d50-3ad1-4eef-a69c-b766a4db4ffc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:to="loc_srt_CounterpartyNameAxis_2dfc7d50-3ad1-4eef-a69c-b766a4db4ffc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2dfc7d50-3ad1-4eef-a69c-b766a4db4ffc_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2dfc7d50-3ad1-4eef-a69c-b766a4db4ffc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2dfc7d50-3ad1-4eef-a69c-b766a4db4ffc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4889a89b-bd7f-4a44-976f-8f3ce8c743b5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2dfc7d50-3ad1-4eef-a69c-b766a4db4ffc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4889a89b-bd7f-4a44-976f-8f3ce8c743b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationLimitedMember_11a14938-8809-4547-b1ef-d504095e1c95" xlink:href="brns-20240630.xsd#brns_OxfordUniversityInnovationLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4889a89b-bd7f-4a44-976f-8f3ce8c743b5" xlink:to="loc_brns_OxfordUniversityInnovationLimitedMember_11a14938-8809-4547-b1ef-d504095e1c95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_6beb31c2-9e8e-4027-bb9e-db12975980a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_6beb31c2-9e8e-4027-bb9e-db12975980a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_6beb31c2-9e8e-4027-bb9e-db12975980a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6beb31c2-9e8e-4027-bb9e-db12975980a9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_6beb31c2-9e8e-4027-bb9e-db12975980a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5b68395a-f86b-416e-9b38-b7123de373f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6beb31c2-9e8e-4027-bb9e-db12975980a9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5b68395a-f86b-416e-9b38-b7123de373f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpensesMember_39883748-1bec-4f69-97f4-8b3372a8d291" xlink:href="brns-20240630.xsd#brns_ExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5b68395a-f86b-416e-9b38-b7123de373f3" xlink:to="loc_brns_ExpensesMember_39883748-1bec-4f69-97f4-8b3372a8d291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ca0382c-a786-4733-8c0d-30bd61d6ae10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ca0382c-a786-4733-8c0d-30bd61d6ae10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1ca0382c-a786-4733-8c0d-30bd61d6ae10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ca0382c-a786-4733-8c0d-30bd61d6ae10" xlink:to="loc_us-gaap_RelatedPartyDomain_1ca0382c-a786-4733-8c0d-30bd61d6ae10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c55cd835-dd6f-4183-9e93-e31f0c1bfdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ca0382c-a786-4733-8c0d-30bd61d6ae10" xlink:to="loc_us-gaap_RelatedPartyDomain_c55cd835-dd6f-4183-9e93-e31f0c1bfdcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_9f1d8b46-5880-4336-8bc1-824d076cad43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c55cd835-dd6f-4183-9e93-e31f0c1bfdcc" xlink:to="loc_us-gaap_RelatedPartyMember_9f1d8b46-5880-4336-8bc1-824d076cad43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ffb05811-1db8-4b89-8006-9d9b75618196" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:to="loc_srt_ProductOrServiceAxis_ffb05811-1db8-4b89-8006-9d9b75618196" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ffb05811-1db8-4b89-8006-9d9b75618196_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ffb05811-1db8-4b89-8006-9d9b75618196" xlink:to="loc_srt_ProductsAndServicesDomain_ffb05811-1db8-4b89-8006-9d9b75618196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2cb0a264-0ce2-47a0-95fd-de7f63886623" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ffb05811-1db8-4b89-8006-9d9b75618196" xlink:to="loc_srt_ProductsAndServicesDomain_2cb0a264-0ce2-47a0-95fd-de7f63886623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ae054627-92f7-4bac-b203-22f314b3e3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2cb0a264-0ce2-47a0-95fd-de7f63886623" xlink:to="loc_us-gaap_LicenseMember_ae054627-92f7-4bac-b203-22f314b3e3f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_146708d6-71d6-4279-975b-52854f9469eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1358f1be-b284-4466-af4c-7b418e72febc" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_146708d6-71d6-4279-975b-52854f9469eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e23582ee-c9f2-4c23-bc66-f3adf457c94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1358f1be-b284-4466-af4c-7b418e72febc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e23582ee-c9f2-4c23-bc66-f3adf457c94d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_410ba25c-53c1-4031-a147-861b7afb9c44" xlink:href="brns-20240630.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_410ba25c-53c1-4031-a147-861b7afb9c44" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>brns-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a110c5a-492b-47ac-b990-632b9a151dae,g:0cb2830b-fcfe-4af5-8a4f-fdc83046615c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_879ac327-7d46-42dd-9bac-121f75f1ec14_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation in General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_1acf8db6-d207-48ae-9f60-e11d3ceef2c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4322a93c-e401-480c-b892-36915e3972c9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net (loss)/income to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredSharesMember_fb26bcb7-70a4-461c-b5e9-0c8ae79000bf_verboseLabel_en-US" xlink:label="lab_brns_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_brns_DeferredSharesMember_label_en-US" xlink:label="lab_brns_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Shares [Member]</link:label>
    <link:label id="lab_brns_DeferredSharesMember_documentation_en-US" xlink:label="lab_brns_DeferredSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to deferred shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredSharesMember" xlink:href="brns-20240630.xsd#brns_DeferredSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredSharesMember" xlink:to="lab_brns_DeferredSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f358cc77-d270-4905-b133-3e6cc344c0f2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_cd4a361a-e0d2-4d84-b7d6-cd6ca979c322_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_48f26aa6-2d10-4e2e-8128-0f2c7230a8d9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_3c5786bb-b5a0-45be-8d52-a1d229f4949c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_25c73747-641b-449b-8221-20b53e9c316b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a8774f7-3fbe-4ae6-9ebd-31bc2d9cd1a4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2b0ecb1f-b203-4824-8091-7ea3562de80e_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of maturities of minimum lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d7cda033-a003-4a75-b4ac-1eb868ac27a8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7c367a96-153a-4937-8070-fcba83d8e6f6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_298afaa9-79c3-4a16-a2a1-9111c7957d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of computation of basic and diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeCurrent_4c644e58-25d5-473e-ba6a-193f92572897_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeCurrent" xlink:to="lab_us-gaap_DeferredIncomeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_38ccac55-bdaa-41d1-beea-68961d2fec30_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment and Contingencies</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_01af48c8-b940-40e3-adf3-daf7ce81ea9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_fca7ff8f-e1fd-409d-9096-4dbc24328090_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable (including related parties)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a8d4e444-a1bd-4cb4-b261-f8f5f3d803a7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2ed632bf-dd5d-4ab9-90f5-db4812adbdd1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c50e5bc6-918d-4859-9196-f079a9ec027d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8dbb27c9-3036-438b-8349-4cdffdd2de23_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ebc28128-3820-4d00-a809-38b8dc2c2588_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_894fcca9-9514-419c-8985-91e184d970f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_bb3e13e1-4201-4000-a8d4-99680e795ae9_terseLabel_en-US" xlink:label="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ordinary shares present to exercise preemptive rights</link:label>
    <link:label id="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_label_en-US" xlink:label="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Shares Necessary To Exercise Preemptive Rights</link:label>
    <link:label id="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_documentation_en-US" xlink:label="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum percentage of shares required to exercise preemptive rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:href="brns-20240630.xsd#brns_PercentageOfSharesNecessaryToExercisePreemptiveRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:to="lab_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9b437a7c-af9c-4dc4-9ec8-ff4e097affb0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability - non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6373dfdd-5ba4-454f-96ad-a01163df204d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_3dc91809-3cb8-41de-9f1d-8e8c1c8b9594_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_df365f2c-880e-44f8-b6d3-8dd38d1a3e69_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ff1da21f-5e66-415f-a1d5-a4262f27a3b8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_2a016933-e3ab-4e72-b480-fcef2c9611c6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross amount of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bdca3423-46d1-4ed1-934c-0db66d8c682b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ExpensesMember_0a426a8f-ccca-4790-960e-af8f9a778d86_terseLabel_en-US" xlink:label="lab_brns_ExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_brns_ExpensesMember_label_en-US" xlink:label="lab_brns_ExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses [Member]</link:label>
    <link:label id="lab_brns_ExpensesMember_documentation_en-US" xlink:label="lab_brns_ExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpensesMember" xlink:href="brns-20240630.xsd#brns_ExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ExpensesMember" xlink:to="lab_brns_ExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2c068eb6-7c1f-42e1-80a7-af03f984b038_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7cfa940-06ad-4dca-be0a-e3e6cc823006_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_331f5b46-f348-44fb-96a0-194a1765f90f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockSharesOutstanding_7482ab55-d3d4-403c-8d41-ebbb1557f544_terseLabel_en-US" xlink:label="lab_brns_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, outstanding (in shares)</link:label>
    <link:label id="lab_brns_DeferredStockSharesOutstanding_label_en-US" xlink:label="lab_brns_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Outstanding</link:label>
    <link:label id="lab_brns_DeferredStockSharesOutstanding_documentation_en-US" xlink:label="lab_brns_DeferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of deferred stock outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesOutstanding" xlink:href="brns-20240630.xsd#brns_DeferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockSharesOutstanding" xlink:to="lab_brns_DeferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_fcd1e9eb-1b01-4edb-b3e4-5ddd2dfb0d5f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_a763a8dc-fb93-4341-ad26-8986c618b635_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayments and accrued income</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d12f0f8a-390b-480e-a2fe-e7f0ca850f11_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6ac95fb2-243b-4d6b-a4ea-e7ce38142e94_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_998010f4-c7d7-41c5-bfed-c8e0c32f5a14_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8891e51b-a0ab-4301-a25b-aa42885d7c52_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c5d40c60-80d7-460a-a537-5259fcec9640_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OrdinarySharesLiquidationPreference_034d2d74-7c0c-41b5-afa2-8a49d585286b_terseLabel_en-US" xlink:label="lab_brns_OrdinarySharesLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, liquidation preference</link:label>
    <link:label id="lab_brns_OrdinarySharesLiquidationPreference_label_en-US" xlink:label="lab_brns_OrdinarySharesLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary Shares, Liquidation Preference</link:label>
    <link:label id="lab_brns_OrdinarySharesLiquidationPreference_documentation_en-US" xlink:label="lab_brns_OrdinarySharesLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OrdinarySharesLiquidationPreference" xlink:href="brns-20240630.xsd#brns_OrdinarySharesLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OrdinarySharesLiquidationPreference" xlink:to="lab_brns_OrdinarySharesLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f5202d3c-c0ec-460e-a6c2-138f9d987bbe_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_35665c3a-3e55-4588-a885-1ec6aff45749_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e804e938-925f-4bc5-aa02-9b3a95dceb8f_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2fad7129-4ffd-41e1-87df-1c1fb90dfd80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeAddition_f0e7a02f-ecdb-409e-b430-e7b05ac99fb6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeAddition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments received</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeAddition_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeAddition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income, Addition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeAddition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeAddition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeAddition" xlink:to="lab_us-gaap_DeferredIncomeAddition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_254b7612-e677-4268-9129-649f76c0a9d7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_ce8d9882-7113-4bd0-a08d-3c97f74b826a_terseLabel_en-US" xlink:label="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enterprise Management Incentive Share Option Scheme</link:label>
    <link:label id="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_label_en-US" xlink:label="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enterprise Management Incentive Share Option Scheme [Member]</link:label>
    <link:label id="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_documentation_en-US" xlink:label="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the Enterprise Management Incentive Share Option Scheme.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:href="brns-20240630.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:to="lab_brns_EnterpriseManagementIncentiveShareOptionSchemeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_bcdb5a1a-bd65-4cdc-a7c0-e08320c21b12_terseLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities And Other Current Liabilities [Table Text Block]</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the components of accrued liabilities and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_34a34066-0f56-46e9-86cf-bee726362ef2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income and Expense [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_0dfa24e3-bd7f-44f7-bff8-d811f1fec85c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d6377a16-14a5-420e-9d6b-e5c5f5558535_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_080b2eda-0930-4965-b4d3-6580912e6375_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5cd5c70b-de52-4c97-b610-4a434cfb123d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_bc4418e3-9e93-4460-adae-06fd815a2b57_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PeriodOfPreemptiveRightsToBeExercised_06fc2e54-67a4-4e04-a11c-3b77bfdd64c4_terseLabel_en-US" xlink:label="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum period to exercise preemptive rights</link:label>
    <link:label id="lab_brns_PeriodOfPreemptiveRightsToBeExercised_label_en-US" xlink:label="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Preemptive Rights To Be Exercised</link:label>
    <link:label id="lab_brns_PeriodOfPreemptiveRightsToBeExercised_documentation_en-US" xlink:label="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period allowed to exercise preemptive rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:href="brns-20240630.xsd#brns_PeriodOfPreemptiveRightsToBeExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:to="lab_brns_PeriodOfPreemptiveRightsToBeExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_76db93c5-1682-4cd1-89b0-9d5ee8b0394e_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_c1da0b2c-c1f7-4190-9f2b-f02f9d22f829_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4fd925fc-a8c7-4cb4-9679-58cfe43127da_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_ec7afaf5-c75e-41fd-a130-28afc4cf002f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_fe07fb3b-f7b5-42d9-90d8-0b368bf85e8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockSharesAuthorized_3eb9cf42-8542-4554-95c2-a4730994f04b_terseLabel_en-US" xlink:label="lab_brns_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, authorized (in shares)</link:label>
    <link:label id="lab_brns_DeferredStockSharesAuthorized_label_en-US" xlink:label="lab_brns_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Authorized</link:label>
    <link:label id="lab_brns_DeferredStockSharesAuthorized_documentation_en-US" xlink:label="lab_brns_DeferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesAuthorized" xlink:href="brns-20240630.xsd#brns_DeferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockSharesAuthorized" xlink:to="lab_brns_DeferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredTaxLiabilityNet_51bf68d4-e576-4ddc-8b9b-cdaf599b6b85_terseLabel_en-US" xlink:label="lab_brns_DeferredTaxLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability, net</link:label>
    <link:label id="lab_brns_DeferredTaxLiabilityNet_label_en-US" xlink:label="lab_brns_DeferredTaxLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liability, Net</link:label>
    <link:label id="lab_brns_DeferredTaxLiabilityNet_documentation_en-US" xlink:label="lab_brns_DeferredTaxLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of classified as non-current liabilities, net value of deferred tax liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxLiabilityNet" xlink:href="brns-20240630.xsd#brns_DeferredTaxLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredTaxLiabilityNet" xlink:to="lab_brns_DeferredTaxLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5981be21-a0e0-4203-a6d4-fa924765f865_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_857b7f32-036d-4eeb-b01d-678b0e8d712e_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d663792c-41b5-4949-abae-7e6a5253b5ac_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_937d11d0-98df-4087-b07c-abf92d403052_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NonCashLeaseExpenses_a755d80c-3c4f-4ba1-9b3e-6a4d25e56d4d_terseLabel_en-US" xlink:label="lab_brns_NonCashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expenses</link:label>
    <link:label id="lab_brns_NonCashLeaseExpenses_label_en-US" xlink:label="lab_brns_NonCashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Lease Expenses</link:label>
    <link:label id="lab_brns_NonCashLeaseExpenses_documentation_en-US" xlink:label="lab_brns_NonCashLeaseExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-cash lease expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashLeaseExpenses" xlink:href="brns-20240630.xsd#brns_NonCashLeaseExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NonCashLeaseExpenses" xlink:to="lab_brns_NonCashLeaseExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_28af2ca1-a921-45cb-9946-7a0b453dab25_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_1ad5ae90-f9c5-4933-b524-0e75a5888b3e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_45d34610-a019-4866-8085-d1a6e8f260b2_terseLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_label_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities And Other Current Liabilities [Text Block]</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure of the components of accrued liabilities and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:to="lab_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_01177cfb-9a04-45a8-9ae1-594b55d804d3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_30667f23-f447-4273-9fe3-38691b45099a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_ccf1929c-5984-4529-8add-45f0c32b54d5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_69fee103-1a58-4f73-ad7d-93d2bea70184_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value (in gbp per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8f395208-18b7-45c3-9b81-c4136d7fbe9d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7bbb64a8-1f34-4b91-b548-123fb2e5f59b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3c9b03a4-63a8-46dc-80a1-2be56416d244_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_69ec918f-7d9b-4f44-b382-4c6e36340c46_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_1dfbdfe1-d871-49f6-b504-a6a0adc2786f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_35590a30-6273-4ae6-8cc6-67965829c5b8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e1cbec73-09c8-45dd-8e25-ab3c809c439b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeLineItems_e67221aa-7e83-4a56-964e-b4d2d2991b05_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeLineItems" xlink:to="lab_us-gaap_DeferredIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockParOrStatedValuePerShare_9ddad486-e4a2-49cb-ba08-5654f1039b51_terseLabel_en-US" xlink:label="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, nominal value (in gbp per share)</link:label>
    <link:label id="lab_brns_DeferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Par Or Stated Value Per Share</link:label>
    <link:label id="lab_brns_DeferredStockParOrStatedValuePerShare_documentation_en-US" xlink:label="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Face amount or stated value per share of deferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare" xlink:href="brns-20240630.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockParOrStatedValuePerShare" xlink:to="lab_brns_DeferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ContingentConsiderationLiabilityMember_9f841ea1-359c-4d0c-8a30-3627aa1761d9_terseLabel_en-US" xlink:label="lab_brns_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Liability</link:label>
    <link:label id="lab_brns_ContingentConsiderationLiabilityMember_label_en-US" xlink:label="lab_brns_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Liability [Member]</link:label>
    <link:label id="lab_brns_ContingentConsiderationLiabilityMember_documentation_en-US" xlink:label="lab_brns_ContingentConsiderationLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to contingent consideration liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContingentConsiderationLiabilityMember" xlink:href="brns-20240630.xsd#brns_ContingentConsiderationLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ContingentConsiderationLiabilityMember" xlink:to="lab_brns_ContingentConsiderationLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_48490687-1f49-4bf2-8813-3f7c0352e10e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_2836ce41-b0a8-4237-a3d7-32dfe1cc1472_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_599f62ba-6dfd-442c-8b2e-a947935d23eb_terseLabel_en-US" xlink:label="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share units, options, share appreciation rights and restricted shares</link:label>
    <link:label id="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_label_en-US" xlink:label="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Units Stock Options Share Appreciation Rights And Restricted Shares [Member]</link:label>
    <link:label id="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_documentation_en-US" xlink:label="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to aggregate awards under a specific share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:href="brns-20240630.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:to="lab_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_3499f2b8-ab44-4490-be71-00cc72523fa0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c46fc262-b2de-48f7-a966-4e63f0589e94_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ordinary shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f285e2c4-9d66-4ea2-a4d0-aca2881a1326_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ordinary shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_cc677442-0bf2-4bee-9bdc-8cebae0fd9fd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc shareholders</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_0674994d-f692-4822-ae89-2de469a58288_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_2f00ae3e-0890-45c6-b3ce-5ba5d90623b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_cade586a-bcfe-47cf-bd5f-aeccdda2a591_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cea60922-269a-4fe7-842c-acf7a80828cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e00652c5-2d9d-4fb1-9331-145c6bff5c2d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear_80ee23b6-5ae7-4b3d-96a7-abbcc63e16a4_terseLabel_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2024</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear_label_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Current Year</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear_documentation_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear" xlink:href="brns-20240630.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear" xlink:to="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_33caf674-767e-4362-a9c6-7c18a7696dcd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LesseeOperatingLeaseExtendedTerm_0d3b560c-a7c3-4fb0-9846-e65fa2191e00_terseLabel_en-US" xlink:label="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional lease term</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseExtendedTerm_label_en-US" xlink:label="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease, Extended Term</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseExtendedTerm_documentation_en-US" xlink:label="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseExtendedTerm" xlink:href="brns-20240630.xsd#brns_LesseeOperatingLeaseExtendedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LesseeOperatingLeaseExtendedTerm" xlink:to="lab_brns_LesseeOperatingLeaseExtendedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyAbstract_7233723e-b50c-45b8-9c41-11f1c00057f3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency [Abstract]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyAbstract" xlink:to="lab_us-gaap_ForeignCurrencyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_b9c3a4c8-302e-4427-9e13-273b48c0445f_terseLabel_en-US" xlink:label="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Barinthus Biotherapeutics plc Share Award Plan 2021</link:label>
    <link:label id="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_label_en-US" xlink:label="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Barinthus Biotherapeutics plc Share Award Plan 2021 [Member]</link:label>
    <link:label id="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_documentation_en-US" xlink:label="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Barinthus Biotherapeutics plc Share Award Plan 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:href="brns-20240630.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:to="lab_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d360dcfb-f7f8-4eeb-9d87-efcd722ac82a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_72f33361-89d4-43f3-8eea-3a203028a55d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_66ec2164-dc83-404b-9f75-4beae53002c5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_866f9bda-5d72-4330-bbff-9868c17d2b72_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_7c541d26-b106-4414-85e0-99a21a15d45d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5179c4ed-e0bb-46bd-8b0e-26344cc1a0a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_0d0932b8-b9e7-4678-8b41-c4ce3b31998d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_71676d80-bcf3-48d9-95d0-094420e7bd40_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_2b7d9195-8667-4ca2-860c-be84f4320a57_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_16c6e816-0966-4a2c-aecb-d742033d26a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income/(expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_e00deeb7-cef6-4aae-8453-d7b95ee8ef41_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_00b783bc-cbb7-449d-86f5-cc6e0419b76c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_472febd2-3a06-4af8-b2eb-37e71aa614c0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_1306b899-3252-4599-89e4-d69fb10ec192_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense for intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_714fe526-1370-4f37-94c7-24977126bcd6_negatedLabel_en-US" xlink:label="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives receivable</link:label>
    <link:label id="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_label_en-US" xlink:label="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Research and Development Incentives Receivable</link:label>
    <link:label id="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_documentation_en-US" xlink:label="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in research and development incentives receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:href="brns-20240630.xsd#brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:to="lab_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_44389724-fa05-4193-ad7f-4a52bc4f7a00_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3c5bca98-5bdd-4237-99a2-120547f73b19_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8b76b048-57b6-48ef-9c42-01169d1bbd09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockValueIssued_b69bce35-c7c0-49db-ad28-74213ec2a202_terseLabel_en-US" xlink:label="lab_brns_DeferredStockValueIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred A shares, &#163;1 nominal value; 63,443 shares authorized, issued and outstanding (December&#160;31, 2023: authorized, issued and outstanding: 63,443)</link:label>
    <link:label id="lab_brns_DeferredStockValueIssued_label_en-US" xlink:label="lab_brns_DeferredStockValueIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Value Issued</link:label>
    <link:label id="lab_brns_DeferredStockValueIssued_documentation_en-US" xlink:label="lab_brns_DeferredStockValueIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate par or stated value of issued deferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued" xlink:href="brns-20240630.xsd#brns_DeferredStockValueIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockValueIssued" xlink:to="lab_brns_DeferredStockValueIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c2c6bd3e-4eec-4c9a-9d63-67c36a4a2755_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted-average assumptions of fair value stock option issued to employees</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_aa51f93f-5650-4d42-a37c-517c58cb32e9_terseLabel_en-US" xlink:label="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights</link:label>
    <link:label id="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_label_en-US" xlink:label="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre-emption Rights</link:label>
    <link:label id="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_documentation_en-US" xlink:label="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:href="brns-20240630.xsd#brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:to="lab_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_bf0f1f3a-5bb2-46b5-a2ef-67058c36eb80_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_22ef838d-c4b1-491f-99e7-0dce01afcb17_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts of related party transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ce4fc25b-c572-49da-b63f-9315af11856d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_ca1c14c2-ca51-4454-b42d-df18a03cf15f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_45df251d-c964-4c1e-8ced-df00d8867e02_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_292118e4-5449-46c4-a623-ef246dc5d858_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d797054c-dd2d-495c-ab61-b2e941932743_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_ed9cf6d8-6c42-41ac-8498-4054e75bde03_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_6c11aeb5-495d-4dcc-9a8a-1bbb9c736a53_terseLabel_en-US" xlink:label="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes to right-of-use asset resulting from lease reassessment event</link:label>
    <link:label id="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_label_en-US" xlink:label="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes to right-of-use asset resulting from lease reassessment event</link:label>
    <link:label id="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_documentation_en-US" xlink:label="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of changes to right-of-use asset resulting from lease reassessment event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:href="brns-20240630.xsd#brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:to="lab_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ebbea949-760f-453c-a18c-165ca98f6a69_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in-Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_44827881-6d59-4c73-9fa5-c473db2c42e1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9e06c2c7-b149-4356-a374-adca08682b96_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares [Line items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fe0ff3c4-ea78-4450-a835-31f31bbef565_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently issued accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0c762d43-e51c-49a3-994c-02f5fc013b38_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b4ab6bba-1c56-4a7d-9500-c676ff36cb85_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_85834a5e-bbd4-4582-8784-1e4fc95b3a15_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeRevenueRecognized_f87a7060-a55c-46e1-9355-cccdd2fb461c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income recognized related to the Funding Agreement</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeRevenueRecognized_ad1fc117-455a-487c-b551-22363842c1d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other operating income recognized related to the Funding Agreement</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeRevenueRecognized" xlink:to="lab_us-gaap_DeferredIncomeRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_041aabf3-b45a-4060-ac54-5cafcae7af98_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_64bd3de3-0032-47b5-a1ac-57a7d1706887_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization for amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8ca0adda-1ae3-40d8-aa45-91db6196ad03_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_b17f5907-87ed-4ca9-8c52-768579030989_terseLabel_en-US" xlink:label="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of issued and outstanding ordinary shares available for issuance under the Plan</link:label>
    <link:label id="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_label_en-US" xlink:label="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation, Percentage Of Shares Available For Issuance As A Percentage Of Issued And Outstanding Shares</link:label>
    <link:label id="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_documentation_en-US" xlink:label="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:href="brns-20240630.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:to="lab_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_45647a00-5ab3-46ee-a4f8-dea627146a7e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_db125f9e-906c-43ad-b776-50937394ac38_terseLabel_en-US" xlink:label="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Liabilities, Current [Line Items]</link:label>
    <link:label id="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_label_en-US" xlink:label="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Liabilities, Current [Line Items]</link:label>
    <link:label id="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_documentation_en-US" xlink:label="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Liabilities, Current [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems" xlink:href="brns-20240630.xsd#brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems" xlink:to="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_65d05f73-b5bb-4c44-8eca-12314b98936f_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value Added Tax receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss_5b576a36-27cf-49b4-aa6f-ef4b43faa5d7_negatedTerseLabel_en-US" xlink:label="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation</link:label>
    <link:label id="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss_label_en-US" xlink:label="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income, Foreign Exchange Translation Gain (Loss)</link:label>
    <link:label id="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss_documentation_en-US" xlink:label="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Income, Foreign Exchange Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:href="brns-20240630.xsd#brns_DeferredIncomeForeignExchangeTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:to="lab_brns_DeferredIncomeForeignExchangeTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_3dbec7bb-81de-4af7-a82b-38c3e638b719_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a1d281ef-7767-4d63-8a36-92e5804c160e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net foreign exchange gain (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7bc9dc8c-d670-4a18-8429-f1166e35ce36_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange (gain)/loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7af3049f-71b4-4471-850d-efb01929412b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_09a58a6a-f9b5-4fe9-a94c-b3b67e650b44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_8a14c21d-fb26-42fb-b9dc-946c177b3fd1_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ddcf7289-208e-4849-9690-d4e2fcfcd42f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c0e07baf-3925-4a2b-b066-bd9abd81ad8e_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_65bd17bf-d01c-4d69-9eb2-b2073b6cdbb8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_eeafd87f-80eb-44ab-bd81-bb2c01c4ea67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_de2417c7-4132-4771-b67e-a3467e804130_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e901e602-628b-4b81-bb68-51a18804937a_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period over which unrecognized compensation cost is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares_cdcf3c6d-c1a8-4e2a-a33e-563d5aa5eb1b_negatedTerseLabel_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of deferred shares (in shares)</link:label>
    <link:label id="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares_label_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Cancelled During Period, Shares, Deferred Shares</link:label>
    <link:label id="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares_documentation_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of deferred shares cancelled during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:href="brns-20240630.xsd#brns_SharesCancelledDuringPeriodSharesDeferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:to="lab_brns_SharesCancelledDuringPeriodSharesDeferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_edd7965a-7d20-4cc2-a5fd-afaf65ced985_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_52460359-0758-49f3-967c-822f1416d7be_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_60d7bc97-dd36-4d4d-8741-5619530eda49_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7db8437c-8e82-4e68-96da-f2193126b898_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_61a78411-a02c-4107-a8d5-339f161ed01b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_5afe158f-8ec2-414d-be6a-13059a9254e5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_73fbc978-11bc-4052-ac6e-b9ca5ea57efb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_eba42969-54cb-41f9-a488-be968cbdaab1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e3f6f63a-90ef-4256-97d7-d9ad6a757635_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_960151f0-9550-435c-a085-c49308e60c0e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a2e18c7e-7747-4026-b43c-87fd33d47f53_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_226ddb1d-bcf1-42ac-bca5-14f84f43fcd8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_ee174ff0-c958-449f-82ec-8fb45e495042_terseLabel_en-US" xlink:label="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of right-of-use assets, lease liabilities and other information</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_label_en-US" xlink:label="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Right of Use asset and Other Information [Table Text Block]</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_documentation_en-US" xlink:label="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure for Company's right-of-use asset and lease liability and other information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:href="brns-20240630.xsd#brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:to="lab_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3215bf77-75d1-4ca8-bc03-681522839415_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f25fe35f-b0c9-4b1d-9d44-fe85b2faa932_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_4b30199c-b29a-400f-8915-d7347f8efdcb_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_945e013c-3b64-48e8-add9-64aebf5212a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_7bff7b02-c373-449b-a3ea-851b7f374d60_terseLabel_en-US" xlink:label="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Shares</link:label>
    <link:label id="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_label_en-US" xlink:label="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders Equity Deferred Shares Disclosure [Text Block]</link:label>
    <link:label id="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_documentation_en-US" xlink:label="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for Deferred Shares as disclosed by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:href="brns-20240630.xsd#brns_StockholdersEquityDeferredSharesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:to="lab_brns_StockholdersEquityDeferredSharesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_InLicenseAgreementsMember_852fc520-7640-486b-8534-be20bc3c3fbb_terseLabel_en-US" xlink:label="lab_brns_InLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-License Agreements</link:label>
    <link:label id="lab_brns_InLicenseAgreementsMember_label_en-US" xlink:label="lab_brns_InLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In-License Agreements [Member]</link:label>
    <link:label id="lab_brns_InLicenseAgreementsMember_documentation_en-US" xlink:label="lab_brns_InLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to In-License Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_InLicenseAgreementsMember" xlink:href="brns-20240630.xsd#brns_InLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_InLicenseAgreementsMember" xlink:to="lab_brns_InLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_58c8f57a-2aa3-46f9-be4f-b9544a16b128_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_35642715-81b3-4dcb-a8d4-069b8d3fb399_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cdaab260-7e00-4f9d-a756-75155d1fe41e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_31465d3d-8347-471e-a95e-284d7931dcf0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_23ea18e6-8b5f-4066-a701-1e681707b45c_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_67e00d8a-ba50-40e3-8132-04fe4adee08b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredBSharesMember_eda649a2-3489-48e6-a172-c828069ced37_verboseLabel_en-US" xlink:label="lab_brns_DeferredBSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred B Shares</link:label>
    <link:label id="lab_brns_DeferredBSharesMember_label_en-US" xlink:label="lab_brns_DeferredBSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred B Shares [Member]</link:label>
    <link:label id="lab_brns_DeferredBSharesMember_documentation_en-US" xlink:label="lab_brns_DeferredBSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to deferred B shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember" xlink:href="brns-20240630.xsd#brns_DeferredBSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredBSharesMember" xlink:to="lab_brns_DeferredBSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8405e30e-6138-4ee3-973a-89d91a745b7a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_846a17bc-5c88-498c-9791-d994e1b782fe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredCSharesMember_0768026d-b907-4a12-9eec-b3ae8de6ff0f_verboseLabel_en-US" xlink:label="lab_brns_DeferredCSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred C Shares</link:label>
    <link:label id="lab_brns_DeferredCSharesMember_label_en-US" xlink:label="lab_brns_DeferredCSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred C Shares [Member]</link:label>
    <link:label id="lab_brns_DeferredCSharesMember_documentation_en-US" xlink:label="lab_brns_DeferredCSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to deferred C shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember" xlink:href="brns-20240630.xsd#brns_DeferredCSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredCSharesMember" xlink:to="lab_brns_DeferredCSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_563d89ed-1bee-4042-8478-0c183b675502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of options outstanding (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9b9bb245-cf1a-47f5-8361-27dbcc093cd4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_7cdf050c-955a-452e-8ed1-b0460645fb91_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_eedb89a9-3b42-487b-9e36-0aeea0ce67c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e2286588-81c8-4053-927f-7565496d48ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AdrMember_5ccfb3ec-daa6-4080-ab09-1310b9fef54c_terseLabel_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Shares</link:label>
    <link:label id="lab_dei_AdrMember_label_en-US" xlink:label="lab_dei_AdrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ADR [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AdrMember" xlink:to="lab_dei_AdrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9521039a-9e1c-4674-9baf-5e131daec2bb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_5a4bd64a-3be1-42ff-8fc1-53bd8db437e4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvement expense</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_efa85f8c-d546-40c6-8168-acee77b54d96_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredShares.Member_f264a3e6-0468-49e6-8bf8-ddcd525568f1_terseLabel_en-US" xlink:label="lab_brns_DeferredShares.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred A shares</link:label>
    <link:label id="lab_brns_DeferredShares.Member_cd44a999-252e-444a-9aa2-15e08592a6e5_verboseLabel_en-US" xlink:label="lab_brns_DeferredShares.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred A Shares</link:label>
    <link:label id="lab_brns_DeferredShares.Member_label_en-US" xlink:label="lab_brns_DeferredShares.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred A Shares. [Member]</link:label>
    <link:label id="lab_brns_DeferredShares.Member_documentation_en-US" xlink:label="lab_brns_DeferredShares.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for deferred A shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member" xlink:href="brns-20240630.xsd#brns_DeferredShares.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredShares.Member" xlink:to="lab_brns_DeferredShares.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeRollForward_225270ab-e7f7-4cdd-b202-2afe23de88d7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeRollForward_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeRollForward" xlink:to="lab_us-gaap_DeferredIncomeRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_40ccc8e2-731d-472a-89b0-e32d28b327cd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0fdbb02e-e43c-4656-a614-a7ce1caa4c82_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_28b337fb-d4c2-486f-a07f-3a20b9887725_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent_6125036a-a4b7-4cc9-8534-bb0f6a639eb2_terseLabel_en-US" xlink:label="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued manufacturing and clinical expenses</link:label>
    <link:label id="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent_label_en-US" xlink:label="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing and Clinical Expenses, Current</link:label>
    <link:label id="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:href="brns-20240630.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:to="lab_brns_AccruedManufacturingAndClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_452d4f11-a036-4856-ac38-8e18be3765e6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of shares from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_DeferredStockSharesIssued_9cd7956a-11cd-4d02-a13b-d76650ad279d_terseLabel_en-US" xlink:label="lab_brns_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares, issued (in shares)</link:label>
    <link:label id="lab_brns_DeferredStockSharesIssued_label_en-US" xlink:label="lab_brns_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Stock, Shares Issued</link:label>
    <link:label id="lab_brns_DeferredStockSharesIssued_documentation_en-US" xlink:label="lab_brns_DeferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of deferred shares of an entity that have been sold or granted to shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesIssued" xlink:href="brns-20240630.xsd#brns_DeferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_DeferredStockSharesIssued" xlink:to="lab_brns_DeferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OxfordshireMember_48de7764-6b4e-4cea-9b66-fd931f7856aa_terseLabel_en-US" xlink:label="lab_brns_OxfordshireMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxfordshire</link:label>
    <link:label id="lab_brns_OxfordshireMember_label_en-US" xlink:label="lab_brns_OxfordshireMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxfordshire [Member]</link:label>
    <link:label id="lab_brns_OxfordshireMember_documentation_en-US" xlink:label="lab_brns_OxfordshireMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxfordshire</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordshireMember" xlink:href="brns-20240630.xsd#brns_OxfordshireMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OxfordshireMember" xlink:to="lab_brns_OxfordshireMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense_75f1a2cf-81ec-44a3-9d6a-d5144c5111b0_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Incentive Income (Expense)</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the research and development incentives (expenses) for the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:href="brns-20240630.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:to="lab_brns_ResearchAndDevelopmentIncentiveIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes_bad6db0c-c03f-41e5-a93e-9d57c1378fd5_terseLabel_en-US" xlink:label="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non cash interest expense</link:label>
    <link:label id="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes_label_en-US" xlink:label="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense On Convertible Loan Notes</link:label>
    <link:label id="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes_documentation_en-US" xlink:label="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of non-cash interest expense on convertible loan notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:href="brns-20240630.xsd#brns_NonCashInterestExpenseOnConvertibleLoanNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:to="lab_brns_NonCashInterestExpenseOnConvertibleLoanNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_84cc15ee-ba17-430b-bac7-8b1b7d474d73_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTable_67700caf-dcff-4187-8e60-9ede13538668_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income [Table]</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTable_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTable" xlink:to="lab_us-gaap_DeferredIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9e20df49-607f-441f-aaca-93c2a428559b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_abb01c37-6fec-48e2-b7e0-da81a89ae87a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_20c790f0-0080-4e35-a9d1-2284fbbbff1a_terseLabel_en-US" xlink:label="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future royalties for direct sales of a covered product</link:label>
    <link:label id="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_label_en-US" xlink:label="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Future Royalties for Direct Sales of Covered Product , License Agreement</link:label>
    <link:label id="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_documentation_en-US" xlink:label="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future royalties for direct sales of a covered product under the In-License Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:href="brns-20240630.xsd#brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:to="lab_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f9a7816d-1bb1-424f-9b8a-511de79eeec1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_CommonStockNumberOfVotesPerShare_38a56fc6-ff54-4423-90dd-e388c9c6db0d_terseLabel_en-US" xlink:label="lab_brns_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes per common share (in votes)</link:label>
    <link:label id="lab_brns_CommonStockNumberOfVotesPerShare_label_en-US" xlink:label="lab_brns_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Number of Votes Per Share</link:label>
    <link:label id="lab_brns_CommonStockNumberOfVotesPerShare_documentation_en-US" xlink:label="lab_brns_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of votes that each common share is entitled.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CommonStockNumberOfVotesPerShare" xlink:href="brns-20240630.xsd#brns_CommonStockNumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_CommonStockNumberOfVotesPerShare" xlink:to="lab_brns_CommonStockNumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ec1b0480-e11d-46c0-be21-21fb61e9b14f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_76662ab0-69f0-4baf-bc9d-facae625838c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5ad49dfc-3f97-45e8-8b23-f1194b04a444_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_d2a96049-5003-4d33-9007-764564efb537_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_36706959-e169-4326-92fa-0b07c91bf935_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_2745d57a-e56c-44c9-bb9e-20422bb9d789_terseLabel_en-US" xlink:label="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_label_en-US" xlink:label="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Text Block]</link:label>
    <link:label id="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_documentation_en-US" xlink:label="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure on prepaid expense and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:href="brns-20240630.xsd#brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:to="lab_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4d4ea604-6e5e-446e-b057-8d5a509540bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_93f1a266-49aa-4b0a-8607-8d5a86468edf_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4f265239-2a93-4a86-ac66-4a7f11e8b90f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_SharesCancelledDuringPeriodValueDeferredShares_6fdd2788-2b04-4891-b8a7-7fb3bca6a275_negatedLabel_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancellation of deferred shares</link:label>
    <link:label id="lab_brns_SharesCancelledDuringPeriodValueDeferredShares_label_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Cancelled During Period, Value, Deferred Shares</link:label>
    <link:label id="lab_brns_SharesCancelledDuringPeriodValueDeferredShares_documentation_en-US" xlink:label="lab_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of deferred shares cancelled during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:href="brns-20240630.xsd#brns_SharesCancelledDuringPeriodValueDeferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:to="lab_brns_SharesCancelledDuringPeriodValueDeferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_368f4435-6c65-4624-b374-dd5214cb1c12_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_ed64fa0d-2477-4675-8dfd-f7c39be08758_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ordinary&#160;Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_85e4c619-9a65-471c-8722-4619b855d1c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of financial instruments carried at fair value and classified within Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTableTextBlock_76e1249d-46a3-44cf-a84a-27eb3690779a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of changes in deferred income</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTableTextBlock" xlink:to="lab_us-gaap_DeferredIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0d6440f8-8ee2-427a-8dd2-86a7aa9a32ae_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of ordinary shares, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncome_3f666875-1068-499a-9384-56bd38036729_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_DeferredIncome_9cf89c36-f36c-4c58-99ca-7e1a01c7869e_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_DeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncome" xlink:to="lab_us-gaap_DeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0c4de06a-e05a-40bf-9640-748dd7e5de94_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_28d39529-6082-46fe-beed-211f954aa979_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_4d026586-4a0b-4a28-af86-e50527872437_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_7861566c-8c8e-44c8-b05a-5fe48cd7aacd_terseLabel_en-US" xlink:label="lab_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease due in year four and after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="brns-20240630.xsd#brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c29b28c6-0adf-4be8-bb26-8b9c58ad0cbe_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_480bb1a4-e47b-4efc-bad3-17e8284961c7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c9562415-7371-4575-8a92-ad7a34ec3f06_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value recognized in net loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_040dc06c-88f3-41ce-8584-dbb48a164da1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8d6819a4-c5de-4cbb-8597-230d745010df_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_90c35a6f-ef9b-4ca8-a822-8bc691097b65_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_bfdef03d-56a2-4ca6-8b53-5970045a5c63_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_29490404-d722-4dbd-bc06-d517c5250f3d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9536ffd8-5fa6-44b3-87e9-1018d55f032c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9134309d-55d1-4a71-b8fa-b4ed7f6029d8_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3b8e9e51-3522-4078-b736-f12fe712335f_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_89e20740-7ff6-4d7a-8d7b-1b5b47b5d4ec_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ed72144e-81fc-4942-aa25-b53fdff0218e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_97366063-fa4e-4915-b0c3-80b49a6d5a23_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b9a25665-1b27-48b0-8cff-42b405760e9b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7022b34e-3b52-4ec4-9ce9-3466c3d9ae95_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f3034ee3-4a73-4cfa-977f-206f3e0f8c24_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_975a7ac1-e8f0-4308-9912-6fb34b5148a8_verboseLabel_en-US" xlink:label="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation recognized in other comprehensive loss</link:label>
    <link:label id="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_label_en-US" xlink:label="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Translation</link:label>
    <link:label id="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_documentation_en-US" xlink:label="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of foreign exchange translation of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:href="brns-20240630.xsd#brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:to="lab_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_450a8361-062f-451a-83b8-07418ec71135_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AvideaMember_4b85a05f-4a6a-44c6-83ce-b73cf5a57a43_terseLabel_en-US" xlink:label="lab_brns_AvideaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Avidea</link:label>
    <link:label id="lab_brns_AvideaMember_label_en-US" xlink:label="lab_brns_AvideaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Avidea [Member]</link:label>
    <link:label id="lab_brns_AvideaMember_documentation_en-US" xlink:label="lab_brns_AvideaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for Avidea.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AvideaMember" xlink:href="brns-20240630.xsd#brns_AvideaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AvideaMember" xlink:to="lab_brns_AvideaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AssetRetirementObligations_421dc605-e697-4453-94da-d653f8015545_terseLabel_en-US" xlink:label="lab_brns_AssetRetirementObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset retirement obligation</link:label>
    <link:label id="lab_brns_AssetRetirementObligations_label_en-US" xlink:label="lab_brns_AssetRetirementObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligations</link:label>
    <link:label id="lab_brns_AssetRetirementObligations_documentation_en-US" xlink:label="lab_brns_AssetRetirementObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset retirement obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AssetRetirementObligations" xlink:href="brns-20240630.xsd#brns_AssetRetirementObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AssetRetirementObligations" xlink:to="lab_brns_AssetRetirementObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_8b84869f-ba07-409e-a39f-40b98451974b_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesReceivable_7bfe3970-9fef-4bf0-8dde-e7f2d49c3194_terseLabel_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development incentives receivable</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesReceivable_label_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development incentives receivable</link:label>
    <link:label id="lab_brns_ResearchAndDevelopmentIncentivesReceivable_documentation_en-US" xlink:label="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of research and development incentives receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:href="brns-20240630.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:to="lab_brns_ResearchAndDevelopmentIncentivesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_d41df308-c189-42a8-83b2-5acbe813b425_terseLabel_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2031</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_label_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Seven</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_documentation_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:href="brns-20240630.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:to="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12b25327-95be-4bdf-af64-d907adf9b660_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_715d19b7-eebf-4784-bc5c-626f3c3f7ac1_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5ee7a0d4-ce1c-403e-bcfa-943d61f4ee99_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_e1d664cd-3648-4398-a3c1-b9635cd13cf4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_ef6f1afb-e173-424e-9907-8d938662256b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cc7c94b5-b165-4145-8daa-677af1a52661_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_49eed5cf-599d-4847-ab25-7ca6dd5c7795_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_25b8453f-0712-4075-8078-b9a6e4511c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_2d7227b8-42b4-4628-85df-cf64b3191c79_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Refundable security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_0dadb0a9-114f-47f3-86a1-f2c874ae7279_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_6429664d-dece-454d-a702-9da44a21a362_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_c05a2879-a298-4c2a-a8c2-72ed42a9490c_terseLabel_en-US" xlink:label="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net payments received for allowable sublicenses of technology developed</link:label>
    <link:label id="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_label_en-US" xlink:label="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Net Payments Received For Allowable Sublicenses Of Technology Developed License Agreement</link:label>
    <link:label id="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_documentation_en-US" xlink:label="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:href="brns-20240630.xsd#brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:to="lab_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9dacc1bd-3399-4fa4-87b1-11229f049e04_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e768f8b4-da32-44ef-be75-f6222ec5ca81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_cffe410b-2973-4d25-9e0c-3d7479ad5216_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_06acf21e-3606-43d9-9a39-85d3300d18f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OxfordUniversityInnovationLimitedMember_6c31c958-09ba-46d3-8779-f97894f209e6_terseLabel_en-US" xlink:label="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford University Innovation Limited</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationLimitedMember_label_en-US" xlink:label="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford University Innovation Limited</link:label>
    <link:label id="lab_brns_OxfordUniversityInnovationLimitedMember_documentation_en-US" xlink:label="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Oxford University Innovation Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationLimitedMember" xlink:href="brns-20240630.xsd#brns_OxfordUniversityInnovationLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OxfordUniversityInnovationLimitedMember" xlink:to="lab_brns_OxfordUniversityInnovationLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_448d2e3a-c170-46ef-b3d0-ebf12ce5cf2a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3fc77b82-97de-42e7-bd09-6d3d9026c7ce_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_e53cf03d-c78c-4e60-afbd-9ad08d58d4fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss &#8211; foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bff81130-d644-4ba4-ae5f-53f9d02f8798_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_4a5661e3-0421-4105-bcef-e1f7b5e58a68_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_b5dd1fd4-d01f-4b8c-987a-7e1e88a4b111_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MD_8417836d-999c-4ff3-893b-92dec5d2a2c8_terseLabel_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maryland</link:label>
    <link:label id="lab_stpr_MD_label_en-US" xlink:label="lab_stpr_MD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MARYLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MD" xlink:to="lab_stpr_MD" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c29cb6a1-5dd7-4a8b-8971-f9066c23e449_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f7da4058-9995-42c8-b8de-1ec50f3ed57f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c0b436b7-7731-4bbd-8ba6-7a17040d6b90_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2a54ae15-61b5-4e18-b9cc-4bd56023dbbe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_81b27cdc-bdc3-4dfa-9fe2-69760f21c2a6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_309f322e-e049-484b-a2b0-0177475b2df2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3663f88e-c95a-4dec-97ee-f40a3adb6f32_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f43b5e07-f9ed-4d53-a70e-1d591dc15cda_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, &#163;0.000025 nominal value; 39,184,338 shares authorized, issued and outstanding (December&#160;31, 2023: authorized, issued and outstanding: 38,643,540)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4eb3a163-f44d-4089-bc15-da333c924312_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_RoyaltyPaymentTermMaximum_eb7cae7b-c58e-462e-9a6d-1023a5e17d2d_terseLabel_en-US" xlink:label="lab_brns_RoyaltyPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum royalty payment period</link:label>
    <link:label id="lab_brns_RoyaltyPaymentTermMaximum_label_en-US" xlink:label="lab_brns_RoyaltyPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payment, Term, Maximum</link:label>
    <link:label id="lab_brns_RoyaltyPaymentTermMaximum_documentation_en-US" xlink:label="lab_brns_RoyaltyPaymentTermMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Payment, Term, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RoyaltyPaymentTermMaximum" xlink:href="brns-20240630.xsd#brns_RoyaltyPaymentTermMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_RoyaltyPaymentTermMaximum" xlink:to="lab_brns_RoyaltyPaymentTermMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2a2139cb-db80-46b2-91c6-e222f8ecfe0d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_94b4b5b9-0101-4b0f-b623-ac4d25d77e14_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_9debf99e-8f6e-4b93-887c-b8c6ce35f399_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6698eb42-9de6-43a7-a5b3-da027514aabb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FundingAmountMaximum_3c1cb59b-a17d-4936-90ab-e50976f0bab6_terseLabel_en-US" xlink:label="lab_brns_FundingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum funding amount</link:label>
    <link:label id="lab_brns_FundingAmountMaximum_label_en-US" xlink:label="lab_brns_FundingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Funding Amount, Maximum</link:label>
    <link:label id="lab_brns_FundingAmountMaximum_documentation_en-US" xlink:label="lab_brns_FundingAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Funding Amount, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FundingAmountMaximum" xlink:href="brns-20240630.xsd#brns_FundingAmountMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FundingAmountMaximum" xlink:to="lab_brns_FundingAmountMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember_38b67dac-aa08-4429-8f39-cc80b14024a7_terseLabel_en-US" xlink:label="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coalition For Epidemic Preparedness Innovations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:href="brns-20240630.xsd#brns_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:to="lab_brns_CoalitionForEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_46089e48-39e6-4f71-bb86-734a993b179a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_eb5bf6b9-babd-4d6c-86a3-a29200d2e44f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ba062d92-0f50-4400-ba2b-ceffba11ac93_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e04efab2-eeeb-4f13-b5e3-f26deccd38b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a8bd2354-71e1-4471-99c7-917a76de7ed7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d1d8ab5a-6ae4-4f3a-9c5c-53cc4c8b7a09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred shares [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4bfca50c-18d7-43d2-aa5a-ffd660aff5cc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1361c814-6b92-49ae-b8a9-78ae679e43e6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1bbf9c61-84e0-4e82-b890-81bf327cd1c0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_68246099-2b93-48be-97cf-824b14f32901_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_938765f0-99e5-46e9-a366-3a48d1ef5ba1_terseLabel_en-US" xlink:label="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Liabilities, Current [Table]</link:label>
    <link:label id="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_label_en-US" xlink:label="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Liabilities, Current [Table]</link:label>
    <link:label id="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_documentation_en-US" xlink:label="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Expenses And Other Liabilities, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable" xlink:href="brns-20240630.xsd#brns_AccruedExpensesAndOtherLiabilitiesCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable" xlink:to="lab_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e33ba9e9-ecc5-4d2c-a313-25f1d57f17ef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_cff862a0-f73d-43c7-9324-87750c880992_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_53493223-36c9-4f3f-b34d-49d4dbbf0b9e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 15)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_9474aeb2-c0b3-438b-8563-01006a60fe8c_terseLabel_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2030</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_label_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Six</link:label>
    <link:label id="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_documentation_en-US" xlink:label="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:href="brns-20240630.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:to="lab_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7500a490-e8bf-4c6d-b878-0920f5d3854c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_03bc8b2b-a08f-4fe0-91b4-145a8aa70929_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_OtherInformationLesseeAbstract_4216ecbc-888b-4bcd-9a60-e89e59f58946_terseLabel_en-US" xlink:label="lab_brns_OtherInformationLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other information</link:label>
    <link:label id="lab_brns_OtherInformationLesseeAbstract_label_en-US" xlink:label="lab_brns_OtherInformationLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Information, Lessee [Abstract]</link:label>
    <link:label id="lab_brns_OtherInformationLesseeAbstract_documentation_en-US" xlink:label="lab_brns_OtherInformationLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Information, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherInformationLesseeAbstract" xlink:href="brns-20240630.xsd#brns_OtherInformationLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_OtherInformationLesseeAbstract" xlink:to="lab_brns_OtherInformationLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_541b7bb6-754b-4cd3-8d56-22551c28aec4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_890e1a57-f533-4aca-9c89-35026bb4a23b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6c129171-71f5-4bb0-ac57-1439262efe7e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_91b6e361-fb33-4962-ac62-1330c6b56ba6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Barinthus Biotherapeutics plc shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6a1e8920-9baa-48b8-8eaf-29585c14d371_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_33a3c755-5b66-4070-9d41-f4f22ebdf302_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5aeb042a-6635-448e-ab76-f6a850479af6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_733bc30a-4a9d-4f89-b9a2-be9d1606149a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0a7d2b13-c652-493f-88c1-ec0dbd22325c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_NumberOfSquareFeetUnderLeaseAgreement_bb6144d1-7794-4494-907e-f0c031d6fdda_terseLabel_en-US" xlink:label="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Size of space under lease agreement (in square feet)</link:label>
    <link:label id="lab_brns_NumberOfSquareFeetUnderLeaseAgreement_label_en-US" xlink:label="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Square Feet Under Lease Agreement</link:label>
    <link:label id="lab_brns_NumberOfSquareFeetUnderLeaseAgreement_documentation_en-US" xlink:label="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to number of Square Feet Under Lease Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:href="brns-20240630.xsd#brns_NumberOfSquareFeetUnderLeaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:to="lab_brns_NumberOfSquareFeetUnderLeaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_36baa9c0-5c61-467b-903f-a532ae9da002_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_65dfd8aa-3141-4d20-a30c-c2a05487315f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_cc30745a-5f90-4a85-ab78-7abf7a4fb0ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2eb579b9-325b-4c9f-80fd-a07b6dc06c15_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fb0dbce0-6e11-4354-abc8-412ed77a22b4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_47eae9da-4a65-4d6b-a7ce-c04dc2cc1322_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_b5b57e72-4aa0-43fb-8115-e613afd29bf1_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_221afe7f-d458-43a1-92e2-71cf3ae39828_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_b8b08e18-e0be-47a3-b271-c2eb119e08bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e3c06d4c-c7ee-4c51-9c36-28b183237635_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_72846b20-046c-40bc-b1c4-96d6c43e0a1c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_77f156f5-c7b7-4c9f-aafc-a643720f6b28_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated annual amortization expense for 2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3c85bc46-079e-4775-b6cd-b4ce1adc93b6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8f26443d-34b3-4172-bc84-a3e9dd0b39c8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10cc4687-e202-460e-9e76-258fb0567e58_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_733ff31a-48e7-4835-a3f7-745591ffbed5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_80f0e9f5-535e-4e33-8d2f-625d2a948e8e_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_648a48b6-a9ce-489c-9628-b24f74d9cca4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07d92da4-fc00-4ca1-a3db-47e9cbad025c_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f6d7dbeb-ad79-432b-9814-dd031299e7a1_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_639b37bd-1d8c-4d26-94b3-961ddb6578c0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_094dd399-d436-431b-a5d5-b145c7a1cd01_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2677d104-e5b9-485d-850c-83435835a7bd_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_96fc1836-b590-44b7-9af5-eee173bf9bc0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_e150c34a-ec52-45dd-8a10-97e2c26d26f1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c09e182c-f4aa-4c26-a20b-50161822558e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c0f9cad1-26c6-4423-82ef-419756229805_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ordinary shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7e1522e0-e3c5-4bc4-8d41-60e467d6b017_terseLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_b586c3ae-022d-4f47-9b2e-1a44fcc23e4f_totalLabel_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:label id="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lab_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncome_e6ba0336-6ae8-4bb2-be48-4d313dff9243_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncome" xlink:to="lab_us-gaap_OtherOperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_bf45aed8-b4bc-494b-82d8-7703e8f446be_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_822160c1-6fb1-4909-aad7-55aa6cddbb10_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_54e3017f-3721-4f06-af70-384af407f159_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_28906e59-e0e8-476f-af95-3da74019038e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a34dc20c-4401-4de0-a5a3-bde5864fc1b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ae16bb4c-347f-417e-9e7a-a7ba9b81e295_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_c4eee1f0-3dde-42ab-a660-98cf266704ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_75b51410-3b59-4475-a655-6a86386fc0dc_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_1d960953-d304-4297-8657-cb47eddbec5b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_3bfaa816-5115-4586-8770-38ce3cca56c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_15ed7cee-a71d-4b58-a822-8db13929a67d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>brns-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:9a110c5a-492b-47ac-b990-632b9a151dae,g:0cb2830b-fcfe-4af5-8a4f-fdc83046615c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Cover" xlink:type="simple" xlink:href="brns-20240630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fa39c7a1-69ac-4843-a460-47624b63cebf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_52330848-cbf6-4c6a-ae2c-153b00695506" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fa39c7a1-69ac-4843-a460-47624b63cebf" xlink:to="loc_dei_DocumentInformationTable_52330848-cbf6-4c6a-ae2c-153b00695506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9f1abdc3-7be4-4b67-8690-79902abe58fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_52330848-cbf6-4c6a-ae2c-153b00695506" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9f1abdc3-7be4-4b67-8690-79902abe58fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a48e3ba5-6a1b-485a-8870-1cab30962789" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9f1abdc3-7be4-4b67-8690-79902abe58fe" xlink:to="loc_us-gaap_ClassOfStockDomain_a48e3ba5-6a1b-485a-8870-1cab30962789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AdrMember_65407f8d-3c9a-4b00-a9fd-a127629617ee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AdrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a48e3ba5-6a1b-485a-8870-1cab30962789" xlink:to="loc_dei_AdrMember_65407f8d-3c9a-4b00-a9fd-a127629617ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_32ee464e-3b26-4d31-be59-248187fd3e99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a48e3ba5-6a1b-485a-8870-1cab30962789" xlink:to="loc_us-gaap_CommonStockMember_32ee464e-3b26-4d31-be59-248187fd3e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_52330848-cbf6-4c6a-ae2c-153b00695506" xlink:to="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4e9f7730-243f-4b94-80f7-03411658b58c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentType_4e9f7730-243f-4b94-80f7-03411658b58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_12ae607d-6dd4-4196-aabe-5ee445d3dfa8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentQuarterlyReport_12ae607d-6dd4-4196-aabe-5ee445d3dfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_125957fd-907e-4f6f-8b8d-ed342833eadc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentPeriodEndDate_125957fd-907e-4f6f-8b8d-ed342833eadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_421aac56-7088-4f32-8183-2b93f004a148" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentTransitionReport_421aac56-7088-4f32-8183-2b93f004a148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_56f28415-f18c-466a-a04d-0507aab8182d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityFileNumber_56f28415-f18c-466a-a04d-0507aab8182d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b6be9baf-36d9-4a05-b3c8-8635f7573001" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityRegistrantName_b6be9baf-36d9-4a05-b3c8-8635f7573001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_23beb38d-99cc-4005-bcb7-f7310ce824c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_23beb38d-99cc-4005-bcb7-f7310ce824c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_97724349-826c-4ad2-b719-8dd91fdaaded" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityTaxIdentificationNumber_97724349-826c-4ad2-b719-8dd91fdaaded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8efa304c-1daa-4f71-98cf-35701eb6aed1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressAddressLine1_8efa304c-1daa-4f71-98cf-35701eb6aed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_85ad6d74-33f9-4adc-9743-c7753af14293" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressAddressLine2_85ad6d74-33f9-4adc-9743-c7753af14293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9dff33f1-9c76-4245-9b88-a89be1fc5f8f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressCityOrTown_9dff33f1-9c76-4245-9b88-a89be1fc5f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_586a8cae-192c-4529-96b4-18b626f96629" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressCountry_586a8cae-192c-4529-96b4-18b626f96629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_28715ff2-bd00-4384-be7e-9872a92304fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityAddressPostalZipCode_28715ff2-bd00-4384-be7e-9872a92304fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4fde6150-c444-4fb1-9525-82890b573a00" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_CityAreaCode_4fde6150-c444-4fb1-9525-82890b573a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d84920c9-7fb9-4458-befa-e3c09aa5a0c2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_LocalPhoneNumber_d84920c9-7fb9-4458-befa-e3c09aa5a0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_472dee30-98c7-4ca4-b768-e54f6359f3b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_Security12bTitle_472dee30-98c7-4ca4-b768-e54f6359f3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9245712b-2621-4dfd-864e-c74c32cd35d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_TradingSymbol_9245712b-2621-4dfd-864e-c74c32cd35d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d5bc9c99-da74-457c-ad94-f8f419ba837c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_SecurityExchangeName_d5bc9c99-da74-457c-ad94-f8f419ba837c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8442ae56-1155-43a9-90b8-50b4185a61d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityCurrentReportingStatus_8442ae56-1155-43a9-90b8-50b4185a61d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ff56c988-b9e7-49fe-b08d-020e99e094a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityInteractiveDataCurrent_ff56c988-b9e7-49fe-b08d-020e99e094a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4c2a4f05-8b96-4a46-a24d-c1be838cddc6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityFilerCategory_4c2a4f05-8b96-4a46-a24d-c1be838cddc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_78f38569-c2e1-428f-85c4-e607fa376efc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntitySmallBusiness_78f38569-c2e1-428f-85c4-e607fa376efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ffd1288b-7672-43e5-9cd0-61c06b4b4a5e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityEmergingGrowthCompany_ffd1288b-7672-43e5-9cd0-61c06b4b4a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_17abc3ca-c8b1-4133-b8d4-c7328bc1959e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityExTransitionPeriod_17abc3ca-c8b1-4133-b8d4-c7328bc1959e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7344db34-ac44-4f27-8ab7-153be7c41ff8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityShellCompany_7344db34-ac44-4f27-8ab7-153be7c41ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_970a3410-b5ea-4a15-8f06-9ae50472c14a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_970a3410-b5ea-4a15-8f06-9ae50472c14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3c820f4a-fba8-4470-914b-e95a5996c6af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_EntityCentralIndexKey_3c820f4a-fba8-4470-914b-e95a5996c6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_61beef97-37cc-4d31-a71a-7ac3d0037d84" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentFiscalYearFocus_61beef97-37cc-4d31-a71a-7ac3d0037d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_755b78b9-14c5-4513-a36a-5d84136a901a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_755b78b9-14c5-4513-a36a-5d84136a901a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_465e7f5f-0372-4400-9198-028ddc0fd6b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_AmendmentFlag_465e7f5f-0372-4400-9198-028ddc0fd6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_39c58080-14e1-4475-9dcd-ab8a379dd8e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_531711fc-b0b7-414a-805f-db4d7862921a" xlink:to="loc_dei_CurrentFiscalYearEndDate_39c58080-14e1-4475-9dcd-ab8a379dd8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_030ca441-b230-47f4-bfff-4f3726d6df64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cfb1788c-dbe0-4302-a3c5-8ab5293530f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_030ca441-b230-47f4-bfff-4f3726d6df64" xlink:to="loc_us-gaap_StatementTable_cfb1788c-dbe0-4302-a3c5-8ab5293530f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d03583b5-dcb8-4307-92b5-b623f418a5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cfb1788c-dbe0-4302-a3c5-8ab5293530f2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d03583b5-dcb8-4307-92b5-b623f418a5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4fc3a7ea-c4e9-43c7-9ffd-6d0b5dfaa03b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d03583b5-dcb8-4307-92b5-b623f418a5d0" xlink:to="loc_us-gaap_ClassOfStockDomain_4fc3a7ea-c4e9-43c7-9ffd-6d0b5dfaa03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_1993b68b-ca9b-4a3f-888c-ffd49bebfa8d" xlink:href="brns-20240630.xsd#brns_DeferredShares.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4fc3a7ea-c4e9-43c7-9ffd-6d0b5dfaa03b" xlink:to="loc_brns_DeferredShares.Member_1993b68b-ca9b-4a3f-888c-ffd49bebfa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cfb1788c-dbe0-4302-a3c5-8ab5293530f2" xlink:to="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b1f781e-89e7-41b4-a612-d99c21634b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1b1f781e-89e7-41b4-a612-d99c21634b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentivesReceivable_0f8a4404-0328-4de2-9621-4c6e2a95c9e7" xlink:href="brns-20240630.xsd#brns_ResearchAndDevelopmentIncentivesReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:to="loc_brns_ResearchAndDevelopmentIncentivesReceivable_0f8a4404-0328-4de2-9621-4c6e2a95c9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_45af7ab7-c428-4398-9e61-810dedbf41d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_45af7ab7-c428-4398-9e61-810dedbf41d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0523fed6-f6fa-41c9-9d1d-91864cf9fb15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22f1f440-2b18-4f97-aadf-f5cb4250536d" xlink:to="loc_us-gaap_AssetsCurrent_0523fed6-f6fa-41c9-9d1d-91864cf9fb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_df404b17-33a8-48fb-8f26-d343ee01dce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_Goodwill_df404b17-33a8-48fb-8f26-d343ee01dce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_42a6f96b-58e4-4bf0-9fd9-67b98eca4b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_42a6f96b-58e4-4bf0-9fd9-67b98eca4b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcc374d7-cc77-445c-9c2e-100b322eda5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcc374d7-cc77-445c-9c2e-100b322eda5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1b2fa41f-a0ab-4e51-8f6e-fbe2c23c3972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1b2fa41f-a0ab-4e51-8f6e-fbe2c23c3972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_d8a00f86-35a1-49fa-b4a1-af883e5c0d66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_OtherAssets_d8a00f86-35a1-49fa-b4a1-af883e5c0d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_56d41286-93c8-467e-a745-42871136e638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_Assets_56d41286-93c8-467e-a745-42871136e638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7fba4614-6570-4fe7-bd18-3365ad343029" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_22bf3da9-cc33-471d-8d1d-03952243197a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_us-gaap_AccountsPayableCurrent_22bf3da9-cc33-471d-8d1d-03952243197a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_20115426-dc4e-4f9a-82dc-d6362bba3a10" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_20115426-dc4e-4f9a-82dc-d6362bba3a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeCurrent_b58a7bc6-9742-4f0e-bffd-b156aeadcc89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_us-gaap_DeferredIncomeCurrent_b58a7bc6-9742-4f0e-bffd-b156aeadcc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2e4bc69d-883b-49eb-9220-04ad95aa9c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2e4bc69d-883b-49eb-9220-04ad95aa9c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5b18c3dc-8047-4fd5-9456-9ee7f973b27a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7cd04d0a-16ae-4843-a0f0-ce092fe0d393" xlink:to="loc_us-gaap_LiabilitiesCurrent_5b18c3dc-8047-4fd5-9456-9ee7f973b27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c76ff814-89d6-4bc5-9ee7-ba8dc30e9660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c76ff814-89d6-4bc5-9ee7-ba8dc30e9660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8d7f82d2-d764-4030-a6e2-840e821ea6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8d7f82d2-d764-4030-a6e2-840e821ea6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9af7d17d-4575-4594-a294-954bd7baddcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9af7d17d-4575-4594-a294-954bd7baddcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredTaxLiabilityNet_3f67aecb-5cf7-4ebc-858e-55ef8228bf2b" xlink:href="brns-20240630.xsd#brns_DeferredTaxLiabilityNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_brns_DeferredTaxLiabilityNet_3f67aecb-5cf7-4ebc-858e-55ef8228bf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_18ba6881-73ec-48fd-9187-a0ce133c4976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_Liabilities_18ba6881-73ec-48fd-9187-a0ce133c4976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fefeb65c-8e92-4f3b-bca1-1156e61421a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a5f73e5-0e69-49fc-a479-74247d0c3913" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fefeb65c-8e92-4f3b-bca1-1156e61421a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2e566c49-4afc-4fc7-a315-59e2001229df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_CommonStockValue_2e566c49-4afc-4fc7-a315-59e2001229df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockValueIssued_9ee3f7ea-fffb-4f94-8c49-7adacc7a4465" xlink:href="brns-20240630.xsd#brns_DeferredStockValueIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_brns_DeferredStockValueIssued_9ee3f7ea-fffb-4f94-8c49-7adacc7a4465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cec70129-683c-4a3b-a32b-407e0177b7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cec70129-683c-4a3b-a32b-407e0177b7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a4a90916-9d6d-4aa5-b67f-528e34e6c692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a4a90916-9d6d-4aa5-b67f-528e34e6c692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_a254ed7e-e03c-4d76-97c4-d06329942d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_a254ed7e-e03c-4d76-97c4-d06329942d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_64983883-b366-42d3-9b15-cba7e0ddc2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_StockholdersEquity_64983883-b366-42d3-9b15-cba7e0ddc2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_95d964bc-e549-4595-b0d4-32759a6b1866" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_MinorityInterest_95d964bc-e549-4595-b0d4-32759a6b1866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7a095eb-a4e0-4754-bef8-c3f787654ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bde45cd3-7888-4a23-8dbc-4da3d9e8cd4e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7a095eb-a4e0-4754-bef8-c3f787654ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8c3a76b-f341-4daf-8559-8945f8f3a1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8348d5eb-cd62-49b5-8bb8-207664ccbcc4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d8c3a76b-f341-4daf-8559-8945f8f3a1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4dd103de-9753-44b0-a8e0-406c8fa08a59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cbafcb8a-0dcb-4d94-985f-c5148cc2d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4dd103de-9753-44b0-a8e0-406c8fa08a59" xlink:to="loc_us-gaap_StatementTable_cbafcb8a-0dcb-4d94-985f-c5148cc2d3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_941b28b1-e19c-481a-9626-c726154e13bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cbafcb8a-0dcb-4d94-985f-c5148cc2d3f2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_941b28b1-e19c-481a-9626-c726154e13bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_14b2233b-c314-4c3b-a0e4-bab6f272ba06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_941b28b1-e19c-481a-9626-c726154e13bb" xlink:to="loc_us-gaap_ClassOfStockDomain_14b2233b-c314-4c3b-a0e4-bab6f272ba06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_685bafff-89ab-40f5-b076-7d9cb6044f21" xlink:href="brns-20240630.xsd#brns_DeferredShares.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_14b2233b-c314-4c3b-a0e4-bab6f272ba06" xlink:to="loc_brns_DeferredShares.Member_685bafff-89ab-40f5-b076-7d9cb6044f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cbafcb8a-0dcb-4d94-985f-c5148cc2d3f2" xlink:to="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c76b56d8-7a17-4012-9c4d-08e458df44e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c76b56d8-7a17-4012-9c4d-08e458df44e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_467926fe-4535-448e-89d8-ccf4d140e947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_467926fe-4535-448e-89d8-ccf4d140e947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_324151c9-51b5-4c62-b562-2651ee36868d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_us-gaap_CommonStockSharesIssued_324151c9-51b5-4c62-b562-2651ee36868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4885989d-dde5-4bca-9c6c-9f88eab5fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4885989d-dde5-4bca-9c6c-9f88eab5fa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_7a2ef4f5-ec95-4394-a4b1-190c7031a1c5" xlink:href="brns-20240630.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_7a2ef4f5-ec95-4394-a4b1-190c7031a1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesAuthorized_c52476b2-cb1f-4316-b28d-c86f2263ee63" xlink:href="brns-20240630.xsd#brns_DeferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_brns_DeferredStockSharesAuthorized_c52476b2-cb1f-4316-b28d-c86f2263ee63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesIssued_37b737a2-a00e-4c61-be7c-e483bc11909d" xlink:href="brns-20240630.xsd#brns_DeferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_brns_DeferredStockSharesIssued_37b737a2-a00e-4c61-be7c-e483bc11909d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockSharesOutstanding_92e0b5bd-3abe-4fd2-8d72-dcc57f452882" xlink:href="brns-20240630.xsd#brns_DeferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c64f4bfa-f3b6-4e70-8c77-30ca92d10501" xlink:to="loc_brns_DeferredStockSharesOutstanding_92e0b5bd-3abe-4fd2-8d72-dcc57f452882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fe8e4918-8c02-49d7-98e9-0f5b129be535" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ac517253-76f1-4e54-85e4-0f30dd0c0bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fe8e4918-8c02-49d7-98e9-0f5b129be535" xlink:to="loc_us-gaap_StatementTable_ac517253-76f1-4e54-85e4-0f30dd0c0bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_567cc87f-d0f3-4ef1-a70e-7f6ddc2341f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac517253-76f1-4e54-85e4-0f30dd0c0bf3" xlink:to="loc_srt_ProductOrServiceAxis_567cc87f-d0f3-4ef1-a70e-7f6ddc2341f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_044d88cb-1a8c-4e95-b9e2-1094a5906c65" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_567cc87f-d0f3-4ef1-a70e-7f6ddc2341f7" xlink:to="loc_srt_ProductsAndServicesDomain_044d88cb-1a8c-4e95-b9e2-1094a5906c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_0cbbd7b2-d2da-472b-b344-1ff54925e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_044d88cb-1a8c-4e95-b9e2-1094a5906c65" xlink:to="loc_us-gaap_LicenseMember_0cbbd7b2-d2da-472b-b344-1ff54925e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ac517253-76f1-4e54-85e4-0f30dd0c0bf3" xlink:to="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e7a06fe-03f5-4fda-9616-fd751774c479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2e7a06fe-03f5-4fda-9616-fd751774c479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e11906b3-02ba-403e-87a3-dfbfe42dd45f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e11906b3-02ba-403e-87a3-dfbfe42dd45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d7db0c66-f54f-48af-8cf6-017fae8bf7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d7db0c66-f54f-48af-8cf6-017fae8bf7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_09699cc3-f7a8-437b-a36e-0842031faa24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b2c7069f-4daf-4340-bc89-1cbc5a186674" xlink:to="loc_us-gaap_OperatingExpenses_09699cc3-f7a8-437b-a36e-0842031faa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncome_6c7dd215-f74b-4c83-933c-fb2117ad74d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OtherOperatingIncome_6c7dd215-f74b-4c83-933c-fb2117ad74d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cdecdd81-0a39-4b78-a797-d9cb58e11e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OperatingIncomeLoss_cdecdd81-0a39-4b78-a797-d9cb58e11e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f4d8b799-78b1-4c46-9c45-6201256c74d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f4d8b799-78b1-4c46-9c45-6201256c74d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_83029919-b3a9-48b0-a69f-a0496a56fefa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_us-gaap_InterestExpenseNonoperating_83029919-b3a9-48b0-a69f-a0496a56fefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_1d5bf584-7f3f-48e4-9193-b3272feccfb9" xlink:href="brns-20240630.xsd#brns_ResearchAndDevelopmentIncentiveIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_brns_ResearchAndDevelopmentIncentiveIncomeExpense_1d5bf584-7f3f-48e4-9193-b3272feccfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_99135549-4276-4739-9fcd-8c8fbaa975c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_99135549-4276-4739-9fcd-8c8fbaa975c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bc7c3116-86a4-408f-bda1-363e8b538a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_014ddfae-6e14-47a0-9714-c807e8410ece" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bc7c3116-86a4-408f-bda1-363e8b538a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a93b1b2-f72d-4097-bac5-c1b5c05d7d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5a93b1b2-f72d-4097-bac5-c1b5c05d7d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a38443b7-1764-4216-b832-e94382a5ae72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a38443b7-1764-4216-b832-e94382a5ae72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_59cf3e4a-3f66-470a-9d51-efe0ca30d935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_ProfitLoss_59cf3e4a-3f66-470a-9d51-efe0ca30d935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7ae8f89f-3ef4-41ad-a43d-fa8e25a7d247" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7ae8f89f-3ef4-41ad-a43d-fa8e25a7d247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6bab2f70-922c-48af-9145-b6ab6adc6a11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_NetIncomeLoss_6bab2f70-922c-48af-9145-b6ab6adc6a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ba8f2955-c89b-41b8-a781-003d712adf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ba8f2955-c89b-41b8-a781-003d712adf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_afebce46-269b-4c07-9b84-20da79691fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_afebce46-269b-4c07-9b84-20da79691fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_76a2db34-2100-49ab-ac40-e7e4845b08e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_EarningsPerShareBasic_76a2db34-2100-49ab-ac40-e7e4845b08e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f1b9f471-324d-434e-8c7c-3508512c5478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f1b9f471-324d-434e-8c7c-3508512c5478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_03aad9fa-f1dd-41ef-8876-1cf5c200baa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_ProfitLoss_03aad9fa-f1dd-41ef-8876-1cf5c200baa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d1e3548d-a2da-4eb5-b4a6-a6d730b8fd66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_d1e3548d-a2da-4eb5-b4a6-a6d730b8fd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_07cba6f8-0bf1-4f55-a522-bf233fc9e894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_07cba6f8-0bf1-4f55-a522-bf233fc9e894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_62c8883d-7fd5-4778-9eb1-0c49d539c4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_62c8883d-7fd5-4778-9eb1-0c49d539c4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9b777b82-3a1f-4607-96e2-78f911f69c22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a905b2f7-83a4-4ccc-bbba-c9de70054b46" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9b777b82-3a1f-4607-96e2-78f911f69c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6c82b9d9-5d53-4b29-af38-2e732449e62d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b7691485-8db1-4ea8-a7e3-c3c3ffee9892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6c82b9d9-5d53-4b29-af38-2e732449e62d" xlink:to="loc_us-gaap_StatementTable_b7691485-8db1-4ea8-a7e3-c3c3ffee9892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90417485-7433-4308-b0fa-a1a4ad48bd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b7691485-8db1-4ea8-a7e3-c3c3ffee9892" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90417485-7433-4308-b0fa-a1a4ad48bd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4b3252ad-5a9b-42c1-aaf2-1def359eea04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_90417485-7433-4308-b0fa-a1a4ad48bd9b" xlink:to="loc_us-gaap_RelatedPartyDomain_4b3252ad-5a9b-42c1-aaf2-1def359eea04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_cd65ff9d-a91b-478a-9882-a96fc6bf0a95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4b3252ad-5a9b-42c1-aaf2-1def359eea04" xlink:to="loc_us-gaap_RelatedPartyMember_cd65ff9d-a91b-478a-9882-a96fc6bf0a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_82d12f9c-4fc9-4e49-ba67-edc12c074d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b7691485-8db1-4ea8-a7e3-c3c3ffee9892" xlink:to="loc_us-gaap_StatementLineItems_82d12f9c-4fc9-4e49-ba67-edc12c074d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e81298a-6995-434b-a611-6be5a95e19ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82d12f9c-4fc9-4e49-ba67-edc12c074d73" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1e81298a-6995-434b-a611-6be5a95e19ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_8691c125-8ebc-46bc-9135-ca098bdd52ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82d12f9c-4fc9-4e49-ba67-edc12c074d73" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_8691c125-8ebc-46bc-9135-ca098bdd52ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_981816bd-440c-4bb4-8532-a56e5bb10f22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_846e0cb6-d57c-4237-a481-bb39b44f0a20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_981816bd-440c-4bb4-8532-a56e5bb10f22" xlink:to="loc_us-gaap_StatementTable_846e0cb6-d57c-4237-a481-bb39b44f0a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_eb5b4a7e-16da-449a-b95b-939777814c97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_846e0cb6-d57c-4237-a481-bb39b44f0a20" xlink:to="loc_us-gaap_StatementClassOfStockAxis_eb5b4a7e-16da-449a-b95b-939777814c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_eb5b4a7e-16da-449a-b95b-939777814c97" xlink:to="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_d5931e27-69d8-478e-b2f4-eebd8e10c676" xlink:href="brns-20240630.xsd#brns_DeferredShares.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:to="loc_brns_DeferredShares.Member_d5931e27-69d8-478e-b2f4-eebd8e10c676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_24166455-e373-4222-969a-4d8c4987f212" xlink:href="brns-20240630.xsd#brns_DeferredBSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:to="loc_brns_DeferredBSharesMember_24166455-e373-4222-969a-4d8c4987f212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_b20101ea-2f6d-4bbe-8d0e-312535fe9e1d" xlink:href="brns-20240630.xsd#brns_DeferredCSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_149440c8-0b5c-4db9-bf6b-0350c8ae3291" xlink:to="loc_brns_DeferredCSharesMember_b20101ea-2f6d-4bbe-8d0e-312535fe9e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7f4d71c5-e627-4f1d-86b8-bf0bc1ae85ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_846e0cb6-d57c-4237-a481-bb39b44f0a20" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7f4d71c5-e627-4f1d-86b8-bf0bc1ae85ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a845f29d-1c44-40e2-8a91-b4e143a28556" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7f4d71c5-e627-4f1d-86b8-bf0bc1ae85ee" xlink:to="loc_us-gaap_EquityComponentDomain_a845f29d-1c44-40e2-8a91-b4e143a28556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a845f29d-1c44-40e2-8a91-b4e143a28556" xlink:to="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_955fafab-f612-4a09-bb97-ce3bff2e3aff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_us-gaap_CommonStockMember_955fafab-f612-4a09-bb97-ce3bff2e3aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredSharesMember_f880827e-ae9b-4f10-a0f6-8cd49582797d" xlink:href="brns-20240630.xsd#brns_DeferredSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_brns_DeferredSharesMember_f880827e-ae9b-4f10-a0f6-8cd49582797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_18975b46-5a54-4ff8-b11f-e5aa57088574" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_18975b46-5a54-4ff8-b11f-e5aa57088574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_069f10fa-fd21-4f4d-9946-0fb563807c02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_us-gaap_RetainedEarningsMember_069f10fa-fd21-4f4d-9946-0fb563807c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_500b0a64-1fed-405b-873b-0b1e4e4309c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_050e6660-d6c0-4ccd-a53d-a63512db98e2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_500b0a64-1fed-405b-873b-0b1e4e4309c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_59753492-9c7e-4228-82fb-4dc50665b41e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a845f29d-1c44-40e2-8a91-b4e143a28556" xlink:to="loc_us-gaap_NoncontrollingInterestMember_59753492-9c7e-4228-82fb-4dc50665b41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d98e313-6b57-4968-80ad-0648342bcbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_846e0cb6-d57c-4237-a481-bb39b44f0a20" xlink:to="loc_us-gaap_StatementLineItems_7d98e313-6b57-4968-80ad-0648342bcbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d98e313-6b57-4968-80ad-0648342bcbd0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_a446c068-3578-4df0-94e4-336fd69703c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_SharesIssued_a446c068-3578-4df0-94e4-336fd69703c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a2229ca-ca6f-45b9-b497-1a22783676d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9a2229ca-ca6f-45b9-b497-1a22783676d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8935513e-04cf-4b6c-83f4-5f8d71bff4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8935513e-04cf-4b6c-83f4-5f8d71bff4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12c63735-c98f-4288-a2f6-9eadcd9aa5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12c63735-c98f-4288-a2f6-9eadcd9aa5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9c3f9953-86a4-4d37-bd30-055983887a64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9c3f9953-86a4-4d37-bd30-055983887a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_71815e5f-d844-4e91-866c-86cac319c723" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_71815e5f-d844-4e91-866c-86cac319c723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares_1565db52-f6cf-4180-bb85-84a7ffdfa38a" xlink:href="brns-20240630.xsd#brns_SharesCancelledDuringPeriodSharesDeferredShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_brns_SharesCancelledDuringPeriodSharesDeferredShares_1565db52-f6cf-4180-bb85-84a7ffdfa38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_SharesCancelledDuringPeriodValueDeferredShares_59fe6e69-c311-4b37-bc43-97689e44dd52" xlink:href="brns-20240630.xsd#brns_SharesCancelledDuringPeriodValueDeferredShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_brns_SharesCancelledDuringPeriodValueDeferredShares_59fe6e69-c311-4b37-bc43-97689e44dd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_39d08004-db69-4d8a-b13f-941673edbff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_ProfitLoss_39d08004-db69-4d8a-b13f-941673edbff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_d510f664-bd44-4a10-9e78-1a6865df436f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_SharesIssued_d510f664-bd44-4a10-9e78-1a6865df436f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa749a56-74d5-4feb-ac2e-c398aa193f75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3ac63190-09f2-442c-afcb-70086b22150a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aa749a56-74d5-4feb-ac2e-c398aa193f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="brns-20240630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8ca04b19-65eb-45e9-9a71-ecd3fbd5bbaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_110cfae1-e520-4e12-96e8-0872e73f2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ca04b19-65eb-45e9-9a71-ecd3fbd5bbaa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_110cfae1-e520-4e12-96e8-0872e73f2fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0e6a783d-55b0-4254-8db5-49218836938f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_110cfae1-e520-4e12-96e8-0872e73f2fdd" xlink:to="loc_us-gaap_ProfitLoss_0e6a783d-55b0-4254-8db5-49218836938f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_110cfae1-e520-4e12-96e8-0872e73f2fdd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_82cf4f63-5b89-465c-9d49-d76493e053a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:to="loc_us-gaap_ShareBasedCompensation_82cf4f63-5b89-465c-9d49-d76493e053a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3dfbd50e-5881-4c5e-90f1-0741b9562c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3dfbd50e-5881-4c5e-90f1-0741b9562c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashLeaseExpenses_92c4ceb0-6627-458f-9310-21454142b5ff" xlink:href="brns-20240630.xsd#brns_NonCashLeaseExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:to="loc_brns_NonCashLeaseExpenses_92c4ceb0-6627-458f-9310-21454142b5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_9069a391-bed5-4e71-87ce-f0208d57c356" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_9069a391-bed5-4e71-87ce-f0208d57c356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e9207897-a87c-489a-9e2a-f8ec55666ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e9207897-a87c-489a-9e2a-f8ec55666ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_c73b2787-e5f2-465b-8157-74697e470167" xlink:href="brns-20240630.xsd#brns_NonCashInterestExpenseOnConvertibleLoanNotes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:to="loc_brns_NonCashInterestExpenseOnConvertibleLoanNotes_c73b2787-e5f2-465b-8157-74697e470167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_429728aa-6cce-43d5-9180-bc5589d53dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_429728aa-6cce-43d5-9180-bc5589d53dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_688f0592-b25a-4469-b64e-dc37b8cc5488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_688f0592-b25a-4469-b64e-dc37b8cc5488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16559abe-4145-44c4-a972-5d5b43b15d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16559abe-4145-44c4-a972-5d5b43b15d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_40f88367-a188-4012-8a42-f73c0c45c4f7" xlink:href="brns-20240630.xsd#brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:to="loc_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable_40f88367-a188-4012-8a42-f73c0c45c4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_be398206-8542-4741-8555-1c3cb88ea9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_be398206-8542-4741-8555-1c3cb88ea9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_77f70e5c-dcda-4247-9b27-40b7c7728cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_77f70e5c-dcda-4247-9b27-40b7c7728cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_78637d70-adbc-4245-b342-4f04cd74f48a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_78637d70-adbc-4245-b342-4f04cd74f48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e4406523-2f3c-4298-ac5f-7124addc386f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e4406523-2f3c-4298-ac5f-7124addc386f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2f44f7d5-ebc3-47c1-a740-874cc36bc8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b2a8bddc-ecee-4db9-9eaf-804cb55ba0c1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2f44f7d5-ebc3-47c1-a740-874cc36bc8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_419b90f3-e599-42d7-9dbe-0b8897e1b477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9716c158-155c-48e6-95b8-de54f09509da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_419b90f3-e599-42d7-9dbe-0b8897e1b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39305441-6944-4844-b6bb-e8b06745d2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ca04b19-65eb-45e9-9a71-ecd3fbd5bbaa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39305441-6944-4844-b6bb-e8b06745d2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_237d2454-97ec-4400-b458-f3d01d6e5c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39305441-6944-4844-b6bb-e8b06745d2b3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_237d2454-97ec-4400-b458-f3d01d6e5c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f114fb39-56e4-4342-8bca-3e62f4093d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_39305441-6944-4844-b6bb-e8b06745d2b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f114fb39-56e4-4342-8bca-3e62f4093d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cb6cc25a-d4ce-4a6b-81c1-908eef39bbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ca04b19-65eb-45e9-9a71-ecd3fbd5bbaa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cb6cc25a-d4ce-4a6b-81c1-908eef39bbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_638fe01e-b420-4da3-a942-22800f432c70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cb6cc25a-d4ce-4a6b-81c1-908eef39bbf0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_638fe01e-b420-4da3-a942-22800f432c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b77b20aa-ff1b-4fd3-85bf-8fb6a58a8d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cb6cc25a-d4ce-4a6b-81c1-908eef39bbf0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b77b20aa-ff1b-4fd3-85bf-8fb6a58a8d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_06c2fe6b-a865-415f-9787-6bd90aec12d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cb6cc25a-d4ce-4a6b-81c1-908eef39bbf0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_06c2fe6b-a865-415f-9787-6bd90aec12d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ba99481-8690-46e0-85c4-5100e178d50a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cb6cc25a-d4ce-4a6b-81c1-908eef39bbf0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ba99481-8690-46e0-85c4-5100e178d50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0ae19f69-c303-49a5-91fe-7b34f5798e74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ca04b19-65eb-45e9-9a71-ecd3fbd5bbaa" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0ae19f69-c303-49a5-91fe-7b34f5798e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b5678ee0-803e-4cf7-b893-b3c5a1d91da6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ca04b19-65eb-45e9-9a71-ecd3fbd5bbaa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b5678ee0-803e-4cf7-b893-b3c5a1d91da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f452c2f-4ac8-4f5d-bc9a-5b424a8daa44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ca04b19-65eb-45e9-9a71-ecd3fbd5bbaa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3f452c2f-4ac8-4f5d-bc9a-5b424a8daa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ce4e9ce-1c5c-4c00-ad73-bed56f977ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ca04b19-65eb-45e9-9a71-ecd3fbd5bbaa" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ce4e9ce-1c5c-4c00-ad73-bed56f977ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_727269b2-8638-46fd-8910-83e9007305d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ca04b19-65eb-45e9-9a71-ecd3fbd5bbaa" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_727269b2-8638-46fd-8910-83e9007305d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8797da6e-b509-498b-8c02-23afb7881faa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_727269b2-8638-46fd-8910-83e9007305d7" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8797da6e-b509-498b-8c02-23afb7881faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1a19843a-756d-48c2-9b72-0cb5dbd46e72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8797da6e-b509-498b-8c02-23afb7881faa" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1a19843a-756d-48c2-9b72-0cb5dbd46e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AssetRetirementObligations_4ba346ed-7bd9-42e1-81fd-9149fbdeaba8" xlink:href="brns-20240630.xsd#brns_AssetRetirementObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8797da6e-b509-498b-8c02-23afb7881faa" xlink:to="loc_brns_AssetRetirementObligations_4ba346ed-7bd9-42e1-81fd-9149fbdeaba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_28a945e0-cae6-4e7d-a8c7-9433e9e5e716" xlink:href="brns-20240630.xsd#brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8797da6e-b509-498b-8c02-23afb7881faa" xlink:to="loc_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent_28a945e0-cae6-4e7d-a8c7-9433e9e5e716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="brns-20240630.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_82fb22bd-6719-4e22-a968-6fb89b50ef3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2c139bbd-ac20-4884-9b1b-837d72b16ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_82fb22bd-6719-4e22-a968-6fb89b50ef3a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2c139bbd-ac20-4884-9b1b-837d72b16ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="brns-20240630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_96ee7b14-4192-49b8-9718-cc01296c9f01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_15e23741-b5c4-4e89-844d-d3fe39e630c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_96ee7b14-4192-49b8-9718-cc01296c9f01" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_15e23741-b5c4-4e89-844d-d3fe39e630c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses" xlink:type="simple" xlink:href="brns-20240630.xsd#ForeignCurrencyTranslationinGeneralandAdministrativeExpenses"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract_83018281-2b76-4ed4-9662-0d9d7ff802c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_76dbac1f-f420-4fe2-b5a0-d5863f869035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyAbstract_83018281-2b76-4ed4-9662-0d9d7ff802c5" xlink:to="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_76dbac1f-f420-4fe2-b5a0-d5863f869035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="brns-20240630.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e81a2ec8-b508-4818-ba60-f402e50551ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_085296ce-cdc0-45b9-b81c-f3bcf1d327b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e81a2ec8-b508-4818-ba60-f402e50551ac" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_085296ce-cdc0-45b9-b81c-f3bcf1d327b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="brns-20240630.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eed55d42-d35f-4dd2-be8f-275ab835096c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4b25dabe-2df0-46f0-8bb8-bec89c22df35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_eed55d42-d35f-4dd2-be8f-275ab835096c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4b25dabe-2df0-46f0-8bb8-bec89c22df35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="brns-20240630.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a816323b-c478-42ac-b255-c03814f2750a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8ce5a323-39cf-449f-b548-aea008bf8d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a816323b-c478-42ac-b255-c03814f2750a" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8ce5a323-39cf-449f-b548-aea008bf8d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="simple" xlink:href="brns-20240630.xsd#PrepaidExpensesandOtherCurrentAssets"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_fc208a3b-937d-4ce4-b410-e7f899f7cf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_3cc6b1a2-0779-46b8-9da2-819b1dc4be5c" xlink:href="brns-20240630.xsd#brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_fc208a3b-937d-4ce4-b410-e7f899f7cf9b" xlink:to="loc_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock_3cc6b1a2-0779-46b8-9da2-819b1dc4be5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="brns-20240630.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_84a25802-6c2f-4314-b7a1-fcd500798e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_174f3191-c453-43cf-bad8-63a1284308fe" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_84a25802-6c2f-4314-b7a1-fcd500798e86" xlink:to="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_174f3191-c453-43cf-bad8-63a1284308fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncome" xlink:type="simple" xlink:href="brns-20240630.xsd#GrantIncome"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GrantIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_a80c2ebf-ba27-4fef-8ed1-4fe213934f38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_ea13fd52-bd08-4787-9e9e-636b22f65ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_a80c2ebf-ba27-4fef-8ed1-4fe213934f38" xlink:to="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_ea13fd52-bd08-4787-9e9e-636b22f65ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinaryShares" xlink:type="simple" xlink:href="brns-20240630.xsd#OrdinaryShares"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinaryShares" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7fe2dc9e-6e54-4d52-9f97-07b1c80effa5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7739b7c7-9a07-4712-a192-e3aadffe1ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7fe2dc9e-6e54-4d52-9f97-07b1c80effa5" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7739b7c7-9a07-4712-a192-e3aadffe1ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/DeferredShares" xlink:type="simple" xlink:href="brns-20240630.xsd#DeferredShares"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/DeferredShares" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e6d807aa-6cad-4dcd-83f7-66f6f5c61e14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_9a910d84-6aeb-4dfc-bf46-f83430e660a3" xlink:href="brns-20240630.xsd#brns_StockholdersEquityDeferredSharesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6d807aa-6cad-4dcd-83f7-66f6f5c61e14" xlink:to="loc_brns_StockholdersEquityDeferredSharesDisclosureTextBlock_9a910d84-6aeb-4dfc-bf46-f83430e660a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValue" xlink:type="simple" xlink:href="brns-20240630.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_452a2f41-9b0f-4f6e-89c6-1e0dbdfd5a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_412efa6f-2936-4736-b3a8-83d4b75768d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_452a2f41-9b0f-4f6e-89c6-1e0dbdfd5a0f" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_412efa6f-2936-4736-b3a8-83d4b75768d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/Goodwill" xlink:type="simple" xlink:href="brns-20240630.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c7d5a341-1fd6-4229-b8df-a739defa2f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_151a1ec8-4e41-400d-bea0-1305748b2f53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c7d5a341-1fd6-4229-b8df-a739defa2f5f" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_151a1ec8-4e41-400d-bea0-1305748b2f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="brns-20240630.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08e0d973-efb5-481e-8610-4bf773b15379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b248cbf2-2e28-4462-869b-b45a9cfea376" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08e0d973-efb5-481e-8610-4bf773b15379" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b248cbf2-2e28-4462-869b-b45a9cfea376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c9b97d7e-ce6b-4de4-9198-aa020645c707" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_70112793-ecb8-4c16-b3da-7ad8e6de5127" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c9b97d7e-ce6b-4de4-9198-aa020645c707" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_70112793-ecb8-4c16-b3da-7ad8e6de5127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="brns-20240630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_017ee3a9-01d4-47d0-be7f-f5a894718a49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1378db50-44e1-4d1a-9e70-8aac507664de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_017ee3a9-01d4-47d0-be7f-f5a894718a49" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1378db50-44e1-4d1a-9e70-8aac507664de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="brns-20240630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d05346da-e988-4df3-a63b-afa8fad2820e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_6673a855-fc4c-4a82-95a0-0e86b3576b92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d05346da-e988-4df3-a63b-afa8fad2820e" xlink:to="loc_us-gaap_UseOfEstimates_6673a855-fc4c-4a82-95a0-0e86b3576b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_15f7aa8e-39f1-4250-aec4-d912e2cb133c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d05346da-e988-4df3-a63b-afa8fad2820e" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_15f7aa8e-39f1-4250-aec4-d912e2cb133c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0a238d49-dce9-4e36-945a-041a92c9a9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d05346da-e988-4df3-a63b-afa8fad2820e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0a238d49-dce9-4e36-945a-041a92c9a9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="brns-20240630.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_39dfa960-9f72-41b5-b1d2-77d68134799e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b6673541-b13c-4d30-9856-d38d4a627c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_39dfa960-9f72-41b5-b1d2-77d68134799e" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b6673541-b13c-4d30-9856-d38d4a627c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="simple" xlink:href="brns-20240630.xsd#PrepaidExpensesandOtherCurrentAssetsTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5bb2e03a-3144-4482-b27d-d1317afeede0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_8f842ed0-1381-4c5b-9310-f402a9e06008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_5bb2e03a-3144-4482-b27d-d1317afeede0" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_8f842ed0-1381-4c5b-9310-f402a9e06008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="brns-20240630.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_62696a19-f73a-4713-ac32-07a19a28c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_1d03add9-9652-4f8f-b789-b73d016337d1" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_62696a19-f73a-4713-ac32-07a19a28c90a" xlink:to="loc_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_1d03add9-9652-4f8f-b789-b73d016337d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncomeTables" xlink:type="simple" xlink:href="brns-20240630.xsd#GrantIncomeTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GrantIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_937ca481-dbb6-42d9-8cdf-29281d754812" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTableTextBlock_866aa240-c659-4c9f-a4da-1251e3be4294" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_937ca481-dbb6-42d9-8cdf-29281d754812" xlink:to="loc_us-gaap_DeferredIncomeTableTextBlock_866aa240-c659-4c9f-a4da-1251e3be4294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueTables" xlink:type="simple" xlink:href="brns-20240630.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ac3e5e41-3b50-468e-a399-4d5c08e352f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_cfd5ada6-9ede-4506-86f6-95254c29e55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ac3e5e41-3b50-468e-a399-4d5c08e352f5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_cfd5ada6-9ede-4506-86f6-95254c29e55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="brns-20240630.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0eb4f24e-3877-498f-ad2d-5474ec42e1af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_36506250-cd51-41c1-9f6c-0062cebefa09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0eb4f24e-3877-498f-ad2d-5474ec42e1af" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_36506250-cd51-41c1-9f6c-0062cebefa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c2a6af8a-bc2c-444c-8ecc-e09b3e4b50d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0eb4f24e-3877-498f-ad2d-5474ec42e1af" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_c2a6af8a-bc2c-444c-8ecc-e09b3e4b50d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_684bad3a-5eea-44d9-bf07-595d91137ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_d49786fe-cc89-44cd-88c3-0d12ffa39560" xlink:href="brns-20240630.xsd#brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_684bad3a-5eea-44d9-bf07-595d91137ea7" xlink:to="loc_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock_d49786fe-cc89-44cd-88c3-0d12ffa39560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_abca2e90-a087-4359-8c17-bf8cbb4a7684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_684bad3a-5eea-44d9-bf07-595d91137ea7" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_abca2e90-a087-4359-8c17-bf8cbb4a7684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dac2584f-04a3-4f04-9be2-a86efbf8507c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_684bad3a-5eea-44d9-bf07-595d91137ea7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dac2584f-04a3-4f04-9be2-a86efbf8507c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3dd65137-dfaf-4191-a75d-ed0474cc158e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_947765cc-7897-47fc-931c-886956d93714" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3dd65137-dfaf-4191-a75d-ed0474cc158e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_947765cc-7897-47fc-931c-886956d93714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d3c7eaa5-1845-49ff-adc9-9107d9faf6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3dd65137-dfaf-4191-a75d-ed0474cc158e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d3c7eaa5-1845-49ff-adc9-9107d9faf6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d17c1bd9-f7f2-4126-a766-7ba4c4b31d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_b7f4d53b-55d2-4695-9d6b-2d724722b6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d17c1bd9-f7f2-4126-a766-7ba4c4b31d5a" xlink:to="loc_us-gaap_NumberOfOperatingSegments_b7f4d53b-55d2-4695-9d6b-2d724722b6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyAbstract_deaa5e80-5544-4da9-bed3-6b1c6ece77c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_fa007904-3875-4ae3-b510-9c0ca2a680ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyAbstract_deaa5e80-5544-4da9-bed3-6b1c6ece77c7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_fa007904-3875-4ae3-b510-9c0ca2a680ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#NetLossPerShareComputationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShareComputationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fb60f9be-d39e-43b4-9237-3aa3385311a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_23ae3eae-b563-4b92-9ef4-98c41208ab38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fb60f9be-d39e-43b4-9237-3aa3385311a1" xlink:to="loc_us-gaap_NetIncomeLossAbstract_23ae3eae-b563-4b92-9ef4-98c41208ab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1abbeb88-7397-4f3c-b75c-904e2b37e576" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_23ae3eae-b563-4b92-9ef4-98c41208ab38" xlink:to="loc_us-gaap_ProfitLoss_1abbeb88-7397-4f3c-b75c-904e2b37e576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d3065b47-67f4-47db-b202-6492a88f69d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_23ae3eae-b563-4b92-9ef4-98c41208ab38" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d3065b47-67f4-47db-b202-6492a88f69d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91c941fd-f105-4f77-962b-1b06380ca5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_23ae3eae-b563-4b92-9ef4-98c41208ab38" xlink:to="loc_us-gaap_NetIncomeLoss_91c941fd-f105-4f77-962b-1b06380ca5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7890cfc3-5a43-4ec8-93da-06fa8e6f7c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fb60f9be-d39e-43b4-9237-3aa3385311a1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7890cfc3-5a43-4ec8-93da-06fa8e6f7c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_de06ec3e-03ec-4670-a6e8-561da66d9bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7890cfc3-5a43-4ec8-93da-06fa8e6f7c2b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_de06ec3e-03ec-4670-a6e8-561da66d9bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de012ae3-2c56-42de-b10f-5804c98b4f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7890cfc3-5a43-4ec8-93da-06fa8e6f7c2b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_de012ae3-2c56-42de-b10f-5804c98b4f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_510e26e7-6454-4440-822c-5bb43eb27fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7890cfc3-5a43-4ec8-93da-06fa8e6f7c2b" xlink:to="loc_us-gaap_EarningsPerShareBasic_510e26e7-6454-4440-822c-5bb43eb27fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f049e4db-0356-4209-a592-a890510398c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_7890cfc3-5a43-4ec8-93da-06fa8e6f7c2b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f049e4db-0356-4209-a592-a890510398c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#NetLossPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_81c40ff8-816e-4c61-9c11-4eea0273d408" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b804ce92-edf1-455e-8a19-317be843fef0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_81c40ff8-816e-4c61-9c11-4eea0273d408" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b804ce92-edf1-455e-8a19-317be843fef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b390c09d-1da2-4e48-94ad-9e5f144e86ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_c0c4202d-1455-41d4-bc2c-25a136c5b82c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b390c09d-1da2-4e48-94ad-9e5f144e86ce" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_c0c4202d-1455-41d4-bc2c-25a136c5b82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9570a67f-edb9-4b0e-9f4a-42328040c7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b390c09d-1da2-4e48-94ad-9e5f144e86ce" xlink:to="loc_us-gaap_Depreciation_9570a67f-edb9-4b0e-9f4a-42328040c7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#IntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/IntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_79ba22b2-8f62-4dfe-96fd-32135b7f77dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e61ae6b6-496b-4f37-83cb-53416e4b68db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_79ba22b2-8f62-4dfe-96fd-32135b7f77dc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e61ae6b6-496b-4f37-83cb-53416e4b68db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51d557c5-5be3-460a-87db-9e46cca4b08c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e61ae6b6-496b-4f37-83cb-53416e4b68db" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51d557c5-5be3-460a-87db-9e46cca4b08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44cc9653-1d04-4c7b-b3d9-f647adf9f4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51d557c5-5be3-460a-87db-9e46cca4b08c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44cc9653-1d04-4c7b-b3d9-f647adf9f4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_87ab2d53-0ce7-40d0-90f9-7cabeca0bd04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44cc9653-1d04-4c7b-b3d9-f647adf9f4f2" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_87ab2d53-0ce7-40d0-90f9-7cabeca0bd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e61ae6b6-496b-4f37-83cb-53416e4b68db" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b3ef8aa-6f41-4237-ba4b-6a94a32b3de6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6b3ef8aa-6f41-4237-ba4b-6a94a32b3de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6afc870f-b19e-4b3e-9f50-db3f05a6e104" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6afc870f-b19e-4b3e-9f50-db3f05a6e104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d05c84a9-8f34-49ff-a655-04447b13954f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d05c84a9-8f34-49ff-a655-04447b13954f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear_d39ba6bd-feea-4549-b8c6-5d8893d5091b" xlink:href="brns-20240630.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear_d39ba6bd-feea-4549-b8c6-5d8893d5091b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f16f9710-d399-4ed2-aa5d-05e19d556422" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f16f9710-d399-4ed2-aa5d-05e19d556422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_32096439-16f8-4e89-a848-19f17b04aa20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_32096439-16f8-4e89-a848-19f17b04aa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_51c9d013-a2aa-4365-8210-37049fd70f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_51c9d013-a2aa-4365-8210-37049fd70f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4d0fc820-06d0-4f87-8707-2252901d901c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4d0fc820-06d0-4f87-8707-2252901d901c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_bc918373-116f-4aa8-bc91-eb78426c5127" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_bc918373-116f-4aa8-bc91-eb78426c5127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_f0c96cee-594e-4885-acee-9a0c4d8ca442" xlink:href="brns-20240630.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix_f0c96cee-594e-4885-acee-9a0c4d8ca442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_8ba455e2-779c-415c-8f40-defaceb46dce" xlink:href="brns-20240630.xsd#brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13388193-0aab-4774-9f76-bb038becd495" xlink:to="loc_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven_8ba455e2-779c-415c-8f40-defaceb46dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#PrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_4df6e784-c30d-4f31-a71f-5dc430151be3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_52b33267-2694-46cf-89bf-4f4cc079be1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_4df6e784-c30d-4f31-a71f-5dc430151be3" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_52b33267-2694-46cf-89bf-4f4cc079be1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_35de2609-5bff-481d-b288-e4586ea11305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_4df6e784-c30d-4f31-a71f-5dc430151be3" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_35de2609-5bff-481d-b288-e4586ea11305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_08fe63eb-b777-4012-ad60-1af76a47d8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_4df6e784-c30d-4f31-a71f-5dc430151be3" xlink:to="loc_us-gaap_OtherAssetsCurrent_08fe63eb-b777-4012-ad60-1af76a47d8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5eb7dab0-268c-4ca9-91d8-23f14080d3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_4df6e784-c30d-4f31-a71f-5dc430151be3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5eb7dab0-268c-4ca9-91d8-23f14080d3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#AccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_26de22d2-2b44-4a2b-b1e5-7d25224d3b68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_5ed05b27-8eae-41ce-bdd5-fcd1042dbf24" xlink:href="brns-20240630.xsd#brns_AccruedExpensesAndOtherLiabilitiesCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_26de22d2-2b44-4a2b-b1e5-7d25224d3b68" xlink:to="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_5ed05b27-8eae-41ce-bdd5-fcd1042dbf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13bdfe34-80d9-4b87-81e2-cfe1e665f855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_5ed05b27-8eae-41ce-bdd5-fcd1042dbf24" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13bdfe34-80d9-4b87-81e2-cfe1e665f855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c316575-cabb-4e8d-af0b-b60f1fce256b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13bdfe34-80d9-4b87-81e2-cfe1e665f855" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c316575-cabb-4e8d-af0b-b60f1fce256b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e185021-bab9-403a-bd27-243c16516a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c316575-cabb-4e8d-af0b-b60f1fce256b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5e185021-bab9-403a-bd27-243c16516a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_909a3838-8364-4a33-a7bc-5a54f496130d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5c316575-cabb-4e8d-af0b-b60f1fce256b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_909a3838-8364-4a33-a7bc-5a54f496130d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:href="brns-20240630.xsd#brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentTable_5ed05b27-8eae-41ce-bdd5-fcd1042dbf24" xlink:to="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_7f99d8e4-88e6-4c9a-9dc7-c4bb57101d5a" xlink:href="brns-20240630.xsd#brns_AccruedManufacturingAndClinicalExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_brns_AccruedManufacturingAndClinicalExpensesCurrent_7f99d8e4-88e6-4c9a-9dc7-c4bb57101d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_731c8e6a-372f-49ea-bcb7-ecaf725c0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_AccruedBonusesCurrent_731c8e6a-372f-49ea-bcb7-ecaf725c0f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1e97d5ed-ab75-48be-86a1-ca1de146a5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1e97d5ed-ab75-48be-86a1-ca1de146a5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_33a13b11-2f4b-4666-976d-29328c547635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_33a13b11-2f4b-4666-976d-29328c547635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a8da95aa-2224-4dca-9a56-5ecbc6860acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a8da95aa-2224-4dca-9a56-5ecbc6860acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_53af2032-6a3f-4f90-9c57-35114e94c967" xlink:href="brns-20240630.xsd#brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent_53af2032-6a3f-4f90-9c57-35114e94c967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_386b0688-45ef-41f2-a3cb-00084c2f3d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems_cdcfc488-f0f9-4596-be3c-65866e867127" xlink:to="loc_us-gaap_SeveranceCosts1_386b0688-45ef-41f2-a3cb-00084c2f3d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#GrantIncomeAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_45306854-dd71-4c10-a3fc-9cef544cdf99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTable_ddef7941-7033-409a-8db6-6b18d10eb02a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_45306854-dd71-4c10-a3fc-9cef544cdf99" xlink:to="loc_us-gaap_DeferredIncomeTable_ddef7941-7033-409a-8db6-6b18d10eb02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e007b9b6-10bb-40e9-a749-0643f9e1e54f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTable_ddef7941-7033-409a-8db6-6b18d10eb02a" xlink:to="loc_srt_CounterpartyNameAxis_e007b9b6-10bb-40e9-a749-0643f9e1e54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26e6b8a3-81d8-4b34-a8be-7115ac2ef442" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e007b9b6-10bb-40e9-a749-0643f9e1e54f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26e6b8a3-81d8-4b34-a8be-7115ac2ef442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember_983f0927-2bd5-4a24-bed5-0e0f5504e1e8" xlink:href="brns-20240630.xsd#brns_CoalitionForEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26e6b8a3-81d8-4b34-a8be-7115ac2ef442" xlink:to="loc_brns_CoalitionForEpidemicPreparednessInnovationsMember_983f0927-2bd5-4a24-bed5-0e0f5504e1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTable_ddef7941-7033-409a-8db6-6b18d10eb02a" xlink:to="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FundingAmountMaximum_0dfca00a-fefa-4d99-8140-f07e7b5c9114" xlink:href="brns-20240630.xsd#brns_FundingAmountMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_brns_FundingAmountMaximum_0dfca00a-fefa-4d99-8140-f07e7b5c9114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RoyaltyPaymentTermMaximum_6e8ef5f8-35d1-4ed2-b283-2b061fa620a4" xlink:href="brns-20240630.xsd#brns_RoyaltyPaymentTermMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_brns_RoyaltyPaymentTermMaximum_6e8ef5f8-35d1-4ed2-b283-2b061fa620a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeAddition_8ea91c18-e12e-42d2-8b86-15aac36c6fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeAddition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_us-gaap_DeferredIncomeAddition_8ea91c18-e12e-42d2-8b86-15aac36c6fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRevenueRecognized_6e115014-70d5-47f1-8277-47e91bdbe035" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_us-gaap_DeferredIncomeRevenueRecognized_6e115014-70d5-47f1-8277-47e91bdbe035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_02f55677-d1d3-4415-b160-5c96eb724253" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeLineItems_8a3e9513-5424-4380-a45d-67e8d5a8d87a" xlink:to="loc_us-gaap_RestrictedCashCurrent_02f55677-d1d3-4415-b160-5c96eb724253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#GrantIncomeChangesindeferredincomeDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_be5b7e47-8c9d-495e-8d71-2bad9be52e10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRollForward_da54dd38-9bf7-4b4f-98fb-a26de1963727" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_be5b7e47-8c9d-495e-8d71-2bad9be52e10" xlink:to="loc_us-gaap_DeferredIncomeRollForward_da54dd38-9bf7-4b4f-98fb-a26de1963727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_0ac02f56-e0d4-47ef-91be-08ea8c679187" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_da54dd38-9bf7-4b4f-98fb-a26de1963727" xlink:to="loc_us-gaap_DeferredIncome_0ac02f56-e0d4-47ef-91be-08ea8c679187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeAddition_1aa43afb-9f1b-4b14-952c-20027812511b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeAddition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_da54dd38-9bf7-4b4f-98fb-a26de1963727" xlink:to="loc_us-gaap_DeferredIncomeAddition_1aa43afb-9f1b-4b14-952c-20027812511b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeRevenueRecognized_76c8b80f-7cc7-4f52-87bb-501d7a01cadb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_da54dd38-9bf7-4b4f-98fb-a26de1963727" xlink:to="loc_us-gaap_DeferredIncomeRevenueRecognized_76c8b80f-7cc7-4f52-87bb-501d7a01cadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredIncomeForeignExchangeTranslationGainLoss_dc23b45a-86a4-4ed2-a798-23825c51bea5" xlink:href="brns-20240630.xsd#brns_DeferredIncomeForeignExchangeTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_da54dd38-9bf7-4b4f-98fb-a26de1963727" xlink:to="loc_brns_DeferredIncomeForeignExchangeTranslationGainLoss_dc23b45a-86a4-4ed2-a798-23825c51bea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncome_3179e7c1-8e9a-41a5-b477-2921d66524ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeRollForward_da54dd38-9bf7-4b4f-98fb-a26de1963727" xlink:to="loc_us-gaap_DeferredIncome_3179e7c1-8e9a-41a5-b477-2921d66524ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/OrdinarySharesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#OrdinarySharesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/OrdinarySharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4cd7451e-c021-4d64-8f9e-3a0c6829000c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dd30dbdf-416f-40ae-8707-6b93bf7ceaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4cd7451e-c021-4d64-8f9e-3a0c6829000c" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dd30dbdf-416f-40ae-8707-6b93bf7ceaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e85b4823-3ec3-4b60-8b13-447fb1c2d90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dd30dbdf-416f-40ae-8707-6b93bf7ceaa8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e85b4823-3ec3-4b60-8b13-447fb1c2d90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b921b9f-e721-4b5e-a8c0-0510c159dd27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e85b4823-3ec3-4b60-8b13-447fb1c2d90c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b921b9f-e721-4b5e-a8c0-0510c159dd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4dcd056e-a058-4a45-a03f-ee71cc899f65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7b921b9f-e721-4b5e-a8c0-0510c159dd27" xlink:to="loc_us-gaap_IPOMember_4dcd056e-a058-4a45-a03f-ee71cc899f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dd30dbdf-416f-40ae-8707-6b93bf7ceaa8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_CommonStockNumberOfVotesPerShare_fe42d4bb-cf96-4e7a-aba5-b8e675268c2d" xlink:href="brns-20240630.xsd#brns_CommonStockNumberOfVotesPerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:to="loc_brns_CommonStockNumberOfVotesPerShare_fe42d4bb-cf96-4e7a-aba5-b8e675268c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_dcd80425-77a8-4cf1-8b46-e8eae8914eb2" xlink:href="brns-20240630.xsd#brns_PercentageOfSharesNecessaryToExercisePreemptiveRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:to="loc_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights_dcd80425-77a8-4cf1-8b46-e8eae8914eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PeriodOfPreemptiveRightsToBeExercised_35fabaf4-ca29-42e2-9880-871745f715c9" xlink:href="brns-20240630.xsd#brns_PeriodOfPreemptiveRightsToBeExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:to="loc_brns_PeriodOfPreemptiveRightsToBeExercised_35fabaf4-ca29-42e2-9880-871745f715c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_9beebca6-a682-41df-b406-66eccfdf32da" xlink:href="brns-20240630.xsd#brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_3739e82c-3eef-4348-b022-bfe86db7863c" xlink:to="loc_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights_9beebca6-a682-41df-b406-66eccfdf32da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/DeferredSharesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#DeferredSharesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/DeferredSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_999acef1-eba7-4395-b575-28d6db4bcf66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_76759be3-6ab4-4106-9589-199654baa0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_999acef1-eba7-4395-b575-28d6db4bcf66" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_76759be3-6ab4-4106-9589-199654baa0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_06144e98-e26d-4608-b065-026ac420593b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_76759be3-6ab4-4106-9589-199654baa0ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_06144e98-e26d-4608-b065-026ac420593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_06144e98-e26d-4608-b065-026ac420593b" xlink:to="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredShares.Member_bb51de3b-c13c-4668-8918-66994d989f40" xlink:href="brns-20240630.xsd#brns_DeferredShares.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:to="loc_brns_DeferredShares.Member_bb51de3b-c13c-4668-8918-66994d989f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredBSharesMember_da58e1f7-51df-4ba4-b4dd-21e98ed6397e" xlink:href="brns-20240630.xsd#brns_DeferredBSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:to="loc_brns_DeferredBSharesMember_da58e1f7-51df-4ba4-b4dd-21e98ed6397e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredCSharesMember_47058bcd-e5a0-459d-a6e8-fb55f2388e24" xlink:href="brns-20240630.xsd#brns_DeferredCSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c8499c7e-04b3-4d2e-92f7-b4dfefe64852" xlink:to="loc_brns_DeferredCSharesMember_47058bcd-e5a0-459d-a6e8-fb55f2388e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_50928cbf-e5a8-4c42-b595-7d4db35f8b49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_76759be3-6ab4-4106-9589-199654baa0ed" xlink:to="loc_us-gaap_ClassOfStockLineItems_50928cbf-e5a8-4c42-b595-7d4db35f8b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OrdinarySharesLiquidationPreference_b11b36de-18e4-498c-add7-056b96205477" xlink:href="brns-20240630.xsd#brns_OrdinarySharesLiquidationPreference"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_50928cbf-e5a8-4c42-b595-7d4db35f8b49" xlink:to="loc_brns_OrdinarySharesLiquidationPreference_b11b36de-18e4-498c-add7-056b96205477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_DeferredStockParOrStatedValuePerShare_01dc4e18-5d20-46b9-9e12-9f9d78c76ba7" xlink:href="brns-20240630.xsd#brns_DeferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_50928cbf-e5a8-4c42-b595-7d4db35f8b49" xlink:to="loc_brns_DeferredStockParOrStatedValuePerShare_01dc4e18-5d20-46b9-9e12-9f9d78c76ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#FairValueAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ed3f26a7-02b8-4547-8f49-a13eeca0db8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1e863cb5-92eb-4e4a-8e7a-b657e642afd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ed3f26a7-02b8-4547-8f49-a13eeca0db8f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1e863cb5-92eb-4e4a-8e7a-b657e642afd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ee34b8c3-b0e9-421a-bb83-682138416d73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1e863cb5-92eb-4e4a-8e7a-b657e642afd5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ee34b8c3-b0e9-421a-bb83-682138416d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44c399ff-2f26-4c41-a2e0-809f38fd7a39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee34b8c3-b0e9-421a-bb83-682138416d73" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44c399ff-2f26-4c41-a2e0-809f38fd7a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_AvideaMember_3aed2550-7cd6-4ab8-a4cb-3364582a4553" xlink:href="brns-20240630.xsd#brns_AvideaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_44c399ff-2f26-4c41-a2e0-809f38fd7a39" xlink:to="loc_brns_AvideaMember_3aed2550-7cd6-4ab8-a4cb-3364582a4553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d0ec80e2-259e-4ff1-b2ac-406466340bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1e863cb5-92eb-4e4a-8e7a-b657e642afd5" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d0ec80e2-259e-4ff1-b2ac-406466340bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cad13dcf-9c24-4c97-808d-63b0f7be35d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_d0ec80e2-259e-4ff1-b2ac-406466340bfa" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cad13dcf-9c24-4c97-808d-63b0f7be35d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details" xlink:type="simple" xlink:href="brns-20240630.xsd#FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9d297d41-1a4c-4543-a8ff-e59989d6c135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_eefb4874-b1e6-4e17-bee3-5817fb6c4c92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9d297d41-1a4c-4543-a8ff-e59989d6c135" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_eefb4874-b1e6-4e17-bee3-5817fb6c4c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_aa85cf48-bf68-437a-8806-f1c913461547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_eefb4874-b1e6-4e17-bee3-5817fb6c4c92" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_aa85cf48-bf68-437a-8806-f1c913461547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c7a72d47-8cd1-45f2-ae29-c7fc64c293fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_aa85cf48-bf68-437a-8806-f1c913461547" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c7a72d47-8cd1-45f2-ae29-c7fc64c293fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ContingentConsiderationLiabilityMember_fa6b3c4c-cf9f-423e-a4d8-3c677cf55a8d" xlink:href="brns-20240630.xsd#brns_ContingentConsiderationLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c7a72d47-8cd1-45f2-ae29-c7fc64c293fd" xlink:to="loc_brns_ContingentConsiderationLiabilityMember_fa6b3c4c-cf9f-423e-a4d8-3c677cf55a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5af8d2eb-b360-41cb-bad4-ba7a6415add8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_eefb4874-b1e6-4e17-bee3-5817fb6c4c92" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5af8d2eb-b360-41cb-bad4-ba7a6415add8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_5af8d2eb-b360-41cb-bad4-ba7a6415add8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f1e087d2-d6ef-4450-92b7-2316b5703fca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f1e087d2-d6ef-4450-92b7-2316b5703fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7e8405f8-17d9-44eb-8480-dd9cc06e9a28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7e8405f8-17d9-44eb-8480-dd9cc06e9a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_0cfdbb2c-d27a-43a7-8bae-945bc5363a63" xlink:href="brns-20240630.xsd#brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:to="loc_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation_0cfdbb2c-d27a-43a7-8bae-945bc5363a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3e73e0ca-ec7b-4ad9-8be5-653197555a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_9fc311e7-f1e3-4fdd-9808-71f754db49b3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3e73e0ca-ec7b-4ad9-8be5-653197555a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/GoodwillDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#GoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/GoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b481acbf-8812-431a-88b7-7c1481eb6e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_785edd7d-a9ae-4be1-9d26-05644a5f2d34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b481acbf-8812-431a-88b7-7c1481eb6e9e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_785edd7d-a9ae-4be1-9d26-05644a5f2d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#ShareBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d63de4c5-617f-4193-b99c-9083e723d11a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0a9b4e5-e254-477e-b7f1-9835dfd17bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d63de4c5-617f-4193-b99c-9083e723d11a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0a9b4e5-e254-477e-b7f1-9835dfd17bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ee5430e1-fcca-4c9b-b077-25c2be9888d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0a9b4e5-e254-477e-b7f1-9835dfd17bdd" xlink:to="loc_us-gaap_PlanNameAxis_ee5430e1-fcca-4c9b-b077-25c2be9888d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3d1ff46e-145e-442d-9509-4fa20735bcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ee5430e1-fcca-4c9b-b077-25c2be9888d9" xlink:to="loc_us-gaap_PlanNameDomain_3d1ff46e-145e-442d-9509-4fa20735bcb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_3b326c4e-04e5-44de-aee3-11a4f6e3824d" xlink:href="brns-20240630.xsd#brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3d1ff46e-145e-442d-9509-4fa20735bcb2" xlink:to="loc_brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member_3b326c4e-04e5-44de-aee3-11a4f6e3824d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d43c87b-69b9-4b08-9bff-d056da266c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0a9b4e5-e254-477e-b7f1-9835dfd17bdd" xlink:to="loc_us-gaap_AwardTypeAxis_5d43c87b-69b9-4b08-9bff-d056da266c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7c1f9b-243d-4660-9a21-57394ad8bb97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5d43c87b-69b9-4b08-9bff-d056da266c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7c1f9b-243d-4660-9a21-57394ad8bb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_819b1e24-094e-433f-aeea-9fdddb3efd4c" xlink:href="brns-20240630.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7c1f9b-243d-4660-9a21-57394ad8bb97" xlink:to="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember_819b1e24-094e-433f-aeea-9fdddb3efd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b0ae9e84-e046-4e9f-a11b-0d2795734097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf7c1f9b-243d-4660-9a21-57394ad8bb97" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b0ae9e84-e046-4e9f-a11b-0d2795734097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0a9b4e5-e254-477e-b7f1-9835dfd17bdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_f6f8e7fe-78a0-4a9c-b303-88f48ef95d4b" xlink:href="brns-20240630.xsd#brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares_f6f8e7fe-78a0-4a9c-b303-88f48ef95d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ebca8223-b395-449b-a72f-d41bb0b1c315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ebca8223-b395-449b-a72f-d41bb0b1c315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b7070ac0-5df9-4211-9972-a04c11a184c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b7070ac0-5df9-4211-9972-a04c11a184c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14221a07-87d4-4387-bad1-2faa55da5792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14221a07-87d4-4387-bad1-2faa55da5792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_33db028a-f67c-4764-908d-4343cbbf4658" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_33db028a-f67c-4764-908d-4343cbbf4658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dccb659d-6a2c-40d5-a393-5e66dcf31c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dccb659d-6a2c-40d5-a393-5e66dcf31c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4acf6ab0-6132-4322-8169-d12c123ffae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4acf6ab0-6132-4322-8169-d12c123ffae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_72cee304-f335-41af-82a5-c3fbfa3c23a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_72cee304-f335-41af-82a5-c3fbfa3c23a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d5426039-1b2c-4499-9d80-ad18e3110ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_71e33c27-5904-4f38-ba07-55a44c423322" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d5426039-1b2c-4499-9d80-ad18e3110ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#ShareBasedCompensationWeightedaverageassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72825a6e-973a-4446-9042-93a481a171ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c787fc09-329d-40b5-8a44-e4dbabd4bd98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_72825a6e-973a-4446-9042-93a481a171ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c787fc09-329d-40b5-8a44-e4dbabd4bd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f5f0e011-94ef-4f12-b24a-448e087dc9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c787fc09-329d-40b5-8a44-e4dbabd4bd98" xlink:to="loc_us-gaap_PlanNameAxis_f5f0e011-94ef-4f12-b24a-448e087dc9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cda0eb92-3fc8-4322-b6cf-26cf4e40b3af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f5f0e011-94ef-4f12-b24a-448e087dc9fe" xlink:to="loc_us-gaap_PlanNameDomain_cda0eb92-3fc8-4322-b6cf-26cf4e40b3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_9b4460a3-851b-4622-97c8-18597dc80b13" xlink:href="brns-20240630.xsd#brns_EnterpriseManagementIncentiveShareOptionSchemeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cda0eb92-3fc8-4322-b6cf-26cf4e40b3af" xlink:to="loc_brns_EnterpriseManagementIncentiveShareOptionSchemeMember_9b4460a3-851b-4622-97c8-18597dc80b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c787fc09-329d-40b5-8a44-e4dbabd4bd98" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_39b9d4aa-354b-4c4b-9c84-d7d02fd764af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_39b9d4aa-354b-4c4b-9c84-d7d02fd764af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c7636273-5c3d-4727-806a-2c2b27bf9ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c7636273-5c3d-4727-806a-2c2b27bf9ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_222ca206-5a99-4a91-ba60-c9627ac27f90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_222ca206-5a99-4a91-ba60-c9627ac27f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f3a3d31a-48e1-4314-a906-d42400172a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1fe66159-9ff7-480c-9863-0a6bc49e01fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f3a3d31a-48e1-4314-a906-d42400172a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#ShareBasedCompensationSharebasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c1f2d06-ad84-4271-b530-22f21b3eceef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8862c929-651f-4a5c-a358-4b313755b390" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c1f2d06-ad84-4271-b530-22f21b3eceef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8862c929-651f-4a5c-a358-4b313755b390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_303c8d45-2944-49e0-b7eb-c73b36d0a12d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8862c929-651f-4a5c-a358-4b313755b390" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_303c8d45-2944-49e0-b7eb-c73b36d0a12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8f469a60-4afa-41fb-8a4b-d29d1e670998" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_303c8d45-2944-49e0-b7eb-c73b36d0a12d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8f469a60-4afa-41fb-8a4b-d29d1e670998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60a3816f-6673-4f1a-b7fe-433b3ee269cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f469a60-4afa-41fb-8a4b-d29d1e670998" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_60a3816f-6673-4f1a-b7fe-433b3ee269cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_caeb5819-43db-414b-b840-ac13a010f234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8f469a60-4afa-41fb-8a4b-d29d1e670998" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_caeb5819-43db-414b-b840-ac13a010f234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75976122-4189-470a-8009-eb9edd67f4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8862c929-651f-4a5c-a358-4b313755b390" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75976122-4189-470a-8009-eb9edd67f4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_289d82da-5454-459a-98d3-233a5b40cdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75976122-4189-470a-8009-eb9edd67f4ca" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_289d82da-5454-459a-98d3-233a5b40cdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_306d833a-d27d-47af-a062-67eba2313875" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_306d833a-d27d-47af-a062-67eba2313875" xlink:to="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44a810dc-70a9-4b35-9d88-cb7277fc79d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44a810dc-70a9-4b35-9d88-cb7277fc79d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f81c26fe-3274-425c-8169-e4e3e38f4dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44a810dc-70a9-4b35-9d88-cb7277fc79d1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f81c26fe-3274-425c-8169-e4e3e38f4dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_InLicenseAgreementsMember_aa63cd64-d6b9-4093-9987-b38d09ed512d" xlink:href="brns-20240630.xsd#brns_InLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f81c26fe-3274-425c-8169-e4e3e38f4dd8" xlink:to="loc_brns_InLicenseAgreementsMember_aa63cd64-d6b9-4093-9987-b38d09ed512d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_535d9205-a9b1-435d-80f1-d929ce5485d3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:to="loc_srt_RangeAxis_535d9205-a9b1-435d-80f1-d929ce5485d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cfefda7a-deec-4e74-bbac-8ea7b7d195e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_535d9205-a9b1-435d-80f1-d929ce5485d3" xlink:to="loc_srt_RangeMember_cfefda7a-deec-4e74-bbac-8ea7b7d195e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_80d33971-4ed2-466b-9ee1-496677365c55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cfefda7a-deec-4e74-bbac-8ea7b7d195e7" xlink:to="loc_srt_MinimumMember_80d33971-4ed2-466b-9ee1-496677365c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8a8b1209-7674-4d59-92e7-d850af03bf71" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cfefda7a-deec-4e74-bbac-8ea7b7d195e7" xlink:to="loc_srt_MaximumMember_8a8b1209-7674-4d59-92e7-d850af03bf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d0c0522c-0b5a-4f97-adb2-05e10085dc5c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:to="loc_srt_StatementGeographicalAxis_d0c0522c-0b5a-4f97-adb2-05e10085dc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_70f9d2cc-5013-4c68-ba86-47aa2a15881d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d0c0522c-0b5a-4f97-adb2-05e10085dc5c" xlink:to="loc_srt_SegmentGeographicalDomain_70f9d2cc-5013-4c68-ba86-47aa2a15881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordshireMember_7fd1c66e-bb38-4a69-855d-4769ac5da91a" xlink:href="brns-20240630.xsd#brns_OxfordshireMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_70f9d2cc-5013-4c68-ba86-47aa2a15881d" xlink:to="loc_brns_OxfordshireMember_7fd1c66e-bb38-4a69-855d-4769ac5da91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MD_c09e5faf-478f-4870-afa4-20c87f87bec7" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_70f9d2cc-5013-4c68-ba86-47aa2a15881d" xlink:to="loc_stpr_MD_c09e5faf-478f-4870-afa4-20c87f87bec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_435834a0-89f8-4c72-b56f-7ae3995ad3c4" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_5bf9b250-2f31-4f52-a7af-d8e9bf195171" xlink:href="brns-20240630.xsd#brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement_5bf9b250-2f31-4f52-a7af-d8e9bf195171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_5087f0d0-6249-493a-b399-84a87db924bd" xlink:href="brns-20240630.xsd#brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement_5087f0d0-6249-493a-b399-84a87db924bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_0c58328d-e535-44b2-bfb7-7a0a720ae893" xlink:href="brns-20240630.xsd#brns_NumberOfSquareFeetUnderLeaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_brns_NumberOfSquareFeetUnderLeaseAgreement_0c58328d-e535-44b2-bfb7-7a0a720ae893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_6971f328-efeb-4fbd-8367-3699d24768d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_us-gaap_SecurityDeposit_6971f328-efeb-4fbd-8367-3699d24768d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseExtendedTerm_8952c6ad-0873-4c65-bf09-132c6c90c7c2" xlink:href="brns-20240630.xsd#brns_LesseeOperatingLeaseExtendedTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_brns_LesseeOperatingLeaseExtendedTerm_8952c6ad-0873-4c65-bf09-132c6c90c7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_becc52bf-0a55-4436-a7d3-34f8ef96a2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a932ad64-7d0a-4c4a-b0fc-a8cc4ae39fae" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_becc52bf-0a55-4436-a7d3-34f8ef96a2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55b19bba-205f-4da3-8501-f9fcec07ad59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5d6ed01-47e1-4bf1-ab99-e262addfd40f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55b19bba-205f-4da3-8501-f9fcec07ad59" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c5d6ed01-47e1-4bf1-ab99-e262addfd40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a8185a77-45fe-4c90-9b50-830dc8a8d731" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55b19bba-205f-4da3-8501-f9fcec07ad59" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a8185a77-45fe-4c90-9b50-830dc8a8d731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43b6094a-87c8-431e-89c0-ba1be75c48e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55b19bba-205f-4da3-8501-f9fcec07ad59" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43b6094a-87c8-431e-89c0-ba1be75c48e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OtherInformationLesseeAbstract_38682c13-b95a-425e-b3a6-87fa9019c593" xlink:href="brns-20240630.xsd#brns_OtherInformationLesseeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55b19bba-205f-4da3-8501-f9fcec07ad59" xlink:to="loc_brns_OtherInformationLesseeAbstract_38682c13-b95a-425e-b3a6-87fa9019c593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5c93534e-2b69-4a3e-b9a2-2e5fb6c36daf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_OtherInformationLesseeAbstract_38682c13-b95a-425e-b3a6-87fa9019c593" xlink:to="loc_us-gaap_OperatingLeasePayments_5c93534e-2b69-4a3e-b9a2-2e5fb6c36daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_93a385d1-1d99-486b-a4aa-c2e745d6d007" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_OtherInformationLesseeAbstract_38682c13-b95a-425e-b3a6-87fa9019c593" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_93a385d1-1d99-486b-a4aa-c2e745d6d007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_32d762bf-b800-46a9-9ab6-6ba7fbb43467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_brns_OtherInformationLesseeAbstract_38682c13-b95a-425e-b3a6-87fa9019c593" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_32d762bf-b800-46a9-9ab6-6ba7fbb43467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingenciesLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6eabdb2f-4d51-496c-96bf-207fe452d47b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_6959c1b2-f229-4fea-8421-8d3ff0a3d0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6eabdb2f-4d51-496c-96bf-207fe452d47b" xlink:to="loc_us-gaap_ShortTermLeaseCost_6959c1b2-f229-4fea-8421-8d3ff0a3d0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_035c1680-50a0-43b1-a5f0-f84bbc356ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6eabdb2f-4d51-496c-96bf-207fe452d47b" xlink:to="loc_us-gaap_OperatingLeaseCost_035c1680-50a0-43b1-a5f0-f84bbc356ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_dd02f61f-db07-45d4-836c-039defe180d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6eabdb2f-4d51-496c-96bf-207fe452d47b" xlink:to="loc_us-gaap_LeaseCost_dd02f61f-db07-45d4-836c-039defe180d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_dc64bdab-1797-4fcd-837d-9af7dea373c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_dc64bdab-1797-4fcd-837d-9af7dea373c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c5380cbb-3cda-49e6-be95-b68e4eb9ed3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c5380cbb-3cda-49e6-be95-b68e4eb9ed3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c8fea84b-9912-4b3f-84d7-f92d38184197" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c8fea84b-9912-4b3f-84d7-f92d38184197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ee6f38f7-3362-4411-be7f-e19fbe8f2db7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ee6f38f7-3362-4411-be7f-e19fbe8f2db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b01d47fc-6c9d-4a64-85a2-7cba811df4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b01d47fc-6c9d-4a64-85a2-7cba811df4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_aca533f5-6327-4f9d-b8d9-50b50c93bdea" xlink:href="brns-20240630.xsd#brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:to="loc_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_aca533f5-6327-4f9d-b8d9-50b50c93bdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3f0db54-a731-4053-9187-f59d16901b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e3f0db54-a731-4053-9187-f59d16901b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_916f90c3-45a0-437f-986d-c0be377f9e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_916f90c3-45a0-437f-986d-c0be377f9e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3eeeaff4-91e8-45d9-bf6c-7ba124595ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f8ef990c-0437-4fe3-9068-fd3d432fa32f" xlink:to="loc_us-gaap_OperatingLeaseLiability_3eeeaff4-91e8-45d9-bf6c-7ba124595ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="brns-20240630.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_45fbdb46-0935-4b11-9033-ae34094731c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_45fbdb46-0935-4b11-9033-ae34094731c3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2dfc7d50-3ad1-4eef-a69c-b766a4db4ffc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:to="loc_srt_CounterpartyNameAxis_2dfc7d50-3ad1-4eef-a69c-b766a4db4ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4889a89b-bd7f-4a44-976f-8f3ce8c743b5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2dfc7d50-3ad1-4eef-a69c-b766a4db4ffc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4889a89b-bd7f-4a44-976f-8f3ce8c743b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_OxfordUniversityInnovationLimitedMember_11a14938-8809-4547-b1ef-d504095e1c95" xlink:href="brns-20240630.xsd#brns_OxfordUniversityInnovationLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4889a89b-bd7f-4a44-976f-8f3ce8c743b5" xlink:to="loc_brns_OxfordUniversityInnovationLimitedMember_11a14938-8809-4547-b1ef-d504095e1c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_6beb31c2-9e8e-4027-bb9e-db12975980a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_6beb31c2-9e8e-4027-bb9e-db12975980a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5b68395a-f86b-416e-9b38-b7123de373f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_6beb31c2-9e8e-4027-bb9e-db12975980a9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5b68395a-f86b-416e-9b38-b7123de373f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_ExpensesMember_39883748-1bec-4f69-97f4-8b3372a8d291" xlink:href="brns-20240630.xsd#brns_ExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5b68395a-f86b-416e-9b38-b7123de373f3" xlink:to="loc_brns_ExpensesMember_39883748-1bec-4f69-97f4-8b3372a8d291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ca0382c-a786-4733-8c0d-30bd61d6ae10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ca0382c-a786-4733-8c0d-30bd61d6ae10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c55cd835-dd6f-4183-9e93-e31f0c1bfdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ca0382c-a786-4733-8c0d-30bd61d6ae10" xlink:to="loc_us-gaap_RelatedPartyDomain_c55cd835-dd6f-4183-9e93-e31f0c1bfdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_9f1d8b46-5880-4336-8bc1-824d076cad43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c55cd835-dd6f-4183-9e93-e31f0c1bfdcc" xlink:to="loc_us-gaap_RelatedPartyMember_9f1d8b46-5880-4336-8bc1-824d076cad43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ffb05811-1db8-4b89-8006-9d9b75618196" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:to="loc_srt_ProductOrServiceAxis_ffb05811-1db8-4b89-8006-9d9b75618196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2cb0a264-0ce2-47a0-95fd-de7f63886623" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ffb05811-1db8-4b89-8006-9d9b75618196" xlink:to="loc_srt_ProductsAndServicesDomain_2cb0a264-0ce2-47a0-95fd-de7f63886623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ae054627-92f7-4bac-b203-22f314b3e3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2cb0a264-0ce2-47a0-95fd-de7f63886623" xlink:to="loc_us-gaap_LicenseMember_ae054627-92f7-4bac-b203-22f314b3e3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1358f1be-b284-4466-af4c-7b418e72febc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c8e8b36f-18d4-4085-bf88-d14fc75553fc" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1358f1be-b284-4466-af4c-7b418e72febc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_146708d6-71d6-4279-975b-52854f9469eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1358f1be-b284-4466-af4c-7b418e72febc" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_146708d6-71d6-4279-975b-52854f9469eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e23582ee-c9f2-4c23-bc66-f3adf457c94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1358f1be-b284-4466-af4c-7b418e72febc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e23582ee-c9f2-4c23-bc66-f3adf457c94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:href="brns-20240630.xsd#brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>brns-20240630_g1.jpg
<TEXT>
begin 644 brns-20240630_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" CF$"$# 2(  A$! Q$!_\0
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M^@M8?^ $='_#>7Q=_P"@M8?^ $=?/-%'U'#?\^U]P>VJ?S,^AO\ AO+XN_\
M06L/_ ".C_AO+XN_]!:P_P# ".OGFBCZCAO^?:^X/;5/YF?0W_#>7Q=_Z"UA
M_P" $='_  WE\7?^@M8?^ $=?/-%'U'#?\^U]P>VJ?S,^AO^&\OB[_T%K#_P
M CH_X;R^+O\ T%K#_P  (Z^>:*/J.&_Y]K[@]M4_F9]#?\-Y?%W_ *"UA_X
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M'7SS177]1PW_ #[7W&7MJG\S/H;_ (;R^+O_ $%K#_P CH_X;R^+O_06L/\
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M-_PWE\7?^@M8?^ $='_#>7Q=_P"@M8?^ $=?/-%'U'#?\^U]P>VJ?S,^AO\
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M!'1_PWE\7?\ H+6'_@!'7SS11]1PW_/M?<'MJG\S/H;_ (;R^+O_ $%K#_P
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M^@M8?^ $='_#>7Q=_P"@M8?^ $=?/-%'U'#?\^U]P>VJ?S,^AO\ AO+XN_\
M06L/_ ".C_AO+XN_]!:P_P# ".OGFBCZCAO^?:^X/;5/YF?0W_#>7Q=_Z"UA
M_P" $='_  WE\7?^@M8?^ $=?/-%'U'#?\^U]P>VJ?S,^AO^&\OB[_T%K#_P
M CH_X;R^+O\ T%K#_P  (Z^>:*/J.&_Y]K[@]M4_F9]#?\-Y?%W_ *"UA_X
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M#_P CKYYHH^HX;_GVON#VU3^9GT-_P -Y?%W_H+6'_@!'1_PWE\7?^@M8?\
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M/2OS!K]!O^"M_P#Q_?!S_L"W'\X:\^MA*$<31BH*SYKZ>1O"K4=.;YNQ\_\
M_#>7Q=_Z"UA_X 1T?\-Y?%W_ *"UA_X 1U\\T5Z'U'#?\^U]QA[:I_,SZ&_X
M;R^+O_06L/\ P CH_P"&\OB[_P!!:P_\ (Z^>:*/J.&_Y]K[@]M4_F9]#?\
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M#_P CKYYHH^HX;_GVON#VU3^9GT-_P -Y?%W_H+6'_@!'1_PWE\7?^@M8?\
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M_ ".OGFBCZCAO^?:^X/;5/YF?0W_  WE\7?^@M8?^ $='_#>7Q=_Z"UA_P"
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M;_GVON#VU3^9GT-_PWE\7?\ H+6'_@!'1_PWE\7?^@M8?^ $=?/-%'U'#?\
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M;R^+O_06L/\ P CH_P"&\OB[_P!!:P_\ (Z^>:*/J.&_Y]K[@]M4_F9]#?\
M#>7Q=_Z"UA_X 1T?\-Y?%W_H+6'_ ( 1U\\T4?4<-_S[7W![:I_,SZ&_X;R^
M+O\ T%K#_P  (Z/^&\OB[_T%K#_P CKYYHH^HX;_ )]K[@]M4_F9]#?\-Y?%
MW_H+6'_@!'1_PWE\7?\ H+6'_@!'7SS11]1PW_/M?<'MJG\S/H;_ (;R^+O_
M $%K#_P CH_X;R^+O_06L/\ P CKYYHH^HX;_GVON#VU3^9GT-_PWE\7?^@M
M8?\ @!'1_P -Y?%W_H+6'_@!'7SS11]1PW_/M?<'MJG\S/M']FG]KCXC_$WX
M]>!O"NNZC:3:/JVIQVMU'#:)&[1MG(##D&NB_;0_:>\>_!7]I+Q=X-\+W]M;
MZ'IHLS;QW%LLKCS+.&5\L>3\TC5\[_L4_P#)U_PN_P"PW#_6NP_X*4?\GI?$
M'Z:=_P"FZVKS_JM#ZXH<BMRWV\T='M9^QOS:W_0RO^&\OB[_ -!:P_\  ".C
M_AO+XN_]!:P_\ (Z^>:*]#ZCAO\ GVON.?VU3^9GT-_PWE\7?^@M8?\ @!'1
M_P -Y?%W_H+6'_@!'7SS11]1PW_/M?<'MJG\S/H;_AO+XN_]!:P_\ (Z/^&\
MOB[_ -!:P_\  ".OGFBCZCAO^?:^X/;5/YF?0W_#>7Q=_P"@M8?^ $='_#>7
MQ=_Z"UA_X 1U\\T4?4<-_P ^U]P>VJ?S,^AO^&\OB[_T%K#_ , (Z/\ AO+X
MN_\ 06L/_ ".OGFBCZCAO^?:^X/;5/YF?0W_  WE\7?^@M8?^ $='_#>7Q=_
MZ"UA_P" $=?/-%'U'#?\^U]P>VJ?S,^AO^&\OB[_ -!:P_\  ".C_AO+XN_]
M!:P_\ (Z^>:*/J.&_P"?:^X/;5/YF?0W_#>7Q=_Z"UA_X 1T?\-Y?%W_ *"U
MA_X 1U\\T4?4<-_S[7W![:I_,SZ&_P"&\OB[_P!!:P_\ (Z/^&\OB[_T%K#_
M , (Z^>:*/J.&_Y]K[@]M4_F9]#?\-Y?%W_H+6'_ ( 1T?\ #>7Q=_Z"UA_X
M 1U\\T4?4<-_S[7W![:I_,SZ&_X;R^+O_06L/_ ".C_AO+XN_P#06L/_   C
MKYYHH^HX;_GVON#VU3^9GT-_PWE\7?\ H+6'_@!'1_PWE\7?^@M8?^ $=?/-
M%'U'#?\ /M?<'MJG\S/H;_AO+XN_]!:P_P# ".C_ (;R^+O_ $%K#_P CKYY
MHH^HX;_GVON#VU3^9GT-_P -Y?%W_H+6'_@!'1_PWE\7?^@M8?\ @!'7SS11
M]1PW_/M?<'MJG\S/H;_AO+XN_P#06L/_   CH_X;R^+O_06L/_ ".OGFBCZC
MAO\ GVON#VU3^9GT-_PWE\7?^@M8?^ $='_#>7Q=_P"@M8?^ $=?/-%'U'#?
M\^U]P>VJ?S,^AO\ AO+XN_\ 06L/_ ".C_AO+XN_]!:P_P# ".OGFBCZCAO^
M?:^X/;5/YF?0W_#>7Q=_Z"UA_P" $='_  WE\7?^@M8?^ $=?/-%'U'#?\^U
M]P>VJ?S,^AO^&\OB[_T%K#_P CH_X;R^+O\ T%K#_P  (Z^>:*/J.&_Y]K[@
M]M4_F9]#?\-Y?%W_ *"UA_X 1T?\-Y?%W_H+6'_@!'7SS11]1PW_ #[7W![:
MI_,SZ&_X;R^+O_06L/\ P CH_P"&\OB[_P!!:P_\ (Z^>:*/J.&_Y]K[@]M4
M_F9]#?\ #>7Q=_Z"UA_X 1T?\-Y?%W_H+6'_ ( 1U\\T4?4<-_S[7W![:I_,
MSZ&_X;R^+O\ T%K#_P  (Z/^&\OB[_T%K#_P CKYYHH^HX;_ )]K[@]M4_F9
M]#?\-Y?%W_H+6'_@!'7UQ>?&3Q/#_P $[[#XNK=1#QK-J1MGN/*'D[/MKQ8\
MOIG8HK\P:_0;4O\ E#WI7_8:;_TY25Y^,PM"'LN6"5Y);>IT4:LY<UY=&?/_
M /PWE\7?^@M8?^ $='_#>7Q=_P"@M8?^ $=?/-%>A]1PW_/M?<<_MJG\S/H;
M_AO+XN_]!:P_\ (Z/^&\OB[_ -!:P_\  ".OGFBCZCAO^?:^X/;5/YF?0W_#
M>7Q=_P"@M8?^ $='_#>7Q=_Z"UA_X 1U\\T4?4<-_P ^U]P>VJ?S,^AO^&\O
MB[_T%K#_ , (Z/\ AO+XN_\ 06L/_ ".OGFBCZCAO^?:^X/;5/YF?0W_  WE
M\7?^@M8?^ $='_#>7Q=_Z"UA_P" $=?/-%'U'#?\^U]P>VJ?S,^AO^&\OB[_
M -!:P_\  ".C_AO+XN_]!:P_\ (Z^>:*/J.&_P"?:^X/;5/YF?0W_#>7Q=_Z
M"UA_X 1T?\-Y?%W_ *"UA_X 1U\\T4?4<-_S[7W![:I_,SZ&_P"&\OB[_P!!
M:P_\ (Z/^&\OB[_T%K#_ , (Z^>:*/J.&_Y]K[@]M4_F9]#?\-Y?%W_H+6'_
M ( 1T?\ #>7Q=_Z"UA_X 1U\\T4?4<-_S[7W![:I_,SZ&_X;R^+O_06L/_ "
M.C_AO+XN_P#06L/_   CKYYHH^HX;_GVON#VU3^9GT-_PWE\7?\ H+6'_@!'
M1_PWE\7?^@M8?^ $=?/-%'U'#?\ /M?<'MJG\S/H;_AO+XN_]!:P_P# ".C_
M (;R^+O_ $%K#_P CKYYHH^HX;_GVON#VU3^9GT-_P -Y?%W_H+6'_@!'1_P
MWE\7?^@M8?\ @!'7SS11]1PW_/M?<'MJG\S/H;_AO+XN_P#06L/_   CH_X;
MR^+O_06L/_ ".OGFBCZCAO\ GVON#VU3^9GT-_PWE\7?^@M8?^ $='_#>7Q=
M_P"@M8?^ $=?/-%'U'#?\^U]P>VJ?S,^AO\ AO+XN_\ 06L/_ ".C_AO+XN_
M]!:P_P# ".OGFBCZCAO^?:^X/;5/YF?0W_#>7Q=_Z"UA_P" $='_  WE\7?^
M@M8?^ $=?/-%'U'#?\^U]P>VJ?S,^AO^&\OB[_T%K#_P CH_X;R^+O\ T%K#
M_P  (Z^>:*/J.&_Y]K[@]M4_F9]#?\-Y?%W_ *"UA_X 1T?\-Y?%W_H+6'_@
M!'7SS11]1PW_ #[7W![:I_,SZ&_X;R^+O_06L/\ P CH_P"&\OB[_P!!:P_\
M (Z^>:*/J.&_Y]K[@]M4_F9]#?\ #>7Q=_Z"UA_X 1T?\-Y?%W_H+6'_ ( 1
MU\\T4?4<-_S[7W![:I_,SZ&_X;R^+O\ T%K#_P  (Z/^&\OB[_T%K#_P CKY
MYHH^HX;_ )]K[@]M4_F9]#?\-Y?%W_H+6'_@!'1_PWE\7?\ H+6'_@!'7SS1
M1]1PW_/M?<'MJG\S/H;_ (;R^+O_ $%K#_P CH_X;R^+O_06L/\ P CKYYHH
M^HX;_GVON#VU3^9GT-_PWE\7?^@M8?\ @!'1_P -Y?%W_H+6'_@!'7SS11]1
MPW_/M?<'MJG\S/H;_AO+XN_]!:P_\ (Z/^&\OB[_ -!:P_\  ".OGFBCZCAO
M^?:^X/;5/YF?0W_#>7Q=_P"@M8?^ $='_#>7Q=_Z"UA_X 1U\\T4?4<-_P ^
MU]P>VJ?S,^AO^&\OB[_T%K#_ , (Z/\ AO+XN_\ 06L/_ ".OGFBCZCAO^?:
M^X/;5/YF?0W_  WE\7?^@M8?^ $='_#>7Q=_Z"UA_P" $=?/-%'U'#?\^U]P
M>VJ?S,^AO^&\OB[_ -!:P_\  ".C_AO+XN_]!:P_\ (Z^>:*/J.&_P"?:^X/
M;5/YF?0W_#>7Q=_Z"UA_X 1T?\-Y?%W_ *"UA_X 1U\\T4?4<-_S[7W![:I_
M,SZ&_P"&\OB[_P!!:P_\ (Z/^&\OB[_T%K#_ , (Z^>:*/J.&_Y]K[@]M4_F
M9]#?\-Y?%W_H+6'_ ( 1T?\ #>7Q=_Z"UA_X 1U\\T4?4<-_S[7W![:I_,SZ
M&_X;R^+O_06L/_ ".C_AO+XN_P#06L/_   CKYYHH^HX;_GVON#VU3^9GT-_
MPWE\7?\ H+6'_@!'1_PWE\7?^@M8?^ $=?/-%'U'#?\ /M?<'MJG\S/H;_AO
M+XN_]!:P_P# ".C_ (;R^+O_ $%K#_P CKYYHH^HX;_GVON#VU3^9GT-_P -
MY?%W_H+6'_@!'1_PWE\7?^@M8?\ @!'7SS11]1PW_/M?<'MJG\S/H;_AO+XN
M_P#06L/_   CH_X;R^+O_06L/_ ".OGFBCZCAO\ GVON#VU3^9GT-_PWE\7?
M^@M8?^ $='_#>7Q=_P"@M8?^ $=?/-%'U'#?\^U]P>VJ?S,^AO\ AO+XN_\
M06L/_ ".C_AO+XN_]!:P_P# ".OGFBCZCAO^?:^X/;5/YF?0W_#>7Q=_Z"UA
M_P" $='_  WE\7?^@M8?^ $=?/-%'U'#?\^U]P>VJ?S,^AO^&\OB[_T%K#_P
M CH_X;R^+O\ T%K#_P  (Z^>:*/J.&_Y]K[@]M4_F9]#?\-Y?%W_ *"UA_X
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MBBBNPQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /?OV0/^0I\3O\
ML1]2_P#0HJ\!KW[]D#_D*?$[_L1]2_\ 0HJ\!KBI?QZOR_(VE\$?F%%%%=IB
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5[]\0O^3._A3_ -A74O\ T:]>
M U[]\0O^3._A3_V%=2_]&O7%B/BI?XOT9O3VEZ?JCP&BBBNTP"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W[XW_ /)M
MOP%_ZX:M_P"CXJ\!KW[XW_\ )MOP%_ZX:M_Z/BKP&N+"?PGZR_\ 2F;5OB^2
M_)!1117:8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7Z#?\ !6__ (_O@Y_V!;C^<-?GS7Z#?\%;_P#C^^#G_8%N/YPUYE?_ 'NA
M_P!O?D=-/^%/Y'Y\T445Z9S!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?H-^S3_P HLOCG_P!AFZ_])]/K\^:_0;]F
MG_E%E\<_^PS=?^D^GU^?->9@_P")6_Q?HCJK?##T"BBBO3.4**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /:_V*?^3K_A=_V&
MX?ZUV'_!2C_D]+X@_33O_3=;5Q_[%/\ R=?\+O\ L-P_UKL/^"E'_)Z7Q!^F
MG?\ INMJ\Q_[^O\  _S1U?\ +A^OZ'S)1117IG*%%%% !1110 4444 %%%%
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M-&U'XU_70\!HHHKL,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W[
M]D#_ )"GQ._[$?4O_0HJ\!KW[]D#_D*?$[_L1]2_]"BKP&N*E_'J_+\C:7P1
M^84445VF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7OWQ"_Y,[^%/_85U
M+_T:]> U[]\0O^3._A3_ -A74O\ T:]<6(^*E_B_1F]/:7I^J/ :***[3 **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M?OC?_P FV_ 7_KAJW_H^*O :]^^-_P#R;;\!?^N&K?\ H^*O :XL)_"?K+_T
MIFU;XODOR04445VF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5^@W_!6_P#X_O@Y_P!@6X_G#7Y\U^@W_!6__C^^#G_8%N/YPUYE
M?_>Z'_;WY'33_A3^1^?-%%%>F<P4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'Z#?LT_\HLOCG_V&;K_ -)]/K\^:_0;
M]FG_ )19?'/_ +#-U_Z3Z?7Y\UYF#_B5O\7Z(ZJWPP] HHHKTSE"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#VO]BG_DZ_X7
M?]AN'^M=A_P4H_Y/2^(/TT[_ --UM7'_ +%/_)U_PN_[#</]:[#_ (*4?\GI
M?$'Z:=_Z;K:O,?\ OZ_P/\T=7_+A^OZ'S)1117IG*%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7Z#:E_P H>]*_[#3?^G*2
MOSYK]!M2_P"4/>E?]AIO_3E)7F8[_EU_C7ZG50^WZ,_/FM?P?X=E\8>+M$T&
M!Q%-JE]!8I(W16ED5 3^+5D5>T+6;KPYKFGZM9/Y=[87$=U ^/NR(P93^8%>
MK'=7..=^5\NY^_7BC4_#?[(/[.=[>Z3HDDN@>$=-'DZ=9C#S$$*"S8/+.VYW
M(/5F.:_/2'_@L5\1%\1>=+X'\,/H7F9^Q(URMUL]//\ ,*Y]_*_"OT1^!?QJ
M\(?M1?">WUO33:W]M>6_V?5M'N LC6TI7$D$T9Z@\XR,,I!'!KQ#XH_\$LO@
MQX]FGN]$AU/P-?2%WQH]QOMB[<Y,,H;"@_PQL@[5^?T)TJ-:HL?!N3?_  _W
M]SZ!KVE"'U=V7Z?\ ]V\,ZUX0_:P^ MI?S6 OO"OBO3B)K*Z +1Y)5T)'1XW
M4@,.C(".U?A3X@^"WB:#XM>*? 7AW1-5\4ZKHE_=6IM]*LI+F=XX93&93'&I
M('W><8&X5]!?M"_\$R?B3\%=(N]>T.ZM_'OAVU7S)Y=/A:&]A0#+.]N2V5'J
MCN>Y  )KR;]DO]H[_AESXIR>,O\ A'O^$FWZ=-8?8OMOV3&]D;?O\N3ILZ;>
M_6O<P-&G3=6MA)\R>T?RO?[ME<XZ\ZGLX4ZT=;K7\_T>Y^S&B?"W2?A_^S+J
M'AOPMX:BT=Y?#DH;3[*V*S37+6I!WC&YY2W!+98GBOPD\:?#/QA\.'M$\6^%
M-<\+M>!C;+K6G369F"XW%/,5=V-RYQTR/6OZ%[[QI]B^&=QXN^Q[_*TAM5^Q
M^;C.(?-\O?M_#=CWQVK\9_VJOVQ]+_:Z\6> )M<\)7/A'1=!FE2^^Q:BM]/-
M!-)"9#&&BB =5B. 3@EAR,5PY5.M+&5-+W:YG?;XK>NNAM74(X.G9Z*_+Y_#
M?\-3RSX4?LP_%/XWVKW7@KP5J.LV*DK]N.RWMBP."HFE9$9AW 8D5WFJ_P#!
M.[]H?1K&6[N/AO<R11*69;74K*XD('HD<S,Q]@"37W/XH_X*;?!KX<_!B&W^
M%ULU]K-E#%9Z9X:N;":TBMT QND<+LVH!R%<EC@9Y+#0_86_;G\??M,^-]3T
M+Q5X,L;73X;1[B+7-#MKA+:*167]S+YCR#+!B0=P^[C!SQWU,9CFIU(4DHQ_
MFW_-?UHFSFC2HQ454E=OM_7];V/R%U32[W1-1N=/U&TGL+^UD:*>UNHFCEB=
M3AE96 *D'J#S7ZI_\$JO@%)X1\/^*/$WC'P%=:-XI%[''IM_KNF203K;&'),
M'FJ,*2QRR=>A)Z5YG_P6(\ Z9I/C3P%XLL[..WU#6+:ZM+Z:-<&?R#$8V;U8
M+*RYZX"CH!7V+^Q'^U)_PU!\/]3OO^$9_P"$9_L*>+3?+^W_ &OS_P!TK;\^
M5'M^G/UK+$XRIB,N]K"-D]'KM9V_'\F5]7C1Q4(2>FZ\]-OEK\T?!?\ P4V^
M$_C?6OVCO$/BC3_!OB"_\,V^E6LDVLVVESR6<:QQ?O&:94* +@Y)/&.:^3_"
M/P7^(/C_ $MM2\,>!/$OB33ED,)O-(TBXNH0X )3?&A&X CC.>17Z7_M_?MS
M?\*[OO''P7_X0G^T/[5T(VW]N?VMY7E?:82-WD>0<[=W3>,X[5UO_!)3_DU^
M^_[&&Z_]%04L'B:N'R]U''2-K>=W9FF*C&>)C&^LM_*T;K[['Y!>(/#NK>$]
M8N=(US3+S1M5M6"SV.H6[P3Q$@$!T<!E."#R.A%=%X3^"OQ#\>:3_:GAGP'X
MF\1:9YC1?;=)T>XNH=XQE=\:$9&1D9[UZC_P4!_Y/#^)7_7Y#_Z30U^B_P#P
M2B_Y-23_ +#EY_*.O1EC91P,<7;5J+MZV_S.&5-1Q*H=+M?<F_T/QU\0>'=6
M\)ZQ<Z1KFF7FC:K:L%GL=0MW@GB) (#HX#*<$'D="*]'^%/[*7Q:^-FFG4?!
MG@?4=6TW.%OY#':VTA!((269D1R""#M)QWKVWX_>![#XE?\ !334/"VJ-MTS
M5?$NGVUT-Q7=$88-Z@CD%ERH([FOTZ_:&\9>+O@;\&DNOA5\/D\67]BT5I!H
M]I&WEVEN%(#K!'AY%7:J[$P?FST!KGK9E*GAJ-2,5S5$GY+1?YF\,,IUZE*^
MD/\ @_Y,_(?Q!_P3Y_:#\-:9-?WGPVO98(5W,MA>VEY*1[10RN['V -?/UY9
MW&FWD]I=P26MU [12P3(4>-U.&5E/(((((-?J'\#_P#@JM>CQI>Z!\<_#]EX
M-A2-BNH:;8W:-;RJ,B*:V8RR?-S\PQ@XR,$D?,/_  4%^,?PF^.?Q&TOQ-\-
MX[TZHT#0:S=S67V:&[V[1#(,G<7"[E)91P$YXK6AB<7[94Z]-6?6.WSW_JW0
M)4J+@Y0E9KH_Z_KU.5_8)\!#XA?M8> +.2(RVMC>'59_15MT,JD^V]4'XU]-
M_P#!8SQ]]I\4?#_P7#-Q:6D^K7,(]97$41/T$4O_ 'U5+_@CKX#^W>/_ !WX
MQEC.W3=/ATR%STW3R;WQ[@0+_P!]5\^_\%"?'W_"P/VL_'$T<OFVFES1Z1!Z
M*($"./\ O[YI_&LL1^^S.E3Z0BY/U?\ P\7\AX?W,-5J]VHK^O\ P)?@>>?L
MW_"F3XV?''P=X-5&>WU&_3[65."MLG[R<Y['RU?'OBOWK\9?$/P_\,/^$5LM
M4F2R37-4AT/3T' \YT<HOTPF/Q%?G3_P1]^$?VS7?&/Q)NX,QV<:Z+I\C?\
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M****[3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK]!O^"M__']\'/\ L"W'\X:_/FOT&_X*W_\ ']\'/^P+<?SAKS*_^]T/^WOR
M.FG_  I_(_/FBBBO3.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-UM7F/\ W]?X'^:.K_EP_7]#YDHHHKTSE"BBB@ HHHH **** "BBB@ HHHH
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M/JZ7+U?E?7\.IX3_ ,%F9&\CX4QY^3=J38]\6U=3_P $<_\ DD_C[_L-Q?\
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MZQH>H^'KY[+5=/NM,O(_OV]Y"T4B_56 (K^@;0/^38]-_P"Q/C_](A7Y#_\
M!0#]I6R_:.^-7GZ#*TWA/08#I^FRL,"X.[=+. 1D!VP!G^%%/!) _7C0/^38
M]-_[$^/_ -(A6>=5)ULL52I'E;Z?)_I]VQG@X1IYG&$7>R?YP/RQ_P""4O\
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ME^VW:W%[^R;\3TM#^\&C22'']Q2&?_QT-7XM_M)>(O 'B3XQ:Y=?##0D\/\
M@V-Q#91QM)_I&WAI]KL2@=LD*,84+P#FOUY_8Y_:4\,_M5?!>#1=7GM;CQ3:
MZ?\ V?K^C7)7=<)L\MI@G\44@/..A8J>V>_'X6V!I2I1:4;NSW7-9Z_/\T<U
M&MRXURJR3NHJZV]W_@/\/,_#>OZ#/V9[>>U_9?\ AK%<H\<Z>%K$,D@(9?\
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M[6S1P[.^/N[R@0 ]06/8UCF6(IYA4I4<.[N_;O;\K79I@Z,J$IU:NBLOPO\
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M*F?\FBZQ_P!A.Q_]&UOG'\?#?XU_Z5$Y\O\ XE?_  ?I,\6_X(T_\B_\4?\
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MTK[+_P""6_\ R7:__P"O2#_TJBKS<R_W2IZ?J=.'_BQ/V8HHHK\Y/HC\/_\
M@HW_ ,G%-_V#(O\ T=-7RY7U'_P4;_Y.*;_L&1?^CIJ^7*_2<!_NM/T/G*_\
M61];?\$M_P#D[S0_^P=??^B37ZX_&'XZ>!_@'X?L];\>:W_86EW=T+.&?[)/
M<;YBC.%VPH[#Y48Y(QQUK\CO^"6__)WFA_\ 8.OO_1)KZ\_X+"?\D!\(_P#8
MSQ_^DES7AYM357&T*<MFDO\ R:1MESY85Y+I+_VR)[IX-_;J^ OQ$UNWT72?
MB%82W]RXCAAU"TN;-9')PJAYXD4DG@#.22!7#?MK?L/^$OC9X!UG7O#NB6FC
M?$&P@>[MKRPA6'^T"JY,$X7 <L!A7/S*=O.,@_CGX(^'OB;XDZY;Z/X6T*_U
M[4IW")!8P-(020,L0,*HSRS$ =20*_H9\&V=UX/^&&B6OB"Z6:\TO2(8]0NF
M?<&>.$"5RQZC*L<FN+,,+'+(QK8>;4O/\^FG<[<+B)8BI[.<;K^M/GT]#^<6
MBOLC_@F;X,\,?$C]IG7;+Q'X>TOQ)I1T.[N8K/5[&*ZB5OM$ 5PDBD!@&(SC
M(R:_2N\_9A^#/@KQQ:?$:?PMX7\,Q:%9,L31V-O8V=LY?<US)@*A=0%"LWW>
M2.3Q]!BLRAA)QA.+U5_S_5'%'"NIS^S=[.WKMK]SN?@97[':/^W_ / 2U^!5
MEX>E\>;=8C\-I8-;?V/?G$XM0A3=Y&W[W&<X]Z\K_P""J'QQ^'?C#X7>%=&\
M+ZIX:\6ZQ>Z@TW]I:7/;WLEE;Q+\RB5"QC+NR#&1D(P[5]+Z'^SK\*)OV=[#
M4G^&/@U]1;PK'<->-H%H9C*;0,9"_EYW;N<YSGFO(S#$T\5@'4Q,'%7:LGKL
M^Z]>FYOAZ+HXZG&E).33?E\2_P" _0_"ZBO1/V?_ (*ZQ^T%\5M$\$:,XMY;
MZ0M<7CH62UMT&Z25@.N%' R,L5&1FOV*M?!OP(_X)^_#&+6;FRM-+$86V.K3
MP"YU74IB,[%;&XDX+;5VHO)PHR:][&8V&#Y4U>4MDOZ^7J<-&C*LVH[+=GX8
MT5^X?PJ_:D^!G[;BWOA&321>7@1I?[!\6:=%YDL:XS)%AI$)&<_*V\8S@8S7
MY\_\% OV+X/V:?$5EXB\*B63P%K4K10PS.9'T^X +>06/+(5!*,<G"L#DC+<
M]',>:LJ%>#A)[7Z_E_6FYN\,G!SI2YK;_P!?CZ:GR%17ZZ_\$W?@A\.?'7[+
MNDZKXD\ >%_$&J/J-XC7VJZ-;7,[*LN%!=T+$ =!GBO?O O@;X-?LBVMY"=2
M\,^#;SQ#?7%X]SJ=U;V+W):1F6&+>RXBB#A%C3Y5 Z9))SKYK"C4E2Y&Y+;S
M)HX>56"FG9:_AH?C]^Q-\2?#GPC_ &FO!WBSQ;J/]D^']/-W]IO/(DF\O?:3
M1K\D:LQRSJ. >OI7U)_P4C_:R^%7Q\^$'AS1/ ?BK^W=4M-=2\F@_LZ[M]D(
MMYT+;IHD4_,ZC .>>E58]7\!_'7_ (*H:=:6F@^'M:\(I]HL946SAGM-3DBL
M9W>>1=I24^;G#G.1&ASP*[C_ (*J?!_P'\._@AX6O_"O@GPYX9OIO$4<$MSH
M^DV]I*\9MKAMC-&@)7*J<'C('I6&(JTZU;"U*L6I-)K7;WGOI_EIYG1"G*E[
M6$&FEO\ <>-_\$V?V1_!7[0ESXC\2>-1<ZC9Z!<P0PZ/&_EP7#.K-NE8?,0-
MH^4$9[DCBN6_X*?:'IOAG]II-+TBPMM+TRTT&QBM[.SA6**) 'PJHH  ]A7Z
M8?L?^-O@_P",O <H^$UOI%N;.*UBUK^RM&;3MUSY7!DS%'YC</\ ,-W?GFO,
MOVWOB=^SUX?TWQEH?C&S\/2_%2;P_+_9TM]X::[N@[Q.+;;<^0RK\W3+C;[5
MQUL95_M%-Q=H[1Z_#O;SW]!X2C&>&=Y*\NO;WMGZ;/S\S\9:*_<+X.?!_P""
MO[17[.VA^(;?X9>"[&;Q!HYBN+BPT&UBEM;DH8IO+=8PRLD@?!!!& 17XJ^,
MO"M]X&\7:UX<U-/+U'2;V:QN%'3S(W*-CVRIKWL/C57K3H.-I1_SL_N_4XY4
M6J,:R=T_PZK]?N,>BOV<_8S_ &5/AUX:_9?\+ZKXY\#>&=:UB_M'UJ\OM;TB
M"YEBBES(BEI4)4+%LXZ [O6OR/\ BUXITWQM\3/$^N:-I=GHFCWU_-+8Z=8V
MJ6T-O;[B(D6- %7"!<X')R>]52QD:V(GAXKX-W\[?Y_<+V+5"-9O?9?U\OO.
M3HHHKT#G"O?OV7?^10^-?_8FW?\ (UX#7OW[+O\ R*'QK_[$V[_D:X\9_!?R
M_-&U'XU_70\!HHHKL,3]VO\ @GO_ ,F>?#C_ *]9_P#TIEJ3Q-^W_P# 3P;X
MEU/0-8\>?8]6TRZDL[NW_L>_?RID8JZ[E@*G!!&02/>H_P#@GO\ \F>?#C_K
MUG_]*9:_'/\ :?\ ^3D/BA_V,NH_^E#U\:\+#&9GB*=1M).3T_Q'KT9NEE].
MI'?W5]Z?^1^W&C^(O@O^UIX;NH+.;PU\0]-C ,]M-$DLMONR%9HW DB)P<-A
M3P<&ORO_ &_/V,8_V9?$]EKOADS3^ M;E:.W69B[Z?< %C;LYY92H)1CSA6!
MR5W-YC^QO\2M2^%G[2G@/5=/G>*.ZU.'3+R-6(6:WN)%BD5AW W!@#_$BGM7
MZZ?\% /!5OXW_9*\?0S(&ETVT758'P"4>!PY(],H'7Z,:=6G+)Z].5.3<);I
M_C]R=T_EZW1FL;&5.:U6S]=OQ6OE^'YR_P#!-?X^> _@#\1O%NJ>/==_L&QO
MM*2VMY?L<]QOD$RL5Q#&Y' )R0!5O_@I;^T'X _: \8>";[P#K_]O6NG6%Q#
M=2?8[BV\MVD4J,31H3D ],UJ_P#!*7X>>%?B)\4?&EIXK\,Z/XGM;?1DEA@U
MFPBNTC?SU&Y5D4@'!QD5=_X*P?#CPE\.?''@"#PGX7T7PQ!<Z=<O/%HVGPVB
MRL)5 +"-5#$#N:]#$>Q_M.AS)\^MMK;2WTOW_ X<-S?5Z_+M=7_\DV_#\3X0
MHK]J?V8_V9_AS^R;\"X/'7BK3;.Y\1PZ7_:^LZ[=6OVB6T7R][10#!*J@.WY
M!ER,GL WX?\ _!3+X*?%+QE9^$?(US26U"86EO=:W80K9S2,=J)E)7*[B0 7
M4#GDBM9YE)U)4\/2<^7=_P!)BA07LU5J2Y4S\6**_2+_ (*=_LV?#/PKX=M_
M'7@^70O#/B..Y6'4- LYXH/MT;G'FQ6X(^=&(W;%Y5F8_=S7SW^P7^R=#^T_
M\2[HZXTT7@S04CN-3\EBCW+,3Y=NK#[N[:Q9AR%4XP2".O#XZGB*#Q#T2WO_
M %]W^9->A*C-0WOM_7]=]CYAHK]Q_BM^TU\$?V&[?2O" TAK">6(3)H?A;3X
MC)%$20)I=S(O)4\EB[8)P>M0^/O@C\&OV^/A$GB;1(;-;Z^B;^S_ !/9VPAO
M+:9,CRYA@,ZJV0T;Y&"2I!(:O._M=\OM72?L[VO_ ,#_ ()T+!KF5.4TI=OZ
M_P C\/J*[2/X6ZA9_%]?A]K=W9Z#J,6L?V/>7E[,L=O:L)?+>1G8@;%Y;.1D
M#WK]EM/C^ W["WP5@U^SAT]=.C$=M_:ME''=:CJT[ L!Y@.79L,V-P10#C:H
MKT<5CH8>G&<5S<VUNO\ 5]#FIT)5*CIO1K?R/PUHK]UO@3^UU\)_VQI=8\,Z
M;IEW)<V]L9[C1O$VGPGS[?<$9@%>1&4%E!!.?F'%?G#_ ,%)/V</#_P!^,&F
MW/A.U&G>'O$EH]Y'IZDF.UG1]LJ1^B'<C!>Q8@8  '-1S%RKK#UJ;A)[=;]>
MWD_N-I89>S=2G*Z6_P"'^9\CT5^OG_!/_P#9(\#_  ]^"NC?$[Q5I-GK/B;5
MK3^UDNK^ 3KIUJ06C$2D$!]@#%P-WS8!P.=[2O\ @JE\"]6\41Z R^(+*PDE
M\A=8N]-C6QQG 8@2F15/J8QCN!14S&7MI4:%-S<=_P"M?^#;0B%!.FJM27*G
MM_7]>9^,M%?J[_P4B_9K^%M]\,;_ ,=Z'+X>\*>-+#%SY<$\-J-8B)^=#'D!
MY<$LK %FQMYR,?"/['_[-]Q^T]\8K/PRT\MEH=K$;[5KR$?/';J0-J$C&]V9
M5&>F2<';BNG"8Z&*I2J-<O+O?[R<11=!K6]]CQ"BOW-^('Q4^!W_  3[\':5
MIB:,ND?;!_HVEZ#9I+?7@3"M+([LN[&1EY'R>@SC%(-!^!W_  4,^%,VJPZ=
M#?AMUK_:!MUM]6TJ?:#MW\D$95MN6C;C[PKSO[7=O:QI-T[[_P# _P""='U2
MS4)S2D^G]?Y'X9T5V_QL^%&J? _XJ>(_!&KL);O2+DQ"X5<+/$0&BE R<!D9
M6QGC..U<17O4ZD:L%4@[IZHX9PE3DX2W05]M_P#!)_X2?\)K\?;WQ?<Q;]/\
M)61E1C_S]3AHXQ^"><?8A:^)*_;7_@FC\)1\,?V8=(U&YB\O4_%,K:U.6ZB)
M@%@'T\M5;ZN:XLQK_5\+.75Z+Y_\"Y5*'M:L8?-^B_X-E\SZEBU*UN+ZXLH[
MB-[NW1))H5;+(K[MA([ [6Q]#7X-?MN?"'_A2O[2GC#1(8/(TN\N/[5TX!<+
M]GG)<*H]%;?'_P  K[1_9A_:L_X33_@H9\1[&6\WZ#XJ#Z=I@W;D+6((@93V
M#QK.WU<5;_X*_?"'^U?!GA3XCV<&Z?29SI5^ZKSY$OS1,Q]%D#+]9J^8P<98
M'%47/:I%?CM\[JWS/;J-5J=6DMX/\OTLW]Q^5U%.C_UB_6OWN\0?L?\ PA\:
M> GT@?#OPKI$E];1H^H:=H=K#=1@[2QCD5 RL0"-P.1G-?48W&1P48RDK\S:
M^ZW^9XU&DZTG%,_ ^BOWR\7?$[X(?!/X=Z[X5.K>#;2RT#39C)X/6\M3*ZK&
M6\HVQ;<S/TP1EBW.2:^!_P#@GA^QOH_Q\U/5OBAX[TV&7PQ;W[QZ?H<:>7;7
M5P#O<LH 'DQ[E4(.&.0>%(;DHYG&K&I4E!QA%)W[WVT[_,VJ89TU%7O)NUOS
M^X^!:*_;KXB_MY_ W]GGQG'\.)8KI#8%;6Z3P_IL9L=,X'[MP&7[H(RL2OCI
MC(Q7,_M<?L8> ?VCOA7<^._A]8:?:>+C9?VII^HZ0BQPZQ&4WA)0N%8NOW9#
M\P.W)QD5C_:_*HU*M)Q@_M?KM\_3:YK]3O)TU+W^W]?UWL?C717IO[-_PPTG
MXO\ QH\-^%O$&N6OAS0[J<M?7UW<QP8B0%FC1G('F/C8O7ELX.#7[!^/_B[\
M#?V$? >C1V^D6^G6E]F.RT_PW:12W=YL"AY6<LN_ *Y>1\G/4FO0QF,6%<8*
M+E*6R1RT:+K-ZV2W/POHK]Z?A-\8OA+^W)X#U;[-HJZSIUK(L%_I'B.PC\V%
MF!*,1EUYP<,K'!4\@BOR%_;-^"%A^S[^T'XB\)Z.9?[# BO=/69][I!*@8(6
M/)VMN4$\D*"<FL,/F'M:[P]6')+^O3IKZ&L\.O9^UIRYE_2_,\0HHHKV#B"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W[]D#_D*
M?$[_ +$?4O\ T**O :]^_9 _Y"GQ._[$?4O_ $**O :XJ7\>K\OR-I?!'YA7
M[@?\$S_^3-_!7_7:_P#_ $LFK\/Z_<#_ ()G_P#)F_@K_KM?_P#I9-7'G/\
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M/UZC]6^M7]W\;]O4YY4)QJJC;7]._I_PVY^7]?M5_P $M/\ DT71O^PG??\
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M$5I7S'DKO#T8.<EOY?GMU\]#"C0]I3]K-VC_ %_2(/\ @EI_R:+HW_83OO\
MT;7Y@?MJ?\G7?%#_ +#<W]*_;?X&>"?!/@?X?VT/P[\H>$-2E?5;%;>4R0A9
M\.?*)Y"$G(!Z9QT  _&/]I[PVOC+]M_QKH3ZC::1'J7B<VKZA?2K%!;*[JID
M=F( 5023SVKR<!4]MFDYI6O%[]-8G94C['+VF[KFO?R]]_D?/-%?N5I\?P&_
M86^"L&OV<.GKIT8CMO[5LHX[K4=6G8%@/,!R[-AFQN"* <;5%7/@3^UU\)_V
MQI=8\,Z;IEW)<V]L9[C1O$VGPGS[?<$9@%>1&4%E!!.?F'%=\LUE+FE1HN48
M[O;]#G6%24?:3LV?A37Z%?\ !-#]COP#\9_"^I?$+QI;2ZZ^FZNVGVNBS'%F
M2D4,OF2@<R<R8V$[< Y#9X\X_P""AG[.GAC]GOX[:!>^';1=/\*^(H_MS:=@
MO%;2)*!.B+S^[(9&"\XW,!@8 _4C]FWQE\)?''@>\OO@Y;Z5;>&X[]H;E='T
M=M,B-T(XRQ,;11[FV-'\V#D8&>.'BL>Y8%5J"?O7U_ELTG?UU2%##\N)]E4Z
M6?K=/_AVC\>O^"@=C;:9^U]\0;2SMXK2T@DLXXH($")&HL;<!54<  =A7SS7
MZS?M^?$S]G:+PO\ $OPS<V?A\_&;[-%&)V\-NU]YQ6)D_P!,\C&?**\^9P.,
M]JX[_@G'^PQX;\0>#;/XJ?$/28=;:_9SHNC7T>^V2%25^T2QL,2,Q#;5;*A<
M-R2-I@\:J>"4ZT6E%15_YM.GJ5B*-ZUH--R;T[>OWGYE45^V>I?\%&O@/HGQ
M$;X?R7EW]EBF^PRZO%8H=)B<':4+;MVT$8W",IWW8YKR3_@H7^PUX3O_ (<Z
MK\4/A]I%MH>LZ3']LU*QTU%CM;ZU',DHC&%61!\^5QN ;()P:(YJU*'MJ3C&
M6S_I?UZ#^IW;C&5Y+H?(_P"SC^P+XP_:6^%&L>,M UBPTR6UOC96=CJ4;JE[
MM4-(PE7.W&X*/D()SDKBONG]I;]FOXC_ !M_9;^#GPYTG3;2QU[3S9-K,E[=
M(MM8F"R>)]S+N+#S& 'EAB>O3FOB?_@G/X;TWQA\9EL-8^)FH>";*%!<1Z/I
MVJ3Z?+K4@/\ JA*C*  .6&[>1PH^\R_>7AS]L'X??M-:_P#%/X:'Q%=^#M-T
MNV:33?%5CJKV4D\$0Q-<I,&7;Y;C< 20\9RP(W"L<RG7C5M#WE&T[6VMIOUZ
MNWY68L&H6;EH]8W[\WE]R/R]_:E_9NU7]EWXEQ^$M3U&/64FL8;^WU"& PI*
MKY5@%).-KHZ]>0 >,X'CU=+\2)Y)O'6M*WBB3QJD-U)%%KTK2DWL:L0LG[WY
MQD8.#T]3UKFJ]W#\_LHN;N^]K?@<M;E4VHJR7S"BBBN@Q"O?OB%_R9W\*?\
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MM?\ T:]>I4RZE@Z%6I3;;<6M;?Y''+%3J\M.25N:+^Y_\$H_\%C/^2L> O\
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M'[?/P'\;? 'Q[X;T7QU]MUK5- N[*TM?[(OX_,F>%E1=S0!1DD#)('O7Q?\
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M96W?*,-]/0CA\!AG.,KPWOH_*RL>35E4K5%&2][;]3X$HK]N/B=^W/\  O\
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MK^<_P'_R//AW_L(V_P#Z-6OWN_:T_P"38/BO_P!BQJ'_ *3O7S.??!1]9?\
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M.KZ?H<W_ ,$;/^1&^)7_ &$;/_T5)7SM_P %6O\ D["X_P"P+9?^SU[_ /\
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MM]S_ %_#34]O_9GT_P"!'AV/7="^"CZ!,+,0/JDVB3F[9MQD\GS+DEC)]V7
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MHE^'_#'H?_!6C1[6_P#V8;2]F3-Q8Z]:O _<%DE1A]"&_05] ? >%- _9?\
M :Z<-PMO"EF\.WG<PM5;/'7)Y_&O@W_@K7^T+IGB&\T/X4:+=)=R:5<_VGK,
MD396*?84A@R#]X*[LP[;D[Y ^I/^"=?QHTSXN?LTZ!I0N(FUOPO;KHVH6>X;
MU1!M@?'7:\87GIE7'8UY+P]1Y3*7>5_E;EO]_P"9W3J1CC::?2-GZWO;[O\
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M /\ @H#_ ,GA_$K_ *_(?_2:&OOC_@D#_P FX>)/^QIN/_26UKKE_P B6/\
M@A^<3.6N/=^DG^3/GSQUIEKJO_!7B"WNU5H1XAT^8!L8WI8PR)_X\JU]9?\
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M+Y?-'T__ ,$S_P#DS?P5_P!=K_\ ]+)J_)O]KG5KS6OVGOBA<W\C27 \07D
M+=0D<ACC7Z!$4?05^LG_  3/_P"3-_!7_7:__P#2R:OFK]N#_@G7XZ\??%[4
MO'7PSM+77+37I%EOM-:[BMI;:XP%D<&1E5D8KN/S;@Q;@BNB%:G1S>LZCLFY
M*_S7^1*BZF!48[W3^Z_^9V__  1UUB[N/A'XZTV3>;.UUJ.:%B>-TD"AP/\
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MC*[PSW@+&5EW,0H7<L>%P,QGBO4ACJ-3%.A35W;=;?UT]3#ZO-474EHET?\
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M6_\ _2ZXKY<_X+-?\A?X3_\ 7#4__0K6OJ/_ ()M?\F9> /K?_\ I=<5Q_\
M,CC_ (_UJ&]3_?ODO_24?GS\#OA]:?$C_@I9J6G:A"MQ86OB_5]3FB89#?9Y
MIY4!'<>8J9'IFOMS_@J%\9->^%'P!LK3PWJ$VE:AXAU-;"6\M9#'-';B-Y)
MC Y4L5121V9J^-/V<?&-KX-_X*<:K->RK#;ZAXIUK3?,<X >:6=8Q^,FQ?\
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M40_Y,W^(_P#UPM?_ $L@KX-_X)!_\G)^(?\ L5KC_P!*K6N?*?\ <\3Z2_\
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MM6@2?LK_ !2W -_Q2U^>1W^SN:_G\@_UT?\ O#^=?T!_M5?\FK_%'_L5;_\
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M#5=?^#_7F?F[?1QPWMQ'$P>)9&5&!R"H)P:@HHK[-:*QXTY*4G)*UPK]0?\
M@C3_ ,B_\4?^OJP_] GK\OJ_4'_@C3_R+_Q1_P"OJP_] GKAS'_<:WHO_2HA
M2_CTO7]&>'?\%9_^3IK;_L7K/_T9/7Q?7VA_P5G_ .3IK;_L7K/_ -&3U\7U
MAE7^YP^?YLZL9_&?R_)!1117K'$%%%% !1110 4444 %%%% !1110!^@W[-/
M_*++XY_]AFZ_])]/K\^:_0;]FG_E%E\<_P#L,W7_ *3Z?7Y\UYF#_B5O\7Z(
MZJWPP] HHHKTSE"BBB@ HHHH **** "BBB@ KTO]F3_DX_X6?]C3IG_I5'7F
ME>E_LR?\G'_"S_L:=,_]*HZNG\:)E\+/WU^(GQ$\/_"CP;J7BOQ5J']EZ!IR
MJUU=^3)-Y89U1?DC5F.691P#UKPAO^"DW[.:J2/B&6/H-$U'_P"1ZN_\%$/^
M3-_B/_UPM?\ TL@K\*:^"RS 4L9"4JC:L[:>GH?28JJZ$(2CU;_"W^9^I_[2
M7_!5[PU;^&K[1?A';WFJ:U=1F)?$%];F"VM PP7CC?YWD'.-RJH.#\V-I_/[
M]FN>2Z_:6^&$TTC2S2>*]-=Y')+,QNXR22>I)KS&O2_V9/\ DX_X6?\ 8TZ9
M_P"E4=?7X'!4<'+]VM7;5[GB8C$3K1M+9'Z^_P#!234KC2_V./';VTC1-,;*
M!RI()1[R%6''J"1^-?CY^SA,T'[0GPQD0X9?$VFD?^!4=?KS_P %,_\ DS7Q
MK_UWT_\ ]+8:_(/]G7_DX#X:?]C+IO\ Z51UX_#W\*;_ +WZ1.S,F_=72WZO
M_(_8C_@I$BO^QOX]W*&Q]B(R.A^V0\U^97['_P"Q#XB_:NN;_4%U./PWX2TV
M407.JR0F9Y)L!O*BCRNY@I4DD@*&'7I7Z;?\%(/^3-_'WTLO_2R&N7_X)7Z]
MI6I_LHZ?8V+1_;]-U.\AU"-<;A(TAD1C]8W3!_V?:O,P%>>&P-:I3WYONT6O
M]=3JQ<%4G1@^M_\ ,YN'_@G_ /LN_ BUBN_'^M?:BY#1R>+=?2S1F')")$8=
M_P#NG=7UO\*[SPA?_#O1I_ *V*^#S"RZ<--A\JW\M693L7 XW!N<<]><YK\U
MOVG/^">/QJ^*G[2WB/7-*^PZOX?UV\-S#K5]J*1I91$?+#)&29?W8 4>6C#
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M:#?:E_8'A[^PWL9]1AG2W^QVWD%&D61P53:F2&88&,FO@'_AA_\ 8X'(^/\
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MO^PTW_IRDKS,=_RZ_P :_4ZJ'V_1GY\T445Z9RA1110 4444 %%%% !1110
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ME%T#P3&Q&/,73[O</?FZ(_2OAZBIJX6A6ES5()LJ%2=-6B['H?QG_: \>_M
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MH4Z5/V4(VCVZ:ZO\0G.527-)Z_Y'V^W_  5X^,[6QB&A>"E?&/.&GW6_Z_\
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M52I[1[Z?A;_(^W/^"FG[1OP[_:$U'X>R^ /$/]OQZ5%?+>'[%<6WE&0P%/\
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M?"&GW#H46^MM.G,T9Q]X!YV3/U0CVKXHHJ*V'HUVG5BG8(5)4_@=CZC^$O\
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MV5;/7K;PGI>@Z@FM20R7!UJWGE*F,.%V>7-'C[YSG/:O!J*B<(U(.$U=/?\
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M2.H_W&7/0Y%?*]%%31P]*@FJ44KESJ3J?$[A2JQ5@0<$<@BDHK<R/K/X8_\
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MC(AM(%(#2R$ G )  ')+ =ZWHXBE7I^UIRNORMW[$U:<J+Y9H\XHK]:?#?\
MP1X^&UMI<":_XT\5:CJ07][/IK6UI"S?[,;Q2D#ZN:Y+XO?\$?=+A\/W%W\-
M/%^I2:K!&SIIOB(12+=$=$6:)(_+/7DHP)QG:.:\_P#M?"7MS?.S.A8.M+H?
MF'15O5M)O-!U6\TS4;:2RU"SF>WN+:9=KQ2(Q5D8=B""/PJI7L)J2NCC:<79
M[A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?9?_  2W_P"2
M[7__ %Z0?^E45?&E?9?_  2W_P"2[7__ %Z0?^E45>;F7^Z5/3]3IP_\6)^S
M%%%%?G)]$?A__P %&_\ DXIO^P9%_P"CIJ^7*^H_^"C?_)Q3?]@R+_T=-7RY
M7Z3@/]UI^A\Y7_BR"BBBN\YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O?OV7?^10^-?_ &)MW_(UX#7OW[+O_(H?&O\
M[$V[_D:X\9_!?R_-&U'XU_70\!HHHKL,0HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#W[]D#_D*?$[_L1]2_\ 0HJ\!KW[]D#_ )"GQ._[$?4O_0HJ
M\!KBI?QZOR_(VE\$?F%%%%=IB%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5[]\0O\ DSOX4_\ 85U+_P!&O7@->_?$+_DSOX4_]A74O_1KUQ8CXJ7^+]&;
MT]I>GZH\!HHHKM, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ]^^-_\ R;;\!?\ KAJW_H^*O :]^^-__)MOP%_ZX:M_
MZ/BKP&N+"?PGZR_]*9M6^+Y+\D%%%%=IB%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?H-_P5O_X_O@Y_V!;C^<-?GS7Z#?\ !6__
M (_O@Y_V!;C^<->97_WNA_V]^1TT_P"%/Y'Y\T445Z9S!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?H-^S3_RBR^.?
M_89NO_2?3Z_/FOT&_9I_Y19?'/\ [#-U_P"D^GU^?->9@_XE;_%^B.JM\,/0
M****],Y0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]E_\ !+?_ )+M?_\
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M **** "BBB@#W[XW_P#)MOP%_P"N&K?^CXJ\!KW[XW_\FV_ 7_KAJW_H^*O
M:XL)_"?K+_TIFU;XODOR04445VF(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5^@W_!6__C^^#G_8%N/YPU^?-?H-_P %;_\ C^^#
MG_8%N/YPUYE?_>Z'_;WY'33_ (4_D?GS1117IG,%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^@W[-/_*++XY_]AFZ_
M])]/K\^:_0;]FG_E%E\<_P#L,W7_ *3Z?7Y\UYF#_B5O\7Z(ZJWPP] HHHKT
MSE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MVO\ 8I_Y.O\ A=_V&X?ZUV'_  4H_P"3TOB#]-._]-UM7'_L4_\ )U_PN_[#
M</\ 6NP_X*4?\GI?$'Z:=_Z;K:O,?^_K_ _S1U?\N'Z_H?,E%%%>F<H4444
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M%% !1110 4444 %?9?\ P2W_ .2[7_\ UZ0?^E45?&E?9?\ P2W_ .2[7_\
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M+]DG_P">,G_?!H^R3_\ /&3_ +X-%P(J]^_9=_Y%#XU_]B;=_P C7@WV2?\
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M)_WP:+@145+]DG_YXR?]\&C[)/\ \\9/^^#1<"*BI?LD_P#SQD_[X-'V2?\
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M_/&3_O@T7 BHJ7[)/_SQD_[X-'V2?_GC)_WP:+@145+]DG_YXR?]\&C[)/\
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M]\&BX$5%2_9)_P#GC)_WP:/LD_\ SQD_[X-%P(J*E^R3_P#/&3_O@T?9)_\
MGC)_WP:+@15[]\0O^3._A3_V%=2_]&O7@WV2?_GC)_WP:]]^(%O*?V/OA4HB
M<L-5U'*[3D?O7KCQ#]ZE_B_1FU/:7I^J/GVBI?LD_P#SQD_[X-'V2?\ YXR?
M]\&NRYB145+]DG_YXR?]\&C[)/\ \\9/^^#1<"*BI?LD_P#SQD_[X-'V2?\
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M[X-%P(J*E^R3_P#/&3_O@T?9)_\ GC)_WP:+@145+]DG_P">,G_?!H^R3_\
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MQO\ ^3;?@+_UPU;_ -'Q5X#7T#\;K>5OV;_@.HB<LL&K9 4Y'[^*O _LD_\
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M_?!H^R3_ //&3_O@T7 BHJ7[)/\ \\9/^^#1]DG_ .>,G_?!HN!%14OV2?\
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M@T?9)_\ GC)_WP:+@145+]DG_P">,G_?!H^R3_\ /&3_ +X-%P(J*E^R3_\
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M^^#1<"*BI?LD_P#SQD_[X-'V2?\ YXR?]\&BX$5%2_9)_P#GC)_WP:/LD_\
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M^_[_ .-=?10!R'_"J/#7_/D__?\ ?_&C_A5'AK_GR?\ [_O_ (UU]% '(?\
M"J/#7_/D_P#W_?\ QH_X51X:_P"?)_\ O^_^-=?10!R'_"J/#7_/D_\ W_?_
M !H_X51X:_Y\G_[_ +_XUU]% '(?\*H\-?\ /D__ '_?_&C_ (51X:_Y\G_[
M_O\ XUU]% '(?\*H\-?\^3_]_P!_\:/^%4>&O^?)_P#O^_\ C77T4 <A_P *
MH\-?\^3_ /?]_P#&C_A5'AK_ )\G_P"_[_XUU]% '(?\*H\-?\^3_P#?]_\
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MX51X:_Y\G_[_ +_XUU]% '(?\*H\-?\ /D__ '_?_&C_ (51X:_Y\G_[_O\
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M <A_PJCPU_SY/_W_ '_QH_X51X:_Y\G_ ._[_P"-=?10!R'_  JCPU_SY/\
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MT?\ "J/#7_/D_P#W_?\ QKKZ* .0_P"%4>&O^?)_^_[_ .-'_"J/#7_/D_\
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M&O\ GR?_ +_O_C1_PJCPU_SY/_W_ '_QKKZ* .0_X51X:_Y\G_[_ +_XT?\
M"J/#7_/D_P#W_?\ QKKZ* .0_P"%4>&O^?)_^_[_ .-'_"J/#7_/D_\ W_?_
M !KKZ* .0_X51X:_Y\G_ ._[_P"-'_"J/#7_ #Y/_P!_W_QKKZ* .0_X51X:
M_P"?)_\ O^_^-'_"J/#7_/D__?\ ?_&NOHH Y#_A5'AK_GR?_O\ O_C1_P *
MH\-?\^3_ /?]_P#&NOHH Y#_ (51X:_Y\G_[_O\ XT?\*H\-?\^3_P#?]_\
M&NOHH Y#_A5'AK_GR?\ [_O_ (T?\*H\-?\ /D__ '_?_&NOHH Y#_A5'AK_
M )\G_P"_[_XT?\*H\-?\^3_]_P!_\:Z^B@#D/^%4>&O^?)_^_P"_^-'_  JC
MPU_SY/\ ]_W_ ,:Z^B@#D/\ A5'AK_GR?_O^_P#C1_PJCPU_SY/_ -_W_P :
MZ^B@#D/^%4>&O^?)_P#O^_\ C1_PJCPU_P ^3_\ ?]_\:Z^B@#D/^%4>&O\
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M #Y/_P!_W_QKKZ* .0_X51X:_P"?)_\ O^_^-'_"J/#7_/D__?\ ?_&NOHH
MY#_A5'AK_GR?_O\ O_C1_P *H\-?\^3_ /?]_P#&NOHH Y#_ (51X:_Y\G_[
M_O\ XT?\*H\-?\^3_P#?]_\ &NOHH Y#_A5'AK_GR?\ [_O_ (T?\*H\-?\
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M5'AK_GR?_O\ O_C1_P *H\-?\^3_ /?]_P#&NOHH Y#_ (51X:_Y\G_[_O\
MXT?\*H\-?\^3_P#?]_\ &NOHH Y#_A5'AK_GR?\ [_O_ (T?\*H\-?\ /D__
M '_?_&NOHH Y#_A5'AK_ )\G_P"_[_XT?\*H\-?\^3_]_P!_\:Z^B@#D/^%4
M>&O^?)_^_P"_^-'_  JCPU_SY/\ ]_W_ ,:Z^B@#D/\ A5'AK_GR?_O^_P#C
M1_PJCPU_SY/_ -_W_P :Z^B@#D/^%4>&O^?)_P#O^_\ C1_PJCPU_P ^3_\
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MG0?^?1O^_P _^-=+10!S7_"N=!_Y]&_[_/\ XT?\*YT'_GT;_O\ /_C72T4
M<U_PKG0?^?1O^_S_ .-'_"N=!_Y]&_[_ #_XUTM% '-?\*YT'_GT;_O\_P#C
M1_PKG0?^?1O^_P _^-=+10!S7_"N=!_Y]&_[_/\ XT?\*YT'_GT;_O\ /_C7
M2T4 <U_PKG0?^?1O^_S_ .-'_"N=!_Y]&_[_ #_XUTM% '-?\*YT'_GT;_O\
M_P#C1_PKG0?^?1O^_P _^-=+10!S7_"N=!_Y]&_[_/\ XT?\*YT'_GT;_O\
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M (5CX>_Y\W_[_/\ XUU5% '*_P#"L?#W_/F__?Y_\:/^%8^'O^?-_P#O\_\
MC7544 <K_P *Q\/?\^;_ /?Y_P#&C_A6/A[_ )\W_P"_S_XUU5% '*_\*Q\/
M?\^;_P#?Y_\ &C_A6/A[_GS?_O\ /_C7544 <K_PK'P]_P ^;_\ ?Y_\:/\
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M!S)^%_AW[)(_V-]R]/WS_P"-4/\ A7.@_P#/HW_?Y_\ &NZ;_CPF_P ^E95
M'-?\*YT'_GT;_O\ /_C1_P *YT'_ )]&_P"_S_XUTM% '-?\*YT'_GT;_O\
M/_C1_P *YT'_ )]&_P"_S_XUTM% '-?\*YT'_GT;_O\ /_C1_P *YT'_ )]&
M_P"_S_XUTM% '-?\*YT'_GT;_O\ /_C1_P *YT'_ )]&_P"_S_XUTM% '-?\
M*YT'_GT;_O\ /_C1_P *YT'_ )]&_P"_S_XUTM% '-?\*YT'_GT;_O\ /_C1
M_P *YT'_ )]&_P"_S_XUTM% '-?\*YT'_GT;_O\ /_C1_P *YT'_ )]&_P"_
MS_XUTM% '-?\*YT'_GT;_O\ /_C1_P *YT'_ )]&_P"_S_XUTM% '-?\*YT'
M_GT;_O\ /_C1_P *YT'_ )]&_P"_S_XUTM% '-?\*YT'_GT;_O\ /_C1_P *
MYT'_ )]&_P"_S_XUTM% '-?\*YT'_GT;_O\ /_C1_P *YT'_ )]&_P"_S_XU
MTM% '-?\*YT'_GT;_O\ /_C1_P *YT'_ )]&_P"_S_XUTM% '-?\*YT'_GT;
M_O\ /_C1_P *YT'_ )]&_P"_S_XUTM% '-?\*YT'_GT;_O\ /_C1_P *YT'_
M )]&_P"_S_XUTM% '-?\*YT'_GT;_O\ /_C1_P *YT'_ )]&_P"_S_XUTM%
M'-?\*YT'_GT;_O\ /_C1_P *YT'_ )]&_P"_S_XUTM% '-?\*YT'_GT;_O\
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M_A6/A[_GS?\ [_/_ (UU5% '*_\ "L?#W_/F_P#W^?\ QH_X5CX>_P"?-_\
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M-=510!RO_"L?#W_/F_\ W^?_ !H_X5CX>_Y\W_[_ #_XUU5% '*_\*Q\/?\
M/F__ '^?_&C_ (5CX>_Y\W_[_/\ XUU5% '*_P#"L?#W_/F__?Y_\:/^%8^'
MO^?-_P#O\_\ C7544 <K_P *Q\/?\^;_ /?Y_P#&C_A6/A[_ )\W_P"_S_XU
MU5% '*_\*Q\/?\^;_P#?Y_\ &K4'PK\-O&";)R?^N[_XUT%7K7_4K0!RO_"J
M/#7_ #Y/_P!_W_QH_P"%4>&O^?)_^_[_ .-=?10!R'_"J/#7_/D__?\ ?_&C
M_A5'AK_GR?\ [_O_ (UU]% '(?\ "J/#7_/D_P#W_?\ QH_X51X:_P"?)_\
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M-=?10!R'_"J/#7_/D_\ W_?_ !H_X51X:_Y\G_[_ +_XUU]% '(?\*H\-?\
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M_P#O^_\ C77T4 <A_P *H\-?\^3_ /?]_P#&C_A5'AK_ )\G_P"_[_XUU]%
M'(?\*H\-?\^3_P#?]_\ &C_A5'AK_GR?_O\ O_C77T4 <A_PJCPU_P ^3_\
M?]_\:/\ A5'AK_GR?_O^_P#C77T4 <A_PJCPU_SY/_W_ '_QH_X51X:_Y\G_
M ._[_P"-=?10!R'_  JCPU_SY/\ ]_W_ ,:/^%4>&O\ GR?_ +_O_C77T4 <
MA_PJCPU_SY/_ -_W_P :/^%4>&O^?)_^_P"_^-=?10!R'_"J/#7_ #Y/_P!_
MW_QH_P"%4>&O^?)_^_[_ .-=?10!R'_"J/#7_/D__?\ ?_&C_A5'AK_GR?\
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M** "BBB@ HHHH X[XE?\>^@_]A:#^35V-<=\2O\ CWT'_L+0?R:NQH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *X[1?^2F>(?\ KW@_]!%=C7':
M+_R4SQ#_ ->\'_H(H [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH \\TO\ Y'CQ5_OP?^@&N@KG]+_Y'CQ5_OP?
M^@&N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "MBZ_P"6?TK'K8NO^6?TH KT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!*W_'A-_GTK*K5;_CPF_SZ5E4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!-9_\ 'U%_O5?N?]<W^>U4+/\ X^HO]ZK]S_KF_P ]J (J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J]:_ZE:HU>
MM?\ 4K0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7'?$'_C^\+?]A6'^==C7'?$'_C^\+?]A6'^
M= '8T444 <=\+_\ D"ZA_P!A";^E=C7'?"__ ) NH?\ 80F_I78T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=
MX^_Y"7A;_L)QUV-<=X^_Y"7A;_L)QT =C1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!QWQ*_X]]!_["T'\FKL:X[XE?\ 'OH/_86@_DU=C0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5QVB_\E,\0_\ 7O!_Z"*[
M&N.T7_DIGB'_ *]X/_010!V-%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!YYI?\ R/'BK_?@_P#0#705S^E_\CQX
MJ_WX/_0#704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !6Q=?\ +/Z5CUL77_+/Z4 5Z*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH E;_CPF_SZ5E5JM_QX3?Y
M]*RJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH FL_^/J+_ 'JOW/\ KF_SVJA9_P#'U%_O5?N?]<W^>U $5%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5>M?]
M2M4:O6O^I6@"6FNVU6;K@9IU,F_U3_[IK.HW&$FNPUN?G3<_\%?OL]Q+%_PJ
M;=Y;E<_\))C.#C_GTJ+_ (?"?]4D_P#+D_\ N2OA3X=Z+9>)?C%X:TC4H?M.
MG7^NVUK<P[F7?$]PJNN5((R"1D$&OUY;_@G7^SXRD#P"5)'WAK6H9'YW%=[A
M&-.,Y+?]+?YF51OVTZ<>C_5_Y'DOP]_X*R>!_$&K0V?BOPIJ?A2"9P@OH+A;
MZ&+/\4@"HX4?[*L?:OM_2=6LM>TNTU+3;N&^T^[B6>WNK=P\<L;#*LK#@@@]
M:_'S]OK]E'0?V;/%'A^\\*W-P= U])_+L;N3S'M98BFX!^K(1(N,Y(P<DU];
M?\$I_'%_XB^!VN:#>RM-#H.JF.T9CG9%*@?8/8/O/_ J48TZM)U(:6_SL1)S
MIU(QEJI?Y7_0@^//_!2__A2/Q<\1^"/^%<?VU_8\J1?;O[<\CS=T229\O[,V
MW&_'WCTK[&\%^(O^$O\ !^A:[]G^R?VI807OV??O\KS(U?;NP,XW8S@9QT%?
MBU^WE_R=O\1?^ON#_P!)H:_1:[_;4^%OP ^%W@C2M?U:?4=>30-/9]'T:$7%
MQ&#;1D;R65$."#AF!P0<8K.G%2PT9OXGR_BG<JHW'$RIKX5S?@TD?5%%?-'P
MA_X*%?"#XP>(+?0[:_U#PWJMU((K6W\06Z0"X<]%61'= 2> &8$D@#)KZ7J)
M1E'=%J2ELPHKQGXW_M>?#']G^Y%CXIUUGUIH_-71]-B-Q=;>Q8#Y8\]M[+GM
MFO%K7_@J]\'KBZ6*31O&%K&3@SRV%L47W.VX+8^@J8IS^$<GR[GV?17#_"7X
MU^"_CCX?;6?!>NP:S9QMY<RJ&CF@;^[)&P#*>N,C!QQFMSQIXXT'X=>&[S7_
M !-JMMHNCVB[IKNZ?:J^@'=F)X"C))X -$DX?%H$7S_#J;E%?'6N_P#!5+X,
MZ1?O;VMIXIUN)3@75CIT2QM[@331M^:BNZ^$7[?7P?\ C%K5KHUAK-UH6LW3
M^7;V.NV_V=IF/15D5FCW$\!=^23@ U:ISELB7.,=V?1=%%><?&7]H7P#\ ]+
MAO/&FO0Z:]QG[-9QJTMS<8Z[(E!8CMN.%&1DBLKV-+-GH]%?&^E_\%5O@U?Z
MDEK/8>*]-@9MIO;K3X6B4>I$<[/CZ*37U+X ^(WAKXI^&[?7_">M6NN:1/PM
MQ:OG:V 2KJ<,C#(RK $9Y%:.$DKM$<T;VN='1114%'FGQS_:(\$?L[^'8]6\
M8:DT#7&Y;33[5/,NKM@.1&F1P,C+,0HR,D9%?'6K?\%?M-AU!TTSX7W5W8@_
M+-=ZVL$I'J46!P#_ ,"->5?MV_"+XS?%+]H'7]:M_ GB+5O#UKY=CI4EC9O<
MIY"+DE0F2 SF1NG\7TKZB^&/_!-#X1Z?\.M,MO%>C7FM^)IK57O-1:_N+=HI
MF4%ECC1P@"DX&Y6/'.:TI13I^UG]W]=>Y-1VG[./WG6_LZ_M[?#W]H/5X= C
M2Z\+^*)5S%INIE2ER0,E895.'('\)"L>< X->R?&3XB?\*E^%OB;QC_9_P#:
MO]BV3WGV+SO)\[;_  []K;?KM/TK\0_C=X#F_9[^/7B#PYI&IS22^'M15[&_
M!VRJ,++$Q(_C4,N2.X.*_6W]HO6I_$O[$?BK5[J/RKG4/"BW<L>,;7DB1B/S
M)HKJ/U?V]+33]+H5*ZQ'L*G]6=F>=_LQ?\%#/^&COBK;>#/^$ _X1[SK6:Y^
MW?VS]JQY:YV[/LZ=?7=Q7V+7XS?\$XM>T[PQ^TE#JVKWUOINF6>C7TUQ=W4@
MCBB01C+,QX K[:U[_@J5\%]&UI["VC\2:U K;?[1L-/C%N?<>;*CX_X!6U:F
MDXQ@M6K_ (O_ ",:4Y2YW+9.WX+_ #/K^BN%^$?QO\%?'3P^VL^"]<AU>VC8
M)/$ 8Y[=C_#)&P#+T."1@XX)%=U7/*+B[-'0I*2N@KYB_:\_;6_X95USP[IW
M_"&_\)1_:]M+<>9_:GV3RMC!<8\F3=G/7(Z5].U\Q?M>?\,W?VYX=_X7I_R$
M?LTO]F?\A+_5;AO_ ./3C[V/O<^E1]J/:_WZ,K[,OZZH](_9G^.?_#17PGL?
M&O\ 8G_"/_:KB>#[#]K^T[?+<KG?L3.<9^[Q7JM>5?LS_P#"L?\ A4]C_P *
MA_Y$G[1/]G_X^O\ 6[SYG_'S^\^]GKQZ5@^(OVW/@KX3\8WOA75?&GV77K.[
M-C/:?V5>OLF#;2N]82IY[@X]ZWFDZG)!:NVG7I^OYF,6U!RF]%UZ=3W.BO _
MCE^V]\+/@'JCZ1K>J7.K:]'@RZ3HD*W$\.>GF%F5$/\ LLP;!!QBL_X+_M\?
M"7XW:]!H>G:C?:#K5PVRVL=>MU@:X;LJ.CO&6/9=P)[ UG&+FKQ5S24E#XM#
MZ,KSSXJ?'WP-\&C8P^)]=@M=2OY4AL]+A/F7=PSMM7;&.0N?XVPH[FM7XH?%
MCPK\&/"K>(_&.J?V/HRS);FY^SRS_O'SM&V)&;G!YQBOP[\6>.K7Q!^T1J7B
MR;4YK[2YO$K7R7T_F,QMA<[D;##?@1@87&0 !CM3HQ]K54'MU?;;3[G<FK)T
MZ4IK?HOO_P C]\J*\Q^$/[2WPW^/%[J5IX%\1_VY<:=&DMTGV&YM_+5B0IS-
M&@.2#TS3_C1^T9\/_@#IT-SXSUZ/3YK@$VUA"C374^.ZQJ"<=MQPN>,U,DXV
MYNI<?>V/2Z*^.-)_X*J?!K4M22UN++Q5I4#-M-[=Z?"T2CU(CF=\?12?:OJ?
MP+\0/#GQ.\-VVO\ A76+77-(N!^[NK1]PSW5AU5AGE6 ([@53A)*[1/-&]KG
M045P7Q<^.G@?X$Z58ZEXYUO^P[*^F-O;R_9)[C?(%+$8B1R.!U( KA]6_;:^
M#^F_"^;Q]%XG;4-!6[:PA6WLYH[BYN556:***548D*RDL<*,\L*CHWV_K]45
MU2[GNM?!NC?\%2/[6^*MEX,_X5EY7VG64TC[=_;^[;NG$7F;/LW/7.W=[9[U
M[U^SS^V=X _:5UB^TGPQ!K5CJEG ;F2UU6R"?N@P4MOC=T'+ 8+ G/ .#7@N
MC?\ #$'_  M6R^P?\CI_;*>1_P AS_C_ //&WK^[_P!9CK\OX5M3@XUHJHKI
M].KU6WXKU,YR3I2<'9KKT6C_ . ?>5%<C\4/BQX5^#'A5O$?C'5/['T99DMS
M<_9Y9_WCYVC;$C-S@\XQ7&>&OVO/A#XN\':]XJTWQI;-H&AM&E_>7-K<6PB9
MP2BA98U9V;:<*@)/2L=TVMEOY?U=&G5+OL>PT5\>_P##T_X+_P!N_8/(\3"U
M\S9_:G]G1_9\?W\>;YN/^V>?:O=/$7[3'PS\+?#2R\?7_BZQ'A>^'^AW<),C
M7+=TCC WEQ@@KC*X.[&#5.,HQYFM!*2<N5/4].HKX]TC_@J=\%]2UE+*X@\3
M:5;LVTZC>:=&8 /[Q$<KR8_X!GVKZRT#7]-\5:+9:OH][!J6EWL2SVUW;.'C
ME1AD,I'44W"27,UH+F3=D]30HHHJ"@HKQ#XW?ME?"WX!Z@VE^(]<>YUU4#MI
M&E0FXN%!&1OY"1D@@@.RD@Y'%>06/_!5SX.WEVD,ND>+[&-C@W$]A;E%]R$N
M&;\@:<4YZQ%)\NY]G45QWPM^+WA#XT^&UU[P9KEOK>G;O+D:(,DD+_W)(V 9
M&[X8#(Y'%4_BY\=/ _P)TJQU+QSK?]AV5],;>WE^R3W&^0*6(Q$CD<#J0!1)
M.+M+0(M25T=[17C^G?M<_"/5?AOJ'CRW\96__"+6-T;&6]GMIX&:X"*_E)%)
M&LDC;64X13W]#CQNU_X*H?!BXUH6,EMXHM;;?M_M*73HS!C^]A9C)C_@&?:G
MRRYN6VH<RMS=#[$HK$\&>-M"^(GANRU_PWJEOK.CWB[X;NU?<K=B#W!!X*G!
M!&"!53XA_$KPQ\)_#-QX@\6ZS;:'I$)PUQ<$Y9NR(H!9V.#A5!)QTJ9>[I+0
M<?>^'4Z:BOC75O\ @JQ\&].OI(+?3?%FJ1*<"ZM-/@6-_<"2=&_-17IOP7_;
MB^$WQRUB#1=%UF?3->N,B#2]9M_L\LQ'9&!:-F_V0Y;VK14Y/9$.<5NSW34K
MS^SM-N[O9YGD1/+LSC=M4G&>W2OA_P""_P#P4\_X6]\5/#7@W_A6O]D_VS=K
M:_;?[>\[R<@G=L^S+NZ=-PK[7\3?\BWJO_7I+_Z :_#_ /8O_P"3I_AI_P!A
M>/\ ]!:JPL54KN$MM/Q;%B9.G0YX[Z_@D?NE17B_Q(_;&^$/PA\6W7AGQ=XL
M;1];ME1Y;5M*O9<*ZAE(>.%E8$'L3W'4&O3O!OC+1OB#X6TSQ'X?OEU+1=2A
M%Q:W2(R"1#WVL P/48(!!'(K))N/,MBV[/E>YM45R7Q/^*WA7X,^%9/$GC+5
MET;1DE2 W#0R3'>YPJA(U9B3@]!V)KGOA#^TI\.?CS>:E:^!?$+:[-IT:270
M_L^ZMUB5R0OS2Q("20> 2>#1%.5^76P-J-K]3TZBO&OC=^US\,?V?[A;'Q5K
MI.LM'YJZ1I\)N+K:>A8#Y4SVWLN>V:\5M/\ @J[\'KBZ6&31_&%K&6P9YK"V
M*#GJ0MP6Q^%$4Y_"$GR[GV?7E/[37QT_X9S^%%YXU_L3_A(?L]S#;_8?M?V;
M=YC[<[]CXQZ;>:WOA-\;/!7QQT%]8\%:]!K5I&P29%#1S0,>BR1N R]\9&#C
MC-8/[37_  K#_A5%Y_PM_P#Y$G[3#Y__ !]?ZW?^[_X]OWGWO3CUJ:BE&R>F
MJ_-?GT*@XRNUKO\ E^AYS^R'^VI_PU5K7B/3_P#A#?\ A%_['MX9_,_M3[7Y
MN]F7&/)CVXV^_6OIROF/]D/_ (9O_MKQ'_PHO_D(?9X?[3_Y"7^JW-Y?_'WQ
MUW?=Y]:]C^+7QN\%? W04U?QKKT&C6LK%($8-)-.PZK'&@+-C(S@8&>2*VJ\
ML;65O^',J?,[W=_^&.YHKXPNO^"KWP>M[IH4T;QA<QAL">*PM@AYZ@-<!L?A
MFO:_@C^UQ\,OV@+AK'PKKW_$Y6/S7TC4(6M[H+W*J?E?'?8S8[TO9RM>P^>*
M=KGLE%%%9EA7RW^T7_P4'\!? /7[GPW!9W?BWQ/;#%Q9V#K'!;-UV2S'.&P>
MBJV.^#7U$V=IQUQQ7X%V\-GH/[0 B^)EM<W-C:^(2/$$.6$LBB<^?R,,<_,>
M.3VJJ4?:UE3;LOZ_I_(4WR4I5+7M_P '_(^[?#?_  5ZT2[U2./7OAK?:7IY
M.'N-/U9+R1?<1M%$#_WU7W%\-_B5X<^+?@^Q\3^%=3CU71[P?)-'D,K#[R.I
MY5@>JGFOA']O[PW^S_H/P)TR?POI7AK3O%6HFWNM"?P[;Q0R3V[$;Y9/+ W1
M%-V&?/S8QSFM7_@D7;ZRG@?Q_-/Y@T!]0MUM=V=IN!&WG%?^ F'/X5T1C&I"
MHTK./_ _S^]&$I2IRAK=2_X/]>A^@%%%%<IT!1110 4444 %%%% !1110 44
M44 %<=\0?^/[PM_V%8?YUV-<=\0?^/[PM_V%8?YT =C1110!QWPO_P"0+J'_
M &$)OZ5V-<=\+_\ D"ZA_P!A";^E=C0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5QWC[_D)>%O^PG'78UQWC[_D
M)>%O^PG'0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''?$
MK_CWT'_L+0?R:NQKCOB5_P >^@_]A:#^35V- !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7':+_R4SQ#_P!>\'_H(KL:X[1?^2F>(?\ KW@_]!%
M'8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'GFE_P#(\>*O]^#_ - -=!7/Z7_R/'BK_?@_] -=!0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;%U_P L_I6/
M6Q=?\L_I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@"5O^/";_/I656JW_'A-_GTK*H **** "BBB@ HHHH
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M]M?]J2QM]>U*6*Y\17SO/,OS?9+2-6D,<8/ "QH54=,XSG)K]@_VBM.N-6^
M?Q%L[1#)<S>'[Y8T'5CY#\#W-?B=^SW\);;XY?%O0_!%SKP\-C53*D>H-:_:
M0KK&SJNS>F=VW'WN_>L,.W4KMRUY5I^/^7]7.FNE3H>[I=N_R2_S/TO^)/\
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M3ME)]A$Q'\S^=9X72%:7;_**_4O$7YJ4>_\ ]L_T/I/]F_\ 9+\'?LP+KO\
MPC%SJ6H3:NT?G7.K21R2JB!MJ*41!MRQ/3K]!7Y#^#?^3JM%_P"QSA_]+17[
MR5^#?@W_ ).JT7_L<X?_ $M%5A9.6-IN3_J\0KQ4<+.W]:,_2W_@J#_R:S<_
M]ABS_F]?!O[#O[/\7[2/Q'N?#NN:A>0>#]+A_M:_L[64I]ID!$<:>BD[VRV,
MA0P&,Y'WE_P5!_Y-9N?^PQ9_S>OG[_@D-_R.GQ&_[!]I_P"C)*SP6]7U?X13
M'BMJ=O+\9-?D9_\ P40_9$^'_P #? OASQ3X%TV;1/.U#^SKNS:[FN(Y-T;N
ML@,K,RL/+(X."#TXKS']@_\ 9MLOVF/&]_:^*+N\?P?X;A%S+8P3LGFS3-A4
M!_@#"-BQ7!.P#/<?8W_!5W_DW'1O^QDM_P#TGN*\X_X) QK]A^)[[1O,FG@M
MCG&+CBM,+)N-63UY=OFH_P"8L5%1]FEI?_-_HCS;_@HI^R?X)^ MCX3\0>!;
M";2+'49I;*ZL7NI;A!(JAT=6E9F!(W@C)' QCG/T#_P2=\57>K?!'Q)HUS.T
MT.DZR?LRL2?+CEB5BH]MX=OJQK+_ ."N7_)*_ W_ &&I/_1#56_X)$_\D]^(
M'_84M_\ T2:6'DY4JR;O;_.+_4*Z2J4K+?\ RD??E1722R6LR02+#.R$1R,F
M\(V."5R,@'MD5+7+?%+QY;?"_P"'/B3Q;=Q-/!HUA->F%3@R%%)"?B<#\:XY
MM*+;V.F*<I)+<^$+?_@EGKFK?%B/7?&OCVT\1>'KJZDO=7FCCDMKZX8Y8@ [
MU 9L9._@9QVK-_:Z^ ?[+?P_^%NM'POJVFZ+XZM$#65G8ZY-?33R C]W+"TD
MFT$9^;"X..<<5\Y6?B'XO_MW_%R+P[-XADN9[YI+A;*>X>'3+"%!DL(ER %&
M!G:6)(R2>:]O^)G_  30TSX-_!7Q;XSU[QW<:MJ.E:>UQ!:6-DMO#YV0%5F9
MG9U)(Z!#]*Z9J5.DN=\J2Z;_ -=.QE%QG5?(N9M_+^OQ,+_@E'XFNM-^/VM:
M,DS+9:EH<KR0Y.UI(I8RC8]0&<?\"->Y?\%<O^25^!O^PU)_Z(:OGS_@E:H;
M]IB[) )&@71'M^\AKZ#_ ."N7_)*_ W_ &&I/_1#5IC?^77R_P#2S/"[U/G_
M .DGSA^P3^S+:?M+:IJT?BR_OF\$>&I%N/[*MYC&+B[G&#R/NC9 -Q&&.$ (
MKO\ _@H1^QGX$^"G@'1_&?@.QFT6'[>NGWNGM=2W$;AT=ED4RLS @I@C.#N'
M QSZ-_P2)4?\*_\ B"V!N.J6X)[_ .J;_&NZ_P""IW_)LL'_ &'K7_T"6IQD
MG"<5'36/XVO^8\)%3C)R_O?A>WY7/+_^"1'BN]N-+^(GAN69WT^UEM+Z"(G*
MQO()$D(],B./_OFO7?VU/V-_%_[4&L:1>Z5XULM,L-*MFCM]%OK:01><S$O*
M948\L B_<X"^YKPC_@D'_P A[XF?]>UA_P"ASU0_X**?M>>,;'XG7WPU\(ZU
M=>'M(TF.-=0N-/D,-Q=3N@<J9%PPC564;01DELY&,5BE>M"V]E^"M<6'TA/M
M_G9_G^IZUX=_84_9Z^$'P]T^+XM7VES^(S"&O=3O]?EL8_-(R5@021@J#PN5
M+'&3UQ7YP_%*#P[X)^,&LCX=ZU-J/A[3[\2Z1J@+"3"[64ABJDE6R V.=N>]
M?6'P;_X)<^)OB1X<TSQ/XQ\8P^'H]4BCO5LK>U:\NFC<!AYCLR*CD'/&_&>>
M<BOEO]HOX;Z7\(/C5XI\&Z->7.H:=I%PEO'<W94RN?*1GW;0!PS,.!T Z]:I
M-PKZR][73IHU^1.DJ.B]W37[_P S]S8M4.N?#1-28Y:\T@7!(&/OP[OZU^*G
M[%__ "=/\-/^PO'_ .@M7[2:8H7X3VBJ %&B( !T'[@5^+?[%_\ R=/\-/\
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M(=<6QM)%Y\NS0B-7^@B0N?QK]L-%T>T\.Z+8Z781+;V%C;QVT$2]$C10JC\
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M/'>F-$T$EM?:1IMM++'=QL. 9'*8*L%8'8>F.]=I_P %-/\ DU'6/^PC9?\
MHT5\,_L5_M6>./A7\5O#/A.]U:\U/PAJ=_#ID^D7TC2+:F1Q&KP[N8RK,"57
M (R",X(^YO\ @II_R:CK'_81LO\ T:*,6I<L)-W5U;_P)?YDX>W-.-K.SO\
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M)$FFB^[+,V7E<>S.S$>Q%=_7-4BHS<8NZ1M"3E%2:M<****@L**** "BBB@
MHHHH **** "N.^(/_']X6_["L/\ .NQKCOB#_P ?WA;_ +"L/\Z .QHHHH X
M[X7_ /(%U#_L(3?TKL:X[X7_ /(%U#_L(3?TKL: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.\??\ (2\+?]A.
M.NQKCO'W_(2\+?\ 83CH [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHI]UZ];KL;XC'RHUW0A3YFK?BD]K'[,T5^+OCCX$?%?X$V\.KZYH.I^';<2
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M% !1110!*W_'A-_GTK*K5;_CPF_SZ5E4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!-9_\?47^]5^Y_P!<W^>U4+/_
M (^HO]ZK]S_KF_SVH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'NL8(_[:BOT]U;2[77-+O-.OH5N+*\A>WGA?H\;J593[$$UXY^QO\%I?@3\
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MDZGK6ISFYN[B_1KA9)#U;RW8H,]\**]7@@CM88X88UBAC4(D<:A550,  #H
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MC>$?B!!J/PMAU"?Q:MO*D::7IJZA-Y1'[S$1C<$8ZG;Q7[/_ +6G_)LOQ/\
M^Q?O/_11K\SO^"8O_)U6F_\ 8+O?_0!487><>R;O_P"!.WIT*Q7PQEW:5O\
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MAIUK_P &$W_Q5'^JE;_GZON8?Z^8;_GQ+[T?>M%?!7_"R?%W_0TZU_X,)O\
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M8?Z^8;_GQ+[T?>M%?!7_  LGQ=_T-.M?^#";_P"*H_X63XN_Z&G6O_!A-_\
M%4?ZJ5O^?J^YA_KYAO\ GQ+[T?>M%?!7_"R?%W_0TZU_X,)O_BJ/^%D^+O\
MH:=:_P#!A-_\51_JI6_Y^K[F'^OF&_Y\2^]'WK17P5_PLGQ=_P!#3K7_ (,)
MO_BJ/^%D^+O^AIUK_P &$W_Q5'^JE;_GZON8?Z^8;_GQ+[T?>M%?!7_"R?%W
M_0TZU_X,)O\ XJC_ (63XN_Z&G6O_!A-_P#%4?ZJ5O\ GZON8?Z^8;_GQ+[T
M?>M%?!7_  LGQ=_T-.M?^#";_P"*H_X63XN_Z&G6O_!A-_\ %4?ZJ5O^?J^Y
MA_KYAO\ GQ+[T?>M;%U_RS^E?GE_PLGQ=_T-.M?^#";_ .*I[?$_QDW7Q;KA
M^NI3?_%4?ZJ5O^?J^YA_KYAO^?$OO1^@5%?GY_PLWQA_T->N?^#&;_XJC_A9
MOC#_ *&O7/\ P8S?_%4?ZJ5O^?J^YA_KYAO^?$OO1^@=%?GY_P +-\8?]#7K
MG_@QF_\ BJ/^%F^,/^AKUS_P8S?_ !5'^JE;_GZON8?Z^8;_ )\2^]'Z!T5^
M?G_"S?&'_0UZY_X,9O\ XJC_ (6;XP_Z&O7/_!C-_P#%4?ZJ5O\ GZON8?Z^
M8;_GQ+[T?H'17Y^?\+-\8?\ 0UZY_P"#&;_XJC_A9OC#_H:]<_\ !C-_\51_
MJI6_Y^K[F'^OF&_Y\2^]'Z!T5^?G_"S?&'_0UZY_X,9O_BJ/^%F^,/\ H:]<
M_P#!C-_\51_JI6_Y^K[F'^OF&_Y\2^]'Z!T5^?G_  LWQA_T->N?^#&;_P"*
MH_X6;XP_Z&O7/_!C-_\ %4?ZJ5O^?J^YA_KYAO\ GQ+[T?H'17Y^?\+-\8?]
M#7KG_@QF_P#BJ/\ A9OC#_H:]<_\&,W_ ,51_JI6_P"?J^YA_KYAO^?$OO1^
M@=%?GY_PLWQA_P!#7KG_ (,9O_BJ/^%F^,/^AKUS_P &,W_Q5'^JE;_GZON8
M?Z^8;_GQ+[T?H'17Y^?\+-\8?]#7KG_@QF_^*H_X6;XP_P"AKUS_ ,&,W_Q5
M'^JE;_GZON8?Z^8;_GQ+[T?H'17Y^?\ "S?&'_0UZY_X,9O_ (JC_A9OC#_H
M:]<_\&,W_P 51_JI6_Y^K[F'^OF&_P"?$OO1^@=%?GY_PLWQA_T->N?^#&;_
M .*H_P"%F^,/^AKUS_P8S?\ Q5'^JE;_ )^K[F'^OF&_Y\2^]'Z!T5^?G_"S
M?&'_ $->N?\ @QF_^*H_X6;XP_Z&O7/_  8S?_%4?ZJ5O^?J^YA_KYAO^?$O
MO1^@=%?GY_PLWQA_T->N?^#&;_XJC_A9OC#_ *&O7/\ P8S?_%4?ZJ5O^?J^
MYA_KYAO^?$OO1^@=%?GY_P +-\8?]#7KG_@QF_\ BJ/^%F^,/^AKUS_P8S?_
M !5'^JE;_GZON8?Z^8;_ )\2^]'Z!T5^?G_"S?&'_0UZY_X,9O\ XJC_ (6;
MXP_Z&O7/_!C-_P#%4?ZJ5O\ GZON8?Z^8;_GQ+[T?H'17Y^?\+-\8?\ 0UZY
M_P"#&;_XJC_A9OC#_H:]<_\ !C-_\51_JI6_Y^K[F'^OF&_Y\2^]'Z!T5^?G
M_"S?&'_0UZY_X,9O_BJ/^%F^,/\ H:]<_P#!C-_\51_JI6_Y^K[F'^OF&_Y\
M2^]'Z!T5^?G_  LWQA_T->N?^#&;_P"*H_X6;XP_Z&O7/_!C-_\ %4?ZJ5O^
M?J^YA_KYAO\ GQ+[T?H'17Y^?\+-\8?]#7KG_@QF_P#BJ/\ A9OC#_H:]<_\
M&,W_ ,51_JI6_P"?J^YA_KYAO^?$OO1^@=%?GY_PLWQA_P!#7KG_ (,9O_BJ
M/^%F^,/^AKUS_P &,W_Q5'^JE;_GZON8?Z^8;_GQ+[T?H'17Y^?\+-\8?]#7
MKG_@QF_^*H_X6;XP_P"AKUS_ ,&,W_Q5'^JE;_GZON8?Z^8;_GQ+[T?H'17Y
M^?\ "S?&'_0UZY_X,9O_ (JC_A9OC#_H:]<_\&,W_P 51_JI6_Y^K[F'^OF&
M_P"?$OO1^@=%?GY_PLWQA_T->N?^#&;_ .*H_P"%F^,/^AKUS_P8S?\ Q5'^
MJE;_ )^K[F'^OF&_Y\2^]'Z!T5^?G_"S?&'_ $->N?\ @QF_^*H_X6;XP_Z&
MO7/_  8S?_%4?ZJ5O^?J^YA_KYAO^?$OO1^A#?\ 'A-_GTK*KX-_X6=XQVE?
M^$LUS:>H_M*;'_H5,_X63XN_Z&G6O_!A-_\ %4?ZJ5O^?J^YA_KYAO\ GQ+[
MT?>M%?!7_"R?%W_0TZU_X,)O_BJ/^%D^+O\ H:=:_P#!A-_\51_JI6_Y^K[F
M'^OF&_Y\2^]'WK17P5_PLGQ=_P!#3K7_ (,)O_BJ/^%D^+O^AIUK_P &$W_Q
M5'^JE;_GZON8?Z^8;_GQ+[T?>M%?!7_"R?%W_0TZU_X,)O\ XJC_ (63XN_Z
M&G6O_!A-_P#%4?ZJ5O\ GZON8?Z^8;_GQ+[T?>M%?!7_  LGQ=_T-.M?^#";
M_P"*H_X63XN_Z&G6O_!A-_\ %4?ZJ5O^?J^YA_KYAO\ GQ+[T?>M%?!7_"R?
M%W_0TZU_X,)O_BJ/^%D^+O\ H:=:_P#!A-_\51_JI6_Y^K[F'^OF&_Y\2^]'
MWK17P5_PLGQ=_P!#3K7_ (,)O_BJ/^%D^+O^AIUK_P &$W_Q5'^JE;_GZON8
M?Z^8;_GQ+[T?>M%?!7_"R?%W_0TZU_X,)O\ XJC_ (63XN_Z&G6O_!A-_P#%
M4?ZJ5O\ GZON8?Z^8;_GQ+[T?>M%?!7_  LGQ=_T-.M?^#";_P"*H_X63XN_
MZ&G6O_!A-_\ %4?ZJ5O^?J^YA_KYAO\ GQ+[T?>M%?!7_"R?%W_0TZU_X,)O
M_BJ/^%D^+O\ H:=:_P#!A-_\51_JI6_Y^K[F'^OF&_Y\2^]'WK17P5_PLGQ=
M_P!#3K7_ (,)O_BJ/^%D^+O^AIUK_P &$W_Q5'^JE;_GZON8?Z^8;_GQ+[T?
M>M%?!7_"R?%W_0TZU_X,)O\ XJC_ (63XN_Z&G6O_!A-_P#%4?ZJ5O\ GZON
M8?Z^8;_GQ+[T?>M%?!7_  LGQ=_T-.M?^#";_P"*KZ9_9EUS4=>\!W]QJ=_=
M:C.NI21K+=S-*P411$*"Q)QDGCW->;F&0U,OH.O*::N>SE/%-'-L2L-"DXNS
M=VUT/7****^8/MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH FL_^/J+_ 'JOW/\ KF_SVJA9_P#'U%_O5?N?]<W^>U $5%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5>M?]
M2M4:O6O^I6@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** . ^+GP'\"?';3["R\<Z FNV]C(TEL&N9H&B9@ Q#1.IY '&>U8?P
MU_9-^$?PBU5-3\*^!M/L-3C.Z*]N&ENYXCR,QO,[LAP2,J1UKUNBG%N/PZ":
M4MPHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KCOB#_ ,?WA;_L*P_SKL:X[X@_\?WA;_L*P_SH [&B
MBB@#COA?_P @74/^PA-_2NQKCOA?_P @74/^PA-_2NQH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[Q]_R$O"W
M_83CKL:X[Q]_R$O"W_83CH [&BBB@ HHKY[^.'[;_@+X!^-SX5U[3M>O]26V
MCN7;2[>"2-%?.U27F0[L#/3H1S5PA*I)1@KLBI4C3BYS=DCZ$HKC?A#\4M-^
M,_P_TSQAH]E?V&F:AYGD1:E&B3821D)(1W&"5..>E=E1.,J<G"2LT$)QJ14X
MNZ84445!8445\X_%;]OGX5?"?Q)<Z#<W&I^(-3M9#%=1Z';)*L#CJK/(Z*2.
MX4G!R#@U<(2J2Y8*[,ZE2%*//-V1]'45X7\#_P!LKX>?'W7SH?AXZM:ZSY+7
M L]1LBA\M<;FWQLZ#&1U8=:]TJJE*=)\LU9BIU85ES4W=!11161J%%%% !11
M10 45D>*O%VB^"-'EU77]3MM)TZ,@-<74@1=QX"C^\Q/ 49)/05K [@#3Z7%
M?6PM%?*?B3_@I!\,_#?C#4O#CZ+XJOKVQO9+!I+.TMFBED1RA*%K@$@D<9 /
MM7U5&QDC5BI0L,[6ZCV-:2I3A&,Y*R>QE&M3J3E"+NX[^0ZBBBLC8**** "B
MBB@ HHHH **** "BBB@ HKFOB1X_TSX6^!=9\5ZRL[Z;I5N;B9+95:5P" %0
M,0"Q) &2!SUKY?\ ^'I7PI_Z%_QC_P" 5I_\DUM3HU*U_9QO8PJUZ=&WM)6N
M?8M%?(%G_P %0OA-=7"12Z1XLLT8X,TUC;E5]SLN&/Y U]%_"_XR>#?C-HKZ
MGX.UVWUFWC(6:--R30$]!)&P#+G!QD8.#C-74PU:FN:<6D13Q5"J^6$TV=I1
M17@'QV_;6\"_L]^,8?#7B#3]=U#49+1+PG2;>&2-%9F4!C),AW?*3P.A'-8P
MA*I)1@KMF\YQIQ<YNR1[_17(?"7XG:=\8OA_I7B_2+.^L--U(.T$.I1HDVU7
M9,D([#!*DCGIBNOHG&5.3C)6:"$XU(J<7=,****@L**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH X[XE?\ 'OH/_86@_DU=C7'?$K_CWT'_
M +"T'\FKL: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,
MWQ)H-IXJ\.ZGHU_&);+4+:2UF1AG*.I4_H:_$VZ_MWX'_%2Y2UF:SU[P[J,D
M22X_CC8KG'HP_,&OW$KY(^/G_!/^S^-7Q,U#Q?:>,/\ A&VOTC^T68TK[2&E
M50IDW><G4!>,=03GFO:RK%4\-5DJS]R2U^6WYL\S,,/+$4E[/XHNZ_7]/N/D
MC]A7X:'XE?M":3<W49FT_00VKW+.,@NA B!/KYC*?<*:_6ZO"_V6_P!EJS_9
MITW78UUO_A(M0U::-GO#9_9MD:*=L87S'[LYSGG(XXKW2C-<7'%5E[-WBEI^
MO^7R)R[#3P]-NHO>;_X;_/YA7Q[_ ,%.?^2*^'_^PY'_ .B):^PJ\>_:<_9[
M_P"&CO!.G^'_ .W_ /A'OLE\M[]H^Q_:MV$=-NWS$Q]_.<]NE>=AIQIUX3EL
MFG^)Z%6+E2G%;M-?>F?,'_!*W_CZ^)/^YI_\[FOT KY__97_ &4?^&9I?$K_
M /"4_P#"2?VRMN,?V?\ 9?)\KS/^FK[L^9[8QWS7T!79FE>GB,5*I2=T[?DC
MBR^C.A1Y*BL[GY@?\%,/^2]:7_V X?\ T;-7UY^P3_R:QX/_ -^]_P#2N:L+
M]IC]B?\ X:*\>6OB7_A,_P#A'_(L4LOLO]E_:=VUW;=N\Y/[_3';K7KWP$^$
M_P#PH_X5Z/X,_M7^VO[/:8_;?L_D>9YDSR?<WMC&_'WCG&:ZJF*HRRR&'4O?
M3O;7^]\NIE["I_:#KV]VRU^21Z%1117@'KGG_P 5/@)X$^-;:<WC30O[9;3P
MXMO],G@\O?MW?ZJ1<YVKUSTK@?\ A@[X%_\ 0C_^5>^_^/U[]171#$5J4>6$
MVEY-F,Z-*H^:<4WYH^1/VUD\8?!/X/>%9OAAJE]X;\.:,W]GW=O8R%C'"0HA
M8R/E\*5*YS_&,UYG^R+^W9IOAG0;_0/BMKNIS3?:&N;37;OSKTE& !A?&YQ@
MC*X!'S$<8&?OO6-'L?$&EW6FZE:0WVGW4;0SVUP@>.1",%6!ZBOCKQ]_P3%\
M):[JDEUX6\4WWA>"1BQL[BU%]$GLAWHP'^\S'WKU<'B<-*E*ABUN[\W7OJ]]
M_7L>?BJ%=3A5PS^'3EZ?Y;'SW^W%^TUHGQZU[1--\++-+H.BB5Q?3Q&,W,LF
MT$JK?,% 48R 22>.E?7'_!/7X<W_ (%^ JWFIP/;7&OWKZE'#("&$!1$C)'^
MT$+#V85C?"?_ ()Q>!? NK0:GXEU.Y\:W-NP>.VN(%MK/<.07B#,7P>Q?:>X
M-?6B*L:JJJ%51@*HP /2KQ6+P\,*L'A;N/5OUO\ F9T,/7J8CZSB=&MDON/Q
MC^//@_4O@C^T%KMJB-!)9:G_ &CI\C+@-$S^;$P]0.!]5(K[C\3_ /!1+X=3
M?":ZOM,N+MO&%Q9,D>BM:2 PW#+C+2D>645CG(8D@=,\5[1\=OV;_!W[06D0
MVWB.VE@O[4$6FJV1"7,&>2N2"&4]U8$>F#S7S';_ /!*_3UU(//\1KF2PW9,
M$>D*DNWT\PS$9]]GX5M'%8/&X>%+&-IP_'\][:_@1*AB<+B)UL*DU+H^G_#=
M/Q/ _P!@_P"'%W\0/VAM'U QL^G^']VJ7<Q' 901$,^ID*GZ*WI7V-_P43^'
M-UXT^!:ZM8Q--<^';Q;Z1$&3Y#*4D/X95C[*:]J^#OP5\*_ SPN-#\+6301.
MPDN+J=M]Q=28QOD? R?0  #L!7;SP1W4,D,T:RPR*4>-U!5E(P00>H(KDQN8
M>WQ,*M):0M;SUO\ CMZ'1@\%[&C*%7>=[_=;_@^I^7/["G[37A_X%ZKK^C^+
MIYK/0=6$<R7L4+3"WF3(^94!;:RMU ."HXYR,_\ ;E_:0T/X\>+-$M/"TDUS
MX?T6&0+=S1-%]HFD*[F5& 8* B@;@#G/'2OI;XG_ /!-7P;XNUJ?4?"^O77@
M[SW+O9?91=VR$]?+4NC(/;<0.P XJ_\ !_\ X)S^"OA[KEOK'B+5KCQI=VKB
M2"WFMEMK0,""&>,,Y<@CH6V^H->J\9E\ZRQLF^==/E;TVTW/.6&QM.E+"PLX
MOK\[_P##Z'<_L0?#:Y^&O[/>AP7\30:AJSOJT\3##)YN/+!]_+5,CL2:]\I*
M6OE\16>(JRJRZL]_#T50I1IKH%%%%<YN%%%% !1110 4444 %%%% !1110 4
M444 %%%% !7':+_R4SQ#_P!>\'_H(KL:X[1?^2F>(?\ KW@_]!% '8UF^)?#
M]EXM\.ZIHFI1"?3]2MI+2XC/\4;J58?D36E14RBI)Q>S&FXM-'X1_$;P'XQ_
M9 ^/$<!+VVJ:)>K?:5J!0^5=Q*^8Y!ZJP&UE]=RFOT<^&/\ P4\^$?BCPW!/
MXMO;OP9K:H!<6<ME/=1,^.3$\*/E<_W@I]N]?0?Q@^!O@OX[^'/[&\9Z+%J<
M"$M;W )CN+9C_%%(/F4\#(Z''((KXT\2?\$A=#NK]GT#XDZAIEE_##J.E)>2
M#_@:2Q _]\UT1J.4/9U>G4RE32G[2GI?I_7X'D_[=7[=FF_'30X_ W@6.Z3P
MN)UGO]2NHS$U\R'*(B'E8P<-EL$D#@ <^G_\$J_@'>Z5!K'Q3UBT:W2^A.G:
M,)5P7BW S3#V)54![X>N\^%?_!*_X<^#-2M]0\5:QJ/C>>%MPM)(UM+-R#D;
MXU+.WT\S![@BOLZQL;;3+."SL[>*UM+=%BA@A0(D: 8"JHX  X %7&4*,&J>
MK?7^O+3T(DIU9+GT2_K\]3\[O^"O_P#QY_"W_KIJ7\K:N^_X),_\F_>)/^QE
MF_\ 2:VKT[]L#]D'_AJZ'PM'_P )9_PBW]AM<MG^S?MGG>:(O^FL>W'E^^<]
ML5O_ +)G[-?_  R[\/\ 4O#'_"1_\)-]LU-]1^U?8?LFS=%''LV^9)G_ %><
MY[].*C#R4*-2$MW?_P!*3_(TK)SG2<>F_P#Y-_F>"?\ !6[_ )(OX._[& ?^
MDTU<_P#\$A/^15^)7_7[9?\ HN6OI3]K?]F'_AJ;P7H_A_\ X27_ (1C^S]0
M^W?:/L'VOS/W;ILV^;'C[^<Y/3I6?^R#^R9_PRGI7B6R_P"$J_X2C^V9X)O,
M_L[['Y/EJXQCS9-V=_MC%%&2A3JJ6\MO_)?\F36BYSI./V=__)O\T?#'_!5S
M_DXS2/\ L7K?_P!'SU]R_P#!/[_DT?P!_P!<KG_TJFKC_P!J[]@G_AI[XC6?
MBK_A.O\ A&OL^G1V'V3^R/M>[:\C[]_GIC._&,=NM>Y_L_\ PD_X47\(] \#
M_P!J_P!M_P!E)*OV_P"S?9_-WRO)_J][[<;\?>/2G3DHX9TWOS7_ !E_FAUD
MY8B,X[)?HD>=?MZ_"2^^,'[-^N6.DP-=:OI4L>KVMN@RTIBR'4#N3&\F!W.!
M7Y\_\$]_VF=&_9\^(VK6/BJ9K3PUXBACAFO0A<6L\98QNP'.PAW4D D9!Z U
M^QU?*WQV_P""='PS^,VL7>NV37?@S7[IFDFN-*"M;SR'J\D##&>YV%,DDG).
M:SHS]C*6EU+?\O\ +T:+JQ56*5[-?\/^?YG0?&C]N3X5_#3P#?:KI/C#1O%.
MM/ PT_2]'O4NI))B/E\SRR?+4'DEL< @9.!7YL_L2_"/5OCI^TAHU]+#)-IF
MD7JZWJUYM^1=C^8BD]-TD@  ZXW'L:^I?#W_  2$T6UU))-<^)=]J6G@_-;Z
M?I*6DI^DCRR@?]\5]J?"3X-^$?@?X4C\/>#M(CTNP#>9*V2\UQ)C!DE<\LWU
MX X  XK:FZ=&3JIWET\OZ_'0QJ*=6/LFK+J?/W_!4'_DUFY_[#%G_-Z^?O\
M@D-_R.GQ&_[!]I_Z,DK[=_:@^ ?_  TE\+)?!O\ ;O\ PCN^\AN_MOV/[5CR
M\_+L\Q.N>NZO/OV0_P!BO_AE36O$>H?\)E_PE']L6\,'E_V7]D\K8S-G/G2;
ML[O;I6>%DJ?M.;K>W_@*7YEXA.:AR]+?^E7_ "-/_@H-_P FA^/_ /KG:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?5_[)__ "3O4?\
ML*R?^B8:^4*^K_V3_P#DG>H_]A63_P!$PU\MQ)_R+WZH^ZX,_P"1M'_#(]IH
MHHK\E/WX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M )K/_CZB_P!ZK]S_ *YO\]JH6?\ Q]1?[U7[G_7-_GM0!%1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7K7_4K5&KUK
M_J5H EHHI&;:I)Z 9I-I*[ 6BOBR?_@K#\([>:2)O#OC4LC%3BQM,<''_/U3
M/^'LWPB_Z%SQM_X V?\ \E5IR2?04FHMI[GVM17RY\/?^"D7P5\?:M#ITFJZ
MAX7N)W$<3:_:"&)F/0&1&=$'NY4>]?4*.LB*Z,&1AD,IR"/6B4)1U:$I*6B8
MZBOE?XM_\%&/AM\&?B)K7@S6M$\576J:3(L4\UA:6SP,6C5QM+W"L1AQU4<Y
MKZ5\,^(+?Q7X;TG6[1)8[34K2&\A28 .J2('4, 2 <,,X)^M)1;CSK;_ #&V
MHRY'O_D:=%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **YCXB?$SPM\)_
M#<VO>+M;M="TJ,[?/NFY=L$A$499V(!^502<'BOE[5O^"JWP:T_4'M[?3_%>
MJ0J<"[M-/A6)O<"2='Q]5%$?>=D#]U79]D45Y%\$?VK/AK^T"7@\):\)-5CC
M\V72;Z,V]VB]R$;AP.,E"P&1DUZ[52BXNS1,9*6P4445)04444 %%%?).H?\
M%,/AAIWQ N?!\FA>+6U.#5&TEI5L[7R3*LIB+ _:<[=PSG&<=NU.*<Y*$=V*
M348N<MD?6U%%%(84444 %%%85OXY\/WGB^X\+6^KVEQXBMK;[9/IL4@>:&'<
MJAG ^YDL, X)[=#1UL'2YNT444 %%%% !1110 45Y]\=/C9H?[/WP]N?&/B*
MUU"\TRWFB@:+3(XY)BTC;5(#NBXSU^:N+_9Q_;$\&?M/:IK5CX6TS7;";288
MYYVUBWAC5E=BH"^7,^3E3UQ3BG._+T_X?\A2:C;FZ_\ #'NM%%%(84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 445\DZ;_P %,/AAJGQ
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M8!,D;C&U'X SR.?7U'_@JEXR%YXX\&>%XY,K86,M_*@/\4SA5S^$1_.O:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M["L/\Z[&N.^(/_']X6_["L/\Z .QHHHH X[X7_\ (%U#_L(3?TKL:X[X7_\
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M;6FEO86(SRI\LJK$]R2<D]R2:_$W0=2UWX(_%+3[^?3_ +-K_AO4DF:QOD(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /G?XY?\BM\2?]^P_P#1J5\F5]9_'+_D5OB3_OV'
M_HU*^3*_4N%O]RG_ (G^43\,XZ_Y&5/_  +_ -*D%%%%?8GYT%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MU?\ LG_\D[U'_L*R?^B8:^4*^K_V3_\ DG>H_P#85D_]$PU\MQ)_R+WZH^ZX
M,_Y&T?\ #(]IHHHK\E/WX**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** )K/_CZB_WJOW/^N;_/:J%G_P ?47^]5^Y_US?Y[4 14444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
MZU_U*U1J]:_ZE: ):9-_JG_W33Z9-_JG_P!TUE6_AR]&-;G\^7@GPY;>,/BI
MH.@WKRQ6>J:S!93/ 0)%22=48J2" <,<9!'M7Z=?\.F?A%_T,7C7_P #K/\
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MQP?8 $G %?DQJ^J?%?\ X*(_&D16L!-O"3Y-MN8:?HMJ6^\[8ZG'+8W.1@#
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MY@05.>.F*Z']I3X[?$[]K[PS<>*W\*/HWPX\+2*2+8M)#'-*RQ@O,P7S9/F
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MQ^WE_P G;_$7_K[@_P#2:&OV&^!=I'8?!/P!;PC;%'H%@JCV^SI7X\_MY?\
M)V_Q%_Z^X/\ TFAK]C/@O_R1WP+_ -@&P_\ 2=*SI?[E'_MW\F56_P!]E_V]
M^:/!?^"FG_)J.L?]A&R_]&BOG/\ X)#?\CI\1O\ L'VG_HR2OHS_ (*:?\FH
MZQ_V$;+_ -&BOG/_ ()#?\CI\1O^P?:?^C)*6#_Y>_/_ -(0\5M3^7_I3/-?
M^"HG_)T<O_8%L_\ V>OT3_8E18_V4_AL%4*/[,!P!CDR.2?SK\[/^"HG_)T<
MO_8%L_\ V>OT5_8H_P"35?AM_P!@L?\ H;T4O]T?^+]9"J_[TO\ #_\ (GYI
M?\%)U"_M:>)2  6M+(G Z_Z.E?J7^R_"EO\ LX_#%$&%_P"$;L&_$P(3^I-?
MEK_P4H_Y.T\2?]>=E_Z3I7ZG?LR_\FY_##_L6M._])DHH_[C\U_[<56_WI?X
M?TB?D9^WE_R=O\1?^ON#_P!)H:_8SX+_ /)'? O_ & ;#_TG2OQS_;R_Y.W^
M(O\ U]P?^DT-?L9\%_\ DCO@7_L V'_I.E.G_N4/^W?R9-;_ 'V7_;WYH[*O
MDC_@J#_R:S<_]ABS_F]?6]?)'_!4'_DUFY_[#%G_ #>N&KM'_%'_ -*1UT]W
MZ/\ )GSQ_P $B;6-_'WQ"N2/WL>F6T:G_9:5B?\ T 5^B'Q>CGF^$_C1+4,;
MEM%O1&%ZEO(?&/QK\]?^"0W_ ".GQ&_[!]I_Z,DK]-98TFC>.10\;@JRL,@@
M]17=CHNI!076+_-G+A)<DW+M)?DC\!?@-X3\3^.?BUX=T+P;KR^&?$][*Z6.
MJ-=RVODN(W)_>Q*74E05^4<[L=#7V_\ \,6_M=?]%W_\O#5__C-?//[37[/'
MC#]D?XQ#Q%H,%W#X;CU!;_0M<@0M' P?>D,C8PKH>,-]X#(R,@>I>+/^"KGB
M[Q%\-;O0K7P=8Z5XDN[4VTNNPWK-&A8;6DCMRGRM@G&9& /KTJW4]I24Z:N^
MW]?B+DY*KC-Z=S2\!_\ !,7XO^&/B/X>\3WGB?PC.VGZK;ZC/(M_=O,^R99&
M(+6PRQP>IY/>OM[]I_\ 9GT']ISP''H6J7,FEZC9RFXT[5(4#M;2$8(*DC<C
M#&5R,X!R"*^&_P#@FU\&OB/XB\:67C*_U;7]$^'VF;I(K?[9-##JLQ&%18]P
M#Q G<S8*DJ%YR<>]_P#!13X*_$;QQX:T_P 4?#[5M<F_LV)H=3\.Z;>3*+F'
M)99DA5L.ZY8$ %B",9VXK/$^[&%.3TO]W]67IOL5A_>E*<?^'_J_Z'QO\2/^
M";/QH\"S32:;I-IXQT],L+C1;E?,V]LPR;7W>R!OK7GWAOXP?&_]F'6K>RCU
M3Q-X2DC&]=%UJ*46[KGD_9YQMP<8W 9]"*]/_9F_X*#>)_V<?"<GA#4_#4?B
MS1[>:22UBFO&L[FU9F+.A?8X*[B3@KD$GGL.7_:7_:>\3_MH>*O#6G6/A!;$
M6)DCT_2M.+WMU-)+MW9<(I;A%P%48P>M;+VBDHQ]Y,S_ '<DW+1H_43]D?\
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M^DZ5^)O@W_DZK1?^QSA_]+16]/\ Y&:]7_Z5$P7_ "+_ )+_ -)9^P'[8_\
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MOG6'=&,( \#J1MSC;GCH17G'_#NW]GO_ *)__P"5K4/_ )(I>T:K5:DOM/\
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M5DI0A4CMM^J?W/\  X:=X5)4Y?UT?Y?B?$W_  4^^/>M?#/PCX4\,^%M=O\
M0=<U:Z>\GN]+NGMYTMHAM"[T(8!W<=^?+-9/_!+^\\?>/K?Q=XT\7^,O$GB#
M3(BFEV%MJVJW%S#YG$DT@21R-P'E@''\3"OD/]OCXH'XI_M-^)6MY?/T_167
M1+3:<C$)(DQ]96E_#%?JO^RG\*1\&?@%X0\,R1"*_CM!=7_K]IE_>2 _0MM^
MBBL\/[N'E5>\MOG_ /:K[V:XC6M&DOL[_+?_ ,F?W(_/O]I?_AIC_A?WC?\
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ME+9:_P!>KT,O]@OQQ\3OVC?V@_$?C3Q%XOU[_A%]*5[E]&BU*==/\^;*PP"
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MK*LD4T;3N5='4D,I!!!!P:_=SP1_R)>@?]@^W_\ 1:U%-?['%O?W?R9I5?\
MM<K;>]^:/Q-^)7[0WQ8M/B9XJL[/XF>,X88M7NH8;>#7KM511,X5542< #
M%= #^UTP!'_"ZR/^XO7DWQ"D6/XT^)7=@B+X@N268X 'VEN:_;N']I3X1+#&
M#\4_!0.T?\S#9^G_ %TIT_=PU.>[:_1$5'?$3AT_X)^1MU\>OVDO@QJEK+K?
MBCQYH=U)EH8?%'VAUD QG$=T"K#IV/6OTG_8B_:U_P"&FO!M]!K%O#8^,=%*
M+?1VP*Q7$;YV3("3C)4AESP1Z$ >.?\ !1C]H[X6^+O@?+X2T3Q%I/BWQ#=W
ML$UM_9,Z726@1LO*94)525RF,Y._IC-<I_P22^'.KP:EXS\<3P20:+-;1Z5:
MR.I"W$GF"20KZA-J@GU?'8U=-^UA/G5K=?N_70BJO92@X.[?3Y_Y:_\  .=_
MX*/>)_B9\(?CE!>:!X_\6:1X=\06*75O:6.MW,,$,T?[N5$17 4<(^ .LAKZ
MH_X)X_&:_P#C!^S[;_VWJ=QJWB#0[R73[RZO)FEGF7/F1.[,26.UPN2>=AKG
M_P#@IU\*_P#A.OV>_P#A(;:+?J'A6[6]RHRWV>3$<P^G,;G_ *YU\L_\$K?B
MA_PBWQLU3PA<2[;3Q-8DQ*3Q]I@RZ_G&9?R%9X5<]*=)[K;\_P KHTQ/NSA5
M6SW_ "?Z2/UDK\COV[/VIO&LW[1FO:1X/\;:_P"']%T)(],\G1]5GM8Y9D!,
MSLL;@%@[,F3SA!7ZD?%+QU:_#'X<>)?%=YCR-'L)KLJ?XV5253ZLV%_&OQ)_
M9]\!WO[0W[1GA[2+_==G5]4-]JDA_BA#&:X8^F0&'U85E0A[6NH]%^O7Y).Y
MK5E[*@Y=7^FO^1^F'A7X8_$/5_V$TL7\9>)_^%CWVFG6X=4;5[@7JS$^=';^
M;OWA2@6,KG&6)KRW_@FO^U=K7C6_U/X:^.=:O-8UE0]]I.H:I</-<2J/]= S
MN2S%?OKDDXWCHH%??T<:0QK&BA(U 5548  Z"OQ7^.L%U^R]^VQJVI:.&@32
M];CUBU1#@-!-MF:/_=*N\?TS6U.<9XF47I&?X6V_3Y(QE"4<.FM90_&^_P"/
MYG[5T52T75[;Q!HUAJEF_FV=[;QW,+_WD=0RG\B*NUSM.+LS:,E))K9GSM^W
MA_PGG_"@Y_\ A7/_  D7_"2?VE;;?^$7\_[9Y66WX\CY]O3/;IFO)O\ @G%_
MPN+^U_'/_"T_^$X\CR+3[!_PF'VS;NW2[_*^T=\;<[?;/:O</VR/CEKW[//P
M7F\7>'+33KW4DO[>U$6J1R20[7+9.$=#GCCFO-?V$?VO?&/[3^I^,+;Q3INA
MV":/#;20'1X)HRQD:0-O\R5\_<&,8[UIA[VJ\NO?RT6Q->WN<VFWYGUY17Q)
M^W!^VYXY_9I^)VC^'/#&E>'K^QO-)2_DDU:VGDD$AFE0@&.9!MQ&.V<D\UP'
MB#_@I%X]\:^$?#NA_#/PBNO?$&ZL!<ZQ/INFSW45G(2?W<%N"S,0-I+.64$X
MP>V<8N<>:.NMOS_R+E:$N66FE_R_S/T:HK\@=(_X*+?M _#?Q>]MXQFCU1[>
M0+=:)K>CQ64B#@E?W<<;HV#P6SU!P:_2;PS\>K+XA_LYW/Q/\-1*/^)/=7T=
MI=980W$,;EHI,$$@.A!P1D<C&:JI!TZ;JO5(F$N>HJ2W9\U?\%&OVNO%WP;U
MC1O _@B]&C7U]9&_OM42-7F2-G9$CC+ A2=CDMC/W<$<U\T?"C1?VP/B3H=I
MXQ\)^(/&FI:+-*PBN[GQ(/+?:VUBL,\WSJ"".$(X(KQ;]H+]H+Q%^TEXTMO$
M_B:RTNQOX+)+%8])BDCB**SL"1)(YW9<]\=.*^E/V,?VWO'6DZ]\-/A##I/A
MT^&GOH].-TUM/]L\N24LS;A-LW9<X.S'3BNK#TG&.UYM_J_^ 88BJKW7PI?I
MK^-S]4=.AFM]/M8KB9KBXCB59)F !=@ "Q XY//%6*^8OVQOVU]+_9ELK?1]
M,LX==\;WT7G064KD06L?($L^TY()!P@(+8/*]3\2P_MH_M7^*[&Y\4Z,-3?P
MW&6:2;3/"L4UA"%^\#,8'( [Y?(]:Y(WJ7DMN_0W:]FE'K^)^N]%?"7[(?\
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MF'.!D5^8_@'_ (*I>-KOXB:=9>,-*\*Z=X5^TLM_=6-C=?:$A4,24S<,-QP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7U?^R?_ ,D[U'_L*R?^
MB8:^4*^K_P!D_P#Y)WJ/_85D_P#1,-?+<2?\B]^J/NN#/^1M'_#(]IHHHK\E
M/WX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K/_
M (^HO]ZK]S_KF_SVJA9_\?47^]5^Y_US?Y[4 14444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5ZU_P!2M4:O6O\ J5H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ/G_ / <=,>U4J^<<G)\TG=L_%<?C*N*JMS84444CS IR2-&P93M8<@BFT4
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M,UAKMO:QIJ6OWMS/=76!OD6.5H8U)_NJ$.!ZLQ[U\K_\%9O^2^^&?^Q;B_\
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MW7PB_9V\&^%[]/+U&UL#-=QG_EG-*S3.G_ 6D*_A7XU_ 7_DY+X??]C58?\
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M_P"_\/\ \:H_UDP'=_<'^IF;?RQ_\"/E"BOJ_P#X9/\ "/\ T$=:_P"_\/\
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M'6O^_P##_P#&J/\ 63 =W]P?ZF9M_+'_ ,"/E"BOJ_\ X9/\(_\ 01UK_O\
MP_\ QJC_ (9/\(_]!'6O^_\ #_\ &J/]9,!W?W!_J9FW\L?_  (^4**^K_\
MAD_PC_T$=:_[_P /_P :H_X9/\(_]!'6O^_\/_QJC_63 =W]P?ZF9M_+'_P(
M^4**^K_^&3_"/_01UK_O_#_\:H_X9/\ "/\ T$=:_P"_\/\ \:H_UDP'=_<'
M^IF;?RQ_\"/E"BOJ_P#X9/\ "/\ T$=:_P"_\/\ \:H_X9/\(_\ 01UK_O\
MP_\ QJC_ %DP'=_<'^IF;?RQ_P# CY0HKZO_ .&3_"/_ $$=:_[_ ,/_ ,:H
M_P"&3_"/_01UK_O_  __ !JC_63 =W]P?ZF9M_+'_P "/E"BOJ__ (9/\(_]
M!'6O^_\ #_\ &J/^&3_"/_01UK_O_#_\:H_UDP'=_<'^IF;?RQ_\"/E"BOJ_
M_AD_PC_T$=:_[_P__&J/^&3_  C_ -!'6O\ O_#_ /&J/]9,!W?W!_J9FW\L
M?_ CY0HKZO\ ^&3_  C_ -!'6O\ O_#_ /&J/^&3_"/_ $$=:_[_ ,/_ ,:H
M_P!9,!W?W!_J9FW\L?\ P(^4**^K_P#AD_PC_P!!'6O^_P##_P#&JOS?L@^#
M8]N-2USD=YX?_C5'^LF [O[@_P!3,V_EC_X$?(-%?7/_  R+X/\ ^@EKG_?^
M'_XU1_PR+X/_ .@EKG_?^'_XU1_K)@.[^X/]3,V_EC_X$?(U%?7/_#(O@_\
MZ"6N?]_X?_C5'_#(O@__ *"6N?\ ?^'_ .-4?ZR8#N_N#_4S-OY8_P#@1\C4
M5]<_\,B^#_\ H):Y_P!_X?\ XU1_PR+X/_Z"6N?]_P"'_P"-4?ZR8#N_N#_4
MS-OY8_\ @1\C45]<_P##(O@__H):Y_W_ (?_ (U1_P ,B^#_ /H):Y_W_A_^
M-4?ZR8#N_N#_ %,S;^6/_@1\C45]<_\ #(O@_P#Z"6N?]_X?_C5'_#(O@_\
MZ"6N?]_X?_C5'^LF [O[@_U,S;^6/_@1\C45]<_\,B^#_P#H):Y_W_A_^-4?
M\,B^#_\ H):Y_P!_X?\ XU1_K)@.[^X/]3,V_EC_ .!'R-17US_PR+X/_P"@
MEKG_ '_A_P#C5'_#(O@__H):Y_W_ (?_ (U1_K)@.[^X/]3,V_EC_P"!'R-1
M7US_ ,,B^#_^@EKG_?\ A_\ C5'_  R+X/\ ^@EKG_?^'_XU1_K)@.[^X/\
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M ($?(U%?7/\ PR+X/_Z"6N?]_P"'_P"-4?\ #(O@_P#Z"6N?]_X?_C5'^LF
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M_01UK_O_  __ !JC_63 =W]P?ZF9M_+'_P "/E"BOJ__ (9/\(_]!'6O^_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
M]:_ZE:HU>M?]2M $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:S/V[OV2/&'[4%QX.?PKJ6B6 T9;I;C^V)YH]WF&+;L\N*3/W#G..W6O&OV
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MZ=15([K_ ('^0JD54ING+9_U^H4445!04444 %%%% 'GFE_\CQXJ_P!^#_T
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MW\Z^K:*Y?J=&^QX"X;RWFYN1^EV<!\._@CX6^&NV;3[0W6I 8.H7A#R\]=O
M"CZ 'U)KOZ**ZXQC!6BK'T-&A2P\%3HQ45Y!1115&X4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5QVB_\E,\0_P#7O!_Z"*[&N.T7_DIG
MB'_KW@_]!% '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'GFE_\CQXJ_WX/_0#705S^E_\CQXJ_P!^#_T UT%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5L
M77_+/Z5CUL77_+/Z4 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH E;_CPF_SZ5E5JM_QX3?Y]*RJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[X@_P#']X6_
M["L/\Z[&N.^(/_']X6_["L/\Z .QHHHH X[X7_\ (%U#_L(3?TKL:X[X7_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''?$K_CWT'_ +"T'\FK
ML:X[XE?\>^@_]A:#^35V- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7':+_ ,E,\0_]>\'_ *"*[&N.T7_DIGB'_KW@_P#010!V-%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YYI?_
M "/'BK_?@_\ 0#705S^E_P#(\>*O]^#_ - -=!0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %;%U_RS^E8];%U_RS^E %>B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** )6_P"/";_/I656JW_'A-_GTK*H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@":S_X^HO]ZK]S_KF_SVJA9_\
M'U%_O5?N?]<W^>U $5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5>M?]2M4:O6O^I6@"6N/^+_Q(LOA#\,O$GC'4%WV
M^D6;W BSCS9.D<>?5G*K^-=A7,?$CX:^'/BYX1N_#'BS3CJNAW;(TUJ+B6#>
M48.OS1LK<,H/![5$DW%J)<6E).6Q^"'Q ^(6M_%#QOJ?BOQ)='4=5U"<S3-(
M3MQVC4 _*B@!0!T %?3GA7_@I[\2/!/AW3]!T/P=X$TW2=/A6"VM8-/O L:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *X[X@_\?WA;_L*P_P Z[&N.^(/_ !_>%O\
ML*P_SH [&BBB@#COA?\ \@74/^PA-_2NQKCOA?\ \@74/^PA-_2NQH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* //-+_Y'CQ5_OP?^@&N@KG]+_Y'CQ5_OP?^@&N@H **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "MBZ_Y9_2L>MBZ_Y9_2@"
MO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% $K?\>$W^?2LJM5O^/";_ #Z5E4 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[Z_^O1_P@NH_]#7JG_?7_P!>@#L:*X[_ (074?\ H:]4_P"^O_KT?\(+J/\
MT->J?]]?_7H [&BN._X074?^AKU3_OK_ .O1_P (+J/_ $->J?\ ?7_UZ .Q
MHKCO^$%U'_H:]4_[Z_\ KT?\(+J/_0UZI_WU_P#7H [&BN._X074?^AKU3_O
MK_Z]'_""ZC_T->J?]]?_ %Z .QHKCO\ A!=1_P"AKU3_ +Z_^O1_P@NH_P#0
MUZI_WU_]>@#L:*X[_A!=1_Z&O5/^^O\ Z]'_  @NH_\ 0UZI_P!]?_7H [&B
MN._X074?^AKU3_OK_P"O1_P@NH_]#7JG_?7_ ->@#L:*X[_A!=1_Z&O5/^^O
M_KT?\(+J/_0UZI_WU_\ 7H [&BN._P"$%U'_ *&O5/\ OK_Z]'_""ZC_ -#7
MJG_?7_UZ .QHKCO^$%U'_H:]4_[Z_P#KT?\ ""ZC_P!#7JG_ 'U_]>@#L:*X
M[_A!=1_Z&O5/^^O_ *]'_""ZC_T->J?]]?\ UZ .QHKCO^$%U'_H:]4_[Z_^
MO1_P@NH_]#7JG_?7_P!>@#L:*X[_ (074?\ H:]4_P"^O_KT?\(+J/\ T->J
M?]]?_7H [&BN._X074?^AKU3_OK_ .O1_P (+J/_ $->J?\ ?7_UZ .QHKCO
M^$%U'_H:]4_[Z_\ KT?\(+J/_0UZI_WU_P#7H [&BN._X074?^AKU3_OK_Z]
M'_""ZC_T->J?]]?_ %Z #XE?\>^@_P#86@_DU=C7E?C3PK>:=#I)EU^^O/-U
M"*)1,W^K)#?./<8_6NC_ .$%U'_H:]4_[Z_^O0!V-%<=_P (+J/_ $->J?\
M?7_UZ/\ A!=1_P"AKU3_ +Z_^O0!V-%<=_P@NH_]#7JG_?7_ ->C_A!=1_Z&
MO5/^^O\ Z] '8T5QW_""ZC_T->J?]]?_ %Z/^$%U'_H:]4_[Z_\ KT =C17'
M?\(+J/\ T->J?]]?_7H_X074?^AKU3_OK_Z] '8T5QW_  @NH_\ 0UZI_P!]
M?_7H_P"$%U'_ *&O5/\ OK_Z] '8T5QW_""ZC_T->J?]]?\ UZ/^$%U'_H:]
M4_[Z_P#KT =C17'?\(+J/_0UZI_WU_\ 7H_X074?^AKU3_OK_P"O0!V-%<=_
MP@NH_P#0UZI_WU_]>C_A!=1_Z&O5/^^O_KT =C17'?\ ""ZC_P!#7JG_ 'U_
M]>C_ (074?\ H:]4_P"^O_KT =C17'?\(+J/_0UZI_WU_P#7H_X074?^AKU3
M_OK_ .O0!V-%<=_P@NH_]#7JG_?7_P!>C_A!=1_Z&O5/^^O_ *] '8T5QW_"
M"ZC_ -#7JG_?7_UZ/^$%U'_H:]4_[Z_^O0!V-%<=_P (+J/_ $->J?\ ?7_U
MZ/\ A!=1_P"AKU3_ +Z_^O0!V-%<=_P@NH_]#7JG_?7_ ->C_A!=1_Z&O5/^
M^O\ Z] '8T5QW_""ZC_T->J?]]?_ %Z/^$%U'_H:]4_[Z_\ KT =C17'?\(+
MJ/\ T->J?]]?_7H_X074?^AKU3_OK_Z] '8T5QW_  @NH_\ 0UZI_P!]?_7H
M_P"$%U'_ *&O5/\ OK_Z] '8T5QW_""ZC_T->J?]]?\ UZ/^$%U'_H:]4_[Z
M_P#KT =C17'?\(+J/_0UZI_WU_\ 7H_X074?^AKU3_OK_P"O0!V-%<=_P@NH
M_P#0UZI_WU_]>C_A!=1_Z&O5/^^O_KT =C17'?\ ""ZC_P!#7JG_ 'U_]>C_
M (074?\ H:]4_P"^O_KT =C17'?\(+J/_0UZI_WU_P#7H_X074?^AKU3_OK_
M .O0!V-%<=_P@NH_]#7JG_?7_P!>C_A!=1_Z&O5/^^O_ *] '8T5QW_""ZC_
M -#7JG_?7_UZ/^$%U'_H:]4_[Z_^O0!V-%<=_P (+J/_ $->J?\ ?7_UZ/\
MA!=1_P"AKU3_ +Z_^O0!V-%<=_P@NH_]#7JG_?7_ ->C_A!=1_Z&O5/^^O\
MZ] '8T5QW_""ZC_T->J?]]?_ %Z/^$%U'_H:]4_[Z_\ KT =C17'?\(+J/\
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M]#7JG_?7_P!>@#L:*X[_ (074?\ H:]4_P"^O_KT?\(+J/\ T->J?]]?_7H
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M@#IZ*YC_ (1&]_Z&+4/^^O\ Z]'_  B-[_T,6H?]]?\ UZ .GHKF/^$1O?\
MH8M0_P"^O_KT?\(C>_\ 0Q:A_P!]?_7H Z>BN8_X1&]_Z&+4/^^O_KT?\(C>
M_P#0Q:A_WU_]>@#IZ*YC_A$;W_H8M0_[Z_\ KT?\(C>_]#%J'_?7_P!>@#IZ
M*YC_ (1&]_Z&+4/^^O\ Z]'_  B-[_T,6H?]]?\ UZ .GHKF/^$1O?\ H8M0
M_P"^O_KT?\(C>_\ 0Q:A_P!]?_7H Z>BN8_X1&]_Z&+4/^^O_KT?\(C>_P#0
MQ:A_WU_]>@#IZ*YC_A$;W_H8M0_[Z_\ KT?\(C>_]#%J'_?7_P!>@#IZ*YC_
M (1&]_Z&+4/^^O\ Z]'_  B-[_T,6H?]]?\ UZ .GHKF/^$1O?\ H8M0_P"^
MO_KT?\(C>_\ 0Q:A_P!]?_7H Z>BN8_X1&]_Z&+4/^^O_KT?\(C>_P#0Q:A_
MWU_]>@#IZ*YC_A$;W_H8M0_[Z_\ KT?\(C>_]#%J'_?7_P!>@#IZ*YC_ (1&
M]_Z&+4/^^O\ Z]'_  B-[_T,6H?]]?\ UZ .GHKF/^$1O?\ H8M0_P"^O_KT
M?\(C>_\ 0Q:A_P!]?_7H Z>BN8_X1&]_Z&+4/^^O_KT?\(C>_P#0Q:A_WU_]
M>@#IZ*YC_A$;W_H8M0_[Z_\ KT?\(C>_]#%J'_?7_P!>@#IZV+K_ )9_2N _
MX1&]_P"ABU#_ +Z_^O6C<>"-079GQ1J;<=V_^O0!TU%<I_PA=_\ ]#-J7_?7
M_P!>C_A"[_\ Z&;4O^^O_KT =717*?\ "%W_ /T,VI?]]?\ UZ/^$+O_ /H9
MM2_[Z_\ KT =717*?\(7?_\ 0S:E_P!]?_7H_P"$+O\ _H9M2_[Z_P#KT =7
M17*?\(7?_P#0S:E_WU_]>C_A"[__ *&;4O\ OK_Z] '5T5RG_"%W_P#T,VI?
M]]?_ %Z/^$+O_P#H9M2_[Z_^O0!U=%<I_P (7?\ _0S:E_WU_P#7H_X0N_\
M^AFU+_OK_P"O0!U=%<I_PA=__P!#-J7_ 'U_]>C_ (0N_P#^AFU+_OK_ .O0
M!U=%<I_PA=__ -#-J7_?7_UZ/^$+O_\ H9M2_P"^O_KT =717*?\(7?_ /0S
M:E_WU_\ 7H_X0N__ .AFU+_OK_Z] '5T5RG_  A=_P#]#-J7_?7_ ->C_A"[
M_P#Z&;4O^^O_ *] '5T5RG_"%W__ $,VI?\ ?7_UZ/\ A"[_ /Z&;4O^^O\
MZ] '5T5RG_"%W_\ T,VI?]]?_7H_X0N__P"AFU+_ +Z_^O0!U=%<I_PA=_\
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MA=__ -#-J7_?7_UZ/^$+O_\ H9M2_P"^O_KT =717*?\(7?_ /0S:E_WU_\
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M]]?_ %Z/^$+O_P#H9M2_[Z_^O0!U=%<I_P (7?\ _0S:E_WU_P#7H_X0N_\
M^AFU+_OK_P"O0!U=%<I_PA=__P!#-J7_ 'U_]>C_ (0N_P#^AFU+_OK_ .O0
M!U=%<I_PA=__ -#-J7_?7_UZ/^$+O_\ H9M2_P"^O_KT =717*?\(7?_ /0S
M:E_WU_\ 7H_X0N__ .AFU+_OK_Z] '5T5RG_  A=_P#]#-J7_?7_ ->C_A"[
M_P#Z&;4O^^O_ *] '5T5RG_"%W__ $,VI?\ ?7_UZ/\ A"[_ /Z&;4O^^O\
MZ] '5T5RG_"%W_\ T,VI?]]?_7H_X0N__P"AFU+_ +Z_^O0!U=%<I_PA=_\
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MI_WU_P#7H [&BN._X074?^AKU3_OK_Z]'_""ZC_T->J?]]?_ %Z .QHKCO\
MA!=1_P"AKU3_ +Z_^O1_P@NH_P#0UZI_WU_]>@#L:*X[_A!=1_Z&O5/^^O\
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M *&O5/\ OK_Z]'_""ZC_ -#7JG_?7_UZ .QHKCO^$%U'_H:]4_[Z_P#KT?\
M""ZC_P!#7JG_ 'U_]>@#L:*X[_A!=1_Z&O5/^^O_ *]'_""ZC_T->J?]]?\
MUZ .QHKCO^$%U'_H:]4_[Z_^O1_P@NH_]#7JG_?7_P!>@#L:*X[_ (074?\
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M +Z_^O1_P@NH_P#0UZI_WU_]>@#L:*X[_A!=1_Z&O5/^^O\ Z]'_  @NH_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X[XE?\>^@_P#86@_D
MU=C7'?$K_CWT'_L+0?R:NQH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *X[1?^2F>(?^O>#_ -!%=C7':+_R4SQ#_P!>\'_H(H [&BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \\TO_
M )'CQ5_OP?\ H!KH*Y_2_P#D>/%7^_!_Z :Z"@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *V+K_EG]*QZV+K_EG]* *]%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 2M_QX3?Y]*RJU6_X\)O\^E95 !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 36?_'U%_O5?N?\ 7-_GM5"S_P"/
MJ+_>J_<_ZYO\]J (J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ J]:_ZE:HU>M?]2M $M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\0?\
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M@ #BOQL^!/QX\3?L_P#C2+7O#T^Z)\)?:;,Q\B\B!^XX[$<[6'*D^Y!^P/\
MA[+_ -4K_P#+A_\ N6M,PH8JM*U/6/;;[^YEEV(PE&-ZBM/OO]W8_0>BO*OV
M:_CG_P -#?#-/%W]B?V!NNYK7[']K^T_<Q\V_8G7/3%>JU\U4IRI2<)JS1]5
M3J1K04X.Z84445F:!1110 4444 %%%% !7'>/O\ D)>%O^PG'78UQWC[_D)>
M%O\ L)QT =C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QWQ*
M_P"/?0?^PM!_)J[&N.^)7_'OH/\ V%H/Y-78T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<=HO_ "4SQ#_U[P?^@BNQKCM%_P"2F>(?^O>#_P!!
M% '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'GFE_\CQXJ_P!^#_T UT%<_I?_ "/'BK_?@_\ 0#704 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6Q=?\L_I
M6/6Q=?\ +/Z4 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH E;_CPF_P ^E95:K?\ 'A-_GTK*H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":S_ ./J
M+_>J_<_ZYO\ /:J%G_Q]1?[U7[G_ %S?Y[4 14444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5ZU_U*U1J]:_ZE: ):**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *X[X@_\?WA;_L*P_P Z[&N.^(/_ !_>%O\ L*P_SH [&BBB
M@#COA?\ \@74/^PA-_2NQKCOA?\ \@74/^PA-_2NQH **** "BBB@ HHHH *
M*** "N;^)'@6R^)W@36_"NHSW%M8ZM;-:S36I42JK=2I8$9^H-=)10!\8_\
M#K'X:_\ 0S^*_P#O_;?_ !BC_AUC\-?^AG\5_P#?^V_^,5]G45V_7<1_.SA^
MHX;^1'QC_P .L?AK_P!#/XK_ ._]M_\ &*/^'6/PU_Z&?Q7_ -_[;_XQ7V=1
M1]=Q'\[#ZCAOY$>>? OX)Z/\ ? B>%-#O+Z_L5N9+H3:@R-+N?&1E%48X]*]
M#HHKEG.523E)W9UPA&G%0@K)!1114%A1110 4444 %%%% !7'>/O^0EX6_["
M<==C7'>/O^0EX6_["<= '8T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 <=\2O^/?0?^PM!_)J[&N.^)7_ ![Z#_V%H/Y-78T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<=HO_)3/$/_ %[P?^@BNQKCM%_Y*9XA
M_P"O>#_T$4 =C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >>:7_ ,CQXJ_WX/\ T UT%<_I?_(\>*O]^#_T UT%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
ML77_ "S^E8];%U_RS^E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** )6_X\)O\^E95:K?\>$W^?2LJ@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K/
M_CZB_P!ZK]S_ *YO\]JH6?\ Q]1?[U7[G_7-_GM0!%1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7K7_4K5&KUK_J5H
M EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KCOB#_ ,?WA;_L*P_SKL:X[X@_\?WA;_L*P_SH [&B
MBB@#COA?_P @74/^PA-_2NQKCOA?_P @74/^PA-_2NQH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[Q]_R$O"W
M_83CKL:X[Q]_R$O"W_83CH [&BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#COB5_Q[Z#_ -A:#^35V-<=\2O^/?0?^PM!_)J[&@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KCM%_Y*9XA_Z]X/\ T$5V-<=HO_)3
M/$/_ %[P?^@B@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#SS2_\ D>/%7^_!_P"@&N@KG]+_ .1X\5?[\'_H
M!KH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K8NO^6?TK'K8NO^6?TH KT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!*W_'A-_GTK*K5;_CPF_SZ5E4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M-9_\?47^]5^Y_P!<W^>U4+/_ (^HO]ZK]S_KF_SVH BHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KUK_J5JC5ZU_U*
MT 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5QWQ!_P"/[PM_V%8?YUV-<=\0?^/[PM_V%8?YT =C
M1110!QWPO_Y NH?]A";^E=C7'?"__D"ZA_V$)OZ5V- !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'>/O^0EX6_[
M"<==C7'>/O\ D)>%O^PG'0!V-%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% ''?$K_CWT'_ +"T'\FKL:X[XE?\>^@_]A:#^35V- !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_HH/A7_ ,'5M_\ %T?\+S^&_P#T4'PK_P"#JV_^+K\>Z*/[+A_,P_U9H_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#CM6M2E'DYHK5;_Y_I]WF<T:C4^66SV]?Z_K8Q_VO/VUO^&5=<\.Z=_PAO\
MPE']KVTMQYG]J?9/*V,%QCR9-V<]<CI7I'[,_P <_P#AHKX3V/C7^Q/^$?\
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M$S[=S#^]&QW#OP1W-:4XTZ\G3CI+^OZ\B*CG1C[1ZK^OZ\S]Q**3KR*6N4Z
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MU%?+OQ)_X*0?!?X<ZM+IT>IZCXKNH7*2_P#".VRS1(P])9'C1_JC,*;\.?\
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M\/O#_B2:;Q'I>N#^V-+C@N(E5%B?AG9!'( Y0X#-S@]JX_\ X)S_ +37PU^
M_@WQA8^.O$G]AW6H7\,UM']AN;CS$6,J3F*-P.?7%.E'VD93[;>>VOXO[A5)
M>SE&*Z[^6_\ D?J916)K/C70O#OA63Q+JNJVVFZ#' MR]_=OY4:QD @DMC&<
MC ZY.,9KY9\1_P#!4WX+Z'J#VUG#XF\01*<"[TW3HUB;Z">6-O\ QVHL^9QZ
MHJZMS=#[!HKYG^%G_!0_X-_%/6K;2(M5OO#6I73B*WA\06P@65ST7S$9XP2>
M!N89/ KZ8JI1E'="4E+9A17A8_;>^"C>-?\ A$AXT_XJ'^T/[+^Q_P!E7O\
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MB?\ Y<_]O?\ MI7HHHKP#X8**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"5O^/";_/I656JW_'A-_GTK*H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":S_P"/
MJ+_>J_<_ZYO\]JH6?_'U%_O5?N?]<W^>U $5%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ _&OQH_;,_Y.F^)?_88D_D*_4K]J/3;C5/V(?%,-L&:5?#L$Q"]=L8B=_\
MQU364YRGEZFWK9?BM?R-8QBL=RI:7?X-?YGYA? ?X=:O^V+^T=%8^(]8N7EU
M22;4M7U($&41(,L$SD DE448PN1Q@8K[X^,7_!,WX8ZE\,]3A\!:+=:1XPMK
M9I;&X.I2RB[F5<B.43.4 <\97;@D'H,5\G?\$N=4MM/_ &H%@GD$<E[HMW!
M#_&X,<F!_P !C8_A7Z\:A?0:78W-[=2K#:V\;32R-T1%!+$_0 UT8FU.G",7
MRJU_Q:_3T,:#<ZDI2U=_T7^9\&_L'_LJ_&O]GWXA3:GKXTK3O"NI6S0ZEI9U
M#S9BP!,4B+&K(65N/O#Y7;VKR_\ X*H?'#4M8^(EC\,[*Z>'1-)MXKR_AC;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\0?^/[PM_V%8?Y
MUV-<=\0?^/[PM_V%8?YT =C1110!QWPO_P"0+J'_ &$)OZ5V-<=\+_\ D"ZA
M_P!A";^E=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5QWC[_D)>%O^PG'78UQWC[_D)>%O^PG'0!V-%%% !114
M=Q<1VL$DTTBQ0QJ7>1SA54#))/8 4;:L#B?BM\</!'P1T^QO?&NNIHL%]*T-
MOFWEG:1@,G"Q(S8 QDXQR.>16%\,OVIOA?\ &+Q(V@^$/% U;5E@:Y-N;"Z@
M_=J0&.Z6)5.-PXSFOS!_:H^,>H?M,?'20Z-'->Z9#*-*T.SC!)E7?C>!_>D8
MY^FT=JL_L)>(F\*_M3>$!(WEI>//I\@/',D3A1_WV$KWZ.6QG0YZC:E9NWY'
MSM?-)0Q'LZ:3@FDW^?ZV]+G[&4445X!]$%%%% !117E7[3GQHD^ ?P?U;Q;;
M6D-_J$3Q6]I;W#$1O+(P4%L<D 9; QG;C(ZTTFVDMWI]XFTDV]EK]QZ?<7EO
M:O"DT\<+SOY<2R.%,C8)VKGJ< G ]#4U?F_^Q'XZ\7_M$?M27/B[QCJLVIMH
M>E7$UM%C;;VK2LL02.,<*-KOSU.WDD\U^D%=6(P\L,XQD]6K^FYR8;$QQ2E*
M"T3MZZ+7\0HKF?$_Q.\'>"9DA\1>+-#T"9AE8]4U*&V8CU =A5KPOXZ\-^-H
M9)O#OB'2M?AC^_)I=[%<JOU*,<5S<LK<UM#JYHWY;ZFY7.^/OB!H'PO\*WGB
M3Q/J"Z7HMGL\ZZ,3R[=S!% 5%9CEF X!KHJ\G_:8^!MQ^T-\-_\ A$8?$7_"
M-1/>17,UQ]B^U>8J;B$V^8F/F*G.3]WI2C9R2>UU?TOK^ Y746UO9V];:?B2
M_"[]I[X9_&C7Y]%\&^)&UG4H;=KJ2$:?=0A8@RJ6+2Q*O5E&,YYKU.OG#]E+
M]C>W_9CU?Q!J3>)_^$FN]4@BMT;^SOLGD(K%F'^MDW;CL],;>^>/H^NC$1HQ
MG:@VUY_\,CFPTJ\H7Q"2?EV^]A161XE\8:#X+L1>^(-;T[0K,G:+C4KN.WCS
MZ;G(&:;X8\:>'_&UF]WX=UW3-?M4;:T^EWD=RBMZ%D8@&N>SM>VAT\R3LWJ;
M-%87BCQYX:\#PQS>(_$6D^'XI#A)-4O8K96/L789JUX=\4:-XNTU=0T+5K'6
MK!B56ZTZY2>(D=0'0D?K1RNU[:!S*_+?4TZ***0PHKD=4^,'@/0]8.DZEXV\
M.Z?JH;:;&ZU:WBG#'H-C.&S^%=8LBR1AU8,C#(8'((]:=FE=K07,F[)ZCJ*X
M]OC%X!CUH:,WC?PVNKE_*&GG5K<7&\\;?+W[L^V*["AQ:5V@4DVTGL%%%%(8
M4444 %%%5-5U>QT*QEOM2O;?3[*(;I+FZE6*-!ZEF( H MT5S7A?XF^#_'%Q
M+;^'/%>A^()XANDBTO48;ED'J0C$@5TM4XN.C1,9*6J=PHJIJFKV.AV,E[J5
M[;Z?9Q#+W%U*L4:#U+,0!7,:+\9_A]XDU)-.TGQUX:U34)#M2ULM7MYI6/H$
M5R3^5"BY;(')1W9V5%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% ''?$K_CWT'_L+0?R:NQKCOB5_Q[Z#_P!A:#^35V- !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 >(:]^VI\&O#&MW^D:IXP:
MSU*PG>VN;=])OB8Y$8JRY$.#@@\CBO8]'U>S\0:39:II\ZW5A>P)<6\Z9Q)&
MZAE89YY!!K\N_P#@HI\-_P#A#?CH=<@BV6/B2U6[!'3STQ'*/KPC?\#KZZ_X
M)^?$;_A./V?;#3II-]]X=G?39 3SY?WXC]-K;1_N&O;JX&G]1ABZ3=]+_D^G
M?0\J.+FL;+#32MT[]U^!]+5Y!XZ_:X^$WPV\47OAWQ%XM6PUFS*BXMEL+J;R
MRRA@"T<3+G##H>,UZCKFL6OAW1=0U6]D$5G8V\ES-(?X412S'\@:_%95U7]H
M#XW8&YM3\4ZS]?+$LG\D4_DM9Y9@HXVI)5':,5^+V_4TQ^*>$I*45=M_\/\
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MVO;602VUQ$LT4B]&1@"#^((JQ7RS33LSZ%-25T%%%%(84444 %%%% !1110
M4444 %%%% !1110 5QVB_P#)3/$/_7O!_P"@BNQKCM%_Y*9XA_Z]X/\ T$4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OW3NO\ EG]*
M_"ROW3NO^6?TKP<U^Q\_T/A>)_\ ES_V]_[:5Z***\ ^&"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH E;_CPF_SZ5E5
MJM_QX3?Y]*RJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (H^(UYHWQ#\(Z;<:Y-86?\ 9^I:?9H9)Q$KL\<J(.7 +L& R1\IQC)'R_\
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M$0H!]=@_.M*>'BLSY8+1:_>EI_Y,14Q$GE7--ZRT^YMW_P#)3](O^"?W@_\
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MZ;E9!@]<,P[U]R_M_>,O^$0_9D\1QHX2?5Y(=,CYZAWW./\ OA'KY%_X)?\
M@PZU\:M:\0R)NAT32F5&Q]V:9@B_^.++2PF(E6P]:52W*DTE;;3\M45C,/"C
MB*$:=^=M-N]V];7_  9]4_\ !13QE_PBO[-.J6<<OEW&MWEOIZ@'DKN\U_PV
MQD?C7Y]?LI^$?B)X]\::KX?^'=X-&NM2L#;ZGK9+(;.S+JSX=>5+LJC"_,<8
MR!N-?2'_  58\8F34O OA6.3B.*?4YD]V(CC/_CLE>F?\$Q/ D>@_!+5/$DD
M(6[U[4G"RXY:"$;%'_?9F_.L,&U0P-2LU?F?_P!K^C9T8U/$8^G13MRI7_\
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M10 4444 %%%% 'RU_P %$OAM_P )G\"FUR"+??>&[E;P,!SY#X24?3E&_P"
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M>KQ5& /$S@ ?]?1K]MZ_$G6/^2^7O_8S/_Z5&OVVKU<W_P!WPWH_RB>=E_\
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M';_M&"-SAI]'NHT]V!C;^2FON?\ ;+OHK']F7QZ\IP'LEB7W9I44?J:G.O\
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M% '8UXA^VQXBF\+_ +*_Q&O8',<LFF_9 PSD":1(3^DAKV^O&/VR_"LWC/\
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ME0(S_"[D-\PY4*<<D$?,G[./_!.OQ-^T-X&7QMK'BN/PM8:BSO9>;9->7%T
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M2K73CJ4SGJL0C\P_CBOQI\9?$#XD_MY?'*RT:"=C]ON632]':9ELM.@4$EV
MSRJ EY,%CT'\*U^DO[47FZ?^PMXDCL]P*>'+6+KSY?[I6_\ '<U\+_\ !+%(
MF_:;F,@4NN@W1CW=0V^(''O@G]:SITX_6JB>T+V_%_HE]Y4IR^K0:WE:_P"'
M^9M_&+_@EWXC^&7PSU/Q5I?C*U\376EVS7=YI@TYK8^4B[I#$_F/O*@$X*KD
M ]^#WO\ P3+^+WQ%M=<_X077]*U[4O!-U TFFZE<6<SP:=*B[O+\TKM6)U!
M!. P7'WCG](:*B-:2YE+5,N5.+4;:-=?Z_$***;)D1L1UQQ7-*7+%OL:GX]?
MMZ_M/Z_\8OBMJ_@S2;ZXB\&Z+=M80Z?;,0M]<(VUY9 /O_."%!R  ".2:[[P
M3_P2;\6ZYX+M]5UGQK9>'/$,T0FCT?[ TZQ,1E4EF$B[6]=J-@]":^6OA&OV
M[]I7P:-4"OYOBRT^TB7H<W:;\_K7[W5UQC['#0:W?7Y+_,SJ>]B)P>T>GS?^
M1^!O[0*^/=,^(DOAWXCW<U]XD\.VZ:3Y\[^8SP(6>(^9UD!63(8\E2,]*_87
M]BC_ )-5^&W_ &"Q_P"AO7YW_P#!4J&"+]I]6B55DDT.T>8KU+;I1D^^T+^
M%?HA^Q1_R:K\-O\ L%C_ -#>G&3GA6WOS?\ R6OSW,IQ4,2DMN7_ .1T^1^1
M,7_)UB?]CJ/_ $NK]2_^"@7QRUKX'? A[KPY.UEK>M7J:7!?1_>ME9'=W7T;
M:A4'L6R.0*_+2+_DZQ/^QU'_ *75^Q7[3WP!L/VD?A3>^$[J[_LZ\$JW=A?;
M-X@N$!"DKW4AF4CT;/45A)7P5'^M/=O^!O%I8NK?^G[UOQ/RY_94_8[O?VN(
M_$.KW/CRUT.2SN LRS0&^O9G8;C*R&1,*2<;RQR0WI6Y\:O^">OQ/^".OZ)<
M^"Y;_P =Q3R9AU#0K*2"YLYEP09%5F\L=P^_&0>G&>'\>?L9_''X)ZM]M7PQ
MJ=XEJ^Z'6?"[/=*,?Q@Q?O(Q[NJT_P  _MR?''X5WZP_\)??:Q#"^)=.\2J;
MP-C^%FD_>J/976NOF4FG2E:W3^M?\CGLXI^T5[GZM?LKZG\2=0^#^FQ?%72)
MM+\6V;M;/+/+$[WD0 ,<S>6Q 8@[2#@DH3CFO@3_ (*'?M8:]XX^(FI?"_PO
M?7%GX9TJ7['?I9N0VI771T<CDQH?E"="P).?EQ]Q?LB_M36'[47@2ZU(:>-'
MU_2Y5M]2L%??&&924DC8\[&PW!Y!4CG )_'?Q%)K5_\ ';4WTWY_$4WB24VW
MF[.;HW1V9\SY?OX^]QZ\5BX<^+C"HO.R^7^=_4TC-0PTI0>NVO3?_*WH?6WA
M_P#X)+^+M4\!Q:G?^-=/TKQ--!YRZ(UB\D2,1D1R7 <$'L<1L <XSUKSO]DW
M]HCQ?^RQ\:H_ _B:ZN$\+MJ1TO5](N)"\=E+O*&>+G"E6Y;;PRYZ_*1[?_QL
M(_S_ ,(]7AOC;]B/]I[XB>+-2\2^(/!?V_6]1E\^ZNAJFEQ>8^ ,[4F51P!T
M K:$VJMY-<CW7]?/\+&<H)T^57YNY^IWQ\U?QMH_PEU^?X<Z0VM>,'A$5A"L
MD2^6S$ S?O&"G8I+!><D 8-?F#\*/V!?BU\>O'&O7'C^;4_!K0D2W6L:]:R7
M,]Y*^<",%U$N .6WX' [U^CGQD^.]K^S7\";3Q5XHM7NM6CMK>TCTV.50]Q>
MM&,Q[^0 "KDL,X"DC/ /Y\0?MD?M/?M*>(KG2_A]#+9ICY[+PWIZ;8$)(5I+
MB4,4SC&XNH)' KFIQ<:LU#WK:7_K[_NOH;2ES4H.?NWUM_7W??;4X+]K3]B_
M5OV4HM!U/_A)H?$FE:E*T,=U':M:30S( V"F]Q@CD,&['@<9_0#_ ()R?&+7
M?BY\ W_X2.]FU/5-#U!]-^VW#%I9H1&CQEV/+, Y7)Y(49YYK\[?VDO@3\9_
M /A_1_%OQ<U2>]N-0N6L[>'4-8;4+J,A2YR0715P.S^G%?:'_!)&%5^#7C&4
M9W/KVT_06\6/YFNF%Y4:BD[V_#5?H_Q,9V52FXJU_P =&?*/[;7QL\1_&_\
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M BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "KUK_J5JC5ZU_P!2M $M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Q'Q:^"O@SXY:#;:+XWT;^V
M],MK@7<4'VJ:WVRA64-NB=">&88)QS5'X/\ [/7P_P#@+'JD?@30/["34S&U
MV/MEQ<>84W;/]=(^,;VZ8ZUZ+133<4TNHFE*U^@4444AA1110 4444 %%%%
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M !=\+^&&,DR7UW&EPY))6W0;I#GVC0X^@%?MI;V\=I;Q00HL4,2A$11@*H&
M!^%>7_#?]E[X8_"/Q'_;WA/PNNEZMY+6XN6O;F<A&QN $LC $X'(&<9&>37J
ME=N9X^.-<%3345W[_P!6.++\%+"\SFTV^W;^OT"O._VBO^2"_$'_ + =Y_Z*
M:O1*SO$7A_3_ !9H.H:+JMO]JTS4('MKF#>R>9&X(9=RD$9!Z@@UXA[,7RR3
M/R2_89_Y.G\#_P"_=?\ I)-7Z_5X_P"!?V2/A/\ #7Q58^)/#?A3^SM:L2YM
M[K^T;N79N1D;Y7E93E68<@]:]@KV<TQE/&U(SIIJRMKZM_J>1E^$GA8R4VM>
MQ\>_\%.?^2*^'_\ L.1_^B):X'_@E;_Q]?$G_<T_^=S7V?\ $[X1>$OC)HMO
MI'C#2?[7T^WG%S'#]IF@VR!2H;,3J3PQX)QS5#X5_ 3P)\$VU)O!>A?V,VI"
M,77^F3S^9Y>[9_K9&QC>W3'7FBCC*=/ U,,T^:3^73_(K$86=7$TZT6K17ZM
M_J>@4445XQZ84444 %%%% 'XDZQ_R7R]_P"QF?\ ]*C7[;5XC-^Q;\&KC7WU
MN3P=NU-[HWC3_P!J7HS,7WEMOG;?O<XQCVKVZO9QV,IXJE2A!.\%K?Y?Y'EX
M7"SH5JM235I/3[W_ )GP7_P4G^!NI:I-IGQ(T>S>Z@M;;[%JPA4LT2*Q,<Q'
M]WYF4GM\M>1_ #]O37/@A\.U\(S^&[?Q':VK.=/GDO&MVMP[%BC#8V]0Q) &
MTC)&>F/U-DC2:-XY$62-P596&00>H(KQ?7OV,/@MXDU)[^\\!V4=PYR197%Q
M:1Y_ZYQ2*GZ5IA<?2C0^JXJ'-'I;?]/S\B<3@ZDJRQ&'ERR_K^MO,_-GX:^"
M_$W[6GQ\9[M'GDU.]^W:Q>1*1':V^[+D>@V_(@SUVBOUS\4^#K#Q5X)U3PO<
M1A--OK&2P9%'"1LA3CZ \?2H_ _P[\,_#71_[+\+:'9:'8YW-'9Q!3(V,;G;
MJ[8[L2:Z*N?'XU8OEITX\L([(UP>%EAI2JSE><MW_7XGXN+'XQ_9-^.$$TUK
M]EU[0KDO&LZGR;N$Y7((^]'(A(R#W/0BO1OVD?VX-9_: \&V_AB'P]#X:TOS
M5GO MX;E[EEY49V(%4'G&"<@<\<_IA\0?A/X/^*U@EGXM\/6.N0QY\IKF/\
M>19Z[)!ADS_LD5Q/A/\ 8_\ @[X)U:+4M*\#60O(F#1R7DTUX$8'(95F=U!!
MZ$#(KTXYIAZJA4Q-.\X[-?\ #_/K8X99?6I.<<-.T9;I_P!/]#R'_@G/\#[_
M , ^!M3\8ZU:/::CXB\M;2&88=+1,E7([;V;/T53WKEO^"DWP.U'78=)^(VC
M6;W:Z?;FRU585W-'"&+1S$#^$%G!/;*GIFONJFNBR(R.H=&&"K#((]*\J6/J
M2Q?UM;KIY6M;[OQU/0IX.$,,\,]GN_/>_P!_^1^5O[//[=VM_ GP"WA.?PY!
MXEL8'>2PD>\:W>VWDLRM\C;UW$D#Y3R>>F//_!'A;Q3^US\?'>>-I;O5[S[9
MJEU"A$5G;Y 9N<X"J J@GD[17Z5^(OV,_@QXHU-[^^\!V27#G+?8IY[2,GU\
MN&15_2O1/ GPW\+_  QTDZ9X5T*RT.S8AG2TB"F1@,!G;[SG'=B37KO-<-3E
M*O1I6J2ZO;^ODKGF?V=B)15"=3]VG\_Z^>ANZ?8P:786UE:QB*VMXEABC7HJ
M*  /P %6***^6;;=V?0I**L@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "N.T7_DIGB'_KW@_P#0178UQVB_\E,\0_\ 7O!_Z"* .QIDT,=Q#)%*BR12
M*5=&&0P(P01Z4^BDTFK,#\9/VQ_V1?$'[./CFYU_0;6YF\"W5S]HT_4K;<3I
M[ELB&1ARC*?NL?O#'.<@>F_#'_@K!XO\*^&X--\6^$;3QC>6Z"--2BOS8RR
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#Q7J57*+B[21$9*2N@HHKRC]HG]I+PS^S-X8TW7?%%CJU_:7]Y]BB32(8I)
M^QGRPDD08PAZ$G..*@NUSU>BO(/V<_VGO"W[3FCZQJ7A:PUBP@TNX2WF75X8
MHV9F7<"OERN",#N17K]7*+B[2(C)25T%%%%24%%%?*'Q,_X*2_#/X5^/]<\(
M:MH?BRXU+2+EK6>6SM+5H688Y0M<*2.>X%$?>DH+=ALN9['U?14%C=)?V<%S
M&&$<T:R*&Z@$9&?SK)USQUX?\-:QH^DZIK%I9:KK$WD:?8R2#SKEP"2$3J0
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M*-F,@8KL\N5\CY3G..U1?M'?M5>&?V88-%N/%.B^(-0M-6:2.&YT>WAEC1T
M)1S),A!(;(P#G!]*N47!J,M'_F3%J:O'7_@;GM%%8/@3QQH_Q)\'Z3XGT"Z%
M[H^J6ZW%O,!@[3U##LP.01V((K>HE%Q;B]T$9*236P4445(PHHHH **** "B
MBB@ HHHH **** "N.^(/_']X6_["L/\ .NQKCOB#_P ?WA;_ +"L/\Z .QHH
MHH X[X7_ /(%U#_L(3?TKL:X[X7_ /(%U#_L(3?TKL: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.\??\ (2\+
M?]A..NQKCO'W_(2\+?\ 83CH [&BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#COB5_P >^@_]A:#^35V-<=\2O^/?0?\ L+0?R:NQH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *X[1?^2F>(?^O>#_T$5V-<=HO_
M "4SQ#_U[P?^@B@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?]$^\5?^"6Y_^(H]I#N@^L4?YU]Z.'HKN/\ A1GQ(_Z)]XJ_\$MS_P#$4?\
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M$C_HGWBK_P $MS_\11_PHSXD?]$^\5?^"6Y_^(H]I#N@^L4?YU]Z.'HKN/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8O\ B_*/_I*.3#_P_F_S85X7^UO\*?AG\6O!>CZ=\4/&'_"&:1;:A]HM;O\
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MPT*W6-#T!>25V(^N1^5=F+]^NJ3V3M]R;?WM?BSFPONTG5Z[_>TE]R_(X?\
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M[PWJ*A=9D#W^HJ.=EQ*=Q3WV+M3/<K733<OJS=3KM]^GX?GJ854OK$5#IO\
M=K^-ON/6_$&O:?X5T._UC5KN.QTRP@>YN;F8X2*-02S'Z 5^'?[5G[0FI?M)
M?%2_\1.LT.@69^R:39MG$%N"<%AT#N1N;\NBBOJS_@I?^TY-KVK1_!GPE/).
MJRQMKC6OS&>8D&*T&.N#AF _BVCL17&_M ?LSQ?LZ?L.:"NH0H?&&M>([2ZU
M:7 )B/V:YV6X/H@)SZL6/3%<M-*WMY;72CYW=K_UT]4=,M_8QW:;?DDKV_K]
M&>I?\$A/^15^)7_7[9?^BY:^D/VW/A+'\7OV<?%.GI!YVJ:;"=6T\@9830@L
M0/=DWI_P*OF__@D)_P BK\2O^OVR_P#1<M?H++$D\3QR*'C<%65AD$'J*WQT
M7*32WM&WK96_$YL%+EBF]KR_]*9^;?\ P2D^.<L>H:W\*]2N&:"5&U72 Y^X
MXP)XA]05<#_9<]Z_2>OPY^'&I2? ?]LO3A 6@AT3Q8^G2#I_HYN&@<'ZQLU?
MN-5UFJE.%9?:7Y6_1K[@A%TZDZ+Z/_/]4W\PHHHKD.@**** "BBB@ HHHH *
M*** "BBB@ KCOB#_ ,?WA;_L*P_SKL:X[X@_\?WA;_L*P_SH [&BBB@#COA?
M_P @74/^PA-_2NQKCOA?_P @74/^PA-_2NQH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[Q]_R$O"W_83CKL:X
M[Q]_R$O"W_83CH [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#COB5_Q[Z#_ -A:#^35V-<=\2O^/?0?^PM!_)J[&@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KCM%_Y*9XA_Z]X/\ T$5V-<=HO_)3/$/_ %[P
M?^@B@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#SS2_\ D>/%7^_!_P"@&N@KG]+_ .1X\5?[\'_H!KH* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K8NO^
M6?TK'K8NO^6?TH KT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!*W_'A-_GTK*K5;_CPF_SZ5E4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!-9_\?47^
M]5^Y_P!<W^>U4+/_ (^HO]ZK]S_KF_SVH BHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDL!-QWYG^<S5J+QD%+:R_P#;3X&\:?ME?'3]J#XC1>&O =]?Z#!J,YBTW1-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7':+_R4SQ#_ ->\'_H(KL:X[1?^2F>(?^O>#_T$4 =C
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >>:7_R/'BK_?@_] -=!7/Z7_R/'BK_ 'X/_0#704 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6Q=?\L_I6/6Q=?\
ML_I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"5O^/";_/I656JW_'A-_GTK*H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":S_P"/J+_>J_<_ZYO\
M]JH6?_'U%_O5?N?]<W^>U $5%%% !1110 4444 %%%% !1110 4444 %%%%
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MUX3U34KI_,GO+S0[6::5C_$[LA+'W)KNZ*+N_-U%TL-CC2&-8XT5(U 5548
M Z "N8\6?"GP3X^N(KCQ/X/T#Q'<1#;'+JVF073(/0&120*ZFBEUN/;0R=#\
M)Z'X7TLZ9HVC:?I.FG(-G8VL<,)SP?D4 <_2N:T7X#?#/PWJMMJ>D?#OPGI>
MI6K^9!>66B6T,T3?WD=4!4^X-=W13N[WZBLK6Z"$!@01D'J*XA?@7\-UU?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N.\??\A+PM_P!A..NQKCO'W_(2\+?]A..@#L:*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ..^)7_'OH/_86@_DU=C7'?$K_ (]]!_["
MT'\FKL: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.T7_DIGB'_
M *]X/_0178UQVB_\E,\0_P#7O!_Z"* .QHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** //-+_ .1X\5?[\'_H!KH*
MY_2_^1X\5?[\'_H!KH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K8NO\ EG]*QZV+K_EG]* *]%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 2M_QX3?Y]*RJ
MU6_X\)O\^E95 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 36?_ !]1?[U7[G_7-_GM5"S_ ./J+_>J_<_ZYO\ /:@"
M*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *O6O^I6J-7K7_ %*T 2T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5QWQ!_X_O"W_85A_G78UQW
MQ!_X_O"W_85A_G0!V-%%% ''?"__ ) NH?\ 80F_I78UQWPO_P"0+J'_ &$)
MOZ5V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7'>/O^0EX6_["<==C7'>/O^0EX6_["<= '8T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <=\2O^/?0?^PM!_)J[&N.^)7_ ![Z
M#_V%H/Y-78T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=HO_)3
M/$/_ %[P?^@BNQKCM%_Y*9XA_P"O>#_T$4 =C1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>:7_ ,CQXJ_WX/\
MT UT%<_I?_(\>*O]^#_T UT% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5L77_ "S^E8];%U_RS^E %>BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )6_X\)O
M\^E95:K?\>$W^?2LJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** )K/_CZB_P!ZK]S_ *YO\]JH6?\ Q]1?[U7[G_7-
M_GM0!%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %7K7_4K5&KUK_J5H EHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCOB#_ ,?WA;_L*P_S
MKL:X[X@_\?WA;_L*P_SH [&BBB@#COA?_P @74/^PA-_2NQKCOA?_P @74/^
MPA-_2NQH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *X[Q]_R$O"W_83CKL:X[Q]_R$O"W_83CH [&BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#COB5_Q[Z#_ -A:#^35V-<=\2O^
M/?0?^PM!_)J[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCM%_
MY*9XA_Z]X/\ T$5V-<=HO_)3/$/_ %[P?^@B@#L:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SS2_\ D>/%7^_!
M_P"@&N@KG]+_ .1X\5?[\'_H!KH* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K8NO^6?TK'K8NO^6?TH KT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!*W_'
MA-_GTK*K5;_CPF_SZ5E4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!-9_\?47^]5^Y_P!<W^>U4+/_ (^HO]ZK]S_K
MF_SVH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "KUK_J5JC5ZU_U*T 2T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCOL/CC_H(Z3_ -^V_P */L/CC_H(Z3_W[;_"NQHH X[[#XX_Z".D_P#?MO\
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MC[#XX_Z".D_]^V_PKL:* ..^P^./^@CI/_?MO\*/L/CC_H(Z3_W[;_"NQHH
MX[[#XX_Z".D_]^V_PH^P^./^@CI/_?MO\*[&B@#COL/CC_H(Z3_W[;_"C[#X
MX_Z".D_]^V_PKL:* ..^P^./^@CI/_?MO\*/L/CC_H(Z3_W[;_"NQHH X[[#
MXX_Z".D_]^V_PH^P^./^@CI/_?MO\*[&B@#COL/CC_H(Z3_W[;_"C[#XX_Z"
M.D_]^V_PKL:* ..^P^./^@CI/_?MO\*/L/CC_H(Z3_W[;_"NQHH X[[#XX_Z
M".D_]^V_PH^P^./^@CI/_?MO\*[&B@#COL/CC_H(Z3_W[;_"C[#XX_Z".D_]
M^V_PKL:* ..^P^./^@CI/_?MO\*/L/CC_H(Z3_W[;_"NQHH X[[#XX_Z".D_
M]^V_PH^P^./^@CI/_?MO\*[&B@#COL/CC_H(Z3_W[;_"C[#XX_Z".D_]^V_P
MKL:* ..^P^./^@CI/_?MO\*/L/CC_H(Z3_W[;_"NQHH X[[#XX_Z".D_]^V_
MPH^P^./^@CI/_?MO\*[&B@#COL/CC_H(Z3_W[;_"C[#XX_Z".D_]^V_PKL:*
M ..^P^./^@CI/_?MO\*/L/CC_H(Z3_W[;_"NQHH X[[#XX_Z".D_]^V_PH^P
M^./^@CI/_?MO\*[&B@#COL/CC_H(Z3_W[;_"C[#XX_Z".D_]^V_PKL:* /'K
M&W\1'Q1KRQW5D+Q6B^T.R'8QVG;MX]*U_LOBW_G]T[_OAO\ "I]+_P"1X\5?
M[\'_ * :Z"@#F/LOBW_G]T[_ +X;_"C[+XM_Y_=._P"^&_PKIZ* .8^R^+?^
M?W3O^^&_PH^R^+?^?W3O^^&_PKIZ* .8^R^+?^?W3O\ OAO\*/LOBW_G]T[_
M +X;_"NGHH YC[+XM_Y_=._[X;_"C[+XM_Y_=._[X;_"NGHH YC[+XM_Y_=.
M_P"^&_PH^R^+?^?W3O\ OAO\*Z>B@#F/LOBW_G]T[_OAO\*/LOBW_G]T[_OA
MO\*Z>B@#F/LOBW_G]T[_ +X;_"C[+XM_Y_=._P"^&_PKIZ* .8^R^+?^?W3O
M^^&_PH^R^+?^?W3O^^&_PKIZ* .8^R^+?^?W3O\ OAO\*/LOBW_G]T[_ +X;
M_"NGHH YC[+XM_Y_=._[X;_"C[+XM_Y_=._[X;_"NGHH YC[+XM_Y_=._P"^
M&_PH^R^+?^?W3O\ OAO\*Z>B@#F/LOBW_G]T[_OAO\*/LOBW_G]T[_OAO\*Z
M>B@#F/LOBW_G]T[_ +X;_"C[+XM_Y_=._P"^&_PKIZ* .8^R^+?^?W3O^^&_
MPH^R^+?^?W3O^^&_PKIZ* .8^R^+?^?W3O\ OAO\*/LOBW_G]T[_ +X;_"NG
MHH YC[+XM_Y_=._[X;_"C[+XM_Y_=._[X;_"NGHH YC[+XM_Y_=._P"^&_PH
M^R^+?^?W3O\ OAO\*Z>B@#F/LOBW_G]T[_OAO\*/LOBW_G]T[_OAO\*Z>B@#
MF/LOBW_G]T[_ +X;_"C[+XM_Y_=._P"^&_PKIZ* .8^R^+?^?W3O^^&_PH^R
M^+?^?W3O^^&_PKIZ* .8^R^+?^?W3O\ OAO\*/LOBW_G]T[_ +X;_"NGHH Y
MC[+XM_Y_=._[X;_"C[+XM_Y_=._[X;_"NGHH YC[+XM_Y_=._P"^&_PK1N+/
MQK\F[4-+/'&(V_PK6K8NO^6?TH XO['XR_Y_],_[]M_A1]C\9?\ /_IG_?MO
M\*ZRB@#D_L?C+_G_ -,_[]M_A1]C\9?\_P#IG_?MO\*ZRB@#D_L?C+_G_P!,
M_P"_;?X4?8_&7_/_ *9_W[;_  KK** .3^Q^,O\ G_TS_OVW^%'V/QE_S_Z9
M_P!^V_PKK** .3^Q^,O^?_3/^_;?X4?8_&7_ #_Z9_W[;_"NLHH Y/['XR_Y
M_P#3/^_;?X4?8_&7_/\ Z9_W[;_"NLHH Y/['XR_Y_\ 3/\ OVW^%'V/QE_S
M_P"F?]^V_P *ZRB@#D_L?C+_ )_],_[]M_A1]C\9?\_^F?\ ?MO\*ZRB@#D_
ML?C+_G_TS_OVW^%'V/QE_P _^F?]^V_PKK** .3^Q^,O^?\ TS_OVW^%'V/Q
ME_S_ .F?]^V_PKK** .3^Q^,O^?_ $S_ +]M_A1]C\9?\_\ IG_?MO\ "NLH
MH Y/['XR_P"?_3/^_;?X4?8_&7_/_IG_ '[;_"NLHH Y/['XR_Y_],_[]M_A
M1]C\9?\ /_IG_?MO\*ZRB@#D_L?C+_G_ -,_[]M_A1]C\9?\_P#IG_?MO\*Z
MRB@#D_L?C+_G_P!,_P"_;?X4?8_&7_/_ *9_W[;_  KK** .3^Q^,O\ G_TS
M_OVW^%'V/QE_S_Z9_P!^V_PKK** .3^Q^,O^?_3/^_;?X4?8_&7_ #_Z9_W[
M;_"NLHH Y/['XR_Y_P#3/^_;?X4?8_&7_/\ Z9_W[;_"NLHH Y/['XR_Y_\
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M;_S^Z=_WPW^%'V7Q;_S^Z=_WPW^%=/10!S'V7Q;_ ,_NG?\ ?#?X4?9?%O\
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M^%=/10!S'V7Q;_S^Z=_WPW^%'V7Q;_S^Z=_WPW^%=/10!S'V7Q;_ ,_NG?\
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M#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\
M"NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@
MCI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_
MZ".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQH
MH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_
M '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D
M_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[
M[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;
M_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?
MMO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX
M_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[
M#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\
M"NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@
MCI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_
MZ".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQH
MH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_
M '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D
M_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[
M[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;
M_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?
MMO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX
M_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[
M#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\
M"NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@
MCI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_
MZ".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQH
MH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_
M '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D
M_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[
M[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;
M_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?
MMO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX
M_P"@CI/_ '[;_"C[#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"C[
M#XX_Z".D_P#?MO\ "NQHH X[[#XX_P"@CI/_ '[;_"L+Q%;^(8=6\-G6+JRG
MA_M.'8MLA!#;AUR.F*].KCOB#_Q_>%O^PK#_ #H [&BBB@#COA?_ ,@74/\
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M** "BBB@#SS2_P#D>/%7^_!_Z :Z"N?TO_D>/%7^_!_Z :Z"@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V+K_ )9_2L>M
MBZ_Y9_2@"O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% $K?\>$W^?2LJM5O^/";_/I650 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $UG_P ?47^]5^Y_
MUS?Y[50L_P#CZB_WJOW/^N;_ #VH BHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "KUK_J5JC5ZU_P!2M $M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<=\0?^/[PM_V%8?YUV-<=\0?^/[PM_V%8?YT =C1110!QWPO_P"0
M+J'_ &$)OZ5V-<=\+_\ D"ZA_P!A";^E=C0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5QWC[_D)>%O^PG'78UQW
MC[_D)>%O^PG'0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M''?$K_CWT'_L+0?R:NQKCOB5_P >^@_]A:#^35V- !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7':+_R4SQ#_P!>\'_H(KL:X[1?^2F>(?\ KW@_
M]!% '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'GFE_P#(\>*O]^#_ - -=!7/Z7_R/'BK_?@_] -=!0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;%U_P L
M_I6/6Q=?\L_I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@"5O^/";_/I656JW_'A-_GTK*H **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":S_X^HO\
M>J_<_P"N;_/:J%G_ ,?47^]5^Y_US?Y[4 14444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5ZU_U*U1J]:_ZE: ):***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *X[X@_P#']X6_["L/\Z[&N.^(/_']X6_["L/\Z .QHHHH X[X
M7_\ (%U#_L(3?TKL:X[X7_\ (%U#_L(3?TKL: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.\??\A+PM_V$XZ[&
MN.\??\A+PM_V$XZ .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH X[XE?\>^@_P#86@_DU=C7'?$K_CWT'_L+0?R:NQH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *X[1?^2F>(?^O>#_ -!%=C7':+_R4SQ#_P!>
M\'_H(H [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \\TO_ )'CQ5_OP?\ H!KH*Y_2_P#D>/%7^_!_Z :Z"@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V+K
M_EG]*QZV+K_EG]* *]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 2M_QX3?Y]*RJU6_X\)O\^E95 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 36?_'U%
M_O5?N?\ 7-_GM5"S_P"/J+_>J_<_ZYO\]J (J*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J]:_ZE:HU>M?]2M $M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<=\0?\ C^\+?]A6'^==C7'?$'_C^\+?]A6'^= '8T444 <=
M\+_^0+J'_80F_I78UQWPO_Y NH?]A";^E=C0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QWC[_D)>%O^PG'78UQ
MWC[_ )"7A;_L)QT =C1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!QWQ*_X]]!_P"PM!_)J[&N.^)7_'OH/_86@_DU=C0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5QVB_P#)3/$/_7O!_P"@BNQKCM%_Y*9XA_Z]
MX/\ T$4 =C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >>:7_P CQXJ_WX/_ $ UT%<_I?\ R/'BK_?@_P#0#704
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
MQ=?\L_I6/6Q=?\L_I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"5O\ CPF_SZ5E5JM_QX3?Y]*RJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL_
M^/J+_>J_<_ZYO\]JH6?_ !]1?[U7[G_7-_GM0!%1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %7K7_4K5&KUK_J5H EH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KCOB#_P ?WA;_ +"L/\Z[&N.^(/\ Q_>%O^PK#_.@#L:*
M** ..^%__(%U#_L(3?TKL:X[X7_\@74/^PA-_2NQH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[Q]_R$O"W_83
MCKL:X[Q]_P A+PM_V$XZ .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH X[XE?\>^@_\ 86@_DU=C7'?$K_CWT'_L+0?R:NQH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *X[1?\ DIGB'_KW@_\ 0178UQVB_P#)
M3/$/_7O!_P"@B@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#SS2_^1X\5?[\'_H!KH*\B^,6I7>CZ%\1;NPNI
MK*[C>QV3V\AC=<RH#A@<C()'XU\S_P#"R?%W_0TZU_X,)O\ XJOI,MR2IF5%
MUH32L[?@G^I\;G/$U')L1'#U*;DVKZ-=VOT/O6BO@K_A9/B[_H:=:_\ !A-_
M\51_PLGQ=_T-.M?^#";_ .*KU?\ 52M_S]7W,\'_ %\PW_/B7WH^]:*^"O\
MA9/B[_H:=:_\&$W_ ,51_P +)\7?]#3K7_@PF_\ BJ/]5*W_ #]7W,/]?,-_
MSXE]Z/O6BO@K_A9/B[_H:=:_\&$W_P 51_PLGQ=_T-.M?^#";_XJC_52M_S]
M7W,/]?,-_P ^)?>C[UHKX*_X63XN_P"AIUK_ ,&$W_Q5'_"R?%W_ $-.M?\
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M%W_0TZU_X,)O_BJ/]5*W_/U?<P_U\PW_ #XE]Z/O6BO@K_A9/B[_ *&G6O\
MP83?_%4?\+)\7?\ 0TZU_P"#";_XJC_52M_S]7W,/]?,-_SXE]Z/O6BO@K_A
M9/B[_H:=:_\ !A-_\51_PLGQ=_T-.M?^#";_ .*H_P!5*W_/U?<P_P!?,-_S
MXE]Z/O6BO@K_ (63XN_Z&G6O_!A-_P#%4?\ "R?%W_0TZU_X,)O_ (JC_52M
M_P _5]S#_7S#?\^)?>C[UK8NO^6?TK\\O^%D^+O^AIUK_P &$W_Q5/;XG^,F
MZ^+=</UU*;_XJC_52M_S]7W,/]?,-_SXE]Z/T"HK\_/^%F^,/^AKUS_P8S?_
M !5'_"S?&'_0UZY_X,9O_BJ/]5*W_/U?<P_U\PW_ #XE]Z/T#HK\_/\ A9OC
M#_H:]<_\&,W_ ,51_P +-\8?]#7KG_@QF_\ BJ/]5*W_ #]7W,/]?,-_SXE]
MZ/T#HK\_/^%F^,/^AKUS_P &,W_Q5'_"S?&'_0UZY_X,9O\ XJC_ %4K?\_5
M]S#_ %\PW_/B7WH_0.BOS\_X6;XP_P"AKUS_ ,&,W_Q5'_"S?&'_ $->N?\
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MKG_@QF_^*H_U4K?\_5]S#_7S#?\ /B7WH_0.BOS\_P"%F^,/^AKUS_P8S?\
MQ5'_  LWQA_T->N?^#&;_P"*H_U4K?\ /U?<P_U\PW_/B7WH_0.BOS\_X6;X
MP_Z&O7/_  8S?_%4?\+-\8?]#7KG_@QF_P#BJ/\ 52M_S]7W,/\ 7S#?\^)?
M>C] Z*_/S_A9OC#_ *&O7/\ P8S?_%4?\+-\8?\ 0UZY_P"#&;_XJC_52M_S
M]7W,/]?,-_SXE]Z/T#HKY=_9=\8:]X@^(&H6^J:WJ.I6ZZ9)(L5Y=R2H&$L0
M# ,2,X)&?<U]15\QF&"EE]=T).[M<^WRG,X9MA5B81<5=JS\@HHHKS3V0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH E;_CPF_P ^
ME95:K?\ 'A-_GTK*H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@":S_ ./J+_>J_<_ZYO\ /:J%G_Q]1?[U7[G_ %S?
MY[4 14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !5ZU_U*U1J]:_ZE: ):*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ..^)7_'OH/\ V%H/Y-78UQWQ*_X]]!_["T'\FKL: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N.T7_DIGB'_KW@_P#0178UQVB_\E,\0_\
M7O!_Z"* .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /G;XY?\ (K?$G_?L/_1R5\FU]9?'+_D5OB3_ +]A_P"C
MDKY-K]2X6_W*?^)_E$_#..O^1E3_ ,"_]*D%%%%?8GYT%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'M_[(O_ "4C4O\
ML$R?^CH:^N:^1OV1?^2D:E_V"9/_ $=#7US7Y+Q)_P C!^B/W[@S_D4Q_P 4
M@HHHKY8^Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"5O^/";_/I656JW_'A-_GTK*H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@":S_X^HO\ >J_<_P"N;_/:J%G_ ,?4
M7^]5^Y_US?Y[4 14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5ZU_U*U1J]:_ZE: ):*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX0WEMXCNI=1U?0+L69OIF+23PL@:,NQ^\P^923R0H)YR:UJ8+EH.O":DEO\
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MOAEAX+FFG+JET]0P^*>(FU&#45LWU]#7HHHKA.\**** "BBB@ HHHH ****
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MF4'H:^D?V#_VLM?O/&5M\._&6JSZQ9Z@K+I=]>R&2:"903Y+.>61@"!DD@@
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M>U1O]J8B(?\ H=<><TX.K!15IR6J7=[?/_@'1E4G[Z;O!/1OMU/R T_1=?\
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M=G?U2_5?YGZJT445\B?2A1110 4444 %%%% !1110 4444 %<=HO_)3/$/\
MU[P?^@BNQKCM%_Y*9XA_Z]X/_010!V-<O\4O^28^+_\ L#WG_HEZZBN7^*7_
M "3'Q?\ ]@>\_P#1+USXC^#/T?Y&U'^+'U1^!/@;P/K?Q)\6:;X9\.67]HZW
MJ,ABM;7S4B\Q@I;&YV51P#U(KVVX_P""?'[05C"T[?#^3$?S?N=6L7?CT59R
M2?H*R?V&_P#D[#X<?]A!O_1,E?N!>7UOIUN]Q=W$5K @RTLSA%4>I)X%>O5E
M[."DNM_PM_F>;37/-Q?E^I^'/PA_:3^*'[,?CA8H[_5(X+&?R=1\+ZN\@A<
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M?[2WQ8O?@=\$/%'C;3K&#4;[2XHS#;W+,L;/),D0+8Y(&_. 1G&,C.:^._\
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MY2Y5=F\8N3LCU:BOQ;\)>%_CG^W]XPU5SKDFH6]H1)<3:G=O!IECNSL1(T#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\JW?^";>D_\ "'_LZ>*_%4R8^UZA/.NXX#16\*@'_OKS!^%?/7_!2[Q>=?\
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M[4W[3W_#-.F^'[O_ (1K_A(_[6EEBV?;_LOE;%4YSY3[L[O;I7SS_P /5?\
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MKTU'^O=?_#FE"3E1JW_KWE_PQ]N?L)_\FE_#G_KRE_\ 2B6O+OVK/^"BVD_
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M[,/[17Q^^%OPK@T;X<?"A?$_AQKN:<:H/#NH7AEE8@.#+#(J';M"X R,<U]
M_P#!0[PC;_M!?L[>$_BOX.274;+2=]V3Y161K&8 -(5ZC:R(2#T!8G&#7EG[
M '[;7A/X+^#;_P "^/[F?3-,6Z>]T_5([>2=$W@;XG6,,X^8;@0I^\V<<9K#
MKEIU*;W3>G?6_P"7Y6#$/FE3FMG^&EOS_.YY[^T?K'[0_P"U!+H4OBGX+:SI
M\VCK,L$FC^%M2C9UDV$A_,,F0"@QC'4]:^[_ /@G7H/B;PK^S99:-XIT34]
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M .":-A#9_LG:#+$@5[J^O9I6Q]YA.R9_[Y11^%?-G_!7C_D>/AW_ -@ZZ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>H$>5Z_W>*_6'_@H-_R:'X__ .N=I_Z605^35YXPU;5/VA;/QAXILVTN_O\
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MQG*I%:O=GS#\3/\ @GS\/?BMX\UCQ;K6N^*DU/5)O.FCM;NV6)2%"A5#6[$
M!0.2>E?2]C90Z;8V]I;IY=O;QK%&@_A50 !^0J>BB56<H1IMZ+8(T:<9RJ)>
M\]V>2_&K]EOX>?'QH[CQ1I##58D\N/5;"0P72KV4L,AP.P<,!DXQFO*_#/\
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M=_ XD@EUZ=9EB8="(T1$)_WE.#R*^AZ*Z(XS$1A[-5';U,98:C.7/*"OZ!7
M_%OX%^"_C?I<5EXMT=+YH,_9[N-C%<09Z[)%YQ_LG(.!D5WU%<L9.+4HNS1T
M-*2L]CY5T/\ X)M?"32=42[N9O$.L0J<FROK^,0M[$Q1(^/^!5]-Z%H.G>&-
M'M-*TFR@T[3;2,106MM&$CC4=@!5^BMZV)K5TE5FV8T\/2HN].*04445S&X4
M444 %%%% !1110 4444 %%%% !7':+_R4SQ#_P!>\'_H(KL:X[1?^2F>(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;^SW_P!$_P#_ "M:A_\ )%?1]%)-Q5D#UU9\X?\ #NW]GO\ Z)__ .5K4/\
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX;%T,9#VE"7,OZW[!1115G6%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<=HO_)3/$/\ U[P?^@BNQKCM%_Y*9XA_Z]X/_010!V-%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!\[?'+_D5OB3_OV'_HY*^3:^U?%_@_\ X3VX\=:%]K^P_:WM/](\OS-NTA_N
MY&<[<=>]>;?\,@_]3;_Y3?\ [;7WN09IA,%A94\1.S<F]F]++LC\IXKR/,,R
MQT*V$I\T5!+>*UO)]6NZ/G.BOHS_ (9!_P"IM_\ *;_]MH_X9!_ZFW_RF_\
MVVOI?]8,M_Y^_A+_ "/B_P#5/.O^?'_DT/\ Y(^<Z*^C/^&0?^IM_P#*;_\
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MT/\ Y(^<Z*^C/^&0?^IM_P#*;_\ ;:/^&0?^IM_\IO\ ]MH_U@RW_G[^$O\
M(/\ 5/.O^?'_ )-#_P"2/G.BOHS_ (9!_P"IM_\ *;_]MH_X9!_ZFW_RF_\
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M^_A+_(/]4\Z_Y\?^30_^2/G.BOHS_AD'_J;?_*;_ /;:/^&0?^IM_P#*;_\
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M]*RJU6_X\)O\^E95 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 36?_ !]1?[U7[G_7-_GM5"S_ ./J+_>J_<_ZYO\
M/:@"*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *O6O^I6J-7K7_ %*T 2T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#COB5_Q[Z#_P!A:#^3
M5V-<=\2O^/?0?^PM!_)J[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***P?'GB0>$
M?!>M:SU>SM9)4&,Y?'R#\6(I-V5V14G&G!SELM3YN_:@^-%Q?ZG<>#M'G:*R
MMCLU":-L&:3O%G^ZO?U/';GF?@O^SG??$BW75]5FDTK0=V$*I^^N?79G@+_M
M'//0'G'%_"[PB_Q*^(VF:7<O))'=3--=RY.XQJ"[G/J<$9]6%?6OBO\ : \&
M_#GQ%%X:N%N=UNB1R-9PJT-J,#:IY!X&.%!Q]>*\6FHUI.K6>A^7X2-+-*T\
MQS*=J:=DF]+]O1+[_O-/1?@'X"T.W6*/PW:W1'62]!G9O<[B?TQ5;Q%^SKX"
M\16[1G0X]-E/W9]/8PLOO@?*?Q!KT+3]0MM5L8+RSGCN;6=!)%-$P974C((-
M9_BSQ9IG@G0;G5]7N!;6< R3U9V[*H[L>PKU73I<NJ5C] G@\"J3YJ<>2W96
ML?$_QD^"&I?">ZAG,ZZAHURY2"[ VL&Y.QUSP<#J.#CMTKG(_&WB_P 07^DV
MT>LZI>7ENRP6,:3N7#%OE"X/)R<9ZXP.@%:7Q2^*&K?%SQ,+B97CM$;R['3X
MR6$:DX'^\YXR>_0< "L32[S5/ASXTMKEXY++5-+NE9X6X8%3\R'V(R#Z@U\_
M)QYWR:1/QS$3H+$R>$<HT6U_7ZI/4_0WP^M\N@Z:NJ%6U,6T8NBF,&7:-^,=
MMV:OU!8WD6H6<%U"=T,\:RHWJK#(_0U/7TJV/W2-E%).X4444R@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N.T7_DIGB'_KW@_P#0178UQVB_
M\E,\0_\ 7O!_Z"* .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** //-+_P"1X\5?[\'_ * :Z"N?TO\ Y'CQ5_OP
M?^@&N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "MBZ_Y9_2L>MBZ_Y9_2@"O1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% $K?\>$W^?2LJM5O^/";_/I650
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% $UG_Q]1?[U7[G_ %S?Y[50L_\ CZB_WJOW/^N;_/:@"*BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O6O^I6J-7K7
M_4K0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >>:7_P CQXJ_WX/_ $ UT%<_I?\ R/'BK_?@_P#0#704
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
MQ=?\L_I6/6Q=?\L_I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"5O\ CPF_SZ5E5JM_QX3?Y]*RJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL_
M^/J+_>J_<_ZYO\]JH6?_ !]1?[U7[G_7-_GM0!%1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %7K7_4K5&KUK_J5H EH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KCOB#_P ?WA;_ +"L/\Z[&N.^(/\ Q_>%O^PK#_.@#L:*
M** ..^%__(%U#_L(3?TKL:X[X7_\@74/^PA-_2NQH **** "BBB@ HHHH **
M** "BBB@!"<<G@5^;G[3W_!1'Q)<>*+_ ,-_#&YCTC2;*5K>36_*66>[=20Q
MBW JD>>AP6/7(Z5][_%RYN[/X4^,Y]/W?;HM&O'@V]?,$#E<?CBOSP_X)?\
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M\??\A+PM_P!A..@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDO# ^D:HY+-=V("^8?5T(PWUX/O7G5L-+F]I2=F?%YCDE;V_UW+I<M3JN_\
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MJ.[/0RO))T:WUW'2YZOY?\'\$%%%%=Y]@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<=HO\ R4SQ#_U[P?\ H(KL:X[1?^2F>(?^O>#_
M -!% '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'GFE_\ (\>*O]^#_P! -=!7/Z7_ ,CQXJ_WX/\ T UT% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5L77
M_+/Z5CUL77_+/Z4 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH E;_ (\)O\^E95:K?\>$W^?2LJ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K/_CZ
MB_WJOW/^N;_/:J%G_P ?47^]5^Y_US?Y[4 14444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5ZU_U*U1J]:_ZE: ):***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *X[X@_\ ']X6_P"PK#_.NQKCOB#_ ,?WA;_L*P_SH [&BBB@
M#COA?_R!=0_["$W]*[&N.^%__(%U#_L(3?TKL: "BBB@ HHHH **** "BBB@
M HHHH 9-"EQ"\4J+)'(I5D89# C!!%?E=^T;^Q9X\^"OC>X\4?#JUU+4O#AF
M:YM)]%+F]TTDYV,J?/A<G#KD8'.#U_52OF3XO_\ !03X9_"?Q%=:!&NH^)]5
MM',5RNDQH8() <,C2.R@L/\ 9# $$$@BNS"5*M.K>BKM].Z_KK_F<6,IT:M&
MU=V2Z]G_ %T_R/RYE^(GC:R\=_\ "33Z_K">,(\Q_P!J3W$AO5_=F+&]CNSL
M.WUQ7J_PL_9B^+7[37BV#4=7BUB+3IV4W?B;Q$93F/UC,AW3'&0 N1G&2HYK
MZ@F_X*L^&5D81> M6>//RL][$I(]QM./SIG_  ]:\._]"!JG_@?'_P#$U] Z
MV)LN2A9KT/G%0PMWSXBZ/M/P7X1T[P%X2T?PYI,7DZ;I=K':0*>NU% R3W)Z
MD]R36U7 _ OXM6WQQ^&.D>,[33Y=*M]0,P6UFD$CIY<KQG+  ')3/XUWU?,5
M5.-22J?%?7U/JJ+@Z<?9?#T"BBBLC8**** "BBB@ HHHH *X[Q]_R$O"W_83
MCKL:X[Q]_P A+PM_V$XZ .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH X[XE?\>^@_\ 86@_DU=C7'?$K_CWT'_L+0?R:NQH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *X[1?\ DIGB'_KW@_\ 0178UQVB_P#)
M3/$/_7O!_P"@B@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#SS2_^1X\5?[\'_H!KH*Y_2_\ D>/%7^_!_P"@
M&N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "MBZ_Y9_2L>MBZ_P"6?TH KT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!*W_ !X3?Y]*RJU6_P"/";_/I650
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% $UG_Q]1?[U7[G_7-_GM5"S_X^HO\ >J_<_P"N;_/:@"*BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O6O^I6J-7K
M7_4K0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG^%'_"3>*O\ H4O_ ">3_"@#L:*X[_A)O%7_ $*7_D\G^%'_  DWBK_H4O\
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M?^3R?X4?\)-XJ_Z%+_R>3_"@#L:*X[_A)O%7_0I?^3R?X4?\)-XJ_P"A2_\
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MT5QW_"3>*O\ H4O_ ">3_"C_ (2;Q5_T*7_D\G^% '8T5QW_  DWBK_H4O\
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M ,FT_P * .GHKF/[?\0_]"W_ .3:?X4?V_XA_P"A;_\ )M/\* .GHKF/[?\
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M4?V_XA_Z%O\ \FT_PH Z>BN8_M_Q#_T+?_DVG^%']O\ B'_H6_\ R;3_  H
MZ>BN8_M_Q#_T+?\ Y-I_A1_;_B'_ *%O_P FT_PH Z>BN8_M_P 0_P#0M_\
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M ,G$_P */^$B\2_]"O\ ^3B?X4 =917)_P#"1>)?^A7_ /)Q/\*/^$B\2_\
M0K_^3B?X4 =917)_\)%XE_Z%?_R<3_"C_A(O$O\ T*__ ).)_A0!UE%<G_PD
M7B7_ *%?_P G$_PH_P"$B\2_]"O_ .3B?X4 =917)_\ "1>)?^A7_P#)Q/\
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M_"C_ (2+Q+_T*_\ Y.)_A0!UE%<G_P )%XE_Z%?_ ,G$_P */^$B\2_]"O\
M^3B?X4 =917)_P#"1>)?^A7_ /)Q/\*/^$B\2_\ 0K_^3B?X4 =917)_\)%X
ME_Z%?_R<3_"C_A(O$O\ T*__ ).)_A0!UE%<G_PD7B7_ *%?_P G$_PH_P"$
MB\2_]"O_ .3B?X4 =917)_\ "1>)?^A7_P#)Q/\ "C_A(O$O_0K_ /DXG^%
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MI_A1_;_B'_H6_P#R;3_"@#IZ*YC^W_$/_0M_^3:?X4?V_P"(?^A;_P#)M/\
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M_P FT_PH Z>BN8_M_P 0_P#0M_\ DVG^%']O^(?^A;_\FT_PH ZVS_X^HO\
M>J_<_P"N;_/:N'M_$'B-9T*^&MS9X'VM.?TJW-XD\3-(Q/A;:?3[:G^% '44
M5R?_  D7B7_H5_\ R<3_  H_X2+Q+_T*_P#Y.)_A0!UE%<G_ ,)%XE_Z%?\
M\G$_PH_X2+Q+_P!"O_Y.)_A0!UE%<G_PD7B7_H5__)Q/\*/^$B\2_P#0K_\
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M)_A0!UE%<G_PD7B7_H5__)Q/\*/^$B\2_P#0K_\ DXG^% '645R?_"1>)?\
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M (2;Q5_T*7_D\G^% '8T5QW_  DWBK_H4O\ R>3_  H_X2;Q5_T*7_D\G^%
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M!V-%<=_PDWBK_H4O_)Y/\*/^$F\5?]"E_P"3R?X4 =C17'?\)-XJ_P"A2_\
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M#TZBBB@#COA?_P @74/^PA-_2NQKCOA?_P @74/^PA-_2NQH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 <=\2O\ CWT'_L+0?R:N
MQKCOB5_Q[Z#_ -A:#^35V- !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7':+_P E,\0_]>\'_H(KL:X[1?\ DIGB'_KW@_\ 010!V-%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YYI?
M_(\>*O\ ?@_] -=!7/Z7_P CQXJ_WX/_ $ UT% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5L77_+/Z5CUL77_ "S^E %>
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** )6_X\)O\ /I656JW_ !X3?Y]*RJ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL_P#CZB_WJOW/^N;_ #VJ
MA9_\?47^]5^Y_P!<W^>U $5%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5>M?]2M4:O6O^I6@"6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M.^(/_']X6_["L/\ .NQKCOB#_P ?WA;_ +"L/\Z .QHHHH X[X7_ /(%U#_L
M(3?TKL:X[X7_ /(%U#_L(3?TKL: "BBB@ HHHH **** "BBB@ HHHH ^=_C%
M^PO\-_C3XUNO%>KMJ^GZK=1JLXTJXBBCF91@.P:-OFQ@$YYP*^3/@3_P3I\4
M:UXZOK?XHZ%J&@^%UM)&MKO3]4LWE><2($4A6D."A<_='0<CH?:/VL/^"@4/
MPOUF]\'^ +>WU3Q%:L8KW5+H%[:SD'6-%!'F2#N2=JGCYCD#X7\3?M3?%WQ;
M>-<W_P 1/$".W_+.QOGLXO\ OW"47]*]_ T\6Z=XNT6M+_FOZ[6/G<PJ8.-2
MTU>:=W;\G^I]_?\ #K_X2?\ 04\5_P#@=!_\8K3T#_@FM\'-%ODN+F/7=;12
M#]GU#4 (SCU\I$;]:_.+2/VD/BMH=Y'<VGQ&\4"1#N"S:M/-&3_M([%6_$&O
MKC]FS_@I'J,VM6?A_P"*WV>:TN&$4?B2WB$+1,3@&X1<*4_VD"[>X/)&]3#8
MZ*O"I?\ ,YZ6*P$I6G3M^1^@VFZ;:Z/I]M86-M%9V5K&L,%O"@5(T4855 X
M  &*LTV.1)HUDC97C8!E93D$'H0:=7S3NWJ?4JR5EL%%%%(84444 %%%% !1
M110 5QWC[_D)>%O^PG'78UQWC[_D)>%O^PG'0!V-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% ''?$K_CWT'_L+0?R:NQKCOB5_P >^@_]A:#^
M35V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7':+_R4SQ#_P!>
M\'_H(KL:X[1?^2F>(?\ KW@_]!% '8T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'GFE_P#(\>*O]^#_ - -=!7/
MZ7_R/'BK_?@_] -=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %;%U_P L_I6/6Q=?\L_I0!7HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"5O^/";_/I656J
MW_'A-_GTK*H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@":S_X^HO\ >J_<_P"N;_/:J%G_ ,?47^]5^Y_US?Y[4 14
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5ZU_U*U1J]:_ZE: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M444 %%%% !1110!YYI?_ "/'BK_?@_\ 0#705S^E_P#(\>*O]^#_ - -=!0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;%
MU_RS^E8];%U_RS^E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** )6_P"/";_/I656JW_'A-_GTK*H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":S_X
M^HO]ZK]S_KF_SVJA9_\ 'U%_O5?N?]<W^>U $5%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5>M?]2M4:O6O^I6@"6BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR7" ,J9D1Q@J)#C&<@5]U:Y_P2W^!_AC2Y]3UGQIXJTG38 #->7VJV,,,>2
M-SM; #)(')ZD5TUXI0C&_*K:6]?ZT,*,FZDI;N^MSQ[_ ()-_$V]T[XC>)O
MDLSOI>I6)U*&$G*QW$3*K$#MN1^?78OI5/\ X*W?\ED\'?\ 8!_]N)*^KOV<
M?V)_A7\'O&UOXY\#^*M:\074=O+;H9]1M+FV*R#!/[J%3GT^:OE'_@K=_P E
MD\'?]@'_ -N)*QKS4ZU%K?K]TOTL:4(N-.K?;I]\?UN>L_\ !/']E'P+K_P<
MM/'_ (Q\/67BK6-9EF2WCUB 7,%M;QN8E58GRI8F,G<1D# &!G/S9_P4>^"O
MASX.?&O3SX5TV+1])UK35O6L;==L,4PD='\M>BJ0%.T< DX %?H-_P $_O\
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M>YT5)V4?=W1SH%)_"1OSK<_X*^?\C)\,O^O2_P#_ $."L#_@D?\ \EB\:?\
M8!'_ *41UO\ _!7S_D9/AE_UZ7__ *'!6V)_BT/G_P"W&&&^"O\ +_VPV?\
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M4 %%%% !1110 4444 %%%% !1110!YYI?_(\>*O]^#_T UT%<_I?_(\>*O\
M?@_] -=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %;%U_RS^E8];%U_RS^E %>BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** )6_X\)O\^E95:K?\>$W^?2LJ
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** )K/_ (^HO]ZK]S_KF_SVJA9_\?47^]5^Y_US?Y[4 14444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5ZU_P!2M4:O
M6O\ J5H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KCOB#_Q_>%O^PK#_.NQKCOB#_Q_>%O^PK#_
M #H [&BBB@#COA?_ ,@74/\ L(3?TKL:X[X7_P#(%U#_ +"$W]*[&@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MCO'W_(2\+?\ 83CKL:X[Q]_R$O"W_83CH [&BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#COB5_Q[Z#_V%H/Y-78UQWQ*_P"/?0?^PM!_)J[&
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY+ZGSE_P4"\*ZUXS_9?\1:5X?T>_UW5);FS:.QTVV>XG<+<(6(1 6( !)XX
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M*RJU6_X\)O\ /I650 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% $UG_ ,?47^]5^Y_US?Y[50L_^/J+_>J_<_ZYO\]J
M (J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ J]:_P"I6J-7K7_4K0!+1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?$'_C^\+?]A6'^==C7
M'?$'_C^\+?\ 85A_G0!V-%%% ''?"_\ Y NH?]A";^E=C7'?"_\ Y NH?]A"
M;^E=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5QWC[_D)>%O\ L)QUV-<=X^_Y"7A;_L)QT =C1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!QWQ*_X]]!_["T'\FKL:X[XE?\>^
M@_\ 86@_DU=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM\4/&3=?%NN'ZZE-_P#%4?ZJ5O\ GZON8?Z^8;_GQ+[T?H%17Y^?\+.\8_\
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MY^K[F'^OF&_Y\2^]'Z!T5^?G_"SO&/\ T->N?^#&;_XJC_A9WC'_ *&O7/\
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MAIUK_P &$W_Q5'^JE;_GZON8?Z^8;_GQ+[T?>M%?!7_"RO%W_0TZU_X,)O\
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M5^Y_US?Y[4 14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5ZU_U*U1J]:_ZE: ):*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHR7)6,F,;257:"><D'DUZ%7)4C[.;C>]NJV.VG/VD%.UK]'N%%%%9F@4444
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M- NUQ(X7+;S@'TR*^@**U-4IN"E?S0J-1U::FXN-^C"BBBL3<**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 5QWQ!_X_O"W_85A_G78UQWQ!_X_O"W_85A_G0!V-%%% ''?"__ ) NH?\
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M3,L4:*Q+-QO^5=F6XX:?_@JGXK%YX^\%^'4DR+#3Y;R1.P::0*/TA_6O=_\
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MA(*:?V*1GO+ZGHG^]TNG+$XJ,<'#5;V[>;?;7^G8F:H4F\7+1VW_ *]#Y/\
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M[O[6%9;N[NFP###D': 2%^4;BP."!UV_^"0G_(J_$K_K]LO_ $7+7SY^W1\
M_&7P=^/&N^.K&SO?^$=U;43J]EKEFK%;6X=PY1W'^K=9"2N<9&".AQ=:,%BH
MQEI&R^^R_P"#\R,.Y/#RDM97?W7?_ ^1JZM\-_VU?#6BS>)+S4?'JV5O&;F0
M)XG\]U4#))MEN&<X'\.S\*]K_8-_;N\3?$3QQ!\._B->1ZI=WR,=*UCREBE,
MB*6,,H4!6RJG:V <C!W;ACQ/X?\ _!4?XN>%8X+;7H=&\8VR'#R7ML;>Y9?0
M/$57/N48U]<?LC_MD?"3XJ:Q%X;TOPC9?#?Q7<[FBT^&WA6"Z;DL(IHT3<V
M2595)[;N:U2EJG%-?C_7I^1FVK)WLSZ_HHHK@.P_++_@J_\ %.;6OB9X>\!V
M\I^PZ)9_;KA >&N9NF?]V-5Q_P!=#7WK^RI\/4^%_P"SSX%T 1B.X338[FZ
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MD@9[BN,_X)Z_\G?> ?\ >O/_ $BGKHPL81JR<7=\OZ2(Q$I.A9K37]#]!/\
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MB)*FX-J][+[Y6_X/X'/0C[3G2TM?[U&YZ%^R'^TO;?M.?#(ZX]G'IFNZ?/\
M8]4LHF)C63:&62//.Q@<@'D$,,G&3X5^VK_P4$U#X,>+IO G@&TLKK7[5%.I
M:I?*98[5F7<L4: @,X!!);(&<8)SCBO^"0-U(R?%&WS^Z4Z=(![G[2#_ "%>
MI_M/>-?V6_A7X\CO_&GA:SUGQ]!<1ZBUKH=IF[\W(=))V5XXR20#ME8DC!VD
M&IQ$(QKQ7V79V6^J6WX_\,70E)TY=6OZ_P E_P $^4-3_:Z_:]\-Z4OB'5FU
MZQT'Y9/ME]X1@AM"K?=_>FV P<C!W=Z^O/V&OVVKW]I*XU/PQXITZUL?%>GV
MWVQ+BP#+!=P!@C'8Q)1U++G!(.[(QC%>&_%K_@I%J?QB\"^+/"_@OX57EUIU
MYIUQ;W>H7DK7)M[=HV#R-#%'A-JY;<7(&,GI7E__  2W=E_:@P&(#:'=@@'K
M\T9K6G'G<HRC96;7?9O]#.H^11E&5W>S[;K_ #/JW]MS]O2[^ 'B"/P5X,L+
M2_\ %)@6XO+V_!>&S5QE$" C=(1\W)P 5X;/'S!)^U1^V.VG'7A;^)$T39Y_
MVD>#8OLHCQG=YAMONX[[OQK=_P""DO[.?C#3?C!?_$W2-,O-5\-ZG#!)<75I
M&TIL)HHUC(D R50A%8,?ER2,BJ'P\_X*L?$KPU;VUKXFT+1?%MO"@5IU#V5U
M)CNSINC_ "C%<U!*5/F^UUOT_K_@]3>LW&:7V;'O/[%W_!0C4/C-XR@\"^/K
M*RM=<O%8Z;JE@ACCN752QBD0D[7(#$,I .,8!QGZ0_:6_:,T']FGX>2>(]7B
M:_O9W^SZ=I<3A'NYL$XR<[4 Y9L' [$D ^1?LI_MB?!WXKZXF@:)X9M?A[XL
MO-TBZ>;2&..[<Y9Q%-&HWMU.'"L>P/-?+_\ P5H\27=Y\:/"NB.Y^PV&B"XC
M3/'F2S2!V_*)!^%%9-RA'EM?_@O]+?B%&UIRO=+_ ("_6YC+^W)^U'\6=0O=
M1\$6=XNG6Q_>VGAOPTM]# .H#N\4K X]6'T%>Q_LI_\ !2C5/%7C2P\%_%6T
ML[>>^E6UM==M8C!MG)PJ7$>=HW-QN7: <97!)'EWP&_X*26'P)^%>A>"]/\
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M< _6%?A_\:)F^*O[:VOVNJ.S0ZAXO&EOEL;8%N%MU&>V$45STX.M6A2[_P#
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M \,IH_BFSD9H&+VE_:L$N;5SU*,01@X&5((.!QD CBCBH4L4JU-/EVWUL_\
M@ZG?+"3JX1T:C7,]=M+K_@:?/Y'GWPY_;$^$Z_!?0]:O_&&EZ;/:Z=%'<Z2\
MP^V1RI&%9%@^^W((! ((QS7A7P[_ ."C'CCXD_%6W\,Z'X TW5+74KXPV$2S
M2PW$<&[[\S_.ORIEF(4 8-.D_P""3]@=2+Q_$JY6PWY$#:,IEV^GF>>!GWV?
MA7TW\!?V5_ G[/%O,_AVSFN]8N$\NXUC4'$ERZYSL! "HN0.% S@9)P*Z)2P
M492JZR;Z:JQRQCCY1A2T@EUT=S _;M\4/X7_ &7?&+QY$M\D.GC'I+*JM_X[
MNKX=_P""<>M>%O#/QLU/5_$^NZ;H0M]'E2SDU.Y2W1Y'DC!"LY R$#<9S@GT
M./TS^*WPOT/XR> ]3\)^(8Y'TV^4;G@8++$ZD,CH2" RD \@CL017Q?=?\$G
MK-KYGM_B9/%9[LK#+HBO(%]"XG )]]OX5G@*]*G3J4ZKLY=?*UO\_O-,PP]:
MK4I5*2NH]/.]_P#+[CJ_^"F'C^TD^ GAJRTN]@OK3Q!J4<\=Q:RK)'-!'&SA
ME920REFC((XK$_X)4^$_LO@_QSXE=.;R]@L(V([1(7;'XS+^5>I_M'?L5K\>
MK'P9IUIXP_X1C2_#%B;*WM?[,^U;P0BAL^='C"QJ,8->E?LX? V#]GGX86WA
M&'5/[:D2YFNIK_[-]G\UW;^YO?&%"K]XYVY]J(5J5+!U*47[TG^%U\ME^(YT
M*U;&4ZLX^[%?C9OUT;_ _.7_ (*+^ +SPG^T5J&LR0L-/\0V\-Y;S8^4LB+%
M(N?4% ?HPK[;_9__ &Q/AKXJ^$NB3:SXNTGP[K-A916U_8:K=);2"6- K-&'
M(\Q6QN&S/7!P<BO6?BY\&_"GQP\*OH'BS3A>VF[S(9HVV3VTF,!XW_A/Y@]"
M".*^/]8_X)0Z7/J#OI7Q'O+*QS\L-YI"7$H'H76:,'_OD4Z5>C5PT</7=N79
M_E^&GXW%6P]>CB7B<.N;FW7Y_P"9X!^VW^T;!^T5\2+"P\,^=<^&='#6]@1&
MP:\F<C?*$QG!(55!&<#/&<5]P_ #X8WW[-G[(^J+=0,GB,Z=>:Y>PJ/F2<PD
MK']51(U/N#4_P%_85^'WP-U:#7,W/B?Q'#S#?ZF%\NW;^]%$HPI_VF+$=B*^
MB;FVBO+>6WGC6:"5#')&XRK*1@@CT(K+%5Z?U;ZIA]NK?7^GJ:X3#U?K/US$
M[]$NG]+_ ()^*?[)_B#P_P"&_P!HOP5J_BN]CL=(MKUI9;NX.(XY/+?RF<]@
M)"A+'@=3ZU]K_ML_MF>$+?X:ZIX*\$ZY:^(]:UJ$VUQ>:9*)K:UMVX?]ZIVL
M[#*@*3C))QQFGXT_X)7^'-9\23WOA[QM=^']*F<O_9L^G+=F+)R523S4PHZ#
M<"1W)KK]2_X)S^#K?X4WGA/PYK$VEZOJ$\,E]XCU"T%Y<2Q1G=Y*('C$:%PK
M<'G:,[L CNQ&(PF)=.<F].GSZ_K;?8X<-A\9A?:0@EKU^3V_X.VY\W?\$P/"
M/]L?'#5]=D3=%HVDOL;'W99G5%_\<$M?2_[7G[8_BG]F_P 366CV'@JTOK6_
MM?/M-8O+MS$[ D.AB50<J=O\?(8'O7;?LH_LIV_[,&G^(81XA_X22ZUB6%WN
M/L/V7RTC#!4V^8^>78YR.O2O2/BM\(?"WQJ\*R>'_%FF+J%BS>9&X8I+!(!@
M/&XY5OT(X((XKEQF)I5L3&=N:"27:_7\&_G8ZL#A:M'"RA?EFVWT=ME^*7RN
M>$_#']J3X/\ [1GPSM(OB3<^%-/UE%VZAI'B!HHH%E''F0&<X*D<C#%ES@G(
MR?A#]K_1_A)HGQ&MX/A'=K<Z:;<F_6UG>>TCFW' AD8DL,<G!*CC'<#ZCU[_
M ()0Z/<7SOHOQ%OM/LR?EAO]*2ZD'U=98P?^^:[CX1_\$UO 7@'6+75O$>J7
MGC6\MG\R.WN(5MK,L#D%H@69L'L7VGN#733JX2C4]M";2_E_K^O,Y:M+&UZ7
ML:D$W_-_7^7?0]*_8CT'5O#G[,/@FTUE9([IH);B.*7.Y(9)GDB!S_L,IQVS
MBO<Z15"*%4!548  P!2UXU>K[:K*I:UVV>Y0I>PI1I7O96/C[_@IWXL_L;X$
M:;HJ,!)K.K1JRYY,<2M(?_'A'7S3_P $^_C%\._@GKGB_6/'&OC1;J[MH+2Q
M7[%<7!=-S/*?W4;8Y6/KBOL_]J[]DN?]IZX\.D^,?^$:M='6;$']F?:O->0I
MEL^<F,! ,8/6O /^'37_ %53_P MW_[JKU<%6P\,-*E5E9R;OOY+MU2_$\?'
M4<14Q,*M*-U%+MYOO?1O\#V+QG_P4>^#OA[29I]&U*_\4WP4^5:6=A- &;'&
MYYE0*N>I&3[&OSJ\7>)O&W[6WQJ^TI9MJ'B#6)EM[2PMLF.VB'W4!/W4099F
M/'WF-?8FB?\ !*'2;>\1M8^(U[?6N?FCL=*2V<CV9I9 ._\ ":^J/@M^SAX#
M^ =C)%X3T?RKV9 EQJEV_G7<X'9G/09 .U JY&<9JJ=7!81NI2O*72__  R_
MS)J4<=C$J=6T(];?\._\C.\"^!]._9=_9QETZWD60:#I5Q?7=UC'GW 1I)'Y
M]6X ] HK\Q?V,/#<GCO]J3P8)P9O)O7U2=FYYA1I03_P-5_.OUE^,WP]G^*_
MPP\0^$;?5?[$?5[?[,;[[/Y_EJ6!;Y-Z9RH(^\.OX5X7^S#^PM!^SE\0+GQ5
M)XP_X26:2PDLHH/[+^R^47="7W><^>$(Q@?>K'"8J-.5:M5?O26GKK^K1MC,
M)*I&C1I1]R+U]-/OTO\ >,_:^_; \3_LVZ]IVFZ?X+M=1L]1MO.M=8O+M_*,
M@)#QF)5!RORG[_(84GPI_:L^$G[17PTM[?XF7'A73=:C!6_TG7S'';;\\20&
M<D$$8/#%E/![$^^_%'X4>%_C)X5F\/>+-,34M/D.].2LD,@! DC<<JPR>1ZD
M'()%?'?B#_@E'HMU?.^A_$2^TZS)^6&_TM+N0?\  UEB!_[YK##O"RI\E96E
MW_K^NIT8A8N-55*#YHV^'^OZZ'S#^V-HOP@T/X@64/PCNX[FS:!FU&.SN'GL
MXY=WRB*1B<Y&<A6*CC&.17Z#?L6>#]3@_9'\/Z/K@DA.HVUTT<<H^:.WFD<I
MP>Q5MP'HPKB/A/\ \$T/ ?@?5[;5/$VKWGC6XMW$B6LT"VMFQ'(+Q LSX/8O
MM/0@BOL".-8HU1%"(HPJJ,  = !6^*Q%.6&6%A)R[M_/_/Y(PPF%JQQ3Q4XJ
M'9+Y?Y?-GXE^ 8M.^!?[15C:?$+0X-3TO1=2DM-5T^^M5N(VC(:,R>6P(< ,
M)%XYP".U?H#\0?B1^RCX'\$SZ_;:!\.?$=QY6ZUTK2],L9;F=R/E1D6,F+W+
M@8^O%>@?M#?L>>!_VB)H]1U,7&B^(XH_+35]/VAW4?=65&!#@=NC#H&QQ7S]
MHO\ P2ATFWU))-7^(UY?:>#\T%EI*6TI'H)&ED _[YK9XJCBH1]M-QDM[=?Z
M_JY@L+6PE27L(*49;7Z?U^/D=K^R=\6/A7\<_%DB^'O@=IOA75])B%VVK6NE
MV1AM6SA0)U1'#GG&%SPW0 U\4_MH7EW=?M5^-3K1F:.*^CC53U%N(TV!<]MO
M(^M?K-\*_A'X5^"_A6+P_P"$M+33;!6\R1LEY9Y,8,DCGEF/OT&    *\J_:
M6_8M\*?M&7D.L2WUQX<\3Q1"'^T[:(2I-&.BRQ$C=C)P0RGMDC &-+%4J6+5
M6*?):VNO;7\+>AO5P=:M@W1DUSMIZ:;7T_&_J10?M.? 3X-_"FWN?#.O:&NF
MQ6P>TT3171KN5MO"O"OS*Y/5I .<DFOS$\(K<?&W]H323J(!F\3>(XWN1U $
MUP"X^@#&ON[X=?\ !+GPAX;UB"^\5>*;[Q9#"X=;&&T%C#)C^&3YY&9?967Z
MU'X&_P"":O\ P@/Q/T;Q?I_Q%#)I>J1ZA#8/H7!5) PB+_:?0;=VWWQVKKPU
M;"8>M*HIMM]7?_ASAQ5#&XF@J7(DET37;[M/U/4OVN_VG-?_ &:--T6[TSP?
M!KFGZB7A_M":[:..VF7!6-HU0YW+D@[A]T^E<9\!_P!M/X?_ ![\%W>D_%5_
M#.A:PLK"6PU4*FGW,.<HRF<LN0#@JS9R,C@\?4'CCP/H7Q(\,7WA[Q)IL.JZ
M1>+MFMY@<'N&!'*L#R&!!!'%?&?BW_@E3X;U#4'E\.>.M1T2U8DBWO[%+W;D
M] RO$<#WR?<UYF'EAG!TZZL_YOZ_R_$];$QQ49JIAW=?R_U_GOY:'S_^V]H/
MP-T?5-(;X47EG+JTSR-J4&BW)N+!4P-I5LE5;.?E0XQU XS]:?\ !,[0=6TC
M]GNYN=162.SU'5YKFP20'F$)&A8>Q='_ "SWKGOAW_P2Y\%^'=3AO/%?B;4/
M%B1.'%G#;BQ@DQ_#)AW<C_=9:^S=-TVTT73[:PL+:*SLK:-88+>! D<:*,*J
MJ.  .U=5?$TXX?ZO3DY7ZLY,/A:LL2L34BH6Z+OL?B[\3_#/_"C/VGM0M_$&
MD1ZEINFZZ+XV-S"K17MF9O,4;6^5E:,XP>,Y!K] -1^('[)&G^"3XE&E_#FY
MA\CSDT^#2+-KYCC(C^S[/,5L\?, !W('->G_ !^_9?\ !7[16FV\?B*":TU2
MT4K:ZM8,$N(E)SL.00R9_A8>N,$YKYAM?^"3^G)J2O<_$JZET_=DP1:,L<I7
MT\PS,,^^S\*<<12KT(4ZLG&4=+KK_7]7"6&K8>O.K1@IQEK9]#9_9M^-WP@^
M.7Q M-!TS]G[2=&U:,-="^M=*L9HK18^1*\GEHR<[0, G<1BON&O.?@K\ ?!
MOP!\/OI?A/3FA>?:;O4+EO,NKIAT,CX' R<*H"C)P!DUZ-7!BJE.I/\ =7Y5
MW/0PM.I3A^^MS/L@HHHKC.T**** "BBB@#COB5_Q[Z#_ -A:#^35V-<=\2O^
M/?0?^PM!_)J[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KXB_X*=?#?^TO!OAOQM;Q9ETNX-A=,/\ GC+RA/L'7'_;2OMVN0^+7PYL
M_BW\.=>\)7TOV>'5+8PK<>7YA@DR"D@7(R58*<9&<=171AZSP]:%5='^'7\+
MF=6FJU.5-]5;_+[GJ?BA?>+-4U+PSI6@7%RTFEZ7+/-:P]HVFV>9^90?KZU^
MOW[)?PS_ .%4_ 7POI,L7E:A<P?VA>\8/G3?.0?=5*I_P"OGCPO_ ,$O;/1/
M$NE:CJ'Q!_M6QM+J*>>Q_L3ROM"*P8Q[_M#;=P&,X/7I7W, %  &!7T&:X^C
M6I1I8=W3=WHU_5[G@Y?@ZM*JZE96LK+K_5OU%KDOBY_R2GQG_P!@:\_]$/76
MUD>+M!_X2KPIK.B^?]E_M&RFM//V;_+\Q"F[;D9QG.,BOE9:IH^EIM1FFS\F
M/V&?^3I_ _\ OW7_ *235^OU?('P+_X)^?\ "E_BIH?C/_A/?[8_LQI3]B_L
M?R/,WPO']_SVQC?G[IZ8KZ_KZ#.,51Q56$J+NDK=>[[GAY9AZN'C)55:[/S_
M /\ @J=_Q]?#O_<O?YPUZ3_P3-_Y(+JO_8>G_P#1,%=O^U/^RC_PTQ+X=?\
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M%A[(:]L@_P""6&G+J@DF^(MU)IV_)MX](59MN>GF&8C/OL_"OK7X0?!GPO\
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M&5V?D;_P3C\2?"OPW\4-:F^)$FCVEXUI&=&OM=V"U@D#$R?/)\B.1MPQQT8
MC.#Z/_P4P_:8\$_$S0_#O@?P;K%OX@:QOC?WM]I[B2U3$;(D:2#Y7)WL25)
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M?C)?#Q6)K+0-7MSIU_*8F+V<JOE)&0#=A2&5@!D;B<<8K]%OC1^W%\+/AO\
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M4 %%%% !1110 4444 %%%% !1110 5]7_LG_ /).]1_["LG_ *)AKY0KZO\
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M+B".,IO9\L)(7.<L>A'TI5Y*I7A4CLK?^DV_,**<*4X/=W_]*O\ D4_V.?\
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MU7L"PX<#L'# 9.,9KQWPY_P2S^"^AZI'=W<WB;7X5.?L6I:A&L+?7R8HW_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKCOB#_Q_>%O^PK#_ #KL:X[X@_\ ']X6_P"PK#_.@#L:*** ..^%_P#R!=0_
M["$W]*[&N.^%_P#R!=0_["$W]*[&@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KCO'W_ "$O"W_83CKL:X[Q]_R$
MO"W_ &$XZ .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?5_[)__ "3O4?\ L*R?
M^B8:^4*^K_V3_P#DG>H_]A63_P!$PU\MQ)_R+WZH^ZX,_P"1M'_#(]IHHHK\
ME/WX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K/
M_CZB_P!ZK]S_ *YO\]JH6?\ Q]1?[U7[G_7-_GM0!%1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7K7_4K5&KUK_J5H
M EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K
M:E9_VCIMW:;_ "_/B>+?C.W<I&<=^M?&'[/7_!-G_A0_Q?T#QS_PL7^W/[*,
MQ^P?V']G\WS(7B_UGVA]N-^?NGICWK[8HJH2=.3E'=Z?G_FQ32J1Y);!1114
MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N.^(/_ !_>%O\ L*P_SKL:X[X@_P#']X6_["L/\Z .QHHHH X[
MX7_\@74/^PA-_2NQKCOA?_R!=0_["$W]*[&@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCO'W_(2\+?]A..NQKC
MO'W_ "$O"W_83CH [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#COB5_Q[Z#_P!A:#^35V-<=\2O^/?0?^PM!_)J[&@ HHHH **** "BBB@
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M\?,,VPV6K]\_>>R6_P#7J?8U%?G-M\6>-&DFVZSKI8_.X$MQD^YYI\.K>+O
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MZR8#N_N#_4S-OY8_^!'RA17U?_PR?X1_Z".M?]_X?_C5'_#)_A'_ *".M?\
M?^'_ .-4?ZR8#N_N#_4S-OY8_P#@1\H45]7_ /#)_A'_ *".M?\ ?^'_ .-4
M?\,G^$?^@CK7_?\ A_\ C5'^LF [O[@_U,S;^6/_ ($?*%%?5_\ PR?X1_Z"
M.M?]_P"'_P"-4?\ #)_A'_H(ZU_W_A_^-4?ZR8#N_N#_ %,S;^6/_@1\H45]
M7_\ #)_A'_H(ZU_W_A_^-5?F_9!\&Q[<:EKG([SP_P#QJC_63 =W]P?ZF9M_
M+'_P(^0:*^N?^&1?!W_02US_ +_P_P#QJC_AD7P=_P!!+7/^_P##_P#&J/\
M63 =W]P?ZF9M_+'_ ,"/D:BOKG_AD7P=_P!!+7/^_P##_P#&J/\ AD7P=_T$
MM<_[_P /_P :H_UDP'=_<'^IF;?RQ_\  CY&HKZY_P"&1?!W_02US_O_  __
M !JC_AD7P=_T$M<_[_P__&J/]9,!W?W!_J9FW\L?_ CY&HKZY_X9%\'?]!+7
M/^_\/_QJC_AD7P=_T$M<_P"_\/\ \:H_UDP'=_<'^IF;?RQ_\"/D:BOKG_AD
M7P=_T$M<_P"_\/\ \:H_X9%\'?\ 02US_O\ P_\ QJC_ %DP'=_<'^IF;?RQ
M_P# CY&HKZY_X9%\'?\ 02US_O\ P_\ QJC_ (9%\'?]!+7/^_\ #_\ &J/]
M9,!W?W!_J9FW\L?_  (^1J*^N?\ AD7P=_T$M<_[_P /_P :H_X9%\'?]!+7
M/^_\/_QJC_63 =W]P?ZF9M_+'_P(^1J*^N?^&1?!W_02US_O_#_\:H_X9%\'
M?]!+7/\ O_#_ /&J/]9,!W?W!_J9FW\L?_ CY&HKZY_X9%\'?]!+7/\ O_#_
M /&J/^&1?!W_ $$M<_[_ ,/_ ,:H_P!9,!W?W!_J9FW\L?\ P(^1J*^N?^&1
M?!W_ $$M<_[_ ,/_ ,:H_P"&1?!W_02US_O_  __ !JC_63 =W]P?ZF9M_+'
M_P "/D:BOKG_ (9%\'?]!+7/^_\ #_\ &J/^&1?!W_02US_O_#_\:H_UDP'=
M_<'^IF;?RQ_\"/D:BOKG_AD7P=_T$M<_[_P__&J/^&1?!W_02US_ +_P_P#Q
MJC_63 =W]P?ZF9M_+'_P(^1J*^N?^&1?!W_02US_ +_P_P#QJC_AD7P=_P!!
M+7/^_P##_P#&J/\ 63 =W]P?ZF9M_+'_ ,"/D:BOKG_AD7P=_P!!+7/^_P##
M_P#&J/\ AD7P=_T$M<_[_P /_P :H_UDP'=_<'^IF;?RQ_\  CY&HKZY_P"&
M1?!W_02US_O_  __ !JC_AD7P=_T$M<_[_P__&J/]9,!W?W!_J9FW\L?_ CY
M&HKZY_X9%\'?]!+7/^_\/_QJC_AD7P=_T$M<_P"_\/\ \:H_UDP'=_<'^IF;
M?RQ_\"/D:BOKG_AD7P=_T$M<_P"_\/\ \:H_X9%\'?\ 02US_O\ P_\ QJC_
M %DP'=_<'^IF;?RQ_P# CY&HKZY_X9%\'?\ 02US_O\ P_\ QJC_ (9%\'?]
M!+7/^_\ #_\ &J/]9,!W?W!_J9FW\L?_  (^1J*^N?\ AD7P=_T$M<_[_P /
M_P :H_X9%\'?]!+7/^_\/_QJC_63 =W]P?ZF9M_+'_P(^1J*^N?^&1?!W_02
MUS_O_#_\:H_X9%\'?]!+7/\ O_#_ /&J/]9,!W?W!_J9FW\L?_ CY&HKZY_X
M9%\'?]!+7/\ O_#_ /&J/^&1?!W_ $$M<_[_ ,/_ ,:H_P!9,!W?W!_J9FW\
ML?\ P(^1J*^N?^&1?!W_ $$M<_[_ ,/_ ,:H_P"&1?!W_02US_O_  __ !JC
M_63 =W]P?ZF9M_+'_P "/D:BOKG_ (9%\'?]!+7/^_\ #_\ &J/^&1?!W_02
MUS_O_#_\:H_UDP'=_<'^IF;?RQ_\"/D:BOKG_AD7P=_T$M<_[_P__&J/^&1?
M!W_02US_ +_P_P#QJC_63 =W]P?ZF9M_+'_P(^1J*^O#^R'X.^RO)_:6N;EZ
M?OX<?^BJI?\ #)_A'_H(ZU_W_A_^-4?ZR8#N_N#_ %,S;^6/_@1\H45]7_\
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M_P"!'RA17U?_ ,,G^$?^@CK7_?\ A_\ C5'_  R?X1_Z".M?]_X?_C5'^LF
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5>M?]2M4:O6O
M^I6@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N.^(/_ !_>%O\ L*P_SKL:X[X@_P#']X6_["L/
M\Z .QHHHH X[X7_\@74/^PA-_2NQKCOA?_R!=0_["$W]*[&@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCO'W_(
M2\+?]A..NQKCO'W_ "$O"W_83CH [&BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB^G6!))W"HI)ZDG^0Y/09)K5M[?Q+\9/&[!!)JFM7[EW8G"HH[D]%11@>@X
MJKXHT&\^'7C6[TUIU>]TNY&V>,$ D896'Z&OG:EI2YU&T;GXKBW3KUGBZ=+E
MHN5M/ZW:[;'Z%Z#I8T+0].TT2M<"SMH[<2O]Y]BA=Q]SC-7ZHZ%J0UK1-/U
M+M%W;QSA1VW*&Q^M7J^E5K:'[G#EY%R[!1113+"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *X[1?\ DIGB'_KW@_\ 0178UQVB_P#)3/$/_7O!
M_P"@B@#L:QO&FC3^(O!^NZ3;-&EQ?V$]K$TI(0,\;*"Q )QD\X!K9KE_BE_R
M3'Q?_P!@>\_]$O6-:RI2OM9FM*_M(V[H^&?V6?\ @GA\1_@?\=O#'C77=:\+
MW>E:6;@S0Z==W+SMOMY(QM#VZJ?F<9RPXS7Z'5^)_P#P3U_Y.^\ _P"]>?\
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MD:N!_P"/5L5E*+A)Q>Z-(R4XJ2V84445)04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'GFE_P#(\>*O]^#_ - -=!7/Z7_R/'BK_?@_] -=
M!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%;%U_P L_I6/6Q=?\L_I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@"5O^/";_/I656JW_'A-_GTK*H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":
MS_X^HO\ >J_<_P"N;_/:J%G_ ,?47^]5^Y_US?Y[4 14444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5ZU_U*U1J]:_ZE
M: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *X[X@_P#']X6_["L/\Z[&N.^(/_']X6_["L/\Z .Q
MHHHH X[X7_\ (%U#_L(3?TKL:X[X7_\ (%U#_L(3?TKL: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.\??\A+P
MM_V$XZ[&N.\??\A+PM_V$XZ .QHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ4%T"BBBF6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QVB_\
M)3/$/_7O!_Z"*[&N.T7_ )*9XA_Z]X/_ $$4 =C7+_%+_DF/B_\ [ ]Y_P"B
M7KJ*Y?XI?\DQ\7_]@>\_]$O7/B/X,_1_D;4?XL?5'X[_ /!/7_D[[P#_ +UY
M_P"D4]?7O_!7+_DE?@;_ +#4G_HAJ^0O^">O_)WW@'_>O/\ TBGKZ]_X*Y?\
MDK\#?]AJ3_T0U>IC?AI?+_TLX</\<_3]&6?^"2,$:_!KQC,% E?7MK-W(%O%
M@?J?SI/^"M\2M\&_!DA'SKKVT'V-O+G^0J7_ ())_P#)$_%W_8P'_P!)X:;_
M ,%;O^2+^#O^Q@'_ *335GC?XJ_[<_\ ;2\+\#_[>_4K?\$CO^23^-_^PVG_
M *(2OF/_ (*<?\G6:I_V#++_ -%U].?\$CO^23^-_P#L-I_Z(2OF/_@IQ_R=
M9JG_ &#++_T73Q7^\T_E_P"D$X?^!/Y_^E'Z8_LL,Z_LO_#8QC=(/#MJ5&<9
M/E#%?BS\/Y?%]]\9='E\(_O/&\FKJ^G%_).;LR94GSOW>=W]_CUK]J_V3_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >>:7_ ,CQXJ_WX/\ T UT%<_I?_(\>*O]^#_T UT% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5L77_ "S^
ME8];%U_RS^E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** )6_X\)O\^E95:K?\>$W^?2LJ@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K/_CZB_P!Z
MK]S_ *YO\]JH6?\ Q]1?[U7[G_7-_GM0!%1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %7K7_4K5&KUK_J5H EHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN>H^O;T_S"BBBNP^F"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:T***&W)W>X)**LM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \\TO_D>/%7^_!_Z :Z"N?TO_D>/%7^_!_Z :Z"@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V+K_EG]*QZV+K
M_EG]* *]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 2M_QX3?Y]*RJU6_X\)O\ /I650 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $UG_ ,?47^]5^Y_U
MS?Y[50L_^/J+_>J_<_ZYO\]J (J*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ J]:_P"I6J-7K7_4K0!+1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7'?$'_C^\+?]A6'^==C7'?$'_C^\+?\ 85A_G0!V-%%% ''?"_\ Y NH
M?]A";^E=C7'?"_\ Y NH?]A";^E=C0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5QWC[_D)>%O\ L)QUV-<=X^_Y
M"7A;_L)QT =C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QWQ
M*_X]]!_["T'\FKL:X[XE?\>^@_\ 86@_DU=C0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5QVB_\E,\0_P#7O!_Z"*[&N.T7_DIGB'_KW@_]!% '
M8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'GFE_\CQXJ_WX/_0#705S^E_\CQXJ_P!^#_T UT% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5L77_+/Z5CUL77
M_+/Z4 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH E;_CPF_SZ5E5JM_QX3?Y]*RJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL_\ CZB_WJOW/^N;
M_/:J%G_Q]1?[U7[G_7-_GM0!%1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#3_^@;JO_@+_ /7H_P"%H:?_ - W5?\ P%_^O78T4 <=_P +0T__ *!NJ_\
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M6AI__0-U7_P%_P#KT?\ "T-/_P"@;JO_ ("__7KL:* .._X6AI__ $#=5_\
M 7_Z]'_"T-/_ .@;JO\ X"__ %Z[&B@#CO\ A:&G_P#0-U7_ ,!?_KT?\+0T
M_P#Z!NJ_^ O_ ->NQHH X[_A:&G_ /0-U7_P%_\ KT?\+0T__H&ZK_X"_P#U
MZ[&B@#CO^%H:?_T#=5_\!?\ Z]'_  M#3_\ H&ZK_P" O_UZ[&B@#CO^%H:?
M_P! W5?_  %_^O1_PM#3_P#H&ZK_ . O_P!>NQHH X[_ (6AI_\ T#=5_P#
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M .O1_P +0T__ *!NJ_\ @+_]>NQHH X[_A:&G_\ 0-U7_P !?_KT?\+0T_\
MZ!NJ_P#@+_\ 7KL:* /*_&GCFTU:'25CLK^+R-0BG;SH-NX -P.>3STKH_\
MA:&G_P#0-U7_ ,!?_KT?$K_CWT'_ +"T'\FKL: .._X6AI__ $#=5_\  7_Z
M]'_"T-/_ .@;JO\ X"__ %Z[&B@#CO\ A:&G_P#0-U7_ ,!?_KT?\+0T_P#Z
M!NJ_^ O_ ->NQHH X[_A:&G_ /0-U7_P%_\ KT?\+0T__H&ZK_X"_P#UZ[&B
M@#CO^%H:?_T#=5_\!?\ Z]'_  M#3_\ H&ZK_P" O_UZ[&B@#CO^%H:?_P!
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M_7KL:* .._X6AI__ $#=5_\  7_Z]'_"T-/_ .@;JO\ X"__ %Z[&B@#CO\
MA:&G_P#0-U7_ ,!?_KT?\+0T_P#Z!NJ_^ O_ ->NQHH X[_A:&G_ /0-U7_P
M%_\ KT?\+0T__H&ZK_X"_P#UZ[&B@#CO^%H:?_T#=5_\!?\ Z]'_  M#3_\
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M0!QW_"T-/_Z!NJ_^ O\ ]>C_ (6AI_\ T#=5_P# 7_Z]=C10!QW_  M#3_\
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M_P#7H_X6AI__ $#=5_\  7_Z]=C10!QW_"T-/_Z!NJ_^ O\ ]>C_ (6AI_\
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M+_\ 7H_X6AI__0-U7_P%_P#KUV-% ''?\+0T_P#Z!NJ_^ O_ ->C_A:&G_\
M0-U7_P !?_KUV-% 'CUCXQM8?%&O79M+TI=-$518<NN%(^89XK7_ .%@67_/
MCJ/_ (#_ /UZGTO_ )'CQ5_OP?\ H!KH* .8_P"%@67_ #XZC_X#_P#UZ/\
MA8%E_P ^.H_^ _\ ]>NGHH YC_A8%E_SXZC_ . __P!>C_A8%E_SXZC_ . _
M_P!>NGHH YC_ (6!9?\ /CJ/_@/_ /7H_P"%@67_ #XZC_X#_P#UZZ>B@#F/
M^%@67_/CJ/\ X#__ %Z/^%@67_/CJ/\ X#__ %ZZ>B@#F/\ A8%E_P ^.H_^
M _\ ]>C_ (6!9?\ /CJ/_@/_ /7KIZ* .8_X6!9?\^.H_P#@/_\ 7H_X6!9?
M\^.H_P#@/_\ 7KIZ* .8_P"%@67_ #XZC_X#_P#UZ/\ A8%E_P ^.H_^ _\
M]>NGHH YC_A8%E_SXZC_ . __P!>C_A8%E_SXZC_ . __P!>NGHH YC_ (6!
M9?\ /CJ/_@/_ /7H_P"%@67_ #XZC_X#_P#UZZ>B@#F/^%@67_/CJ/\ X#__
M %Z/^%@67_/CJ/\ X#__ %ZZ>B@#F/\ A8%E_P ^.H_^ _\ ]>C_ (6!9?\
M/CJ/_@/_ /7KIZ* .8_X6!9?\^.H_P#@/_\ 7H_X6!9?\^.H_P#@/_\ 7KIZ
M* .8_P"%@67_ #XZC_X#_P#UZ/\ A8%E_P ^.H_^ _\ ]>NGHH YC_A8%E_S
MXZC_ . __P!>C_A8%E_SXZC_ . __P!>NGHH YC_ (6!9?\ /CJ/_@/_ /7H
M_P"%@67_ #XZC_X#_P#UZZ>B@#F/^%@67_/CJ/\ X#__ %Z/^%@67_/CJ/\
MX#__ %ZZ>B@#F/\ A8%E_P ^.H_^ _\ ]>C_ (6!9?\ /CJ/_@/_ /7KIZ*
M.8_X6!9?\^.H_P#@/_\ 7H_X6!9?\^.H_P#@/_\ 7KIZ* .8_P"%@67_ #XZ
MC_X#_P#UZ/\ A8%E_P ^.H_^ _\ ]>NGHH YC_A8%E_SXZC_ . __P!>C_A8
M%E_SXZC_ . __P!>NGHH YC_ (6!9?\ /CJ/_@/_ /7H_P"%@67_ #XZC_X#
M_P#UZZ>B@#F/^%@67_/CJ/\ X#__ %Z/^%@67_/CJ/\ X#__ %ZZ>B@#F/\
MA8%E_P ^.H_^ _\ ]>M&X^)5@^S&GZH,#O;?_7K6K8NO^6?TH XO_A8]C_T#
M]3_\!O\ Z]'_  L>Q_Z!^I_^ W_UZZRB@#D_^%CV/_0/U/\ \!O_ *]'_"Q[
M'_H'ZG_X#?\ UZZRB@#D_P#A8]C_ - _4_\ P&_^O1_PL>Q_Z!^I_P#@-_\
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MH Y/_A8]C_T#]3_\!O\ Z]'_  L>Q_Z!^I_^ W_UZZRB@#D_^%CV/_0/U/\
M\!O_ *]'_"Q['_H'ZG_X#?\ UZZRB@#D_P#A8]C_ - _4_\ P&_^O1_PL>Q_
MZ!^I_P#@-_\ 7KK** .3_P"%CV/_ $#]3_\  ;_Z]'_"Q['_ *!^I_\ @-_]
M>NLHH Y/_A8]C_T#]3_\!O\ Z]'_  L>Q_Z!^I_^ W_UZZRB@#D_^%CV/_0/
MU/\ \!O_ *]'_"Q['_H'ZG_X#?\ UZZRB@#D_P#A8]C_ - _4_\ P&_^O1_P
ML>Q_Z!^I_P#@-_\ 7KK** .3_P"%CV/_ $#]3_\  ;_Z]'_"Q['_ *!^I_\
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M_P ^.H_^ _\ ]>C_ (6!9?\ /CJ/_@/_ /7KIZ* .8_X6!9?\^.H_P#@/_\
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M['_H'ZG_ . W_P!>NLHH Y/_ (6/8_\ 0/U/_P !O_KT?\+'L?\ H'ZG_P"
MW_UZZRB@#D_^%CV/_0/U/_P&_P#KT?\ "Q['_H'ZG_X#?_7KK** .3_X6/8_
M] _4_P#P&_\ KT?\+'L?^@?J?_@-_P#7KK** .3_ .%CV/\ T#]3_P# ;_Z]
M'_"Q['_H'ZG_ . W_P!>NLHH Y/_ (6/8_\ 0/U/_P !O_KT?\+'L?\ H'ZG
M_P" W_UZZRB@#D_^%CV/_0/U/_P&_P#KT?\ "Q['_H'ZG_X#?_7KK** .3_X
M6/8_] _4_P#P&_\ KT?\+'L?^@?J?_@-_P#7KK** .3_ .%CV/\ T#]3_P#
M;_Z]'_"Q['_H'ZG_ . W_P!>NLHH Y/_ (6/8_\ 0/U/_P !O_KT?\+'L?\
MH'ZG_P" W_UZZRB@#D_^%CV/_0/U/_P&_P#KT?\ "Q['_H'ZG_X#?_7KK**
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M *!NJ_\ @+_]>NQHH X[_A:&G_\ 0-U7_P !?_KT?\+0T_\ Z!NJ_P#@+_\
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M* .._P"%H:?_ - W5?\ P%_^O1_PM#3_ /H&ZK_X"_\ UZ[&B@#CO^%H:?\
M] W5?_ 7_P"O1_PM#3_^@;JO_@+_ /7KL:* .._X6AI__0-U7_P%_P#KT?\
M"T-/_P"@;JO_ ("__7KL:* .._X6AI__ $#=5_\  7_Z]'_"T-/_ .@;JO\
MX"__ %Z[&B@#CO\ A:&G_P#0-U7_ ,!?_KT?\+0T_P#Z!NJ_^ O_ ->NQHH
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M#CO^%H:?_P! W5?_  %_^O1_PM#3_P#H&ZK_ . O_P!>NQHH X[_ (6AI_\
MT#=5_P# 7_Z]87B+Q?;>(M6\-PP6MY;M'J<+EKF'8#\P& <]:].KCOB#_P ?
MWA;_ +"L/\Z .QHHHH X[X7_ /(%U#_L(3?TKL:X[X7_ /(%U#_L(3?TKL:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N.\??\ (2\+?]A..NQKCO'W_(2\+?\ 83CH [&BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#COB5_P >^@_]A:#^35V-<=\2O^/?0?\
ML+0?R:NQH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[1?^2F>(
M?^O>#_T$5V-<=HO_ "4SQ#_U[P?^@B@#L:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SS2_^1X\5?[\'_H!KH*Y
M_2_^1X\5?[\'_H!KH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ K8NO^6?TK'K8NO^6?TH KT444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!*W_'A-_GTK*K5;
M_CPF_P ^E95 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 36?\ Q]1?[U7[G_7-_GM5"S_X^HO]ZK]S_KF_SVH BHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MKUK_ *E:HU>M?]2M $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<=\0?^/[PM_V%8?YUV-<=\0?^
M/[PM_P!A6'^= '8T444 <=\+_P#D"ZA_V$)OZ5V-<=\+_P#D"ZA_V$)OZ5V-
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7'>/O^0EX6_P"PG'78UQWC[_D)>%O^PG'0!V-%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% ''?$K_CWT'_L+0?R:NQKCOB5_Q[Z#_P!A
M:#^35V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-_97^'VG?%+]H3P/X9U>/SM+O;\-=0YP)8XU:1D/LP3;^-?KG\-_^3)O#_\
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MO_@D#?3-;_%"S+?N$?3IE7T9A< G\E'Y5[%_P5!_Y-9N?^PQ9_S>O%?^"/\
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M%% !1110 4444 >>:7_R/'BK_?@_] -=!7/Z7_R/'BK_ 'X/_0#704 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6Q=?\L_
MI6/6Q=?\L_I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"5O^/";_/I656JW_'A-_GTK*H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":S_P"/J+_>
MJ_<_ZYO\]JH6?_'U%_O5?N?]<W^>U $5%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5>M?\ 4K5&KUK_ *E: ):*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *X[X@_\?WA;_L*P_SKL:X[X@_\?WA;_L*P_P Z .QHHHH X[X7
M_P#(%U#_ +"$W]*[&N.^%_\ R!=0_P"PA-_2NQH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[Q]_R$O"W_ &$X
MZ[&N.\??\A+PM_V$XZ .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH X[XE?\>^@_]A:#^35V-<=\2O\ CWT'_L+0?R:NQH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (=V_M"?]$__ /*UI_\ \D5^UE%94W[.]NKO^"7Z&LUSVOT/Q3_X=V_M"?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K8NO\ EG]*QZV+K_EG]* *]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 2M_QX3?Y
M]*RJU6_X\)O\^E95 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 36?_ !]1?[U7[G_7-_GM5"S_ ./J+_>J_<_ZYO\
M/:@"*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *O6O^I6J-7K7_ %*T 2T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QWQ!_X_O"W_85A_G7
M8UQWQ!_X_O"W_85A_G0!V-%%% ''?"__ ) NH?\ 80F_I78UQWPO_P"0+J'_
M &$)OZ5V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7'>/O^0EX6_["<==C7'>/O^0EX6_["<= '8T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <=\2O^/?0?^PM!_)J[&N.^)7_
M ![Z#_V%H/Y-78T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=H
MO_)3/$/_ %[P?^@BNQKCM%_Y*9XA_P"O>#_T$4 =C1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>:7_ ,CQXJ_W
MX/\ T UT%<_I?_(\>*O]^#_T UT% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5L77_ "S^E8];%U_RS^E %>BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )6_
MX\)O\^E95:K?\>$W^?2LJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** )K/_CZB_P!ZK]S_ *YO\]JH6?\ Q]1?[U7[
MG_7-_GM0!%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %7K7_4K5&KUK_J5H EHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCOB#_ ,?WA;_L
M*P_SKL:X[X@_\?WA;_L*P_SH [&BBB@#COA?_P @74/^PA-_2NQKCOA?_P @
M74/^PA-_2NQH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *X[Q]_R$O"W_83CKL:X[Q]_R$O"W_83CH [&BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#COB5_Q[Z#_ -A:#^35V-<=
M\2O^/?0?^PM!_)J[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTIQ]I&<OY?\ @?YDU)>S<%_-_P '_(^_****S*"BBB@ HHHH **** "BBB@
MHHHH **** "BBF3?ZI_]TU$Y<L7+L,?17X5?LK_\G7?#O_L8X/\ T;7[JUTR
MI\L(SOO_ ,#_ #,W*U6=+^7_ #?^04445B6%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'GFE_P#(\>*O]^#_ - -=!7/Z7_R/'BK_?@_] -=!0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %;%U_P L_I6/6Q=?\L_I
M0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"5O^/";_/I656JW_'A-_GTK*H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":S_X^HO\ >J_<_P"N;_/:
MJ%G_ ,?47^]5^Y_US?Y[4 14444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !5ZU_U*U1J]:_ZE: ):*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MX[X@_P#']X6_["L/\Z[&N.^(/_']X6_["L/\Z .QHHHH X[X7_\ (%U#_L(3
M?TKL:X[X7_\ (%U#_L(3?TKL: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N.\??\A+PM_V$XZ[&N.\??\A+PM_V
M$XZ .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X[XE?\>^@
M_P#86@_DU=C7'?$K_CWT'_L+0?R:NQH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *X[1?^2F>(?^O>#_ -!%=C7':+_R4SQ#_P!>\'_H(H [&N7^
M*7_),?%__8'O/_1+UU%<O\4O^28^+_\ L#WG_HEZY\1_!GZ/\C:C_%CZH_$/
M]E3QQHGPV_:$\$^)O$=[_9VB:=>-+=77E/+Y:F)USM168\D= :_57_AXE^SW
M_P!% _\ *+J'_P CU^1OP-^&'_"Y_BQX;\%?VE_8_P#;%P8/MWD>?Y.$9L[-
MR[ONX^\.M?<?_#GO_JK?_EM__==>Q5LX+FVU_3_@'FT_B?+OI^I]+Z;_ ,%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!*
MW_'A-_GTK*K5;_CPF_SZ5E4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!-9_\ 'U%_O5?N?]<W^>U4+/\ X^HO]ZK]
MS_KF_P ]J (J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ J]:_ZE:HU>M?\ 4K0!+1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?$'_C^\+?
M]A6'^==C7'?$'_C^\+?]A6'^= '8T444 <=\+_\ D"ZA_P!A";^E=C7'?"__
M ) NH?\ 80F_I78T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<=X^_Y"7A;_L)QUV-<=X^_Y"7A;_L)QT =C111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QWQ*_X]]!_["T'\FKL
M:X[XE?\ 'OH/_86@_DU=C0 4444 %%%% !1110 4444 %%%% !1110 4444
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MA+R3OC&^21B6=O<G@<# XHI3ITY.JE[W3R_K\;:BJ1G4C[)O3KY_U^!\J_\
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M@AC7:I?!(#$Y8@$@9QDXR?V8_9XNH[[]GOX=SPMNC?PY8X/_ &[H*\V^+G[
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M44 %%%% !1110 4444 36?\ Q]1?[U7[G_7-_GM5"S_X^HO]ZK]S_KF_SVH
MBHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "KUK_ *E:HU>M?]2M $M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\0?^/[PM_V%8?YUV-<=
M\0?^/[PM_P!A6'^= '8T444 <=\+_P#D"ZA_V$)OZ5V-<=\+_P#D"ZA_V$)O
MZ5V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7'>/O^0EX6_P"PG'78UQWC[_D)>%O^PG'0!V-%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% ''?$K_CWT'_L+0?R:NQKCOB5_Q[Z#
M_P!A:#^35V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_A9?B__ *&K6_\ P8S?_%4?ZIU_^?J^YA_KE0_Y\O[T??E%? ?_  LOQ?\
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MF_\ BJ/^%E^+_P#H:M;_ /!C-_\ %4?ZIU_^?J^YA_KE0_Y\O[T??E%? ?\
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M/N@HHHH **** )6_X\)O\^E95:K?\>$W^?2LJ@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K/_CZB_P!ZK]S_ *YO
M\]JH6?\ Q]1?[U7[G_7-_GM0!%1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %7K7_4K5&KUK_J5H EHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,[TTU=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!P:UJYI1<7:2LS:,E)7B[H****0PHHHH **** "BBB@ HHHH **** "BBB@
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M?[]A_P"CDKY'KZX^.W_(I_$K_?L/_1R5\CU^I\*_[E/_ !/\HGY!QA_O\/\
M OSD%%%%?9'PP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z9
M^S;_ ,EJ\._]O/\ Z32UYG7IG[-O_):O#O\ V\_^DTM>?F/^Y5_\,OR9Z>5_
M[_0_QQ_]*1]R4445^%']"A1110 4444 2M_QX3?Y]*RJU6_X\)O\^E95 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M36?_ !]1?[U7[G_7-_GM5"S_ ./J+_>J_<_ZYO\ /:@"*BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O6O^I6J-7K7_
M %*T 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<PP]*E4H*$;7E9_?$^I[/_@F=\,+&\@N$U[Q<7A=9%#7EKC(.1G_ $:O&?\
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M'.%.H6UQ91_]_)XT3]:_+_X/_#[Q5^W3^T1<IKVN2+<7:R:CJFILF_[/;J0
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MP3X/^'?P@T/0/ >O?\)-X6M3.;35/MD-WYVZ9W?]["H1L.S+P.,8/(->9_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4G&2 ,Y Z'',W.N?%[]AOXN'11K<VGZA8&.X>RM[IIM.OH6&1F,X#*PR.5#
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M:QXY4J> >H!:I\J3J.UQ<_,VJ>MC]F*^ O\ @HE^R[\3OCK\3/#6J^!_#/\
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MESX!"L58JRMC/)'K1\1/VC/C3^U];VWA6#2?M5EYBN^E^&;"4),X/RM,2SG
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ML:X[XE?\>^@_]A:#^35V- !1110 4444 %%%% !1110 4444 %%%% !1110
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M29"/7*DBOR^_:G_;T^(OC7XHZGX&^&.H7&AZ-;WITN"32T'V[49@^PLLF-R
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M;YJ])_; ^)3?&'_@GK8>,WM8[&36)K&X>VB<NL3>>5*AN^"",UYQ_P $@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5Z9^S;_P EJ\._]O/_ *32UYG7IG[-O_):O#O_ &\_^DTM>?F/^Y5_
M\,OR9Z>5_P"_T/\ ''_TI'W)1117X4?T*%%%% !1110!*W_'A-_GTK*K5;_C
MPF_SZ5E4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!-9_\?47^]5^Y_P!<W^>U4+/_ (^HO]ZK]S_KF_SVH BHHHH
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M'Z@5^[L@W1L#TQ7X6?LK_P#)UWP[_P"QC@_]&U^Z;_=;Z5TXC7#17K^2)?\
MO=7Y?G(_"G]GV,6?[67@>.$LBQ^*[=%P><"Y _E7Z\_M+?M,^&OV8_!<.M:Y
M%-J%_>2-#IVE6S!9+J0#+?,>$1<C<V#C(P"2!7Y$? ?_ ).W\%_]C=!_Z5"O
MJ'_@KMHNJ+XN\ :NRR-HK6-Q:(P!V).) S GH"RE?KL/I2FV\/07=O7Y)_\
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M@$C!=2[QE7D>MW^;M^J_,4+?5:?.KK3\E_7RT/-? '_!2SXU^#)(UU'5=/\
M%UFN%\G6+)0P7OB2'8Q/NQ;\:_17]E']KSP]^U)H=]]DL9-"\2::%:^TF:02
M *W EB< ;T)XY (/!'()^3/VQ_V@/V8_B/\ #'5T\*Z78ZYX[O-GV34K'1);
M&:!]P)>69XXRZ[0PV_-DD<#J,K_@DKX'U>X^)'BWQ>(GCT*UTLZ89F!"RW$D
ML<@4>I58R3Z;U]:<+55/GC:RW_K[OF3.]/E<97N]OZ^_Y'S9^UQJEUK'[4WQ
M'GGC:6===F@6-P3N6-A&@P.VU%KZUMOVS/VMK:WBAA^ X6*- B*O@_5\!0,
M#]]Z5XS_ ,%(/@_J'PV_:$OO$\4$BZ)XHVW]M=*/E6X"@31Y_O!@'^CCTKZ[
M^%G_  4U^%=]\,["Y\8ZC>:-XKM;98[O3H[":;[3*J@%H712F&(R [+C.#ZU
MC1?^R06_+HU\K?H:UO\ >9/H]4_74^!O'GPU^.'Q!^)FI^.+OX2>*M-U?4+[
M^T)(]-\-WT<,<V024#*S#D9Y8\DU^WNFS27&GVLLR-%,\2LZ,.58@$@_C7Y_
M?!;_ (*4>._BW\6K#PE8?#G3=3AU2_,=L;:ZEMY;:UW9,DQ(D4E$^9B  <<
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M_O\ S9\9_P#!5;6+O3_V<=.M+=F6WO\ 7K>*XV]&58I9 I_X$BG_ (#7G?\
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M /2;?H3BI)\B3VM_Z5<_3BBBBN8W"BBB@ HHHH **** "BBB@ HHHH ****
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MB@ HHHH E;_CPF_SZ5E5JM_QX3?Y]*RJ "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH FL_^/J+_ 'JOW/\ KF_SVJA9
M_P#'U%_O5?N?]<W^>U $5%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5>M?]2M4:O6O^I6@"6H[B!;JWEA8D+(I0E>N"
M,5)12:4E9C3L[H^2/ O_  3.^&'P_P#'.B>*M.U[Q=-J.DWT=_!'=7EJT32(
MX8!@ML"5R.<$'WKZWHHK1SE)*+>B(Y5S.75A2,NY2#T(Q2T5FTI*S*/D_P
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MRNY?ALOR7XG-*+J."2LE_FW^9W=%%%<ATA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7'?$'_ (_O"W_85A_G78UQWQ!_X_O"W_85A_G0!V-%%% ''?"_
M_D"ZA_V$)OZ5V-<=\+_^0+J'_80F_I78T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<=X^_Y"7A;_L)QUV-<=X^
M_P"0EX6_["<= '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<=\2O^/?0?\ L+0?R:NQKCOB5_Q[Z#_V%H/Y-78T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<=HO\ R4SQ#_U[P?\ H(KL:X[1?^2F>(?^O>#_
M -!% '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^_A+_(/]6LU_Y\_^31_S/F^BOI#_ (8[_P"IN_\ *;_]NH_X8[_ZF[_RF_\
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MC_ACO_J;O_*;_P#;J/\ 6#+?^?OX2_R#_5K-?^?/_DT?\SYOHKZ0_P"&._\
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M^_A+_(/]6LU_Y\_^31_S/F>BOIC_ (8Q_P"IP_\ *9_]NH_X8Q_ZG#_RF?\
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MC_AC'_J</_*9_P#;J/\ 6#+?^?OX2_R#_5K-?^?/_DT?\SYGHKZ8_P"&,?\
MJ</_ "F?_;J/^&,?^IP_\IG_ -NH_P!8,M_Y^_A+_(/]6LU_Y\_^31_S/F>B
MOIC_ (8Q_P"IP_\ *9_]NH_X8Q_ZG#_RF?\ VZC_ %@RW_G[^$O\@_U:S7_G
MS_Y-'_,^9Z*^F/\ AC'_ *G#_P IG_VZC_AC'_J</_*9_P#;J/\ 6#+?^?OX
M2_R#_5K-?^?/_DT?\SYGHKZ8_P"&,?\ J</_ "F?_;J/^&,?^IP_\IG_ -NH
M_P!8,M_Y^_A+_(/]6LU_Y\_^31_S/F>BOIC_ (8Q_P"IP_\ *9_]NH_X8Q_Z
MG#_RF?\ VZC_ %@RW_G[^$O\@_U:S7_GS_Y-'_,^9Z*^F/\ AC'_ *G#_P I
MG_VZC_AC'_J</_*9_P#;J/\ 6#+?^?OX2_R#_5K-?^?/_DT?\SYGHKZ8_P"&
M,?\ J</_ "F?_;J/^&,?^IP_\IG_ -NH_P!8,M_Y^_A+_(/]6LU_Y\_^31_S
M/F>BOIC_ (8Q_P"IP_\ *9_]NH_X8Q_ZG#_RF?\ VZC_ %@RW_G[^$O\@_U:
MS7_GS_Y-'_,^9Z*^F/\ AC'_ *G#_P IG_VZC_AC'_J</_*9_P#;J/\ 6#+?
M^?OX2_R#_5K-?^?/_DT?\SYGKTS]FW_DM7AW_MY_])I:],_X8Q_ZG#_RF?\
MVZNF^&W[,G_"O?&FG>(/^$D_M#['YG^C_8/+W[XV3[WF'&-V>G:N/&YYE];"
MU:<*EVXM+26[7H=V X?S*CBZ-6I2M&,HMZQV37F>Y4445^3G[(%%%% !1110
M!*W_ !X3?Y]*RJU6_P"/";_/I650 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% $UG_Q]1?[U7[G_7-_GM5"S_X^HO\
M>J_<_P"N;_/:@"*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *O6O^I6J-7K7_4K0!+1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?$'_C^\
M+?\ 85A_G78UQWQ!_P"/[PM_V%8?YT =C1110!QWPO\ ^0+J'_80F_I78UQW
MPO\ ^0+J'_80F_I78T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<=X^_P"0EX6_["<==C7'>/O^0EX6_P"PG'0!
MV-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''?$K_ (]]!_["
MT'\FKL:X[XE?\>^@_P#86@_DU=C0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5QVB_\ )3/$/_7O!_Z"*[&N.T7_ )*9XA_Z]X/_ $$4 =C1110
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M((Z@BB4)12;6@U.,G9;DE%%5M2U*TT73KJ_O[F*RL;6-II[B=PD<2*,LS,>
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M87C>4@*[F,I0\GG"#\*^MJ^;?!'[8W_"9?M4:[\&O^$1^Q_V6URO]M_VGO\
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M?_(\>*O]^#_T UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5L77_ "S^E8];%U_RS^E %>BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )6_X\)O\^E95:K?
M\>$W^?2LJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** )K/_CZB_P!ZK]S_ *YO\]JH6?\ Q]1?[U7[G_7-_GM0!%11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%7K7_4K5&KUK_J5H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KCOB#_ ,?WA;_L*P_SKL:X[X@_
M\?WA;_L*P_SH [&BBB@#COA?_P @74/^PA-_2NQKCOA?_P @74/^PA-_2NQH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *X[Q]_R$O"W_83CKL:X[Q]_R$O"W_83CH [&BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#COB5_Q[Z#_ -A:#^35V-<=\2O^/?0?^PM!
M_)J[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<N!7FW["]N_QN_:T^+'Q@N5,ME;226VGR,.!YSE8\>ZP1;?^!UZ7_P %3O\
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M?4;=+>\"#S/+E8H\9;KM.0V/517>_LI>/SI?[#_ACQ1?%I1HV@W,C[^Z6QE
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M[G;=-/912NWJS1@D_F:_/'_@DK_R.'Q7_P"N=G_Z,GK]"/!W_(C:'_V#H/\
MT4M?GO\ \$E?^1P^*_\ USL__1D];126)KI=G^;,UKA(-]X'Z2T445R&X444
M4 %%%% 'GFE_\CQXJ_WX/_0#705S^E_\CQXJ_P!^#_T UT% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5L77_+/Z5CUL77
M_+/Z4 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH E;_CPF_SZ5E5JM_QX3?Y]*RJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL_\ CZB_WJOW/^N;
M_/:J%G_Q]1?[U7[G_7-_GM0!%1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %7K7_ %*U1J]:_P"I6@"6BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N.^(/_']X6_["L/\Z[&N.^(/_']X6_["L/\ .@#L:*** ..^%_\ R!=0
M_P"PA-_2NQKCOA?_ ,@74/\ L(3?TKL: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "N.\??\A+PM_P!A..NQKCO'
MW_(2\+?]A..@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M.^)7_'OH/_86@_DU=C7'?$K_ (]]!_["T'\FKL: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ IK,L:EF(55&2Q. !3JY#XN:I)H_P -O$%S$VR3[,8@WIO(3\_FJ92Y
M8N78SJ35.$IOHKGRW\5/'5Q\1?&,UQ$9)+&-_(L80#]S.,@?WF//X@=J]_\
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MW?3 "6\G( :1\=.@ 7L !SU/I%%5SOE<8JU]_,GDU4F[VV/B'6OV<?B)=_\
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M)8HD;>3Y@D($R $;1D9Y YK]"J*UE4<JGM7O:WX6^_3[S*$%3@Z:V?\ G?\
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M(KE25[A1114E!1110!YYI?\ R/'BK_?@_P#0#705S^E_\CQXJ_WX/_0#704
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6Q
M=?\ +/Z5CUL77_+/Z4 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH E;_CPF_SZ5E5JM_QX3?Y]*RJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH FL_^
M/J+_ 'JOW/\ KF_SVJA9_P#'U%_O5?N?]<W^>U $5%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5>M?]2M4:O6O^I6@"
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N.^(/\ Q_>%O^PK#_.NQKCOB#_Q_>%O^PK#_.@#L:**
M* ..^%__ "!=0_["$W]*[&N.^%__ "!=0_["$W]*[&@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCO'W_(2\+?]
MA..NQKCO'W_(2\+?]A..@#L:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** ..^)7_'OH/\ V%H/Y-78UQWQ*_X]]!_["T'\FKL: "BBB@ HHHH
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MY*9XA_Z]X/\ T$5V-<=HO_)3/$/_ %[P?^@B@#L:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SS2_\ D>/%7^_!
M_P"@&N@KG]+_ .1X\5?[\'_H!KH* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K8NO^6?TK'K8NO^6?TH KT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!*W_'
MA-_GTK*K5;_CPF_SZ5E4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!-9_\?47^]5^Y_P!<W^>U4+/_ (^HO]ZK]S_K
MF_SVH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "KUK_J5JC5ZU_U*T 2T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1I/[1?C33(5BDNK;4 O1KN %OS4KG\:@US]H#QGKD#0C4(]/C;AOL,0C8_\
M CEA^!%?1VH?!GP5J<CO-X>M59CD^06A'Y(1BI=+^$?@[1IEEM?#]GYB_=:9
M3+CW^<GFN7ZMB=O::?,\W^SLP?NNOIZO^OQ/EOP+\*_$/Q%O!+;PO#8N^9=2
MN0=G7DC/+M[#\<5]9^"/!.G> ="BTS3D.T'=+,^-\SGJS?YX K>55C4*H"JH
MP% P *=770PT*&N[/4P674L'[RUEW_R"BBBNP]8**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \\TO_ )'CQ5_OP?\ H!KH*Y_2_P#D>/%7
M^_!_Z :Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *V+K_EG]*QZV+K_EG]* *]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 2M_QX3?Y]*RJU6_X\)O\^E9
M5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 36?_'U%_O5?N?\ 7-_GM5"S_P"/J+_>J_<_ZYO\]J (J*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J]:_ZE:HU
M>M?]2M $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXXT;Y3(00Q+@JJD9!SE>"A_9+_:VOK/^W+CXX2VFN-^^&E_V[>"$'KL8(GE
M]1@*5]\5\\^&_BCXU\-_MK>/_&/A?P5<?$+Q);ZEJ:II\%K-<M#'YQA\W;$"
MP"KA,]!NQ7TE_P -O?M)_P#1N.K?^"74O_B*FG']U":^*2NWV\D.H_WLH/X8
MZ>OFSI?V3_VOO&LOQ3N?@Q\:K,6GC2%FCL]2,:1-.ZKO\J4)\A+)\R2)@,,=
M203M?\%./'7B3P#\%/#]]X8\0:KX<O9==CADN=)O9;61T,$Q*%HV!*Y ..G
MKY.\>7GQN^-'[1W@GXB7_P &/$WAF^TRYL8Y'L]#OA&RQ7&_S'9X^.&P>V%K
MZ5_X*S?\D%\-?]C#'_Z3STJR_=TYO23:3MY-:_.Y5&WM9PCK'E;5_.+T^5C@
MO ^H?M)_ME>%K"]\*^*V^&_@33[>*PBU"2[ECO=3GBC"2S&6,&5R7!R=RKSC
MYF#&N07X]?&_]A?XR6/A[XH>(KSQ[X7NXA<.);IKQIX&)7S()I@)%="IRC$+
M^8:OO#]DS28=%_9G^&=M BHC:#:SD*,#=)&)&/U+.37Q?_P5JM8[CQQ\*5=?
M];!=QN1U*^;!Q^I_.NF5XXM48[.33_'7[U\CGII2P[J2Z)->6WZ?>=.O@3]J
MG]JO2U\:1>.X_A7X>OU,^C:'9WMQ:R^2>8VD:!=Q##!W.Q/.0B@@51_95_:*
M^*OPU_:0?X'?%W4Y==:9VMK>\NY//FAF\LRQLLY&Z2.1>F_)&Y?NX(K]"-/M
MX[2PMH(4$<4<2HB*,!5   'X5^<7QF4+_P %5/!1  )DT\GW_<M65.457C22
M]V3MY[;W[Z#G>5"563]Y*_\ P/0^R_VG/VA=*_9K^&%SXHO[?^T+V206NG:>
M'VFYN&!(!/90 68^@]2*^+_ GA7]K#]KS34\9/\ $*3X>>&KIF:PCM+J;3Q*
MG8Q1P#>R9& TK9/4%A3_ /@K5?7%YXN^%^BM*RV+174Q0=-[21)N^H _4U^B
M_A_2;70=!TW3+&)8+*SMH[>")!@(B*%4#Z "LZ:7LG6>K;:7E;?YFM27[Q4E
MVN_GM\K'YNZU\5?VD/V%?$VDM\0M5/Q%\"WDOE?:)KAKD2'J56XD42QRA02%
M?*G!QG!(_13P'XVTGXD>#='\3Z'<?:=)U6V2ZMY",':PZ,.S Y!'8@BO'?V]
M-!L]>_90\>K=Q"0V=M'>0MCE)$E0@C]1]":X?_@E[JUSJ7[+L%O.6:.PUB[M
MX-W0(=DF!_P*1OSJH2]K":E\4;._=/3[[DS7LY0<=I75O-:W^X^N****Q-0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \\TO_D>/
M%7^_!_Z :Z"N?TO_ )'CQ5_OP?\ H!KH* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K8NO^6?TK'K8NO\ EG]* *]%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 2M_P >$W^?2LJM5O\ CPF_SZ5E4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!-9_\?47^]5^Y_US?Y[50L_^/J+_
M 'JOW/\ KF_SVH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "KUK_J5JC5ZU_U*T 2T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'^&O% M[>U\6RZA]D$T:A9;FW\MF;?CE@A"8)Z;L=Z^;8_\ @H/\=([,0?\
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M0?R:NQKCOB5_Q[Z#_P!A:#^35V- !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7':+_R4SQ#_ ->\'_H(KL:X[1?^2F>(?^O>#_T$4 =C7GO[0_\
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MSW;OK5J]EK'B"[;59;:5=KQ1LJI$K#L=B!L'D;\'I7SW_P $Z?\ D[7XS?\
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M%MM"6W"SBU" Q >F6@+X_P"!9]Z(R_=QI2^SHGY>8I+]XZD?M;KS[HXWP_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!*W_'A-_GTK*K5;_CPF_SZ5E4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!-9_\ 'U%_O5?N?]<W^>U4
M+/\ X^HO]ZK]S_KF_P ]J (J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J]:_ZE:HU>M?\ 4K0!+1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX6_["<==C7'>/O\ D)>%O^PG'0!V-%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% ''?$K_CWT'_ +"T'\FKL:X[XE?\>^@_]A:#^35V- !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7':+_ ,E,\0_]>\'_ *"*[&N.
MT7_DIGB'_KW@_P#010!V-%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!YYI?_ "/'BK_?@_\ 0#705S^E_P#(\>*O
M]^#_ - -=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %;%U_RS^E8];%U_RS^E %>BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** )6_P"/";_/I656JW_'A-_G
MTK*H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@":S_X^HO]ZK]S_KF_SVJA9_\ 'U%_O5?N?]<W^>U $5%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5>M?]2M4
M:O6O^I6@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR!_T+VM_^ G_ ->C_A9 _P"A>UO_ ,!/_KUV-% ''?\ "R!_T+VM_P#@)_\
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MA>UO_P !/_KUV-% ''?\+('_ $+VM_\ @)_]>C_A9 _Z%[6__ 3_ .O78T4
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M>!71_P#"R!_T+VM_^ G_ ->CXE?\>^@_]A:#^35V- ''?\+('_0O:W_X"?\
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MZ/\ A9 _Z%[6_P#P$_\ KUV-% ''?\+('_0O:W_X"?\ UZ/^%D#_ *%[6_\
MP$_^O78T4 <=_P +('_0O:W_ . G_P!>C_A9 _Z%[6__  $_^O78T4 <=_PL
M@?\ 0O:W_P" G_UZ/^%D#_H7M;_\!/\ Z]=C10!QW_"R!_T+VM_^ G_UZ/\
MA9 _Z%[6_P#P$_\ KUV-% ''?\+('_0O:W_X"?\ UZ/^%D#_ *%[6_\ P$_^
MO78T4 <=_P +('_0O:W_ . G_P!>C_A9 _Z%[6__  $_^O78T4 <=_PL@?\
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M_P +('_0O:W_ . G_P!>C_A9 _Z%[6__  $_^O78T4 <=_PL@?\ 0O:W_P"
MG_UZYS3?&8@\;:Q??V/JC^?#$OV=+?,J8 Y89X![5ZI7':+_ ,E,\0_]>\'_
M *"* #_A9 _Z%[6__ 3_ .O1_P +('_0O:W_ . G_P!>NQHH X[_ (60/^A>
MUO\ \!/_ *]'_"R!_P!"]K?_ ("?_7KL:* .._X60/\ H7M;_P# 3_Z]'_"R
M!_T+VM_^ G_UZ[&B@#CO^%D#_H7M;_\  3_Z]'_"R!_T+VM_^ G_ ->NQHH
MX[_A9 _Z%[6__ 3_ .O1_P +('_0O:W_ . G_P!>NQHH X[_ (60/^A>UO\
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MZZ>B@#F/^$Y'_0%U;_P&_P#KT?\ "<C_ * NK?\ @-_]>NGHH YC_A.1_P!
M75O_  &_^O1_PG(_Z NK?^ W_P!>NGHH YC_ (3D?] 75O\ P&_^O1_PG(_Z
M NK?^ W_ ->NGHH YC_A.1_T!=6_\!O_ *]'_"<C_H"ZM_X#?_7KIZ* .8_X
M3D?] 75O_ ;_ .O1_P )R/\ H"ZM_P" W_UZZ>B@#F/^$Y'_ $!=6_\  ;_Z
M]'_"<C_H"ZM_X#?_ %ZZ>B@#F/\ A.1_T!=6_P# ;_Z]'_"<C_H"ZM_X#?\
MUZZ>B@#F/^$Y'_0%U;_P&_\ KT?\)R/^@+JW_@-_]>NGHH YC_A.1_T!=6_\
M!O\ Z]'_  G(_P"@+JW_ (#?_7KIZ* .8_X3D?\ 0%U;_P !O_KT?\)R/^@+
MJW_@-_\ 7KIZ* .8_P"$Y'_0%U;_ ,!O_KT?\)R/^@+JW_@-_P#7KIZ* .8_
MX3D?] 75O_ ;_P"O1_PG(_Z NK?^ W_UZZ>B@#F/^$Y'_0%U;_P&_P#KT?\
M"<C_ * NK?\ @-_]>NGHH YC_A.1_P! 75O_  &_^O1_PG(_Z NK?^ W_P!>
MNGHH YC_ (3D?] 75O\ P&_^O1_PG(_Z NK?^ W_ ->NGHH YC_A.1_T!=6_
M\!O_ *]'_"<C_H"ZM_X#?_7KIZ* .8_X3D?] 75O_ ;_ .O1_P )R/\ H"ZM
M_P" W_UZZ>B@#F/^$Y'_ $!=6_\  ;_Z]'_"<C_H"ZM_X#?_ %ZZ>B@#F/\
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M_P#7H_X3D?\ 0%U;_P !O_KUT]% ',?\)R/^@+JW_@-_]>C_ (3D?] 75O\
MP&_^O73T4 <Q_P )R/\ H"ZM_P" W_UZ/^$Y'_0%U;_P&_\ KUT]% ',?\)R
M/^@+JW_@-_\ 7H_X3D?] 75O_ ;_ .O73T4 <Q_PG(_Z NK?^ W_ ->C_A.1
M_P! 75O_  &_^O73T4 <Q_PG(_Z NK?^ W_UZ/\ A.1_T!=6_P# ;_Z]=/10
M!S'_  G(_P"@+JW_ (#?_7H_X3D?] 75O_ ;_P"O73T4 <Q_PG(_Z NK?^ W
M_P!>C_A.1_T!=6_\!O\ Z]=/10!S'_"<C_H"ZM_X#?\ UZ/^$Y'_ $!=6_\
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M M8_\!O_ *]'_"P!_P! +6/_  &_^O7644 <G_PL ?\ 0"UC_P !O_KT?\+
M'_0"UC_P&_\ KUUE% ')_P#"P!_T M8_\!O_ *]'_"P!_P! +6/_  &_^O76
M44 <G_PL ?\ 0"UC_P !O_KT?\+ '_0"UC_P&_\ KUUE% ')_P#"P!_T M8_
M\!O_ *]'_"P!_P! +6/_  &_^O7644 <G_PL ?\ 0"UC_P !O_KT?\+ '_0"
MUC_P&_\ KUUE% ')_P#"P!_T M8_\!O_ *]'_"P!_P! +6/_  &_^O7644 <
MG_PL ?\ 0"UC_P !O_KT?\+ '_0"UC_P&_\ KUUE% ')_P#"P!_T M8_\!O_
M *]'_"P!_P! +6/_  &_^O7644 <G_PL ?\ 0"UC_P !O_KT?\+ '_0"UC_P
M&_\ KUUE% ')_P#"P!_T M8_\!O_ *]'_"P!_P! +6/_  &_^O7644 <G_PL
M ?\ 0"UC_P !O_KT?\+ '_0"UC_P&_\ KUUE% ')_P#"P!_T M8_\!O_ *]'
M_"P!_P! +6/_  &_^O7644 <G_PL ?\ 0"UC_P !O_KT?\+ '_0"UC_P&_\
MKUUE% ')_P#"P!_T M8_\!O_ *]'_"P!_P! +6/_  &_^O7644 <G_PL ?\
M0"UC_P !O_KT?\+ '_0"UC_P&_\ KUUE% ')_P#"P!_T M8_\!O_ *]'_"P!
M_P! +6/_  &_^O7644 <G_PL ?\ 0"UC_P !O_KT?\+ '_0"UC_P&_\ KUUE
M% ')_P#"P!_T M8_\!O_ *]'_"P!_P! +6/_  &_^O7644 <G_PL ?\ 0"UC
M_P !O_KT?\+ '_0"UC_P&_\ KUUE% ')_P#"P!_T M8_\!O_ *]6H?B,%C _
MX1_6C]+7_P"O715>M?\ 4K0!R?\ PL@?]"]K?_@)_P#7H_X60/\ H7M;_P#
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M <=_PL@?]"]K?_@)_P#7H_X60/\ H7M;_P# 3_Z]=C10!QW_  L@?]"]K?\
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MH_X60/\ H7M;_P# 3_Z]=C10!QW_  L@?]"]K?\ X"?_ %Z/^%D#_H7M;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% ''?$K_ (]]!_["T'\FKL:X[XE?\>^@_P#8
M6@_DU=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QVB_\ )3/$
M/_7O!_Z"*[&N.T7_ )*9XA_Z]X/_ $$4 =C1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >>:7_R/'BK_ 'X/_0#7
M05S^E_\ (\>*O]^#_P! -=!0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %;%U_RS^E8];%U_P L_I0!7HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"5O^/";_
M #Z5E5JM_P >$W^?2LJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** )K/\ X^HO]ZK]S_KF_P ]JH6?_'U%_O5?N?\
M7-_GM0!%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %7K7_4K5&KUK_J5H EHHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!QWQ*_X]]!_["T'\FKL:X[X
ME?\ 'OH/_86@_DU=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MQVB_\E,\0_\ 7O!_Z"*[&N.T7_DIGB'_ *]X/_010!V-%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YYI?\ R/'B
MK_?@_P#0#705S^E_\CQXJ_WX/_0#704 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6Q=?\ +/Z5CUL77_+/Z4 5Z*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
ME;_CPF_SZ5E5JM_QX3?Y]*RJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH FL_^/J+_ 'JOW/\ KF_SVJA9_P#'U%_O
M5?N?]<W^>U $5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5>M?]2M4:O6O^I6@"6BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7':+_ ,E,\0_]>\'_ *"*[&N.T7_DIGB'_KW@_P#010!V-%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!YYI?_ "/'BK_?@_\ 0#705S^E_P#(\>*O]^#_ - -=!0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;%U_RS^E8];%U_
MRS^E %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** )6_P"/";_/I656JW_'A-_GTK*H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@":S_X^HO]ZK]S_KF_
MSVJA9_\ 'U%_O5?N?]<W^>U $5%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5>M?]2M4:O6O^I6@"6BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*X[1?^2F>(?^O>#_ -!%=C7':+_R4SQ#_P!>\'_H(H [&BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \\TO_ )'C
MQ5_OP?\ H!KH*Y_2_P#D>/%7^_!_Z :Z"@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *V+K_EG]*QZV+K_EG]* *]%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 2M_QX3?Y]*RJU6_X\)O\^E95 !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 36?_'U%_O5?N?\ 7-_GM5"S_P"/J+_>
MJ_<_ZYO\]J (J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ J]:_ZE:HU>M?]2M $M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\0?\ C^\+
M?]A6'^==C7'?$'_C^\+?]A6'^= '8T444 <=\+_^0+J'_80F_I78UQWPO_Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% ''?$K_CWT'_L+0?R:NQKCOB5_P >^@_]A:#^35V- !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5ZU_U*
MU1J]:_ZE: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *X[X@_P#']X6_["L/\Z[&N.^(/_']X6_[
M"L/\Z .QHHHH X[X7_\ (%U#_L(3?TKL:X[X7_\ (%U#_L(3?TKL: "BBB@
MHHHH **** "BBB@ HHHH _/?X^?\$VO$7B_XG:SK_@34_#^FZ%J+_:C9:E//
M$\,S9,BH$A<;"W(YXW8QP*^1?@;\ /$/Q^\<7WA7P]>:99ZA:6DEY))J<LD<
M11)$0@%(W.<N.W0'FOVB^(6I:AH_@+Q)?Z1$9]5M=-N9[2)1DO,L3%!CW8"O
MS6_8E_:6^(NH?'+PSX1U?Q9-J.A:I-,D\>J*D\F1"[JJRN/,7+*H"AL<]*^@
MR_$5YPG"-FH15K_/[]CYS,<-AX3A4E=.<M;?*_I>X?\ #K7XK?\ 0P>#O_ V
M[_\ D:M#1/\ @E?\0I]0B36/%GAFRL21YDUBUQ<R =\(T48)_P"!"OTYHKE_
MM/$=U]QU_P!E8;L_O.8^&?P^TSX5> M$\)Z.'_L_2K<01O)C?(>2SMCNS%F/
MN:Z>BBO+E*4Y.4GJSU80C3BH15D@HHHJ2PHHHH **** "BBB@ KCO'W_ "$O
M"W_83CKL:X[Q]_R$O"W_ &$XZ .QHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH X[XE?\ 'OH/_86@_DU=C7'?$K_CWT'_ +"T'\FKL: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N.T7_DIGB'_KW@_]!%=C7':+
M_P E,\0_]>\'_H(H [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ^0/VEO^1V?_ 'W_ /0(Z\@KU_\ :6_Y'9_]
M]_\ T".O(*^@PO\ !C_74\?$?Q&%%%%=9SA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!]U?#G_DGOAC_ +!=K_Z*6NAKGOAS_P D]\,?
M]@NU_P#12UT-?+S^)GO1^%!1114%!1110!*W_'A-_GTK*K5;_CPF_P ^E95
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 36?\ Q]1?[U7[G_7-_GM5"S_X^HO]ZK]S_KF_SVH BHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "KUK_ *E:HU>M
M?]2M $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<=\0?^/[PM_V%8?YUV-<=\0?^/[PM_P!A6'^=
M '8T444 <=\+_P#D"ZA_V$)OZ5V-<=\+_P#D"ZA_V$)OZ5V- !1110 4444
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M!7K%?GU_P2_^(WDZGXL\#7$OR3QIJUHA/\2XCF ]R#$?^ FOK3]ISXC#X5_
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M:J-BD] 7+YQUP,]!7GX&E1HX66-K1YM;)=.WYW^X[\95JSKPPM*7+=7;^_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.V^OI;\C]%J*Y+XI?%3PU\&O!E[XH\5ZBNG:3:X!;!9Y7/W8XU'+.>P'N3@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KCOB#_Q_>%O^PK#_ #KL:X[X@_\ ']X6_P"PK#_.@#L:
M*** ..^%_P#R!=0_["$W]*[&N.^%_P#R!=0_["$W]*[&@ HHHH **** "BBB
M@ HHHH **** ,SQ-KD/A?PWJNLW +0:?:2W<@'4K&A8C\A7XQR6?Q1_;$^)F
MJ7MC97GBC6G#7#0+,J06<.["HK2,J1H,@ 9&>3R<U^P?Q:T>?Q%\*_&.EVHW
M7-[H]Y;1 #.6>%U _,U^<W_!-;XN>'OAW\1-?\.:]*UE=^)A:VVGSM&S*9T=
MP(3@$J6\T8)XRO)Z5Z^6^[[:I%7E%*WSO?\ +\#QLTLU1IR=HR;O\K6_-GS5
MX%^#OB_XE>-+GPEX=TC[=XBMA*9;&2YA@9?+;;(-TKJI(/8'/7TJ7QG\%?%W
MPU\5:?H'C/3&\*7-\RB.XU)O]&VE@"_F1[@57/S%<X]*^BOB)K4'[,O_  4(
MG\0W2O;:))J(OIFC4G_1KJ(B9@!R=K/(<#NG%=U_P46^/'PX^)/@#PUHOAG6
M;+Q'K4=^+T7%BWF+;0>6RLK-T#,63Y>HV<@<5ZZQ=67L)1C>,TK^3Z_=_F>*
M\%1C[>$I6E!NWFNGS?ZH^N?V6?ACJ'P=^!?AOPIJE[8ZA>V8GD:YTV1I+=Q+
M,\JE&95)&UQS@5ZQ7AG[$6N7_B']EWP)<ZB[23QVTMJKOU,44\D<?Y(BC\*]
MSKYS&<RQ%12=W=_F?38)Q>&IN"LK(****Y#M"BBB@ HHHH **** "N.\??\
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MW!%=QXFAU+X,_P#!/!8M*WVNIV_ANW#O%D/&]PR><P(Z$><YS[5\??\ !/\
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M10 4444 <=\2O^/?0?\ L+0?R:NQKCOB5_Q[Z#_V%H/Y-78T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/Q,\%6_P 1OA]XA\,W0'DZI92V
MVX_PLRG:WU#8/X5TU% T[.Y^,'P!\8W7P1_:$\/7]_FU.GZF;#448XVQL3#,
M#_N@D_517U/_ ,%/OB0/(\)^!K:;.\MJUVJMV&8X0?\ R*?P%>)?M^?#?_A
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M[U]-==GK\G8^F?\ @J9^\USX=R+RC6MYANWWH:]T_P""=_\ R;/I?_80N_\
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M5G_\<H_X:4^$7_15/!/_ (45G_\ '*4:\X24DMBIT83BX-[G5^//^1'\1?\
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MQ1AVCSUCD7(WQDX.,@@C(/4'<_9A^/%A^T1\(])\56WEPZCC[-J=FAS]GND
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MX4%%%%04%%%% $K?\>$W^?2LJM5O^/";_/I650 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% $UG_P ?47^]5^Y_US?Y
M[50L_P#CZB_WJOW/^N;_ #VH BHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "KUK_J5JC5ZU_P!2M $M9OB;_D6]5_Z]
M)?\ T UI5F^)O^1;U7_KTE_] -85_P"%/T?Y&U'^+'U1^&?[(O\ R<]\,?\
ML/6O_H8K]#O^"KO_ ";CHW_8R6__ *3W%?GC^R+_ ,G/?#'_ +#UK_Z&*_0[
M_@J[_P FXZ-_V,EO_P"D]Q7HXO\ A4_\7ZQ.'"?QJG^'])'S)_P39_9S\-_&
MSQ3XCUSQC8C6=&\.K"+;3+@DV\MQ*6.YUZ,%6+[IX.X9!Q7J'_!3;]G/P/X)
M^&^@>,_"?AG3O#5]'J2:==1Z1;+;0S1/'(REHT 7<&C^]@$[L'/&-/\ X)"?
M\BK\2O\ K]LO_1<M>B_\%3O^398/^P]:_P#H$M3C9.,XJ/3D_&U_S*P:4XRD
M^O-^%[?E?U//?^"0^M3S>#_B)I+.QMK>^M;J-<\!I(W5C^(B7\J^=_\ @IQ_
MR=9JG_8,LO\ T77O'_!(+_D'?$[_ *ZZ?_*>O!_^"G'_ "=9JG_8,LO_ $75
M8K_>:?R_]((PW\&HO7_TI'Z$^ _@OX-^.'[*/PJT;QMHW]M:;:Z#IUW##]JF
MM]LHM%4-NB=2>&88)QS7Y*? 'P=I'C;]H/P9X:UJT^VZ)J&M16ES:^:\?F1,
M^"NY2&''<$&OVA_9K_Y-O^&G_8L:?_Z3)7X\?LK_ /)UWP[_ .QC@_\ 1M;0
M_P"1C4CTO_[<R)?\B_FZI+\F?K_X?^"/@KX%_"SQ;I'@?1?[$TZ[MKFZFA^U
M3W&^7R"N[,KN1PH& <<5^3/[!/\ R=O\//\ KYG_ /2:6OV?\>?\B/XB_P"P
M=<?^BFK\8/V"?^3M_AY_U\S_ /I-+6.#DY8F3;Z+_P!N-L2DL.DO[WZ'ZE_M
M1_LKZ5^U%H^CV.K>)-5T*/2I))H8[$1M"\C #?(C+EBH! PPQN;UKPOP7X&_
M9/\ V7_!;Z+XRU_P9XUUY)7-[?7]E%J-V6R<(($$S0A1@8'<$GK7GW_!5+X[
MZ_IOB+1OAGI%_<:=I,M@-1U,6[E#=EW9$C<CDHHC)V]"6&?NBLO]E/\ X)M^
M'?BO\,M$\<>,_$NHB'5XS<6^EZ-Y<7EQARH\R5U?).WD*HQGJ:QHING*2=HW
M_K\BZS2G&+UE;^OS_$^1OVAM8\":U\8M?U'X9VDVG^$)I4DL[>2'R0C;%\S8
MF250N&*@XP#C QBOV;U'X7^%/VBO@KX1LO'FDMKEA+96>I^0]S-;L)S;_>+1
M.K9Q(W&<<U^0O[8?P_\ "GPK_: \0^%/!L#0:+I:6\6U[AIV\TPHTF68DYW,
M<CL01@5^U?PS_P"29^%/^P1:?^B4JY.+P=X[*UK^CU_(S?-'%:Z.SV^7],_#
M?X2^#](\3?M%>&/#&I6GVG0[SQ%#83VOFNF^!IPA3>I##Y>,@Y]Z_:'P1\"_
M!'P)\"^(],\#:)_8=C>QRW-Q%]KGN-\@B*[LRNY' ' (%?CO\!_^3M_!?_8W
M0?\ I4*_<3Q-_P BWJO_ %Z2_P#H!J<1)_44^Z=_/2)M22^OR71-6\M6?B5^
MPW_R=A\./^P@W_HF2OM7_@JU\8+[PSX#\.> M-N'M_\ A())+K4&C)!>WB*A
M8S[,[ G_ *Y^]?%7[#?_ "=A\./^P@W_ *)DKZ9_X*\>&[E/$/P\U\1L;.2U
MNK%I/X5D5T<#ZD.?^^36V)UC2B]G)_DFOQL88?251K?E7YO]+E__ ()P_LC>
M#O&7@&;XC^-=&M?$<UU=26VF6&H1B6VBCC.UY&C/RNS/N'S @!<CDUK_ /!1
M']C[P9H?PNG^(O@K0K/PU?Z1+$M_9Z9"L-M<6[N(]WE+A5=693E0,@MG/&/5
M_P#@F3XQL?$/[+VFZ3!,C7NA7UU:W,(/S+OE:9&(]").#_LGTK8_X**^,-/\
M+_LJ^*+6[F1;K6'M["SA+8:20S([8'?"(S?A6>-DXS]WI:WX?G^II@TI+WNM
M[_C^1X;_ ,$G?C%?ZMI?B?X<:C<-/;Z8BZGI@=LF*-WVS1C_ &=[(P'J[>M?
M,G_!1C_D[WQK_N6/_I'#7L'_  2/\,WEQ\3/&WB (1I]II*6328X,DLRNH!^
MD+?F*\?_ ."C'_)WGC7_ *YV/_I'#6E;_>:;ZN+O]_\ E8SP_P#"JKHO\XO\
M[GWI^R=^QO\ #?1?@IX=U3Q)X1TOQ3XCUZPBU&_O-<M5NV5IE$@1!("$VA@,
MJ 20237YN_MA?"_2_@W^T5XM\,Z%"UKHT$L5Q9PEBWE1RQ))L!/)"EB!GL.I
MK]HO@O\ \D=\"_\ 8!L/_2=*_)C_ (*4?\G:>)/^O.R_])TJ*LG'&66VJ_R_
M(K#VEA;OLG\]/\S]:O@]K,_B+X2^"M5N6+W-[HMG<2LW4NT",Q_,FNOK@/V?
MO^2$_#O_ +%[3_\ TG2N_HQ&E::7=_F3A]:,/1?D?GM_P5B^,%]I.B^%_ASI
M]PT$&J!M3U((<>;&C;88SZKO#L1ZHOI2?\$[/V/_  5X@^%\/Q&\::%9^)K_
M %::5+"SU.$36UO!&YC+&)LJSLRMRP. %QC)SP7_  5P\-W%M\3_  1KY1OL
MEYI#V2OCY=\4S.1]<3+7U=_P3I\96/BK]E7PO:6TT;7>BO<:?=PJ>8W$SNN1
M[I(A_&EAM,-.:WO^%VOT2^9>(_C0A]FWXVO^=W\CY\_X*._LB^#_  AX C^(
M_@K1K7PY+9W,=OJ=AI\8BMI8I#M218U^5&5]H.T $-D\BMC_ ()C_$3_ (6E
M\*?&OPF\4%]3TNPAQ!%)(RDV5R'26 ,I#!0V2,$$>9P1@5ZG_P %-/%VG^'_
M -E_4M*N9D6^UN]MK:TAS\SE)5E<@>@5.3[CUKP+_@D1X:O&\0?$+Q 8RNGI
M:VU@LA'#REV<@'V"C/\ O"C#>_3JPGK'_@)_G^=@Q'N2I3CI+_@V_+\KGSK^
MW5\*_"_P;_:!O_#7@_2_[(T6*QM9DM?M$L^'=,L=TK,W)]Z_0O\ 8Y_99^%^
MA?#WX:_$FQ\,>1XTDTB&[;4_[0NFS++ 5D;RC*8^0[#&W SQBOA__@IQ_P G
M6:I_V#++_P!%U^FW[)__ ";1\,?^Q?L__12U=&4OJKE?7FM\KR)JQ7UA1MIR
M_I$]7KS']I[_ )-S^)?_ &+U]_Z(:O3J\Q_:>_Y-S^)?_8O7W_HAJ\^M_#EZ
M,[L/_&AZK\S\7OV<OC/_ ,,__%S1_'']C_V]_9Z3+]@^U?9O,\R)H_\ 6;'Q
MC=G[ISBOL?4_^"P%[+9RKI_PLM[6[*GRY;G76FC4]B46W0D>VX5\O?L5_#?P
MY\6OVBO#?ACQ7IW]JZ'>1W33VOGR0[REO(Z_/&RL,,H/![5^GD?_  3Q_9\B
M<,OP^4D?WM8U!A^1GKUJ]K1Y^VGWO]3RZ7Q2Y-^I^3\</CG]K3XW2.D+:OXK
M\178>4PQE8H%X7<<9V11H ,GH%[GK^Q?Q$\'V_P]_9&\3^&+1O,MM'\%W5@D
MF,%Q'9,FXCU.,_C79?#KX/\ @KX26,MIX.\,:;X>BF $S64 62;'3?)]Y\9.
M-Q/6LW]H?_D@7Q)_[%O4?_2:2N#$U(_5I4H*R2_33[CNPT)/$QJ3=W=?F?C!
M^RG\([3XX_'KPKX1U$R#2KJ9YKWRB58P11M(Z@CIN"[<]MV:_4+]HK]D/X42
M_ #Q;%I'@31M&U'2=(N+RPO]-M$ANEEAB9UW2@!I 2N#O)SD]^:^!_\ @FG_
M ,G:>'?^O*^_])WK]8_C9_R1OQW_ -@&^_\ 2=ZWS"3A17+_ "M_/7_(PP*4
MZ[YNZ7RT?ZGY1_\ !,W7KC1_VJ]'M(I'6'4["\M9T4\.HB,HS]&C4U^AO[57
M[(.D?M0+I,^K>*M5T%M'BD6WCMUCDM07(+2.C $MA0,[QP/K7YO?\$Y?^3N/
M!_\ URO?_266O6_^"I'QV\07GQ*A^&EA?SV/AW3[.*YO;>%RHO)Y!N'F8^\J
MKMPIXR2?3&F+U=%+=K]9&>&T=5]-/T1[/X:T/]D/]F_P';Z!XFU;P5XSUB$,
M+W4;BPBU2\FER<_(@E:$#H%! &.3G)K\XOBEKGA?_A<FM:Q\.X;C3O# U$76
ME13)Y;PJ"&  W$@!L[><XQTZ5]N?LU_\$R?"WCCX<^'/&'C;Q)J=R^LVD6H1
M:;HY2"...10RH\C*S.2I&=H3!) )QD_'7[2_A/PYX#_: \7^'?"47D>']+OE
MM+>/SVF*E$02 NQ))\P/GG@\<8Q6E)<N,C&4O>_#=?TAZ2H/EC[NGXIGZL?M
MW3:OJ'['?B^?2%E\V6UM9+D)]_[.9HS+T[;<Y]L]J_-G]CWXI_"'X8^)-6D^
M*_@A?%4%XL<=E=R6L=['9X+;]UO(0K!LK\P!8;< <FOV*\:>-/"7@GP>MUXT
MU?2]'T2YC%J[:O,D<,Q9#F+#G#$J&^7G(!XKX1NOV(?@)^TQJ&NWGP7\?R:1
M=V$B?;+.&W>ZLH2^XKL638X#%6Y5V48P .E<E*7).I973_#^OU\RK>THT[NS
M_/\ X/\ 70T/&WPE_99_:UNM&'P_\:>'_A]K44VR6VL;!;%[U"/]4MM)Y0+@
MX(= W<$'C'U[^SW\"M._9U^'J>$=*UK4]:L([F2Y234VC+1%\;D0(JX3(+8.
M3EFYYK\G/VC/V&?'O[-_A\>(M6O-)UKP\URML+S3IG#QLV=GF1NJD9P?NEA[
MU]D_\$L_C%XB^('@'Q7X5UZ^GU.'PY);&PN;ER\B0S"0>3N/)53%QGH&QT
MU2O2FZ+VW7W?=T?]:J3<9Q]HO1_?]_8^'/C1XT;]H?\ :LU&YUS6(M-TB_UQ
M=+BO;J94AL;%9O*5MS':JJF7.>,ECWK]"]6^&O['FH_#N3PG%K?PTLT^S>3%
MJT.LV(U%'Q@2_:=_F,P//)(/0C'%?F+#X-TZV^/@\*^+KBYTW2U\1'3=3N(G
M5988_M'ER.&8$ @9.2".,X-?I W_  2=^#Z1F1O$OC18P-Q8W]G@#US]EZ5*
MC'ZI!-Z/K\E_P_S-)M_6IVU:_P V?$_[%_CZZ^#O[5_AVVM=06YT[4-1.@7;
MVSAH;J*5_+1@0<$;_+<$>GO7[8U\0_##_@GO\!3XDT?Q%X3^(.M^(;C2[R*^
M@%IK5A<Q,\3AP&\NWR5RHS@CZBOMZJJR4J<$]U?]/UN1"+4Y2V3_ .#_ , *
M**^6_P!M[]L:V_9Q\-)HN@M#>>/M4B+6L3X9+&(Y'VB1>YR"%4]2"3P"#QR=
MMM6=,8\PS]MK]LK2_P!GWPO<^'M#N([[X@ZC 5M[=&##3T88^T2^A[JO<\]!
MS\E?\$U_V;=2\>_$B'XH:Y;2IX=T.5I+*6<'_3K[D KG[RQY+%O[VT<_-A/V
M0?V*M8_:6U9_B;\3KR\D\-75RTX2:1OM6LR;OF8OU6+/!8<G!"XZU^I^B:'I
M_AO2+/2M*LH-.TVSB6&WM;:,)'$BC 55'  KKA'ZM>3UF_P_K\]>R.:4OK'N
MQ^!?C_7_  .[+U%%%<QN%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\
M0?\ C^\+?]A6'^==C7'?$'_C^\+?]A6'^= '8T444 <=\+_^0+J'_80F_I78
MUQWPO_Y NH?]A";^E=C0 4444 %%%% !1110 4444 %%%-DD2&-Y)&"1J"S,
MQP !U)HVU8#J^89_V$_#&G_M!Z+\3- U!M+@MK\ZA=Z&T(>%YL,0T39!C^<A
MMI!'7&.E?*W[2'_!0GQEXL\47^D_#W4F\->&+61H8[RW1?M5[@X,A<@F-3U4
M+@XZDYP/&/#?[7GQC\+ZDE[;?$+6[MU/,.I7)O(F'H4EW#\N?>O<PN!Q*2JQ
MERM_EY_U^)X.+S#"MNC./,E^?E_7X'Z+_MA?L=P_M(6]AJ^CZA!H_BW3HC!'
M+=*?(NH22PCD*@LN&)(8 XW$8.1CY6\%_P#!+WXA:AK\$?B;6M%TC1E?]_/9
MS/<3LOI&A11D^K$8SG!Z5]C_ +(O[3EO^TEX'N+B[MX=.\3Z4RPZE9PD^6VX
M'9-&#R%;#<$D@J1D\$^\US1KXG -T.WZZZ?F=,L/ALP2K[W^6W?TV,7P9X1T
MOP#X4TKPYHMO]FTK3+=+:WCSDA5&,D]R>I/<DFMJBBO.E)R;E+=GIQBH148J
MR04445)04444 %%%% !1110 5QWC[_D)>%O^PG'78UQWC[_D)>%O^PG'0!V-
M%%% 'RG^VU^R[XX_:2OO"R^&M3T.PTW28YS*FJW$T;/+(4Y41Q.,!4'4CK7;
M?L=?L_ZG^SK\+KK0-<N=/O-7N]1DO9IM-=WBVE$1%#.B$X">G>O=J*Z8XB<:
M/L%\/_!N<LL-3E76(?Q+_*P4445S'4?)O[;'[*WCG]I+6O#$GAO5-"L=,TFW
MF5X]5N)HW:61ER0$A<8VHO4CO7J/[*'P3OO@#\&[#PKJL]G=:L+F>ZNYM/9V
MA9W?Y=I958X0(.5'(KV&BNE8B:H_5U\/_!N<KP]-U_K#^+_@6"ODW]I?]@#0
M/C9KUSXH\/:H/"WB6Y^:[5H/-M;M\??9004<]V&<]USDU]945E3J2I24X.S-
MJE.%:#A45TS\P]-_X)8?$:74$2_\5>%[:RS\TUM)<S2 >H0PH"?;<*^S/V;?
MV2_"7[-]A-+ISR:SXDNH_+NM:ND"N5X/EQ("1&F0#C)).,L<#'N%%=E7'5ZT
M>24M#BHY?AZ,N>,=3\T/^"J'B[[?\2/"/AM')33=->\=>P>:3;^>V$?G6C\,
MOV ]-^,O[,O@_7K74?\ A'O&5RL]T;B2,R07,+2MY:2*#D855(8?WCD'C%3]
MK;]E7XT_&+X]>(_$>C^#S>Z(YBM[&<ZI9Q[HHXU7.UY@PRVXX(!YK]!_AUX7
M7P1X \-^'D4*-+TZWLR%Z9CC52?S!KK594,#3C3E[U[^:O=Z_>CC=!XC,*DJ
ML?<2MY:66GXO3U/ST\*?\$K?&5QK"+XF\7Z%8Z4#EY-)$US.PST"R1QJ"1WR
M<>AK[]^%/PG\-_!?P99^&?"]E]DT^#YG=SNEN)"!NED;'S.<#GH,     =A1
M7#6QE;$+EF]#NH8&AAY<T%J?GC\6O^">OQ,^*7QD\1>+)M=\+Q:=JNIM<"-K
MNY,R6^["J1]GQN" #&<9'6OT)M;:.SM8;>%0D4*"-%'0*!@#\JEHK.IB)U*<
M*3VCM^7Z&M/#TZ=6=:/Q2W_,_/+XN?\ !/;XF?%3XR>(O%L^N^%HM.U74VN!
M&UW<F9+?< JD?9\;A& ,9QD=:_0>SM8K&T@MH%"0PHL:*.@4# 'Y"IJ^>_VS
M/ _Q3\=>!]%M_A5>7=EJUM?F>Y>PU3[!,\?ELH59-ZY&6R06'2J=:=:-.A)V
MC'1?@M250A1G4KQ5Y2NW^+T]3YI_X*K:GHEUXA\"V4-Y')K]K!<M<VR')C@<
MQ^66],E7P/J?K3_X)E_ G^W/$M_\3=5M\V6DEK+2@XX>Y9?WD@_W$;:/>0]U
MKD_!/_!/'XP_$+QA]J\>LOA^TFE$E]J5]J,5]=S#OL$;ON<^KL!]>A_33P+X
M'T;X;^$=,\->'[1;'2=.A$,$*\G'4LQ[LQ))/<DFO5E6A@\)]7ISYI.^W2[N
M_P#+\=#R(T9XW%_6*L.6*MON[;?UZ+4WJ_._XG_\$\OB9\3/C'K_ (LN]=\+
M)IVJZJ]T8_M=SYR6Y?Y5Q]GQN$8 QNQD=>]?HA17CX>O/#5/:4]_Z_R/:Q&'
MABJ?LJFV_P"?^9C>(_".E^+/"=_X;U.U6XT>^M6LYK?H#&R[<#TXZ>F*_.[Q
MC_P2O\71:_,/"OBW1+K1&;,;:P9H+E%)^Z1'&ZL0/XLKGT%?I513HXBIAY.4
M'ON*OAJ6(@H5%HMO(_.O6/\ @EAJEOX"C32O%EA?>,GNT>22]62VL8[<(P9%
MVK([/N*G<0!@8P._T'^Q1^SGXK_9Q\,^)=)\3WFC7PU"[CNK>329Y9,80JP?
MS(DQT7&,]37TC16T\=7J0E3F[J7_  /\C"G@*%.<:D%9Q_X._P!YXS^TM^R_
MX<_:4\.VUKJ4[Z5K=CN-AJ\$8=HMV-R.I(WH<#Y<@Y&01SGXHN/^"6'Q&746
M2'Q3X7DL-V!/))<K*5]?+$)&?;?^-?I[144,75PZY:;T[&F(P='$M2J+7N?-
M'[,O[#GAC]GW4%\07E\WBCQ:$*1WTL(BAM 1AO)CR<,0<%R2<= N2#[#\9_A
M98?&GX::WX.U&XDL[?4H@JW,0RT,BL'1\=\,HR.XR.*[:BL:M:I7ESU'=_UL
M;4:-/#QY*:LC\P[S_@EI\2K;4F_L_P 5>%Y;16_=W$TUS#*1ZE%A8 ^VX_6O
M>OVCOV.?&'Q,^%WPS\$>$M3T.SL/"UH8[IM3GFB\^;RT0.H2)\\B0G.#\_>O
ML*BNJ6.KU.7F=^5W^?\ 3.6&7T*?-R*W,K;]#PG]CG]G_5/V=?A?=Z!KEU87
MNKWFHR7LTVFN[Q;2B(BAG1&. F>G>M7]I+]F7PY^TEX7@L-5EDTS5[(LVGZO
M @=X"V-RLI(WH<#*Y'0$$5[#17-4K3J5/;-^\=-.A3I4O8I>[_F?F'=?\$L/
MB,FI,EMXJ\+RV&["SRR7*2E?4QB%@#[;_P :^G_V9?V%?#/P"U2/Q%J-^WBG
MQ8BE8;J2$16]ID8)BCR3NP2-['IT"Y.?IVBNJ>88BI'D<CEIY=AJ<^=1"BBB
MO./2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH X[XE?\>^@_P#86@_DU=C7'?$K_CWT'_L+0?R:NQH **** "BBB@ HHHH
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M)_ 8  KJ***\Z<Y5).4G=L[(1C3BHQ5D@HHHJ"PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N.T7_DIGB'_KW@_P#0178UQVB_\E,\0_\ 7O!_
MZ"* .QKEOBIX6N_''PQ\7>'+"2&&^U?2;NP@DN&*QK)+"R*6(!(7+#. 3CL:
MZFBIE%2BXOJ5&3A)26Z/@;]CW]@/Q]^S_P#&RQ\8^)-6\-7VG6UI<0>7IEU<
M23;Y$V@@/ BXY.>>]>F?MV?LAZ]^T_:^$Y_"]]I.GZMH[SI*^K2RQI)#($.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ZOAS_R
M3WPQ_P!@NU_]%+70USWPY_Y)[X8_[!=K_P"BEKH:^7G\3/>C\*"BBBH*"BBB
M@"5O^/";_/I656JW_'A-_GTK*H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@":S_P"/J+_>J_<_ZYO\]JH6?_'U%_O5
M?N?]<W^>U $5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5>M?\ 4K5&KUK_ *E: ):S_$,;S:!J<<:-)(]M*JJHR22A
MP /6M"BHG'GBX]RX2Y)*78_%W]EOX!_$[P_^T5\.]2U3X<^+=-TZUUJWEN+R
M\T.ZBAA0.,L[M& H'J37W9_P4R\$^(O'GP#TG3_#.@:IXBOT\003-:Z39R74
MJQB"<%RD:DA06 SC'(]:^MJ*Z*M1U8QB^CO^7^1C2C[*<IKJK?G_ )GPQ_P2
MS^'?BOX>^&OB#%XI\,:SX:ENKNS:!-8T^6T:4*DH8H)%&X#(SCU%=Y_P4D\&
M^(/'7[/,.F^&]"U+Q#J(UJVE-II5G)<R[ DH+;$!.!D<X[BOJNBIK2]M)2>G
MP_\ DMO\AT8^Q32\_P ;_P"9\&_\$L?AOXM^'MA\1%\5>%M:\--=2V)MQK&G
MS6AFVB;=L\Q1NQD9QTR*\6_X*(?!CX@^-OVEM2U3P[X%\2Z_ICZ=:(M[I>D7
M%S"66/# .B$9'<9K]6Z*JI-U*D:CZ?Y6)IP]G"4%U_SN>>_L\Z7>:+\!/AWI
MVHVD]A?VOAZQ@N+6ZC:.6&1;= R.K %6!!!!&017Y3_%S]D3XR?!/XQ76J>$
M_"VMZO:6VIM?Z+K'A^S:\VJ)-\198U8HR\ JZ@9!QD<G]FJ*)5&Z[KK1N_XN
MXXP2I>Q>JT_#0^3OV4=7^-7B[X0_$*?XO66K#5[A'&F)J%C':RO&8&4HD$:J
M5^8#JH)W<9KXK_8H^!?Q)\*_M0>!-5UOX?>*M'TNVN)FGOK_ $6Y@@B!MY0"
MSN@5>2!R>I%?L+150J\E5U8K=)6]+_YDRI\U+V;??\3XG_X*'?L?^(/CF-(\
M9^";=+_Q'IEN;.ZTQI%C>ZM]Q=6C+$#>A9_E)&0W'( /RC\);/\ ; \%Z.W@
M+P;HWC+1-*F=PL-WI2PPPEOO&.YN(P(@3D_(ZC))ZFOV&HK.G+V:<-T^AI47
M.U+JNI^*OQP_8@^+?PZU;26?1M8\>ZCJ]H;[4+O0M/N+Y;>Y:1M\4DJJQ9L;
M6+'&2QQG&3^L_P"SSJVH:U\#_!,VKZ3?Z'JL>E06UW8:I;26\\4L2"-]R. P
M!*$@D<@@]Z]#HJ_:-TW3:ZW_ #T_$S]FN=37:WY?Y'XV?'+]D'XO_"+XT:AK
M'A/PMK6M6"ZJVI:-JWA^T>[:,>9YD>Y(PS(Z' .X 97C(K[D_8YUSXV^+/ /
MCRY^,-GJZ7\P4:6-2L8[1V7RI ZK"BJ1SMZJ,Y[U]7T5E>]!T'M:WIM^.AK_
M ,OE66][^O\ P#\<?V-_@3\2O"_[37@#5-9^'GBK2=,MKYGGO;[1+F&&)?*<
M99V0*HR0.3WK]1/V@_@3H7[1'PUOO"6N%K<N1/9W\:[I+.X4$)*HXSU(*Y&0
M2..H]*HK2K/VL%!K;_@?Y$4X^SDYI_UK_F?CZW[-?[37[)/B^ZU+P/9ZK>(W
M[H:EX7C%]%=)U DMBK,<>DD> >A/6DG^ ?[4'[77BNQN/&UAK-O% ?*%]XFM
MQIMO:(<;F2WVH23@9\N,DX&>F1^P=%-57HYJ[7]?UL)P6O+I<\P_9U^ 6A?L
MY?#>T\*Z*QNI=QN+_49$"R7EP0 TA'88 "KDX '4Y)_-S]O7X(_$7QA^U+XN
MU;0? /BC6]*G2S$5]INC7-Q!)MM8E;:Z(5.""#@\$$5^N5%9N3E5]K+?^O\
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M[-O[2_[7'C*TU#QW::M8Q1_NFU/Q/"+&*TCX+>7;;5//HB $XR1UK]/?@/\
M!'0/V?OAOI_A'0%:2&#,MS>2 "2[G;&^5_<X  [  =J]#HK5U/=Y(JR,O9^]
MSR=V?E)_P40^#'Q!\;?M+:EJGAWP+XEU_3'TZT1;W2](N+F$LL>& =$(R.XS
M7Z'_ +,NDWV@_L]_#O3M3LKC3M0M=#M8;BTNXFBEA<1@%71@"I!Z@C->F45$
M9<M)TO._Y_YERCS5/:>5OR_R"O._VBM+O=<^ OQ"T_3K2>_O[K0KR&"UM8FD
MEE=H6"HBJ"68G@ #)KT2BLI1YHN/<UA+DFI]C\D/V"/@E\1?!W[47A75=?\
M /B?0]+ABNQ+?:EHUS;P)NMI%7<[H%&20!D]37ZWT45T5*KJ*-UM_G<YH4U!
MM]PKAOCMIUWK'P1^(%C86LU[?76@7\,%M;QF2261K=PJ*H&68D@ #DDUW-%<
MTX\\7'N=,)<DU/L?DW_P3Y^"OQ"\%_M/:#JOB'P'XFT+2X[2\5[W4]'N+>%2
MT#!07= H))P.>:_3;XO6-SJ7PG\:6=G;RW=W<:+>10V\"%Y)':!PJJHY))(
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MERO&<[21R4)_&NYKY^<)4Y.$E9H^DA.-2*G!W3"BBBH+"BBB@ HHHH ****
M"N.\??\ (2\+?]A..NQKCO'W_(2\+?\ 83CH [&BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#COB5_P >^@_]A:#^35V-<=\2O^/?0?\ L+0?
MR:NQH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[1?^2F>(?^O>
M#_T$5V-<=HO_ "4SQ#_U[P?^@B@#L:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y _:6_Y'9_\ ??\ ] CKR"O7
M_P!I;_D=G_WW_P#0(Z\@KZ#"_P &/]=3Q\1_$84445UG.%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'W5\.?^2>^&/\ L%VO_HI:Z&N>
M^'/_ "3WPQ_V"[7_ -%+70U\O/XF>]'X4%%%%04%%%% $K?\>$W^?2LJM5O^
M/";_ #Z5E4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!-9_P#'U%_O5?N?]<W^>U4+/_CZB_WJOW/^N;_/:@"*BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O
M6O\ J5JC5ZU_U*T 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5QWQ!_X_O"W_85A_G78UQWQ!_X_
MO"W_ &%8?YT =C1110!QWPO_ .0+J'_80F_I78UQWPO_ .0+J'_80F_I78T
M%%%% !1110 4444 %%%% !6)XV\,Q^-?!NN^'I9VM8M6L9[%IT7<T8DC9"P'
M<C=FMNBDU=68TVG='PE_PZE\._\ 0_ZI_P" $?\ \51_PZE\._\ 0_ZI_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\G_M >']4U[Q
MM/\ V9IMYJ/E.WF?9('EV92/&=H.,X/Y&O,?^%?>*?\ H6M8_P# "7_XFOKO
M2_\ D>/%7^_!_P"@&N@KNIXJ5."@D<L\.IR<FSXD_P"%?>*?^A:UC_P E_\
MB:/^%?>*?^A:UC_P E_^)K[;HK7Z]+^4S^JQ[GQ)_P *^\4_]"UK'_@!+_\
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M_P#$T?\ "OO%/_0M:Q_X 2__ !-?;=%'UZ7\H?58]SXD_P"%?>*?^A:UC_P
ME_\ B:/^%?>*?^A:UC_P E_^)K[;HH^O2_E#ZK'N?$G_  K[Q3_T+6L?^ $O
M_P 31_PK[Q3_ -"UK'_@!+_\37VW11]>E_*'U6/<^)/^%?>*?^A:UC_P E_^
M)H_X5]XI_P"A:UC_ , )?_B:^VZ*/KTOY0^JQ[GQ)_PK[Q3_ -"UK'_@!+_\
M31_PK[Q3_P!"UK'_ ( 2_P#Q-?;=%'UZ7\H?58]SXD_X5]XI_P"A:UC_ , )
M?_B:/^%?>*?^A:UC_P  )?\ XFOMNBCZ]+^4/JL>Y\2?\*^\4_\ 0M:Q_P"
M$O\ \31_PK[Q3_T+6L?^ $O_ ,37VW11]>E_*'U6/<^)/^%?>*?^A:UC_P
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MC6?_  7R_P#Q-'_"N?%G_0L:S_X+Y?\ XFONFBCZ]+^4/JL>Y\+?\*Y\6?\
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M%<^+/^A8UG_P7R__ !-'_"N?%G_0L:S_ ."^7_XFONFBCZ]+^4/JL>Y\+?\
M"N?%G_0L:S_X+Y?_ (FC_A7/BS_H6-9_\%\O_P 37W311]>E_*'U6/<^%O\
MA7/BS_H6-9_\%\O_ ,31_P *Y\6?]"QK/_@OE_\ B:^Z:*/KTOY0^JQ[GPM_
MPKGQ9_T+&L_^"^7_ .)H_P"%<^+/^A8UG_P7R_\ Q-?=-%'UZ7\H?58]SX6_
MX5SXL_Z%C6?_  7R_P#Q-'_"N?%G_0L:S_X+Y?\ XFONFBCZ]+^4/JL>YA>
M[>6S\#>';>XB>">+3K9)(I%*LC")05(/((/:MVBBO-;N[G:M%8****0PHHHH
M E;_ (\)O\^E95:K?\>$W^?2LJ@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** )K/_CZB_WJOW/^N;_/:J%G_P ?47^]
M5^Y_US?Y[4 14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !5ZU_U*U1J]:_ZE: ):*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[X@_\ ']X6
M_P"PK#_.NQKCOB#_ ,?WA;_L*P_SH [&BBB@#COA?_R!=0_["$W]*[&N.^%_
M_(%U#_L(3?TKL: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "N.\??\A+PM_V$XZ[&N.\??\ (2\+?]A..@#L:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ..^)7_'OH/_ &%H/Y-7
M8UQWQ*_X]]!_["T'\FKL: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%\9Z\/#'A35
MM5ZM:V[R(,=7Q\H_[ZQ6U7!_'-9&^%/B 1G#>7&3]!*A/Z9K.I)QA)KL88B3
MIT9S6Z3_ "/ESX=^&7\?>.M/TZX=W2XE,MS)GYB@RSG/J<8SZFOICQ-\;?"W
M@/6DT&9+AFMT5'^R1*8[<8&U3R.@QP <5XM^S*\:_$E@_P!YK&4)]<J?Y UU
M?Q_^#MQ-=77BO1T:<.-]]:J,LN!CS%]1@<CMUZ9QXU#GIT'4IK6^OH?(X+VU
M#!2KX=7E?7T1[]97MOJ5G#=6LR7%M,H>.6,Y5E/0@U2\2^)=/\(Z-<:GJ<X@
MM81R>K,>RJ.Y/I7RS\'?C+<?#^Y%AJ!DNM!E;)C7E[=C_$GMZK^(YZX_Q,^)
M6H_$[7%8J\5A&VRSL5YQGC)QU<__ %A72\='V?,OB['H2SJG]7YXKW^W]="'
MXB_$/4OB;X@$\JLELK>79V,>6" G]6/&3_3%9&GW6H^!/%<$[1R6FHZ=<!GC
M/!!!Y4^Q&0?8U]&?!'X++X3ABUS6H@^M2+F&!N1:J1_Z&1U].GK7B/QM>.3X
MI^(3']WSE!^HC4']<UY]6E.$%6F_>;/!Q.%K4J4<76E[\G_7]=#[+M+J.^M8
M;F([HID61#ZJ1D5-6)X(62/P7H"RG,JZ?;A_KY:YK;KZ.+NDS] A+FBF^H44
M44RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.T7_ )*9XA_Z
M]X/_ $$5V-<=HO\ R4SQ#_U[P?\ H(H [&BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \\TO_D>/%7^_!_Z :Z"N
M?TO_ )'CQ5_OP?\ H!KH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K8NO^6?TK'K8NO\ EG]* *]%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 2M_P >$W^?
M2LJM5O\ CPF_SZ5E4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!-9_\?47^]5^Y_US?Y[50L_^/J+_ 'JOW/\ KF_S
MVH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "KUK_J5JC5ZU_U*T 2T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5QWQ!_X_O"W_ &%8?YUV
M-<=\0?\ C^\+?]A6'^= '8T444 <=\+_ /D"ZA_V$)OZ5V-<=\+_ /D"ZA_V
M$)OZ5V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7'>/O\ D)>%O^PG'78UQWC[_D)>%O\ L)QT =C1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!QWQ*_P"/?0?^PM!_)J[&N.^)
M7_'OH/\ V%H/Y-78T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69XFT6/Q)X>U'2Y<
M!+NW>'<?X200#^!P?PK3HI-75F3**DG%[,^&_"^LWGPX\=6MY-"R7.G7!CN(
M#P2.5D7ZX)%?;.EZI:ZWIMO?64RW%I<()(Y%.0P/^>E>)?'[X.SZO+)XFT.
MS76W_3;6,9:0 <2*.Y &"._!]<^5?#;XO:Q\-Y7AA5;W3)'W2V4Q(&>[(W\)
M_,>U>+3F\'-TZGPL^/P]:64UI4*R]Q[/]?\ ,])^,'[/\]Q>MJ_A2V5_.;-Q
MIRD+M8_QQY(&#W7MV]!N?!3X'_\ "*LFMZ_"CZOU@MLAEMO]HD<%_IT^O30T
MG]I;PA?0JUVUYILO\22P%Q^!3.?TJ#7/VG/"^GP-_9T-WJL_\*B/RD_%FY'X
M UNHX6,_:\W]>AVJ.60J_65->E^O>VYZ-XP\56?@SP[>:M?.!% A*IG!E?\
MA1?<G_'M7QGH>G7OQ&\=PP,#)=:G=F29E_A#,6=OH!D_A5KQQ\0M<^)^K0M>
M#<JMLM;&V4E4R>@'5F/'/4_I7T#\"?A(_@>Q?5M5C UJZ3:(N#]GCZ[?]XX&
M?3@>M82D\;548KW4<52I+.,3&$%^[CO_ %^1ZO#"EO#'%&H2.-0JJ.@ & *?
M117MGV04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QVB_
M\E,\0_\ 7O!_Z"*[&N.T7_DIGB'_ *]X/_010!V-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YYI?\ R/'BK_?@
M_P#0#705S^E_\CQXJ_WX/_0#704 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5>M?]2M4:O6O^I6@"6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.^(/\ Q_>%O^PK
M#_.NQKCOB#_Q_>%O^PK#_.@#L:*** ..^%__ "!=0_["$W]*[&N.^%__ "!=
M0_["$W]*[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KCO'W_(2\+?]A..NQKCO'W_(2\+?]A..@#L:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** ..^)7_'OH/\ V%H/Y-78UQWQ
M*_X]]!_["T'\FKL: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\\\<? WPWXV
ME>Z,+:7J#'+7-GA=Y]77H?KP?>O0Z*B<(U%:2N8U:-.O'DJ1NCYHU#]E368Y
M'^PZU8SIGY3<(\1/UP&J72_V4]1>9?[2URUAB_B^RQM(WT&[;^=?25%<GU*C
M>]CR_P"Q\'>_+^+.*\"_"/P[X!VRV5J;F_QS?76'E_X#QA1]!]<UVM%%=D8Q
M@K15D>K3IPHQY*:L@HHHJC4**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!*W_'A-_GTK*K5;_CPF_SZ5E4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!-9_\ 'U%_O5?N?]<W^>U4
M+/\ X^HO]ZK]S_KF_P ]J (J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J]:_ZE:HU>M?\ 4K0!+1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5X:_Z"B?]^W_ /B: .GHKF/^%E>&O^@HG_?M_P#XFC_A97AK_H*)_P!^W_\
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M+*\-?]!1/^_;_P#Q-'_"RO#7_043_OV__P 30!T]%<Q_PLKPU_T%$_[]O_\
M$T?\+*\-?]!1/^_;_P#Q- '3T5S'_"RO#7_043_OV_\ \31_PLKPU_T%$_[]
MO_\ $T =/17,?\+*\-?]!1/^_;__ !-'_"RO#7_043_OV_\ \30!T]%<Q_PL
MKPU_T%$_[]O_ /$T?\+*\-?]!1/^_;__ !- '3T5S'_"RO#7_043_OV__P 3
M1_PLKPU_T%$_[]O_ /$T =/17,?\+*\-?]!1/^_;_P#Q-'_"RO#7_043_OV_
M_P 30!T]%<Q_PLKPU_T%$_[]O_\ $T?\+*\-?]!1/^_;_P#Q- '3T5S'_"RO
M#7_043_OV_\ \31_PLKPU_T%$_[]O_\ $T =/17,?\+*\-?]!1/^_;__ !-'
M_"RO#7_043_OV_\ \30!T]%<Q_PLKPU_T%$_[]O_ /$T?\+*\-?]!1/^_;__
M !- '3T5S'_"RO#7_043_OV__P 31_PLKPU_T%$_[]O_ /$T =/17,?\+*\-
M?]!1/^_;_P#Q-'_"RO#7_043_OV__P 30!T]%<Q_PLKPU_T%$_[]O_\ $T?\
M+*\-?]!1/^_;_P#Q- '3T5S'_"RO#7_043_OV_\ \31_PLKPU_T%$_[]O_\
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M#7_043_OV_\ \30!T]%<Q_PLKPU_T%$_[]O_ /$T?\+*\-?]!1/^_;__ !-
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M8_X65X:_Z"B?]^W_ /B:/^%E>&O^@HG_ '[?_P")H Z>BN8_X65X:_Z"B?\
M?M__ (FC_A97AK_H*)_W[?\ ^)H Z>BN8_X65X:_Z"B?]^W_ /B:/^%E>&O^
M@HG_ '[?_P")H Z>BN8_X65X:_Z"B?\ ?M__ (FC_A97AK_H*)_W[?\ ^)H
MZ>BN8_X65X:_Z"B?]^W_ /B:/^%E>&O^@HG_ '[?_P")H Z>BN8_X65X:_Z"
MB?\ ?M__ (FC_A97AK_H*)_W[?\ ^)H Z>BN8_X65X:_Z"B?]^W_ /B:/^%E
M>&O^@HG_ '[?_P")H Z>BN8_X65X:_Z"B?\ ?M__ (FC_A97AK_H*)_W[?\
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M  H_X6%X>_Z"2?\ ?M_\* .BHKG?^%A>'O\ H))_W[?_  H_X6%X>_Z"2?\
M?M_\* .BHKG?^%A>'O\ H))_W[?_  H_X6%X>_Z"2?\ ?M_\* .BHKG?^%A>
M'O\ H))_W[?_  H_X6%X>_Z"2?\ ?M_\* .BHKG?^%A>'O\ H))_W[?_  H_
MX6%X>_Z"2?\ ?M_\* .BHKG?^%A>'O\ H))_W[?_  H_X6%X>_Z"2?\ ?M_\
M* .BHKG?^%A>'O\ H))_W[?_  H_X6%X>_Z"2?\ ?M_\* .BHKG?^%A>'O\
MH))_W[?_  H_X6%X>_Z"2?\ ?M_\* .BHKG?^%A>'O\ H))_W[?_  H_X6%X
M>_Z"2?\ ?M_\* .BHKG?^%A>'O\ H))_W[?_  H_X6%X>_Z"2?\ ?M_\* .B
MHKG?^%A>'O\ H))_W[?_  H_X6%X>_Z"2?\ ?M_\* .BHKG?^%A>'O\ H))_
MW[?_  H_X6%X>_Z"2?\ ?M_\* .BHKG?^%A>'O\ H))_W[?_  H_X6%X>_Z"
M2?\ ?M_\* .BHKG?^%A>'O\ H))_W[?_  H_X6%X>_Z"2?\ ?M_\* .BHKG?
M^%A>'O\ H))_W[?_  H_X6%X>_Z"2?\ ?M_\* .BHKG?^%A>'O\ H))_W[?_
M  H_X6%X>_Z"2?\ ?M_\* .BHKG?^%A>'O\ H))_W[?_  H_X6%X>_Z"2?\
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M+*\-?]!1/^_;_P#Q-'_"RO#7_043_OV__P 30!T]%<Q_PLKPU_T%$_[]O_\
M$T?\+*\-?]!1/^_;_P#Q- '3T5S'_"RO#7_043_OV_\ \31_PLKPU_T%$_[]
MO_\ $T =/17,?\+*\-?]!1/^_;__ !-'_"RO#7_043_OV_\ \30!T]%<Q_PL
MKPU_T%$_[]O_ /$T?\+*\-?]!1/^_;__ !- '3T5S'_"RO#7_043_OV__P 3
M1_PLKPU_T%$_[]O_ /$T =/17,?\+*\-?]!1/^_;_P#Q-'_"RO#7_043_OV_
M_P 30!T]%<Q_PLKPU_T%$_[]O_\ $T?\+*\-?]!1/^_;_P#Q- '3T5S'_"RO
M#7_043_OV_\ \31_PLKPU_T%$_[]O_\ $T =/17,?\+*\-?]!1/^_;__ !-'
M_"RO#7_043_OV_\ \30!T]%<Q_PLKPU_T%$_[]O_ /$T?\+*\-?]!1/^_;__
M !- '3T5S'_"RO#7_043_OV__P 31_PLKPU_T%$_[]O_ /$T =/17,?\+*\-
M?]!1/^_;_P#Q-'_"RO#7_043_OV__P 30!T]%<Q_PLKPU_T%$_[]O_\ $T?\
M+*\-?]!1/^_;_P#Q- '3T5S'_"RO#7_043_OV_\ \31_PLKPU_T%$_[]O_\
M$T =/17,?\+*\-?]!1/^_;__ !-'_"RO#7_043_OV_\ \30!T]%<Q_PLKPU_
MT%$_[]O_ /$T?\+*\-?]!1/^_;__ !- '3T5S'_"RO#7_043_OV__P 31_PL
MKPU_T%$_[]O_ /$T =/7'?$'_C^\+?\ 85A_G5K_ (65X:_Z"B?]^W_^)KGO
M%'BS2?$&J>&H=/O%N9$U.%V5588&X#/(% 'I%%%% ''?"_\ Y NH?]A";^E=
MC7'?"_\ Y NH?]A";^E=C0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5QGQ!19-0\+HZAE;4XP589!KLZX[Q]_R$
MO"W_ &$XZ .F_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?
M*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\
MWZ7_  JW10!4_LFQ_P"?*W_[]+_A1_9-C_SY6_\ WZ7_  JW10!PWQ%T^UAM
M]"\NVA3=JL*G;&!D8;@^U==_9-C_ ,^5O_WZ7_"N9^)7_'OH/_86@_DU=C0!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?
MV38_\^5O_P!^E_PJW10!4_LFQ_Y\K?\ []+_ (4?V38_\^5O_P!^E_PJW10!
M4_LFQ_Y\K?\ []+_ (5R.CZ?:M\1]?C-M"8UMX2J&,8'RCH*[FN.T7_DIGB'
M_KW@_P#010!TW]DV/_/E;_\ ?I?\*/[)L?\ GRM_^_2_X5;HH J?V38_\^5O
M_P!^E_PH_LFQ_P"?*W_[]+_A5NB@"I_9-C_SY6__ 'Z7_"C^R;'_ )\K?_OT
MO^%6Z* *G]DV/_/E;_\ ?I?\*/[)L?\ GRM_^_2_X5;HH J?V38_\^5O_P!^
ME_PH_LFQ_P"?*W_[]+_A5NB@"I_9-C_SY6__ 'Z7_"C^R;'_ )\K?_OTO^%6
MZ* *G]DV/_/E;_\ ?I?\*/[)L?\ GRM_^_2_X5;HH J?V38_\^5O_P!^E_PH
M_LFQ_P"?*W_[]+_A5NB@"I_9-C_SY6__ 'Z7_"C^R;'_ )\K?_OTO^%6Z* *
MG]DV/_/E;_\ ?I?\*/[)L?\ GRM_^_2_X5;HH J?V38_\^5O_P!^E_PH_LFQ
M_P"?*W_[]+_A5NB@"I_9-C_SY6__ 'Z7_"C^R;'_ )\K?_OTO^%6Z* *G]DV
M/_/E;_\ ?I?\*/[)L?\ GRM_^_2_X5;HH J?V38_\^5O_P!^E_PH_LFQ_P"?
M*W_[]+_A5NB@"I_9-C_SY6__ 'Z7_"C^R;'_ )\K?_OTO^%6Z* *G]DV/_/E
M;_\ ?I?\*/[)L?\ GRM_^_2_X5;HH J?V38_\^5O_P!^E_PH_LFQ_P"?*W_[
M]+_A5NB@"I_9-C_SY6__ 'Z7_"C^R;'_ )\K?_OTO^%6Z* *G]DV/_/E;_\
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M-C_SY6__ 'Z7_"C^R;'_ )\K?_OTO^%6Z* *G]DV/_/E;_\ ?I?\*/[)L?\
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MH_LVT_Y]8?\ OV/\*LT4 5O[-M/^?6'_ +]C_"C^S;3_ )]8?^_8_P *LT4
M5O[-M/\ GUA_[]C_  H_LVT_Y]8?^_8_PJS10!6_LVT_Y]8?^_8_PH_LVT_Y
M]8?^_8_PJS10!6_LVT_Y]8?^_8_PH_LVT_Y]8?\ OV/\*LT4 5O[-M/^?6'_
M +]C_"C^S;3_ )]8?^_8_P *LT4 5O[-M/\ GUA_[]C_  H_LVT_Y]8?^_8_
MPJS10!6_LVT_Y]8?^_8_PH_LVT_Y]8?^_8_PJS10!6_LVT_Y]8?^_8_PH_LV
MT_Y]8?\ OV/\*LT4 5O[-M/^?6'_ +]C_"C^S;3_ )]8?^_8_P *LT4 5O[-
MM/\ GUA_[]C_  H_LVT_Y]8?^_8_PJS10!6_LVT_Y]8?^_8_PH_LVT_Y]8?^
M_8_PJS10!6_LVT_Y]8?^_8_PH_LVT_Y]8?\ OV/\*LT4 5O[-M/^?6'_ +]C
M_"C^S;3_ )]8?^_8_P *LT4 5O[-M/\ GUA_[]C_  H_LVT_Y]8?^_8_PJS1
M0!6_LVT_Y]8?^_8_PH_LVT_Y]8?^_8_PJS10!6_LVT_Y]8?^_8_PH_LVT_Y]
M8?\ OV/\*LT4 5O[-M/^?6'_ +]C_"C^S;3_ )]8?^_8_P *LT4 5O[-M/\
MGUA_[]C_  H_LVT_Y]8?^_8_PJS10!6_LVT_Y]8?^_8_PK7NM*LALQ9V_3_G
MDO\ A5&MBZ_Y9_2@#-_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR
M_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_
MWZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^
M_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_P
MJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?2#_OTO\
MA1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5
M_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\
M/I!_WZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y
M](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]
M^E_PJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?2#_O
MTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU
M10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V7
M9?\ /I!_WZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_SZ0?]^E_PJU10!5_L
MNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?2#_OTO\ A1_9=E_S
MZ0?]^E_PJU10!5_LNR_Y](/^_2_X4?V79?\ /I!_WZ7_  JU10!5_LNR_P"?
M2#_OTO\ A1_9=E_SZ0?]^E_PJU10!$VEV7V&4_8[?/\ UR7V]JR_[-M/^?6'
M_OV/\*WF_P"/";_/I650!6_LVT_Y]8?^_8_PH_LVT_Y]8?\ OV/\*LT4 5O[
M-M/^?6'_ +]C_"C^S;3_ )]8?^_8_P *LT4 5O[-M/\ GUA_[]C_  H_LVT_
MY]8?^_8_PJS10!6_LVT_Y]8?^_8_PH_LVT_Y]8?^_8_PJS10!6_LVT_Y]8?^
M_8_PH_LVT_Y]8?\ OV/\*LT4 5O[-M/^?6'_ +]C_"C^S;3_ )]8?^_8_P *
MLT4 5O[-M/\ GUA_[]C_  H_LVT_Y]8?^_8_PJS10!6_LVT_Y]8?^_8_PH_L
MVT_Y]8?^_8_PJS10!6_LVT_Y]8?^_8_PH_LVT_Y]8?\ OV/\*LT4 5O[-M/^
M?6'_ +]C_"C^S;3_ )]8?^_8_P *LT4 5O[-M/\ GUA_[]C_  H_LVT_Y]8?
M^_8_PJS10!6_LVT_Y]8?^_8_PH_LVT_Y]8?^_8_PJS10!6_LVT_Y]8?^_8_P
MH_LVT_Y]8?\ OV/\*LT4 5O[-M/^?6'_ +]C_"C^S;3_ )]8?^_8_P *LT4
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M'5E;VM_X7:&"*)CJL()C0*>OM7<5QWQ!_P"/[PM_V%8?YT =C1110!QWPO\
M^0+J'_80F_I78UQWPO\ ^0+J'_80F_I78T %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<=X^_P"0EX6_["<==C7'
M>/O^0EX6_P"PG'0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% ''?$K_ (]]!_["T'\FKL:X[XE?\>^@_P#86@_DU=C0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5QVB_\ )3/$/_7O!_Z"*[&N.T7_ )*9XA_Z
M]X/_ $$4 =C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >>:7_R/'BK_ 'X/_0#705S^E_\ (\>*O]^#_P! -=!0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %;
M%U_RS^E8];%U_P L_I0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"5O^/";_ #Z5E5JM_P >$W^?2LJ@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )
MK/\ X^HO]ZK]S_KF_P ]JH6?_'U%_O5?N?\ 7-_GM0!%1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7K7_4K5&KUK_J
M5H EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KCOB#_Q_>%O^PK#_ #KL:X[X@_\ ']X6_P"PK#_.
M@#L:*** ..^%_P#R!=0_["$W]*[&N.^%_P#R!=0_["$W]*[&@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCO'W_
M "$O"W_83CKL:X[Q]_R$O"W_ &$XZ .QHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH X[XE?\ 'OH/_86@_DU=C7'?$K_CWT'_ +"T'\FKL: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.T7_DIGB'_KW@_]!%=C
M7':+_P E,\0_]>\'_H(H [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \\TO_D>/%7^_!_Z :Z"N?TO_D>/%7^_
M!_Z :Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *V+K_EG]*QZV+K_EG]* *]%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 2M_QX3?Y]*RJU6_X\)O\ /I65
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $UG_ ,?47^]5^Y_US?Y[50L_^/J+_>J_<_ZYO\]J (J*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J]:_P"I6J-7
MK7_4K0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7'?$'_C^\+?]A6'^==C7'?$'_C^\+?\ 85A_
MG0!V-%%% ''?"_\ Y NH?]A";^E=C7'?"_\ Y NH?]A";^E=C0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QWC[
M_D)>%O\ L)QUV-<=X^_Y"7A;_L)QT =C1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!QWQ*_X]]!_["T'\FKL:X[XE?\>^@_\ 86@_DU=C0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5QVB_\E,\0_P#7O!_Z"*[&
MN.T7_DIGB'_KW@_]!% '8T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'GFE_\CQXJ_WX/_0#705S^E_\CQXJ_P!^
M#_T UT% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5L77_+/Z5CUL77_+/Z4 5Z*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH E;_CPF_SZ5E5JM_QX3?Y]*RJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH FL_\ CZB_WJOW/^N;_/:J%G_Q]1?[U7[G_7-_GM0!%1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %7K7_ %*U1J]:
M_P"I6@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N.^(/_']X6_["L/\Z[&N.^(/_']X6_["L/\
M.@#L:*** ..^%_\ R!=0_P"PA-_2NQKCOA?_ ,@74/\ L(3?TKL: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.
M\??\A+PM_P!A..NQKCO'W_(2\+?]A..@#L:*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ..^)7_'OH/_86@_DU=C7'?$K_ (]]!_["T'\FKL:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.T7_DIGB'_ *]X/_01
M78UQVB_\E,\0_P#7O!_Z"* .QHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** //-+_ .1X\5?[\'_H!KH*Y_2_^1X\
M5?[\'_H!KH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K8NO\ EG]*QZV+K_EG]* *]%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 2M_QX3?Y]*RJU6_X\)O\
M^E95 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 36?_ !]1?[U7[G_7-_GM5"S_ ./J+_>J_<_ZYO\ /:@"*BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *O6O^
MI6J-7K7_ %*T 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5QWQ!_X_O"W_85A_G78UQWQ!_X_O"W
M_85A_G0!V-%%% ''?"__ ) NH?\ 80F_I78UQWPO_P"0+J'_ &$)OZ5V- !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7'>/O^0EX6_["<==C7'>/O^0EX6_["<= '8T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <=\2O^/?0?^PM!_)J[&N.^)7_ ![Z#_V%H/Y-
M78T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=HO_)3/$/_ %[P
M?^@BNQKCM%_Y*9XA_P"O>#_T$4 =C1110 4444 %%%% !1110 4444 %%%%
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M%_\ %5\1T5M]1C_,9?6I=C[<_P"%A>%O^AET?_P/B_\ BJ/^%A>%O^AET?\
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MT,NC_P#@?%_\57Q'11]1C_,'UJ78^W/^%A>%O^AET?\ \#XO_BJ/^%A>%O\
MH9='_P# ^+_XJOB.BCZC'^8/K4NQ]N?\+"\+?]#+H_\ X'Q?_%4?\+"\+?\
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M-X4_Z&?1O_!A%_\ %5\*T4?48_S!]:EV/NK_ (6-X4_Z&?1O_!A%_P#%4?\
M"QO"G_0SZ-_X,(O_ (JOA6BCZC'^8/K4NQ]U?\+&\*?]#/HW_@PB_P#BJ/\
MA8WA3_H9]&_\&$7_ ,57PK11]1C_ #!]:EV/NK_A8WA3_H9]&_\ !A%_\55C
M3_&GA[5KR.TL==TR]NI,[(+>\CD=L DX4-DX )_"O@VO0_V?_P#DKF@_]O'_
M *3R5$\'&,7*^Q4<2Y22L?9%%%%>4>@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!*W_'A-_GTK*K5;_CPF_P ^E95 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 36?\ Q]1?[U7[G_7-_GM5"S_X^HO]
MZK]S_KF_SVH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "KUK_ *E:HU>M?]2M $M%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\0?^/[P
MM_V%8?YUV-<=\0?^/[PM_P!A6'^= '8T444 <=\+_P#D"ZA_V$)OZ5V-<=\+
M_P#D"ZA_V$)OZ5V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$L92C4E2>\5=_(^S**_,7_AYW\4O^@!X0_\  .Z_^2:/^'G?Q2_Z 'A#_P
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MN/,\TL\@'RI]Q<*"V.?F.<!Q3G?EZ;_U\Q2:@DY==CZ$HHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /D#]I;_ )'9_P#??_T".O(*]?\ VEO^1V?_ 'W_ /0(Z\@K
MZ#"_P8_UU/'Q'\1A11176<X4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z'^S_P#\E<T'
M_MX_])Y*\\KT/]G_ /Y*YH/_ &\?^D\E8UOX<O1FE/XX^I]D4445\T>X%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!*W_'A-_GTK*K5;_CPF_SZ5E4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!-9_\
M'U%_O5?N?]<W^>U4+/\ X^HO]ZK]S_KF_P ]J (J*** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\0?^
M/[PM_P!A6'^==C7'?$'_ (_O"W_85A_G0!V-%%% ''?"_P#Y NH?]A";^E=C
M7'?"_P#Y NH?]A";^E=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5QWC[_ )"7A;_L)QUV-<=X^_Y"7A;_ +"<
M= '8T444 1W%PEK;RS2MLCC4NS'L ,DU^'5O'+\:OV@HU(:5_$_B/GN=L]QS
M^0;]*_7[]I3Q8? _P#\>:PKB.6'29XXF/_/21?+3_P ><5^,GPR^(%_\*_'F
MC>+-,M;.]U#2IO/@AU!&>$OM(!8*RDXSD8(Y KWLGC^\G4[)6_-_DCY[.I?N
MH4N[=_DM/S9^T8_9U^%*J!_PK+P=_P""&U_^-U^>G_!1[X6^!_AGXZ\+_P#"
M):9::'=ZA9RRWVGV*".$!758Y!&.$+?..  =N>N<Q:C_ ,%/OBW?6SQ0Z;X5
MT]V&!-;V$Y=?<;YV&?J*\:T'PS\3/VMOB;)*@O?$VNWCJ+O4IUQ!:Q]F=@-D
M2 9PH ]%!)Q6V%P>(IUE4JRM%7Z[Z?TS'%8W#5:+I4H7E*UM-M5_PQ]^?\$W
M]2GTO]E_4+W4&<6%KJMY-"6Z")8XV;'MNW_CFN>^&_\ P4VT_P ;>,[?2M3\
M$)X=T@I-/=:O-K?FBWBCC9RWE_9UW$[0H4-DE@!7I_Q.\-V'[-'[$_B#0=,F
M^73M$DLA<D;6FN)SL>3'JSRL?;\*_-/]FGX'W7[0'Q7T[PM'.]GI^QKK4;J,
M M#;(1N(SQN)*J,\98'M4TZ=+&UJ]67PK9]K)Z_=9V*J5*V!H8>E#XFW=?-:
M?BU<^J]4_P""EWC+Q?\ $6QT/X=^"]+ELKV[2SM(]7$LEU<LS!5/[N15CSGI
M\V/6OI[]H3]K+PM^SCHUJFMC^UO%5U")(=$T]P&;C!=V/^KCW9 8@DX. <''
M1>%?@#\+_A'IMM?Z/X,T>QFT:)IH]4:T22\3"'<QG8&0G&?XN]?DQ<W6M_M4
M?M%1BXN'-]XGU984=OF%M 6P !_=CC'3_9K&C1H8RHJ5*-HQU;ZOM^IO6K8C
M!4W5K2YI2T2Z+OZVT/>]6_X*H?$2:^9],\*>&+2RS\L-VEQ/(!Z%UE0'_OFO
M>?V;?^"AVB_%SQ#9^%_%VE1^%]>O&$5I=0S%[.ZD/1/F^:)B>%!+ GC<"0#]
M)_#_ .$_A7X8^#;?PQH&C6MKI4<0CE0Q*S7)QAGF./G9NY/\N*_)G]M+P#I7
MPG_:0U[3_#4:Z=8,(+^"WMCM%J\B!RJ8^Z V2 .@( Z5=%X3$U?8*G9='?7^
MOO,ZRQN%I?6)5+OJK:?U]Q^R4TR6\+RR,%1%+,QZ #DFOA33?^"J&DW'BR*P
MOO C6&B_:3'+JHU@RLD()_>"(6V6.!D+NZG&>]>^^//B=<Z?^QS>^-;IPFH7
M/A..X+9_Y>)X%4?^/R"OS2_8X^"UK\<OCAI>C:I&9="LHWU'48P2/,BC( CR
M.@9V13WP3BL<'A82G5]OM#_@W_(VQN,J1IT7A]Y_\"WYGO'C;_@JEXIFUJ3_
M (1#PCH]II"L0AUOS9YY%SPQ\N1%0G^[\V/4U](_LF_MGZ9^T=)=:)J&FKH'
MBVTA\]K6.3?!=1@@,\1/(()&4.2 003SCUSQ]\(_"GC3X9WW@^]T6QCT,VC0
MV]O' L:6I"G8\0 PA4X((QC%?DQ^QOJ5QX?_ &I? AMI2&;46M'*G 9'1T8?
M3!K7#PPV+A.G"'*XK1W[WM^6OX&6)GBL'.%6<^92>JM:W]+9_>?HK^W_ .+#
MX5_9A\2I&^R;5)(-.3W#R N/^^$>OA3]B/XH>%O@7K/C+Q]XGE9VL]-33[#3
MX #/=S32!BJ ],"'ECP WN ?H/\ X*K^+!!X9\#>&D<[KF[GU"10>T:!%S^,
MK?E7/_\ !.+]F?1?$NFW/Q-\36,6I>3<M:Z19W,8>)63&^X*GAB"=J^A5CUP
M0\$HT\%5J3>DG^&BM]]_S%CW*IC:5."NXJ_SU=W\K>OS,"[_ ."J?CAM?\VU
M\'>'XM$WY^QS/.]R4[CS@X7/OY?X5][?!+XP:/\ '3X<:9XNT56AAN@8Y[20
MY>VG7AXF/?!Z'N"#WKXP_P""K.GZ1!)\/[N.WACUN87<;S*H#O OE[0Q[@,Q
MQZ9->F?\$P=-N;/]G_5+F;<(+S7IY( >FU8H4)'_  )6_*LYTZ%;!.O"'*T_
M7K8TA4Q%''*A4GS)KM;I?Y?Y,QO#_P#P4E_M7XLV'@B]^'7]FM<:RNCRWO\
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M45-J#NNGH>[3<W!.HK2Z^H4445F:!1110 4444 %%%% !1110 4444 %%%%
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M6\OUB?I#'\ ?AA#(KI\./"*.I#*RZ%:@@CH0?+KX?_X*C?\ )0O!7_8+E_\
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MLZEJ_P &/^$;\G^R[VSO_P"V_MV[S<V^_9Y'EC'^NQG>?N].>/#/V0?VR/\
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M%%?-'N!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 2M_QX3?Y]*RJU6_X\)O\^E9
M5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXK^$/BYHIU7P=XAL?$%BI"R-:29:)B,A9$.&0X[, :ZJ21(8VDD941069F.
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MUM[B*Z@CG@D2:&10Z21L&5E(R"".H(K\V?C7_P $M;&'P?;ZO\'-<U#Q)?\
MF+NL-6O+5DN(F."\4RK&@V]<'.1G!S@'Z8_8;^$OQ0^"?PWO?"_Q"NM/N;&&
M99=(BM;MIY;5&!\R)LH%"AL,N&/+-T&*KEA*+:=FN_4GFFFKJZ9]$:GJEGHN
MGW%_J-W!86-NADFNKJ18XHD')9F8@ #U->$WW[>_P#T_5GTZ7XB6;W"OL+P6
M5U-#GVE2(QD>X;%?$?\ P4V_:%U7Q=\49?AGIEY)#X;T$1_;((F(%W>,H?+X
M^\$#* .S;CZ8].\ _P#!)W0-3^&EG<^)O%>L67C.[M1,RV2Q?8[21ER(V1D+
MR;<X)#KG!QBLZ<>:G[:7P]//^O\ +O8TJ/EFJ2W_ "/O/PAXVT#X@:)%K'AK
M6;'7=+E.%N]/G6:/(ZJ2I.".X/(K;K\6_P!GCXD>)OV//VGW\/:E=LFFIJO]
MC:]:*Y\B:/S-@F /=<B16ZXR.C&OVCZ\BKG"*C&I!WC+^OU(C)\\J<U9H6O+
MOCM^TEX$_9VT1+[Q=JGE75PC-9Z7:KYEW=[>H1.PSQN8A1ZUZC7R_P#M7?L9
M/^U)X_\ ".H7GB)="T'1[66&Y2"'S+J<O(K;4SA4X!^8[L'^$UAJY);)[OMH
M;:)-GYG?M2?M1>(?VGO&D>IZC$-,T.Q#1Z7I$;[EMT8C<S-QND; RV!T  P*
M_1#_ ()9?\FPR_\ 8>N__0(:^</^"D'P5\(? KP/\*?#W@_2DTZS$FHO-,QW
MSW4FVV!DE<\LWZ#H !Q7T?\ \$LO^389?^P]=_\ H$-=M%P]A44-E_\ )(Y*
MRE[2E*>[_#22/L&BBBN,ZA"<<G@5XEXS_;8^"'@'5'T[5_B'IOVN,E7CT^*:
M^",.JLUNC@$>A.:^6_\ @J%^TMJV@7%E\*O#E])8)=6HN];GMV*O)&Y(CM\C
MD*0"S#N"HZ$@\?\ LJ_\$U=.^*WPWL/&/C[7-4TN'5XA/IVFZ.8HY5A/W99'
MD1Q\XY"A> 0<\X%TX^TBZCTBM":DE!J&\G_7]?YGZ!_#'X^?#SXS1N?!GBW3
M==E1=[VL4ACN47.-S0N%D SW*XKOZ_%O]J#]G'Q%^Q7\3-"U7P[K]W+IURS7
M.CZU'^ZN(9(R-T3[>-P#+R.&#=.HK]/OV1_CL?VAO@GI'B>Y6./68V:QU2.(
M847,>-S =@RE7 [;\=JTY(SI^TIO1;_U_70CFE":A/KM_7]=3L;#XW?#K5/$
M":%9>/O"]YK;S&W73;?6;9[EI02#&(P^XL"#\N,\5S/Q,_:P^$GP?U9M+\5^
M-[#3]30XDLH$ENYHCC($B0H[)P0?F ZU^-6M>(-=\+_M#:WJ7AF5X/$$/B&\
M6QDC4%UF:=T4J#QNRW'OBON[3?\ @D[HVI>"9;CQ!XXUF;Q]=1-/)=1>6UDM
MPWS$.K*9)!N."WF*6ZX'2LXQ_<QK/9K].G]=BG*U65)=/ZU_KN?9GPQ^-7@;
MXRZ?)>>"_$]AK\40!ECMW(FA!Z&2)@'3.#C<HSBNVK\*_P!FCQ;K/P7_ &G/
M"K0SM:W$.M1Z1J$:,=LD3S"&9&]1R2/=0>HK]0OV^OCMJ'P+^ ]S<:'<-:>(
M=;N%TNRN$.'M]RLTDJ^C!%(![,RGM55HQA3C4AJI;>NGX:H*3E*I*G/1K_@_
MY,[/XD_M<_"#X1ZPVD^*/'-C8ZI&<26=M%->2Q'TD6!'*'V;!KHO"/QZ^'7C
MKPE=^)]%\9Z/=:#9J&O+V2Z6%;0'IYPDVF+/^V!7Y1?L7_L>R_M4ZUK6JZ]J
MUWI?AC3)%2YN;4*US=W#Y;8C."%('S,Q#=5&.<CM/VO?V-+S]E#PVWBCP'XD
MU2\\)ZJO]D:K;7S(9T63E0Y1562-BG]T%6"]<Y#G!4DHS?O/;M=[7]11DZC;
M@M%^F]O3_@'Z>^$?BIX*^(%S<6WA;Q?H/B2XMT$DT.D:G!=/&I. S"-B0,\9
M-=.[K&K,S!549+,< #UK\OO^"1?_ "4KQ[_V"(?_ $=6U_P5 _:7U:W\01_"
M;P_?266GQVR7&N/ VUKAI!NCMR1_ $PQ'\6\9Z<JM#V;C&.KE_P?\@I2]ISM
M[1_X'^9];>+/VX?@9X*U)[#4_B)ISW*'##3H9[Y%/<%X(W4'VS7=?#/XX^ ?
MC);/-X,\5Z;KYC7?)!;R[9XESC+PL ZC/<J*^!/V:?\ @F+I?Q"^&NF^*OB#
MKVK:;/K$"W5EINCF*)H86&4:5Y$?)92&V@# /4GIX-^T3\"_%7[#_P 8M'O=
M U^Y,$F;W1-;A'E2_*0'BD4<%ER P^ZRL..2HTY(0G[*;U)4I3@ZD%H?M8W*
MGM7YM?#7]CKX9>'?CEX?\167[2'A/6-4M-=BO8M#MUM?/N)1,&$"XO6;<3\O
M"DY[=J^T/V9/C5'^T!\%-"\8&-+>_GC:WO[>/[L=S&=L@'H#PP'HPK\?_@/_
M ,G;^"_^QN@_]*A10A*.,5.]GW^:_P"'%5FI824]UV^3_P"&/V_\4>,-!\#Z
M6=3\1ZWIV@::'6,WFJ7<=M"&/1=[D#)[#-9>D_%CP1KV@:AKNF>,= U+1-._
MX_=2L]3@EM[;C/[R16*IP0>2.M?.?_!4'_DUFY_[#%G_ #>O@W]C_P"#/B;]
MIJ]OOATGB&?0O =G,-;U<VZ!C))A8XU R-S$ [=V0N&;!/!QHQ=932W3_1-_
M@V:U)*GRM[/_ #:7XV/TNA_;O^ T^N#25^(U@+HOY?F/;7*V^?\ KN8_*Q[[
ML>]>Y:;J5IK&GV]]I]U#?6-Q&)8;FVD$D<J$9#*P)!!'<5^4'[;'[!NB?LY^
M!=.\7^$M;U34M,:[6RO;75S&\B,ZL4D1XT0;<KM*E<\CFO:O^"2GQ#U'6/!O
MC7PA>7+SV6CW%O>622'/E+,)!(J^B[HPV/5CZUK"$*D).#UCO^'^=S.<I4Y1
MYEH_Z_/0^[]=U_3/"^D76JZQJ%KI6F6J>9/>7DRQ11+ZLS$ #ZUXI8?MW? ?
M4M=&D0_$:P6[+^6))[:XAM\_]=WC$6/?=CWKX(_X*7_'K5/'7QDN? 5I=21^
M&O#)2-K:-B$N+QD#/(X[E0P09Z8;^\:];^$?_!*?0M=^&MAJ7C7Q-K-CXHU"
MV6X%KI@A6"RWJ"L<@=&:1AGYL,HSD#IDYTH\U/VTOAZ>?_#FE27+-4H[_P!?
MD?<_B3XQ> O!LEHFO^-_#FAO>0BXMEU+5K>W,\1X$B;W&Y3_ 'AQ71:/K6G^
M(M+M=3TJ^MM3TVZ02V]Y9S++#,AZ,CJ2&!]0:_!_]H3P+XI^$?CZ?X>^)M2?
M4U\-@P:=*<^6;60^:C1@\JK;RVW)VDL*_8O]CS_DU[X9?]@2#^57[.+I>UB[
MZ_@[_CH0Y2514VNG^7^9[%1116!J%%%% !1110 4444 %%%% !1110 4444
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M^1S8O#5(T:$5'F4-TOD>J?MS?#/X0? 7X.0Z)X7\+:7I_BG6+F-+>0DW%W%
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M*/\ @!KYQ\??&+4_'W@#P%X6NR_V;PM:36Z,S9\PO*2IQ_LQB-!_NFOU(_;
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M^OE%>M#.:ZJ*I-)V37;>W^1YDLKH^S<(-J[3^Z_^9^/.N?\ #27]BZA_;/\
MPM3^R/L\GVS[=_:7V?R=IW^9N^79MSG/&,YKSCX<?\)K_P )(O\ P@/]O?V_
MY3X_X1OS_M7E\;O]3\VWIGMTK]H_BMHM[XD^%_B_2--A^TZA?Z1=VMM#N5=\
MCPNJKEB ,D@9) KXJ_8J_9<^)WPD^-D6O^+/#/\ 96DKI]Q ;C[?:S?.VW:-
ML<K-S@]J];"YI"I3JN<8Q:6B[Z/3^NYYV)R^<)4U&3E=Z^6VO]=CJ?C5X5\3
M^)O^"?&ER>(X]4E\3:7'!J%ZNK^9]K!69E<R>9\^0CD_-V%>;?\ !,GXC:9X
M?\8^*O"VHWD5I/K4,$]D)G"B62(N&C7/5BLF0.N%-?HIJNEVFN:7=Z=?VZ7=
MC=Q-!/!(,K)&P(92/0@FOS>^,W_!-_QCHNO7-U\/&M_$6AS.6AL;BY2"[MP?
MX"9"J.!V;<">X[GS\'BJ-:-;#UWRJH[KLGV^5E^)VXK"U*?L:M+WG35O-I=?
MQ=SK_P#@I[\1-,O(?"?@VTNX[G4;:>34+R.-PQ@&W9&& Z$[G.#S@>]>G_\
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MB-V?'T4GVKHE+#9G1I^VJ<LHZ._7O;]-]]B/W^ Q%2=*',I.Z\M[?GKW+?\
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M'^NIX^(_B,****ZSG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O0_P!G_P#Y*YH/_;Q_
MZ3R5YY7H?[/_ /R5S0?^WC_TGDK&M_#EZ,TI_''U/LBBBBOFCW HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** )6_X\)O\^E95:K?\>$W^?2LJ@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K/_CZB_P!Z
MK]S_ *YO\]JH6?\ Q]1?[U7[G_7-_GM0!%1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %7K7_4K5&KUK_J5H EJIJ_\
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M$/\ WNK\OSD?A5\!P%_:V\%@# _X2VW_ /2D5^E/[>G[7&H_LW>&=)TKPO'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!QWQ*_P"/?0?^PM!_)J[&N.^)7_'OH/\ V%H/Y-78T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<=HO_ "4SQ#_U[P?^@BNQ
MKCM%_P"2F>(?^O>#_P!!% '8T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'R!^TM_P CL_\ OO\ ^@1UY!7K_P"T
MM_R.S_[[_P#H$=>05]!A?X,?ZZGCXC^(PHHHKK.<**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *]#_ &?_ /DKF@_]O'_I/)7GE>A_L_\ _)7-!_[>/_2>2L:W\.7HS2G\
M<?4^R****^:/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH E;_CPF_SZ5E5JM_Q
MX3?Y]*RJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH FL_^/J+_ 'JOW/\ KF_SVJA9_P#'U%_O5?N?]<W^>U $5%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M>M?]2M4:O6O^I6@"6FNBR*RLH96&"K#((]*=10!P6F? 'X8:+J=MJ6G?#CPC
M8:C;2K-!=VNA6L<L4@.0ZNL8*L#R"#FN]HHIW>PNMPI.O!Y%+12&<)I7P%^&
M6A:M;ZIIOPZ\)Z=J=M()H+VUT.UBFBD!R'5UC#*V>X.:[NBBG>ZLPZW.$L/@
M+\,M+U>'5;+X=>$[/5()A<17UOH=JD\<H.0ZN(]P8'G(.<UW+*LBLK*&5A@J
M1D$>E.HI=+!UN<58_!'X=:9K2ZQ9^ ?"]IJZOY@OX-&MDG#?WA($W9]\UH^,
M/AKX0^(7V7_A*O"NB>)?LN[[/_;&G0W?D[L;MGF*=N<#..N!7244=@\S)\+^
M$="\$Z4NE^'=%T_0--5VD6STNUCMH0QZL$0 9/<XI?$7A/1/&%A]AU[1M/UN
MRSG[-J-JEQ'GUVN"*U:*'KN"TV.*\/\ P1^'7A/4$OM$\ ^%]&OD.5N=/T:V
M@D7Z,B BNUHHIW;W%9"5PVI? ?X9ZUJ+ZAJ'P[\)W]^[;VNKG1+:25F]2S(2
M37=44NMQ^17L=/M=+LXK2RMH;2UB7;'!!&$1!Z!1P!5BBB@ HHHH YSQA\-_
M"/Q"6U'BKPMHOB86FXVXUC3X;OR=V-VSS%.W.U<XZX'I5OPKX-T#P+I9TWPW
MH>F^'M.\PR_8]*M([:'><9;8@ R<#G'85L44;:(-]PHHHH *Y3Q5\)_!'CJZ
M2Y\2^#?#_B&X086;5=+@N7 ] 9$)KJZ* ,OP[X7T;PCIZV&A:18Z+8J<BUTZ
MV2WB!]0J "M2BBG>^X;;'"1_ 3X91ZPNK)\.O"::JL_VH7RZ':B<3;MWF;_+
MW;]W.[.<\UW=%%'2P=;G"-\!/AD^L'5F^'7A-M5,_P!J-\=#M?/,V[=YF_R]
MV_=SNSG/-<?^UW\8?%GP(^$,GC+PGH]CK4ME>PK?PWZ2,B6K[E9QL92"',8R
M<@ GBO:Z@OK&VU2RGL[VWBN[2X1HIK>= Z2(1@JRG@@CL:B7-:R>W]?CL5&U
M[M;GYT>!_P#@H5\*?C%KZ6_QL^&>@6,4,!,&M7-B-617R/D\IH&= 1DY4MTQ
MCG-4_P!M+]LCX3>,/@+-\.?ABXO5OIH-WV/37L;2TACD$A 61$.25  5<<DY
M['WOQM_P3*^"?B^_DN[2RUCPLTC%WCT2^"QY)R<),D@4>RX ["J?A7_@ES\%
M?#NH)<WH\1>)$4Y%MJNHJL1^OD1Q,?SKH?LYI)Z6U^YW_K8R3G!MK4\N_P""
M2/P[U#3]#\;^-;J!X;'47@TZR=E(\WRB[2L/4 NBY'<,.U?H95#0=!TWPOH]
MII.CV%OI>F6<8BM[.TB$<42#HJJ!@"K].M4]I*ZV7]?\$FG#D6N[.2\4?"'P
M)XXO!>>(_!7AW7[L# N-4TJ"YDQ_O.A-;F@^'=*\+:='I^BZ99Z181_<M;"W
M2")?HJ@ 5HT5ALK&N[N%<)8? 7X9:7J\.JV7PZ\)V>J03"XBOK?0[5)XY0<A
MU<1[@P/.0<YKNZ*%H[H'JK,R/%'@_0?'&EG3/$>B:=K^FEUD-GJEI'<PEAT;
M8X(R.QQ5+P?\-/"'P]-T?"OA31/#)N]OVC^Q].AM/.VYV[_+4;L;FQGID^M=
M)10M-@WW,GQ-X3T/QMI+Z7XBT;3]>TQV5VLM3M8[F%F4Y4E'!4D'IQ6?X/\
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MZA_V$)OZ5V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7'>/O\ D)>%O^PG'78UQWC[_D)>%O\ L)QT =C1110
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=HO\ R4SQ#_U[P?\
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M_P#)N#_XNCVU/^9?>'LY_P K. HKO_\ A0_CK_H!_P#DW!_\71_PH?QU_P!
M/_R;@_\ BZ/;4_YE]X>SG_*S@**[_P#X4/XZ_P"@'_Y-P?\ Q='_  H?QU_T
M _\ R;@_^+H]M3_F7WA[.?\ *S@**[__ (4/XZ_Z ?\ Y-P?_%T?\*'\=?\
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M_'7_ $ __)N#_P"+H]M3_F7WA[.?\K. HKO_ /A0_CK_ * ?_DW!_P#%T?\
M"A_'7_0#_P#)N#_XNCVU/^9?>'LY_P K. HKO_\ A0_CK_H!_P#DW!_\71_P
MH?QU_P! /_R;@_\ BZ/;4_YE]X>SG_*S@**[_P#X4/XZ_P"@'_Y-P?\ Q='_
M  H?QU_T _\ R;@_^+H]M3_F7WA[.?\ *S@**[__ (4/XZ_Z ?\ Y-P?_%T?
M\*'\=?\ 0#_\FX/_ (NCVU/^9?>'LY_RLX"BN_\ ^%#^.O\ H!_^3<'_ ,71
M_P *'\=?] /_ ,FX/_BZ/;4_YE]X>SG_ "LX"BN__P"%#^.O^@'_ .3<'_Q=
M'_"A_'7_ $ __)N#_P"+H]M3_F7WA[.?\K. HKO_ /A0_CK_ * ?_DW!_P#%
MT?\ "A_'7_0#_P#)N#_XNCVU/^9?>'LY_P K. HKO_\ A0_CK_H!_P#DW!_\
M74S?L]^/X\;M QGI_IEO_P#'*/;4_P"9?>'LY_RL\ZHKT/\ X9_\??\ 0!_\
MG+?_ ..4?\,_^/O^@#_Y.6__ ,<H]M3_ )E]X>SG_*SSRBO0_P#AG_Q]_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )K
M/_CZB_WJOW/^N;_/:J%G_P ?47^]5^Y_US?Y[4 14444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5ZU_U*U1J]:_ZE: )
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *X[X@_\ ']X6_P"PK#_.NQKCOB#_ ,?WA;_L*P_SH [&
MBBB@#COA?_R!=0_["$W]*[&N.^%__(%U#_L(3?TKL: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.\??\A+PM_V
M$XZ[&N.\??\ (2\+?]A..@#L:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ..^)7_'OH/_ &%H/Y-78UQWQ*_X]]!_["T'\FKL: "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCOB#_Q_
M>%O^PK#_ #KL:X[X@_\ ']X6_P"PK#_.@#L:*** ..^%_P#R!=0_["$W]*[&
MN.^%_P#R!=0_["$W]*[&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KCO'W_ "$O"W_83CKL:X[Q]_R$O"W_ &$X
MZ .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X[XE?\ 'OH/
M_86@_DU=C7'?$K_CWT'_ +"T'\FKL: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KAO
MC=:->_"OQ!&H)*PK)\OHDBL?T6NYJOJ%C%J5C<V=PN^"XC:*1?56!!'Y&HG'
MFBX]S&M#VM.5/NFOO/E+]FW4([+XF112,%-U:RPIGNW#X_)#7LGQD^#<'CZT
M;4=.5(-?A3"MT6Y4=$;W]&_ \=/FS5=/U/X8^.'A#^7?Z9<AXI<<. <JV/1A
MCCT.*^O_  #X\T[X@:#'J%@^)%PMQ;M]^&3'*GU'H>_YBO)PG+.$J%3<^7RO
MV=:C/!5UJG_7S1\B^$?&&M_"WQ))-;JT,\;>5=6-P"%D /*L.Q'8]1^>8G?7
M_BMXPYWW^JWKX '"HO\ [*BBOISXI_!73_B,R7D,PTS5T&TW*Q[EE7L'&1DC
ML>O;GC&G\,?A;IWPUTUXX&^UZC-_Q\7K)M9AV51SM4>F>3U[8A8.KS>S;]PR
MCE.(=3V$I?ND[_TNX[X8_#.P^&^BB"';<:C, ;J\QRY_NCT4=A^-?+GQBU"/
M4OB=XAFB8,@N?*R.F44(?U4U]-?%OXG6GP[T&3;(KZS<QLMG;]2#T\QO11^I
M&/7'S-\*_",_C[QW9V\FZ6W23[5>2-S^[4@MD^K'"_\  JK%\ONX>F:9IR/V
M>!H+6_W=O\SZ]\'VC:?X1T2U<$/#8P1D-UR(U'/Y5L445[*5E8^MC'EBHKH%
M%%%,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCM%_P"2F>(?
M^O>#_P!!%=C7':+_ ,E,\0_]>\'_ *"* .QHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //-+_Y'CQ5_OP?^@&N@
MKG]+_P"1X\5?[\'_ * :Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *V+K_EG]*QZV+K_ )9_2@"O1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $K?\ 'A-_
MGTK*K5;_ (\)O\^E95 !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 36?_'U%_O5?N?]<W^>U4+/_CZB_P!ZK]S_ *YO
M\]J (J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ J]:_ZE:HU>M?]2M $M%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\0?^/[PM_P!A6'^=
M=C7'?$'_ (_O"W_85A_G0!V-%%% ''?"_P#Y NH?]A";^E=C7'?"_P#Y NH?
M]A";^E=C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5QWC[_ )"7A;_L)QUV-<=X^_Y"7A;_ +"<= '8T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY*9XA_Z]X/\ T$5V-<=HO_)3/$/_ %[P?^@B@#L:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SS2_\ D>/%7^_!
M_P"@&N@KG]+_ .1X\5?[\'_H!KH* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K8NO^6?TK'K8NO^6?TH KT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!*W_'
MA-_GTK*K5;_CPF_SZ5E4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!-9_\?47^]5^Y_P!<W^>U4+/_ (^HO]ZK]S_K
MF_SVH BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "KUK_J5JC5ZU_U*T 2T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QWQ!_P"/[PM_V%8?
MYUV-<=\0?^/[PM_V%8?YT =C1110!QWPO_Y NH?]A";^E=C7'?"__D"ZA_V$
M)OZ5V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7'>/O^0EX6_["<==C7'>/O\ D)>%O^PG'0!V-%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% ''?$K_CWT'_ +"T'\FKL:X[XE?\
M>^@_]A:#^35V- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7':+_
M ,E,\0_]>\'_ *"*[&N.T7_DIGB'_KW@_P#010!V-%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YYI?_ "/'BK_?
M@_\ 0#705S^E_P#(\>*O]^#_ - -=!0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %;%U_RS^E8];%U_RS^E %>BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )6
M_P"/";_/I656JW_'A-_GTK*H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@":S_X^HO]ZK]S_KF_SVJA9_\ 'U%_O5?N
M?]<W^>U $5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5>M?]2M4:O6O^I6@"6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.^(/_ !_>%O\
ML*P_SKL:X[X@_P#']X6_["L/\Z .QHHHH X?X:WUM;Z1?I+<11-]OF.UW /;
MUKK?[6LO^?RW_P"_J_XUB-\-?#;,S'2U+,2Q_>OU/_ J3_A6GAK_ *!:?]_'
M_P#BJ -S^UK+_G\M_P#OZO\ C1_:UE_S^6__ ']7_&L/_A6GAK_H%I_W\?\
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M_A6GAK_H%I_W\?\ ^*H W/[6LO\ G\M_^_J_XT?VM9?\_EO_ -_5_P :P_\
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M_OX__P 51_PK3PU_T"T_[^/_ /%4 ;G]K67_ #^6_P#W]7_&C^UK+_G\M_\
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MQH_M:R_Y_+?_ +^K_C6'_P *T\-?] M/^_C_ /Q5'_"M/#7_ $"T_P"_C_\
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M /Q5 &Y_:UE_S^6__?U?\:/[6LO^?RW_ ._J_P"-8?\ PK3PU_T"T_[^/_\
M%4?\*T\-?] M/^_C_P#Q5 &Y_:UE_P _EO\ ]_5_QH_M:R_Y_+?_ +^K_C6'
M_P *T\-?] M/^_C_ /Q5'_"M/#7_ $"T_P"_C_\ Q5 &Y_:UE_S^6_\ W]7_
M !H_M:R_Y_+?_OZO^-8?_"M/#7_0+3_OX_\ \51_PK3PU_T"T_[^/_\ %4 ;
MG]K67_/Y;_\ ?U?\:/[6LO\ G\M_^_J_XUA_\*T\-?\ 0+3_ +^/_P#%4?\
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M_P *T\-?] M/^_C_ /Q5 &Y_:UE_S^6__?U?\:/[6LO^?RW_ ._J_P"-8?\
MPK3PU_T"T_[^/_\ %4?\*T\-?] M/^_C_P#Q5 &Y_:UE_P _EO\ ]_5_QH_M
M:R_Y_+?_ +^K_C6'_P *T\-?] M/^_C_ /Q5'_"M/#7_ $"T_P"_C_\ Q5 &
MY_:UE_S^6_\ W]7_ !H_M:R_Y_+?_OZO^-8?_"M/#7_0+3_OX_\ \51_PK3P
MU_T"T_[^/_\ %4 ;G]K67_/Y;_\ ?U?\:/[6LO\ G\M_^_J_XUA_\*T\-?\
M0+3_ +^/_P#%4?\ "M/#7_0+3_OX_P#\50!N?VM9?\_EO_W]7_&C^UK+_G\M
M_P#OZO\ C6'_ ,*T\-?] M/^_C__ !5'_"M/#7_0+3_OX_\ \50!N?VM9?\
M/Y;_ /?U?\:/[6LO^?RW_P"_J_XUA_\ "M/#7_0+3_OX_P#\51_PK3PU_P!
MM/\ OX__ ,50!N?VM9?\_EO_ -_5_P :/[6LO^?RW_[^K_C6'_PK3PU_T"T_
M[^/_ /%4?\*T\-?] M/^_C__ !5 &Y_:UE_S^6__ ']7_&C^UK+_ )_+?_OZ
MO^-8?_"M/#7_ $"T_P"_C_\ Q5'_  K3PU_T"T_[^/\ _%4 ;G]K67_/Y;_]
M_5_QH_M:R_Y_+?\ [^K_ (UA_P#"M/#7_0+3_OX__P 51_PK3PU_T"T_[^/_
M /%4 ;G]K67_ #^6_P#W]7_&C^UK+_G\M_\ OZO^-8?_  K3PU_T"T_[^/\
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M7_&C^UK+_G\M_P#OZO\ C6'_ ,*T\-?] M/^_C__ !5'_"M/#7_0+3_OX_\
M\50!N?VM9?\ /Y;_ /?U?\:/[6LO^?RW_P"_J_XUA_\ "M/#7_0+3_OX_P#\
M51_PK3PU_P! M/\ OX__ ,50!N?VM9?\_EO_ -_5_P :/[6LO^?RW_[^K_C6
M'_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5 &Y_:UE_S^6__ ']7_&C^
MUK+_ )_+?_OZO^-8?_"M/#7_ $"T_P"_C_\ Q5'_  K3PU_T"T_[^/\ _%4
M;G]K67_/Y;_]_5_QH_M:R_Y_+?\ [^K_ (UA_P#"M/#7_0+3_OX__P 51_PK
M3PU_T"T_[^/_ /%4 ;G]K67_ #^6_P#W]7_&C^UK+_G\M_\ OZO^-8?_  K3
MPU_T"T_[^/\ _%4?\*T\-?\ 0+3_ +^/_P#%4 ;G]K67_/Y;_P#?U?\ &C^U
MK+_G\M_^_J_XUA_\*T\-?] M/^_C_P#Q5'_"M/#7_0+3_OX__P 50!N?VM9?
M\_EO_P!_5_QH_M:R_P"?RW_[^K_C6'_PK3PU_P! M/\ OX__ ,51_P *T\-?
M] M/^_C_ /Q5 &Y_:UE_S^6__?U?\:/[6LO^?RW_ ._J_P"-8?\ PK3PU_T"
MT_[^/_\ %4?\*T\-?] M/^_C_P#Q5 &Y_:UE_P _EO\ ]_5_QH_M:R_Y_+?_
M +^K_C6'_P *T\-?] M/^_C_ /Q5'_"M/#7_ $"T_P"_C_\ Q5 &Y_:UE_S^
M6_\ W]7_ !H_M:R_Y_+?_OZO^-8?_"M/#7_0+3_OX_\ \51_PK3PU_T"T_[^
M/_\ %4 ;G]K67_/Y;_\ ?U?\:/[6LO\ G\M_^_J_XUA_\*T\-?\ 0+3_ +^/
M_P#%4?\ "M/#7_0+3_OX_P#\50!N?VM9?\_EO_W]7_&C^UK+_G\M_P#OZO\
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M_OZO^-8?_"M/#7_0+3_OX_\ \51_PK3PU_T"T_[^/_\ %4 ;G]K67_/Y;_\
M?U?\:/[6LO\ G\M_^_J_XUA_\*T\-?\ 0+3_ +^/_P#%4?\ "M/#7_0+3_OX
M_P#\50!N?VM9?\_EO_W]7_&C^UK+_G\M_P#OZO\ C6'_ ,*T\-?] M/^_C__
M !5'_"M/#7_0+3_OX_\ \50!N?VM9?\ /Y;_ /?U?\:/[6LO^?RW_P"_J_XU
MA_\ "M/#7_0+3_OX_P#\51_PK3PU_P! M/\ OX__ ,50!N?VM9?\_EO_ -_5
M_P :/[6LO^?RW_[^K_C6'_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5
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M_0+3_OX__P 50!N?VM9?\_EO_P!_5_QH_M:R_P"?RW_[^K_C6'_PK3PU_P!
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MH?\ OX/\:/[2M/\ GZA_[^#_ !J3_A6GAK_H%I_W\?\ ^*H_X5IX:_Z!:?\
M?Q__ (J@"/\ M*T_Y^H?^_@_QH_M*T_Y^H?^_@_QJ3_A6GAK_H%I_P!_'_\
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MKK5+([,7<'3_ )ZK_C6;_P *T\-?] M/^_C_ /Q5'_"M/#7_ $"T_P"_C_\
MQ5 %O^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &JG_  K3PU_T"T_[^/\ _%4?
M\*T\-?\ 0+3_ +^/_P#%4 6_[4L_^?N#_OXO^-']J6?_ #]P?]_%_P :J?\
M"M/#7_0+3_OX_P#\51_PK3PU_P! M/\ OX__ ,50!;_M2S_Y^X/^_B_XT?VI
M9_\ /W!_W\7_ !JI_P *T\-?] M/^_C_ /Q5'_"M/#7_ $"T_P"_C_\ Q5 %
MO^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &JG_  K3PU_T"T_[^/\ _%4?\*T\
M-?\ 0+3_ +^/_P#%4 6_[4L_^?N#_OXO^-']J6?_ #]P?]_%_P :J?\ "M/#
M7_0+3_OX_P#\51_PK3PU_P! M/\ OX__ ,50!;_M2S_Y^X/^_B_XT?VI9_\
M/W!_W\7_ !JI_P *T\-?] M/^_C_ /Q5'_"M/#7_ $"T_P"_C_\ Q5 %O^U+
M/_G[@_[^+_C1_:EG_P _<'_?Q?\ &JG_  K3PU_T"T_[^/\ _%4?\*T\-?\
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M^?N#_OXO^-']J6?_ #]P?]_%_P :J?\ "M/#7_0+3_OX_P#\51_PK3PU_P!
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M^-']I6G_ #]0_P#?P?XU)_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5
M$?\ :5I_S]0_]_!_C1_:5I_S]0_]_!_C4G_"M/#7_0+3_OX__P 51_PK3PU_
MT"T_[^/_ /%4 1_VE:?\_4/_ '\'^-']I6G_ #]0_P#?P?XU)_PK3PU_T"T_
M[^/_ /%4?\*T\-?] M/^_C__ !5 $?\ :5I_S]0_]_!_C1_:5I_S]0_]_!_C
M4G_"M/#7_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4 1_VE:?\_4/_ '\'^-']
MI6G_ #]0_P#?P?XU)_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5 $?\
M:5I_S]0_]_!_C1_:5I_S]0_]_!_C4G_"M/#7_0+3_OX__P 51_PK3PU_T"T_
M[^/_ /%4 1_VE:?\_4/_ '\'^-']I6G_ #]0_P#?P?XU)_PK3PU_T"T_[^/_
M /%4?\*T\-?] M/^_C__ !5 $?\ :5I_S]0_]_!_C1_:5I_S]0_]_!_C4G_"
MM/#7_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4 1_VE:?\_4/_ '\'^-']I6G_
M #]0_P#?P?XU)_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5 $?\ :5I_
MS]0_]_!_C1_:5I_S]0_]_!_C4G_"M/#7_0+3_OX__P 51_PK3PU_T"T_[^/_
M /%4 1_VE:?\_4/_ '\'^-']I6G_ #]0_P#?P?XU)_PK3PU_T"T_[^/_ /%4
M?\*T\-?] M/^_C__ !5 $?\ :5I_S]0_]_!_C1_:5I_S]0_]_!_C4G_"M/#7
M_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4 1_VE:?\_4/_ '\'^-']I6G_ #]0
M_P#?P?XU)_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5 $?\ :5I_S]0_
M]_!_C1_:5I_S]0_]_!_C4G_"M/#7_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4
M 1_VE:?\_4/_ '\'^-']I6G_ #]0_P#?P?XU)_PK3PU_T"T_[^/_ /%4?\*T
M\-?] M/^_C__ !5 $?\ :5I_S]0_]_!_C1_:5I_S]0_]_!_C4G_"M/#7_0+3
M_OX__P 51_PK3PU_T"T_[^/_ /%4 1_VE:?\_4/_ '\'^-']I6G_ #]0_P#?
MP?XU)_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5 $?\ :5I_S]0_]_!_
MC1_:5I_S]0_]_!_C4G_"M/#7_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4 1_V
ME:?\_4/_ '\'^-']I6G_ #]0_P#?P?XU)_PK3PU_T"T_[^/_ /%4?\*T\-?]
M M/^_C__ !5 "V>I6@NHR;J$?-_ST'^-7KC5+/SF_P!+@_[^+Z?6J'_"M/#7
M_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4 6_[4L_^?N#_ +^+_C1_:EG_ ,_<
M'_?Q?\:J?\*T\-?] M/^_C__ !5'_"M/#7_0+3_OX_\ \50!;_M2S_Y^X/\
MOXO^-']J6?\ S]P?]_%_QJI_PK3PU_T"T_[^/_\ %4?\*T\-?] M/^_C_P#Q
M5 %O^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&JG_"M/#7_0+3_OX__P 51_PK
M3PU_T"T_[^/_ /%4 6_[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:J?\*T\-?]
M M/^_C__ !5'_"M/#7_0+3_OX_\ \50!;_M2S_Y^X/\ OXO^-']J6?\ S]P?
M]_%_QJI_PK3PU_T"T_[^/_\ %4?\*T\-?] M/^_C_P#Q5 %O^U+/_G[@_P"_
MB_XT?VI9_P#/W!_W\7_&JG_"M/#7_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4
M 6_[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:J?\*T\-?] M/^_C__ !5'_"M/
M#7_0+3_OX_\ \50!;_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_QJI_PK3PU_T"
MT_[^/_\ %4?\*T\-?] M/^_C_P#Q5 %O^U+/_G[@_P"_B_XT?VI9_P#/W!_W
M\7_&JG_"M/#7_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4 6_[4L_^?N#_ +^+
M_C1_:EG_ ,_<'_?Q?\:J?\*T\-?] M/^_C__ !5'_"M/#7_0+3_OX_\ \50!
M;_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_QJI_PK3PU_T"T_[^/_\ %4?\*T\-
M?] M/^_C_P#Q5 %O^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&JG_"M/#7_0+3
M_OX__P 51_PK3PU_T"T_[^/_ /%4 6_[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q
M?\:J?\*T\-?] M/^_C__ !5'_"M/#7_0+3_OX_\ \50!;_M2S_Y^X/\ OXO^
M-']J6?\ S]P?]_%_QJI_PK3PU_T"T_[^/_\ %4?\*T\-?] M/^_C_P#Q5 %O
M^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&JG_"M/#7_0+3_OX__P 51_PK3PU_
MT"T_[^/_ /%4 6_[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:J?\*T\-?] M/^
M_C__ !5'_"M/#7_0+3_OX_\ \50!;_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_
MQJI_PK3PU_T"T_[^/_\ %4?\*T\-?] M/^_C_P#Q5 %O^U+/_G[@_P"_B_XT
M?VI9_P#/W!_W\7_&JG_"M/#7_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4 6_[
M4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:J?\*T\-?] M/^_C__ !5'_"M/#7_0
M+3_OX_\ \50!;_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_QJI_PK3PU_T"T_[^
M/_\ %4?\*T\-?] M/^_C_P#Q5 %O^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&
MJG_"M/#7_0+3_OX__P 51_PK3PU_T"T_[^/_ /%4 6_[4L_^?N#_ +^+_C1_
M:EG_ ,_<'_?Q?\:J?\*T\-?] M/^_C__ !5'_"M/#7_0+3_OX_\ \50!;_M2
MS_Y^X/\ OXO^-']J6?\ S]P?]_%_QJI_PK3PU_T"T_[^/_\ %4?\*T\-?] M
M/^_C_P#Q5 %O^U+/_G[@_P"_B_XU=MM5LO)7_3+?_OZO^-8__"M/#7_0+3_O
MX_\ \51_PK3PU_T"T_[^/_\ %4 ;G]K67_/Y;_\ ?U?\:/[6LO\ G\M_^_J_
MXUA_\*T\-?\ 0+3_ +^/_P#%4?\ "M/#7_0+3_OX_P#\50!N?VM9?\_EO_W]
M7_&C^UK+_G\M_P#OZO\ C6'_ ,*T\-?] M/^_C__ !5'_"M/#7_0+3_OX_\
M\50!N?VM9?\ /Y;_ /?U?\:/[6LO^?RW_P"_J_XUA_\ "M/#7_0+3_OX_P#\
M51_PK3PU_P! M/\ OX__ ,50!N?VM9?\_EO_ -_5_P :/[6LO^?RW_[^K_C6
M'_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5 &Y_:UE_S^6__ ']7_&C^
MUK+_ )_+?_OZO^-8?_"M/#7_ $"T_P"_C_\ Q5'_  K3PU_T"T_[^/\ _%4
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M_P#%4?\ "M/#7_0+3_OX_P#\50!N?VM9?\_EO_W]7_&C^UK+_G\M_P#OZO\
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M_OZO^-8?_"M/#7_0+3_OX_\ \51_PK3PU_T"T_[^/_\ %4 ;G]K67_/Y;_\
M?U?\:/[6LO\ G\M_^_J_XUA_\*T\-?\ 0+3_ +^/_P#%4?\ "M/#7_0+3_OX
M_P#\50!N?VM9?\_EO_W]7_&C^UK+_G\M_P#OZO\ C6'_ ,*T\-?] M/^_C__
M !5'_"M/#7_0+3_OX_\ \50!N?VM9?\ /Y;_ /?U?\:/[6LO^?RW_P"_J_XU
MA_\ "M/#7_0+3_OX_P#\51_PK3PU_P! M/\ OX__ ,50!N?VM9?\_EO_ -_5
M_P :/[6LO^?RW_[^K_C6'_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5
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M_0+3_OX__P 50!N?VM9?\_EO_P!_5_QH_M:R_P"?RW_[^K_C6'_PK3PU_P!
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M7_&C^UK+_G\M_P#OZO\ C6'_ ,*T\-?] M/^_C__ !5'_"M/#7_0+3_OX_\
M\50!N?VM9?\ /Y;_ /?U?\:/[6LO^?RW_P"_J_XUA_\ "M/#7_0+3_OX_P#\
M51_PK3PU_P! M/\ OX__ ,50!N?VM9?\_EO_ -_5_P :/[6LO^?RW_[^K_C6
M'_PK3PU_T"T_[^/_ /%4?\*T\-?] M/^_C__ !5 &Y_:UE_S^6__ ']7_&C^
MUK+_ )_+?_OZO^-8?_"M/#7_ $"T_P"_C_\ Q5'_  K3PU_T"T_[^/\ _%4
M;G]K67_/Y;_]_5_QH_M:R_Y_+?\ [^K_ (UA_P#"M/#7_0+3_OX__P 51_PK
M3PU_T"T_[^/_ /%4 ;G]K67_ #^6_P#W]7_&C^UK+_G\M_\ OZO^-8?_  K3
MPU_T"T_[^/\ _%4?\*T\-?\ 0+3_ +^/_P#%4 ;G]K67_/Y;_P#?U?\ &C^U
MK+_G\M_^_J_XUA_\*T\-?] M/^_C_P#Q5'_"M/#7_0+3_OX__P 50!N?VM9?
M\_EO_P!_5_QH_M:R_P"?RW_[^K_C6'_PK3PU_P! M/\ OX__ ,51_P *T\-?
M] M/^_C_ /Q5 &Y_:UE_S^6__?U?\:/[6LO^?RW_ ._J_P"-8?\ PK3PU_T"
MT_[^/_\ %4?\*T\-?] M/^_C_P#Q5 &Y_:UE_P _EO\ ]_5_QH_M:R_Y_+?_
M +^K_C6'_P *T\-?] M/^_C_ /Q5'_"M/#7_ $"T_P"_C_\ Q5 &Y_:UE_S^
M6_\ W]7_ !H_M:R_Y_+?_OZO^-8?_"M/#7_0+3_OX_\ \51_PK3PU_T"T_[^
M/_\ %4 ;G]K67_/Y;_\ ?U?\:Y/QU>6]S?\ A=89XY2-5A)".#W]JT/^%:>&
MO^@6G_?Q_P#XJI+;X>>'K.ZAN(=.6.:%UDC82OPP.0?O>M '1T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7FGQK^+Z?##2[>*UA2ZUF\#>1')G
M9&HZNV.O. !QGGTKTNOD[]K1V/Q#TQ,G:-+C('N9I<_R'Y5TX>"J5$I;&%:3
MA!M'.S_M&_$":5F76TA4](X[. @?FA/ZTS_AHGXA?]#!_P"25O\ _&Z\WHKW
M/8T_Y5]QY7M)_P S/2/^&B?B%_T,'_DE;_\ QNC_ (:)^(7_ $,'_DE;_P#Q
MNO-Z*/8T_P"5?<'M)_S,](_X:)^(7_0P?^25O_\ &Z/^&B?B%_T,'_DE;_\
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M(7_0P?\ DE;_ /QNO-Z*/8T_Y5]P>TG_ #,](_X:)^(7_0P?^25O_P#&Z/\
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M-Z*/8T_Y5]P>TG_,STC_ (:)^(7_ $,'_DE;_P#QNC_AHGXA?]#!_P"25O\
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M/^&B?B%_T,'_ ))6_P#\;KS>BCV-/^5?<'M)_P S/2/^&B?B%_T,'_DE;_\
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M5+5I=9?YG\_XGBK.*=><(UM$VOACW_PGT[_PVM_U)O\ Y5/_ +31_P -K?\
M4F_^53_[37S%16W^K^6_\^OQE_F<W^MF=?\ /_\ \EA_\B?3O_#:W_4F_P#E
M4_\ M-'_  VM_P!2;_Y5/_M-?,5%'^K^6_\ /K\9?YA_K9G7_/\ _P#)8?\
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M:W_4F_\ E4_^TT?\-K?]2;_Y5/\ [37S%11_J_EO_/K\9?YA_K9G7_/_ /\
M)8?_ ")]._\ #:W_ %)O_E4_^TT?\-K?]2;_ .53_P"TU\Q44?ZOY;_SZ_&7
M^8?ZV9U_S_\ _)8?_(GT[_PVM_U)O_E4_P#M-'_#:W_4F_\ E4_^TU\Q44?Z
MOY;_ ,^OQE_F'^MF=?\ /_\ \EA_\B?3O_#:W_4F_P#E4_\ M-'_  VM_P!2
M;_Y5/_M-?,5%'^K^6_\ /K\9?YA_K9G7_/\ _P#)8?\ R)]._P##:W_4F_\
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MM_U)O_E4_P#M-'_#:W_4F_\ E4_^TU\Q44?ZOY;_ ,^OQE_F'^MF=?\ /_\
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M4?ZOY;_SZ_&7^8?ZV9U_S_\ _)8?_(GT[_PVM_U)O_E4_P#M-'_#:W_4F_\
ME4_^TU\Q44?ZOY;_ ,^OQE_F'^MF=?\ /_\ \EA_\B?3O_#:W_4F_P#E4_\
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M.:>9PY7[M1;K]4;U%%%=9]&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "ODS]K/_ )*-IW_8*C_]'35]9U\F?M9_\E&T[_L%1_\ HZ:NW!_Q
M3EQ/\,\4HHHKWCR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHK1T/P[JGB6[^S:5I]SJ$_4I;Q%]H]3CH/<T@,Z
MBO1E_9Y^(+(&'AYL>]W #^7F5R?B3P7KO@^81:SI=SIY8X5I4^1S_LN/E;\#
M4*I"3LI(MPDE=HQ:**UM)\):YX@MWGTO1=0U*%&V-):6LDJAL X)4'G!''O5
MWMJR-S)HJ]JVAZEH-PL&IZ?=:=.R[UBNX6B8KDC(# ''!_*J-"=]4/5;A111
M3$%%%=%'\.?%DL:NGA?6G1AE673YB"#W'RTFTMQV;V.=HJ2XMY;6>2">-X9H
MV*/'(I5E8'!!!Z$'M4= @HHHI@%%2VUM->7$5O;Q///*P2.*-2S.Q.  !R23
MVK:NOA_XHL;66YN?#>KV]O$I>2:6QE5$4#)))7  ]:EM+<:3>Q@444^&&2XF
M2*)&EE<A51 2S$] !W-4(917>:;\"_'>K6ZS0>'+A$;H+F2.!O\ OF1E/Z4W
M5O@?XZT6W,]SX<N6C'7[,R3G\HV8_I67M87MS(OV<]['"T4Z2-HI&1U*.IPR
ML,$'T--K0@****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ??7PU_Y)SX5_[!5K_Z)2NDKF_AK_R3
MGPK_ -@JU_\ 1*5TE?+S^)GO1^%'YU_%+_DIOB[_ +#%Y_Z.>N8KI_BE_P E
M-\7?]AB\_P#1SUS%?N^&_@0]%^1_*F,_WFI_B?YA11172<@4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6V"V35K=I-WIM#YS77]>11Y@+15>_P!0M=*LY;N]N8;.UB&Z2>XD"(@]2QX
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M5Y=LT; '"LQ!W+G')Y'OP*^F?BC\0M'^'/A:XOM7"7'G*T4%B<%KIB/N8/\
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M6_:W^$_C7Q%8:%HWBO[9JM_*(;:W_LZ[CWN>@W-$%'XD52_X8M^#'_0DQ?\
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M5U9W$5W:RKNCF@<.CCU##@BLGQ%X\\,^#[BU@U[Q%I.B3W6?L\6HWT5NTV"
M=@=@6Y(Z>HI];!TN;M%%8&J_$#POH6N6VC:EXDTC3M8NM@@T^ZOHHKB7<VU=
MD;,&;)X&!R>*/(/,WZ*R/$GC#0?!MG'=^(-;T[0K61_*2?4KN.W1GP3M#.0"
M< G'L:BUKQQX<\-Z=;ZAJ_B#2]*L+@!H;J]O8X8I01D%69@"""#QZTK@;E%9
M7A[Q5HGBZS-WH6L6&M6H.TSZ?=).@/IN0D50\0_$KPAX1O%M-=\5:)HMVP!6
M#4-1A@D(/0A78&GMN&^QTE%5['4+75+.*[LKF&[M9EW1SP.'1U]0PX(^E3T
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M\EEH_C'0-6O'^[;V.IP32'Z*K$T]]$&QU5%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\F?M9_\E&T[_L%1_P#HZ:OK.ODS]K/_ )*-IW_8
M*C_]'35VX/\ BG+B?X9XI1117O'DA1110 4444 %%%% !1110 4444 %%%%
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MJ:=YHM8-US>S7<R;MHRSD*X [G %?*'BN\TJ^\07DNB6']FZ5OQ;VYD=R%'
M)+$G)Z]>,XIT\1&K)QBM@G1E3BI2,BBBBNDP"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /OKX:_\ ).?"O_8*M?\
MT2E=)7-_#7_DG/A7_L%6O_HE*Z2OEY_$SWH_"C\Z_BE_R4WQ=_V&+S_T<]<Q
M73_%+_DIOB[_ +#%Y_Z.>N8K]WPW\"'HOR/Y4QG^\U/\3_,****Z3D"BBB@
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M@,Y4;I'8G@ <9P  ./+-,_X*3?"+4-:6QFC\0Z=;LVW^T;JP0P#W(21I,?\
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M5IB,7["I"GRWYFOQ=CNQ&:^PS"G@.2_.KWOMOTMY=S\K:**^NO\ @FS\,O\
MA*OC%>^*KF+=9>&K0M&QZ?:9@R)]<()3[';7;4FJ<)3?1'?CL7' X:>(DK\O
M3N]DOO/D6BOWSCU"VEOYK))XVO(8TEE@##>B.6",1V!*/C_=-?D=^W1\,?\
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M_+$MC( P ,=<X'*?M3?LWWG[//A2\U'P7K.H/X*UQX[+5=,NI _EN'$D39
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M_LRBEZ-I_@7%*-5-?:BV_EH8?[/O[(>B?&+X:Z=XQ^(6H:IJ6I:G;K%910W
MB6UM8QY40'!R=J9';!'&<FM_]I_QY_PRY\'?"_PY\ S365_?(\,=X"#<1PJ?
MWD@( _>2._W@!CYL8XQ[K^S4H7X ^ 0H ']CVYX_W!7RM^W]_P 2WXX?#;4[
MP?\ $L6"/<6'R_)<[I!G_=9:ZZ\?WRH[)RL_E?\ IF%%VI.K:[2NOP_I'9?"
MO_@GUX8?PU;:AX_N]2U7Q%>QB:XAAN?*B@9N=N0-SL,\L3@GM7F?Q>^%^O?L
M/^,-&\:> M:O+CPW?3BWGL[QP<L 6\F;: KHRAMK8!7![X)_0R.19HUD1@Z,
M RLIR"#T-?+_ /P42U"VMO@1:VTK*+BYU> 0KW)5)"Q'X?SK&K)TVIPTLU^+
MM8TIQ4TXRUNG^5SI?C[^TA'X'_9ZL?&OA]E^W^((H4TOS &\II4+ER.Y10W'
M3<!FO%_@'^Q?9_%3PU;^/?B=JNJ:GJ.N#[7%:K<%6,;?=>60@LQ88( ( !'7
MH.(_:'TF]M_V.?@G+*C"*/._(Z>9&SQ_^.@U]V_!_4+75/A1X.NK(JUK)I%H
M8]IR /*48_ C'X5MR152L[;227DK7,^9N%)=U=^;O8^-/V@OV8+C]FRSA^)?
MPNUS4M/33ID%W;RRAWA5F #*P W1Y*JR.#G/4CBO?O#^E^%?VSO@CX8U7Q39
MRMY;M+-;VL[1".Z0-&^".=IY('HPK=_:XO[;3_V<_'#W3JJ260A3=W=I%50/
M?)%<+_P3YM9K?]GE7E!"3ZI=219[KA%_]"5JQ7O1J0>J237D^WZ_<:2]UPFM
M&[I_=_2/FK]CSX!^$/C)XH\;6/B:TN+BWTOROLH@N6B*[GD!R1UX45^CWA_0
M[3PQH.G:/8*R65A;QVL"NQ8A$4*H)[G %?$W_!.G_D>OB;](/_1LM>@_'?X"
M?&WQU\2M0UCP7\1O^$>\/S1PK#I_]N7UML98U5SY<49498$\'G-:<SC3II+=
M*XG%>UJ>3T_#0^J*^*?VQOBCXG\:_%#1_@KX-NWLWOO*349(G*&5Y>5C9AR(
MU3#L!USSTK7^%O[.?Q]\+_$/0-6\2?$_^U]"M+I9;RQ_X2#4)_.C'5=CQA6^
MA.*X>1UT/_@I0'U+Y4N+D"!GX&9+';'CUY./K4J*J5(1EL[Z=[=/G^@.3A3G
M);I?T_E^IZ?H/_!.SX;V7A]+75;O6-2U1HP);^.Y$.U\<F- I &>@;=]:\?T
M.\\1_L._'[3O#-QK$VJ> -;='"R_=\IWV>9MZ)+&WWBOW@/< ?H17P;_ ,%(
MIH[_ ,9?#S3+8A]2\F=MB_> >2-4_-E;\JJ,FJT+=79^@<JE3DGT5[]C=_;W
M^"/A72_!^H_$2WMIQXFOM0MH9IFN&,94H5X3H.$6NR_9-_9M\$:;X0\"_$6"
MSNE\3O8_:#,;IS'O=&1CLZ=&-3_\% %:/]G-%;[RZG: _D]=Y^SO:W-]^R_X
M1MK.7[/=S:&(X9MQ78Y5@K9'(P<'(YJ:?N0JN/1JW_@.PI?O'3YOM)W^\]@J
M.>=+6&2:5@D4:EV8]  ,DU\-_P##*O[3'_18/_+GU/\ ^-5ZU\(?A'\4/A_X
M!^(5MX[\7'Q9=:CI[)IVW4[F\,+"*4,,S*NW)9/N]<>U*<N6$I=E<J.LHQ[L
M^?O#>CZ]^WI\9=;N-7UF[TWP%HK[H;6W(_=QLQ6-$!&WS'"LS.0<8QTP*]0^
M*'_!/GP@/!EY<^"IM3L?$=G"TULLUQYR73J,[&&,AFQ@%2,$]#6-_P $S;RW
M_L'QU9[E%VMU;2LG\6PHX!_,'\Z^UI)%AC9W8(B@LS,<  =353IQIP44[:7O
MY[W%&;G-REWV_0^:/@A\5_&G@?\ 9QU[6?B;HVIVE_X:B;[-+JD;137T>T>4
MK;OFW;SL+$="IY.:\/\ @9\#-7_;$U;5/B%\2=<OGTD7#6]M;VKA#(PP2B9!
M$<2Y P!DDGD$$GV7]H[XL>%?C1^S+X]/@K6TUG^SUM9+M8X9(RB?:$/(=5/1
M&/\ P&MW]@N_M;S]F_18K<KYMK=W45P >0YE9QG_ ("Z54?WE2<Y+5)6^?7Y
MDR_=TXPB]V[_ '7L>;?&C]@W1/#_ (7NO$GPWOM3TK7])C-W':R7)=9=@W'R
MWP'23C(.2,@# SFO2OV*_CM?_&?X<W,&NS?:?$.ARK;W%P1@W$; F.1O]KY6
M4^I7/>O>]7O+?3M)O;N[94M8('EE9N@15)8G\ :^'O\ @FC;2R:K\0KQ5(M"
MMI&#V+%IB/T_G2I/WYP>UK^CO^NPZB2A&:WO;U7_  -SRGX:>"?$/Q4_:"\?
M>"-)UJ;0M)U74;N76KFW'SM:Q7#_ "#_ 'F=1CIR,Y P?I#QC_P3P\ 3>#[J
M+P_<ZM9Z[# S6]W<7(E660#@2)M P3_=VX_2N&_8LC5OVIOBNY&647N#Z9O5
MK[HE_P!6_P!#6#7+A(-;\O\ F:2E_M%2_27^1\A?\$Z?B)J_B+PAXD\+ZG<R
M7<.@RPM9M,VXQ1RAP8@?[H,>0.VXBN+^-?B#Q+^U-^T?)\)M%U:32_"FE2-'
M>&,DHQBP9I74$;R&^15)QD \9)IW_!-?_D:?B'_UQMO_ $.6H_V2'&D_ME?$
MBROOW=[+_:*1A^I(NU8@?\!&?H*ZI)5*M/FV<6_FD9R_=1J*/227R9Z?J7_!
M.OX;3>&WLK*\UFVU4)^[U.2Y5SOQP6CVA2N>H !QW'6F?L8CXD^!V\1^"_'&
ME:E%X?TDN=-U2^C98EV/M>.-V^]&1AUQP #CK7U57EVM?%_PEXT;QAX(T+7(
M[OQ;:V-Y#)IZQ2*R2+&RGYBH4X8@9!-8RDZ:E*/9Z>G7Y%J*GRQ>FJU_3YGR
M3IEIK_[>GQFUB.]UBYTKX=Z$^Z.WMSTC+,L>U2-OFN%9B[ [1D8Q@5ZUXN_X
M)V_#_4/#TD/AZ\U31]9C0F"[FN/.C=\<>8A7I_N[<?I7S)^R?\"=0^-4?B./
M3/B%>>"[O3VA,EM:6[R&X5M^&.V:/[I4CH?O5]!_\,&^+O\ HN>M?^ 4W_R7
M3=-1@HI=-^K\R>;FFY?AV\C0_8B^,WB'6+_Q#\,O&-S)>:WX=W?9[B9]\ACC
MD\N2-F/+;&VX)YPV.PKQ/X])XGO/VWM:TSP=<FRU[55M].AN5)4Q)+9QK(^X
M<KA"QW#D#)'.*]O_ &;OV;=$^&/Q<O-?M/BQI_C35D@N+:[T^&)!/O9AO:0B
MXD;(9>05Z]:X^2\M+/\ X*7.;LJOF(L41;_GHVFJ%_$]/QIZ5*M+FU;3OY_\
M.OS%K3A5Y=$MO+5?DSN+/_@G7\.U\,_8[W4=9NM:9,OJRSJG[S')6/:5VY['
M)_VN]>??LP^+O$OP"^/U]\%O$E^U_H]P[)8LQ.R.39YD;Q@_=61>J] Q'OG[
MKKX/^+3+K7_!0[PA!IX$D]K)8BXV-GE%:5\^F(R/RIP;]M!=):-?K\@E%>RD
M^L5=',?M^_"#PW\/?$&@ZYHUO-%J'B2[OKK4'DG9U=]T394'[HS(W2OLSX,_
M /PA\%(;^7PM:W%L^J)";GS[AI<[ Q7&>GWVKYG_ ."F?W?AS_OWW_MO7VY9
M?\><'_7-?Y5-'W:+MW:^78=;6<+]4W\[D]?.W[:&M?$6'P/I^A_#W2=7N[C5
M)66_O=(A=Y((5 P@*<KO+=1V4CO7T37SE^UI^T]>_!%=*\/^&K&+4/%FKH7B
M\]2Z6\9;8K;!C>S-D*,X^4YST,5+.R?5[=_(TA=7:Z?AYG.^!?\ @GGX"L?#
M=J/%$VIZMKDL2M=2QW7E11R$?,(U49P#W8G.,^U>&_%'X=S_ +&?QX\'ZEX/
MUB^DTO4G5S#<."[1B15E@D*@!U(88R!C/J,UZG;?!O\ :C\?6T-QKWQ+M_#2
M3 %[>UN##/$#V(MHU7/T>O _VCO@K=_!GQ]X/AU7QA>>,=9U,_:+BZO$92BK
M*JJ 6=V/.[DGMTK:-_;TWMK_ $CGE;V,^NF_ZGUW^W]_R;I?_P#80M?_ $.O
M'OV<OV7Q\?/ NB^*_B+K.HW>E6\/V#1='M9?*CBMXCY>XG!QN93PN"<9).<#
MV']O[_DW2_\ ^PA:_P#H==E^R3&L?[./@0*,#["3^)D<G]36=)+]XWW7Y;_U
MW-*C=Z:79_G_ %]Q\B?M1_L^V_[+NH>&O'/P_P!6U"P1KSR?+FEWO;S!2ZE7
M !*,%8%6S]2#@?7/Q*\1-XN_94U[7'C$4FI>%7NVC'12]MN(_,UY1_P4D_Y)
M!X?_ .PVG_HB6NVF_P"3&5_[$=?_ $D%1*[P]9/H]/G%LV@K8FBUU6ORE8^6
M?V3_ (%7W[1'AN:R\1:[?67@+0;IO*TVQ8(;FZD&YF)((X7;R03@@#')KM/V
MHOV-?#/PO^'=SXU\$W6H:?=:3)$\UM-<&160NJAT;&Y75F4]<8!Z5Z/_ ,$X
MXU7X'ZJP&&;7)B3Z_N817HG[9'_)M?C;_KWA_P#1\=:8K]W&\=TD_P $88?]
MY*TNK:_&Q!^SW\89_$'[,^G^-?$L[2SZ=9W!OKAB-THMRXW_ .\RJ,^I)KY=
M^%?P\U_]NCQYK7BSQMK%Y9>%=.F\F"SLV VEN1!#N!50%VEFP2<CN<CNO@O9
MW%]_P3U\50VP9IC;:DP51DD!B6'Y UU/_!./4+6?X*ZM:1%?M5OK,K3+GG#1
M1;2?R(_ UM**E7FWTBFO66Y";C1BEUDU\EL9_P 3/^">OA23PW/=>!+S4-(\
M16J>;;)<7/FPSNO(5B1N5CCA@< ]C6O^PQ\>-8^)/A_5_"OBBYEO-?T$J4NK
M@YEF@)*X<]V1A@L>2&7/.2?J5F"J23@#DDU\%?L,LNK?M*?$K5++YM->*Z97
M7A<27:LGZ _E6=-OVCI]&F_1HNHE[-36Z:7R9;_9]_Y/X^(OUU+_ -')7W77
MPG^S^P7]OCXB D DZD![_ODK[K9@JEB< #)-33TPU%O^7]6.7\:I_B_1'P;^
MP!_R6SXE?]<7_P#2DUS?[3TGB+_AM6"W\*736/B"]@M;&TN5.#$TT/E%@>V%
M=CD<CJ*Z'_@GS,EQ\9OB/+$P>.2W9E9>A!N<@U:^)$:R?\%&O#(89&ZT/XBW
M8C]14TX\T<+!];+[^9!-V>(:\_T/1]-_X)X_#L:&T.K:CK>J:U,NZ;5?M0C;
MS#U94VD8SSAMQ]S7EW[)-UK?P8_:>\1?">74)+_1G-PH1LA/,C3S(Y@O\+,G
M! ZY'7 K[VKX+\._\I*=1_Z[S?\ I!6E-OVR2V:D*HK47+JFOU.W_;D^,GB'
M3-2\/?#+P?=2VFKZ]M:ZFMGV2LCOY<4*L.5W,&R1@X '0FKW@[_@G9X!T_PY
M'#XCO=4U?6I(_P!_=6]P(8XW(Y\I0O0>K[LXS@=*\Y_:)D&C_MY> KW4/DLG
MDTQD>3[NWSF7//8,#7WK44XITG-[MR7W;%5&_:<G1)/[SXH^#GPT^(G[-G[1
M3>&M'L]7\0_#;4BIENS"Q@B5P=LC-C8LJ,,-CJO;D8@_:?\ 'WBCXU?'"Q^"
M/A'4&TW3LJFIS1L0)7*>9)YA')C1/X>C-G/;'U1XH^-'@OP7XOTWPOK6NQ6&
MO:BJ-:V;Q2,90[E$PRJ5!+ @ G-? &L?#>]^(7[:WBSPU_PD\_A#4+S4+J2W
MU&"-G?[GF*@ =#\R?[7YTE><H0:YDK_.W1^E_4;]R,YK1Z?*_7Y_<?25G_P3
MM^&,.@BSN+G6[C4"F&U(72HX;U5-FT#/8@_4]:\W^"WB+Q'^RU^T5'\(M:U9
M]7\):LZBPDDX$32Y,4B GY,L"C*#C//;GIO^&#?%W_1<]:_\ IO_ )+K%L?V
M-;#P_P#%#0+K6OCE;7WB+3[JVNXM/O[=1=R*LH9%4/=EP&((! /)Z&M:?\6+
M>B>C]#.2_=M):K;U-?\ ;B^*WB&\\3>'?A'X2N)+:]USRS>R0N4>02N8XH=P
MZ*2&9O48[9!W/#__  3I^'EKX92TU>^U:_UEXQYNHP7 B5),<F./:0%SV;<?
M>O./C,RZ)_P4(\(7FH?N[2>6P:)W.%P08P<^S@U]YUG3BG2YGNY27W;%U&_:
M<O1)?CN?EIK7PYUWX3?M5>!?"NLZG-J]OI^JZ<NF7<Q/S6;7(9  2=H#%QMS
M@$''%?J77PQ^UE=V\W[9/PEAC=6GADTX2@=5S>L5!_#G\:^YZNFW+#J_\TOT
M)FDJSMVC^H4444#"BBB@ HHHH **** "BBB@#X>_:EO6NOC)J<3%B+:"WB7/
MH8U?C\7->UKX8UB7]E?3]/\ #&]+^:PCN'C@.))E=O,E53ZD,>._3O7E'[7&
M@RZ;\3(M1(_<:C9QNK8_B3Y&'Y!3^(KWC]FCQ7#XD^%6FP!U-UI>;.9 >1@Y
M0_0H5_$'TKR*44Z]2,NMS\XP-.,\VQF'JNSFI)=[-]/EJ?+_ ,(?C%JOPGUO
M!\RZT:5MMWI['ISRZ _=<?KT/8CZ[U[XS>&=#\!Q^*Q?+=V%PO\ HL<1_>3R
M?\\P.S ]<],'->;_ +0G[/:^)EN/$OAJW"ZPH+W=E&,"Z'=U'_/3V_B^O7Y2
ML[&^U.\M],MH9KBYDEV16J EC(V!@+ZG _*H]I5PMZ;U70Y/K>/X><L')<T7
M\#_R_6/?\>D\6>+/$/QD\:)-*DEW?73B&TL8,E8E)X1!Z=R?J37JWCKX V/P
MY^!]YJ5Z5NO$@FMY)9E/R1 OM,:>WS\GN1VX%>M? GX&VWPQTT:AJ"QW/B2X
M3$L@Y6W4_P#+-#_-N_TZ\[^U]XKAT_P38Z"KJ;O4;D2LF>1%'R3^+%<?0^E5
M[#DI2J5=V="RGZM@:V.Q^M62=K]&]OG?[C@_V-;YX_&VN68+>7+IWFD=LI*@
M'_H9_6OKFOEK]C'096U#Q%K3#$*11V:''WF)WM^05?S%?4M=>#O[%7/H^&XR
MCEL.;JW^84445VGTX4444 >:?M+?\F__ ! _[ UQ_P"@&O@W]FG]KJ;X ^"K
M_08_!C^(A=7[7OVE=0-OLS'&FS;Y+Y^YG.>_2OO+]I;_ )-_^('_ &!KC_T
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MBU>Z^,WCD->ZSJDCS:8MRN2-Q^:YQVS]U!V7D<%:Y?\ ;A_Y.:^&/_7*T_\
M2QJ^N?@K\3-$^+'PXTC7]"2.WM6B$,EDF!]DD0 -"0.FWC'J"#WKY&_;A_Y.
M:^&/_7*T_P#2QJZ&N7$4()62DK?<S!/FHU9MW;6OWH]?_;U^(NN> ?@Y;Q:'
M<2V,NL7RV,]W"2KI#Y;NRJPZ%MH&1VSZUQ?P7_8F^$WC+X;Z1K$^J7OB2\OK
M5)9[JUO@D<,K*"R*JCY2I.,/DY'/I7T7\:=!\#^+?!-SH?CV_L=/TB\Y6:\N
MX[9HY%Z/&[D89<^_7!!!(KY0UO\ X)[^*O"FHG5/AM\0/(D^]%]J>2SG1>H
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MC,:# SD*1P"%&<8XR<[_ (*9?\BGX'_Z_;G_ -%I7UQX)C6+P;H*(-JKI]N
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MCS4V@;2>NW:?Y5I_L7ZE\2-&\)ZUX;\>Z'J\-OHY!TR\OX6#RQC(:%2W+ $
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M#1M+N[^Z?R[:UA>>5O1%4L3^0-6JX[XR6<^H_"/QK:VH+7,VBWD<:J,DL87
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M?]AFY_\ 0(J^GJZJOQ7\E^2.>E\/S?YL****R-0HHHH **** "BBB@ HHHH
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M^<G,> I/U0H?QK[/B:C**I8RGO%V_5?<_P S\SX)Q493K9=5UC-7M^#7S3_
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MUBPQ(F>F],.OU!)'X5\^_'KX3_$#XB?$.YO[#0C/I<$26UI)]L@7<@&2VUI
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M7^4E:U<0L1.A/K=7]>9'U#QL,PSC"8B'6*NNSO*Z_KH?E;7ZX_L&?#,?#O\
M9[T>YGB\O4?$#'5YSU.QP!"/^_:H<>K&OS ^#OP^G^*GQ0\,^%( W_$SO4BE
M9.J0@[I7_P" HKG\*_9SX@0:SI/PQUNV\&Z<+K7(=->WTJS1TB'F[-D?+LJ@
M+P>2.!7I9I5Y**IK>7Y+_-_D=O%.(YY4<"G;F=W?9=%?RW^X^/?@]^TD=?\
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M:[,'2^IT)2JZ7=WY;(][+XPR/+X_7)6UUW=F^FESY@HK[]_X=3_]51_\M_\
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MF1D8ELA<_,^/15Y)KN_!/[;WB?X0Z/#X;^*?@O6I]7M-RC4I6,4TXR2-ZR*
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M(O@/Q-X:_:.^)VIZOX=U;2M-O!=_9KR]L9889LW@8;'90&RO(P>G-?94G,;
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M1M%1R_NXP_E*YG[253N?$OAC]H/]H[2=(M_#D_PENM4UF!1;QZM=6%PD3X&
MTC B-C_M!U!KA-<^ _Q1T_X]_#SQ1XGL]1\1ZSJ>J6NH:M=:=9R3VNG*MR@$
M32(I50J+D\@ =,@9/Z*T5I%VJ1J/=.YFXW@Z:V:L?,'_  4 \(:]XR^%>AVG
MA_1-1UVZCU=97@TVTDN'5/)D&XJ@) R0,^XKW'X0V-SIOPI\'6EY;RVEW!H]
MI%-!.A22-Q"H*LIY!!X(-==12C[JDN[3^Y6*E[SB^R:^]W/BG]K'X?\ BCQ'
M^U)\.]6TGPWJ^J:7:Q6(N+ZRL99H(2MY(S;W52JX4@G)X!S7VM111'W8<GFW
M]X2]Z?/Y)?<?&7P.\!>)M)_;8\>:[?>'=6LM$N3?^1J5Q8RQVTNZ9"NV0KM;
M(!(P><57_::^ _Q!\/\ QLMOBY\.+-M8N0T<T]I$HDEBE1!&?W9.9$=  0O(
MR>G!K[5HJ%'EC347K!63*O=S;VEN?'%K^T=^T5XLA33=)^#;Z7JDB[3?:C9W
M$$"G^\/.**/Q8_C7ES_ OXF_#/\ :)\#^*_$%GJ?C*ZO+V#4M6U+1[&:YCMV
M,I5XV94(^5,'H!@X P,U^C%%7'W9QGU3_I$27-!P>S/D?_@H9X)\1>-?#/@Z
M+P]H&J:]+!>7#3)IEG)<M&"B@%@BG ..]?4?A.&2W\+:-%+&T4L=E"KQN"&5
M@@!!!Z&M6BB/NJ2_F:?W*PY>\XOLK?C<^+?V_? /B?QEXM\ 3:!X<U;7(;:.
M<3R:;8RW"Q9DB(W%%.W(!Z^AK[.A!6&,$8.T?RJ2BB/NPY/-O[PE[T^?R2^X
M*^3OVG?V9?%&J^/;/XI?#"=8/%EKL>XLPRQO,Z#"RQEOE+;<*R-PP'?D'ZQH
MJ6M5):-#3T:>S/BR3]I?]HNZT_\ LF+X.W,&N,/*_M(Z9=>0#TW -\@/?)<K
M[8XKNOV3?V:M:^&^J:MXZ\=7"W?C760VZ/>)#;*[;Y"SC@R,V,[> !@$Y-?3
M-%7'W6Y=2&KI+H?&7P.\!>)M)_;8\>:[?>'=6LM$N3?^1J5Q8RQVTNZ9"NV0
MKM;(!(P><57_ &[? 'BCQ?\ $GP!=:#X;U?6[:VA83S:=8RW"1'SE.&**0O'
M/-?:M%3!<BI+^3\=_P#,J7O>T_O_ / _R/$OVRO#^J>*/V?/$.G:-IMYJ^H2
MR6QCM+&!YI7Q.A.$4$G !/3M5S]D?0]2\-_L]^%-.U?3[K2M0A2<2VE[ T,L
M>9Y"-R, 1D$'D=Z]AHIQ]U27>WX!+WN7RO\ B?.7[>'A76O&'P3M['0='O\
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M-IZ[6&?IR*Z#QSX;_:!_:@\,WL.O:/;> _"]M"]VFE[&%Q?S(I:.-D+%R=P
M^;8HSG#$"ON&BG)<ZM)W_K3[A1]UWCH?,?[ >D:]X7^%>KZ'XAT#5M!N[?5&
MGC35+&6V\R.2- "F]1NP4;.,XX]:^G***TE+F=_3\%8SC'E5@HHHJ2PHHHH
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M)##\/<5\I_M&?"/_ (5YXE_M+3HMN@ZDY:(*.+>7JT7T[K[9':N$^'?CN_\
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M?7'_  3)_P"3@-5_[%^X_P#1]O7L_P#P5*_Y)[X)_P"PI+_Z)KX\_9E^/O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\F?M9_\ )1M.
M_P"P5'_Z.FKZSKY._:T1A\0],?!VG2XP#[B:7/\ ,?G7;@_XIRXG^&>)4445
M[QY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?]"__P"3MO\ _'*/^&=OB%_T+_\ Y.V__P <K[6HH^O5.R_KYA]5AW9\4_\
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M.WQ"_P"A?_\ )VW_ /CE?:U%'UZIV7]?,/JL.[/BG_AG;XA?]"__ .3MO_\
M'*/^&=OB%_T+_P#Y.V__ ,<K[6HH^O5.R_KYA]5AW9\4_P##.WQ"_P"A?_\
M)VW_ /CE'_#.WQ"_Z%__ ,G;?_XY7VM11]>J=E_7S#ZK#NSXI_X9V^(7_0O_
M /D[;_\ QRC_ (9V^(7_ $+_ /Y.V_\ \<K[6HH^O5.R_KYA]5AW9\4_\,[?
M$+_H7_\ R=M__CE'_#.WQ"_Z%_\ \G;?_P".5]K44?7JG9?U\P^JP[L^*?\
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MX9V^(7_0O_\ D[;_ /QROM:BCZ]4[+^OF'U6'=GQ3_PSM\0O^A?_ /)VW_\
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MHH^O5.R_KYA]5AW9\4_\,[?$+_H7_P#R=M__ (Y1_P ,[?$+_H7_ /R=M_\
MXY7VM11]>J=E_7S#ZK#NSXI_X9V^(7_0O_\ D[;_ /QRC_AG;XA?]"__ .3M
MO_\ '*^UJ*/KU3LOZ^8?58=V?%/_  SM\0O^A?\ _)VW_P#CE'_#.WQ"_P"A
M?_\ )VW_ /CE?:U%'UZIV7]?,/JL.[/BG_AG;XA?]"__ .3MO_\ '*Z?P/\
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M;_XY1_:."_Y_1_\  E_F']CYE_T#3_\  )?Y'F%%>G_\,T?$G_H7/_)ZV_\
MCE'_  S1\2?^A<_\GK;_ ..4?VC@O^?T?_ E_F']CYE_T#3_ / )?Y'F%%>G
M_P##-'Q)_P"A<_\ )ZV_^.4?\,T?$G_H7/\ R>MO_CE']HX+_G]'_P "7^8?
MV/F7_0-/_P  E_D>845Z?_PS1\2?^A<_\GK;_P".4?\ #-'Q)_Z%S_R>MO\
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M;_RKV'_Q^CZQ1_G7WH/[2P/_ #_A_P"!+_,\ HKW_P#X8+^.O_0C?^5>P_\
MC]'_  P7\=?^A&_\J]A_\?H^L4?YU]Z#^TL#_P _X?\ @2_S/ **]_\ ^&"_
MCK_T(W_E7L/_ (_1_P ,%_'7_H1O_*O8?_'Z/K%'^=?>@_M+ _\ /^'_ ($O
M\SP"BO?_ /A@OXZ_]"-_Y5[#_P"/T?\ #!?QU_Z$;_RKV'_Q^CZQ1_G7WH/[
M2P/_ #_A_P"!+_,\ HKW_P#X8+^.O_0C?^5>P_\ C]'_  P7\=?^A&_\J]A_
M\?H^L4?YU]Z#^TL#_P _X?\ @2_S/ **]_\ ^&"_CK_T(W_E7L/_ (_1_P ,
M%_'7_H1O_*O8?_'Z/K%'^=?>@_M+ _\ /^'_ ($O\SP"BO?_ /A@OXZ_]"-_
MY5[#_P"/T?\ #!?QU_Z$;_RKV'_Q^CZQ1_G7WH/[2P/_ #_A_P"!+_,\ HKW
M_P#X8+^.O_0C?^5>P_\ C]'_  P7\=?^A&_\J]A_\?H^L4?YU]Z#^TL#_P _
MX?\ @2_S/ **]_\ ^&"_CK_T(W_E7L/_ (_1_P ,%_'7_H1O_*O8?_'Z/K%'
M^=?>@_M+ _\ /^'_ ($O\SP"BO?_ /A@OXZ_]"-_Y5[#_P"/T?\ #!?QU_Z$
M;_RKV'_Q^CZQ1_G7WH/[2P/_ #_A_P"!+_,\ HKW_P#X8+^.O_0C?^5>P_\
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M;_RKV'_Q^CZQ1_G7WH/[2P/_ #_A_P"!+_,\ HKW_P#X8+^.O_0C?^5>P_\
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M;_RKV'_Q^CZQ1_G7WH/[2P/_ #_A_P"!+_,\ HKW_P#X8+^.O_0C?^5>P_\
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M5;T<3"KILSU,MSW"YA:%^6?9_H^OYGH=%%%=9](%%%% !1110 4444 %%%%
M!14<\\=K#)--(L4,:EWDD8*JJ!DDD] !6'X9^(7A7QK-/%X>\3:/KTL"AI8]
M,OXKEHU)P"P1C@'WH\@.@HHK,\0^*-&\(Z?]OUW5K'1;'>(_M6H7*01;CT7<
MY R<'B@#3HJGI.L6&OZ;!J&F7MOJ5A<+OANK2598I%Z95U)!'T-7* "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\-_8<^?YEG]HVXZ^0=W_ )#QUJ3]KJ%+C]LKX4Q2+NC==-5E]0;^2NN_9/\
M@7XNOOB)JGQ@^)%N]GKE_P"8UE8SILE0N-K2,AYC 3Y%4\X)R!QGE/VM/^3T
M/A+_ -PS_P!+Y*NE%TYX>#WY[ORO?3Y$5)<\*\UMRV^ZVI]TU\$_ C'_  \
M\;_;_P#CY\_4_(W=<[QC&?\ IGFOO:OC+]J+X%^,_"OQ6L_C'\-+5[[4(626
M^L;=#)*)%787$8YD1T^5E'/4]R1"?)5C4>UFOOZEM.=-P6^C^[H?9M?!/[:&
MS_AK#X:"RQ_:'EV&[R_O9^V/LS[UT4/_  4>6'3_ +)=_#O4%\3K^[-FEUMB
M:3IW3>.?X=I/;/>H/@+\%O'?Q@^-0^,'Q,L)-(AMY1/8Z=<1&)W=1B(+&WS)
M&G!!;EB ><DU<%>M"?2+O<B4E[*<>LE:QB_%;;_P\2\,?VA_Q[>?8>3NZ?ZK
MY.O_ $TK[UKY9_;,_9UUWXB3:1XY\$J6\5:*H5[>-@LL\:-O1HSWD1LD#N#Q
MR #Q>B_\%#K_ ,,::NE^.? &H0^)K=?+D\EOLXF<<9:.1=T9/<#=_2HIR4:?
MLWNFW\F5.+]ISK9I+[@_X*:?9O[#\!YV?;/M-WM_O;-L>?PSMKTW]I[SO^&+
MM2^T;O/_ +,TWS-W7=YUOG/XUXEHOP_^(/[9WQ9TSQ;XRT2;PQX$T\KY-O.K
M*'A#;O+BW &0N?O28"XZ= M?1'[:RA/V8_&*J %"6H ';_2H:RJ1<*$N;>4D
M[=K:?B73DIUX<NT=/O=_P(/V'\_\,Q^%,==UYC_P*EKQ.;_AM3SG\O[FX[?^
M0+TSQ7MO[#O_ ";+X3_WKO\ ]*I:]XKLKQ_?2=SFHO\ =V\W^;/FSX&_\+\^
MQ>,?^%K?ZC^S6_LS_CQ_UV&S_P >W/3;][CTKR__ ()E_9O)^(&<?;M]GG/7
M9B;^M?<5?!/C#X=^/_V0/C%J/CGP1HTGB+P7J3.9[2!&<1Q,VYHI0H)3:?N2
M8( QGN#E&2A4][1-6O\ .^OKL:RBY4[1U:=[?A^%K^I][U\$^!]I_P""D&L_
MV?CR?M%UYOE],_9/GS_P/.?>M_4_^"B%YXDTXZ;X,^'VH7'BBX4QQQRR>>L3
MGN$C7=)@]OE_I74_L;_LZ^(O!>L:O\1/'@9/%.L*XBM9B&EB61@\DDF. [D#
MY?X1G/)P'33]KS]$FOO)J-.GR+=M?@<%^V?_ ,G4_"GZ67_I:U?3_P"T)_PL
M;_A7I_X5;_R-/VN+'_'M_J?FW_\ 'Q\G]WW]*^8/VS_^3J?A3]++_P!+6K[K
MJ*:YL,E_?G^:-)NU9_X8_D?"_P#QFM_G^Q*V_P!JL^-!^QKH/_";[O\ A*CJ
M4/\ :N/)QG=-MSY/[OIY?W?YU]FUQ?QD^&=I\7OAOK?A6[D\@7T7[F?&?)F4
MAHW^@8#/J,BIJINFTNZ?W.XZ=N=-ONOO.:_91\C_ (9U\!_9]OE_V<,[>F_>
MV_\ '=FO2M:U[3/#>GR7^KZC::581E0]U>SK#$I)  +,0!DD ?6O@WX:_&SQ
M[^QK;3^"O'O@Z[U+P]#.[V5];,55-QRWE2%2DB$_-M)5E+'/H#XC?%CQW^VS
M]A\'>"?"-UI'AC[2LUYJ%VQ9&*]#+(%"HJY)V LS$#'3%;U)>TES4];O[N_W
M&4(^SCRU-+?TOO+G_!1S5+?6;KX;WEK=Q7VC2)>%;BUD$D;$/"&VL"0>!7W5
MI/D_V79_9MOV?R4\K;TV[1C'MBOGWXQ?LFVOB[]GS0_!&@RQIJWAN-9-.N+C
MY1-)@^:KGMYA)/LVWM7C?P^_;$\6_ /1+7P=\3_!&IR2Z:@M[:]SY4K1J,*I
M##;( . ZMR .O6HBXP4Z5^MUYI_Y#ES3<*ENEGY'MO[>'V?_ (9MUWS]N_[3
M:^3NZ[_.7I[[=WX9KSSP;YW_  [@O?/W9_LN\V[O[OVJ3;^E>?\ C;Q-\2_V
MZ-8TK1M#\,7'AGP+;3^=)>76YH2W3S9)"JAV"D[8TR?F.2>H^EOC?X/L? '[
M(_B7PYIH(L=,T/[-&6ZMMVY8^Y.2?<UE-..'JN7VMODC6+4JU)+[/^>QR_\
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MP7]FW6P2 6N[0#/?]\I_I7S;\&?CMXJ_8W74_!GCGP9?2:;)=-<0R*?+99"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME?$+==6%C$+L_+M_UNW?]WY>O3BMZB/NTX0[()>]4E/N%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608663248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BARINTHUS BIOTHERAPEUTICS PLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">X0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Unit 6-10, Zeus Building<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Rutherford Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Harwell, Didcot<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">OX11 0DF<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+44 (0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1865 818 808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,414,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001828185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRNS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, nominal value &#163;0.000025 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689603084240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 117,774<span></span>
</td>
<td class="nump">$ 142,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentivesReceivable', window );">Research and development incentives receivable</a></td>
<td class="nump">4,523<span></span>
</td>
<td class="nump">4,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,582<span></span>
</td>
<td class="nump">9,907<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">131,879<span></span>
</td>
<td class="nump">156,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,209<span></span>
</td>
<td class="nump">12,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,962<span></span>
</td>
<td class="nump">11,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">23,527<span></span>
</td>
<td class="nump">25,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">7,286<span></span>
</td>
<td class="nump">7,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">186,749<span></span>
</td>
<td class="nump">214,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,556<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,278<span></span>
</td>
<td class="nump">9,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred income</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="nump">1,916<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,589<span></span>
</td>
<td class="nump">12,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability - non-current</a></td>
<td class="nump">10,654<span></span>
</td>
<td class="nump">11,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">1,888<span></span>
</td>
<td class="nump">1,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredTaxLiabilityNet', window );">Deferred tax liability, net</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,959<span></span>
</td>
<td class="nump">27,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, &#163;0.000025 nominal value; 39,184,338 shares authorized, issued and outstanding (December&#160;31, 2023: authorized, issued and outstanding: 38,643,540)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">390,273<span></span>
</td>
<td class="nump">386,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(209,010)<span></span>
</td>
<td class="num">(176,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated other comprehensive loss &#8211; foreign currency translation adjustments</a></td>
<td class="num">(24,732)<span></span>
</td>
<td class="num">(23,315)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="nump">156,618<span></span>
</td>
<td class="nump">186,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">156,790<span></span>
</td>
<td class="nump">186,995<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">186,749<span></span>
</td>
<td class="nump">214,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member', window );">Deferred A shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockValueIssued', window );">Deferred A shares, &#163;1 nominal value; 63,443 shares authorized, issued and outstanding (December&#160;31, 2023: authorized, issued and outstanding: 63,443)</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockValueIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued deferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockValueIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredTaxLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of classified as non-current liabilities, net value of deferred tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredTaxLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentivesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentivesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608583888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#163; / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 0.000025<span></span>
</td>
<td class="nump">&#163; 0.000025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, authorized (in shares)</a></td>
<td class="nump">39,184,338<span></span>
</td>
<td class="nump">38,643,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued (in shares)</a></td>
<td class="nump">39,184,338<span></span>
</td>
<td class="nump">38,643,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding (in shares)</a></td>
<td class="nump">39,184,338<span></span>
</td>
<td class="nump">38,643,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member', window );">Deferred A shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesAuthorized', window );">Deferred shares, authorized (in shares)</a></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesIssued', window );">Deferred shares, issued (in shares)</a></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockSharesOutstanding', window );">Deferred shares, outstanding (in shares)</a></td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of deferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of deferred shares of an entity that have been sold or granted to shareholders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of deferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689602498080">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,662<span></span>
</td>
<td class="nump">13,543<span></span>
</td>
<td class="nump">22,787<span></span>
</td>
<td class="nump">23,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,201<span></span>
</td>
<td class="nump">13,128<span></span>
</td>
<td class="nump">13,195<span></span>
</td>
<td class="nump">25,266<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,863<span></span>
</td>
<td class="nump">26,671<span></span>
</td>
<td class="nump">35,982<span></span>
</td>
<td class="nump">48,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncome', window );">Other operating income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">577<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,286)<span></span>
</td>
<td class="num">(26,337)<span></span>
</td>
<td class="num">(35,200)<span></span>
</td>
<td class="num">(47,821)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income/(expense):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">635<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense', window );">Research and development incentives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">693<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">2,693<span></span>
</td>
<td class="nump">4,122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,950)<span></span>
</td>
<td class="num">(24,960)<span></span>
</td>
<td class="num">(32,507)<span></span>
</td>
<td class="num">(43,699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,943)<span></span>
</td>
<td class="num">(23,824)<span></span>
</td>
<td class="num">(32,463)<span></span>
</td>
<td class="num">(42,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (16,931)<span></span>
</td>
<td class="num">$ (23,802)<span></span>
</td>
<td class="num">$ (32,420)<span></span>
</td>
<td class="num">$ (41,982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares outstanding, basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,041,111<span></span>
</td>
<td class="nump">38,407,672<span></span>
</td>
<td class="nump">38,907,296<span></span>
</td>
<td class="nump">38,211,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares outstanding, diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,041,111<span></span>
</td>
<td class="nump">38,407,672<span></span>
</td>
<td class="nump">38,907,296<span></span>
</td>
<td class="nump">38,211,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to ordinary shareholders, basic (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to ordinary shareholders, diluted (in usd per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (16,943)<span></span>
</td>
<td class="num">$ (23,824)<span></span>
</td>
<td class="num">$ (32,463)<span></span>
</td>
<td class="num">$ (42,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive gain/(loss) &#8211; foreign currency translation adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">164<span></span>
</td>
<td class="nump">5,604<span></span>
</td>
<td class="num">(1,413)<span></span>
</td>
<td class="nump">10,184<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,779)<span></span>
</td>
<td class="num">(18,220)<span></span>
</td>
<td class="num">(33,876)<span></span>
</td>
<td class="num">(31,863)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,768)<span></span>
</td>
<td class="num">(18,205)<span></span>
</td>
<td class="num">(33,837)<span></span>
</td>
<td class="num">(31,811)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Includes <span style="-sec-ix-hidden:f-213"><span style="-sec-ix-hidden:f-214"><span style="-sec-ix-hidden:f-215"><span style="-sec-ix-hidden:f-216">license revenue</span></span></span></span> from related parties for the three and six months ended June&#160;30, 2024 of nil and for the three and six months ended June&#160;30, 2023 of $0.3 million and $0.8 million, respectively.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ResearchAndDevelopmentIncentiveIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the research and development incentives (expenses) for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ResearchAndDevelopmentIncentiveIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689704667488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">License revenue<span></span>
</td>
<td class="text">License revenue<span></span>
</td>
<td class="text">License revenue<span></span>
</td>
<td class="text">License revenue<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689602177648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total stockholders&#8217; equity attributable to Barinthus Biotherapeutics plc stockholders</div></th>
<th class="th" colspan="2"><div>Ordinary&#160;Shares</div></th>
<th class="th"><div>Additional Paid-in-Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Non-Controlling Interest</div></th>
<th class="th">
<div>Deferred A Shares </div>
<div>Deferred Shares</div>
</th>
<th class="th">
<div>Deferred B Shares </div>
<div>Deferred Shares</div>
</th>
<th class="th" colspan="2">
<div>Deferred C Shares </div>
<div>Deferred Shares</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,683,531<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">570,987<span></span>
</td>
<td class="nump">27,828,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 243,201<span></span>
</td>
<td class="nump">$ 242,896<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 379,504<span></span>
</td>
<td class="num">$ (103,243)<span></span>
</td>
<td class="num">$ (33,460)<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">2,222<span></span>
</td>
<td class="nump">2,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,494<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">4,580<span></span>
</td>
<td class="nump">4,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,574<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_SharesCancelledDuringPeriodSharesDeferredShares', window );">Cancellation of deferred shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(570,987)<span></span>
</td>
<td class="num">(27,828,231)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_SharesCancelledDuringPeriodValueDeferredShares', window );">Cancellation of deferred shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(18,223)<span></span>
</td>
<td class="num">(18,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,357,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">233,569<span></span>
</td>
<td class="nump">233,301<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">383,523<span></span>
</td>
<td class="num">(121,423)<span></span>
</td>
<td class="num">(28,886)<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,683,531<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">570,987<span></span>
</td>
<td class="nump">27,828,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">243,201<span></span>
</td>
<td class="nump">242,896<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">379,504<span></span>
</td>
<td class="num">(103,243)<span></span>
</td>
<td class="num">(33,460)<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">10,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(42,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,524,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">217,462<span></span>
</td>
<td class="nump">217,209<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">385,636<span></span>
</td>
<td class="num">(145,225)<span></span>
</td>
<td class="num">(23,289)<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,357,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">233,569<span></span>
</td>
<td class="nump">233,301<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">383,523<span></span>
</td>
<td class="num">(121,423)<span></span>
</td>
<td class="num">(28,886)<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">1,990<span></span>
</td>
<td class="nump">1,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">5,604<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,597<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(23,824)<span></span>
</td>
<td class="num">(23,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,524,059<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">217,462<span></span>
</td>
<td class="nump">217,209<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">385,636<span></span>
</td>
<td class="num">(145,225)<span></span>
</td>
<td class="num">(23,289)<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,643,540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">186,995<span></span>
</td>
<td class="nump">186,784<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">386,602<span></span>
</td>
<td class="num">(176,590)<span></span>
</td>
<td class="num">(23,315)<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,416<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,577)<span></span>
</td>
<td class="num">(1,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,580)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(15,520)<span></span>
</td>
<td class="num">(15,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,952,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">172,016<span></span>
</td>
<td class="nump">171,833<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">388,720<span></span>
</td>
<td class="num">(192,079)<span></span>
</td>
<td class="num">(24,895)<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,643,540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">186,995<span></span>
</td>
<td class="nump">186,784<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">386,602<span></span>
</td>
<td class="num">(176,590)<span></span>
</td>
<td class="num">(23,315)<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(32,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,184,338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">156,790<span></span>
</td>
<td class="nump">156,618<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">390,273<span></span>
</td>
<td class="num">(209,010)<span></span>
</td>
<td class="num">(24,732)<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,952,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">172,016<span></span>
</td>
<td class="nump">171,833<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">388,720<span></span>
</td>
<td class="num">(192,079)<span></span>
</td>
<td class="num">(24,895)<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue of ordinary shares, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,382<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue of ordinary shares, net of issuance costs</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(16,943)<span></span>
</td>
<td class="num">(16,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,184,338<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 156,790<span></span>
</td>
<td class="nump">$ 156,618<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 390,273<span></span>
</td>
<td class="num">$ (209,010)<span></span>
</td>
<td class="num">$ (24,732)<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Indicates amount less than one thousand</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_SharesCancelledDuringPeriodSharesDeferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of deferred shares cancelled during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_SharesCancelledDuringPeriodSharesDeferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_SharesCancelledDuringPeriodValueDeferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of deferred shares cancelled during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_SharesCancelledDuringPeriodValueDeferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608756048">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (32,463)<span></span>
</td>
<td class="num">$ (42,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss)/income to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,810<span></span>
</td>
<td class="nump">4,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">2,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NonCashLeaseExpenses', window );">Non-cash lease expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">717<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gain)/loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(583)<span></span>
</td>
<td class="nump">7,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NonCashInterestExpenseOnConvertibleLoanNotes', window );">Non cash interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(1,652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable (including related parties)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">262<span></span>
</td>
<td class="nump">3,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable', window );">Research and development incentives receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">352<span></span>
</td>
<td class="nump">1,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">967<span></span>
</td>
<td class="num">(1,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">839<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(819)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(23,828)<span></span>
</td>
<td class="num">(20,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(5,530)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(5,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issue of ordinary shares, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">861<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Issue of shares from the exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">861<span></span>
</td>
<td class="nump">1,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(849)<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,316)<span></span>
</td>
<td class="num">(21,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142,090<span></span>
</td>
<td class="nump">194,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">117,774<span></span>
</td>
<td class="nump">173,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AssetRetirementObligations', window );">Asset retirement obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent', window );">Changes to right-of-use asset resulting from lease reassessment event</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (47)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Indicates amounts less than one thousand</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AssetRetirementObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AssetRetirementObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of changes to right-of-use asset resulting from lease reassessment event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in research and development incentives receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NonCashInterestExpenseOnConvertibleLoanNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash interest expense on convertible loan notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NonCashInterestExpenseOnConvertibleLoanNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NonCashLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash lease expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NonCashLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689606716432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barinthus Biotherapeutics plc is a public limited company incorporated pursuant to the laws of England and Wales in March 2021. Barinthus Biotherapeutics plc and its direct and indirect subsidiaries, Barinthus Biotherapeutics (UK) Limited, Barinthus Australia Pty Limited, Vaccitech Oncology Limited (&#8220;VOLT&#8221;), Barinthus Biotherapeutics North America, Inc., Barinthus Biotherapeutics Switzerland GmbH and Barinthus Biotherapeutics S.R.L., are collectively referred to as the &#8220;Company&#8221; or &#8220;Barinthus Bio.&#8221; The Company is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. The Company is headquartered in Harwell, Oxfordshire, United Kingdom. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in an environment of rapid technological change and substantial competition from pharmaceutical and biotechnology companies. The Company is subject to risks common to companies in the biopharmaceutical industry in a similar stage of its life cycle including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its immunotherapeutic product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of any of its products that are approved, and protection of proprietary technology. There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. If the Company does not successfully commercialize any of its products or mitigate any of these other risks, it will be unable to generate revenue or achieve profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain notes or other information that are normally required by GAAP have been omitted if they substantially duplicate the disclosures contained in the Company&#8217;s annual audited consolidated financial statements. Accordingly, the unaudited condensed consolidated financial statements should be read in connection with the Company&#8217;s audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2023. The condensed consolidated balance sheet as of December&#160;31, 2023, was derived from the audited financial statements but does not contain all of the footnote disclosures from the annual financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had cash, cash equivalents and restricted cash of $117.8 million and an accumulated deficit of $209.0 million, and the Company expects to incur losses for the foreseeable future. The Company expects that its cash, cash equivalents and restricted cash will be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. The Company expects to seek additional funding through equity financing, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#8217;s stockholders. If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Condensed Consolidated Financial Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Balance Sheets as of June&#160;30, 2024, and December&#160;31, 2023, the Condensed Consolidated Statements of Operations and Comprehensive Loss, Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity and the Condensed Consolidated Statements of Cash Flows for the three and six months ended June&#160;30, 2024 and 2023 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the Securities Exchange Commission (the &#8220;Annual Report&#8221;) on March 20, 2024. In our opinion, the unaudited condensed consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of June&#160;30, 2024, our results of operations for the three and six months ended June&#160;30, 2024, and 2023, and our cash flows for the six months ended June&#160;30, 2024, and 2023. The results of operations for the three and six months ended June&#160;30, 2024, are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2024, or any other interim periods.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608921312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Annual Report, except as discussed below related to newly adopted accounting pronouncements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker ("CODM"), the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts and approves the Company's consolidated operating budget. The Company views its operations and manages its business as one operating segment, the research and development of vaccines and immunotherapies. The chief operating decision maker uses net loss to monitor budget versus actual results and decide how to use the Company's resources. As the Company operates in one operating segment, all required financial segment information can be found in these condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our current operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607341408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Foreign Currency Translation in General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyAbstract', window );"><strong>Foreign Currency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">Foreign Currency Translation in General and Administrative Expenses</a></td>
<td class="text">Foreign Currency Translation in General and Administrative Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate, net foreign exchange gain or loss recognized in general and administrative expenses for the three and six months ended June&#160;30, 2024, was a loss of $0.1 million and gain of $1.1 million, respectively (three and six months ended June&#160;30, 2023: $4.2 million loss and $7.7 million loss, respectively).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-13<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608902416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended  June&#160;30, 2024, and 2023 (in thousands, except number of shares):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(32,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(42,047)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16,931)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,802)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(32,420)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41,982)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average ordinary shares outstanding, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,041,111</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,407,672</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,907,296</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,211,625</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,041,111</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,407,672</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,907,296</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,211,625</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.43)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.62)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.83)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.10)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.62)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. As of June&#160;30, 2024, 7,779,884 potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect (June&#160;30, 2023: 6,781,099).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689606742576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2024, the Company&#8217;s additions to property and equipment, net were $0.5 million which primarily related to an increase in lab equipment in the Company's U.K. office (six months ended June&#160;30, 2023: $6.4 million, primarily related to an increase in leasehold improvements from the Company&#8217;s U.S. office in Germantown, Maryland).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and six months ended June&#160;30, 2024 was $0.7 million and $1.3 million, respectively (June&#160;30, 2023: three and six months $0.5 million and $0.9 million, respectively).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607289200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount of amortizable intangible assets, consisting of acquired developed technology, was $31.6&#160;million and $31.6&#160;million as of June&#160;30, 2024 and December&#160;31 2023, respectively, and accumulated amortization was $8.1&#160;million and $6.5&#160;million as of June&#160;30, 2024 and December&#160;31, 2023, respectively. The amortization expense for the three and six months ended June&#160;30, 2024 was $0.8&#160;million and $1.6&#160;million, respectively (three and six months ended June&#160;30, 2023: $0.8&#160;million and $1.6&#160;million, respectively). The estimated annual amortization expense is $3.2&#160;million for the years 2024 through to 2031.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2024, the Company announced plans to prioritize its pipeline to focus on the development of VTP-300 for chronic Hepatitis B virus infection and VTP-1000 in celiac disease. Given this change in Company focus, management identified circumstances that could indicate that the carrying amount of the Company's intangible assets may not be recoverable. Therefore, the Company performed both a qualitative and quantitative assessment as of June&#160;30, 2024 and determined that the carrying amount of the Company's intangible assets are recoverable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608890496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepayments and accrued income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,813&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,402&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.64pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,907&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on prepaid expense and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608648208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,124&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,003&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">942&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,278&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,212&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Included in Accrued other as of June 30, 2024 is a provision of $0.8 million for severance costs for the reduction in workforce following the Company&#8217;s announcement in June 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to prioritize its pipelin</span>e. Of this expense, $0.7&#160;million is included in research and development expenses and $0.1&#160;million is included in general and administrative expenses in the statements of operations and comprehensive loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689716369376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock', window );">Grant Income</a></td>
<td class="text">Grant Income<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) Funding Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2023, Barinthus Biotherapeutics (UK) Limited (the &#8220;Company&#8221;), the Chancellors, Masters and Scholars of the University of Oxford (&#8220;Oxford,&#8221; together with the Company, the &#8220;Partners&#8221;) and the Coalition for Epidemic Preparedness Innovations (&#8220;CEPI&#8221;) entered into a Funding Agreement (the &#8220;Funding Agreement&#8221;) pursuant to which CEPI will provide funding of up to $34.8 million to the Company to advance the development of VTP-500, the Company&#8217;s vaccine candidate against Middle East Respiratory Syndrome (&#8220;MERS,&#8221; and such development activities, the &#8220;Project&#8221;). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Funding Agreement, the Company has agreed to pay CEPI on a country-by-country basis increasing mid-single digit percentage royalties of net sales and net income with respect to future cash sales of VTP-500, less certain deductions, for a period starting on December 20, 2023 (&#8220;Effective Date&#8221;) and ending the later of: (i) the expiration of the last valid patent claim included in intellectual property developed under the Project covering VTP-500 in such country, (ii) the expiration of Regulatory Exclusivity (as defined in the Funding Agreement) for VTP-500 in such country, and (iii) the tenth (10th) anniversary of the first commercial sale of VTP-500 (the &#8220;Royalty Term&#8221;). The Company shall also pay CEPI a mid-double-digit percentage of net revenue earned on VTP-500 until CEPI has received payments from the Company under the Funding Agreement equaling the total amount of funding paid by CEPI to the Company and a low double-digit percentage of such net revenue thereafter. Sales for the benefit of end users in specified low and middle income countries (&#8220;LMICs&#8221;) and upper and middle income countries (&#8220;UMICs&#8221;) are excluded from the calculations of net sales and net revenue. Sales of the product for the benefit of end users in LMICs and UMICs are subject to tiered discounted pricing requirements under the Funding Agreement. The Company is further required to pay a low to mid-double-digit percentage of any proceeds earned on any priority review voucher related to VTP-500 during the Royalty Period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the six months period ended June&#160;30, 2024, $1.6 million proceeds have been received and $0.8 million income has been recognized in relation to this contract. This is presented as other operating income in the condensed consolidated statements of operations and comprehensive loss. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Funding Agreement cash payments are restricted as to the use and management of the funds. The remaining unused amounts of the Funding Agreement cash payments of $0.8 million as of June&#160;30, 2024 are reflected in Cash, cash equivalents and restricted cash in the condensed consolidated balance sheets until expenditures contemplated in the Funding Agreement are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Deferred income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred income primarily relates to payments received from CEPI in advance of the eligible research and development expenses being incurred and are disclosed as deferred income separately in the condensed consolidated balance sheets. Deferred income is released to the condensed consolidated statements of operations and comprehensive loss in the period in which such research and development activities are actually performed in a manner that satisfies the conditions of the Funding Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in deferred income during the three and six months ended June&#160;30, 2024 and 2023, are as follows (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income recognized related to the Funding Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other operating income and other operating expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607301456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Ordinary Shares</a></td>
<td class="text">Ordinary Shares<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All ordinary shares rank pari passu as a single class. The following is a summary of the rights and privileges of the holders of ordinary shares as of June&#160;30, 2024:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidation preference: in the event of the liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to holders of the ordinary shares shall be distributed amongst all holders of the ordinary shares in proportion to the number of shares held irrespective of the amount paid or credited as paid on any share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends: The Company may, subject to the provisions of the Companies Act 2006 and our Articles, by ordinary resolution from time to time declare dividends to be paid to shareholders not exceeding the amount recommended by the Company&#8217;s board of directors. Subject to the provisions of the Companies Act 2006, in so far as, in the board of directors&#8217; opinions, the Company&#8217;s profits justify such payments, the board of directors may pay interim dividends on the Company&#8217;s ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Voting Rights: Each holder of ordinary shares has the right to receive notice of, and to vote at, the Company&#8217;s general meetings. Each holder of ordinary shares who is present (in person or by proxy) at a general meeting on a show of hands has one vote and, on a poll, every such holder who is present (in person or by proxy) has one vote in respect of each share of which they are the holder.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preemption rights: Pursuant to section 561 of the Companies Act 2006, shareholders are granted preemptive rights when new shares are issued for cash. However, it is possible for our Articles, or shareholders at a general meeting representing at least 75% of our ordinary shares present (in person or by proxy) and eligible to vote at that general meeting, to disapply these preemptive rights by passing a special resolution. Such a disapplication of preemption rights may be for a maximum period of up to five years from the date on which the shareholder resolution was passed. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at least every five years) to remain effective.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;21, 2021, our shareholders approved the disapplication of preemptive rights for a period of five years from the date of approval by way of a special resolution of our shareholders. This included the disapplication of preemption rights in relation to the allotment of our ordinary shares in connection with the IPO. This disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;6, 2023, we held a general meeting where our shareholders approved resolutions granting our board of directors or any duly authorized committee of the board of directors the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from pre-emption rights. Pursuant to such approval, our board of directors was authorized to allot shares up to an aggregate nominal amount of &#163;1,928 free from statutory pre-emption rights. The granting of this authority and the corresponding disapplication of preemptive rights was in addition to all subsisting authorities. This disapplication will need to be renewed upon expiration (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607312560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_StockholdersEquityDeferredSharesDisclosureTextBlock', window );">Deferred Shares</a></td>
<td class="text">Deferred Shares<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All deferred shares rank pari passu as a single class. The deferred shares do not have rights to dividends or to any other right of participation in the profits of the Company. On a return of assets on liquidation, the deferred shares shall confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst the shareholders (subject to the rights of any new class of shares with preferred rights) the amount credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares of the amounts paid up or credited as paid up on such shares and the sum of &#163;1.0&#160;million in respect of each ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;29, 2023, all deferred B shares (nominal value of &#163;0.01 each) and deferred C shares (nominal value of &#163;0.00000736245954692556 each) previously in issue were transferred back to the Company and subsequently cancelled. These deferred shares had previously been issued to certain pre-IPO shareholders in connection with the implementation of certain stages of the Company&#8217;s pre-IPO share capital reorganization. The Company received shareholder approval on </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April 21, 2021 (pursuant to the shareholder resolutions passed on that date) in order to effect the transfer back and cancellation of the deferred shares for nil consideration in accordance with sections 659 and 662 of the Companies Act 2006.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s deferred A shares with a nominal value of &#163;1.00 each remain in issue for the purposes of satisfying the minimum share capital requirements for a public limited company as prescribed by the Companies Act 2006.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_StockholdersEquityDeferredSharesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Deferred Shares as disclosed by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_StockholdersEquityDeferredSharesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607193424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash, cash equivalents and restricted cash, accounts receivable, accounts payable, certain accrued expenses, and contingent consideration. The carrying amounts of cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued expenses approximated their respective fair value due to the short-term nature and maturity of these instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had a contingent consideration liability of $1.9&#160;million related to the acquisition of Avidea Technologies, Inc. The fair value of the contingent consideration is a Level 3 valuation with the significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Significant judgment is employed in determining the appropriateness of certain of these inputs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes to our financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,867&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,710&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,823&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,711&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value recognized in net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,888&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,117&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,888&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,117&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689606775520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text">Goodwill<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified qualitative indicators of impairment due to a sustained decline in the price of the Company&#8217;s American Depositary Shares, whereby the market capitalization continues to be below the value of the net assets of the Company, and the plans announced in June 2024 to prioritize its pipeline to focus on the development of VTP-300 for chronic Hepatitis B virus infection and VTP-1000 in celiac disease. Therefore, the Company performed both an interim qualitative and quantitative assessment as of June&#160;30, 2024 to determine whether it was more likely than not that the fair value of the reporting unit is less than its carrying amount. Based on this assessment, management determined it is not more likely than not that the fair value of the reporting unit is less than its carrying amount and hence no impairment loss has been recognized.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607314512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six month period ended June&#160;30, 2024, in accordance with the terms of the Annual Increase of the Barinthus Biotherapeutics plc Award Plan 2021 (the &#8220;Plan&#8221;), the total number of ordinary shares available for issuance under the Plan increased by 4% of the Company&#8217;s issued and outstanding ordinary shares as of January 1, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2024, the Company granted 1,951,377</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">options to employees and directors with a weighted average grant date fair value of $2.71 and a weighted average exercise price of $3.41 per share (June&#160;30, 2023: granted 2,142,905 options, weighted average grant date fair value of $2.00 and a weighted average exercise price of $2.51 per share). For the six months ended June&#160;30, 2024, 229,430 options (June&#160;30, 2023: 217,860) were forfeited.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued to employees was estimated at the date of grant using the Black-Scholes model with the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">108.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.0</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, 7,779,884 options with a weighted average exercise price of $6.19 were outstanding. As of June&#160;30, 2024, there was $5.4&#160;million unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted average period of 1.9 years. As of June&#160;30, 2023, 6,781,099 options with a weighted average exercise price of $9.51 were outstanding. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share based compensation expense is classified in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">505&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,217&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,146&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608609312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a number of licensing agreements, most of which are with related parties. These agreements serve to provide the Company with the right to develop and exploit the counterparties&#8217; intellectual property for certain medical indications. As part of execution of these arrangements, the Company paid certain upfront fees, which have been expensed as incurred because the developing technology has not yet reached technical feasibility, the lack of alternative use, and the lack of proof of potential value. The agreements cover a variety of fields, including influenza, cancer, human papillomavirus infection, (&#8220;HPV&#8221;), hepatitis B virus (&#8220;HBV&#8221;) and MERS. The Company&#8217;s obligations for future payments under these arrangements are dependent on its ability to develop promising drug candidates, the potential market for these candidates and potential competing products, and the payment mechanisms in place in countries where the Company retains the right to sell. Each agreement provides for specific milestone payments, typically triggered by achievement of certain testing phases in human candidates, and future royalties ranging from 1 to 5% for direct sales of a covered product to 3 to 7% of net payments received for allowable sublicenses of technology developed by the Company. The obligation to make these payments is contingent upon the Company&#8217;s ability to develop candidates for submission for phased testing and approvals, and for the development of markets for the products developed by the Company. The Company has not made or accrued any material payments under these license agreements during the six month periods ended June&#160;30, 2024 and 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain laboratory and office space under operating leases, which are described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Harwell Science and Innovation Campus, Oxfordshire</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;3, 2021, the Company entered into a lease agreement for the lease of approximately 31,000 square feet in Harwell, Oxfordshire which expires in September 2031. The property is the Company&#8217;s corporate headquarters. As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date, being the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company has provided the lessor with a refundable security deposit of $0.7&#160;million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Germantown, Maryland</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;14, 2022, the Company entered into a lease agreement for the lease of approximately 19,700 square feet in Germantown, Maryland. The site houses the Company&#8217;s state-of-the-art wet laboratory in the United States of America. The lease expires on February 28, 2034, with the Company having a single right to extend for an additional five years on the same terms and conditions other than for the base rent. The Company had a rent-free period up to February 29, 2024, and was entitled to up to $3.5&#160;million for leasehold improvements to the premises desired by the Company. The Company has provided the lessor with a refundable security deposit of $0.2&#160;million which is included in Other assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a right-of-use asset and a lease liability on the effective date of the lease term. The Company&#8217;s right-of-use asset and lease liability are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,286&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,581&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, current</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,916&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,785&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:72.799%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.711%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">819</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.25</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term lease costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">151</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">303</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">358</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">316</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">717</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">595</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">358</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">467</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">717</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">898</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of June&#160;30, 2024, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.424%"><tr><td style="width:1.0%"></td><td style="width:82.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Remainder of 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other contingencies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. However, from time to time, we could be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607307968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2024, the Company incurred expenses of $0.3 million and $0.5 million, respectively (three and six months ended June&#160;30, 2023: $0.3 million and $0.4 million, respectively) from Oxford University Innovation Limited which is a wholly owned subsidiary of the Company&#8217;s shareholder, the University of Oxford. </span></div>During the three and six months ended June&#160;30, 2024, the Company recognized license revenue of nil (three and six months ended June&#160;30, 2023: $0.3 million and $0.8 million, respectively), from Oxford University Innovation Limited.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689702123920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">$ (16,931)<span></span>
</td>
<td class="num">$ (23,802)<span></span>
</td>
<td class="num">$ (32,420)<span></span>
</td>
<td class="num">$ (41,982)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689612992400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607316096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker ("CODM"), the Company&#8217;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts and approves the Company's consolidated operating budget. The Company views its operations and manages its business as one operating segment, the research and development of vaccines and immunotherapies. The chief operating decision maker uses net loss to monitor budget versus actual results and decide how to use the Company's resources. As the Company operates in one operating segment, all required financial segment information can be found in these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our current operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607317888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net loss per share</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended  June&#160;30, 2024, and 2023 (in thousands, except number of shares):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.948%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(32,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(42,047)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Barinthus Biotherapeutics plc shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16,931)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(23,802)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(32,420)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41,982)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average ordinary shares outstanding, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,041,111</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,407,672</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,907,296</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,211,625</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average ordinary shares outstanding, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">39,041,111</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,407,672</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,907,296</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38,211,625</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders, basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.43)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.62)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.83)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.10)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to ordinary shareholders, diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.62)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.83)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689699423936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text">Prepaid Expenses and Other Current Assets (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepayments and accrued income</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,813&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,402&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Value Added Tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.64pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,907&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689778127792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued manufacturing and clinical expenses</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5,124&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,003&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued bonus</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,412&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">942&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,278&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,212&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Included in Accrued other as of June 30, 2024 is a provision of $0.8 million for severance costs for the reduction in workforce following the Company&#8217;s announcement in June 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to prioritize its pipelin</span>e. Of this expense, $0.7&#160;million is included in research and development expenses and $0.1&#160;million is included in general and administrative expenses in the statements of operations and comprehensive loss.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607162288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTableTextBlock', window );">Schedule of changes in deferred income</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in deferred income during the three and six months ended June&#160;30, 2024 and 2023, are as follows (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income recognized related to the Funding Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">839&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689704040144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of financial instruments carried at fair value and classified within Level 3</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes changes to our financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,867&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,710&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,823&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,711&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Change in fair value recognized in net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Foreign exchange translation recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Ending balance</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,888&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,117&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,888&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,117&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689606718384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions of fair value stock option issued to employees</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued to employees was estimated at the date of grant using the Black-Scholes model with the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">108.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.0</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of share based compensation expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share based compensation expense is classified in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">505&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,027&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,217&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,146&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,990&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689606450144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock', window );">Schedule of right-of-use assets, lease liabilities and other information</a></td>
<td class="text">The Company&#8217;s right-of-use asset and lease liability are as follows (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">June 30,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Right-of-use asset</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,286&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,581&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, current</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,916&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,785&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Lease liability, non-current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10,654&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11,191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:72.799%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.711%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended June 30,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">819</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">442</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.25</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Weighted average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost</a></td>
<td class="text"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three months ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Short-term lease costs</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">151</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">303</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">358</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">316</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">717</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">595</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease cost</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">358</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">467</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">717</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">898</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of minimum lease liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual minimum lease payments under operating leases as of June&#160;30, 2024, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.424%"><tr><td style="width:1.0%"></td><td style="width:82.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Remainder of 2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16,797&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for Company's right-of-use asset and lease liability and other information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607252432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 117,774<span></span>
</td>
<td class="nump">$ 142,090<span></span>
</td>
<td class="nump">$ 173,030<span></span>
</td>
<td class="nump">$ 194,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 209,010<span></span>
</td>
<td class="nump">$ 176,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689609796864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689610804864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Foreign Currency Translation in General and Administrative Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyAbstract', window );"><strong>Foreign Currency [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Net foreign exchange gain (loss)</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (4.2)<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="num">$ (7.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689603277408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (16,943)<span></span>
</td>
<td class="num">$ (15,520)<span></span>
</td>
<td class="num">$ (23,824)<span></span>
</td>
<td class="num">$ (18,223)<span></span>
</td>
<td class="num">$ (32,463)<span></span>
</td>
<td class="num">$ (42,047)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Barinthus Biotherapeutics plc shareholders</a></td>
<td class="num">$ (16,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,802)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32,420)<span></span>
</td>
<td class="num">$ (41,982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average ordinary shares outstanding, basic (in shares)</a></td>
<td class="nump">39,041,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,407,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,907,296<span></span>
</td>
<td class="nump">38,211,625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average ordinary shares outstanding, diluted (in shares)</a></td>
<td class="nump">39,041,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,407,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,907,296<span></span>
</td>
<td class="nump">38,211,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to ordinary shareholders, basic (in usd per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to ordinary shareholders, diluted (in usd per share)</a></td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607201632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares)</a></td>
<td class="nump">7,779,884<span></span>
</td>
<td class="nump">6,781,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689607186800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689600423328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear', window );">Estimated annual amortization expense for 2024</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization expense for 2025</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization expense for 2026</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization expense for 2027</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization expense for 2028</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated annual amortization expense for 2029</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix', window );">Estimated annual amortization expense for 2030</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven', window );">Estimated annual amortization expense for 2031</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross amount of amortizable intangible assets</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization for amortizable intangible assets</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, Current Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, Year Seven</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, Year Six</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689606711504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayments and accrued income</a></td>
<td class="nump">$ 7,813<span></span>
</td>
<td class="nump">$ 5,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">Value Added Tax receivable</a></td>
<td class="nump">1,143<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">626<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 9,582<span></span>
</td>
<td class="nump">$ 9,907<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689610864848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems', window );"><strong>Accrued Expenses And Other Liabilities, Current [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedManufacturingAndClinicalExpensesCurrent', window );">Accrued manufacturing and clinical expenses</a></td>
<td class="nump">$ 5,124<span></span>
</td>
<td class="nump">$ 4,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued payroll and employee benefits</a></td>
<td class="nump">985<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">1,888<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">10,278<span></span>
</td>
<td class="nump">$ 9,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems', window );"><strong>Accrued Expenses And Other Liabilities, Current [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems', window );"><strong>Accrued Expenses And Other Liabilities, Current [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses And Other Liabilities, Current [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_AccruedManufacturingAndClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_AccruedManufacturingAndClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689704642864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeLineItems', window );"><strong>Deferred Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeAddition', window );">Cash payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,629<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeRevenueRecognized', window );">Other income recognized related to the Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_CoalitionForEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeLineItems', window );"><strong>Deferred Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FundingAmountMaximum', window );">Maximum funding amount</a></td>
<td class="nump">$ 34,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_RoyaltyPaymentTermMaximum', window );">Maximum royalty payment period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeAddition', window );">Cash payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeRevenueRecognized', window );">Other income recognized related to the Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FundingAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding Amount, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FundingAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_RoyaltyPaymentTermMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment, Term, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_RoyaltyPaymentTermMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized previously reported as deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=brns_CoalitionForEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=brns_CoalitionForEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608693712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Income - Changes in deferred income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeRollForward', window );"><strong>Deferred Income [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Beginning balance</a></td>
<td class="nump">$ 1,434<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeAddition', window );">Cash payments received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,629<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeRevenueRecognized', window );">Other operating income recognized related to the Funding Agreement</a></td>
<td class="num">(577)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(782)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredIncomeForeignExchangeTranslationGainLoss', window );">Foreign exchange translation</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Ending balance</a></td>
<td class="nump">$ 839<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 839<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredIncomeForeignExchangeTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Income, Foreign Exchange Translation Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredIncomeForeignExchangeTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized previously reported as deferred income not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608693840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Ordinary Shares (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 06, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th"><div>Apr. 21, 2021</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>vote</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_CommonStockNumberOfVotesPerShare', window );">Number of votes per common share (in votes) | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights', window );">Percentage of ordinary shares present to exercise preemptive rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PeriodOfPreemptiveRightsToBeExercised', window );">Maximum period to exercise preemptive rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights', window );">Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights | &#163;</a></td>
<td class="nump">&#163; 1,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PeriodOfPreemptiveRightsToBeExercised', window );">Maximum period to exercise preemptive rights</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of votes that each common share is entitled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfSharesNecessaryToExercisePreemptiveRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of shares required to exercise preemptive rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfSharesNecessaryToExercisePreemptiveRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PeriodOfPreemptiveRightsToBeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period allowed to exercise preemptive rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PeriodOfPreemptiveRightsToBeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689603286928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Shares (Details) - GBP (&#163;)<br> &#163; / shares in Units, &#163; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member', window );">Deferred A Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Deferred shares [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_OrdinarySharesLiquidationPreference', window );">Ordinary shares, liquidation preference</a></td>
<td class="nump">&#163; 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 1<span></span>
</td>
<td class="nump">&#163; 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember', window );">Deferred B Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Deferred shares [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember', window );">Deferred C Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Deferred shares [Line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_DeferredStockParOrStatedValuePerShare', window );">Deferred shares, nominal value (in gbp per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 0.00000736245954692556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_DeferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of deferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_DeferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_OrdinarySharesLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_OrdinarySharesLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredShares.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=brns_DeferredCSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689599663376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Additional information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=brns_AvideaMember', window );">Avidea</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration liability</a></td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=brns_AvideaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=brns_AvideaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689610186800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Change in Financial Instruments Classified within Level 3 (Details) - Contingent Consideration Liability - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,867<span></span>
</td>
<td class="nump">$ 1,710<span></span>
</td>
<td class="nump">$ 1,823<span></span>
</td>
<td class="nump">$ 1,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recognized in net loss</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation', window );">Foreign exchange translation recognized in other comprehensive loss</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 1,888<span></span>
</td>
<td class="nump">$ 2,117<span></span>
</td>
<td class="nump">$ 1,888<span></span>
</td>
<td class="nump">$ 2,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign exchange translation of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=brns_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=brns_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689694729392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689602113648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,951,377<span></span>
</td>
<td class="nump">2,142,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted (in usd per share)</a></td>
<td class="nump">$ 2.71<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price of options granted (in usd per share)</a></td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="nump">$ 2.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="nump">229,430<span></span>
</td>
<td class="nump">217,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="nump">7,779,884<span></span>
</td>
<td class="nump">6,781,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price of options outstanding (in usd per share)</a></td>
<td class="nump">$ 6.19<span></span>
</td>
<td class="nump">$ 9.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to options</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which unrecognized compensation cost is expected to be recognized</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member', window );">Barinthus Biotherapeutics plc Share Award Plan 2021 | Restricted share units, options, share appreciation rights and restricted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares', window );">Percentage of issued and outstanding ordinary shares available for issuance under the Plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689606711632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted-average assumptions (Details) - Enterprise Management Incentive Share Option Scheme<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">108.70%<span></span>
</td>
<td class="nump">97.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=brns_EnterpriseManagementIncentiveShareOptionSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689694867104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 1,195<span></span>
</td>
<td class="nump">$ 1,990<span></span>
</td>
<td class="nump">$ 2,810<span></span>
</td>
<td class="nump">$ 4,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
<td class="nump">2,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 963<span></span>
</td>
<td class="nump">$ 1,593<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689599579184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 14, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 03, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=brns_OxfordshireMember', window );">Oxfordshire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitment and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfSquareFeetUnderLeaseAgreement', window );">Size of space under lease agreement (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Refundable security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MD', window );">Maryland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitment and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_NumberOfSquareFeetUnderLeaseAgreement', window );">Size of space under lease agreement (in square feet) | ft&#178;</a></td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Refundable security deposit</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_LesseeOperatingLeaseExtendedTerm', window );">Additional lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvement expense</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember', window );">In-License Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitment and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement', window );">Percentage of future royalties for direct sales of a covered product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement', window );">Net payments received for allowable sublicenses of technology developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember', window );">In-License Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitment and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement', window );">Percentage of future royalties for direct sales of a covered product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement', window );">Net payments received for allowable sublicenses of technology developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_LesseeOperatingLeaseExtendedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_LesseeOperatingLeaseExtendedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_NumberOfSquareFeetUnderLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to number of Square Feet Under Lease Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_NumberOfSquareFeetUnderLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future royalties for direct sales of a covered product under the In-License Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=brns_OxfordshireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=brns_OxfordshireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=brns_InLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608775904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 7,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current</a></td>
<td class="nump">1,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, non-current</a></td>
<td class="nump">10,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_OtherInformationLesseeAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 819<span></span>
</td>
<td class="nump">$ 442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">8 years 8 months 15 days<span></span>
</td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_OtherInformationLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Information, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_OtherInformationLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689606446800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating leases</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">717<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="nump">$ 717<span></span>
</td>
<td class="nump">$ 898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689609050064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of minimum lease liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2024</a></td>
<td class="nump">$ 958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">1,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">7,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">16,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(4,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 12,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due in year four and after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>brns_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689608573360">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited | Related Parties | License revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember', window );">Oxford University Innovation Limited | Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amounts of related party transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Includes <span style="-sec-ix-hidden:f-213"><span style="-sec-ix-hidden:f-214"><span style="-sec-ix-hidden:f-215"><span style="-sec-ix-hidden:f-216">license revenue</span></span></span></span> from related parties for the three and six months ended June&#160;30, 2024 of nil and for the three and six months ended June&#160;30, 2023 of $0.3 million and $0.8 million, respectively.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=brns_OxfordUniversityInnovationLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=brns_ExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=brns_ExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #1!"%D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  T00A9#F.3[^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)^V*K*';B^))07!!\1:2V=U@\X=DI-VW-XV[740?0,@E,[]\
M\PVD4T$H'_$Y^H"1#*:KR0XN"14V[$ 4!$!2![0RU3GA<G/GHY64KW$/0:H/
MN4=H.;\!BR2U) DSL H+D?6=5D)%E.3C":_5@@^?<2@PK0 'M.@H05,WP/IY
M8CA.0P<7P PCC#9]%U OQ%+]$ULZP$[)*9DE-8YC/:Y*+N_0P-O3XTM9MS(N
MD70*\ZMD!!T#;MAY\NOJ[G[[P/J6M]<57^>S;5K!;T6[?I]=?_A=A*W79F?^
ML?%9L._@U[_HOP!02P,$%     @ -$$(69E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ME>7,A8D=)4R)]X,1@AG.I?G$>B#G3H9U[C@"8B#$S0*-O%4($\N%B1TE3).
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MNC(4S5C=ZH#K #6_9$R^=O2]H;XGAK\!4$L#!!0    ( #1!"%F<^L+[JP<
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M$B!_?^)<O&Z4!UB_-S7X#U!+ P04    "  T00A9SVO4WQ0#  !""@  &
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*U6;6_:,!#^*Z=LFCJI:T("K.H
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MC067=]W4KW?*M]41#5!WW5 5%$7K!DVK@EIZ%730(^?H&$+*:E,HS;54E?&
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M)^S$^)!75;[>OKQ+DT5:- ;UYS=Y7GW^HW'PD!<?MTV]^#]02P,$%     @
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M-"0W'MFPBKB;$ZT;NFFWE-B(QG1-[\,I2U$X$R_$ GYM^#T3-/FLGG3Q-J*
MDDH/:T320=[O?&2Z<0=P:1SRBV-@'(['TW RR5X-1RDQIO%Y=XF@JS"_ U6[
MS!C8H>/S0,Q=TV^TJHX=87OUNY>[\_M-2<QSUI@N'7Z$ *M#;24K2-IS=8";
M#3TPX.Q07CJ#43B>Q&$TG9X/CMT)PX,;FXZDK7^7&*+?2-M>WOUH__2Y;&_\
MI^7MN^D3TUM.&1&X(==H,+X(0+=OD?;#JMK?_VMEZ37AS9*>;ZC= IK?*"I
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M%9)&F<KQS,*'<[&G]_F.>F;04#UBQ^<$IB5:,44*/4$CR:4N*,2\3KFUJ+M
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MWIN"+S,E,>EI Y[/C?'-@@RTGRNO_P)02P,$%     @ -$$(68TI=&7*!@
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M TT'/U_J]:(DJRP:I%Z.L1H:VF(QJU^F0SE2;]V"LX(JCY((%X+I]?'V><?
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MR@LP7SC<TMT#&UB^:SK[%U!+ P04    "  T00A9>!N[^>@$  #*"P  &0
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M63!YS@\_<#;5"M/>P.\IM,S(6/]MR,,I1LH))PEBXCQ?0RE!"QA$JN72GGG
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M^.8B(]>_-/TBV#9-=]P-O!7IL\;CS"X:X+RR-AP6T<'QN5_\"U!+ P04
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MM>=$*8CD9"^93SD9=<<Q.N :G(RNBYS(6JTX+)HH0[7A?I\/#7=2%QSL,O0
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MI[[-TQMV3!;O%!B3)V()U3"<$>$2'I[2<);0<$[#^9R&^(0^9TI1A$-P#MC
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M1;_:-]IEVU_^AK==^@'+@G*%&.0F-1C-S>N4;>=K)UK4KMOLA#:]RPU+\[,
M:0/,\UP(?9S8#?K?3_H'4$L#!!0    ( #1!"%G@>7'*8P<  +$3   9
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M9T#[.Z7L<>$"C/\AUG\!4$L#!!0    ( #1!"%EY066XM0(  .(%   9
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M6=)$OZSI3PBU<R![I93=;5R"X6]M^0]02P,$%     @ -$$(657$T^'K @
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ME0V@]:649N?8 LV7*OX/4$L#!!0    ( #1!"%G$C42S^0(  ,8&   9
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;(U6VV[C-A#]E8&VNTB
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M2Z[T8+;'4B]G$$9!OZ\X5[N+,="O^^0/4$L#!!0    ( #1!"%EJ 9JK=@0
M "06   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;+58:W.C-A3]*QJZ
MTTEF$O,T?M3VS#HVWG::3F;3=#\KH!AF 5%)Q+O_OA=!",8RQ5N:#S&(>^ZY
MTKE7K\6!LJ\\)$2@;TF<\J46"I'-=9W[(4DP']&,I/#EA;($"WAE>YUGC.!
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M'R]W0<L+R?)BU^Z92<FRXC0!' /7%=3])6-R?Z$3U'O1LZ]02P,$%     @
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M&T&09@#>WPA<\-0-\X!F:QG^"U!+ P04    "  T00A9J4KXFBH#  #X#P
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M2B@+$I>$BGN?+QB8Y@HV@=-5./8+[>@2A>&:7BTT/H'6EUJ[7>!O4O<.9G\
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M8&70/S(\;C,\B.)VPP>-S,'K#,_8FF4@,K)EP+,VF8,6F4<:3X94^OR]IEN
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M7?1@,D1U-:@ZBJ_*LV_.%9RD93.%VQ01&@#?%YRK;4<G:.YGX1]02P,$%
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MNT:)PB@X6$QDM]8>V;0KKKY?$1V8*"B3?)F*[4>NVWQ4#NRM0]T"T5EY_,[
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M"#7TD\;DV=OG=.B'\7O?LW3C(J5#__;D[8]%H2[>>/9^].[HJ'-[>K%K/S'
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M:0,/+ Y$>EJN\=7&*^3A.L#6]*$*P6:*5R(V4SS7@+CS!AY)XEYM+ YX8*N
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M9'9.R"2 O$(@K\X)F0:0[Q'(][20<^YJ(YC>L)O:2B6L95P5[(9;::$T@/R
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MU#O^I]ZYG'8I7WN^U_C\_Z2ZG.]-U\=?EM\G1^Q<< [P"\CC%U!+ P04
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MI:"_YZVIN_=\-ORW<?4*4$L! A0#%     @ -$$(60=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  T
M00A9#F.3[^\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  T00A9F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #1!"%D::B"?
M@08  )8E   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  T00A9;DR"4B('   S'P  &
M@('%#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ -$$(
M61IM**_H @  ,PH  !@              ("!'18  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( #1!"%F<^L+[JP<  $,E   8
M      " @3L9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  T00A9SVO4WQ0#  !""@  &               @($<(0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ -$$(63U:(-^/#P  &*L  !@
M             ("!9B0  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( #1!"%E0;T]RR <   0A   8              " @2LT  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  T00A9N[3@?AD+   V
M'P  &               @($I/   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ -$$(61NC;,:!!P  G1,  !@              ("!>$<
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( #1!"%FM8A>:
MF@(  &P&   9              " @2]/  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ -$$(66J$CY<@!   ' H  !D
M ("! %(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  T
M00A9M@8LW>T"   (!P  &0              @(%75@  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( #1!"%GD\#95W ,  $T)   9
M          " @7M9  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#
M%     @ -$$(655=&B^8 @  S04  !D              ("!CET  'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  T00A9_L>KZ!L#  #-
M!@  &0              @(%=8   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM
M;%!+ 0(4 Q0    ( #1!"%GW;3W''P@  +H4   9              " @:]C
M  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ -$$(68TI
M=&7*!@  =Q(  !D              ("!!6P  'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6Q02P$"% ,4    "  T00A9>!N[^>@$  #*"P  &0
M    @($&<P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M #1!"%GU@\K+2 0  /P)   9              " @25X  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ -$$(6;815AR< P  ^@<  !D
M             ("!I'P  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  T00A9-R?]K3@%  !G#   &0              @(%W@   >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( #1!"%D*(='Z. H
M 'X8   9              " @>:%  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ -$$(68ACFI:C @  / 8  !D              ("!
M59   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  T00A9
MT><VMI4"  #:!P  &0              @($ODP  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( #1!"%D0PNQ 1 (  (H&   9
M      " @?N5  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ -$$(6>!Y<<IC!P  L1,  !D              ("!=I@  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  T00A9 X;/:F\#  !/"
M&0              @($0H   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( #1!"%EY066XM0(  .(%   9              " @;:C  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ -$$(6?H@!N@Y
M P  X@8  !D              ("!HJ8  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    "  T00A95<33X>L"  "U!@  &0
M@($2J@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( #1!
M"%G$C42S^0(  ,8&   9              " @32M  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ -$$(6>="(\*K P  ? @  !D
M         ("!9+   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    "  T00A9V+NXW ($  #P"0  &0              @(%&M   >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( #1!"%D,J#Y/R0(  &D(
M   9              " @7^X  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ -$$(64N[*0@G @  M 0  !D              ("!?[L
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  T00A9U$;\
M@*P"  #Z!P  &0              @('=O0  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( #1!"%EJ 9JK=@0  "06   9
M  " @<#   !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M-$$(69:*CZVA @  ( 8  !D              ("!;<4  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    "  T00A90.(C2<0"   :"0  &0
M            @(%%R   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( #1!"%DH/<'=0 0  ,\<   9              " @4#+  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ -$$(61_X5!*] @
M%P<  !D              ("!M\\  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    "  T00A9"=[TA\<#  ![#P  &0              @(&K
MT@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( #1!"%E#
M,71V' 0  )<6   9              " @:G6  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ -$$(6;1)CNE= P  APL  !D
M     ("!_-H  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #1!"%F;^#A$40(  -,%   9              "
M@03L  !X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ -$$(
M61L&S0"I!   WA$  !D              ("!C.X  'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    "  T00A9,MP0"? "   H"   &0
M        @(%L\P  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( #1!"%EV' KF>@,  +\0   9              " @9/V  !X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ -$$(6<9WUUNV!   &QL
M !D              ("!1/H  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    "  T00A9A.N4JZ\#  ![#0  &0              @($Q_P
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( #1!"%G2F'H,
M[P(  *L)   9              " @1<# 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ -$$(63V$1YK0 @  "P@  !D
M ("!/08! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  T
M00A9S(OC 3($  !H&0  &0              @(%$"0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( #1!"%E) PB#;@,  /06   -
M          "  :T- 0!X;"]S='EL97,N>&UL4$L! A0#%     @ -$$(69>*
MNQS     $P(   L              ( !1A$! %]R96QS+RYR96QS4$L! A0#
M%     @ -$$(6<?#7&>[!   VR4   \              ( !+Q(! 'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( #1!"%GS((MYZ0$  !(B   :
M      "  1<7 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( #1!"%FR:$G8U0$  +\A   3              "  3@9 0!;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@    !! $$ OA$  #X; 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>149</ContextCount>
  <ElementCount>237</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Foreign Currency Translation in General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses</Role>
      <ShortName>Foreign Currency Translation in General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Grant Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GrantIncome</Role>
      <ShortName>Grant Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Ordinary Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinaryShares</Role>
      <ShortName>Ordinary Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Deferred Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/DeferredShares</Role>
      <ShortName>Deferred Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Grant Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GrantIncomeTables</Role>
      <ShortName>Grant Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/GrantIncome</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/FairValue</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/ShareBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Foreign Currency Translation in General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails</Role>
      <ShortName>Foreign Currency Translation in General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Net Loss Per Share - Computation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossPerShareComputationDetails</Role>
      <ShortName>Net Loss Per Share - Computation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Net Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/IntangibleAssetsNet</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Grant Income - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails</Role>
      <ShortName>Grant Income - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Grant Income - Changes in deferred income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails</Role>
      <ShortName>Grant Income - Changes in deferred income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Ordinary Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/OrdinarySharesDetails</Role>
      <ShortName>Ordinary Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/OrdinaryShares</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Deferred Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/DeferredSharesDetails</Role>
      <ShortName>Deferred Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/DeferredShares</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Fair Value - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails</Role>
      <ShortName>Fair Value - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Fair Value - Change in Financial Instruments Classified within Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details</Role>
      <ShortName>Fair Value - Change in Financial Instruments Classified within Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/Goodwill</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Share-Based Compensation - Weighted-average assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Weighted-average assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Share-Based Compensation - Share based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Commitments and Contingencies - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of minimum lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="brns-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.barinthusbio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="brns-20240630.htm">brns-20240630.htm</File>
    <File>brns-20240630.xsd</File>
    <File>brns-20240630_cal.xml</File>
    <File>brns-20240630_def.xml</File>
    <File>brns-20240630_lab.xml</File>
    <File>brns-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>brns-20240630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="564">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="32">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "brns-20240630.htm": {
   "nsprefix": "brns",
   "nsuri": "http://www.barinthusbio.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "brns-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "brns-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "brns-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "brns-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "brns-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brns-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 197,
   "keyCustom": 40,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 17,
   "memberCustom": 14,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://fasb.org/us-gaap/2024": 4
   },
   "contextCount": 149,
   "entityCount": 1,
   "segmentCount": 32,
   "elementCount": 461,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 564,
    "http://xbrl.sec.gov/dei/2024": 32,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.barinthusbio.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "brns:ResearchAndDevelopmentIncentivesReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "gbpPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "gbpPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "9952153 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
     "longName": "9952154 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-55",
      "name": "us-gaap:SharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation",
     "longName": "9952157 - Disclosure - Nature of Business and Basis of Presentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses",
     "longName": "9952159 - Disclosure - Foreign Currency Translation in General and Administrative Expenses",
     "shortName": "Foreign Currency Translation in General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.barinthusbio.com/role/NetLossPerShare",
     "longName": "9952160 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNet",
     "longName": "9952161 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.barinthusbio.com/role/IntangibleAssetsNet",
     "longName": "9952162 - Disclosure - Intangible Assets, Net",
     "shortName": "Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssets",
     "longName": "9952163 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "9952164 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.barinthusbio.com/role/GrantIncome",
     "longName": "9952165 - Disclosure - Grant Income",
     "shortName": "Grant Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.barinthusbio.com/role/OrdinaryShares",
     "longName": "9952166 - Disclosure - Ordinary Shares",
     "shortName": "Ordinary Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.barinthusbio.com/role/DeferredShares",
     "longName": "9952167 - Disclosure - Deferred Shares",
     "shortName": "Deferred Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:StockholdersEquityDeferredSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:StockholdersEquityDeferredSharesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.barinthusbio.com/role/FairValue",
     "longName": "9952168 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.barinthusbio.com/role/Goodwill",
     "longName": "9952169 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensation",
     "longName": "9952170 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingencies",
     "longName": "9952171 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.barinthusbio.com/role/RelatedPartyTransactions",
     "longName": "9952172 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.barinthusbio.com/role/NetLossPerShareTables",
     "longName": "9954472 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "longName": "9954473 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "9954474 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.barinthusbio.com/role/GrantIncomeTables",
     "longName": "9954475 - Disclosure - Grant Income (Tables)",
     "shortName": "Grant Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DeferredIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.barinthusbio.com/role/FairValueTables",
     "longName": "9954476 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationTables",
     "longName": "9954477 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables",
     "longName": "9954478 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails",
     "longName": "9954479 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails",
     "longName": "9954481 - Disclosure - Foreign Currency Translation in General and Administrative Expenses (Details)",
     "shortName": "Foreign Currency Translation in General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails",
     "longName": "9954482 - Disclosure - Net Loss Per Share - Computation (Details)",
     "shortName": "Net Loss Per Share - Computation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails",
     "longName": "9954483 - Disclosure - Net Loss Per Share - Additional Information (Details)",
     "shortName": "Net Loss Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.barinthusbio.com/role/PropertyandEquipmentNetDetails",
     "longName": "9954484 - Disclosure - Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails",
     "longName": "9954485 - Disclosure - Intangible Assets, Net (Details)",
     "shortName": "Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9954486 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
     "longName": "9954487 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "brns:AccruedManufacturingAndClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "brns:AccruedManufacturingAndClinicalExpensesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
     "longName": "9954488 - Disclosure - Grant Income - Additional Information (Details)",
     "shortName": "Grant Income - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DeferredIncomeAddition",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-104",
      "name": "brns:FundingAmountMaximum",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails",
     "longName": "9954489 - Disclosure - Grant Income - Changes in deferred income (Details)",
     "shortName": "Grant Income - Changes in deferred income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "us-gaap:DeferredIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "us-gaap:DeferredIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.barinthusbio.com/role/OrdinarySharesDetails",
     "longName": "9954490 - Disclosure - Ordinary Shares (Details)",
     "shortName": "Ordinary Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "brns:CommonStockNumberOfVotesPerShare",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "brns:CommonStockNumberOfVotesPerShare",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.barinthusbio.com/role/DeferredSharesDetails",
     "longName": "9954491 - Disclosure - Deferred Shares (Details)",
     "shortName": "Deferred Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "brns:OrdinarySharesLiquidationPreference",
      "unitRef": "gbp",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "brns:OrdinarySharesLiquidationPreference",
      "unitRef": "gbp",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
     "longName": "9954492 - Disclosure - Fair Value - Additional information (Details)",
     "shortName": "Fair Value - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-115",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-115",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details",
     "longName": "9954493 - Disclosure - Fair Value - Change in Financial Instruments Classified within Level 3 (Details)",
     "shortName": "Fair Value - Change in Financial Instruments Classified within Level 3 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.barinthusbio.com/role/GoodwillDetails",
     "longName": "9954494 - Disclosure - Goodwill (Details)",
     "shortName": "Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "longName": "9954495 - Disclosure - Share-Based Compensation - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails",
     "longName": "9954496 - Disclosure - Share-Based Compensation - Weighted-average assumptions (Details)",
     "shortName": "Share-Based Compensation - Weighted-average assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails",
     "longName": "9954497 - Disclosure - Share-Based Compensation - Share based compensation expense (Details)",
     "shortName": "Share-Based Compensation - Share based compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "longName": "9954498 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-138",
      "name": "brns:NumberOfSquareFeetUnderLeaseAgreement",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-138",
      "name": "brns:NumberOfSquareFeetUnderLeaseAgreement",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails",
     "longName": "9954499 - Disclosure - Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)",
     "shortName": "Commitments and Contingencies - Right-of-use Assets, Lease Liabilities and Other Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails",
     "longName": "9954500 - Disclosure - Commitments and Contingencies - Lease Cost (Details)",
     "shortName": "Commitments and Contingencies - Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails",
     "longName": "9954501 - Disclosure - Commitments and Contingencies - Maturities of minimum lease liabilities (Details)",
     "shortName": "Commitments and Contingencies - Maturities of minimum lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails",
     "longName": "9954502 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-147",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "brns-20240630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r638"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued bonus",
        "label": "Accrued Bonuses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and employee benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "brns_AccruedExpensesAndOtherLiabilitiesCurrentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrentLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses And Other Liabilities, Current [Line Items]",
        "label": "Accrued Expenses And Other Liabilities, Current [Line Items]",
        "documentation": "Accrued Expenses And Other Liabilities, Current [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedExpensesAndOtherLiabilitiesCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrentTable",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses And Other Liabilities, Current [Table]",
        "label": "Accrued Expenses And Other Liabilities, Current [Table]",
        "documentation": "Accrued Expenses And Other Liabilities, Current [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accrued expenses and other current liabilities",
        "label": "Accrued Liabilities And Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accrued Liabilities And Other Current Liabilities [Text Block]",
        "documentation": "The entire disclosure of the components of accrued liabilities and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "brns_AccruedManufacturingAndClinicalExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "AccruedManufacturingAndClinicalExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued manufacturing and clinical expenses",
        "label": "Accrued Manufacturing and Clinical Expenses, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss \u2013 foreign currency translation adjustments",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r359"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r9",
      "r13",
      "r334",
      "r337",
      "r387",
      "r473",
      "r474",
      "r764",
      "r765",
      "r766",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r638",
      "r885"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in-Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r774",
      "r775",
      "r776",
      "r777",
      "r835",
      "r887"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r274"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net (loss)/income to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AdrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdrMember",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depositary Shares",
        "label": "ADR [Member]",
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS)."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r687",
      "r697",
      "r729"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r690",
      "r700",
      "r732"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r691",
      "r701",
      "r725",
      "r733",
      "r737",
      "r745"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r308"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense for intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r216",
      "r223",
      "r619"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable for stock options that were excluded from the computation of diluted weighted-average shares outstanding (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "brns_AssetRetirementObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "AssetRetirementObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset retirement obligation",
        "label": "Asset Retirement Obligations",
        "documentation": "Amount of asset retirement obligations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r95",
      "r115",
      "r142",
      "r174",
      "r178",
      "r193",
      "r194",
      "r201",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r327",
      "r331",
      "r360",
      "r443",
      "r529",
      "r614",
      "r615",
      "r638",
      "r663",
      "r803",
      "r804",
      "r844"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r121",
      "r142",
      "r201",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r327",
      "r331",
      "r360",
      "r638",
      "r803",
      "r804",
      "r844"
     ]
    },
    "brns_AvideaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "AvideaMember",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Avidea",
        "label": "Avidea [Member]",
        "documentation": "This member stands for Avidea."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "brns_BarinthusBiotherapeuticsPlcShareAwardPlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "BarinthusBiotherapeuticsPlcShareAwardPlan2021Member",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Barinthus Biotherapeutics plc Share Award Plan 2021",
        "label": "Barinthus Biotherapeutics plc Share Award Plan 2021 [Member]",
        "documentation": "Barinthus Biotherapeutics plc Share Award Plan 2021"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r321",
      "r623",
      "r624"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r321",
      "r623",
      "r624"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in contingent consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r769"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r81"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r66",
      "r139"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r66"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "brns_ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes to right-of-use asset resulting from lease reassessment event",
        "label": "Changes to right-of-use asset resulting from lease reassessment event",
        "documentation": "Amount of changes to right-of-use asset resulting from lease reassessment event."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/Cover",
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r116",
      "r117",
      "r118",
      "r142",
      "r164",
      "r165",
      "r167",
      "r169",
      "r176",
      "r177",
      "r201",
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r251",
      "r252",
      "r255",
      "r258",
      "r265",
      "r360",
      "r482",
      "r483",
      "r484",
      "r485",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r517",
      "r539",
      "r563",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r756",
      "r771",
      "r778"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares [Line items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r176",
      "r251",
      "r252",
      "r253",
      "r255",
      "r258",
      "r263",
      "r265",
      "r482",
      "r483",
      "r484",
      "r485",
      "r620",
      "r756",
      "r771"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "brns_CoalitionForEpidemicPreparednessInnovationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "CoalitionForEpidemicPreparednessInnovationsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coalition for Epidemic Preparedness Innovations",
        "label": "Coalition For Epidemic Preparedness Innovations [Member]",
        "documentation": "Coalition For Epidemic Preparedness Innovations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 15)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r87",
      "r445",
      "r516"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r234",
      "r235",
      "r588",
      "r798",
      "r800"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary\u00a0Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r774",
      "r775",
      "r777",
      "r835",
      "r884",
      "r887"
     ]
    },
    "brns_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per common share (in votes)",
        "label": "Common Stock Number of Votes Per Share",
        "documentation": "The number of votes that each common share is entitled."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, nominal value (in gbp per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r517"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r517",
      "r535",
      "r887",
      "r888"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, \u00a30.000025 nominal value; 39,184,338 shares authorized, issued and outstanding (December\u00a031, 2023: authorized, issued and outstanding: 38,643,540)",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r446",
      "r638"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r127",
      "r129",
      "r135",
      "r437",
      "r457",
      "r459"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Comprehensive loss attributable to noncontrolling interest",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r37",
      "r40",
      "r127",
      "r129",
      "r134",
      "r436",
      "r457",
      "r458"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r83",
      "r127",
      "r129",
      "r133",
      "r435",
      "r457"
     ]
    },
    "brns_ContingentConsiderationLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "ContingentConsiderationLiabilityMember",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration Liability",
        "label": "Contingent Consideration Liability [Member]",
        "documentation": "Represents the information pertaining to contingent consideration liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r249",
      "r253",
      "r394",
      "r398",
      "r441",
      "r606",
      "r608"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredBSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredBSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred B Shares",
        "label": "Deferred B Shares [Member]",
        "documentation": "Represents information pertaining to deferred B shares."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredCSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredCSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred C Shares",
        "label": "Deferred C Shares [Member]",
        "documentation": "Represents information pertaining to deferred C shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of prepaid expenses and other current assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Deferred Income",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r853",
      "r881"
     ]
    },
    "us-gaap_DeferredIncomeAddition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeAddition",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments received",
        "label": "Deferred Income, Addition",
        "documentation": "Amount of increase in deferred income not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r881"
     ]
    },
    "us-gaap_DeferredIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income",
        "label": "Deferred Income, Current",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "brns_DeferredIncomeForeignExchangeTranslationGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredIncomeForeignExchangeTranslationGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign exchange translation",
        "label": "Deferred Income, Foreign Exchange Translation Gain (Loss)",
        "documentation": "Deferred Income, Foreign Exchange Translation Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Income [Line Items]",
        "label": "Deferred Income [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r881"
     ]
    },
    "us-gaap_DeferredIncomeRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income recognized related to the Funding Agreement",
        "negatedTerseLabel": "Other operating income recognized related to the Funding Agreement",
        "label": "Deferred Income, Revenue Recognized",
        "documentation": "Amount of revenue recognized previously reported as deferred income not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r881"
     ]
    },
    "us-gaap_DeferredIncomeRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeChangesindeferredincomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Income [Roll Forward]",
        "label": "Deferred Income [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTable",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Income [Table]",
        "label": "Deferred Income [Table]",
        "documentation": "Disclosure of information about deferred income not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r881"
     ]
    },
    "us-gaap_DeferredIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of changes in deferred income",
        "label": "Deferred Income [Table Text Block]",
        "documentation": "Tabular disclosure of deferred income not accounted for under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r881"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax benefit",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r104",
      "r773"
     ]
    },
    "brns_DeferredShares.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredShares.Member",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred A shares",
        "verboseLabel": "Deferred A Shares",
        "label": "Deferred A Shares. [Member]",
        "documentation": "This member stands for deferred A shares"
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred Shares",
        "label": "Deferred Shares [Member]",
        "documentation": "Represents information pertaining to deferred shares."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, nominal value (in gbp per share)",
        "label": "Deferred Stock, Par Or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of deferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredStockSharesAuthorized",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, authorized (in shares)",
        "label": "Deferred Stock, Shares Authorized",
        "documentation": "The maximum number of deferred shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredStockSharesIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, issued (in shares)",
        "label": "Deferred Stock, Shares Issued",
        "documentation": "Total number of deferred shares of an entity that have been sold or granted to shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredStockSharesOutstanding",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares, outstanding (in shares)",
        "label": "Deferred Stock, Shares Outstanding",
        "documentation": "Number of shares of deferred stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredStockValueIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredStockValueIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred A shares, \u00a31 nominal value; 63,443 shares authorized, issued and outstanding (December\u00a031, 2023: authorized, issued and outstanding: 63,443)",
        "label": "Deferred Stock, Value Issued",
        "documentation": "Aggregate par or stated value of issued deferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "brns_DeferredTaxLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "DeferredTaxLiabilityNet",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability, net",
        "label": "Deferred Tax Liability, Net",
        "documentation": "Amount of classified as non-current liabilities, net value of deferred tax liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r22"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r174",
      "r183",
      "r194",
      "r614",
      "r615"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r796",
      "r797"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r276",
      "r304",
      "r305",
      "r307",
      "r626"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r162",
      "r164",
      "r167",
      "r168",
      "r169",
      "r173",
      "r319",
      "r324",
      "r341",
      "r342",
      "r438",
      "r460",
      "r609"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to ordinary shareholders, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r164",
      "r167",
      "r168",
      "r169",
      "r173",
      "r319",
      "r324",
      "r341",
      "r342",
      "r438",
      "r460",
      "r609"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r170",
      "r171",
      "r172"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average period over which unrecognized compensation cost is expected to be recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost related to options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "brns_EnterpriseManagementIncentiveShareOptionSchemeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "EnterpriseManagementIncentiveShareOptionSchemeMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise Management Incentive Share Option Scheme",
        "label": "Enterprise Management Incentive Share Option Scheme [Member]",
        "documentation": "Information pertaining to the Enterprise Management Incentive Share Option Scheme."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r107",
      "r130",
      "r131",
      "r132",
      "r147",
      "r148",
      "r149",
      "r151",
      "r156",
      "r158",
      "r160",
      "r175",
      "r202",
      "r203",
      "r230",
      "r266",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r324",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r375",
      "r387",
      "r456",
      "r473",
      "r474",
      "r475",
      "r492",
      "r563"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r677",
      "r687",
      "r697",
      "r729"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r684",
      "r694",
      "r726"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "brns_ExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "ExpensesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Expenses [Member]",
        "documentation": "Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r353"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r350",
      "r351",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r433",
      "r630",
      "r634"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r353"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r353"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of financial instruments carried at fair value and classified within Level 3",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r349",
      "r353"
     ]
    },
    "brns_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange translation recognized in other comprehensive loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Foreign Exchange Translation",
        "documentation": "Amount of foreign exchange translation of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value recognized in net loss",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r353"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/FairValueAdditionalinformationDetails",
      "http://www.barinthusbio.com/role/FairValueChangeinFinancialInstrumentsClassifiedwithinLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration liability",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r353"
     ]
    },
    "brns_FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Current Year",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Current Year"
       }
      }
     },
     "auth_ref": []
    },
    "brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSeven": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearSeven",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2031",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Seven",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Seven"
       }
      }
     },
     "auth_ref": []
    },
    "brns_FiniteLivedIntangibleAssetExpectedAmortizationYearSix": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationYearSix",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Six",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, Year Six"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization for amortizable intangible assets",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r206",
      "r222",
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r601",
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r601",
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r601",
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r601",
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated annual amortization expense for 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r601",
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r225",
      "r226",
      "r401",
      "r402",
      "r601"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross amount of amortizable intangible assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r222",
      "r402",
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, net",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r222",
      "r225",
      "r226",
      "r228",
      "r401",
      "r601",
      "r619"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r225",
      "r226",
      "r601"
     ]
    },
    "us-gaap_ForeignCurrencyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency [Abstract]",
        "label": "Foreign Currency [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation in General and Administrative Expenses",
        "label": "Foreign Currency Disclosure [Text Block]",
        "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r372",
      "r664",
      "r665",
      "r666",
      "r667",
      "r757"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/ForeignCurrencyTranslationinGeneralandAdministrativeExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign exchange gain (loss)",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r560"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign exchange (gain)/loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r537",
      "r661",
      "r838",
      "r839",
      "r886"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r691",
      "r701",
      "r733"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r691",
      "r701",
      "r733"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r691",
      "r701",
      "r733"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r691",
      "r701",
      "r733"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r691",
      "r701",
      "r733"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "brns_FundingAmountMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "FundingAmountMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum funding amount",
        "label": "Funding Amount, Maximum",
        "documentation": "Funding Amount, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r541"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r208",
      "r434",
      "r615",
      "r618",
      "r631",
      "r638",
      "r787",
      "r788"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/Goodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r210",
      "r212",
      "r618"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r209",
      "r211",
      "r213",
      "r618",
      "r631"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "brns_InLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "InLicenseAgreementsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-License Agreements",
        "label": "In-License Agreements [Member]",
        "documentation": "Represents the information pertaining to In-License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r90",
      "r94",
      "r439",
      "r452",
      "r611",
      "r614",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r345",
      "r349",
      "r353",
      "r470",
      "r472",
      "r547",
      "r601",
      "r632",
      "r854"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r345",
      "r349",
      "r353",
      "r470",
      "r472",
      "r547",
      "r601",
      "r632",
      "r854"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r105",
      "r159",
      "r160",
      "r174",
      "r184",
      "r194",
      "r311",
      "r312",
      "r315",
      "r461",
      "r627"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable (including related parties)",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income",
        "label": "Increase (Decrease) in Deferred Revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r769"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "brns_IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development incentives receivable",
        "label": "Increase (Decrease) in Research and Development Incentives Receivable",
        "documentation": "Amount of increase (decrease) in research and development incentives receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r691",
      "r701",
      "r725",
      "r733",
      "r737",
      "r745"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r749"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r749"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r749"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r227",
      "r229",
      "r600",
      "r601"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r794",
      "r795"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r768"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r181",
      "r194",
      "r614",
      "r767"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r637"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of lease cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvement expense",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "brns_LesseeOperatingLeaseExtendedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "LesseeOperatingLeaseExtendedTerm",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional lease term",
        "label": "Lessee Operating Lease, Extended Term",
        "documentation": "Term of lessee's operating lease extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of maturities of minimum lease liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remainder of 2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "brns_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due in year four and after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "brns_LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of right-of-use assets, lease liabilities and other information",
        "label": "Lessee Operating Lease Right of Use asset and Other Information [Table Text Block]",
        "documentation": "Tabular disclosure for Company's right-of-use asset and lease liability and other information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r142",
      "r201",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r328",
      "r331",
      "r332",
      "r360",
      "r515",
      "r610",
      "r663",
      "r803",
      "r844",
      "r845"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r89",
      "r449",
      "r638",
      "r772",
      "r786",
      "r837"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r111",
      "r142",
      "r201",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r328",
      "r331",
      "r332",
      "r360",
      "r638",
      "r803",
      "r844",
      "r845"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "MD",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maryland",
        "label": "MARYLAND"
       }
      }
     },
     "auth_ref": []
    },
    "brns_MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum aggregate nominal amount of shares authorized to be allotted free from pre-emption rights",
        "label": "Maximum Aggregate Nominal Amount Of Shares Authorized To Be Allotted Free From Statutory Pre-emption Rights",
        "documentation": "Amount of maximum aggregate nominal amount of shares that the board of directors are authorized to allot free from statutory Pre-emption rights."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r271",
      "r309",
      "r343",
      "r399",
      "r469",
      "r471",
      "r478",
      "r507",
      "r508",
      "r571",
      "r573",
      "r575",
      "r576",
      "r578",
      "r598",
      "r599",
      "r617",
      "r620",
      "r625",
      "r633",
      "r634",
      "r635",
      "r636",
      "r648",
      "r805",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r271",
      "r309",
      "r343",
      "r399",
      "r469",
      "r471",
      "r478",
      "r507",
      "r508",
      "r571",
      "r573",
      "r575",
      "r576",
      "r578",
      "r598",
      "r599",
      "r617",
      "r620",
      "r625",
      "r633",
      "r634",
      "r635",
      "r648",
      "r805",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r88",
      "r142",
      "r201",
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r360",
      "r448",
      "r519"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r68"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Barinthus Biotherapeutics plc shareholders",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r68",
      "r91",
      "r109",
      "r126",
      "r128",
      "r132",
      "r142",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r159",
      "r160",
      "r166",
      "r201",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r319",
      "r324",
      "r342",
      "r360",
      "r455",
      "r538",
      "r561",
      "r562",
      "r661",
      "r803"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r84",
      "r126",
      "r128",
      "r156",
      "r159",
      "r160",
      "r454",
      "r766"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently issued accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "brns_NonCashInterestExpenseOnConvertibleLoanNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "NonCashInterestExpenseOnConvertibleLoanNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non cash interest expense",
        "label": "Non-Cash Interest Expense On Convertible Loan Notes",
        "documentation": "Amount of non-cash interest expense on convertible loan notes."
       }
      }
     },
     "auth_ref": []
    },
    "brns_NonCashLeaseExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "NonCashLeaseExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expenses",
        "label": "Non-Cash Lease Expenses",
        "documentation": "The amount of non-cash lease expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r681",
      "r691",
      "r701",
      "r725",
      "r733"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r266",
      "r774",
      "r775",
      "r776",
      "r777",
      "r887"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r781"
     ]
    },
    "brns_NumberOfSquareFeetUnderLeaseAgreement": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "NumberOfSquareFeetUnderLeaseAgreement",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Size of space under lease agreement (in square feet)",
        "label": "Number Of Square Feet Under Lease Agreement",
        "documentation": "Represents the information pertaining to number of Square Feet Under Lease Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r611",
      "r780",
      "r782",
      "r783",
      "r784",
      "r785"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r637"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesMaturitiesofminimumleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability - current",
        "verboseLabel": "Lease liability, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability - non-current",
        "verboseLabel": "Lease liability, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r382"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets, net",
        "verboseLabel": "Right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r637"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r637"
     ]
    },
    "brns_OrdinarySharesLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "OrdinarySharesLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, liquidation preference",
        "label": "Ordinary Shares, Liquidation Preference",
        "documentation": "The amount of liquidation preference on ordinary shares to be paid after which the deferred shares have the entitlement to receive out of the assets of the Company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business and Basis of Presentation",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r82",
      "r479",
      "r480"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "parentTag": "brns_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r114",
      "r442",
      "r615",
      "r663"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r638"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and Contingencies",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive gain/(loss) \u2013 foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r456"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income/(expense):",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "brns_OtherInformationLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "OtherInformationLesseeAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesRightofuseAssetsLeaseLiabilitiesandOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other information",
        "label": "Other Information, Lessee [Abstract]",
        "documentation": "Other Information, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_OtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other operating income",
        "label": "Other Operating Income",
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant Income",
        "label": "Other Operating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for other operating income and other operating expense items."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r679",
      "r689",
      "r699",
      "r731"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r734"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r682",
      "r692",
      "r702",
      "r734"
     ]
    },
    "brns_OxfordUniversityInnovationLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "OxfordUniversityInnovationLimitedMember",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxford University Innovation Limited",
        "label": "Oxford University Innovation Limited",
        "documentation": "Represents the information pertaining to Oxford University Innovation Limited."
       }
      }
     },
     "auth_ref": []
    },
    "brns_OxfordshireMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "OxfordshireMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oxfordshire",
        "label": "Oxfordshire [Member]",
        "documentation": "Oxfordshire"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParentMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stockholders\u2019 equity attributable to Barinthus Biotherapeutics plc stockholders",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "brns_PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future royalties for direct sales of a covered product",
        "label": "Percentage of Future Royalties for Direct Sales of Covered Product , License Agreement",
        "documentation": "Percentage of future royalties for direct sales of a covered product under the In-License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net payments received for allowable sublicenses of technology developed",
        "label": "Percentage Of Net Payments Received For Allowable Sublicenses Of Technology Developed License Agreement",
        "documentation": "Percentage of net payments received for allowable sublicenses of technology developed under the In-License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PercentageOfSharesNecessaryToExercisePreemptiveRights": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "PercentageOfSharesNecessaryToExercisePreemptiveRights",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ordinary shares present to exercise preemptive rights",
        "label": "Percentage Of Shares Necessary To Exercise Preemptive Rights",
        "documentation": "The minimum percentage of shares required to exercise preemptive rights."
       }
      }
     },
     "auth_ref": []
    },
    "brns_PeriodOfPreemptiveRightsToBeExercised": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "PeriodOfPreemptiveRightsToBeExercised",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum period to exercise preemptive rights",
        "label": "Period Of Preemptive Rights To Be Exercised",
        "documentation": "The period allowed to exercise preemptive rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "brns_PrepaidExpenseAndOtherAssetsCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expense and Other Assets, Current [Text Block]",
        "documentation": "The entire disclosure on prepaid expense and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments and accrued income",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r204",
      "r205",
      "r605"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issue of ordinary shares, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of shares from the exercise of stock options",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r11"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r400",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r603",
      "r621",
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r801",
      "r802",
      "r806",
      "r853",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r882",
      "r883"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r400",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r603",
      "r621",
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r801",
      "r802",
      "r806",
      "r853",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r882",
      "r883"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r126",
      "r128",
      "r137",
      "r142",
      "r150",
      "r156",
      "r159",
      "r160",
      "r201",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r319",
      "r324",
      "r326",
      "r329",
      "r330",
      "r342",
      "r360",
      "r439",
      "r453",
      "r491",
      "r538",
      "r561",
      "r562",
      "r628",
      "r629",
      "r662",
      "r766",
      "r803"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to property and equipment",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r99",
      "r102",
      "r103"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r386",
      "r440",
      "r451",
      "r638"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r269",
      "r271",
      "r299",
      "r300",
      "r301",
      "r309",
      "r343",
      "r396",
      "r397",
      "r399",
      "r469",
      "r471",
      "r478",
      "r507",
      "r508",
      "r571",
      "r573",
      "r575",
      "r576",
      "r578",
      "r598",
      "r599",
      "r617",
      "r620",
      "r625",
      "r633",
      "r634",
      "r635",
      "r636",
      "r648",
      "r655",
      "r799",
      "r805",
      "r836",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r269",
      "r271",
      "r299",
      "r300",
      "r301",
      "r309",
      "r343",
      "r396",
      "r397",
      "r399",
      "r469",
      "r471",
      "r478",
      "r507",
      "r508",
      "r571",
      "r573",
      "r575",
      "r576",
      "r578",
      "r598",
      "r599",
      "r617",
      "r620",
      "r625",
      "r633",
      "r634",
      "r635",
      "r636",
      "r648",
      "r655",
      "r799",
      "r805",
      "r836",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r674",
      "r684",
      "r694",
      "r726"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r270",
      "r391",
      "r392",
      "r444",
      "r450",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r534",
      "r536",
      "r570"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Parties",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144",
      "r391",
      "r392",
      "r393",
      "r394",
      "r444",
      "r450",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r534",
      "r536",
      "r570"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts of related party transactions",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r391"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r843"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r542",
      "r543",
      "r547"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r270",
      "r391",
      "r392",
      "r444",
      "r450",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r534",
      "r536",
      "r570",
      "r843"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r392",
      "r395",
      "r487",
      "r488",
      "r489",
      "r544",
      "r546",
      "r547",
      "r567",
      "r569"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r249",
      "r253",
      "r394",
      "r398",
      "r441",
      "r607",
      "r608"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r601",
      "r614",
      "r852"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentIncentiveIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "ResearchAndDevelopmentIncentiveIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development incentives",
        "label": "Research And Development Incentive Income (Expense)",
        "documentation": "Represents the research and development incentives (expenses) for the period."
       }
      }
     },
     "auth_ref": []
    },
    "brns_ResearchAndDevelopmentIncentivesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "ResearchAndDevelopmentIncentivesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development incentives receivable",
        "label": "Research and development incentives receivable",
        "documentation": "Amount of research and development incentives receivable."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r675",
      "r685",
      "r695",
      "r727"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r676",
      "r686",
      "r696",
      "r728"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r683",
      "r693",
      "r703",
      "r735"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r770"
     ]
    },
    "brns_RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share units, options, share appreciation rights and restricted shares",
        "label": "Restricted Share Units Stock Options Share Appreciation Rights And Restricted Shares [Member]",
        "documentation": "Information pertaining to aggregate awards under a specific share-based compensation plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r78",
      "r447",
      "r476",
      "r477",
      "r486",
      "r518",
      "r638"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r147",
      "r148",
      "r149",
      "r151",
      "r156",
      "r158",
      "r160",
      "r202",
      "r203",
      "r230",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r324",
      "r333",
      "r335",
      "r336",
      "r338",
      "r340",
      "r373",
      "r375",
      "r473",
      "r475",
      "r492",
      "r887"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r174",
      "r179",
      "r180",
      "r192",
      "r194",
      "r196",
      "r197",
      "r199",
      "r267",
      "r268",
      "r400"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "brns_RoyaltyPaymentTermMaximum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "RoyaltyPaymentTermMaximum",
     "presentation": [
      "http://www.barinthusbio.com/role/GrantIncomeAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum royalty payment period",
        "label": "Royalty Payment, Term, Maximum",
        "documentation": "Royalty Payment, Term, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of share based compensation expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of computation of basic and diluted net loss per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.barinthusbio.com/role/IntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r222",
      "r225",
      "r226",
      "r228",
      "r401",
      "r601",
      "r619"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.barinthusbio.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r542",
      "r543",
      "r547"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of weighted-average assumptions of fair value stock option issued to employees",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred shares [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r74",
      "r76",
      "r77",
      "r78",
      "r116",
      "r117",
      "r118",
      "r176",
      "r251",
      "r252",
      "r253",
      "r255",
      "r258",
      "r263",
      "r265",
      "r482",
      "r483",
      "r484",
      "r485",
      "r620",
      "r756",
      "r771"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refundable security deposit",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r504",
      "r505",
      "r506",
      "r572",
      "r574",
      "r577",
      "r579",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r604",
      "r622",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r650",
      "r655",
      "r806",
      "r853",
      "r855",
      "r856",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r882",
      "r883"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r195",
      "r197",
      "r612",
      "r613",
      "r616"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/AccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationSharebasedcompensationexpenseDetails",
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average grant date fair value of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of options outstanding (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r281"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "brns_ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of issued and outstanding ordinary shares available for issuance under the Plan",
        "label": "Share-Based Compensation, Percentage Of Shares Available For Issuance As A Percentage Of Issued And Outstanding Shares",
        "documentation": "Total number of shares available for issuance under the Plan as a percentage of the Company's issued and outstanding shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.barinthusbio.com/role/ShareBasedCompensationWeightedaverageassumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "brns_SharesCancelledDuringPeriodSharesDeferredShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "SharesCancelledDuringPeriodSharesDeferredShares",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancellation of deferred shares (in shares)",
        "label": "Shares Cancelled During Period, Shares, Deferred Shares",
        "documentation": "The number of deferred shares cancelled during the period."
       }
      }
     },
     "auth_ref": []
    },
    "brns_SharesCancelledDuringPeriodValueDeferredShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "SharesCancelledDuringPeriodValueDeferredShares",
     "crdr": "debit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancellation of deferred shares",
        "label": "Shares Cancelled During Period, Value, Deferred Shares",
        "documentation": "The value of deferred shares cancelled during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease costs",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r637"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r140"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/Cover",
      "http://www.barinthusbio.com/role/DeferredSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r116",
      "r117",
      "r118",
      "r142",
      "r164",
      "r165",
      "r167",
      "r169",
      "r176",
      "r177",
      "r201",
      "r240",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r251",
      "r252",
      "r255",
      "r258",
      "r265",
      "r360",
      "r482",
      "r483",
      "r484",
      "r485",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r517",
      "r539",
      "r563",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r756",
      "r771",
      "r778"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r56",
      "r57",
      "r107",
      "r130",
      "r131",
      "r132",
      "r147",
      "r148",
      "r149",
      "r151",
      "r156",
      "r158",
      "r160",
      "r175",
      "r202",
      "r203",
      "r230",
      "r266",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r324",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r375",
      "r387",
      "r456",
      "r473",
      "r474",
      "r475",
      "r492",
      "r563"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r504",
      "r505",
      "r506",
      "r572",
      "r574",
      "r577",
      "r579",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r604",
      "r622",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r650",
      "r655",
      "r806",
      "r853",
      "r855",
      "r856",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r882",
      "r883"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r175",
      "r375",
      "r400",
      "r481",
      "r503",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r540",
      "r541",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r563",
      "r656"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r175",
      "r200",
      "r375",
      "r400",
      "r481",
      "r503",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r536",
      "r540",
      "r541",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r563",
      "r656"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r678",
      "r688",
      "r698",
      "r730"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of ordinary shares, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r53",
      "r78",
      "r482",
      "r563",
      "r581"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of ordinary shares, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r52",
      "r53",
      "r78",
      "r492",
      "r563",
      "r581",
      "r662"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity attributable to Barinthus Biotherapeutics plc shareholders",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r56",
      "r57",
      "r70",
      "r519",
      "r535",
      "r564",
      "r565",
      "r638",
      "r663",
      "r772",
      "r786",
      "r837",
      "r887"
     ]
    },
    "brns_StockholdersEquityDeferredSharesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.barinthusbio.com/20240630",
     "localname": "StockholdersEquityDeferredSharesDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/DeferredShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Shares",
        "label": "Stockholders Equity Deferred Shares Disclosure [Text Block]",
        "documentation": "The entire disclosure for Deferred Shares as disclosed by the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r38",
      "r107",
      "r108",
      "r131",
      "r147",
      "r148",
      "r149",
      "r151",
      "r156",
      "r158",
      "r202",
      "r203",
      "r230",
      "r266",
      "r313",
      "r314",
      "r316",
      "r317",
      "r318",
      "r320",
      "r323",
      "r324",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r366",
      "r367",
      "r371",
      "r374",
      "r387",
      "r474",
      "r475",
      "r490",
      "r519",
      "r535",
      "r564",
      "r565",
      "r585",
      "r662",
      "r772",
      "r786",
      "r837",
      "r887"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinaryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r141",
      "r250",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r266",
      "r339",
      "r566",
      "r568",
      "r586"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.barinthusbio.com/role/OrdinarySharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.barinthusbio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.barinthusbio.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.barinthusbio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r97",
      "r98",
      "r100",
      "r101"
     ]
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/PrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value Added Tax receivable",
        "label": "Value Added Tax Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average ordinary shares outstanding, diluted (in shares)",
        "totalLabel": "Weighted-average ordinary shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r169"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.barinthusbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average ordinary shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r169"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.barinthusbio.com/role/NetLossPerShareComputationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-5A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-13"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-14"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-15"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-16"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001828185-24-000075-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001828185-24-000075-xbrl.zip
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M#>_&7V\>^O<WC^/A8,3=?QN<!+B:!<QN7O2I7U<MCS%5TZ4[LYHN?*M1:DH
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MLO+UB84XW^'L-W%US@P#ZW#O_G03%M-\>_31WZ'[V-EWFA&5*2VV$!+<?*T
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MP!W@#G 'N /< >X"=VO)W73=(Y/V=+UWG9GIDXA0ZKA.A_2?::J\>'H'2);
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MR&%+E"3\!QW!FX%=0M+]GS%4[+!'(&DB[)I3TJ^-?'^*2WO"U4;F9#R7_,>
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M06:HO3+J((8R^^-W$9^EID#V"X%;ZGV1UOC;8'"KM$;F@PLZLQ?:0MVY)BZ
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M@.+HL5"D"_\%-4V0KCH*T7V9MIBC]Y'+HH@J@!FQ'33"+0D6N6C.:G2? /T
M43%86A',@6EL@302?\*'1V$#\P8+/9@DZ#+J/:RH.)?%YFX$A+X0/W(,;!C(
M<\,Q[RM(-!*I:&/T DG/A8<*&EBSXA1#N'-M#'(X -W?%,,@?B<AK R^4*'Y
M;N@9:#=';@%RI.E#5X& V+5\*?)%1..@_S 08%&G1']ZEU-]3HP.H*[,#VGS
MQ1="74<9T_2$\*:P)@:^CAZI113*&9,B-JB;N(M;B%:K>QYJC(F3H)F4\1XO
M!X?738"OC]Y$G0NKX_P3US85)"GI9%%MBJ09]1S%QV&0C,5'%N4",!(8*4\G
MQ[H<$G48[*DP002"G :M(C3(@HOT+#C7*=MT+%202):Z!L#> WQ!@"LS=0:6
M\ ADH8L8"L=*?@I/TF+*,&5U1]K.( HG%DQ@D/3/P,\BR2=C$#"53\A?T=(.
M!H)]RE95H84$8:(>BJD90!@@@'0^TNA!(BC2J(4TB&?8P)# Z2&=KG:FY/A*
M4(7A8T+L2)R4(E/4^0B5DECLID:-V RODMZ*-D0>!4;V(Y3A]UMKBCF&*![,
ME%G?PI%$B*"C)W[L,K="SXP3HQYP@>G,9F>@#BQZ+&D_F"#=,DF!5AKA+M(^
M9KCY$8_!GI?^2(_<<XF+P/0,XK\5*$.*7HG:T0/J>]QS6&'ZPG'^NA!%>^O)
M,NWER3)EWDN9]U+FO91Y+^OS#PXHTZ"@9_I[)#7/(ZEYGI2:45:(=A7[EXY3
M0TCY+9=L]Y/TN]RAWT6Y=?*< RB(ESED6''('3_.K<&!X[8?-!XJ&YZ8P&L@
M;K4O8)16-AM'W8D";> NH?9+6T"[9-LMMF$V&1*-U<^V^QB;Q6 *"AF'MGXJ
MZY,]7%D(T7,(#G)#1LH963W^#K4UUY$Z$]@;0PJSR'P+-;[T5JT??*T[<\ C
M?1-HGN#$GX$>M'KM]-^;._TJ,+=-D4?IA$P$%?(""N\2J2.I^:,PAALG\S#D
MP=@#M3$$FW,&Y@+Z/[9WI"H_/9IQNHDD'"&(+GW+H,RBXX*"W)SJY0BT6E ;
MC1PJNN6E8E\X "XQGE3ICBM(#E_@^WWTR(*;I#"&5B(4Y4\X?%2Q+AZST$AL
MU.]VD>3%#R*H6A0.HEL#R"6D]:^F!",/#$?VZXBL,QI/*1<Q6^SMP""N#"9P
M$(O+"V]F1&R8=-D]W*3+QHZ2+N_BT/L@BF'> JF!T>[GI%)V<O(7.]E4RKMP
M.D6R@C-/S*#%4VAJCNT2*3NYB92=0U)O-A+R*F8L@9$)+&*&A0B0. (L$:==
M8ZBCH?PE6TB*%&>N8/M#,:.H#<9/0A]Y[5!@'4P5-(*I'/&(KBG3I0AV*M3M
M.B[F>^1%5 JAX7=?W(PNX42FZ(Z(T:V[B%B'<KI%E5?V=$0[/$ZUE%692"QN
M*Z@SV1,4Y95A7S_II@3DF^H_0$HHN'&P!]U>,Q95'#Z.O<X>(3:BZ30*U2><
M5HL.JG2@&!]FIH(MZI>^QS/A%A6]%MF_FC9OI2@-'8SOF*&G_'K\')$;2;AT
MQ&!(":SH+UX.(SBMB>4'KD?9?#B'9PG*N0 %7M,?=,N.2OK!LP\@N3$]%OUZ
MF!LH8T?(%S#I24EN+%7@LN>9O",,",LSPJE/B7Z+$9P'W0XYGW3=:NE&(3LM
M25%.#10'P3FA3ND3Z PW+< $+XHS^4G,X47R$_)TXSD].D*+/>;'1YR#2'(H
MK%R(L&UKQZ3C*A:'X?5'W8O3.#FX!5H<"GFN64'P3& "H] CQ3HDF2_Z^\,9
MK3R%&I74&2&>_!6:8ZG6HX+]8/D\D*%['MG*B&-1*J^D7W@T0;[*K(L1 Q%'
M92[[E/Y*FX 7#8RX$G[&T<9D[@IFRLGL37[,0[(P7%!X_HE%[G9L$I;BNVQD
M4*K+4% :^P_'?70P^R2%^QQ&2F._ZV?XIC/GC"E%!(;</5 S/H6YQ@NAF(C8
M-DBA6%3DBNFA@@[VFV)VI![.^=\<-;3W2O0"N>TD5AT?]Y&^(0SW"4F>2 D6
MWN('ID"!*HJ(NTYDDCL<A)YY2,+ZT T#&9;R6<5@L>R)()D<L$![L>1"XU'*
M%_QM.&>N,+%$9-?"ZC"U@UP5J%-XVKN3\YN+KR?O*[D(?TXO7_X41DC6ZPT&
M,C&-F7+:?R3'PX#Q6*=D,*1(RA- /X1KQ$F37 %"2G':!5"?E&NP"I6J[6L_
MQ#RQ9+*]H\2!:,)D$@*^$*\$M2MU>2 9N:9HG/HA,7Y47;K"!X)?4F) ,B<;
M:1=S520;44M-@.U_^VF6%L\P!)8M@K0J\&")1U8#W+1;D54_/QW_!N19FL,C
M$6YE,9VKZ\^+W :8TE!X-Z,(<R4=IHO? 3T8V#KB$6_X""=*Z:G%?*A_<@9(
MG4WH<1=)0D53ER06 $D\X%4R1[+JY V.Z!K,&GP.41-TP%K$'"%2G5T';W?(
M(] PQR#,J$V\$@,O4$W [$-1[(N%HU5(C<D$J6-/W1$ZU$-JUC8_)/0>1OFG
M"9F79=/JLLD(JZ)(4?^D2A 9/\BJ\/?&LN#L/X?>K\LCCF\PC-XIP^@'L)8R
MC%Z&T5]^4^O#Z)M;,+"DA <]Y1E=;<PT,][S%6[O W)P%S1UO@D\:@P)@5&_
MRH]\? ;09[*X842RGN&_%7(C+-TAFT<,!FFK?![<?4KF"H-:!A8%.O]9BW9-
M2_C9_$MRRJO@/\4 V1$# PMRBJ+I@BI(6@'_&S1 ?(K>!'C)L"VL#B$\UL:>
M^QA,U 5]=<.?+F^,DM&$_PJG,UBK%V@WH1=7S;C#K\*9CVX*7%BC5F^0HCF!
M(83- 3_T) &XY-2P#0V,P*C8 .\&#IC#C90RS5%7]H(FXQ-T-Y?</^1-1M!'
M[J$4GBFP1NFW4Z$K'S+[0F/(@WTI3R@Y%EWTHFTD'(DSOG:$B^/:!&B.RCH8
M^ ;P$/E7E!:>]JNA*DDG*1/G4^N/5B2/GO L9\A-1D C$.8RP;P#/1^ 8K-#
MB'%W$;F$1<CXSGJO61X,!O;L$.B7#M!?>78TZ(K#<W%4&-9QP5AQQC#)(D8N
M0<4C],W^*3@9!$]#/"(2D8V19H819DHR0:H5F"9-U$8G0S"-GZ,T7Z0A>EB/
M'7@6 ,J@I ]*$RC@<H13 <S ,8D+/9)K!I";'+0T6.;:Q]IH^Z)5LWGTO54[
MW.A[<VGT72NF-'QV/1C7.2? &O-558R:C6S$N]G(AM[ED)H:4[M'\K.E(N%H
MO_&E9$*T@0D(9I&#"07%I0P_;163I[4<!TE2]'T\1J]=0+*:(NP$-:$RFZAX
MA<L7KA:<^N,$!/4T!*, WI8I-(^4KT]S%KV[5F]N>'EM >?NX]M(O\&>,9?O
MDT!PW.L_<VZQ-9LG9[5J??5U/ 9>T0VLOEGXQ&7C/<(5R\:[073+AJLBO2MR
M;LT/!3?:>IZ3:I^<M:K97@+121&:X1:+K7[32Y)/7'WGY*Q;S59$3JT^?6KO
M=YC[U6H>KO1I[2CW2]U>O17>W43/E3G=')G3S:F<!QP4#U2#H30::SL1TB41
M4BQP:$R$&=J8/K2P'2QE8@P<\\)"SZ1)/J2<+18));Z@O!JYMNT^4E((.<,H
MM,UY89R!,IV%<<8JIDVP\6'R[N/ P SM2X3/)C)J90HIZ/!.5/;9CY+)'/+;
MDQF T_CO/VRJM -XY>:4GYFZ#-,=U9DO/J@/'U476<LA8-%+'^5@TCF=4ZF;
M] _^.7;55FOLKI5M2N3,\N<J_/1K]OM6K]JOY?\$HO&7%^NWN]'BZ[5JO]5;
MM_@-OV_5&H7>*!>UBT6U5^/>FK8[&[;)6(6%_<Q@.>TMV+/[,ET@LN[>%O%1
M9'0994X#UK9!;^65<#M2B-SE*;<9>.P?H?;S5*)+/?;"(/<'-:E?;)-QV(>$
M4G>3WM]K=[NN,<ZK 5?SJ>3\&H%2XM 3<&A'K>Q>IOW3>C.#=&"RN+"<Z(<-
M,.4%N/DR&"=PKD;-:A)H5P1U]]57K%S?,Z]O[ZV?#XIJI6'_\C1;!+POW!!O
M@_2EH^UON^'>BK7$:ZYIB:?<<;=4$1E]@>G.DTXX/35=2@;#07(ZX#7[)V?U
M3J7?:CZA"]Z!-+XMB>%5$T-K[\2 P>]&L])#I;TDAI(8#I@8]D\+]9.S9J/2
MZI2"H:2%PZ:%=8V#=T ,V">X4:D]J5?PCHAA1SZ1XS*S-#T(/&L81H5+X0CH
M?IQKV_+RG,!*RB]OCD5/-8H=22[3.3S*W(OY J=\Y>!%:Z3-0>*D[]WKU#E?
MR6/.(]$F&#+9M!N9H7%D_;Q+/-I*\]\)'K7 !BCQZ%7BT7.B$:8!9E7G$HU>
M 1IMJF_N!(\Z)V>=]H'@T9OT\&=4S]7M<"G[3M97?7EM=-W);!KD><5F<2$0
M'#87VT]P(<7&"EO.78XO-+.7  I;SD5.ZD#=3"6]O5UZV\J**4QO/0YAU+(F
M3$EO);V])7I[%G+K<Y2DD6TO5Y);26YOB=RVLHJ+TEN[=G+6JE?ZO2,0;V\A
M>?5"."YU]"O35U\Z_;)<7YF^NC'=_DE_"/-4AU7IXT2#0+X]BI5EJ.J)A9U<
MZ5[KD9!W_JD<MJ!=7L.3#F.UYZ:V*&#5V0[X:%5!3[J=[=_$YTHWM3<3P'%9
MSS:F!?4K-1#"]7K6I[/)99<B"F=YY'G.@V<^\@8<>:_2JG4KG6Y6[RJ/?$]'
M_H(GWJ03[\.)-_J=\L2?Z\3;+WCD+3KR1KU>Z32R\<8BM_*>7PLHGUKVU)M*
M%BRFU,H2+4>BUJ[W#1P_^]M*K95UAC)<L# #;.]>L=V1*?NJ#WTKQ79GA][9
MO6I;'OI^5-N=G7EW]\IM>>9[4FYW=NB]G:FWK\L1>)TM4+>8[Y;6HF1JV\$X
M!<N09!F2E"%)58)RM6+96!J9S"UEF<=,^EB,=Q<WYLN0?TE?![7W[>BKM5OZ
MZM20OCI'$.(OZ:NDKV>@KQV35QW)JU>*KY*\2O+*6*8[H*\&-3TX@HS0-Q4=
MV-[2/9A(P88Y3[(6>Q-.QG1#W)N";@*A<GY]S;QN#Q!ZC:QP2TM9NNGRF&'S
MR;;R[H_NA>Y0E^1;DN]!&N(KR+?U9%.\)-^2?$ORW:.=OX)ZVT^V]$OJ+:FW
MI-Y]NA%6D&_GR8Z$PR!?\C/\2F9VLDO@8H=:N8N#;6!Z9SF&2/5JQL:AEJ-Z
MA\Y<V6\96[QAOV'NNPP_>,+'9ANFC)KGM86S?.XD#KA"+;^7-I"KX,_X**S&
M#GW9>HZF<P.8!=L+IQT9FO@[M!X N:C=<)Q$H3VZH2W['@\%-N*&MT]I9NM!
M5+4!M4/-ZT6WTWR? <RJ)KT31N@!$(5_^1-V9PH3N[R?QVWVL@T'!U-L-%XT
M(:33/3GK5KK=?J77RU9[7@I*;D]._B(\9#]PC1^:.Z.NS-JC0%C+=6LC:D^?
M;1*H3O9Q,5LUFZ0*IV+HH2^/FKZ! :?)<YOHV& \?7*R";WV+J]GZF[3=E[F
M['HG9YU*MU>OU/K]+'/<J!]I/J^1C.7L/X?>KPO-,PLT,>ULWL1TV4SR)<E^
M6MA647&7#YZPJ>UQW$WQEW3[3,GF:_$K^M!W$>N6OI)I"_0"DK<-:_I\VETX
MO<2_$T\M9P;T<CKTA/[C5!_!:C_H]J,^]U'6)$$.\):C=U&0+&Y^Z19'H[UM
MD:49X+;+O=P_@+ 6'CX%:](/9BW:Q$/Z_X_UV%ZOG9Q1DU?D;>?(.T#*_.>O
M^G*D3E!"/Z\CU0OU]_TT^'9U??_[]SOMT]7-_>^7WP:WE]_OK\[OM-LOYTLW
M<P"K)\*YOKF_O-/N;[3SF^N+R^N[RPO\='?SY>IB< ]_?+ZZ'ER?7PV^:'?W
M\,77R^O[NX/?U+OOUX/O%U>P_O=Y7.'@6D2W=]0B^M9S0=T+YK<VR/6!8UZ"
M_C:;PDE<6+X!VF"8US6ZT\]VC>[TLUVCU>#44#@:N0(P"+9J'TUS'(<"?P'Z
M">M0&_27!S4WH>K_K__H->K=C[Z&IA"K>X$+BGT"EB*&)6KMI T6Z_&^V.)]
M0ZP8J"6=9!NZ=RF7*IOQ'#5T?YQ8Q@0V M-Z '&-M N !^P.#@@43Y"RI(%J
MMCZ,]ZA1$^H(//_;U[Y7_UT%&3"RP$9ZMQZ\H(H6 TY['] !S.U4<_1_"9W*
M9H#!#Q@MUJPI8,2#F)*E%1D BRCTO7H700I>_TV \NL$[B-,]Q4L#=B N:C$
M'@5U";!S#8N9@_@Y$XZ_4;?S+.6175T,.YJKL2.YMCP\:""59)L[1%2""]\E
M+:];#Q:SKV;]MC%>@JDV QL/S ! S5Q#+Q?BQ?;0>MHF6FM83W&@KN$!ZQ9$
M[O"LQ9@/U<WLR U-PO[F)N%S*RV='2DM5TZ@.V,++(&![XO 7Z6K=#M97:7;
MR>HJ\9@:#[J]FD+#'P<CO0=^.?:H]#3Y1\B_-W6]P/J'#"TKAHHNH0([]BU8
M,V@W^+ !PL\#UFH*P&20BR"UA#%Q8/WC>64+[EJKK2:\SQ:\+;X W9B+:/";
MMW&9MP2EXAV]>C5[.X\1<WL&4EO#EW>^D=YF&UGB::4=7@A#X&TX^5.=^'N:
M5U7H0=TPPFG(6HK"%P+)LQ[X(%[%(+&(PI #EMFK9B]BOR &[&AGO1HRW64U
M_;="B4H.3E0UY",I/#@PI2P)Q)O1(K0+@Y73VG>.,,^Z!TH=7L,M%I6_(J=8
MV.I:HP+N>/O-_1SA&K5QQYMH%3[#]TRK @3XE+FW ]J+G4^\5D$J7++YH>?X
M*YC=Y4]<79K1_8_0O3OK9V& M(OU5UES6JL8=&*QEPPN7/-G-_0*+[KSTHN&
M9PLONKN316^+&J!L%A>&O1>&\SURS\*K[K\4H,]#SQ-.@"LONNA^[:5!_>@6
M7G/]!==\#>/>/PK[07PEH5IX\5@XL9I75N9%ODA+4:4#SN%@?%;P0)%PP_$$
M/9R-&E@MF\2'TI;RDG#V\U_XZ?Z"S@/2?[*^?!2O8%<;(&AGMJX\^9:+R0O_
M@( -?&UFS02.B#^-7",$99S]W=*B)A<XZ.=_W-^>-FLU@J8!X',L0_M=S "+
M I#3G[0'RPLQ10CS,93N@N^ @55#WZ\!L^B&9EH^^I"KVF^ FC@1O&Q, #_)
M0:R630NI:  8?2S8"6]BELK(@IT8E@?6"6:.& +S@_0 2 /31"S'M S0*O@[
M2DC1/6^.KH+8O9!VY6<<###G7'/<0!L*4%P,%S-6X%=26SP!FQ=I ,^$AZ0"
MRQJZP433M;]!G;$"2EL@&,#?L'#U!<SA^[2AE5:/*0+A3>%4S"?M!3.BDIO8
MP,VWB[00+*-ZJ#[ [A-]@"3(;CU ?,N4S'/@F#?8'(VYJQ1;64]@OY7U!/9;
M64]@,5_DA1@)F- \=WV86Y\!IMD #E,N,;VV58[*?C-G><V\H"H-K,G-^X2O
M-(<FMRX=F-H["IRY(1R7Z;__D/5E;N';)( M_[6YQO,)/_(5R"A_B))! ?EL
M?>:+#^K#1W4ET7((A>BECW(PF72$F4H+>: D+?CG. 6G6N,T''G[5,XL?Z["
M3[]FO^_6J_UF_D^U:CWW^V5#U1O56B__E65#+?^^5>OL;E'-E4,]M3;5'LKN
M<H;(\^1O]]:FC6#Z-DE]D!S$KE%Z'&C!XL.#G/(K:LUZ!+WFTXJC'5=3$X("
M,?,Y!_&E7QV8/&I2V+9FR]S[-UEA8AL0'/;5D.V-T68V8R6I+TDUH6A#I'X;
M\]A[]5VUFCZ4DBY/O\E5$MR;([C.<Q!<Y^2L76GE]-<\3(+;4373@Z://W0[
M%-K Q)#7O?X3K7MA/:!ULE3S6]7&/@<"K["-_1KI1# ED )$OT4 W99JL UT
MI9Y3!Z0@U:RHM?O,E<5*5-J4[^X8E3"EIE++:2C^,JCT%BPB\F1MQ4MS-OL*
M"6 -+\TZ0O/PNG]RUFDLRQLHJE8<@)Y>XL>F##(//PHQQ7:MAO*UU<U>97@9
M]-EE#?U^M=,Z&/Z8[S>[=P/=WK*ZXT9%&=Z<(;L7&+T>AE+(M90;BBO,8>HG
M9_U*.Z?Q]G9JUTY/]K"+"Y<47E+X?GU9NZ'P!E)XOY:]!G>D%+ZD[% ZN^,I
MU[JP9]RAIG3T=I'2,>#(UQ=+'UHVE791F"9Q+/%+)GD"X)9)GH#OMLWM*+X@
M//B<5653.N"[[*KD5*M2.A*3[2.O0P(K!X2-I=D><BLY&VR4.2!O(@=DPX2%
MH\I+V":CXS7"H<S/0"@HS@P#A2-04;BJ![)G Q[&5:K+,GZ9K%'&CI]D42>U
MCJ])? .]XUQBF](0MM6[VQA1KC=VY;L[%,.Y3.$HR7!79N]SD&'GY*Q5J=6.
M)9-J0S7P&(A#"?2AZX09D9T31GKET:(USET)K4\(K.VQG1(R&LV"[MS]R(X-
MHX>O_-C7>/QV<^R]D[-&I55_YF-_2U;)3)][KFUS2<#IS';G LMK.V)D!9LP
MM[<:(]^,ZUU*B'Z2 %V:3]&N]4_.^KUE95;*?(ICQI7-6.7FN()%C+N];&6X
M@TR>.$JFZ+DCX6.S MW61B+KF'E[XGXS?G>; -QGL;7<K]=1W:NU"J)XJ>Z]
M- ];>O[9(\;P;>N5*W8O44PBQ<C<9";L3A?2J;8W6$E.&PCT,)PVJSE1MZ'N
M"VXM4%\H<E"JGUNE\&:BS]NR8ZSO6^GUEI4Z*[738T:EC;)]=X9*+9+LG4-)
M'"^FO-+PO6KC8-38+?)[RR2__8#B]3"$#6*+.1E-.^ -;> -M4JC6U3.O'3F
MWN9V0TF$)1'N++*X'R+L8%IMHZC+_<5I\ G9LTM3#)?G.39R\QR;*_,<\]YI
MTCO/;9@U:D\VS)Z9?"A'6+MR9+-*R]%2%FZB$)\6U>"S?$U'3]Z#I;J.[K*2
M-I:/];!Z(15MJV?K:;;KW?SRT%%#$6K)J8:!V7WLPB/K7'K"#'F-L-='U_L!
M/QA8"MVVW4?5%2K3[$D6BE0=CZ)ZDEK>L2W-A'^N\UQ:QS+B,1L0\$L@X@K&
ML)H%P*^BJMV,N&2FS/JK%&T)T"B(F87*P+;KO?SF0NEZK)8ON[PR-6+'8-TS
M)K+P95QT5"33T0ON<TT]_J?NLX_[7->Q86&?8^' G!PMU<VIY5A^X'%9T&BG
MLM68'^B!;*T%K >[?1$V,"2PR:XG)O "OHH=DZN;8+N6]HOMN3-LNY>\+U)V
M@,WO -LK.\ >P%K*#K!E!]B7W]3Z#K OLZY^58/_%2M*3/;D#8LM9WQ%Q22Q
M426+N>Q%M48M:]\T:MF+:K^!S ZT*UF<<M4ULY5"9XF213-N5OU]#X= (WZ@
M\LW&!L+CW-5MDG>D]E_.+%-,X6#HLBP8 ([P?0"4XSY(S>$=:OJ-VL?SR]LK
M^EC_^%[[#$P0#8+!V!.D;Q0 X@N!::5R?>-$_:+ =E&MHC[IGN4$D]#7/EED
M\@%&A6"C E"^__N]]L6:6MB)YAUJ7@I*L76$@)(EWR>H,8(1Y?G8OM0'7L$:
MV9TQ<6WL+2!+LG]W0&/Q0!V9XS<W/^&$S.@ ^,^*'%H+W+$@,_31"B9)RXSG
ME"_=ZEX VJ,?G1Q.RP_O  V([9&2BAU?LUB1 DWFUVB86>CY6.P>.PEPKUV<
M!39FVVQ+FV"$RK<!+N$,'RRHUR]ITL3M17CL 97'_ZK_M*;A-$=Y;P"1-UNK
MC&M85K+$/P+%?"!#>TE?A':MEM]"^4$W#.RM8,!Y62:V)M#'NN7X@?;5,DW0
M(RX!C;1OPI]9P"M=;Z[=S1W3 _86G=37RV]W$;90ZZL0()M<!"[_@?QV:9SQ
MW+^$$1U/%? @21U(&7+MLHH@8,#MMZNOE]H[^ ^:UG/MZZ5IX0;\]S"C#P3.
M#',XIXDN0^Q$#&3^5<C' "N$8\RKRXV-H@TU#H['W":P'(&0H8=T?XB)#CP"
M?Z)VRC-]SD2!#3*P:X43>//3X?Q4?M2&NL]F([9<QF&GEGF*'P!73&ML!=AP
M O44, HTSYWK-EW)!CS$1MP^H#JS)/R+BS@S8Y$]N*C)1QB$'J*D/Y$O)+'8
M1HYA""\ -(4SEYXDP"SD+SK.;KGHN06&1'2<PW$CU+T<C;COEW8!J)_B78*!
MAI#"+H,>K.&#]LYZ3]^ .6RQEJXXJHUD\J"CTW>FH]:M&;9N35/V-7 O8,XP
M(?83B]J5QWU!2>&GT21E:-08 Y>AZ !&(>J2IU&!%>4NZ9L88W-$I-?+G[ "
M'^EOKKV#LS;%B-IV2$L^@QWO"9!+)T38P*1R5MSI1'NW6OFJI;G@-T**^2V7
M];X7WC1BA0DG!V"_\<$,O3EU5U*<$7ORU185JV""1\8B3??FZDA&EN<C"*?P
ME&$!R!&7$JB4$AIR41HN)V9(]PDZ\2<Z9I+;?H)(=,)^#@:<9K!?XKR'O;A"
M."'=0[C# :D% $@MFT="*HR87%3Q?+%M>0)%LC)04&,7B;,!1LD3C5B46*/.
M&$.Y_ 4Q0GX?S78?M14[(FQ(;@MU T%V?U6[(VI5;EZ9:(]O 35IH8_J""(4
M$#HWRL&Y<-8IRQK)#QC7J)"#/)TO7Z_.TZI%.)NA9WR#=[^GW_605"1-1N %
M"6P@O9 &DLNJY&[5%B6* 1$C_UF[8UH_C?6=/\$J_'#XEV1XP"&I0[#ET_(I
M1Q?%U1BFI>[!C TK#C^-JL"@1Z%'2IL<(.+M?+[PQQK$I<Y!GFN 6/ 3F,M?
M6RQ[ 286B*P'%U""IN)VMS"X0G"3KX/CDA6!W1)_WET_JT,2OV3W7,1[3O0
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M4.,\E4N@PIQOI_5Y8?JH%U+WXDRFS>FDOC,Z*1N>'R("%6*PVR!0HT2@5XU
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M:8K!(TS&V+B/&F_P\ ^1*O<X$8[FP.*5IH:ES$$_Q.+5**5U?U+5?G<?$=6
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M7@,C1;V5F6Y'-4-^%.PARVK%C]AI< 5/COF2S_H\V;?P>(XS0P+2#.'\]3
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M)V*GE759XF@:#;>5MY*&/%[>-@(&YE">A^7X !"F8)(#/KE.,..Q0O]J2./
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MJ4"U+;J%_RAH2$=0G=;H5LXH=$R*'D]%G+DH@Y"8),QWLF98UT)Y,65AA@6
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M]0NY3G)E87*#"WI74C*2A0WLM]NHY(K')<)0"CC%>B-.R-* 2[9*YX+C.E&
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MOQP%C+B\E^,FJPOA?0V\:V'A%0R.;,:CPH\X:$4V38V&^@1*/-:XA:^_8<L
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MG>OP5.EJ( G1V+_=1,]B:7Z!IQ=%;A27D(\R:B*=MF:$.;?(#7(\[CIGN 2
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MN5*X0&:+>6GK=6+U'%0ETRZ;L%7V4 %,ERA>CDI_*9J2+#>W53R,L(=4C-F
M:^1GZ00H3-ZP+I$T-)(YQ=)M<\,$-2<AX",$HE3;9F802?B(U$.X7-8:9]B
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M5%XJ%KD;/M J)0<;[:IW354^KA-0*WHTG<YQ?335/!KGH=65FZ8J5\+7^(@
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MGVF/*GZ-'?OP<+Z3YV7V:4VV3GU?ZONRTGUIVYV#!P;TZOM2WY==NR][#G8
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MBZKQ[%=Z:G>"AAB(H0A#3)BD%8U=WX>QSK]\M-SI%/;>U2Q83P)>A//HRWG
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M@QV.@O' <NQ.&Y%:.DM-L/QN\WG+I/IYW*=.\$@3/ [K!(\*S.7%$SRJ(\R
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MZPS$;8 '&R6]"!N+@*!!JAB/51E&J!">".HYO'%][R^%YP)/@)8D"UGZW!X
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M^R)%4H,GCS$)D1[V\KL5.L]TAB&RI,K+-WFDY?'!LB9(*\68E!$K$3B-=H/
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MK^9G+C?J :1/E:6)2#58:[]\^OP,;+]R!&F#:XX>/CM>31(OS35BZ0&S.7N
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M,'^500P0UWOG/DQP&E#[*Y4#T;LW4I+BP%*W'PA))2*E0^CV8A0 Z>[_;@1
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MZF"G(Z\.)%=OY5#?RDEOG2P*^]3SU G^N+#^#MOEG'#*W*'^XH4;\.A-""(
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M*S*$9JE2WW6*UP\G"A7TX8]O_@]02P,$%     @ -$$(6;V!1VN6&0  =O,
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M#J)@7/DZKLP[YK/43&0KDXU1@FX_(VDSFE>"WP]6N-^IGK>(SC,WO]P1,,@
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MO,/R<M@1&OX;83HHB23A?6 ^6ZPCY#3SCJQMLE$ZPX.GP.\QI'(CM?UR>%O
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M#;,93,ZTB7!O(-!?@B9U4SK+7()KPN>M@4^(VEU$VM&K^@['_5%^,<R_DO%
M@+37M$: 9Q9!%5/ 1=HR,$LEG)08<IMW]L:P)\3P]N*\RZ]HLA2/ UF/=9(+
MG5,T@Y"T <N<(TQ2 .T+$D3TLC"F E=M7N/;(Y\0RSL)]2[1<A>B7PRG_>GW
ME_T!OKF8[?_:%.$4UU"X2Z!,=?>9RL TL[2Z$"Z1=R+X]H@G0.Q.0KQ+J-J=
MT/?XJ3^9DIY-WX1S[$43T<=00)KL006F(<KDR(V3NEA-E@+C#4B].>K)$+N#
M,.^2JW<G]]4PC<:T<,PF.7/;GX\NAM/Q]^>CC#TA(T9)VX3WB72/57B)9EVL
MY"RA$RKI!EP_".)DJ&\GZKN:8';7A(_AVZM,,^^7_OPT>K'^>&O)\E<>G# $
M+&0!T7+Z-F?/2PZAGAGMK@,KAC\9]EN(]R[O=G?>SW(>XV2R^+\Z7=YS6()D
M*@$G &1$6 [>)5JEM&4<HPF86ZSQ]PQ],GSO*M:[7+LNN!8]IT,VV2J0LM0M
M*"?P5DE(UFH9"E?"RTZX%B?,]69BO<NU;\;U<_KR[?CCZ(]AS^=2" TI7;(&
ME% :?"0G(3@?D2:OBROMF+X:^-1XWE*D]X1-=HJ.W<0T-R5ZVIG@4D#@7M!V
MHH4';Z("[J(1IGA#<VS(\7S4DR-X"V'>P^Y.4;$;@-Z-)M,P^/_[7^:FHK-<
MET*&0F8,E'0*(EJDO<2*X 7M,&6W3)K58Y\:T]L+]AZ^=XJ2U47E;(QA!D25
MC(9K!DDI189"I 5&"TTVHO,LDEL8&-N)X>NCG0"G6POO'A9W"H'53-[!N\^C
MX3)ZDYWR@B4/MD0R Y1VI%(E ,K$? @ZL"1V8O+VB"? YDY"O(?1G6)@'S!=
MC$F]N(@?^],!J9<5&5&R:KK3K%*@1<(:!ZA5,5+[(N-N67^W1SP!1G<2XCV,
M[A3X^C@.]?K#A^_G<33H>;+9+.$"800'E4L&5X^LDU5)BI2ESG8G.F\,=P)<
M;B^^>XC<*6ZUU*H7W]+G,/R$LXAJUC'YY#WD0,X7@4L0LE= AKCB/@8G[6[G
MAO>->@*T[BS,>]AM$)UZ?C$>TU3GAUM5[:9A>C'I.:5$0&V <ZW)4@MDF;/H
M0+.H.+G>AN_XUCXT^@FPW4RX][#>($[U:CC%<4C3_E?\-4S# F>O%&V2)_<Z
M>J39^H(T;Y>!"8;>(_,JM#F.N&_TDV&]@7#O8;U!Q*H>>HZ?ARE^&I'SK9((
MJC"RVZ,WH((R$(3*D'A$)UW*.>UF9]TSZ,EPO+TH[TG^:!"E^G >!H-G%Q.:
MWF32LZY(IXV'))",!N$*.)T4U RD$J0U6';;H^\9]&2HW5Z4]U#;($3UXAS'
MGVCS^&T\^F/Z^?GH_$L8?J?5)'/A7 1KK* ]!#7XE!D8GIB)*M)BLEM.] .#
MGPS5NXOV'LIWBE(M<'V[2CN:IYGUN TQR10@N4AZR*6$Z+(B/T *%Q/WVC?A
M^\[(IT/V;D*]A^D&R5P?/N-@L%0\*Y7*42H(:198$Q9<H)G6VUMHD^*E[):O
M=W?,DV%W:T'>PVN#G*YKN?H?/H<Q3MY>3&L)@^K9][QE02K.(&H,9"YP,AP*
M,^#)*6#*BD1S;^%</8#A9'AO)NA[]*!!^M=SFO4X#%X-,W[[G_B])Y,3K- 4
M"SGWH)1EX+F*@%X'[;U))K0X(KXU[.FPO8,X[R%XI^C8<IHO^Y,4!O^)8?R2
M?C+I&3+ZL7@+TM9$LWHI)U@>P(8D,V/29J>:9%W?&O@$2&XATGMHWBE,=A/3
MW'"8H[):1TL>'W"5-"C-)01I FA"P^D+SQH57+@S],E1O:U8[R%[I^C8&4'*
M,UB#\*FGC$9;:#*D8>0(*%97%^^ "4<>/2N9O(&="+XQW F0NKWX[B%RIX#7
M(NAVM9 L[^E(G[1CCI%V57]>67+N<LH0HB-OWN?L<+?,RU4CGP"]381ZSYV8
M1?SK7W^Y)1I"_,^=2@&]??/KBS<?7OQ*7WQX^_K5KV<?7_SZ[.SUV9OG+S[\
MQXL7'S_<!+5FG:#'G]JJB-"&^'>L,'2GN,"5QEBRKY3A"HPF$TL5M! S=R"E
MT2%+)=F#66\[%5RY1-&LGLR\5DHJD5OG$JD]UF0D)FB?2;4J7M3"2RU9>2AS
M9*<Y[:7*4",^5]:)V5R,QU]9*#.IG8P:<HJNSL:"%_1M-$(6Q5W0^:'$L"==
M6:@%P6O7%-I$T/NI)K,.HA^VIM!&=#U>5F8;6>]'"U1),E@,D!1Z0I8(62GU
MVCZ+.I<0F(Q/E/VM:PHU)G\3$3<DO5IRO5^Q(!FQ>1XK_,NBC@KW7D;C(J3@
M(Z@@"[BZXA$JY2/&$EQ^S"Q<_?BC*#RSD=!'3276086AL\D$IY.S6&_ZIFE/
MB,(+.9@@(J]W\KV%$'*!HE-40C,MS4-7*+=Y:6\BV#_%C8VZ'03:10&I,/E<
M__?BOR[Z7\. 9CEYCP2MGZ:8ZR_.AOGF#ZY]LL<C+]9Q!#=+M.%103!<0/8^
M"6ZDB@\>C6^UA.\">/_*LPO;M]?WO5'5>BL@5$A/JP!_Q:\X&'V9!TQ2O43\
M%6D:"0EH-8%9<8'DHX!)00+**,#/TG&301&\3H1^K?UA_3&?I%)T*=>&17.6
M,WXWQB^AGU]\^T(F$A+>M]//.)[+89FUIW0HMIX=)U4A2N_ H^'@.,N8(YD_
M^:$S^6T6DS5@/4GMZ$KL#:OLW)SM$@S39.=B-E!,";1*)0\^\PR>.Z-2\>0@
M/Y06N[UY<0IL;R_*AL5VEF!^&XWR'_W!H)<++3N16S*.ZL&Q*Q%<$0:JF83(
M>$ZW5_2=*5V._>1MQ:V$V('W_FX\^H+CZ?=W@S"<TC)2#8O97O,&:YFN4"\0
M1]!N5@>W,/)WL@=CHW>8 N%N;00^A.?)D]Y,V!WLXZ^&TS#\U">+8K[8$*07
MW]+@HN8 72IK3$E:E6E'2=;6.XX)R,9$X(Q%*03FH%L'=M;!]>05H[GP.]C.
MWY+JAGH!YS6&";ZOS93>EK]-YHC)"1$E*%X@L!!!H28SHQB$$E$D(9/TMO5!
MT(. GKQ*M!-W!R; -6.SEUU@Y(,8D#KP>B4G0%3T52C.2=2)9?/0%9BMF+\:
M_NGSO*4H&Q;:NVEE]K3)B@M"X6N1/V4L0K!*UWL;EG-IT,C6WMJ)<+F% !M6
MR5NB>-T/L3\@R>&$;(Q9_/KS:$#/GE1[8_K]TB-Q4KFL,4+*1I"ZQ7KW*CJB
MQQIR)!)M. ^E9FU#]+K8GKPJ=$)"P])Z]^!<N)>7R&S*3&46@)N Y)DH2;L-
M6:4)F1<%698/UES;43UNH=F_0G3#X&HUV47\'3B&9RG5 E.3=^%[#3,N8P]"
MQ")S\&2$2@G*\@RNQAZ8]%H();FW#^7K;K4YW(ODH JQ$U>W-XW=!=TZJD^0
MQA>8;[X!,T/EK@QZ@G&N58U8)%6+MOL 3N0$V4@C8@PR\%O9/BOB^IN,^N39
M[U;.'<0'ED?8M4#P^:661NV"C<G4LI&T]A6&$.N)>.2:9!%R2LV[1]T+Y,GK
M0SLQ=^[Z+V?^_5(S41$V3PN4D^2,>MH*O1 ,F K9ZQ!\:N\!/HCH9+2AH> [
MB +<LTCIR%V2M"HYIBPI:M;@E2:]1;3%6QE%<_/@!#>'1@+N($1P#=&;T3#=
MFJL+NMAZU9^A\35^D2 HZX$6+64S2]+S#CV&NX!.WVG8D80.[(052]85T%ZR
MIA1';K7SV0"M8'JFO1"#RTDR],:T3@]_%-1!-657$M?;-+9DH /7<ED7YOGH
M//:'LWM5ST?#BK@FSHZ&DW[&\>*ZU5WP+MM"AJ^ ;(T"Q22#8%" 4PR=X$C?
M/'3[>QOUV0GP*:G6_ICK8F6ZY5A=0^9#L9G;7*L'UNNR7D$0](_7*F8;0\ZI
M];GF:C2GI#"-9-[0I[F1C_TQ?+M25)SV9#$V8(J@4R'K"B/96=HA:(VDN<+%
M(F[IP2,Y[+<&. 5JFPFP6X^DQUT,QCD.-,%4$VMF"5*6K.^$7,JDO&WME5X;
M_A28WE6J'?@?M5)-?UJ/::I]?;GWI JMD$Y&HTGCT-<@";G$,05>"X0:-+SV
M'&R=CO8 G%-2@%92[^"P\ZZ+]6JX2)QY5^O%DL"GTW$_7DQK</WCJ$J&\)-<
MZ8F?9E5&<7(EI9A1Z90E6%<;4P8AP>58RZ4$F3VZE%7KC+>V,SA1E_> -'<0
M3[U6;^OO87"!/8':&%H["0J]EZHD6E EUZ ]"L:X$#ZW]FEN8SC$B?OA.%W=
M%7YS0CJ[7GD)Y]5D<H&Y1SZZ+/7Z82DEUA,@<N K1AMR2,D&I8S>R#J]/<(/
MJ0/M9-Z!SWJ6\XR!,'@7^OG5\'GXTI^&02]ALJ2&'HR3M2$C[;I!"@+(+#)N
M;;3EH0H\6QW#WP_EA]29EO1TL+^\QRD)$O.+,![2E"=G*5V<7PS"%#,I>C_U
MI[V@@F>>&_#9D L>0KV);@MHX5 J-,GXUOFZCZ/ZH76I,6D=>-?7$,WB.K52
M[!@_U]((7W%^8/UZ-)F\'(VQ_VDX/[%*WV<%@P>SH.!9_C\7D^GBPL/;\C%\
MZP6A%6:+@*R^*=G6,^ZD(-..);Q7(IO61T8=3..'5MQ#JT4'88:[TNT9Y9UT
M3D*4IC;1)%GY2!9ABH'6])R3:!XBOHOBA]:S'4GI(/CP>W\X&B^;E= T>UYG
M;Q3-!W7U';2G!9IE!5)8[8.)W#7/A+F-X8=6D9T(Z2"[NHUH>F@#\S5R$E2M
M'F9U;?E9'"1R39PUM%1B^X)J+9#_T,IX /(;]F-?-[S7RZX613(1BE2UN5ZH
MS5VT!^=5;2PM X^MP^Z/83K1(&A3*E;Z!P>H(/LNU*.*SSCMIS"X";!5.=F;
M0^RMMNP#,^NNT&PRJJA8 M0&I:#0,G#URK!D*7B1.=.L=7"H^T*S,90470"6
M4R35KHD"3A=(FBN7$EE^IUMH=A,^'RLTNX$8C[_0K%<\BMIU"+FOA]$\U-)'
M!I(5AM/&R&5L[Y,=>:'930A>N]#L)H+>3XG1=1#]L(5F-Z+K\5JCV\AZ/UK
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M60JSYEEKFS3HB++6  W@;(ZTHRF34E"1N=;A\ W@'>P22$<*,MH/41V<'3X
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MQW0QKN7LGH5)?_*WX2A.</RU^N2OAE\NIC5K>YCHK\)BV@M-S R38RA Z-J
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M%!7H&[#L2MH;E3TC$O#@^BW#BE$LQ#Q?(.'ZS0/!OWP7:+:V7IX*_+!NI@*
M.#+C00GZXRQJ>9P8'5)AO.3R XV=!O,A5N3N48''G'U4@'T1YT\)'18ET G#
M=G1%39H1O15[3)7YI.Y_Y[K9:VK0?7S]#'X(]"93!]$<"+.C N\J(BF OCY)
M-:45?<!JA9AA\-WIX0[19Z<"VB.3(N-Y.THK4 )4X05JE[>4"C0PKU"!B&U"
M#16X#.$@ ;'U@5EQ?S8W;.(VQ3F$_:\,%/U+VT=ZE4U^"JF2B.!'P6Z9W;WO
M47]E8?9?&K^_%*6='4$%,B%;'.YF^V]V5?_"0I^_LAVLU:<_^ B]LQG2N%F
M4-*.^&L#X_[2^/7EU+,'L8*4$.27B_\=P5T?UF:B#*&.U?K/4H'GED'U[R&R
M!WR1DH-%T7[/GIRYY)<8FSTZTJ*"07_"D*)$!:C AF$-1>_K>2LM+5=5 4B>
ML3+D>H6^IKIB^S_#RP[Q9\?X?\?A=Y+_!O<WN+_!_3? W<2,8?#%A'"< +&M
M#Q(47M290W#8,:_8WN2\T,L??5)M3=NQ-1#TEY< XR]1@9=Y+1@BYT\%,HLT
M5F A+ZRY>HCK0U'Q0,>P>8&7[HYVWK_CFB_Y7ZQP^A\(VN^,_ WN;W!_@_M_
M#]R@]A<H-_0S:] &9@9TPL:-M[!XG6\O><^K(HO[?LRH&.N/1XPP'7LRCI5R
M$S-K3 [W52 +_.P$,T5&YX^G#MO5OBG6&!)(6L"331S_N?9"_8OVJOL?C]GO
MA/P-[F]P?X/[&]Q?X$)AAN3"^I,$\,Q($Y)SU(VW;"WC5!09LP"YZN3-_3&_
M A%)%W=]&_&7IJVAVJC _@7T8]3/9@LJT(>S?#QRAH\I,NG"HB%4/G/:N4+F
MMFF_L=.^Z#\-'<_(GR'V3/F=$?^-,N(WN+_!_8?@^OYL)W$SS4L^IP(N-<A(
M@YF)+\5\-@/.7VN)-Z^X?_^@Q5F3-WU19N<PZC)JII@*X,A8;TI#E>AW@9WU
M>V?UN?2D67I3#P(%FXKUC:!I93M4X)]%SC[RSZ%K^^\)QN],^PWN;W#_$'#S
MT(P4Q8#,-G1I5:MHE$#NI&E U:7!O,JR#+70JQ]+Q\^QGYC]^N;@(.[ZONA?
M7O6 'N]*!5[=@7E3@=*>$4KBZL_]'7LX'^L5LX)<ADWYZ6LKA199T7+RD?^.
MX4'_8KD0Y7< ?^^.W^#^SP:7J(]W)9=HBY,,"3]GH"SKU3$YX]K%^>T07Z$+
MSP7+W=,?-[^$9)'+0:X8$1(/.:?6;@;-BIZP60EZ\/D";M)&MD2K2\T)5K9
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M1N'ON^>9Y<8JDIW3V,4=X:#_ZJ)?1TE8?E-)('($&@IB(\D1Q>#?RRY+-[M
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M8AUS%4T.:X/>$6>$2@3K4Z%[\(N,]F_5KJA(U>0-(%/VA1!-<6/+<_KM1YS
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MO$3Z!N:[F='+;E]0-1 '5*^U2(>;D(=,?EC.8C;Y<:X4=9@[SC^FVQ!ZN##
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MZ.X4:&ZK:J[W!0B;.'UGRI4BG&R\824[1.F[6"O?%R\%33+BYF$V:&=P_J)
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MIL7HTJX<F,@ 0:PE0DK W'"5(- <*&KK$"W@CABWL9OY5QZ)^&7TLO%9['Q
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MO5)6^=?AXW#LG0\ZU[#W4:.@J;HYZ5;I"_!N=?61 U"4/?N O/L+SUBN$QI
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MJZOJ>/_U)P[-8.<$&D^U)EPM)&03A:W5-/-L>)BDRH/S4!/ ; <AUWOJN-C
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M"1V.O.B7H3#8:3_4F^A^QW[FQI35%XE,D>F>WZ7[W&>6(T50ANX+"(((./(
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M?:^[E*QXM2HX9LJWTC?^MT#245Q4$S(<?(;D6@1[A'R$K0ZWM_I>$;GSHOB
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MVR88^K#Z)/.]IZ_::Z]E\QG![XZO #QJ@'/FM81PHA*B6=4_;^#Y4-XPR;=
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M5G7FXQ!#@8>O&6(N!_D+%0%SPD+M"5'9:Z.U+K%^]%Q#L]9M-Q2KYEZ+]5;
MEBU76(*ORJ2SVW\NA[@H%5:D.TJF40'2_7:7>_E$[B[RY-\<HC 2<)JG+JKT
MQP3V.70<@FM576WX@%!Q5X#CMX' #NY:HFG&E[>QMZYGRD_^)2(F&")1 U1
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M[\P!9]+?G+ AIS;[3$>Y)Y<ASZ_QA]04/+R@C\R;5._:.O$XGU];+!H >$D
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MCT]8]NV8E!U*1S!K&;P&3 (5INAR_T:"W:^!=;PM@ 'PT,F &&V<DM^F%Q1
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MC0IU8S\';?U^HW 'P@G5Y8)'7HKZ?,/96+1V(%IANW5TFO#X'^#T87JW <L
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MQ]?X3?E3581_,0'L$;6*-H>(I8Y2*?\N1PM-*SL08V8N)P8@EC*G30N40N[
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MHN7>1H]QS75'HV93@VL(Z) K_P=U[QW4Y->U"\>"" A([P0%I(-*1R V0$1
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MBT!5J+:*(#+]1$L.]>$\X+VI01<VJ>PV#\W1?0JXK7(*B#\L]#(A$_^B#K[
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MR $?A1YS"@!B:$%;#*]("\C;*.(L,S%T3\WM%$ /%_[OQ7!6_EV]4&4H[2E
M>"@2OB5,50@YYJ@<9DY"B1Y6+OS0BP62 GXQ7%5B)2<G"ZU-[(M0/&NKYOSS
MXOSY,!JX*N7"*>#S:CL*ST+5F,,EX&9,=0$IG;833N149":+A1QG$.=SJ"RP
M:JO?OV/<_BEI)7B=.@V)L,&[U"=F8-/$_$FC8ITP^A,I@/KYCR"V]A/& 40[
M P3) =G7-A>XOS>Y7>KQ\:*7$U3W&BVMYS@ML3T/]MC(IEND72Q@FBIS$A1.
M#NU[UF3\2W99@TX8;4SJ$XZ,6\:25U963%*2+;[(WSH2200WG0*J8=\T4XAR
M4,/ZFD^=:@3/ ZFB5I[P-\)810+'_[G,/DT$PWN+H52@KO#9/05H\;9K1L7R
MLNCI]>]]V#M6_IB1/C%,FB2P%,QH9'WS4'=AU9)LR B\R )&8:I=6?^5V%0+
MP.#TP%DZ\,IZY.H>\R%5_36!,N%WX=46I#14)Y#(09WJ@]3-)T2"@H;3\=U@
M."Y]#YQ*F"2*4WIA-\@E4+O@ C>NIVM3LFG1-_)*9[H<+2^PLK"<NZ3C47K_
M[Q4)D3CY$X8":AQ3.@6XR+WCM7:'LT ?O"I\$&Y1A[M1E>;Q#4:\Z'Q;GCRR
M;07"ZH3YZJ4O,,<>!/V-@2B=S#=FJ<>NT G%.GCEKRUS],)F$=^'NIAC457"
M005M%=.;)Y?R:)J;G%>?QIW+NWBWM#3AIBB#9^+1\SB[%MO#(9Z/1=)>X\T%
ME5%ZX(10J@^L<+L_]1-PKD=X9:+F$0%0NO2%=I)&3?3"TY%3P,+5FBS+:VIJ
M+V9Z"EBO_CD>#&DQ,/0%1V-86T3M2!+D.I+%DLUECAT%,*_=' -TF[5X5I.P
M'Z<LNSQ$-".R$"5)S/!)S+Q79!/+JS#!/+BS2-K>RM6''NKECMZI@"2:FK=W
M1<15>#IA.H2<=L$K$R"O>$Y7,)NLEP*2'A/T@\)7TFB5?"GR5_(#MLK;-UF2
M)>KFG^NJ<I>_K$QRV/#1='+9'X<Y$Z*;+JS&(D4+/$1//&%(J H!A_7"5V&C
M+*W!:RW7X_:NB:+##PL7(5][6J_KN<DWNH'"[MD>.-B'XM@H=/%8J6XW]60U
M@=UWNWEA*ZOWFOUM3R[G87B1/XHI'"N(*CD2ZU!K6D&[ I#VX&!$_;G;[4'1
M,7^)OWJ$FD_#K+]Z8G2O<(OSV+*>Z\DC7B71D8M:!$CZE74X2G-8/H%I0I5U
M56?<O^[PFH]Z#4OI9:1X-)/9QSY^6=5UV\_A? ;EG)7A#1IR:#V-4(\-FZ1'
MA5VEJLCIDU/ :Z@9T9[2E25,_J*XR>8+%T0MA!FEOE3\D'U+8..<:]Z3S+AS
M/:W77O>LW25'DK]6-=H!J03/S>UBB4 #P;GSU_#52]:S5AE GX[5N18JF+UM
M"]K4J24X49D(3TXBN&$<7LT)N.=:MA3UJ!^A/R!T 0T)X<4#"6*@KC#EQ=6M
MT6]KV^I>94'V-,/(;?E]:=?+;W#DB9AS9QO;)>Z'4@ZW6X)+JF5(I>.4HQ?!
M$K^[M*?L053*98HD"Z^F4C$7_&=GP^U&"O[M;3UAKD OGK5)D8P$N"_8+@BT
M>/1SZ")):03*Y8&+;#V)2,E?+\KKE/VV"*&[D< >WR_XW,),S'45P.Q.PA'R
MJ!*EC% $P5GO];<&I 44S$_WYR>,FJ915+2^2'<4&_(!;R;1\L2"56ACYD-T
MNN,)-\3:@>]. 9?]X[EFH%IHA7J%=#DEBY8(A@\[8EV<XK\O]\@2S&@^\D7>
MB#H%6)3=OU7RP4,OKQQ=;%]#BHJOC@WL9;0 $T#HU./&,'[ON1D=-MJ/CD[:
MM$*%8I?^R8XB*F97+!D\-O9YC*8GWZ/.K,(IH >%TZ&TE((.Z#;W3E!/X?.Q
MH#VY,[J(+&$FGP]9^ 6?@83(D26OZ1$.FN':08$D#@3%(&V:TKD)(O-H0,%@
M5WBK%35>K9>AMNPKJ8"<B.X\C#"CK#(C5@9+77"(_G_I\-)7-.Q&=__C!?P'
M4VE(RNY?0I C/%$'",-_U5<CI\&7.<'4.+,E3V5[N2=A,"@Z]1U%U L'^[!1
MAFW_38U,!X-/_U,- CUR*NCO$H43_F<T'[YNZK^2M ZO%"-EP-N&B+Q^0V3)
MN')$U\>4MB$,^ ."11V$S6EM2(DBF17"G=9X?4KL[(YOZR]'^&L="YL[)#OQ
M7YAHNH::S\54IA4)+_(XK"GHZU #S\8NB?T!Y0EFD1I1S\Y=]DAA\UL8I,_J
M0!O_CSK0(R^*&ZZ^SQE'M6%68 64$3#6;)?1AN!.U"+H> 470RR,OJ9T<$VL
M,$#NMM,LQ5("/_G&]A4S,0_$%NP3\9 L/>24S<+[T4<C V)1!^A@_H1?73NW
M=<6*;C1U-<OA'4\!B?$$ZI0[&%"M-<\(C9[W-O7V(4^-3UO4+[ZXQ5;&I^<(
M.VO4I:LH%2N'5\%-3S\:5NCJHY5\)"JXQ_&\NU $ID@X)JH\^0W[C;CB^" "
MS.:6"Y\W]3_9IY)K>>KXBC@D.?!,_=?PDMZ1,^%_YS5YX7_Z\T\!U&E=PAYA
MJ?\UGSS<^I5^9*$'0Y+B_\03)%BE*%T4C9EO%?CKM]6 -0\&8$YGK4DJF#^@
MW#?3R??\54C*"S)*1C2#)2(W7!)>7MK+CI>J?YLDDG ^0B#$8KV6Q/Z..K'=
M&#TYLG1$/9P@"FO.<X?_B$,XO!@FH_3'=J^-"=MZLBI$/'0XC!VE)2/<]V]R
MK$;\G"@RA'DU:B$/QS8Z6TTSN36IO$ ^/9)"=PH@RI(N5T?M=I^@IZ(_#?<N
MSH9)#W_UN2^B+7 *V,D</T2U-0Y=!I/N#!=@Z?\@W_V2;O >?;Y71JIV-JGP
M5IGAR_!%9ZR@%%%N0P2Q^"YD%**J]L/A@-26&BKR<+K=EZDZK##7S8D%*'U;
M6S?EZ!F-H/7-G_89;TX>8+T6FD"786P$<*OYD?:Q@K[F'7D?$Y>,#93\]G:R
MR%*&2U'Y$\?F?%9%,:L^KZT#ZSOK&*??WO&5'2KW!3=:F@_-:Q/16! 3[ +)
MCRJL&(AZ5D'$+1F-\)IOWK7)2H0K$R.[NASR;Y(8D_C/FUYY Z[,$L"MMB*F
MIML^TI2A(]7#"JZ*A<E2Q)>S9O8N:#2]@^JC+Q;B%8_/$6^1Y GPI:$I=T,:
MJ$E]\^B6;+FG]';:Q++'.#+95L187N(:F"F'SV#QG3IZ$E'-16+=U?=B7#M)
M^9FIZ%<&-_@\M=&U:9H>MI'![KJ<U)?[H?]GWWGN!)\<S4&-Y\62MPIG[))R
MJ\WWC_&[10FKEFD[22UB_I@3:VC9[X-3P$<05@_X%J90FU1U1]^PE6O55WK*
M;FF Y87*+/MRUV]X.'V8%NP%A6I\/W8_@IQ0P-8%<D"0OXSF\9433^3+<.&&
M#TI\DKX58Y_K?5Y][KW(2[Y.?J=YE3("9X;J%=E"K7$TJZ3K$0/9[[3&_?W'
M5I7Y$AT_](U<_BWN??=59OORCKH.A8%CJ0QHC--IWZ6W'DR$J)DJ6]1&1=Y@
M3^]CD0IA6Y9W&*6M*_WNO_D<5[46:NA&B[*/W1WU7$I2,<]1[5,O@X/CY@K6
M:NH79CE@S!A7Y:D4/&TDZOM<5Y@VSPAF*V#NGO9G1V\SI?Q'SMS<O<C7\(5(
MJK>^Z2&< JCH[I!%#39=D$WX)&I1*9)H!NMO\+5[DJ(?EJ?TL7RZA!%G<'TO
M_V+ #-,AWE_Q^ ]H_@N<RV(QP36FP9< VA8.C.+$WT2YS/;NT>U#9U'M5>4[
MR@YI*VV=(QWC!<;(RD!,"Y(B$-CRUL>X;?2+\(!G9A5XV66J>XVY2RX60ZO^
M "O<9<]M&$5A'+-?;4>;WWJWR*?JG!K;*)E9(C3S=^FUJH84-AM%#0\0JLT'
MMH,FEQ9D<Y;X@$!( /KJCW:G_(V*5F_T:,7Q"^.WUU7Z.=L]S!S>19$(2+!D
M@5;HXR_.RZ'V&U.;%&?N(L,$]F7VLE 8PP&IK8;$-E_FNZ@<585A)'CI(RPF
M#GD>*DT$+$EOHXOF >=$/P( ND+G(:PHEU/ ? ;H1UE\*SP\P%YA?&N<Y+48
M:E:78,6U^J,2JN M&VRLC88;WP5Y6Q1%=W33Z8XG-[/N#/)Z^SL7=2/_6I-3
MX4Z8\Y2V4P"C%PFR9&?>3F'U^K$SWG3/^Q5C-C\\9]K1L_4ETZ5U/OZP<2 "
M7@O<+@@E&@4E8_1&KJ<_P7(FRFLDE1:PSNG%HER_N@"6KED0'BBK.L3_1DSU
MXX5QAML6BY#@W1:9FC<+T4*:[0MK?L(*1KHQ"C] 4RF_/OU]W:D]/L^4U_(2
M%TEB.0506 SI-JTQ)!ED-=QY4C_X+[Q-N?+7WI++=..V"T^7_+N8 V1R^POO
MP8()7)*<9M1@/Y;2-%=0*:DH#'P>$4?V+-\EP]*$]Q.H8JI*7>C?+8Y/46D+
MXEB-"A08/%_D"?KL(((X%<='".\.1E$'LQZV\"V34X 8&-M(:?<^!5AO@>;S
M@'LAX*NPM$!*>EG)+_CN)HEY7\>"5 =#?=L793>R3^W[=SE(L''X_[&*=0#\
M *Q5;F4.;[DY1I):C.>#.T.F(*6!YHA)Y='@EZ8J?$MOOI!*F2\>(C6IC,,:
MWIN]AL&S4</3</4QE2[0G*/^S/:SHB#@3]3HHJ"(\V*\8N]B_&4V*7VT/PE6
M4**=D_?.).X(@DLY!N;!)*F#9$//_U:H+_?;O;JA*5IOM&?E-J7?X:-Z"@CQ
MB[U[4KL*3H%7NVSK(BGCP*O":'\]IY&J$N[8EM1<+8G/'CEBTGI7E>]<55:B
MG36*D^H41X8R)C_'5N(_-\+"F$*^%B<)]QP\(:=3O\<(WELD1HZ4 WWQ/^XG
MAKFS;8"JCSJ*Q'RV!0Z\RPVU'@F; 3]QG"C^WPI?KU"%V&>J^J8:)+ZM"-[3
M2,' ,X:&D021@?8!HLR,,'^IO5"CV0GW NA7&H$+/X;-*E@RG$9T401_EUH3
MS<<.(1"(C>7=2[KV<U=IU:\D]JHSZ2*;4?_G$>/5M>H!J?93 -:2(3K3;BEJ
M3M]B:UA/BL8LS4Y!A\M^>=(T]'MQ9&.&68+-/92=T/;^#36G#<RO4X"J8#@6
M2:%C7M 7UGY["EATB=[=W1TWM]HZ,->S>134+ZQWO;)''O$U&/[XY (^&.NU
M-8Q%=]]>@]/?P,ZB8T2JD_+#0$8>C[>?FQL)N>FADF^;2"7U=O,;$6%0>AQB
MFP8K1V'9O6@G/K9]>!F9-YI;M\?U-):C.\'R4_U,SU(PPQ?^.,:@71);+5X
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MJ+';;'JH^2JX (-H,Q-!IL)3+>+9V36"L0'_:R6JD,)*]5D=V$VH6'J'+[E
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MY3X"9$@.KD>2OBA#1?O]0VE7R4;IYPIL7&]+I1M'#5QY?W;B_G?[QEW!(]C
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M[^VY ,*&5O#\=3#6_L8$K"5R]OH IFX9&OWG36^SW_^+X/_]Y^<KM+\V ?V
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MHCRVRUT-=H.K<$WCH"%O7<;</&B/EBYW*@5E!VCIE1ZJ-[@&\;KSNF+YX</
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MD]"?%>IG(QLD5S C9:_TVGCT'P[CEXW7'#*6[\I<NI^[4;1Y%/,32I5MH*-
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M-. -RG^I<$:J_G6F[,_-9)PD?N+YN<*7SV'\1/8NKPO VC)$:&'U6"UGW?-
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MPQ##@E02>XF;\"\#;,B=J^HF=6I,O\R[7';;=)2XDS\1GF;*WG@LMM:K4>'
MWZP-#8+. *N[WXKBLW;:L:?=*U>/H1EOJ]4W)-G\?QGKV(G[]>8L,<0Z+XF<
M@JP$X%@7#B/)EQ&<+KAMI%,^(R]XNL2WQ#<ZA*N":<_BN7KTJWC_Z-7V9>_2
MJQ,EIK<,/0ZVQGU^]K: IL:?%[7^*-T:W<,4D=2U(;HD1NKX-+I#6,<GBJJ
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MQXR(?)CE:\EC:W.PNJI!9J;8UXFH:N:N/(O%RG^)'7^/(]HT0.+'!>#Q(1U
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MY]6-Y,TTB4I!>K^T+[]G>\CVWN-@.GI@$(K&2" /*+*=73<L*$EVP'BMJS1
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M@$X9)'HI'^];>7^?\PS12%L9]4@G<5!9XI"&'G,PQM7>#NV0+R;/-B8_Y+*
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M&8<!\;#MF&,K!=^H$].9?J5\T3!.=I__$MTK) NTI59V=#G3+UK'LY1I2L_
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M(I3U.+;L&/"6\&.W[49GO7+BJ;2 ;VN6'[ >!Z9HA6G[2T$+]VY:O%Z3PJ.
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MN?U'@BX8.J^(C,;@U)B_Y+5QY/\2^)3>37'<1(EM8Y>_*6#XNWRJMA"53!X
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MU=PQBG:0+ ,PKQ>%,[HBXWCFJUW/^#2XXIVP^LD3;^]8O%S8">JYAG'8: C
ME3JW[I(CNMI#+"8B\7H>BJ%>?[Y6Q9FK__G%_WDZ/"OG5A]<@]X+JG3HVE3
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MV320V^*56:84G>D%.B7;\VVDSV'(5MC*M-?HZIC>;/1B8W;H87*R LN6,IZ
M^H5Y#]=JH.5J:86A.M6(0^CU31.;F.)7MC*R@[UH)[]FBX4=^1<&:QXC+45_
M"DW>HA,@V1@N3^?&>%Z5J"X;.["%W]X(7:AW#CS5D$ &.V.S?])_-S+E95BP
MNN]VQCX#<"J(TH:X<#NQ*,C9_L=$B0)ZP$GMUX7R[-+PE&<O512)J;D,P(DN
M<O \F)56T^*H/N8#=8D)J]K;G7:8?.#;=?1]=%,K-UX!F^]$[T940+HXWV"X
M2V!W_?T;@=JN2D>E;Z?2/OEL]NM:/+$R^_6\-TF5O_O$>'P$EVG2.]VO]0P
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M$]WAZ]9FUL2L!5EY'GFH5@JA=QE@]FJ'(HVMW^NH:S$ M]6VTSA5-:V@R:"
MJKY (T)_LE^1E^"[LI1OMF6'V] ":Z<HO]C*\F-Z8DE>+*U(/@TV?.]D"541
M#^8,BM[BC]V97E4KX3,3?_S*(5597%9?0..%U #"&W6H"(H"D9@$:RH*DHBL
MU(N 08A"\Y<(K&\5S?,,YK\+MIDV"!Q*?XS*[U?M%!,PT=VNS[KU/8_/\L6;
M%<P 8; HZ='<MR/,#C4 9-=@2O&%L1/@/Z\E%\*T?RB75W?Q6A[P)1:[G1"X
M'#=X/H3ZUZHX2*HK1YB<D*M3&@2Q+9] _SPW5E>>_M2DK2@K;%Q@T?CT'FH
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MZ@;D'NED*["P#3)-6D*UA 9+2<7]*X(>WG;BF"/"[9T_2H9'Z,CNM[4X\S\
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M>?2-#XT^_O-_:W/_?WQ8CM$ E7!R<I,>M:T2OO;9_>_Y$S0!3-_L +K@G[0
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MS'WTX,X.] N>G\K<CZ]JD7M(J#\C)/TCEH=D$>Y=F:3&+DKH!5<6G4P(+]
MTPQ8^-8@LKVPO&+I O-V6"J.!HAR2/DJD1TQ_VPO/-;S;N&?F$/X5!_UO,X2
M^*T]0RT.AEQT@4(*74FI719H=[6H1Q4._$II5U\Q*R]<5.[!"H60[D(#\?#M
M!KS\O0]&N+1D/R].:]=ZS52^#?_9F?1LH]P K0%N,]:3C*$0<T7N7=G-'%##
M*^_46(K4'TT%U#8WB8>(Z"18P)^-[I UBF8&G3D=]7P_/BB]F-VQ&!'4SCJQ
M7+A%HG]W[L"CI9VW7XEB'5*+7ESV"B5.Q8K+X]FFY[(^,S^S\)/.27L[L!6
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M'OV)[796-Z48L2A)M+$BEGU%=Q@9KXRT[=M'^]ETQ!4DIHE&O71J=FA]EL3
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M IA5FZOHE]PQB#6MU[+MCF[F(<IWH:(#EH#GUJP/9QW<P$7K/V9_??5GW7C
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M$M-Q2"SX0^.UO#489]V([X>CFC";/L."]$\.:5*OOF:'G(*\(EL3([\3V1?
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M\SZO&]O-KT_D_!6U;9$8S2"2R::B2#""!<!;;\&DB< 6X#FHB?-2PI5 >'M
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M@(Y\-VP450N/I@!<33A=\8G1Y;Z9%PX^.-6\\OW@'&_-G#88E*Q]-_0,_OY
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M.S_L_D,R+WN^?1*MRVE.&X5LHR>J8"WA/J6;8#:(=+E;NIC2,1(O4[L_<!W
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MV1W(LY4DYHZU#R>MCJW^"4!N9-L[W2PW#5ZP'^I>^1UW(.;^<BDL]TG^E:^
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MA:DZ#*\9N0BQ@EGGRJ4%SO=\J9SJ^$1S6C[B@/< WK.+NP0C9A='03<'"!2
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M&#M#9CRYAJTY8L25820Z]@/3+1M&#RO8Q\/] O)F:SMF.5X.)XNHS";UF3-
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M%MW30]F[PWIF7JRKW%MVOL:@_7%]B'/[4$VUNHZ\@T@L:NV $\:;FV=VUW'
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MN(U5+E3:I]$GY4TQ<YFW^\Q>UIY8\[U/ 0RFWMR"[U6!]XYG_,@?,6Q;400
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M\H32).'.%78]^]T+G<6 Y\V;;KXNUG7&]OE\=24_;UL(IOP@W(A9UA8B.F#
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M*-+4HJ@A9XV6]$O6V8_$:QZ&!-?-1Q 4 A_HO9:QZ@E^X[3>='>'\X7F2=5
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MA[Z/C7\NRKU^MBJN<05YWTCFU9.Y]HJDF;FV.AH/R2U.%J/HF%A$3R K1\D
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M);Z/WE& DHS)C\1.R24R+3X*!;XP<X#AS2T_#3O>>L)CJGVF1>?:\B!#$>"
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M?,^3XMK5Z8#IQOYRQQB?L$^KLXU/;(^>V%HE&Z[8K9E3U).ZS8_%0+LIKG1
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M4;PD*'1 FXZSR++O5!(QC_1^J=^D W41#YX]^*D/UMWXZYGUT-EUD0UGE&X
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M%<*88"3#G:=C!Z:<]\/5<?5L#O9?N/*[G)+D6C0>YAE:Y 4C!C S)HOF73
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M-]2;5OQ'D<+M2C.I?\]0[LYI=(#QQ6^<-!;0HBBX#59+1)>#;UT<#;N9O/#
MB4]+TB9*(H!YW)[#X)'U(=]Q!#Z#^( $QBL[-TZ$<6&3MDR--^9F3$#$J/&N
MOW&R?+-RWYBO%E]TC]VBA/X'$/#ZJPTWVW^>VCR&B+:Q3D5L>;F^$"N9HDE=
M)$^D>\J8\21-VY)G82N/C3FNY[C5YM)6,H[@9\(86/JV),BN#<2\[P2TQ/M4
M@F+]*W5EI6)[VC[R?!JZ5/_)T?]1U*DW(JZ?^\. A(A.,7'"3H>H7>?"Y>]I
MYF-A>M+$K*ZAVF>/7]Q]>FWN0]NB^O.&7XAI159H.^PD1;3B<G%QF-;H#(YC
ME1QV*%!5NIER85?3';]4A[I*^PUB0:E!)F8FXRF7LU#%OEYU?F;UDVI3[^TS
M[<[_?KU8\T(_N%BF<XQ8-[[#4%CC4Q)"^O :5)SOYLB?PL0WA6&NU+RM_?<%
MF )27'O*K3_= ]R.SYDX_9*A7]% _] D$6@[J-;[Y\"7HC6;X:?/'R>G1U@@
MG]^OUM4PL'P^AY-(2;^$]J2P+H8+8.LC]W?8@UY-F(@*F,=W0KRE.FH^C4KB
M."64SY^[<0I_X\():Y1XF P>UID@[[\C&.1K1F O>]*E^(B#P#/6Q2AGG(W)
M'IJ)JJL.(KI4)!T ^K1\ZJ]^@AE\<GU7EY]43P><ML6OQ>@*;F2!(RC7*Z=)
M<(M:"!ADN6N[,-28[FYK\#3YF]D)F[53QW;9L%:5L-/+=( 0Q;Q^<M)A4DZ;
MZ;-/:,P(\1G.5X$%*]_VCH4DJ<5V_N1K*!Y1MX^>$ECD3RJ1V@)RX)YDBCQW
M+"<WQ: %5S*3DURN.Z]__1L2^&Z_R5O9Z#MR9'_SR>YB34V42ZS4OO5] /"6
MS;G1HM4KE> #TL/,K@#NR+RX8XK)F(7>2Q%X'*QNLB7\)3&<A(-53M]2$1.;
M4,RV'CZX4E.GP7J4P+^#]0];A 5Z'"!*M'D8'?3$C^F>J0?SD0SL,SJ_MW";
M;Z$EI^=ZSJAO![(+NOX2$1':@&QC^((,[A(FHOWR@^*,:B;VR^.#ZP+Q<L-J
MFJ(59WNT(\;$TI<=P%LB> '#\7?YS.WE0@I,/M,! 2_].&";\:FU0<39V)&<
M!H\RJVEO*LSN4D%P,<ZU:8X212(0./\YSH4',T:.V][H2<"N6[5IQ25^ ES>
M\A)T]]M\8=-WGR/$%'PJGV9JAZVGONVFO3O()R@334GFA+=[)@T$<*0X.NU>
M+;\:Q#?XI<>%\R<-$QB@]_R<3OF0-L_B3Q'L9)0_AIT4,D@&Z8VZ['I[ATUF
M]-Y+2QCH3)(\N(S(NYI4;3RS_A=!VK@3F6MC@8+'U6._D/P$*+DNL*D-T'XC
MV@;F8TYR=/!M^W& B3SN7TU8R)0P*IV::KV0]M#QO-)Z@U"]OO[S2.Z*[AR6
M<>!W=,L!X0'A"MZ<8A:U0TR:02,1__S(]M1Q>T3JME]\J,O//]4^I!#_CP1R
M'7C%LQ:AF0ND /= TO\>S9)D^*OP:+*C&2EG9BVA=O,7;93C<_VET%[;&2;]
M<MG3UW-.\BKA-!:WEV6)"]3:9B&R,0EB,-RLC!7IU:C8CNK=U.RXW^U?QI?Q
MZY8(^K?)DU5TI-\<-):A.XBW2!H$+8N,^P3.U_Y-<4>?FNMMH6XYU54; T-*
M M+CU9[%;^D %_1;9\!8*AU@0 HNHGY38TOUY%0E=C&+?WBH%77Q\,+$M_LE
MHUG(ROJ,N=N6Q0',:)AR&WKQ(^@,<O $18, C$.6VWOQ='([4M\NN,W@?,^F
M\;B6<+C=&+S?\/<6(@WF"WOM,-@*3'1(BO62_V/.'O26@-1BORVE=;'A*492
MD@Y@99[KW2AP_=*]E2PHR'2R!+(@-D*Q*9CS")G(]BCWR)"MAFC]Y7_V1"P^
M_BPHX6JZV]7?M?X0\X_P%22+_YA'XXL).@!^4/P%#V+HV<5*9V ]"<9"2FO3
M1';'8^NG,(^NA[_[<_]Z<].-H'8QP[-3@Z<FXZ%]<&'8,U@2Z$)J^RT"JL:W
M:!XL@K/!>/<7Y7H.V(_SNP7<BO]Z9>?-5!:Y^I!X@L14XLD>K-C>ZY:9[?<@
M@+4G?[#6X]I-G=>=H9QO:&)!KMB\V$;S*!413L[UEFTUXGFY6[."<U-"3[L)
M%[)&5&6ZH*,9SO-G/US&;HV.HL&;QV-'YC26S$51UT[XB=J?CB9O37ZHL-]S
MPA@(IUKR)R3_OKE58:?[YOU?]K X,AMM.DMQJUT@9A_!_3=PYF-*N9'H[[EU
M69&'G5=EG J=DI7.PYK5DH.T?E"CLGA_1"VE\QOF&E??^/U=^[R!GS/7-V@;
MZ 1%KT*W.!"_T:65X;U5%VBG]GV-UJ!WM4LW&R*L1 S[A5,D 5<2//6L+2",
MT&G]1Q:2B+^IY:J*,XTF&K6^[ L>SF?QLZF7<P-[GF:OVF5FR J)7RLY][=;
MNGX,CC>D6IY#\9(P9G9 SP@'HWGE'J.+-E9)%=Y'=N,SB*T]_/(#$D3]]65\
M(IPYXH]_JJE"I\.XT'@$LSR7[7RZD-?*<JIG1IOB= 86W1*N3R.WH,3"6?[0
MI-ZM).AO!*1;K[Y(_;V9_/+M&7US[:P1GDCQ&U+Y=,#K@Z/RD/"NE_%K5XR/
M$219<Q0-'7S43;:BN%"_HDY3/#YV.Q)0M3/6ZFCOX3^1\LA":C5JQ?9\F>SB
M8R=.5-!%>/@H:+$2R*FHK82>=68E<$,X.2[7(!V#*X6J>KA5RF;-FV&YX:7+
MG$RDT"6.Q&/S][6F(/#H@VVUQH1J4T&?/B:FMUI</0@>..W<'ADTYZ3:3M&)
M,>S_41%2N"M-Q4NS,-?)7C$*536#^!2EV<%KD^:'*$5XAI Z ,]D$%\WU.(S
MHEU'8/5(&87^!$82YJ_7;1T%N@!.G!?[(70#\.0-N!*-[&[1T+T!'0S)B-P?
M$;&O>K"C4G/YS!'VU"GIN@.%S"U'U74P)XV/!,*:?3J&16JK%Y%")NX)V7;-
M6Q1*?$FA[:5L=&1ME)7]5BH4OC:L.%@\_]CJCXVH_09F$[T O4+[10?4=E62
M@6&&$Y\G:DW*<Z\>\H=TI6+^-_;>,ZRI=EL7GHB*H( B2"<*" @"@O064>E2
MI4@S"B)-B%*D)XKT*B"@*$6ZM(#T&CHB(DV(= (H'1)*"*1]8:^SSMGOVGN?
M?79YOW6N[UL_GA_SRLQ\YAQS/&/<8SYCW*.A/DS[YX8W(]%)+[;TQ2T^K9/-
M/K@B*A9)FB+>&=IM%D [$@7YF**X7WKZ%.E+3]KJO;C9F<W)\:2WM\_S90\/
M.81H0/H XR0ZO#5< )U<:>C_/8AT$QV<VN!E_QY3\I;O?84-*AA.-4 09F^G
M/55V-.Y#;<4UWU_(%-<M\9=?',XWAE[<O?C(3"FJ0++:JJQS6\G]_@#",YX4
M7*8FOC9[>@DKV27NOV]D:_QZ&2>/T4SL<L_Z_?@2;>:UA-A.8A$SUF*DRMC8
MQ,6CP9R'?X%;_FEVE-CU&_\!MA7:Q:V_3;+9K<6U4H!$9:PGB21)18L?$?VB
MAT\J\9*H7:T5'GGRBB06W'M47UB_]V^63?Q7!J3!![(]L ()3284>%. J^3D
MN=](^Z5#T.E."K"]1*8&NI.ZN\8:OG0=?V:>!<M?>X!66Y-5A"B 6G+RGYK7
M<?Z/5(-FI\'XPVC2*M*37(\<< &B_HRVJW\=?VD#FF-1"O]1"NAIL,9,FB8-
MGAEVN_S\V!#D@B$553W$:T%E$N3# UTL.3YUQ>8K*%!=4I$C4?4]FIUT.D..
M&G-R@\FZI8J"APSZ&E7[:F/9+3;XHY)#?KS8PH85KY*^A1&FN7-3(+*:H'[F
M3D^6M(#2Q7V/G)F6CUJ6YVPYI*]]<5 \[C\DHJM4=?FR^'E>C4 $%DIFD,),
MS@UTZKNVI8U%SA>7WM5)L,MP/:WG^#):LTPNM<Y<@$FI<$EV%Q$6J Z=1S*N
M*$UGZ_'FYSDS+EZY1C,J>&.5X]@-A8<?SN_E9D_YC<W^EOOA\.7HV[I!E,BG
M?Y/"V5C#3W[C'.&.[RV<(V8SO=BW%%J&K))0&W"SS^OA295^J'<]U$>]PK=W
MP!QB95$^#+4?<T*(DS+@3O%,L.$9YF:L<-C5:CUN;KW?Y8FJ5B(+;[Y4Y"0>
M]U"8C&1O\6!F6S7SB(ZN2CB7F-C (((0(67#G27/D+_-<(QXS[+>6T7A4O<S
M[2)E(NP2;Q XM]MUSMJ?\F?QC!,]73U@D=WT"N=)*F@2)Q@X'7;GH5T9[=H9
M)=#BOVWO<^0\?FS;BD@5"[ZFG' ?:2%2UZ@=T7O$1F]L8F2L$?@1>YW,H(<9
M0$/B]P9.N4R HB5DQ?E_E3JF?!\>_?B8X]=IFRL"&7/&('_=T\^Y)1PK]H+8
M3L0.0\;;/#D>\@R51'$7'G_DN%.2[MES'X09J\A94<JO<'8H6COOQQ44D\BL
M]*M5,,0@%U!4:-UT'B_H^Z&37Y_2O<%V8F_>&6?!;G+2:2XV[T&SMI%.#Y)M
M&]D!PE\1[@!'D=4&B9=RG6!7:W]41[]T.UY;D]+'4''\U]<I*=JXUB'6)8E[
MFRPNYWZG](SN_C4!BRT3X?OJ#J8EWKMH32FT+#G?ZF-B0%^ON4BV\?2[".!N
ME:I+7V>:>%AI_I3X3'K0,9M)@ZR7@NX?DU\(J 0SR]#X1QVD+L")K+3HI59P
M1&H+(_9D[+QKO\FP0EZBF]S8-)K_-E.=I)+<4[\#U]FFT_,$< 3?Z<$FPP(-
M%3FN_AAY''9:M*28IY#W5JC@R8XS<PD9O],,C):LZ:LY/9HI &)'7B0[ZM:_
M2' 36T+0DZ?X:+!+/71X6_0T^/Z8K%==RG2ULJLO4X9*GI#6SIDV'&.N^WAO
MM_0IX66KYX%%MGSMR*:%47=6BV]P'N3<1_!I-895%)?HE*UO+:3V<9RKZCGC
MA=IG1.D[WUAY%L\V1@@<9\!H4)U8ZR2IV!E_5Z1FX+!MG@;)UPCKCR'+++#+
M^H:DA26"-981[V&TY%G(:;+2ZFNG<EL;O'WGW=>O5QJ&2^S0R$;6HBZ.Q;DK
MHCV?TPYU/WP4(6H;)Z:T:3S +_1D\.%=T8V(L[XY%M5#,@%&9VHM#*O555F9
M2GH^O]!9%_L5=)?,\ GC:#C*-WP:S.9B).;&/M;@I7>:V4CP'0AD2C>1K[;S
M^0JA:)W %;4S^PH)4CF-7=-(-<'<;V0J+#\KX69I)1;MX4_/_X"#]CLWMP$3
M?9<_FZ)&U_C'*U?$LK*C2C^YF*>I93X+@GLS)B=7N5U%R;.<6H@$>A_;MP(^
MLMPN7V=O6V:WZ&-KB:P+<XA7>\*55?5C32;V=O%JD7;Y%]5[&&42POC67@=P
M+<-8J&A078V):#,FOAOM=G^G(ZVZ+V)C0T7=79PXILJJ78)=S  DZ%7.C"6$
MY'WF-XGQ<1R6,;9A[F:.FZ'#G\OJ*<*/V(;KA-F9SS"6"NZ?48I8,+*L2$B*
M.1.38%EK1[4.+=DMBB/PN:+,D]!JTZJTOBZKH$:Y$;AGP>V'QJ1Y@7>9H-L#
MU4%F<T@>)]"Y)GE'!-[1O&:L*J!ZFG&Z>/-N7-:^.5UPP7&^4VPY(8F_76\J
MY@383&5GM;34#*\7-#7510T/'W=^7)?>KL5%D_BMYP6PZ?H+SD-]+'TU!E]Y
MD\2O8SOWL'>[N_C<F'JM+JJW=7S#_N7A0XL_3Y6E.H[N6O2#&>!S'S-/DL5<
M+QS>4:I>"JM63CW7!IT__0Q(CK]Q6=.W315XS*ER!C4\ZA&3TW!91^\Q%0-8
M$M1APWQG26E$<>=2?"E"F#V)E#'6HQ\K6)]>D2):MBQ7N)C8P<G[A>V]L[N5
M_KI_.MM"9F7\AC[:<"+ $"6I(EZP)G?.F:6+=>%>F,AXS,NH]>U?@?%OEA0V
MC&%#L]468?#''#+6\:S++1=_B,L^3E1P]PKP=8CE!2[S]$J?U7X20_L!I%NO
MT5;8IT5^U/6IN >"Y\X8HFKI^1XN<&<FW8J:\*!$Z&9\D75I5U/K@PW56TS?
MF-1Y(_AK"]_86$=/'W^4FV1]XM_BL_N_D8ON[S1H_X89XMDL"W)A]F@7L0K4
M6USQYX&3?V_4;;"3=1TCX&LSS*3C%O9_K-@5^;O*[/\$;6_A\@?W)%F(4OCB
M_!6NH+'BPF^'T&1G!UK]JV_K(^-^&.FT!QO0W="'P>#M,?@$"G";T 7!7ZZG
M /-B*]+CFC)64,1R_"#^><FED,0WB?N9BW%\49M@M&:@-@7(#II'$%FF* "6
M]5_^>PSW>C/^TV$7: GBK^ O5D<!0CFQ N3(_2@D1L^3 G0:4P"&Z_-:I/-;
M;/"YE"4*$)$S<:N!N<28[+V?$Y[=&(\WSF0!+V?Z%E. X[5@H@8(DZ,F"!]2
MPUJ0Z=WA^"C57.6L?US_']?_Q_7_+[S^7VG]NPW_=AI8_S]5OOA:YKZIOTH@
MAW=B+VN;XE1BP=&[1Q4O:!#+/RI>_I2*%VGHGB%YI6!$B *84H#-M*^UF%_+
MW;7@3,GC>(_);A";#._)O5]1 Z9C#SZ_F[NH_4EP-<;T]0T%^YA@U>)=-'(N
M"40OE]XBB,UZ\E1_XR/H4 _REDR/Y:U]119U4MI;U1//2"UI"Y"^09.0J#CZ
M4T3PV-,"SHL!J)7.3(PY/.0EO2$C?BBSW%7L!AA<S;7[B\CAL858+#U\^X,"
M^'[JI]ZE>: >P0'6>QW6IR8Z;%\]^MX*LUF5J!K;N<SB.R'=N/":B9YF,(SC
MN_\9BQD0YHYD5%IJ?,NQZ>6&ZLY43_QCPKK<CJZ>_/@[VNZ0S,WT5556D0W(
M2=C/HS9O/1OZ\Z6B3C(I0RK@'"W^>Q-]%Q,=G1FV$F^>I+ETUHVS6^D#:A:"
MN8,,22OH@+^H7)WH:IRPQ6?L$VYR^[&[BI??2)#BK7WX-D!ZN&!@SX]@F#I;
M\!UU8/,=(5D37GE ^DX!Q":_4D/_G1W<-@5(JL53@0+D*7Q%1O;P?2X1A@_
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M4P!;6<E?;D9D!7]RS%CFQ"X\27D++SA ?+\?"5YW>$\!=$J+-XKPJ63ZZQ1
MB#1O2.!\3 &&75T(+HU8>->!%O4,+280'BY_4(X(/2JDF]W6(/)2C0U /<VY
M>/.H*PO#- 40A+3-XJXQDX32ZBZ/C,*<-L(A6@?7)<GTYZF_[<_3D4+%*<"N
M#N(M<BX/M/T\0Y!J&94E2<*ZAS[__CGKG?#FCA$*X*8EQ$V:@8-)5TE@4N+"
M/>1C:)CN*R=R:Q4X,N;\81IQDRK;,GAOMS,()TE]^.6#M=V[.$.JO73"VU,
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M>)&52JWYT,M0LX?\Q2=XY8O]/13*=)^970'_MD:L8;:57.0-LFO;J?*%1/;
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M;2_RM20DU%R@Y;0C+Q:2E(G!2DZ<)T?1D8V]* !9"]&,M >SN\Q6%ZR/S(O
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M>.K"6'G9SMU@H,MB>QYE>Y77W7-&'.^--@1I,?AF=G#)1PR#]ER+G;&VQRF
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MGO#UZ;18X0AUKW83/?W)C$;PHO/9UUF)SSYXN)9EQT[_?%(2L\6,]]3!9"1
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M<W!NZ'-Z?NO%UL5R.52J^3"5M=H&]1H]^9142?-/@M"! R<1A >(O_DO_73
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MF7^'Z_9 UB6SJVM4[SD'0>[#[*E&KN)HT#JY<RA;=/W)SS#/"AOY(>24JOB
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M]JU].#P]!VMF/GSD:Q=T?=R(J?V$7/^9=V^;/MC(B\I;87?7SQM$/QDV\H[
M5(A.@D@7.%=*<BB"?7&3<S[YAIT-3M>*[%Y^V3/>PFMU+I#WE:!$NS&U2UU!
M 1Q7Q4P^1G&FIL*4.,-1KJ(> UNP);,(#COGQ)P&Y:"3A\X>]N(434Y]S?)8
MY[*C,UDTJVK85V^Q<W!8E- VB5B1)G@1)4G)X^R$Z(3PE-3!UB^+_'Q]^4=;
M"W@?KSP56M[1F1EVDW<<A2?#M$B$- \)HG<?[>)"NJS]915QV2,<8R4.1RMO
M7=)]7I2ITBSS(/@-R"X)1X5['_)USEI.*([0^X0^I<P]B0A#E&V'E:!(6:>V
MEQ\[7 :50)./'+DR[:<Y>6W$N:2@A/7&[9:6=U/0Y6Z&N)5/O(/)VW+W%VUI
MK#*-\T/-73K?-!/4]TG.F*E6/V.?EP%9U<Q+ Q*"3* $$T$V2PP#EW2A;,45
MAWB]2TN< !]H.18^'/M>(E\VG6<U6J908Z81&0/J?U>YCS)J+R@R1@>>(D/X
M)4GU^.M0F%7*XFF)$+&V(6WQL7?#1T;/7'3DLM+;L&:&[HG&,>U%"Z%M.IDI
M!GAPF+BXZF7=[(>0GJ&@/#/#_CB]MZ;QO!=.B!7:F]?2'H;/\0XX9=BU?D@.
M(70O[-*>O4U:4 R"[-B54%DQX,%W^I4#("LD@ 6/:7MY.4)DBAX^U'P:I2$O
M%=7>,!WEE;!]FE)%]87SPA!@3I@207!L"8O/E)8.1$R>TRWP5!+6HP7-S?%#
MH1(HU:TN1*V:*@AF$-*L/1%Q:-@CI+[F5(EQC[U.T[#'L0PE'[>TB:--\ON'
M,XZ.%"5+=@=&K'F/38\GE2PZ3S*45/YFL.GV)DAS'O6=!T4Z#VWJQU>2$B!A
M+*C&\DIO\1)N;=J-U0NZ,3-K*[0B[C5S"<K),F(Z(1E)"+A-<D=!C!*P_ELI
M0L?5,MM[5:+;>!2YAH(N93S63U)]/L$[HQZ<^"*T>EKA@6-PHJE "J*XK#$$
M^PJ[3UD/9Z_8Q*).U@J69JENDVKJ%&HY+AZNR;/AH^X8&CI;H\00/>X49T)9
M,W3X2%,%.K2D94O!Z(:J6J:2>-Z#4;7UQN,[#USFLKZUB"1$T Y[3F!#Y!/>
M= ;*)(89P-F'%^2Z%]\VYHJY/4,4?]F_ NMZN&H#MP_X.#>#PTD,86H1G##[
M*6T=S,164QXT[Z;MK(5<9&Y^PBS+XI4?/<U?'437IW>G4@^_<TKL7ZR6*:,(
MW" HJDN:]Z(1;T8VMT >\ZCWJH(4UP&TE< 03[UB1L@)[9M3;%_*>@U'[E60
MM=K@EFW%A0>4ZE:>/3OJ["/] [*Q\0U\J.8J?'QX-B^O+9]:,_!#NW#Q]-9T
MI'&]X-' QV%LI1\>K=SZML^:F]NBH]4IU+S/W1N$VK@YJ^=G)<Y;JK'"P4%J
M9 ZMD8=_$V"W+[:_>2\^M]\0L9Q1X14FH5<FLC^5>?7#:WD@/\VYF7D+,QG1
M("X]559/96X<5K#,L"-F.9]&CX<F<_-0TQ^U>O?UQLBVK)Q9#;H/HT096NNI
M<<R BK'-B0)#G9.7,Z9&,D^M;TH-+PS<'>3DO'RL483\\8#E<@;O5/G,90,W
M*%>YDF!_)JH1?<@#C$.N4'$L!C_*SZ= ;6[%G;1SAQZ(MZQ48A.\]NVDKT^@
M[CZD:09.]S %0GT-<_Y\!I/>DS#/$P().[\RVXNZ\9;/5-Z -30T)X-[GYML
M3]90NMY0T3&OL5IS06)=\#IT"(5K1#6OO=X%AYW +F/>6+"H_P# +>41:]GA
M:?S<&B+'F$TI_20T+B*<85#$-3--<HEMT0%6$_#H;?[$R;;TA+KQ(RXM&R+[
M6-K9'9X]TM%A=^%(S)" +%?0 3 FY8ZC"Q5UDW@LF/*(5$L^3C&EOJ=<I .'
M&@?RTENL(#*VXM@ UT,-Q,81NX(Q7FN>0&Y]S\=@*X82D0792IR$/<67!59)
M3RWMR(;IUH_?BAV.J1U3'EAWX'GJD-]Z?XU?T^%V$T1-^X[4"_<R1K^8N^+D
M3Y7'AI+U@RG+C"V>1M$G(.O7N$C'!(YX5%K@^^3E."647ZJFRWYJK;L%? GS
MG]JC NFH.I0'[Z(#I66O7%"'2/=-OO; )"?):B7]KAVZ#V*EL\R/&^]L7+!]
M.NDO"/@ XBVFK1_,-9V;*RD\1A00^\/IK,Y8<W2;;C,>9'0!58?F]=":0BV;
M$VZ+/>U?A8'R]VE]E=CT*I7;CCQU]?D$U+SUNI'%:"@_XA'Z&2BDD.)$XIF$
M<IMK\')N?Y%Q#^*J.X1S"[_!_,CDR)[!T]V]%IW#C6-L/_IVA')?QG#L2))-
M:$/C"J0A@BIB#TR^#[JYQI(^1[0O-KWKKQ1FZDV6E\[GL90_[..C?N3IYJRR
M+1F V9.T)RJ1 M4_DC>,;Q+;,F7"U W[Q-^R_)A>-E#2$+$LNZ%N)\A3:Y!8
M#-ZBPN5DWA53/[C&,7YJ++MR["S0@7USU$+EFSC4"?EZ$-]BU))\E%GQKER6
MVT@^3]O#JA,@DV-=#Z6M:@SW)4L.(VIOH)_;&TU$G[(X@#=H'?;(T2\C:X^G
M =8%94+9?LRO!-^.(BL.: @=7[K>8Z>T84^%)5$5W]VY\PD*<?!&J<'E2:S$
MTZ1) AVH<Z3<\K[15[U+_32@RV;G[%VQA?!74Q+84\EIU<F<<J ".:1+K"-L
M?T.$'(>IDMXA$-Z3LS6T]LJR 6&ISK2.RD<N;D+++&%M495.1LD5V?)Q1>CJ
MD5U:97QK7NJ*^.HV#9W?O*3"P=!I91)!LM!#\#95^?YB<?UM]7[QGKYZ[XQ1
MY9/-B9D/5ES.^E\7].V*!,>JGJ#FJTJ,D*P;5#E+".Y!)6.Z#?90"$O'CW1'
M=V<'GQK22KTTA^>1CZ-?KSX\IBF8_,%<QXJONRKO8)8*<L%R^W0PI9BQ,UT8
ML"4QA=;%DN,1<)M@Y.>BI731P>&=7FEY8<B]R!I-W(O)6U\O@YE!3FC])=/H
M?B6(5_P-V,K"%X8L"<K\1\\(;93];X'NW!H%Q/<\@@B5S$KEC5FWAZ?785?O
MTX&3E$]P[F;PNE0&;3_#J-.\\"F8?'+CX[\[F>2OQ#3"P!'@G8NGXZBOGS+P
M=A<&([LN_[]%P]'"4[H[7*!;<&HM<OUB!"F-74\-5K!]_1_,P]GW'[E&>?]Q
MO.%?^LGU?0._?@V\_\;?1,)]SOTKI_6/=*/,_I^'&ZZ=&$ $6GFXL.AHCJ5&
MBJ=;65T]XW?US.[ FV>D1)I:M1&M6OCG^15+,Y+^YK._V#A\'CQ3<\T10:IB
MO3#IR<Y FER?:[7Z38X\%$5HF\TSE+U47KDUU>=EI 7&"Z]!'.O)2UXTUVAV
MB&1I?$SX]*.9%Q_DTECC<WI==Q!*TZF?;*;Z\="!6RW@KUN+_=MGTOD8T/$(
M(G[N_G;:U*[9%N@L'&"HA>OP\[#SA(Z:& +K@QJ"A/\ ;KDB+#\W$97[9<1D
MX ;3VOU^WK<O-)@C=]G(3SP*R1K4&)@MBN1L5-&;/]#$O2(K+C<Y&7-3^Q2W
MD#Z7E:YE%V8&M8++LS'=7KF/"T&Q5DF;'DKQM\W[?E&X[D:(Y#['I,E7VP?0
MUV@*)N.V/R,9_B5]-\4W54_V]+R@WHPH>LU: XDJ,GAA5Y*[24%,HD]^CO9.
MEM2OQE X:"]W^1DX:U\Y*0L'#A0XKFQO/X7D7!H7*BOKF8KB<O76\4H+"_TJ
M]DG]#*]C)#C5E>1*OD!Y1D#753N#>U5Y;<)R29T-Q.X%HM*3C; :WDI-P?F&
M/13PI76S,T\J)4)4SU%S:0? QJ1W330A@EM@V3OX%'CES=="6\G*Q\$7^3FN
M[ENVX@8(M?D)W=K-G\IP;LX]]LZN[A2QB"%%T=G.P?O$^#Z0K<";,N>EA>,$
M]8 7I7$]WUZ=F#%QUY#KKHO=\XHI-(NA\%1=J.4@APBN><2)_)K3%*DJ>_%<
M/GO4EJBQ7YP1IQCSZKGO2C=6@1B>D*=[@;F$%]&7+IF54<'K\GZXJXJ)0O (
M/7!$\D4\8B5R@O5()XX/8DR828Z " Q;OR>];W^LDYZ\/RG^VEHTKD9T(8(D
M@E@)FT*'*<[F3(!Y1\_G99N:\)#%S=J,9Z)D737"KWT49:O6?+1GLBBYY-.G
M&;B16Z"KPO/A;J1K-Q@)+L.L5$]A_<<502PT_M'+[[RA1YWL3 L;"G5KU(Y^
M:> ZCKZH;[9OQH>K6?4"]C =L,^2Z45Y5S;77-<%M8'9]YR7_'#DL2,:M+S<
M66)Y<*,Y:8%_M@A6.#V&S&<WFL,N"Y"-82:$N+"3M>.@'ED$FZWT6KC \23)
M_N5GUW3:@MCV1BMI,GCWRA,I365O%K(EO"\67<1:/PC-6TGI@^EE5UY/-V[7
MC+BTQS.M6?BDZ+<S4=^>/GV[J#$TDD=DZ"+RX0_5J1 (/U4-KN)A9$;-IP.V
M@:L4@\DP2&-< LQ)BMNEPT0F4;L^*O)CE+"3(E]*!$IV'E2DNT(@,$]V-GQ7
M9B9$07*HLJN&=9 D?8'+=$ K.BDE[?G>A2AY:!O@Q,JEV!2:MB.QYB8=8\#1
M0?1"9D;K,R5KG(LM[PB-..51J8:_[.N>1PIX4-)=G&@P)CLS_>EJW\NG6R(?
MF:(\.'8NDLUHX_S"I P"&W,]Z@1DG!V?_#YL?U6"Z^: /K9 P3:-[<O5B?V&
MT\<\Q*[MOB-64,-JSL)[T7RYE_-*!F7 >TT6OMQZ5O75\T9'C:Y,_?.,N-J[
ML1=8!20;87ID>]A^/!U8GB.(7,=G!*15E >0C_'D)%8VCPDWK(C5?GA5%WK)
MY^,+8-%)^[Y6@E3BP&K;6C\E#K>M8-%S;_X==+7;FPY@P /(H3C#&@S:&AWP
M,CS#RS%SD=.4+Q?#Z>Y47-@^>T5+J4 X2.6V NHNZ@+U'1V8'E;EH@.#:&LZ
M\"FVVJ*L8<'"UAT1WWG3]-XF^*V>=M0M?[DH]8/!1Z0EOP&NY]$,.6@K,+(Q
M)=(8$<C)?YKT. L\;\%GABH8S ]. R_J5MK5;/$TX;;U)&NY6Q8ZV.=D#^84
MN=LT_C 3R%:5^1J+J1U>[OJ.[^#S6XU2;S0Q5F\XKG&#!:X+K\/RJ@J2*HF?
M\3KO\DETH/'T0,P+#-PU/#5WM'/?^^)X_VGW2R^^L47V,9F](+41BZD),'G'
M/-)B\T,,C-/[I-EX8S[V<^I,;DB9X]O;0J5SR4<>.UT[LXEB[(+7+^E "]:#
MF;K423V77/FB>,748?LA.IBA.GV<GYP?X\M#S\,']<!B\'&!DO2YY9%)%GD=
M_' =31(C3TTP\QN/??&9J?T!OB-JKV^3D^:91Y3;D^8BQ";29 HKU[PB)DQ"
M)O%3!U\C.I!3._PA[TE>51?/AZ]5U9IYC83.+8H(%RZZ:&>:J&!O$@]_%0C'
MGLJK.0 3(3"'K6[NN&JZ9$:^^7"9+=TZTO+Z5VIW>9/.L0,>*J(;$.)CZE?5
MBZ0CN%/O)M"!BGEK@3)>U;==$D?L;1RJ"N+3UK>#-+$Q3E*YFM_./-JP2*0#
M^Y4)<8V)*C?FZG>U:[*QAQV*$VUE;W_J'M"2! T;^VQ;Z%UP%P-=)O0Y;C@9
M9%S(_%HMC"$@_,<S7=+2SZ?5\)C#5E+&X;4,4X<S#&$+#;8 51%D\",+I6YR
M3?6:1>:EQ)0T6#+<V@EHD]Q]Y BV-YJ46,;AD*'CS/VR6?!C9A!.><SQIHK
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MJ?HJ=]HU.3536[SPK7O'I5L=!? GF7*OPO*9.:;0>$-04*\=]H2R](2Q,+3
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M'&8+]6DI8XC .;FQ;W]:,JE^^9I6F7%,S[FWP^H"KR'G$E^:7N"F_5G'PR1
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M:&[M Q\"7W%.:3[#?X%<YJGOO9ZSV*?Y.JDTA_5S=E0]C?%:KUG:<VIZU4Y
MP!N2O52M/"[#ET T!8,NCI7$;:5K5F2Z8#)@I8KD9WX[<,$-9X2<#X(OF!(!
M5D3 :S-FQ5E\_=J)C/+K;:S8+O8'MK7DS3Q2/RK0-QX__AZEHE;AERSG9YGK
ML,K3_99"B*886*=>'CNY<Y29)UM$53%5#:<[^*Z]LIPJX^Q,6H\LQ4.,H4 ?
MLO,G_:W?45E3Y37Y]W@O!XCA[*I!5P)F.'@J:WA!E9B^DH[^G(C!1Q1+(%4(
M+0DNI-G-TP:0DYQE%$6HA[EF.ZO0Y[+RI+%,K%#/S1G*^*E@Y4<ANB&0G0$(
MW1U\B"+C5CHGW+X+YU+0/+QAHOCM=#?/M^>)H[M1-X,#M.'5K;(I/:RA&==K
MKVJLP"[!4//P_JN)T<9/F-1$Q,1FP,\*,IU?C_)9N \93^*Q;@'S])A,C<<+
MG:V"':RZUQP+P>._O,S3(LC(W*/*7(Y/+JRL- ()5#Y8Y7D($!F9BMQJ/=8
M%V#"KB?KI/&V=KZB!-WER/KUHCE]-XMN$18,M(%&I#%CJ)?X4,I5B(NH_B(
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M.*IH5H\=8HMN3'+55=1]S$BB-'1]&G[)FNO'S6@+$2PPH"O@*C[I".^E@TR
M+5+>&K_"?>J4Y493W5OUZ=:#,D'KA]9D90N1KCZ%N:.6LCH8BZ() BU<JEW;
M34;#J3(@'0E\\O(WM$4!:HLM^FB;W*RL^NKE[DZ) XL-'W?Z891)%(%]!JM
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M]"@P$\=67)_93I,.OTML=(\6:)L_Y',ZAI] #>1_^9M\UMO0\73SA(--<40
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MK[\T83+8W&7(=E#37/ZUD2;7^Q\':_VO'I3VG[BL?'?W/I]O V^L,E%#=NM
M?ZB7X_RG<NW?<'$N%4J.%Z:K 3@;!<!>M*+^6(C]Y[')D@>ZAEDPVRCSH0%G
MJ$\9K/_DN<\'_V46L\6_5,K]N0"+?YQR4ACZ8\,VH/EG/H6_#F0V^K5,[O[)
M?U:IZ'_55:J*8R,C_"VI+:]IP&Z/S0^UV+^-.U!:#:5'1?N^@)>/*W[?50<_
M?/S;R^;]B.TD%K(BL6_:$L6UN%*TL%/RQ:D\5@)W.NOYTUNJ^V,;76YQ9-R3
MG,$\ .,-D)S.UBJ-U<2L5T[\;*$#O5I5]7T;>HI)<T>/:1ZWN!P2BAD38A)Y
MM1D_W$IEWL?60KF[U4P%JJO[U32=.B3'C.=YJLH?^\1RLL]>44WP+9B>5=X[
MA>" ?YG@@5GZ8Q5I +O:A;B)M>Z.[64<#4#?>PKM?4MF5;/,\Z_7+)'91BU5
MQJ=_E+@U;=P'2?7S)2,7@RDTX#":J$/7*H;TD'#2&T2^4_&=C7BJNOD3][:T
MM W6I\*8;6B#]<*!;G58MA;%>3WZ"B5;0]+![\GH,$R+<.')X<ERI[Y/?. 5
MD3)3\D54*?@NAB@NG*50:3]% Z(F[%-[IQX9$1/&C[/\TC8I\,A*W'#SL?3X
MY)K6QMG!^:(6NN=Q/B-9DD'<PGME&_1RV"W-.6MA<X!;H<=\R*+C=;,[\[XK
M/5I<UP\# $-4N7[<+ZGR"0J0V/MV=LJ,PH_X?6!]]8%(X^*DY.;=L<X_UD1.
MKVX?W#URC]TI-_'HF9-3[J2#G;^50_ZSIN\(_E"#[?R'#JM_X@2#O[>VYI\]
MM>AWEW# C[T]7)@?WE3^>4SZS=(DQ?]F>2YPS?_)E>=)?QD#<J/PK].V_E1P
MJ7](?N;_N!7@&N/U/_,)W!T%TL^_.VK+88_%?X.I,_]7UP^]/;NV) ),H-#5
M#W,K^;>>SO_36 BE1GD%"U9LH0$A<%F"?-&^AK*^&86/05<'KV F/U;.^^ F
MJNX^!$>@[\J ABTEU0KN2%?E=TER1DK"(QP=EC/&@E6H>R$&2U[K#S?E*1DX
M2C9<8NP46FYEBB(-KG9R26 _^>'\[1-C7]Q5(]UJ3)L9'T*+QUF)?E.(\#I/
M,Z)]ZXYON--]UF2%+CXWV>1C=O$%HHGC:&7TY#/PT0HT"UF/  K=X)NN3&LS
M?9TF]N2U:"JWUU>VS>>V=]1];0JX=ORL-YV5"Z.00U5(["1LT^B BF=!0ZDM
M,;XE4"Q&;JL,ZQTD=/=3!_\X=>C49>+9$^BS:'?$D,D5HDC!0H8$_JF^\U3)
MG;O5*89GS%V^ :-[.+H[&"*87ID,W@=?7Z*K :*$=MN*.$QD"L/0["$X_#'E
M0Z'5I?!3!Q(4?QF;-ZMM^FYB#3^<<P42DM>_V%!'^6#2VVF29\*F:)+I"P_6
MV'JU#,(;TH"(%.@1L#WK<?=9Y^A/AW$WCV=[)=O&2&HBLSU/T( FYP7F;3'J
MP:275H[@\LI/R^^ZA M*K*Q:D3C-*[AW-."!5BL>55*XSI@LX4M%0MLP4I[^
M5[P0NCMPND<%R0B\^(.7_Z\FZ6;L[T.D?VYCY1^:?.F.$X0<- _>Y'ZX+?_O
MC7[[_Z7#X>]UH\JGX$K<J>S(0TX[Z,1-Y#))N92<3E+#2+&XCCV,F>9K+M']
M2A5'=,D2$)0'J^#O>@/RV=.ZQI;9GQPU=;/O;+J"&&E ZQ1X,0'QM8L&C#XM
MH@'['@F$K3[*E@X0:7L.WM&!"L+?9S#U:(A2/V<<Q&,BEM$5WOI:A,RZRG5K
M&=E?# 9'8XJ5][[BVGE%-Q2,<Q1DJ=2X$IGU9/GKIF2IN\0WI-B^)]L/K9].
M,7L8.R/ZJ()3,3GB2GEE'\C,=+E.@FD0ZW%Z8#9G%9^Y$)^@3O81^>4N^>PW
M'*'QW0RZ9>J*IYER/2^ K2%3X!4[O/3$I@^QOX"HVT*]>?FJ66;#FU180(LX
MPW&K^PQVQV+NG[]_[WP4!4%YJN883&#9],3O?UOPOF^1A_^.Z/H5S]X&VS8K
MI.E0XD:^QZ.%(#._ZCGJU5+'2Z@W*<Y4Z&S@)ZXUPQ4&.@>.X9F:@P-76X<U
M0SMC-TB*LJ.==BK-CGL?AL7F'7\S77/]UN&+QT(D'Q(1]"\[X>&U19K.N(G]
M3AI<E4]"*'7=!)\#TQB"RK;'Z[V4QYW#98]N:OJG&>@>[M58R\QW4-E,Q\5R
M?X#TRMSZ4O%A,#DHJ-Z>33"_]?C3N,Q&%R+]J/>Q$;WP$)Q6T62)ER9!<Z H
MM\)9;C@XI[RI?1HBH#<J*2SH8]3M>+K6<"@'=7M5V*YL@XN+8-]I2!2?>$3E
M).(0K/Z(5A-BKZ68+'1<BE@1)LZPG16S[1D0&L#T+29FC_.H"]@)RB33) 3&
MC==OH@\1 S>E"",3+Q6E1Y[?8#^2_C4JH681+=O4S844JUB@P(,94SVO66:T
M:\(#_1]2F;>S1IP.IXJUJJYHM8&272]#]'38^H_R7: !C;&!,LT@HGCU?0UQ
M_ZC."]CO:1A&)[\W!UQG:]/=S@QUM;QZMD]"1]U\S\X3"ZVG7]^<N"$B-+0I
M*2@NCT?=I[OC^2!\&LRJ!\9. YC[EJ'#%@V!D!%T=0-&QKL1^OPKY9F]D.\W
MD 6IH*QB+E=RW7D*U>8^Q+\^G1*^_)TMM/%,&>%1ZK+1T"(/CS&O2/UYX,U9
MQ66%\+EOPN#P2HF#NG4Q25BW^KARCU?BFD-;"^5@G?Q2",ZOC0:PDD%XUZTH
M-4A^;EJV!<!_B46U;,J(T_.CX07PXU.-QP@\9*Y5S<HO0G(R82G#21'@,SMA
MQ<D)H$)1XP<T(-C48RL]TW+KQM .AR;,'F])90Z>9(NT/O;F,UD[:]S_!'7M
M(B</1W>U@F47PXT<!KYSAL9IVIZ2\S0@=H*OPO ^\C"JP1''8DGZ)-U])2M!
MZIQ<PAW;QR<F53.GSYQ?]RYZ86?0?5,GYNF(T?P]&L"/=HD/1^_;&)$Y;$4W
MHF[$-]]F5>UZ*@8.X\^_OM:''HLX]/!A\K$8<4%L'7:2)THM.&\)*E0)YK_(
M^M[1S_I$L/GQ)]<-CCL_/&V\EVNLNFK9'AU(>4Q)HP'.[@?@7UA1J%#O,7=#
ME=/W1Q$N%P\%-4R<=\-(FY^/ERI_X2/DK*E#XOVT6K\V&'E=MSBSD<LY8)%^
M=,(CFK ATA7XN# #)7U#7$[<IH8 CGJR5R,I[USAR(S=+VL91YX,[G>[>&P/
M_?D,14R64H4;^X_*L)-5O\@%[5=2M(#GII0VSBI$26O$IKYG]Y&/S$X-;X,_
MZ+':W0$782U,S)E2!1TE0J^'0WI0$&_(D1E/E2+QKV;"S(\/J#N_0SL@1TR:
M0>6*D15C;.W\D-_6>E7]LJ/9<%2+(^@4;]<YP:^&%^ 5J1XIDJ/.XU8?;";F
M44EP"1K0K-DH0);'QX=O*$GYL+J;8^6(E9+!AV6DE4MP3_8>KPW^6); ICD>
M-"V(32.KTC57A;]V&_]W4VLIO-U6Z)E<'\TO4NZA.]J)L;TR*0+[A#;#-/H]
M\L05.:L^1^K*ZC3FC=^8@@HA=D]MS^JK'I0[#:@BW_"0N"P<GOLZP.;,A?UW
M%X[,",/O*#,[5Q$K">6M$TQ4KC'RA2\#2S<^2_4>9.@U5;9-.NESW79T,1LV
M.>>G2[Y(C)U> 7> !,F7IU65W.[T;K#"74U/V]_@*#94?BP)M/O=^GY(*ZA'
M2VWCZ<EL4QH0AHRXD1A[\'H<*F^Z@$32]/=;GB99$U4WD0U8UP:IW*5DMJS.
M0XGI=P[8'!(]PV.?(CGW37!.J&C4R8Y/6^=X@;A+@-^*.*&:RC<W)5PPC5B&
MKM" ,CU&Z&T29*AZ.Z$X8%U!0[8>[#W']17T!KQ"-RFL^M.LSI=HP"-)*GO\
M\@A;%26+!%F!VZ]R*:RLB72.=WL&>A?0GYT<T)JCL!@]]*H'4<3C&HWH'-:F
M&[\[A#S*?6WJ4VV+VYF%009N*32@UWW[261B[LOI@8F=&VB1#8W&<Y0<\&3F
M!!X#YJZ4H1NTED;J!$GPK-[FZ@JJW'U=A"T6:0^S42*-8H<JB9_HZO4T#4BL
M((A1 H80"RJF+,2R>&TO1)G8$#R?XDHTG$83+4"'R+*XU=<TX"["U1$_$1S?
MO0Y#REYVF:CTLU&_IY$T 'FZN\!HS15TB,Z%<AK0HV>MY[Q[:Z*='^&$S+Y3
MH;CFPJXB5L&K [Z-VB_NKE7;KPA4N<VI>L6-%166@#<CC7/KZF72XP*]*!^=
M#-^@1X-M-+G6#.@2N.\L\78A[$(E_I$%3S3$N.8+5E?'NOO+I9..OUR,Y%$>
MJ=GH\!BI]&I7[KJD6FXNSUNK_F2CDFL67 %:V3<U,53=;#I^FB"?7!!\VP.6
MS"*<R.FI*VKKQQ@I>K&:/6-[QL-:QW77QA$-/?"-6QVEJ?U/C:RKD*[9-YL/
M-#8\-Q**<4AXL\R E?X(+'RY;]RO4(=HH@%R)CW9.S0 FJ51D(G6^ XB2G:&
M?]OX_M",Z)/O6'=>HR_8N?#DQ_>UI Z.HVSY;-O8"I@#_0P?PLX2#:?>GJ*V
MK)!M\A<WBP+L\A9<LM@5QP+2T?U[+O(VN\37CY=>>VKLZG8I(='CZHYG%/'R
M%(K,E=BB<8K R8^(A@D%3 F(SYAAC4/(4$UN T5=M9JAZWX2 @M0GY%1S0!W
M3OR5Q(L2X7%7!L_5/7E\4>@BYU<#(XB#KD?BF\ $(Z@TO >!OP8%R R$?9UA
MT^4-!/O(DLX=S?2'Q?<L%:\E?!QJO?7]AHM?N[\ODLZ7^V\2"-RD*=O-S=KM
MG&JL*63O$&O=0[J"9WZF^042:>S$?X7"F=F G02O[*-[8<.2+5(H?]UOIF96
MFGXVOB&J:3H'WIES'E46##.^OO[P\86O-,!A=9C4/%&^[UNH,RY=T0J=:!;G
MZ-H=SWAN'_M35O3'I+-PCQC[MT>C8YZ>1']OD=)5ZQG9T:XU@DKYKU.9Q?$?
MFL&L9%5<:+@)&DW85W_3C!AL+%]_I?6-^XMPVTB]X\T?. 8%!0.T0^AB5*K!
MV^_S;J7!<%+J<NNP2PS/RH!%R 3OFD?MM&R';UR>H\T\J_&N6JJTX,!P<4G.
M;VB0?W5)D+C8HZUFO6XX=)_,*[UHYWP#8[/!/<5LK_:COLCUE8O+]7^FNZ1A
M/\>19/X<1_(_]OJO'T?R\FWY0^/RC-[%DQG#_L/B=SR2O&^'9 <>T3?4E/IN
M\[92>T9FY0;I.#%Q,YB@V5W[:F0,ZG]*IV%)77?DS*;:C+:LX"N3GAUAY6[-
MRY/QQ-,\'>[[AC3O#E/0$5*OKN77]1=^G&0SYW&)W;A["@W-CCT5F_7D1D_8
M@"D?H_#+J#5#3G@7B EV^U[?(IBMPN.\T,=-(_GG-HNPA.=@B\V"NP>;3=HZ
MGTN_1:#.MY:DZ%SWN=<WXYYGN/2.O$R D#EMIL&14M;C(\:]9(W2LY@<L],P
M&UY6\<?Q^<U;I:!)5).A,/S+N$I EF(U=\*H>W^#?C[WDQ/S9BDVI"[9'H:N
M=]W[KU# GVF #2@D0ZB>I(]J'9,V5Y=)M:R@!P*G?*&];Q\:]+G*!?&>*9:Z
M_:;\P25-=W?>.*4OWLPO;['=MJ# 0SG'A=.1OC:4=.MR/0[3I3?G&@Y.OI69
MPCRL0!R:?[W-;YWB4O59G-3&\$'VVT?/MBW1U/',*/Q7,65EG;'RB9CK)[*X
M;$.B3A><_O&8?^@.5^V<6#N*KZ8\FO[MA/_,UU?_T77XA[2"_!_>Q/X3\W8_
MI+UOQOZX^XG.LUI$%'3M*HP>9]P*PE".;GR!R!#TJ#KQT31@F2V !F1:UQ)
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M@245CJK-8-O9#J,!R*.DGJT2+CR$? ;%@_C<5X*8;'&G2L03S:VE:<"K/+I
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MJU<O*W2(TIA;B..( 6TV0 CTQ*XI4"A7#A>CO+[AG-<.?ET(19^[]5KBT>E
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M JYJ,U^PZ"L/?S\<-S!7"_9@S!"R&.9U:JKRR:SUVJVU/9\_\#4B 9]!-$K
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MM> <=EB8V5WM+U-/,B8J-T&5@0P!F?NT/N(%71[BFI*2XS.*[4I#89@(L3[
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MS[3E6X=Z;H5**=%[T<I&P)RMGD(7IX_7#222C;N).L#ZW3T%SA@]9 -2XH9
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M/MY7;[F7')Q<0E63"&<=@5BP?B!T6;^9;\LU0RVLM5J K,'>GW[1SH$9HCN
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MRB7^2'P[)J4YHGL)&)O7=46_WUV3,$&]VW[P$<MAZT.MOE/1E<,V@T@@:+9
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M5\,E3#*8"K7 5]T>:IVI-+]='CFU,N;OLA<4ZCDKI=(78TE5IM" /'K$;;H
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MQ(GC?"AO-E [SD/[S#C(C/5F$R;<A@^?&GQT)5!PR4JN1H&SXVV96,!SWM
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M&>['_J> ?*3$'S<U =_A33V'H4W/ND]5ODW IU!3T'=$:IZ#;JIF7PVQ6&8
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M+CV!>ME+99<,+R;XO#J:*Z C_JU82X/XFP[Q6I-^]M^(X2>ZF0Q]D+ITJ3+
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MQ0?QC&,D-T@OZG4-PR?OKFGA=]BN"_F/OLD>5Y5ISZIX<I+97.=ET5$+)]]
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MZDN'#W_<R>QR2?0<HK]HY=$*U8PB>J#V;\RO_[J=0I&]=:A^8A?++*A*PC1
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M(\H%(H]<MRMXXES)\2 ZX:JR-W#J.4.:B_M,CT1(>-Q<%Q\-0&XJYHIM#K2
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M+E@_OQ5"*7KB*2KLT]/=[JM598*K$I$?"F9=EL^:TL7OP3D:$%N!@U-<:VE
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M5K]/6JFXFI@%=WY(S33[?6M73W;?+&NIO$H%X?C0VIDO,_ZS]K'3N$]&D;+
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MD6M:#P+P3 P$E(KD'A&+?\XB69[U<F@^K08\2X.GNPR5N^]TSH&1>X>H[PQ
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M]::I:2[J?HZ96;[COKGB&K$R(T]@"%D*,6M$8&=@!4PC?,( Q+//HBG\S@S
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M"]3KH1T,P)G"I6&K!V[TOL'S<R;0 5ZG1L_R9X4VGX1/OP:P?"'. BOYFH7
M8RB\WD=MWKJ:JD'O1\@'@Y^S)#T-SEZ1!>:-_V25^L+=):8R_J/:W'//$G<=
MH8W#3C^O=U0>I7GI^;Y8\T+3@CO7M:!]D9AGD#!1.6(X.KP<Q4<K<ZBMH0BK
M%F1/ [;GHR%7PCI9%J5$=BSEX0HJ^^OYVI?LXT1^I?/=^%CWG 5%\C4$$K03
MR0<$C 'Q>I1F<-:*XUDE%/>JA591W>T)ZY=ONS?JR#?U?>U^=&W8C]KS5>99
MIAEXF_>!6W4+^&+]W2WR3&&()-0B/ MVFVE#X3 )\LLY=W]=OWQHU"++=DZJ
M;F7LTTN/AR OSZB"1B=!@H<:)D,\E@,;BIE13\\NGOOL7&T:?\'U^$G'7\H_
MUSWG@>$(PATF0R&KKK4>=KY5V;CO@+U&>;NY6(7LCFVQLN"_&/W-M^98/%YM
M63F*<JFFA+NU1?::':2  1 KX+I\9T'&TE@N8VV'WCB3$27W=O,_"[+\;SZ'
M+S??1Y9F %H19&,Z^P0T?EI^/UVXSL8Z?YZ6;B\>NBS4 VG"C@2\QYNSVT+Q
M+8+8R*V/*MEY;O+?:P2: N10N;V(4R.)5K>^>W1"ZQ@ QSH>:=DX_X4R2TI?
M7Q]94K$-LHX1AB8T6YV=$[$<@Q0]1(KZ2W&RU.CWT<K0_37BUIEN+UBCE'YU
M HY,8W@;!<D1E!FNSBG)PQW_ZZ+ X=\-V]'1'<+M-^C2X!WT$&@</^<$NT%+
MAYD6V$X>"4 \NWS917=XZ2!0AG3K-P-P!/VM-W=G),<RJ;%?O'ZZA_"4L)WR
M)2[M5*VO!D8"N^F.^H3CHYH&$RFDB!&%70)6V=.V=,R]Z\NB5HNT 6W['%T2
M<X<:3)$@&\Q9,=D7*Q3XH&YH_5H?1Z?@A':BN(]&:?N/))Q0:+KY3=]7V#8@
MP0P3@2"DP)YK7ZA^'QP9X14S,J<-+C?Z^!;NZ!Q\UVK5R]'+:G6ZDT-O(D[J
M4''M5W0CT#K1WE2/J(JQVAZ#(</@2HAFK481F!;YX1R&QWT<&R6)&?!?05^(
M75T=RW#3$S_)[LTF_$)L#2P'[\:P7H/$@ODOU\N@[7&V[H.V?1HF.8;OI%U,
MFXXNMPJ0T$/(<03=%#>G2'N]B=FU0?=QD:40U"\=R0S (TH?C<]! "[;8*_U
MLM?*Q_;ETU]^I[5D'TI+ZV,343B>U2 063*PE5WHIP*/(]$'ZN!R%YM4_5-=
M@ '01PO\]:8(1-<M@A4M9($!Z._ &'CNO*>?BF$ )-B;P21VYAT,!'>>\Z>,
M1GLI>LJ-,P"')EK"EJ*)PA)N9JJUX+ /6V-6)#'"]4[%L/-P.6P%^,RXA[*#
M^3&]'/NFN!,&31<T+_LA7X'<P62IZ60"9G8Z<VZ+96T\?-[6]B4VZ08F:;/?
MY6C7)5F E?JX55RZ_A5SYN]-$JXWX9B_QXLM1Y^96KTR9<Z<$+N;1-[ GX#Z
M;C^D!V1#ANFTQP;ATC"M(9C8#.TDO4/DGF9J'<VNQ\JZE.UVC$"$';]XU3'-
M0-$BR :PB+Y*K7),HC<&5VB. ^\=UI(J%ZM^M?Y3>9_>T#50M!7\[,Y4>9IO
MKQ%'C7C^Y.VZD9L:(F^&#HG+<KN+&&703,I?37M$(',-2S&"YY$&_?(N;]PN
MO)%H*RB_L-?")S4HMP;.#EAT^X*RM:\; V/! YV.YK_7)7Y73#5<QMB%P[B9
M\BJ0?P>[2B()>-.:I_+%%P1C<\74E/*<+D4S &6)3\1J)E; 0=AY-/7<T6T3
M]'AHFT]-]\3$6%MZ#\D?LMA1HY3B4Q =DFR"J:.SW]GL'$K4O#P9.+&%F'^E
MN%Y'.;Z"X6L4UIW;XEN[D93*F6&],I)B$P/LL91;-.R-^6"H=I<%(+SSIF64
M_AO%U\A.#>2!@EI?]99?$]%Q+1_^5O'T:UUD:,S&]NR'Q$=LJRU?4TFKY-"O
M4//6='["G9%IO@%_!VWVBU)C3C7IL_%71":["[^>/_XZ_VIZ=D,HR9<YD^\\
MKZ=+EC Y=5N_IY_SRTNMH@V0,R&&(K%'/O.QWE?KNIOU:F=B98F6*9A0="Y+
MQ(MO(F=VX'#RX"=-_T&F<:#%P/;.*B;KSR&&])G\S8> FC%_IVGB85J97=ES
M(OWY';_N6S*'>5XX@B!UC);  +A9TK)AP?FZ!1Z!EK;:J#.U0PHSK?;&FVVR
M<E<N*)]9MP[=-V=1(4&HY_)79FGIZW%";*HUWLA-S;S4@UPTB"FP]4W4&(C[
M2>?6:9),W>CESD-L7'+/Z".YN<=$1USR0=E@)]HSZEMD4M[: 3U.4XC40DN2
M9P">T)QOU_2K"/TV:3W,KVV7( U>XY%DLW0YQ:E[E/7>GT.K:5P)HMT$\QX$
MV'70M?A<'."EA;M3][G75O^]D'WZ?,=/HTT_1P.F.=R*,6]!LJD#;ZP%Z9"N
M&*'F92.I/%+WX[3/D;>G;##]>[QI#VA_; '*3/+6.2^;/Y0D)9-H6]O-A6 :
M(ZA)S$P-UGTF*R-E8HL!D$/)T_NG58<Q3\W'S>B] Y;IJD/)N@,7G%Y<8M.L
M:-JHZ7)"C)/00>0:)BG!#VCR$$(ML.6*W!ZODM_YI^K7U40M.%-4NK].78CA
MU;W8).Z:FJVQV.A%^_S1 UB^](:9(NOEBSOE>*9"D_H6Y?;V.Z\63K,1CZI-
MQN1,RHA^[1BN=';,=C".D>4< 0<7,0 GZ=]G<@<[G3RZ2QNF&A01 R,@+09@
M)@7$"[F&>GLCY_6FE-O GJ=;?65X[.W JZ^M<S=JM<88@&)/\/=$\A:%%Z>-
MHIA#N8<_!TZ9L$U,:IY5T/Z"7=?S72H?\N%.6<7P,@!'VUUVO#]^/03UT3E:
MHJ31J5J$_Y0MP&HF!0-RRS>>I2H2KT<K_#$YCW26Z&XQTQP#M$@&>?L6D(>Z
MC:_Z!I^*MD^)6M4E*N*MWL YQPP"\*!S[M- (YVG&;7)RL8L%G$*#D1Z=\I.
M'P=\"G%4TR9/(AS99L=:+#QK]LW+QQ5(HZ9?,Q_!*-*YJ-I$JXU!RFW[[(9B
MPRH^3\G,?(]GJ?0^[^^ N(MJQRZ_+?CCIE6P#!SWI+,A/9D^-GN I?-/0]^W
MC2<6EA3UQ@0(.IC?T#B!8XU04;?0D=4Y\/6]VF=P*8>_MB$H&/<9>;T\(48A
M<J506:)-YK)9Z>U5 0?.AV_FSP1%-1,Q;8JGJ2K]O05S14'F!'I:6@;^;K5U
MXH3 >(WZ$Y* RO86E2='A]PP8WYRM9&7_&ZVAZ;<2JISZU=087/&G9^#_53U
M5N#+/!W-]>G5J6W<A!Q)A[Q$I."5URQS3#"$4LT7*:[UKV)Q/R8(H@:Q-S%7
MU5^,57\!*+^YK^8[=/=]_QZ]E@E58K_4?%V0J#)?.UP.9J8E+E8:JG%P'M'2
M@H3[H-8+-E#[V+BJ/?13 N@O<4WZK:P(Q76/YSBN5;;Z/+[1G3_:.]+<7<EZ
M8,:E0L @,3/)0 ZJ"*'O_C"P,Z4]ML+-9?O]AEF0=:&@ZZV;TLZG\PT[#UOT
M7Z4<X.EL>?C?!BV8<A(R4R= _!7DK?RFO,+&_ISZJ5O;'6W^DP)7N,"?8A<K
M<LQX7:7U5A.9SK>M_&7)3-;K*0. ;EE:PT35N\XR[7$EU((H69=-#C)38@V?
M+@@4*;?K-738O-G5C->*>;*".0_C+H1"[A(Y47B1HTSS&^SB2\DJSCE>.3(/
M,(S7<\I_KM.LU0[K8\8&,P8@P364WCJ".3Q>0619?TDP:$-5',<V A!G)I\B
MN'9K.BKRV?U/#_3..NL!"/:%7N65MV9CV=34^M\7YG@)@Y=3J4*J!1(F<0VH
M@W*,$/ ["5,5V.3Y^[G[5:K^#[L,.OBS?$7;BP.FRVWPOQ>EE&PYKC@CO/)M
M=%ZZ^O!.9;5<_C%Y<Q8?Q_K3]7'S<5]6=!=B(I#$VX]XLL7J+BI'R*[(6[6]
ML^_4LHFSO%I?\O/GKUBTX(7Q%U<NH%F$OV ;&8!F2?A%CQO[K6@^L@5I85/>
M7ZY:JM2&$Y:[=-9;9[DN0QYIJ5+X^-3'!>D&9\PLW?VSF46.=)Z\! WNT3DY
M7EGB_-6]ZD9L3A DQYWTTS5]<_-AE/2'@"=/+DB+9M=+6= :&X^XWT@8[2.>
M'5[4'[<=;]F$EFV(/R_EWN24FU4DR_S5D82J2\8$$G;,:^,TK\YV69ZL"(]5
M0+\(V9P)W@BOE-Z(T%H;^ZM.Z7@J86._M<Z(>F_NMP>V@T^UQ<KN"-?HAHOK
MSUO1X=_'S=@X:SKY"_,Z4U"5R2VD'3JFIR%&\L!M/8D&PZ#7G#<A1ZB&A*HV
M&I!BU?**CIKCT%0=26D)2.AYYN;YIEM5X\K)6F-J(NTS_"3]#^@(YBGKEC_H
MQ!K?C8?I7\=?Y(F=J"P?NMR6ZM"?+2OR_'HFYXQ38RDS02'A?U)0S<BP2EO%
MR.+IUC91Z203U[KPRB[(L]<"::S+G;[26J%7A5^[#]^+=I;6V'F&*481@DYH
MNYO=3:E@^I0C*MEO&'Z1/@IFT>9=X_I.3NA,"2[.$N)-&AE01[N$1S[\<!/Y
M@Z+*X8]@IX.H&N1?:"8X=GOOO^'[%!LTWK:H$6:/][LUZW),JWL.HX)PZAN5
M,Z=E4(%!>$7^-=NDSQDJ/>-C=BOZ*NDO[D#BTF\_/\=3SO$]7B@N%@H<]YM1
MK:#PP)S_;%*OSK%W5G[6QF5Z3!KX\(AY07&0X]'1,X\3.PS$+=-[S\3GW%ME
M +H9@*1LV/87^Y4BOH.)'9"[2^+%F/FX$;4_YY\XOP:L&NT67V_%"#6*0%LM
M(XW_P()G@R'W/UV-[3$;\2J6?/ZUC/>V;R?@['.UHS5]H1C>9#QD?24+VN.D
MYY.[8D'+EZ:OVE\J-6:IW'L6Q V.H',,[_V6LH^&^MK,#:,S$\R0ZYE*U6EW
M3 4II36.Z@?Y8F:.(_Z.:SM8:I2?8[>*91]A@MHWX4HKUV:KBDYET@C"C]V2
M@L)&HTF)\Q.'SAL2FNGUP?1ZJ_+0N+B?Z![F^C&I)==;05 ;%\L:_6H#8759
MM>K#-&[EAT./Q)\'&M0,3=3E^":9UKB0YZ;PKX-?Q/@+-!HSHK-DM"[7GCAW
MSSH%I0Z?1 C):PM03Q&]LI%X#9%CG;ZV32.J/KAVT:_]#2UB]?<2ZJGI;K\R
MH\^RBHG-@<F2YFU%QYB9C%_3+9_<TW[#^ZVB?W1PG<.0<]7.PG7N$J&%QS5(
MJ>)7*20<629RG2DEFRHR'^;, (0EK.-&;;V*DDF*HX$'!S43=;T[)W%[!QVM
M^Z]V.CM0I:!U# / 88KG\+S%_'8RG1NY/L%52<M<!WKN@*!Y59!446V27\)@
M%B2LJO%P#2$!V1[JX?4V+$X&(^IR<-\._WJZ472X,&!KE,0 W!M4]-H3T5XE
MM7@&U1E96F?K2E^,&_K0%!LF;-6'(A@U>)H3-K#M7B8/&RL'KZW9:0A(U=4G
M.D5)<*G:I+T%!"4X=E*\H3QT7L0ZN_,LL KAS@ XI2EU;J2;)RZ]].:#__Y=
MI;:2L(<.![D F<#"FI:EZ1<\RQ]0E\;5RMV2?/CKST)H_E7KCY*WRI)>C-N%
M"R'5FNMOV _C3:<<UA:Z*RCOBFGC9J^>-M+=OAU&8ZJ035984*E!FQVPXF4Z
M^).7MUZC'[;OZDLH ^#Y0FMM<G?*K,]V<&-KEU*M6.A]UX3C=WF(X<(M)0%K
MYM)4H[O[)G1)1YF9>_V ,,(E0#9Q'%;<N% ;.W+89_TTC0%X^:%4GYCA?!H@
MJT,9Z^/79GKB\01R3.YJHP 1';*E(!@D(FFM6'AO0OMN*C21KS_P4B6+P!.M
MU<>L#\*^.)8P &\.-6)]$]4-/O^5E/ITM]+LK$O^7)M(,[C?4#583G%1Z@L,
ME&T_9WBC3/G,.:[[CGP!%!CL6-EPJEG"G$2FO=RZ(F_,Y(>E\8=O.PP:UZU:
M@00+]#B[%7&IO0<9*>@Z5$*&M*['F7JR77"83CS]BQE!4T-RM5B=IQO\6D $
MHYBC.[,-Y4Q@^K["$RQD;\?&/U:HWS%N:1]V]2/N@L5SPX!>3L _(FCK8-\A
M Z"P6 8K(YD@?E+Z6N!7_]2_S- MA/I9EV#]\TK/[IBG/8F.&_*VT#?P&0K\
M3K2*K@?-.%SQ<!3'^N.XW#MTSM0->^,KW[_L8F_X*:"FZ5:"[D2/!<XEOT.X
MX,;]Z-PQ9BN9 ]^',3_V)B[,-^'JM\-F1)?;KCQS*3;01U<RH6@>;OO9#\3H
M*RP#<#,IJNO6F3P6:!>Z';U3G7==IOO+\!?( 6A;^UTJOJKU$^QB'C0+YC=+
M07.N%)[=LB@;<JJ.X+MP)JSC]\Z7:.F#6/TCA:AP4#FNE2L&.SA*5FPGO6JG
MRCH4CJM[+<G>*.U4$E.*CDX\?AJ+-V]B "*TM6C? O@;A<AF#SPE/N^]'%G5
MY2T\S>VL;-QLM%)Q$X#Z-./KN0LA"='>P70I*M"$-OI%HL/B^[S5?<MWKCDB
M"NXNMZ-+7@;RO6,5+W1^#3U9Y9_)7M,@G[.WZKPA7)A1T8C!9N<,@'FTU:$L
M,QOUON2^]E?>KP<4R%^KDY5_?IWY^,YW77E2!GUM$#'S%0@(\&RK")T3J35>
M.E+LO_93C.IH^-!@SA// )S]J[T:784*)N])EA%/'3:YVU;@?R.*W/=[U"K#
M7 KOZ<^"O[)F>K,<W\TD5?\5\V#:9!Y"!*4=#B1&Y*K8&2"]46@'NROUEL\+
M2X['JDX?\^[\W8(J>BQJW6R<B:O2#7QIVH(R;Z.I]@?\UFA+>5B9\QTWX9'B
M-?#R@Z/-K])VV<."O O(K,?DNKG.$&W@M*[;'%( BF@-]#-8;(<4K'ZP[;KD
M$M-=JB;NPAVW F;BJF:Q^I=Y)KG0M>8=A_I:^^>Z>1-V&JZ/$UX:G8J=>','
M3\FH 9+E JE)YBR(46;V]Q;/+^!RLSAC9T)%K1;JR009FIDSO3J%)G"H/,<
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ME&\#2=["$@XSK[BTS<]\^/Z\.9(N!N9 LR%+DB$.WB;#1<#_>V5G@Y-4F%!
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M0%0EL> B,)&X#IO@%]4I-NQNVEN"UR8$9?^\;#P.9WN$.7X$JV4-8B*SD!N
M#JE(&)P!D]SJURL325*]7CN*><^\WF8B^>>VVMD'1O>'6(_2GX9V&Q=(C=:!
M)$ X$G.>O)%QGD M,'URE0#G#NV'EH,PC#@9M'1J">D^X8_:772D0X:23^G2
M?<W1;M\O$7W/.[IJ7*L9TE:.2JH[A+#Z0C,R2QR6<$[(LV&UIV[^S-Z_P3.Q
MJ(0Z_JK I'5WSWMQ?SE74.5BF!]+>],LE7!F%W4^-T>=X*0D-SZ*6=G?\AJ
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MN>3H]RO6PA5&@=[AGL7?*4[3.M<D+CJ*Q1(V<:.=T*KC=BF^B<&'GL-AX.P
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MMMPW#DM!+F92 ?M."[*TB)0$/37E5*4PTH2#:-@B]!B!/*P*\B!= 5'T^#M
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M^]!&W$9__^9]Q?+SCX_VFQ _@$XTD+I,>F %BW8@$4IV!U3#^:)_?77KO?.
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M$4XTA1-1\2.;'5#<E"0&\'@4L'*6C?XMX\D]?"?Y)] !^/E?22<?;$FR?4G
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M;8VWQ3"8&I V1PC"W<PM1F]_[Z58OYO*"BF?LOC:4,87[U:OC!\9A)'X?Y&
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MUV$Z_N8.X[J:[CWJM.K'>B;.]UD69TH+"E2@S8N[4^EJ:"!*N( @/G8@6]$
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MI[8*O5EY3,_]Y%J"_%154Y"X:6OGYD71QJNFA[T]5^1QU8B01!JB-59<S6A
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M5Z2M1*80(X*UY'-4YJ<2(14#1:5$[70N,W$3NY>F)6]3C1]S!2<P778E&)V
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M0XL#?[2QO="SBLN3H"2J\Y[X4@YS&&'G<FS>K/#,F%GIIBSOO,G=QG.=I53
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M*B^ON=AM="+T<H::*15EB&G__)5^MVK[+XV_U:KMG\BS_\##[TRCYF0-.PI
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MW6X[9*VXIZBT)Y=V!R=R5"KB#&KE$D3697M+\DIV]45K')R%P!ZB:*6\YAY
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ML2@6U'WJ/Q00 8EX3JJMO^KXQ,F<518JXJ1HV6+HHL'$66&\.R*8]A\6C+O
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M5W1!IJ($M\R"OE>?A=W!H6N1M%:$E$:?H(51G5R:AQS>%J3A:;UV^66ZLLM
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M@S3BWP6M;%(DCA$U&.RLCLN!F.V,I DP >QX*I#Z9*:%E8!X4%>KBHO+>%K
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M_V&A0G(H-L!E]+1%")7J>;%CEKP5N.ZI-.?V-.LI>V).;.5E;0! 3HVXU)9
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M?.UXIJS/Y]3]?O_?);S\)\V94=$V*;M%@'.M-/3^4#J.<%.:?.6G("HHO25
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M]K;K?I?$T,K6PH4[IN8!SW8=A%OE+UO>T#O](/4_^XW:_^6,+BL5DDJ+)1/
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MQ1?N#I&\WC$!1# Z#L3U-',0PS5;J@EJ#"&,4BT)3(#MBW-LC$,)/O8&,TS
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M(6FR<HLG+38<$4S/)AK\0!^%GB0JO]W!'G%%C/EKE'?[> OAENKP9]_^2P@
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M&&G0-$+S07.T_>8^XF, A&C,\[:KZ(I-8''KUMCS5JQBVH4+D/O"$:]T)Y@
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M/KE_B_R1'NZ+B,6M=T9KJQ09$-!\MM!1[U[>$)O:3KQG4\=2(^!&Y]WYT:A
M*\;)D#F17=?.=]HVV6/+KQ;P=_AM>S!]"IVBL0?S<WVCR\<$!@VNM!&6J5>-
M]6H3XYYQL6^3D^/1G[IIJA2O;.@YXE,$(8$;1_]\M]*6J],WJ7XASW^C)TB.
M* Q@7V'%Z?)O"YD%.?_?/_559W,%G/[.\%'\#Y?G_8<K!A=0\H'6FYU 3J@=
MH?ND9"35:N#YVMDD0G1'A3&'5.I9/B%%E5>F6J(KKD4?'N3,'J2(7#4R>I[P
M&NV('^/IQ%<R 1W=0&%*LB5QF)SIZ>;-EE9@9VNDOL_O>E;[1-W\4M;N,J+6
M92T*"1LDH_@1K7LX4T2QZZ;FG8.JBHZD6V=OO7*,^WU+[H4N:1%5FE.=,67
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M>>,RRT'I*,^&=6.-[@.B(45<7AH\5+.ZIAHD*E(WJ*0O9/&NHN.MW*$&JM7
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M6V*FK:5A?"W6\(*FUM%QZL,'KK[_2'6/46HSC_6:O7PBS :$ T]KRPK=-7\
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M(%]!E0Q$O1P';6U2>H,*"U5_QS_?JOQF75:A2U0HHH$%II@,#,0[3J=-*3R
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M4R"<35$ DU,[4V]QL =9ZNJL,)@ +]*F66'9TU)J:#1V9H9].EY'HZ1=>W5
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M(EI6%KU@!.91[,7H";:05$Q?R$^)G@+J"6Z55ZW5TEQ?'T[KE50LF-5A@R>
MLI-E,8W!Z-':<MA318W,AG3;01\_QX;NID!N@ )J-0#!CWP/Y:0L:T?8.BN9
M4<,**NV+J5W%2<JL9:4E ;<L5=FI1[\F:_#%$S 4393Y7*G46MGON7_D3L3'
M%-_;RQ2L5SK!(H<U+X1G8;,1U[J?WSJ$L-Y"OO>[',+RWB"1")FMWMQZ3J(
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MU.2!9-[SN@/19(>BHEQ_UH+UQ#=2<#=8_FRSM8UKJ%9I:;8).H)>Y,OG0.!
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MMS19<W. I]^I7^T\K,6) C!<HC:C)360D$MJ5.&]1QY=PM:1]'[6Y/JZ(Z;
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M$W&H^>N<H@_.]^AN]/H&O#F4I,(E596+BA'@%R3%1ZS<U;\DMJ7M_%YF9T2
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M%?3CLB9WP,_>.MY^&=D-B#>"R+KIRM\HR?;C-PLS%:VL6?JY$&1AW7U^-RA
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MHY#Y!DGBJOO$=<ENRUST<Y'L]['3GS_&MM)6!<CZT5. CS48""EF$+;VJ*1
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MG!VLC>7L5GE_0V!#J<JA]M4#;?N1H=2;!;G#,\=FD5<0::J!_P$IT$X84;$
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M;.E" R T8,,0L?%OM0,M_=I+5T1S(3XB\N(&R32 !K0\H0$_D/=I0#T,T9=
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M3_;/E(19EB<J%+Q]^KA,5;O_XU:GY+6Y#ZDQ+<([E6Q@E6O>)K U T5?&A"
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MFW)HNI]_U.:6K1*)=+6,$O#A9,M[?M=Z8>=:AKJ>JR*$Z$ #+ARO!Q'.EM"
M[ARH#5R7OKY@4^&DPV.(A:)'J>@CY+-3H1J_#9*O$Z0&I3C>=\XMO@37"J@R
M:T??[WHA&\([?3,?-95!CH*R(H:DZ$69<OQF@62T'@]8$M&UGJ39ZV R1KS=
M,P C9=KE3=OD7W0)D^E[5G3V%5/?X CTB"*+#0TXL?5Q+EYFS64WBG)^G6L8
MN6L9MY RB'XXQ(*D 99VAQ6LIIS/ME9&:95&+AR4&:\37]HE@Q?0H8FBR%KT
M21>Y9=6-=:'C=@Q^OKGS/(%E/.%84\[62/TT?C3NQWQ=KX[]RP4]?&PSZ@CQ
MXH8&.*$<M9XL]ZST:\B]!WOL0I<4AW]DN(M/-[^I<O3@B\X;*Y'NX56U0W"&
M?MJ[S)BE.-Q9#%?_:?1.6&A#+4W?>NAZ9&Z&@)_O"9W:A\4)?3J-]W>"NDB0
M::9:;\C4Q5C)_M1K(^X!DN-LK:$UKDQC47W\S9E[ST A^:*S164Q1U.LT]\%
MR3^_JO>ZEM%SKF:6>'.JO,H"MWROSS[!>Z*>><6S*(7MBG?' 3)L'A+.K1GN
M[W.]NK\Q:&)QT%=N..^XQ--;+_,9+C.>T?TTGY7[M2=:-O]-*/A27WIV7N?Y
MY)K&+I^CY&MX_4!8UN*(=)R-"S]QQF0T)(0@^'/2KY:I#/5IFP:\J:B)P@NX
MJQ\9\9C_X!WS]&KA[9=W X< IP7=00OYN[::]9:5GWI2+M4CG5_T&0RUT0ML
M^2[G<U)9&1[) R<&I8M,?R:4A!2]SP?67AR")TU5MHN0&C@B%V) PQ7Z9)/1
M.+X?VM^%"H2%468W@ISQIW.$.?-\G2WNB^A<OY0<M'CU;[V(I;CWZ[J$T'P=
MFG"LF#Y-+YM><$+\\;H-*A;9T.D).0:1I5Y&M&CBW2@!XI MI\%KII _7[;9
M@4OCSBV@!7<?<E$W'Y*U-ND0%?=O_?5K6H3UX=')9Y!3<U$F@Z?17_-2-WH
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MMB/NWA8Z6,!9:*@R3X-B?+XW8$\4"]7" G?@&1C'@=?0,]0N ESH,35CB$#
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M^O>#-OM+'1LT8F0+C"?L]M>U#)7Z07<1L3IT[8B(X?@H[I5Q*N=F7.>T]/I
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MHUN5'@SG.1&OW*.-'\P?^#K"W0[YC:. (=OPN-Y:2?HYT6:!C.C-#<FTIIQ
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M5([9(L8QT#'0^W>C- =&GC^'=[EB>Z;JOCRBYLL2YCZMAY+&%G\8E>V!GWC
M&0!L'*Q)#30?YX&CB"2S<6"VX$=F@?G .I)QK3!M/M^?@ICW!1+)/8@#\3(V
M0"ZS &25$._U/9JC,6FR XZOT>*3C!Y],5]+LW67>!F0*A2P?QT;:$=9@=PW
M PN+U'[<^D/DF>2DA)C&9W.HU=H!J"@#_;2N% #VQ.BL)-HG=>?IID<'E(<Y
M.39SGLI9,!GT.8YY@T@N3HW_M<\3_N677AW]TQ4:WB  65GI:36L.RRW*WR'
MH&DD]#C#;2D%[Z@GZ"+YYQ D&7A.3H):,+<E&/: B'MWF*K?\3#&"/%QW[CF
M=_&U?K\K=K\=,FG/)7FB3#("S'$]]DR78@<I3_>J;3(3TWF H,A217]28\&U
MU+ZYC]C:_@+1OA^RW?/Q'8LU'2\8(\+IB4TV"^RT ]R_B8P"[78/LP!&%]$U
M5&F2\EUJ*7'N'G9'+&%F-.=,E],GH%,BX-0)CA\SBJO'M=?FO2>CF28>>#C#
MMX(MK^TE434^YRZG)B6AIGKY%G.M/*<KD3-P"*,!>G4M^Q#UIO?Y:!_9N-HV
M\M^!P!-2*SQIF]V_-,Y/'#-X<8 5($(H$E3C.?FH _U2G8)0@E'/VJ.TT"+;
MV<06Z6LR,84ZYM_G>)(3!_+"!4CYMXF@V# ^OV]4"K/#=$C^IC52;J[*==X!
M+E1SP7D 8W?F]E7TPS'VJ&8SI8@_<OQ-HW!GM#[H[$#<@V66]%8!&<*3</0H
M_]MPK)QSZ"0DK7UH+^4%!9VUB]O1@+QC <I-6X&O017GE*DZP97R47OBT+_8
MP,0KBK\O%W5\M+G7?T'!++'#5TJ>>DVR&7BJ9782\=[(6XTN5C8],7YCQB\8
MZC!V87Q8W:S/5^0"XYN.$K2?!>"M\#Y)MYPN6MXK>2]6<UTF1R(<_<HB7^[V
M*C*Y7<=NL0'./,G' DA06  *?Q73]#Z*^&RXUM0 ZY]/.,<"?! ;S4+;:L,
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M$WB"V7HQ#4E<FT,EZ)R?@AB&YMG$1NE)SEM_2[7HM00%AJ#4=R#W-UF %Q[
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M9VWNZ/WBUN W.2'2A@*VUV=X3SS[DHO:@>LAG:,6PF']2[8T=3H[R-^";42
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MA3BGNUR(LYN2PD_?2-L\V'=/W*?XI3Q5.,?XS[&ZV<>RK5N17$%9)"%S8([
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M6$^4@XHS5*$DH<G@_\'?#QO.6QL:/LW-.&+P[,CJ_:NMN;EIAFI'?]0S]:=
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MVQB?L7%]3]3@Q4L_4E^!CN2QU=,NEN*![TLAK",QPTF6F9Y%)1[/0D_,;^J
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MY+V^]TX]7+B6BE96F>-25LK3^?;0J?:WD1*WV=!M)J;$^S@N98]UB&V?F?!
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M"S)'0Z"Z9NY@^UR5#6S!8737IH)X(7("9D-^^4<[7"<1\ -/^VJ5\AR)EP*
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M6HRIW]%,E'MX.J"URR4,R7ISW*3J+-_ V,-TC1=QY]00GMHOU>\>.=/>L=K
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M/-7=3?0H?]X'DM=\#2-=(-'2X0V0YT=<_-%Q(_N>J?O^5+]S;(Y[TSSP0:*
M(GYH,RS'6\RCK-/Z]1#(?L2M$%.UQB;;I'ZSQ<9D2)G/9[7T<YGF#G3(ORWG
M8\^M.YN6BJ;A<8I]3BVC98O%OF\0(E4[.'9=R&OX,P[B?D//1ZM+_30.;\_^
MG>9JE:P)H^27 7ZDZ-X%O$'Y/=1'>Y2@5%=:HIY!MICIQ/ZVQ92/Q%63T-=Z
M3N801MF\#VT]ZZ-THUWJ]C%_1Y[K*%/[?.]_>WH<^,\5VJB4O#XX"\R*,7[5
M7$=YY"AX;/I5X(M1(E+$EO=.=^MO'Y\LGB_A_(\-XA:&D3X;"Y6A)D]:(WR[
M^\*&Z( F@12R[1,"-)7]Y8NL*RF?(]O<W ]/'VHV^O9[QS8>JN4B/;>';] "
M/U\ 2T/.4>Q)S7!)B$,"<!0\>K53/EQD#(8C?[S3W=+V> /.1QOL)[$U5'N^
MEPQ&E)W]\M(<67%@JM?R=GRQXJXKM@P6+R+28M!U72\<['-BL[#<J6[+N6U%
M0?M*?5_/;9,0 ^KO1ZW=/=Z9Y0RX34Y#$-NQM*&Y%#9U_>TQL[*FR/',5VS]
MX&%TPI")QHQ?JWZ<TYUV.@"CACY%2IC/@0N2.LE6\=,;+^9?9%4D+OD\SF4_
M.\*]HJ.]MU$"'Q'P"EX8 ,]>:%W7=UIB%"/?[Y,CVY@G0]92X08_O1UETKS.
M3!MF>/I#%KA=SC][GF1]6R$T_L-&.D[<X,U*2BG6''C'N'>Z:#H,W31G:=PT
MH/$1E<9Y+D?9)YHZPYRCCR0=A^V8PT\1#-L"8,99Z_$=2YHVMV*[)BM^684G
M-K0:1'_U0OW\=6O:HG$P;:A Q0L2<H V#O>!R\6+9%JAD\&-RRNYJT9Y>:#,
M*Y#R6C%GVS:0R8L&A!1T7F<LHQ6,CX$]]E<4F81F-(L'L:I_@3NPT0(P^-.X
M<>*PDO8T\[/Y  ]E!MCR')3H#8H,E?'FK2?L2#C;.&2Y&+W0 ">B8MJWP[5Y
MSZW/94#%Q/6G^^H2EN"!+7P/ EIGAGF90,YV/O;#84/BD^@Y.N ]Y8X\HT!D
MK0S/'"14G&*=D2[3.$C&<X,#X6])"6;%)-<9O[H''< 7_05@+^>""L]>CG-\
MKK'O2-@FX"G:97.*-.'%>HD#</R"ZIDV%K7YCNW1GV>6H7:+$[>CY@K'YZ9Q
M0N!F.N!T!*OX1?)5X12A))URGZD7A8\L?*!1R<S@#:RSZ]OF):[<I^$(#_Y)
MK'%A KHMH2GQ._/UACDQ;00FH3'_4%RVK,S%TI<?]?^D&A4SR+&QZ18KL?Y=
M/R0KPE;5_]9[',1EQU/Z-4;RLW1\_?H46CU'?/-:666DO47;S5?\_-JG?]XY
M!I<=!0&[LBYE:/?4+=+L4E@EN@6O+9JMOEF,1$-.[8O@1/YL_JL)NK3&=L&E
M9N D.HSIZW6E-BK>G' 4S8EB:(39DMIU\-7EAB[0"O$QHO0G4) YZMH,\/%!
M\>)<S)Q1@%S0)3<].:<68^6CKZ7?37/$/PAJF5G5#A*^9%P]!+9,'&KQWL!(
M%>A<?)^R"-4P16GU;V(GU%79C0>1)]EU50'_;XUC@"+.$"_)LT RBRE#O"P4
MOJA&!&*V]?\4Q.=A8"I?7,]'&@L5N.#YC Z8<D"$P.U6LAA%*@ X%#P'_)<E
MW%Y_3M2@)/2$0(C2CHA#0Z'7'/N?:2</@;U?7&;T=R&?=%4YTOK_1SWZ=WNY
M"]P0*_!VT:2FR>3IL#L<^N^EYAV+E_O]HX$OYWB'*$%ABG582.[HG5]?MB @
M_?2XF;AK$6-WS@49ZP=DNIU4B;BAJJ& KN;[4@L>_KF3YN<N!BDZG"3;PG\G
M /E!W*,-LY5.Z81+(=(6(_7C+S3Z$B[<YTV/;_RDPWWW%& !_KJ-+ ZSC#6C
M=0)9:Q]*5!S K4TJ*WJH7H)=;>@-/VP?\/B?0]RJ>P)W\[1$VL8$2?$*)QKR
M31\+UEQG%GCY2JY]&N>LK;BP@'S.0!$D17(TFD%J.5UVR4*%8'"I\;O'"K7\
MLUP[@K,_8[J+JQ&&$1P*>:.'%"*Z>C2U@GP-=GD(?9)RL9^B5/@KQA%WLR+A
M7(OP;H4#*RQ+!0_H5I@P/Q8)W7E ;"/X1T6"'<"\CKZO\E22)MILBU'J]E<>
MF43I5LLU;-Y!V9*6Z8#CE[&UKAE6]G#F?DACN;'HBUB#U.="ZVKJ5XY&%%UL
M;[_ITR[J@PK/RSAS'U4>+UP>L4O&=%%Z]*]VN7(YEKE^J1/1._2MP;2V;4H&
MTP$+8:L8HF0;'9#9B+E D9\3?]!H1D,6.,A+VN6L[F3]KB7LJ>M_\C]\LP5Q
M<* #\/HZ/TD2XPR]A2_8/U#T':%FD+VXFY_+X\CRY:[(5C1?7D-OSN,ZT]^F
M2N9;B"6[IBIGP>-J!<H6XK^=)%)VO49+B-@9YE8MI7E4TUFQ%CDEP<IH6#)9
M]54R-([IUP-<^_/4W$X_;"2B00.\,('9O VE9**"P39TP%BL$35IKT[/OG0>
MM3+V^8I=?]+ZQOI2SH&0\0CILC-SY+WE;X7KQ!AJ%68V#<1'!S3>H -.ZA"9
M#U\:(Z"T8;+.!(O<QO;%PLTJG(7LZXN15Z4RZ\:S5PNS$X+:7164^V5OM.[&
M5GN9FP\?OO("XY](!JGK$>Q"E+T\6)\-/.-Q2K[%):T1]"G*XV[&JK@_)UF/
M-GH)46)5E>YP:K9A#DJ]/[F9%>X(M"$K/P]( U?[CW]$/'FUE73 2_2CUKQ"
M RC2Q?BX[*:B7 V^_@F+->#X5297P7(O=K*2]>GS<,*LJG=PVU9X!5( +N((
MDJ@IH?W6_!#)Z\<&[KY$2 >P@X:ZM9=6[EA;&OX<:'YQD"OIBK"J6?-D<*RA
MMJ6XVUQKB)K50F+?J\U2[.#A/$V@B XP8+ >"3;:(BJ#H?@Q8[X]Q(1>C[SF
MON#@LK,2BR_BFW!(!V%YB\SDVM+61Y^L@0W8)(H[ZB7U"\+A3,]H22M/9-&E
M&(]U,3*XN">;BMIH^'+K92R\;?%U$Q=-VLRH:Z7:C>BZ7^U(!Z $+;J"\#UG
M)7/TR[3$\[#50^/6_9B9#"0+8O8L:1+X$9<^^GP.^OSU(ZZC<[<$/[/]V!Y?
M6T+W4-]C%H:4S],!+LA#<Q68"ED;/AH/*4T(V) QK3WY1JR+M\'+Y8=$OL3I
MB"S+TSZG/M5'S?']* R; 5/8S]#8$QI3+C8@\.\03@C;@^G5Z7$!]<2E)]O4
MGBM%$21RFT)/V8L5;/R1IZ[[GQ,,BW6VZ\)ODUC@TJ)I]P:H"V;5U:/"L76X
M$8++6!Y-6WY.A!HD0O-8-!RB&!*PE)O3'Z>N$B CB!)$V9; UD:J2_*B\YUQ
MC.-F6^%QM[C5YVFB;ZZ<<HZ!O-MG?S&O?=LO,Z ./!N,NTT0F1E^#PJ;V;J
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M<_D(V95D*$X<XT<^5-F/C/4A)<GU):!AL"=,_Y_^/B.:E&",[J4Q&*.($QU
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M^WV&B<3L"B(6K9KH@"@&(63A)&!I'UPH>2,(PB$F7Y?FL9^10=9DH@/ LW3
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M0'(HG,(^ Y<I>K_L-[90[;Y[W7##G <M<ZC20DL&+\U2F=]Q %+NXB9PW0R
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MC,4GRUORTON@*80DK5S7HB0(3 HEQA<7S>I5[,QTLYN)\/OQ_$JLLOJ#]QV
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MXB_^XB_^XB_^XO\$)QA3_P502P,$%     @ -$$(67HLJR(,RP  S\8' !4
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MN$?S/LL8__8B'$<1RB+H9ZE(KF<A3%A*H>^FQ*,)H2Y&JV:;A3EY0BZ+OI:
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MOW!HKI,&+O<0KFGYQ/?^L,;WJH?]F<=G5D4"*A!@H3OT)D&'@;HU<([Z:;O
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M[_Z<IVA=AVI;1>9*,)<M"M=APU$1M];#9DI"5'%_PH_L7?F(\V)%,S\,,H_
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M&Z'"6QST; <-MJK9#O,P2T_Y"#X))$"/A6@O^\-O+=-^'#0@N)[FFK8AH<\
M2X:$!N!%#0E]AAP:$@8[S*UDKM.ZJ;C0K6A$,BQ:>#LB]H^X#P-3YF#(?!82
M$GN^XVA=9^BC,+-9\O;ZZW^"#Q\__]=7\.'+YU_!Y]OW7Z[O;C[] J[?WMW\
M]>;NYOW7G^=2.ELVVU8^)LR;70F!WWNT+#HVYCQ97"]M$?A.]=,A@\SUU-%.
MAD''2E@ C6PAW5P7]/T_-OF3;$1-:2XLV7KE^VX6I"B$F8]B$8A,19:2 ]T$
M83<*@RQQ,JU Y"3(F?71%HY(@WSJL)%]UEB/BF:T<IJ):MK'+FOTM$T/^TJV
MT6_'M&SA7X$M!A9CG<K4VHI_3@-<-B:JS("C.*GZDP87(OV(HS/%8A&*/9P&
M :0^11 Y/H$Q12YD:9JZ01!E 5+*4U* -;,FV$[0LE)II\([A0L6>QS14P!;
M9NQ5VBD5VFFS0>-&QAX[S&YHVICF((F>_XUNOQN!U/"KL94[KT;UZ,7.Q!;+
M7?2HT;)W\:/XR&6)5M??\GJ5$>JRA*7031T9,TIAZC,$ RJ:'V2I0P,]ZV:P
M^7))5@*:88J5Y(*B>6)(FZ8AHDJ6<7+5$'_+J55RZU=)K!H2=2ZM:F^-J</
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MC#P4Y;J\?VD'('7GDQ^$84!\#'T6!! %<0QQ' ?0923$68:""&FUT)^ -[/
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M%=1WY1OV_ANK2%XSNN+B0#P6(!A&&$'$' 2QZQ+HIU&49I2&B"@->%$'.;,
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M$H] Y(IKV 0E$*>8P8B%./ "/PTP635E@]=J$C4"2TN^MA"5O\,]R&!=UC7
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MB+V$!&FLUWO+'ON,.FQ]W&?;U2Q<4U/"]CBAIW7'.F>]G>"&MI)5(]*25IT
MMJ@:52/\4&\J/F5P0R-R.;_N6LM\:0J-"7RGGYY9U[7IIP.HX MK-E6A/4+O
M#.T*]S87DZUY<V-(L=ZMS2A19O<VI[=<[N9FE*2]NYOQE1=GSK6]?6]D:^45
M<TG*"#\WG83$$ 64PIAY <2I3V+^,^3K!9[.P%DZ0ZYK'*W==WR*76JGI@4F
MZ GE?N[;UXX)+=19DMU.D64_P6T/RFLEM9TB=221[>1R_;/P_3^:E^L_*EI?
MT[]_*+33T\X\/G?,0N9:MT&_&G#0F[J1,9TK\*$LFZ+4B6.<X\#TD6B!>#WQ
M4Z![AD2Q"3*-3LES>RYV3$X0-3PGIY::CK%J&TNW7>,^Y@6[:=ACO6)AY'DN
MQC!BL? R@Q F(6(P1=2C7I*XJ:-5['$&SLP2NFW?WK4P_%T !A*RYI7?.3ZI
MG9 6J-<342/"#49AC9)E;2K6:2@+#\@:)?5X5M;X<OT3\J:H<[[RKJ*WY3HG
M.:MOJY)<T_*I8?3#&M^KGI63&\TLDQU\T,?$>RSDC;- A5$Y'*K#2/T$G>;0
M]%EJE3EZ(JO)%_"[0,?2V:I,MM$I.[W[8N>M,J'#DU?]H4O'99TM2$HHQ13%
M(60(>Q E)(4I=F(8A '*7(=[K8%K-C;KE8J\CL9GV2GRTF#IN#*8AU&&A_B@
MR.NS=I&7*7],AVW9X)-98Y@/F.P:5/+OIN53^T%M/Z3].5P"X5FF::F5QZE,
MU7K=LC=]RLY/V9JAZ$WTX:7OOS&R:?)G]CG+<L)UD<$-PN1&,^M#"1]L$0 ]
M!B97"=-,F3:$K/)#3^U-LV*&VP5E>HTLH.G=%[. E D=6D#J#QE80&_+0H37
MN+KG?Y.6EE3[VTA;-]HDR6+D,NQ"/T@(1-0A,!9A<#_T(HS=*'1IHFP"J<&<
M6>9W2( ]+';17XU#79&+"E:/?=[HWNY/L65ZHHPQ?S2L'OM\,C-[OHBYW+4L
M2Q$=\/(B*ZO'EF.BF1+."^%.-B4@.\:2/<9:'\RGQYI16TAQJ^6,(3W:]JPA
MS4=G*,'MOG(4H\0)XPBZ&4H@2C,/QK'K0S^+B.,''G,=S1[&DS!GUJ4+E.-J
MC=BRS!$]#3I5FCO#1"X->I>HU'V-Z5T:+-"JVK6B%63?S#;;<^7%?D@8<F'J
MB#H5SX\@]FD$?4\D91+BHDBIA_&)O>=.?)!]6[$$I9D>.*!?38(-J=*3U):@
MZW&"]#/\CE&WE<XWV'G9W+UCDHX2]4XL,7!'N"PV54X:1N7EQ&]%WM3R^N+S
MDSBL:_G3ZR=N<Y%<'M]?\ON'1O2F/7BR[@Z,($FRT$LQ#&E&(4*>&/SM,8@3
M%"5^0#V?*>4<S8+=_,=R![2[?=L(A*] V6)[U?T4#Q &E<18GEW5P>,Z_<:M
MOT<%U^DUWXZVB=!S5@($$M?VIAETV':_&>(+6H1E0_/#+6H3M\SZ6])PX%[S
M;9FY>C=G?3M\?U^Q>]QP66K3<C:%""9B4#]Q[+.\&V()4]FO@ P;&XBV0+8<
MO[E8.NHB6@>ZG#,Y%[_VW,[9@%C*S;W>- ]EE?^3T96/^&'II3'$*4+\K$P<
MF++(A8Y#2.0%GI]AYZ+\W!VLN4W5PQQ=O(5L,4]WP#HUJ]820W1O]([S=<$.
M\(PIN\?4S96V.X#TNJF[QR1/IN^>>,1,M/^+"<W!Z/4SJ_ ]^[01ZN)S]BY?
M;[8ZY/.FJ1MNW/&#:T50F!$O]&#J4091G'%/- E#B%CH9TX0)RS1ZIB@"7]F
M%=!C W&+CF#E4"> <H?*%: MDN;*09?YF1<'S",()E2R''L0(^I 3+ 7QRYV
M?2_4Z8(_)_/U.^5_Y\Q7T]8SLE1/@_>(@ X3T**R;9A5@\]#=G8(VE/LAHRP
MI.QUH2]Z !BRYO!0,-U&/V?CU^(I%Q7G=_DCHQ_*2G3&^BM>Z^2PCFPQLT[_
M]=/MS; +@L0 <*]LOUF<S&]1S]@88\FXIK#(#3V-H,,(J[FJ"M0:Y6B,[;M8
M=H8"<<.\#)7EAKT^A778%F36;;W/BI PBA#RH"/BA2AE#":IZ'%%6(J9D]$D
MHSKVPC&(F4V"MI:W'H#]W_\2>V[TKW("EAB&=3 TXPVN\J)YV-3@32Y'QN$G
MMFER4H.G=7>ATFVDV8+SF+EJ]L!E+-,3\'.31&ZQW78$YVFRU:7R&,"R[2;/
M$GC4-_+\RLLG&7?WHTX8H21!%&9APJ4X]KC5S^($<@<,A0D.8F[[FXXO7BBD
ML!O4JST ZP1#U"3O,C)U[^:'HXCGB-6?HV6&F<.O$XD_1^#8=&$KEYO]Y)\N
M=O^I+,J^?\C*RQP',Y]!)TX<T?X^A*E/& Q2'-#$"3T_]5:%O,6G=^H2. )2
MZ1M-VF_T"+!&5*)% +")SN_:'%.3S4L98%BNU1'=0;T"0[CVA%6!.$M2.P9I
M4?%5(/E0CE4>L5$@?8>_=2#>L()E>;,BF+(@#C%,2<8@BD@&4QID_% EA%+L
MX2!Q]=IQ34#4^:2-^G%MRXX:_ VD+=!+BJ6/>:8FUA;YH"?:A\73'/0V<^Z'
M#OKYZ\$+JZC/TCE+-?4QM%>LJCY+^GAU]?G'+,^ WMUV["II",.ADW CVN/&
M,T09BV L,GPPR2(<.]R:)EH-A72 SVQH[\V(5AR-?#E#U73#7&S24Q2C,Z3W
M>J5:K5>ZA ESCYD^!?K[&#L]PA3E,=1C>Q@JFW;D@[R[&R\.^) 7N"![K:-7
MS''"P",!]]X3RK5/ZL+$]UWH"N<BS;* >+3W*!3USR7X&+@;FBJIF[-29F>+
M6315TT7L5]15L[/43'EUO&RO[*=*KJ[ %KE!EWJ+NLP&DVPIMXMP65;;V6#;
MD?JSLJE!ZC7?+F_8Q_R9';:H%@:>2$.[?BRK)O^GQ*+KP/HWAJM5[##F^6D(
M \PM,)3Z%"8ACB!.4T)"G[DA5DHDN0R-F0VR]W63/\J;05P4&[P6O0ZV:/27
M+U*>Q2>MD81KSO=Q#;@<-_547XL2E#@=-;F70U E7F"(V+81,Q"X+<)<C53F
M19ALV)5C/F;KY29?S*/1)&3SW9?+-KZ8 WMIQ9?OIG=$4):OWO/SJ'FYII1_
M</5;T>FE>EGY/L%9&"$8A1&#R \]B!,2PHBX,8[")*1$::SL.0!SJW4)$G0P
M^:??0E53,6>9,JZ9;9"JIW-UJ526[2E21I)!^*.M/<C_LC,#SVZXB*!.D=.+
MX.0Z _OK(]^&L?V&]^^_-:R@,B[TN'*HGP:A0R".B"_\30<F,0HA"X,,>V[B
M<H=4V<R:@C:SV'&VY4(Q<3NJ'=S!]WC4.-<GF:5@&]ED@9XXMI#!T>")'CJX
ML\P-#6/&)E?,;!8!15PRK"4F?Z[!-IK4?2NL0^<*Y 7X\VWQM^+7XMU=\9_\
MCZ]_!FV1UI4TQ=DW_/BTYIS]\ZW[M^!7UW_W9U#M.G;PO_(S4F3.82+O-<J"
M@1=^2/*G1?.C1^Z!/8CJD8*"YB'G2UD!*'ZI;55LJ3)[U/B9W&0Y&T>5GCU3
M1ODALTL^[DFS_+XS@<C+=C)8Y/D^_S\3TX\(1$$:PX0@%[INYA+'<8(H\W6"
M!V?@S*Q(.ZB@!VL\5NT<F]2NV2P0K^E%&M"M?2\V096E&Z]S4!:]RYH@]?"6
M:FJY@?VSS?<\2/>\79.V1E*4UHJ@ &>@VZ6/I0GQ,2(Q]!V/B>K^"";,]:$7
M^2F*B8-0H#3+S!2!F85[/ 6V*Q"74\\%6N+BR=6P&DP8KF!6S<Q&/35AP$&3
M0GH35FK89#.SU,Q,L_EQZEE-%[!CU) RV7<YV^H"JO?,K4OV,2QG$-N^$;T/
MAM4I@W'L;UYV2[KXA\2B*Y'_A2]LZIOBEE5Y27^IRKI>43]T*,E2F$59#!%C
M*4QH'$&6$1IY'B:QAW6LMQEPG/EPZ/N$W O(EU1/SO%ZU*S&5V:ZWE$B,8$2
ME?TJJP&^8K3X<%T?YI5(7_6M7:Y B[AP7UO4Q4\X\A;K.N;CK*W"D!DP7+:R
M9#X6'Y6FS C*4*7C-?N<R9(9T9[X<W;'0=3< ^#@WI6/."^X?YWYOA^Z,$XH
M@LC/?!@SAJ&//8>;ZS$. J7 @#K(F16N0$#67,LV3;^W,#6]; 6^*:I.J]S0
MU(1ZC-!77LJTV=)%TP"752W*##C2%.I/ZM>.WQ9U<4W_7M]6U==G\K9N.D]&
ML6[\S.,S2^TM5Y?RE-Y-R@.W7 U6X"NKGG/"^&%>:PS//<>$<;&U1+^>G*J1
M;K'&38%*H^KP<WLN5AD^0=2P*GQJJ7[8_5WGGG_(:X+7[1G^@?^L7H4A(YX;
M(DB)F!/H(.X$95$@RL,Q"WS'\8C2G,!1*#/+9P\7M( [@QA(T.I1^/,\&I=+
M:Y3K2:81T5I!^4FBC"+SYW==+#P_2=@P1C^]6/\4O%ZOM\,XWN*&W9=5OFV
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MM1,(E/']GY%.H,M^:\D%VH"-1VIV8U#>XOJAJV1<.=1)?#&K)$U$S7D8Q?P
M0"XDB# _]=TDB;7LLI-09E;:@QE.A /5GI9Y@BUJ"O9B8O64XH!. 6];7VQU
M .9Y@NR-O#P!8^DAE^?)/#'6<F2Q>1CRCC^ZBMPP"FGLB,9[/D0Q36 24 <Z
M"4*>PZ*4(J5:Q,.-EPHV"ECZT45)NGI 49<@PQCB*"U&0<,AXA?%">5&BX<&
MA^B?B@;N_=XL#>9-D7%OB?[=X*+NS.,+I<%T7?KJ85*(R77=.29,7]59H%]/
M4-1(G^'";H)2XU284WLNF@HS0M1A*LS84GW1DT,$ONY:_W]IBK_6VTM ;5%4
MW&YFT6PG(PS0 %]8LZD*\-=Z<+6L+IJJ3)H6U1GXHR>Z:JR9070U*3<29548
MBXFV)M%#4==]U,P5?+.I\T)VVWA,\Z+M;#/1).T3)[OSC;PTHHF;!# .0^XR
M$NSQOSD$IBQ&&?(]!P>1CLMX$39SQ^2L-&B\C-]JONAB7-33/#U:8(#7U=E6
MC5?#7HT[].PYN%:X9,D1O@R711UF*VP[=*SM;&JF 3^+BLVV\[9HC=OF'^RB
M=6Y(0A:[(??#Q51)+'IA,Y)"&G&OW/>I%V*EA& U<#/K, D<Y!+Z3S]T>4L_
M_JRGPB88IJ:C[+%!3PFU'.@:X<O^UAWH62*@:E1:4B(3P!;5$FJ$'ZH!Q:=,
M.U,+9='EU#+'H8RE$20L$U*-&8Q1X'.I3I. L9AER-5J<S_8?!'?QM[4M\%&
MNKVF!PQ5DWI3-FG>3D@H,PR:.H6^M1[-@ZT7;KE\3-1Q!^43:[Z#1(8O>?W?
M'RK&^G$Y,B+N.&D4^RF!).4"CE!"N5.2!9#P@]Q!;I)&(7FU1(93&,\=$^,@
M8<9A\H._F_%4C86Y7^FUJ6F0[^IEZ*FE&1,9!"% 4 *V8[R^XTR&,;9_CYD,
M)_']GYO),,;^63,91@'KG29UU:Q^Q=_RQ\UC9X"@R,M82CWH8Y%5BK,8IAY+
MH1^QR,4X=!%1"I\>[3RS=NY@J6GC8[+'M>9%Q.AIMPZ,1:OK+/)C.H(_-- /
M_%\[W7"\WR(R?):,7M;.+S!,MQZ44WS.#HLM5J[OA&F<)-#W @^B@/\M3AB"
M-$RRU'48<1.M/,]Q<#-+S_6Y.JQ\5UV$)2*:*=OC/%2S5>QQ1D\4]YA29D>5
M5A:;(JF1:"OE>QS8LBG@2H0?I82K/:4?Q6VG:XL#MSV@MX?NNSS+F&@HR@SR
M*O1VG5G46V3 %IN!!0QV^)@D7F@R;SK(.Q_?]!2!+LMFB/J:L<(H^*L):K$8
ML!D+AJ%@PQT,.@;?%*02S<+?L?;/F^(+JQG?X^&ZH._8,UN7<G @7\?_FS^S
M^@LC+'\6=XVKR$49"[P0NG[D0)3Y$4P0B:"'DBARO3 E-%2;WG<Q+DHR=<GD
MOAX5&4.@.V1$<*7#!E1;=#3ZWE[T!L95TS)<-9P^WF(#?NCQ^E&T<MSC\@ Y
ML,,.?%F<RQIMAI?BMEF_86Z.;-KID_F6_W3(_TKK*[<UPL$&TT:[$E\$8+GV
MQ#;XL->GV,J&ADXI(>);JV_QB]BM+ZY R(^3R$,PPTX D9OX$-,H@P@'7DI0
M%F&U 3SC8.9V0CN@X*F%JNEJGN:,HHMY,;V:KF5/:@=PAL*3<9)LN9*G@2SK
M0HX2>N0ZCJ^^2"KSXOZV7.<D'Z1Q^"1("4YB&*240N0)8R[!'G0])T!1%OFI
MFQA(Y@E0RTBGF'740S:>Z#+"+RUYO9 +1C*KRP!3P1VAS:[PG@+T&@(\0O 9
M(1Y[PK!U5Q]NZ?/C9$\P+":[T\_\E!>I<ASJ&USG]6]%F=:LDJ?Z3?&T:?BO
M.<'\*6D]WDD;-TZC,'40%_\H#2&*629&.7G0<=TPH6Z:4D=+_&TC.+/2V 5:
M=WFH0FYZE$$IG),.:2"QO@)#O(%$'.QC#GZ7N.N.D;+];M54U6N^,3T%]THO
M2[_MV$P<M=61S#9ZRS8KFXFY1WW,YH)C<%OWCF6,FX%4-B>72-W4]8;151HF
M*6%^ $E$'(@2FG*WRHMAA#S79\3#_.4K#_$Z!V5F%=R#!=?=#)8K\+__Q0W]
M?W5!43[F8L[ILT#F7T'H7W$_LEL%\*9Y**O\GW*8I414WEZ4FZ9N^%^$"A"7
M3#+2*C9T_M5WKT3?1O]GA6=_[J I#H09?TT*UW4VF*^G3;=\ER"ONG2C%JH-
MHC5NSVP0;W@S=G]?R6MA[M-77" !?_^BV8+\XN2%6?MUT)Y9,HW6U@78%-VC
MEUMG'U[NXFH*_[U+J<G%AGFFY('1C1S=<#)!28+KAKF<B*S44CGO@G[$(V%*
M?2;F8A&(2()A0D,?AA'Q0XRP%P5:92!VT9M9%??(B@__#Y;?/W!1@/B95?A>
MIE?T2(G?9\(8:\5$R@0HVWAC)S!-"=CCT[I\8:K]L6=ZH6I&\.N])CVE/7Q#
M(_FC[7B9[<RL4X'ANK-[@=50\+S\M)4T:A>Y93-$9V'L43KH/% ,3-\N86Y[
M3G]J3<(VHM6A5U]OS;F[\@V[7J_+AFLND8+Z@3/P*S_2-_QS?;FMV/L6P2]"
MM]4KC ,W2_P,!F' S6>*/(C]B,# C4@0D]3WF-+EQ^R8+I.;"O#6&NHM;[R-
M'!Y9W4+%I_Q8Z&@ LO) ?+#@B:LEUJ6?5!)_#7MRUA>N8(A_+Z]1[USHW^#.
MGNWP!EWL]W-W7M1@ASNX*\$;!GKTV\("00#84@!N!^_RRW?U+C7\B^_EG5X:
MO7]4E]/F 3?\/PRDI9@CS']!\XH13@&7X8H=R+$4XH$$UR???RO+MIR?)5[*
MJ ,U*P++.6%+\''/D5L$H'Z3O2Y2VLXK$G,%WA?TG2@X2S,G<S,?PR!-/='P
M.(#88QEWZ1Q^R/LA2V/EAGOG@,Q\0'=@^YE7<E+&>Y$JI5S?-\JA\6/1%MUZ
M)YH1R5HM^Z9H,FK?=W;3Q5KY39$U;.LWN=:T[^Q:W*+=XJIY&4S1;#5$O3=9
M<^5Q48S]F$*"4A>BQ,U@(OK2.I0PQ\4925VMUD(:L.=.2&A!BK.W:I$2EXS-
M"VAV*&C>C>@P5NWB8R9VZ<EZAP206( !R"LP8.+@YS;;WVK3;ZTIKCKDA5OE
M:K/DN(&N_A9FJN8CJVO&/C_)MD'%_4>1[KCM'?1;0;EF$S 9??^-\*4M!BO"
M4$:\((4D$+/,$HIA&OI<\_AN@#/7C8.0JF6P7X2'DD1=DKTNL/H9Y(]/&R%>
M?5L /9UCQF$U[3,?UXST4(O.%=@B!"1&>RW*AEB!%JU.2=E32A>QQ9)Z,L-A
M445U$9L.5=9EFYDJ+PY$#))>$>P2%Q$/$AQP*P@%"*;(HY!F;HP=GV1ND*T:
MT1%(51UU.VO9.-O]E26F;5*TEB4%1'D8^#']JNK"@"I=%2 %?G2PN8$\'^!M
M34;[?1>6NP-RCF7I<(%^UX<OHO/$];>\7J& 9E[@<@\A"1%$Q&4P)DS(AN/0
M. XCII;DLK?KW)%4<<=7-[EP7;NL(1F?^UW 5LP+W.?"N(08TZ89?C0C2ZL5
MQ!$9%[2!V.VU6 N((_2'[1^.?VG00Y^5G_ C4^Z9WRZ?^7N_??\9"# :7? [
M,L:_:T,*]+[J2>3U6M?OHVO6JK[;8[G6]/M([[6B/_B5_A?[J2R^;-;,==+
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M!]!8C6NR2TK+-6>_D7R="D.SEFTJ+W-V)9[/*%FVSDMUM18;EGRU"!S7M[V
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M,4,XPB$BB>NCD)* B3^$8>S#:FT;@NV<<MIS *=FQ<Q^0S#+MJ%M;?<!'[K
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MD[_484/V,[TJF 7<,6W=IW7!\ W?UH9Q6<+.VK)N=7B70W;<6UOVK99_:RO
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MQ.UO.JU%-^7B/3M./=?EB-LX1CC""2)N8B/;"4,<^HG+4E#K3R#]_P4++NB
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M[XDN+2S]?=,TFOM-;;^OY<WJ64^NU%YEW/7+Z>!N6-V#<T&3G"<IEQ#)3!B
M?PIS4Y6:4R0EIR3-1.17BWHY<Q.O*5^IFTY^;<N^AEO0\7$%#NL]^0OH?:P;
MWW8G]RZ##?!&[5SE6[TG-R_J\8JNP(.>]>Q[N* R-YS"@A?S!F#MC>I_PREU
MN&0X( W_FS</&[9J6GDW'9(748ZE3/(<2IQ0O9Q$>F%))($<82+T4E+(R J!
M<8S(U+5*W;645[IM_V?W&S@G^AGW9Z&D=O-+'@)[W<09DNBBRS@GD\Y^'V=(
MK+XK.8-C_4WPWT]LHW_ERY?V%Q;3-)4HPE 1KA.ZC$B8D4C +,$)R1+"]/K(
MU0*/:,QE@#NRWO9WK!Q[\[M 9$_KLY;6R_@&Y+G(]H[GG-WT!H3JL[RAH;YX
MX.U^33.;3H=,(Y6G:I'30J!,ASY.3$LBS%.8LX) I11*$U[DW"X#.4=H8A-L
MP;%;VF!''#3474'!!Y1UWAI#J<#-)'VE]T &'Q?M G#P@8EGQ@<?%^\4(OS,
M>+\MAB_*M&%5LFMLW_:W4TB'Q00SJ(1I%$ZD#I0,13!/52QB*F/J!A;>3V;J
M$UNAW=O3LH:O^*B*4I2.NY<#RK'+NR\7V<TP.WJ@(SA!P[]QF0(EN0-$9DU7
MQP4]3CS/C/8H.%I5J_?RO]7]L_BPZSEI6V[4\^S49[9*+]Q-=<VNC* "]VKS
M7+:0]@YU1GV"C]M;")D=SQ;/B!O0\,X)YU=EU#?A?#5&(^(<5!B-C?,-=G4P
MN-.KW9<ZVV3"I)O5]<O^-W5ICHARA;)8P (S!K&.>9#%$8<D0E1_'A.266'=
MNI.>V%9;<J"FYP7EX*!%VT@YA6Y<H^>RA;F2YKQNLZ<E@[(=&OW!7>1@P=6:
M\,P!UU4AIT'8>89I^P5>LZH4VI$4N6 2P9@*JI/>.(%9K J(49X2&L=Y%CG=
M5G6B/K$OZ7B!'9*E5F.Y,F<X5=.U;OW*SQ7@AB/PKERUWSIB6[JIW<[S3*9,
M-^?CU/[O"M3<S-_K[T ),[?T:VC_+3OW':C%MT'?X23N"</]]H^[C?A]\U!M
M6LA&[?J:TZ\']=?V6@OVAVT"83/7U ?V]1'\W<:LJ-<;\'#_!;RRTAX+VR<5
M5LHYGV2$UHN;C[!1"?AJ& $U)X&2#Q>AO9(1*P*S)2<NXNXG*T[/N9DWWZRJ
MQ7!7CYX&6ZE")(Y5!%4B",1<8)A)C""-%*:II#Q"J8TS<*8\_7Y>\)9#[MKE
M)*,B80I&<2PA+G *<QXKB!C&A1!QHG!A4R4^K78GK15W5]JX=YU4%6YN=KS%
MDE,[N M5)MO#N=J5O(WJ#EBP5V%]Q\XL7G>&6JYJ Y6 /VW!:KT%+VH+ZOK\
ME8YEY>IYK<.:O*HUO6?"0"Q9595%:1+SJC'UG\%_*OW?[1KH:+-48@OTISO[
MKX]&=#S4Q,W'^W.]DT\*_*_<?M<)B.F68_#U321M/S+#-3./; G6N^O#XD4L
M%2@+L%ROOJG-3S]?'E2]7U@37<WC=0"-:!+50=1]PEFBJ;><75CUG^""YIZ[
M^\1-G>]"4<ZB)*&0,I7I4,ICR!76?\D$);(H\A@GSBT]CXA,'#4;S_7ZF_9!
MF>K5C5V*?:G$;N[[N!/>S;BP?AT[!Z0)V:?SF,3\W3D'A.SMR3DTUK]PZV95
M&%]L?'E3Z\P+3)B2&>1Z/0MQCCG,8OW?-(T2E1484VZU'S]&9*[2K3VZ;E7D
MHQH:-\=0<KN9HY?(7B5<0S)=5,-U,NGL15Q#8O55<0V.#8AJ?KM#9<OB&-%(
MZ*RRX$@;9)1#QF0*"6&,"BDY1Y[72?K(3;W?M"-^? W$"LG-1W]VT3.<5AQW
MFRY32!@T]!,YIX1$OYT7^,Y-<"MP]-.G/ W?3/9]O=1/5-W-"+%\,MO4=TUZ
M9761DV"51"@M8)+&VD$4$86L2".89)@5.#+=DW*7V_1AV)IC$P54>ZS^^(\L
M1NDO0-4L.[J0,&\BSO*(*I)#%9DD)J6%?A,Y@8ED*8Y0'B696OQ9-\2XW[+-
M]N_Z/HY9M'XKU^I;N:I[PG&FOQ".V4^@U\ 2+$4<Z=6K5KK.(%4$&3%=XJ4B
M&<6%0#QM7\.GE>5]\K=Z"1V#UJ_@4X/+^);ZMXRXLVO4+3(W/)D6SRU7H&5K
M_FOG8545*KB'86K>14!019XL%L+.'@K6_92M+YKBY_7&-*=8,(4HYUC !*>F
M6":MFT0PR%+.<IXA%><7@KR/TI\XWQB /-]GZ9_=)>BOABW0\N68@[AJW<Y%
M3JA+-U\X@1H#@,E;*6,R:/EQZF\,-&^EFO.P\W;3^#FJ]L3A;K,N5&7*O-GR
MLWH]E1/8W%8K=!HCI8(X9APR2B.89Z*(*4TCK)QZ4X^3F^E _<\]ZJ!0MF?G
MEBJS<RKA%.%WX+M/&!C*$R"$V<D8R#6<(3:K)[ 3_-CP+9]RKY;[])<23]OR
M67U@6_5MO7EQP1SM?7AB0]W1!!U1!\S1?FG'K3*(H(Z)S8F,0;%'1Z7QJESK
MGW&V4K51@?9KT\8'>G91K#XLUY5.%DP+N8]E)6Y6\E_LT>H([MP<$]N2(>'8
M.7%(V/,V%$I.QYA64P4U6;,@?B@?ZQV!NJ&BX4!_\;0Q(4ZS4CZ7TG1V']6+
M>V_%,T+[=U@<FGC>/HMGQ#OIMGANO"_4PN=RJ3:=82]2P@G"2*]..<DAQBG1
MJU-"(&4933):B$A:K4X'YI\ZRC70 C7)71!PA5,X5,BXA080TS'&.4GH 9G0
M*\<%2 F'\\T,D- KS"DN0O\PS[.O^F+&357I=><"R9Q&.4F@3"*L<[T\A1DE
M*10<ITI*K@3A'N<F>R3>YO3#_P[6@7H27C"6(0H)0@1BDE&8I?4!GU")$(Q0
M09S/,RY2SH6G$H'T8GG.X"FIF\-IJ.@X7],)N/7?PWVH#?S]J>?=AN\1ZF0S
MO6^,]Y;X^E$9%)>Z:^"M4;I.<C^N'UFY6B"B9"J4@BQ%$F).,LBR.(:9Y"C)
MXYS1U JJS(K:]-O=!AYY1QQTU,'7AK[[MO:(YJPWL</HP]$@=SI8%QUL=$?;
MW.QL'-%9M?AL4Y\7-]RF] BMN;>@SXO=L^%L\9![XOQA?:_,C04E?U/,)& N
M&7/OPQ/;K6EDPE8OH*,,6M+CN:*EW.>3YXM%=C--/VF=,N-1B;Q2XOX99\N%
M1P7:3X+'!P[9TK[6;_5?O_[0?:+_X:Q2O_[P?U!+ P04    "  T00A9YL/;
M_$EQ  #S-04 %0   &)R;G,M,C R-# V,S!?<')E+GAM;.R]69/;N7(O^.Y/
MT7/F=?(T]L5A^T9)+;455RWI2CKV];PPL"0D7K-(F62I)7_Z29"L?>,"UA]E
M3]A'+=5"Y/)#(A/(Y1_^QX_3R2_?<;X8SZ;_^!?^5_:77W":9GD\_?*/?_G;
MY]?@_O(__NGO_NX?_B^ __WBX]M??INELU.<+G]Y.<>PQ/S+G^/EUU^67_&7
M?YW-_WW\/?SR81*6938_!?BGU:^]G'W[.1]_^;K\13"ASG_L_+OSO_>!<Y9T
M .5%!&5#@N@] R-%I.]IG@/^/U_^GJ4HG&012BH(*A0-+J@")2?ZLC*&Z[3Z
MT,EX^N]_7_^(88&_$'O3Q>J?__B7K\OEM[__]=<___SSKS_B?/+7V?S+KX(Q
M^>OY3_]E\^,_;OW\GW+UT]Q[_^OJNQ<_NAC?]8/TL?S7__W'VT_I*YX&&$\7
MRS!-=8'%^.\7JR^^G:6P7$G]4;I^N?<GZK_@_,>@?@FX ,G_^F.1__)/?_?+
M+VMQS&<3_(CEE_K?OWU\<VW)&.;CZ?+KV2*.9W]-L]-?ZP_]^G)&H"!R5[^^
M_/D-__$OB_'IMPF>?^WK',L__B7.IPNH>F5&LKKH_[W^Q5\OU_XVQP4!9L7K
M6_K"YO?K*OO1@3^6.,VXYN]\E<DL7?NA297N[.(W)R'B9/754<;Q:/6I)W&Q
MG(>T')4@?;*!@_$$/N64A* ,(RP:H:*1"6.YSG8E>T%TKY2QP/37+[/OO]('
M_UI%4?^RDLE*'K>66\MF/[K/=]^;:=UA*Y%^#G&"(RVD9$XY2+$84,D$""@2
M<"TC8\9KS<Q!+-RW\G5NKNKZ9)Y^F<TSSLFLG"\=YNF6WJ\#>O,3OWX+<_H@
M2%_'DWS^VV4^.VVAP^6LL437JB/2__(+2:#@?([Y[5IS]S*ZXG))AA=7/[DO
M*LX6\"6$;Z-/)'2LC+R<A,7B??FTG*5_/_DQ7HQ\X2'F),%&5$"RL. ,V5=+
M1E;0!VE7\ %HE+"(*ZHW*ZWQ@9/EXOPKET!YE)CAT-)&S[-C"+T#]%RE_[?9
M:1A/1T$YE#%H,('3L>SH@';.,N I1,F\$=;YQK"Y3<4P>&FLWEE360^(EKJ/
M3O+\#SR-.!\9K9@M+H-,GIPWVBP0?,D0N"";ZPVW^)!=>?S(N5AJ6!0<JJ_9
MH<+KP3[,3D]GTY4(-@Q(@:B,0I!1D-G,D@/!WH-0CCM;LD3?W#S<)&(K7(C.
M<=%&Q -;A3M.5W+U\0V9S\5(2VXY+Q36L6A!<4528;I CBI;1V@7/+3V32]6
M'P8CS3V.ID+N!"R?Z6='"GVQ5C)"M2QD"+TBNHL%)A7G1KNH76H"CKI:5^[G
MGKJ[ Q ["[(3 /ROLS"G3YS\_(C?9O/EB(N AMD,)F?RJK@W$.@W09,=5#K+
M7()K@H4;"W=E(]K!XA#Q=H*0#S@?S_*K:?Z-/'%B0'M-!Q]X9A%4,05<)!\*
MLU3"28DAM[$5UY;="AWRV:%C?]%V@HW/\S!=C*M0-OA6Q'%(VH!ESA$/4@ Y
M2A)$]+(PI@)7;<S'S96W0HAZ=@@Y2, #@^35=#E>_GP]GN"[LY4SK4T13G$-
MA;L$RE2GBZD,3#-+5I#X$/D@<-Q<<2M0Z&<#BH,$V@48/N*7<;TLGB[?A5,<
M11/1QU! FNQ!!:8ARN3 &:F+U>1),=X $-=7W0H4YIF!X@#!=@&,-],TFY.!
M6PEE=>?W<G8V7<Y_OIQE' D9,4HZ"KU/A'-6V4DDI6(E9PF=4$DWP,F#1&P%
M&_O,8--.[%V@Z'/X\2:3I,9EO'[7W=A);RU%9,J#$X88"5E M)S^F;/G)8=0
M7S(/Q\\]RV^%'/?,D--"U%U@YB1GTLAB\Y\J'CYR6()D*@$G@LG)LAR\2V1-
MM64<HPF86YQ+=RR]%5;\,\/*H2+N%"=BY'3()EL%4I9ZS.8$WBH)R5HM0^%*
M>'D4G(CM;M'8LP?*;C+N"2@OZ:_OYY]G?TY'/I="U!/"DS6@A-+@(T5OP?F(
M)"Q=W&&Y+?<LO!U(GL]=:POY=@61M:\UTLX$EP("]X+.3"T\>!,5<!>-,,4;
M$DE#?*Q7W0X<S^?&]6#)]H2,#[/%,DS^W_&WM1_N+->ED">5&0,EG8*(%NG
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M?7=P9?ENHKW&QF-?"7<0Z=7>=>-E?:JLT<O%^9HJ*X5(BD83NM'7:S,9(:;
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MC@R9#2G;@>:Y),:TD'<'L+D2N#(90O:U?0+/1#G' LY9 SP5G6CM^IHP[&T
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M=)899+1'DP+-&4-N76X_!FA[ZH9-!GEBC!Y):1U$8:]*P43!PJL?:57Q])&
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M>NH @)N$T54M9!XOS^K0@6FJ_9?RB[/EN]GRWW!91T*.>.#>*1G :I-!N23
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MS@$J[0P&SB5KG7[S,$4#3YD<$&X--=4![J[(Z9P#Y@H:B1&BK3,X&1<0LF'
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M[%/GSW+5*$1)C"02E;SPL UR@Q3E C%-"UIQKFE\S^G75>.!.GN\J\9#X,_
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M+3(P,C0P-C,P7VQA8BYX;6Q02P$"% ,4    "  T00A9YL/;_$EQ  #S-04
M%0              @ &ZT D 8G)N<RTR,#(T,#8S,%]P<F4N>&UL4$L! A0#
M%     @ -$$(68[_.W3_!P  XRH  !@              ( !-D(* &)R;G,M
M,C R-# V,S!X97AX,S$Q+FAT;5!+ 0(4 Q0    ( #1!"%G,\-L^[P<  *DJ
M   8              "  6M*"@!B<FYS+3(P,C0P-C,P>&5X>#,Q,BYH=&U0
M2P$"% ,4    "  T00A9$GP=7<@$  "A&   &               @ &04@H
M8G)N<RTR,#(T,#8S,'AE>'@S,C$N:'1M4$L%!@     *  H G@(  (Y7"@
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>brns-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:brns="http://www.barinthusbio.com/20240630"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="brns-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2024-08-01</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">brns:DeferredSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:CoalitionForEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-21</startDate>
            <endDate>2021-04-21</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
        </entity>
        <period>
            <instant>2023-11-06</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-06</startDate>
            <endDate>2023-11-06</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredBSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredCSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">brns:DeferredShares.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">brns:AvideaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">brns:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">brns:RestrictedShareUnitsStockOptionsShareAppreciationRightsAndRestrictedSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:BarinthusBiotherapeuticsPlcShareAwardPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">brns:EnterpriseManagementIncentiveShareOptionSchemeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">brns:InLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-03</startDate>
            <endDate>2021-09-03</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">brns:OxfordshireMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-03</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-14</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">brns:ExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001828185</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">brns:OxfordUniversityInnovationLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="gbpPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:GBP</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>brns:segment</measure>
    </unit>
    <unit id="vote">
        <measure>brns:vote</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001828185</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-32">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-16" id="f-213">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-17" id="f-214">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-18" id="f-215">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-19" id="f-216">http://fasb.org/us-gaap/2024#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40367</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">BARINTHUS BIOTHERAPEUTICS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">X0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">Unit 6-10, Zeus Building</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-9">Rutherford Avenue</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Harwell, Didcot</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-11">GB</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">OX11 0DF</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">+44 (0)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">1865 818 808</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-2" id="f-15">American Depositary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-16">BRNS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-18">Ordinary shares, nominal value &#xa3;0.000025 per share</dei:Security12bTitle>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-25">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-26" unitRef="shares">39414722</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-33" unitRef="usd">117774000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-34" unitRef="usd">142090000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <brns:ResearchAndDevelopmentIncentivesReceivable contextRef="c-5" decimals="-3" id="f-35" unitRef="usd">4523000</brns:ResearchAndDevelopmentIncentivesReceivable>
    <brns:ResearchAndDevelopmentIncentivesReceivable contextRef="c-6" decimals="-3" id="f-36" unitRef="usd">4908000</brns:ResearchAndDevelopmentIncentivesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-37" unitRef="usd">9582000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-38" unitRef="usd">9907000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-39" unitRef="usd">131879000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-40" unitRef="usd">156905000</us-gaap:AssetsCurrent>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">12209000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-42" unitRef="usd">12209000</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">10962000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-44" unitRef="usd">11821000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">23527000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-46" unitRef="usd">25108000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">7286000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-48" unitRef="usd">7581000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">886000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="c-6" decimals="-3" id="f-50" unitRef="usd">882000</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">186749000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-52" unitRef="usd">214506000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">2556000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-54" unitRef="usd">1601000</us-gaap:AccountsPayableCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">10278000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-56" unitRef="usd">9212000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">839000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="c-6" decimals="-3" id="f-58" unitRef="usd">0</us-gaap:DeferredIncomeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">1916000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-60" unitRef="usd">1785000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">15589000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">12598000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">10654000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-64" unitRef="usd">11191000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">1888000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">1823000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">1338000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-68" unitRef="usd">1325000</us-gaap:OtherLiabilitiesNoncurrent>
    <brns:DeferredTaxLiabilityNet contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">490000</brns:DeferredTaxLiabilityNet>
    <brns:DeferredTaxLiabilityNet contextRef="c-6" decimals="-3" id="f-70" unitRef="usd">574000</brns:DeferredTaxLiabilityNet>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">29959000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">27511000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-73" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-74" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-75"
      unitRef="gbpPerShare">0.000025</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-76"
      unitRef="gbpPerShare">0.000025</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-77" unitRef="shares">39184338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-78" unitRef="shares">39184338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-79" unitRef="shares">39184338</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-80" unitRef="shares">38643540</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-81" unitRef="shares">38643540</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-82" unitRef="shares">38643540</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-84" unitRef="usd">1000</us-gaap:CommonStockValue>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-85"
      unitRef="gbpPerShare">1</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-86"
      unitRef="gbpPerShare">1</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockSharesIssued contextRef="c-8" decimals="INF" id="f-87" unitRef="shares">63443</brns:DeferredStockSharesIssued>
    <brns:DeferredStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-88" unitRef="shares">63443</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-89" unitRef="shares">63443</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-90" unitRef="shares">63443</brns:DeferredStockSharesOutstanding>
    <brns:DeferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-91" unitRef="shares">63443</brns:DeferredStockSharesIssued>
    <brns:DeferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-92" unitRef="shares">63443</brns:DeferredStockSharesAuthorized>
    <brns:DeferredStockValueIssued contextRef="c-8" decimals="-3" id="f-93" unitRef="usd">86000</brns:DeferredStockValueIssued>
    <brns:DeferredStockValueIssued contextRef="c-7" decimals="-3" id="f-94" unitRef="usd">86000</brns:DeferredStockValueIssued>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">390273000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-96" unitRef="usd">386602000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">-209010000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">-176590000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">-24732000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-100" unitRef="usd">-23315000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">156618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-102" unitRef="usd">186784000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">172000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-6" decimals="-3" id="f-104" unitRef="usd">211000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">156790000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-106" unitRef="usd">186995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-107" unitRef="usd">186749000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-108" unitRef="usd">214506000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-109" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-110" unitRef="usd">334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-111" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-112" unitRef="usd">802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-113" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-114" unitRef="usd">334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-116" unitRef="usd">802000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-3" id="f-117" unitRef="usd">11662000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-118" unitRef="usd">13543000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">22787000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-120" unitRef="usd">23357000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-121" unitRef="usd">7201000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-122" unitRef="usd">13128000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">13195000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-124" unitRef="usd">25266000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-13" decimals="-3" id="f-125" unitRef="usd">18863000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-14" decimals="-3" id="f-126" unitRef="usd">26671000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">35982000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-15" decimals="-3" id="f-128" unitRef="usd">48623000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncome contextRef="c-13" decimals="-3" id="f-129" unitRef="usd">577000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome contextRef="c-14" decimals="-3" id="f-130" unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">782000</us-gaap:OtherOperatingIncome>
    <us-gaap:OtherOperatingIncome contextRef="c-15" decimals="-3" id="f-132" unitRef="usd">0</us-gaap:OtherOperatingIncome>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-133" unitRef="usd">-18286000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-134" unitRef="usd">-26337000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">-35200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-136" unitRef="usd">-47821000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-13" decimals="-3" id="f-137" unitRef="usd">635000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-14" decimals="-3" id="f-138" unitRef="usd">522000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">1410000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-15" decimals="-3" id="f-140" unitRef="usd">2110000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-13" decimals="-3" id="f-141" unitRef="usd">12000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-14" decimals="-3" id="f-142" unitRef="usd">14000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">24000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-15" decimals="-3" id="f-144" unitRef="usd">14000</us-gaap:InterestExpenseNonoperating>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-13" decimals="-3" id="f-145" unitRef="usd">693000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-14" decimals="-3" id="f-146" unitRef="usd">559000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">1287000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <brns:ResearchAndDevelopmentIncentiveIncomeExpense contextRef="c-15" decimals="-3" id="f-148" unitRef="usd">1716000</brns:ResearchAndDevelopmentIncentiveIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-149" unitRef="usd">20000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-150" unitRef="usd">310000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">20000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-152" unitRef="usd">310000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-153" unitRef="usd">1336000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-154" unitRef="usd">1377000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">2693000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-156" unitRef="usd">4122000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-157" unitRef="usd">-16950000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-158" unitRef="usd">-24960000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">-32507000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-160" unitRef="usd">-43699000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-161" unitRef="usd">-7000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-162" unitRef="usd">-1136000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">-44000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-164" unitRef="usd">-1652000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-13" decimals="-3" id="f-165" unitRef="usd">-16943000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-166" unitRef="usd">-23824000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">-32463000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-168" unitRef="usd">-42047000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-169" unitRef="usd">-12000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-170" unitRef="usd">-22000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">-43000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-172" unitRef="usd">-65000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-173" unitRef="usd">-16931000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-174" unitRef="usd">-23802000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">-32420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-176" unitRef="usd">-41982000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="0" id="f-177" unitRef="shares">39041111</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="0" id="f-178" unitRef="shares">38407672</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-179" unitRef="shares">38907296</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="0" id="f-180" unitRef="shares">38211625</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="0" id="f-181" unitRef="shares">39041111</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="0" id="f-182" unitRef="shares">38407672</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-183" unitRef="shares">38907296</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="0" id="f-184" unitRef="shares">38211625</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-185"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-186"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-187"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-188"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-189"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-190"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-191"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-192"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ProfitLoss contextRef="c-13" decimals="-3" id="f-193" unitRef="usd">-16943000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-194" unitRef="usd">-23824000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-32463000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-196" unitRef="usd">-42047000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-13" decimals="-3" id="f-197" unitRef="usd">164000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-198" unitRef="usd">5604000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">-1413000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-200" unitRef="usd">10184000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-201" unitRef="usd">-16779000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-202" unitRef="usd">-18220000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-33876000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-204" unitRef="usd">-31863000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-205" unitRef="usd">-11000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-206" unitRef="usd">-15000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">-39000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-208" unitRef="usd">-52000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-209" unitRef="usd">-16768000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-3" id="f-210" unitRef="usd">-18205000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">-33837000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-212" unitRef="usd">-31811000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-18" decimals="-5" id="f-217" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-19" decimals="-5" id="f-218" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-5" id="f-219" unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-5" id="f-220" unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SharesIssued
      contextRef="c-20"
      decimals="INF"
      id="f-221"
      unitRef="shares">38643540</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-222" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-21"
      decimals="INF"
      id="f-223"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-224" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-225" unitRef="usd">386602000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-226" unitRef="usd">-176590000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-227" unitRef="usd">-23315000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-228" unitRef="usd">186784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-229" unitRef="usd">211000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-230" unitRef="usd">186995000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-3" id="f-231" unitRef="usd">1615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-28" decimals="-3" id="f-232" unitRef="usd">1615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-29" decimals="-3" id="f-233" unitRef="usd">1615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-30"
      decimals="INF"
      id="f-234"
      unitRef="shares">309416</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="-3" id="f-235" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-236" unitRef="usd">503000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-28" decimals="-3" id="f-237" unitRef="usd">503000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-29" decimals="-3" id="f-238" unitRef="usd">503000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-31" decimals="-3" id="f-239" unitRef="usd">-1580000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-28" decimals="-3" id="f-240" unitRef="usd">-1580000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-32" decimals="-3" id="f-241" unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-29" decimals="-3" id="f-242" unitRef="usd">-1577000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-33" decimals="-3" id="f-243" unitRef="usd">-15489000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-28" decimals="-3" id="f-244" unitRef="usd">-15489000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-32" decimals="-3" id="f-245" unitRef="usd">-31000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-29" decimals="-3" id="f-246" unitRef="usd">-15520000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="c-34"
      decimals="INF"
      id="f-247"
      unitRef="shares">38952956</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-248" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-35"
      decimals="INF"
      id="f-249"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-250" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-251" unitRef="usd">388720000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-3" id="f-252" unitRef="usd">-192079000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-3" id="f-253" unitRef="usd">-24895000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-254" unitRef="usd">171833000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-255" unitRef="usd">183000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-256" unitRef="usd">172016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-42" decimals="-3" id="f-257" unitRef="usd">1195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="-3" id="f-258" unitRef="usd">1195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-259" unitRef="usd">1195000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-44"
      decimals="INF"
      id="f-260"
      unitRef="shares">231382</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-44" decimals="-3" id="f-261" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-262" unitRef="usd">358000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-43" decimals="-3" id="f-263" unitRef="usd">358000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-264" unitRef="usd">358000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-45" decimals="-3" id="f-265" unitRef="usd">163000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-43" decimals="-3" id="f-266" unitRef="usd">163000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-13" decimals="-3" id="f-267" unitRef="usd">164000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-46" decimals="-3" id="f-268" unitRef="usd">-16931000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-43" decimals="-3" id="f-269" unitRef="usd">-16931000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-47" decimals="-3" id="f-270" unitRef="usd">-12000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-13" decimals="-3" id="f-271" unitRef="usd">-16943000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="c-48"
      decimals="INF"
      id="f-272"
      unitRef="shares">39184338</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-273" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-49"
      decimals="INF"
      id="f-274"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-275" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-276" unitRef="usd">390273000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-3" id="f-277" unitRef="usd">-209010000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-278" unitRef="usd">-24732000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-53" decimals="-3" id="f-279" unitRef="usd">156618000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-3" id="f-280" unitRef="usd">172000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-281" unitRef="usd">156790000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-55"
      decimals="INF"
      id="f-282"
      unitRef="shares">37683531</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-283" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-56"
      decimals="INF"
      id="f-284"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-285" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-57"
      decimals="INF"
      id="f-286"
      unitRef="shares">570987</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-287" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-58"
      decimals="INF"
      id="f-288"
      unitRef="shares">27828231</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-289" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-290" unitRef="usd">379504000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-291" unitRef="usd">-103243000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-292" unitRef="usd">-33460000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-3" id="f-293" unitRef="usd">242896000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-3" id="f-294" unitRef="usd">305000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-295" unitRef="usd">243201000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-65" decimals="-3" id="f-296" unitRef="usd">2222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-66" decimals="-3" id="f-297" unitRef="usd">2222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-67" decimals="-3" id="f-298" unitRef="usd">2222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-68"
      decimals="INF"
      id="f-299"
      unitRef="shares">673494</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-68" decimals="-3" id="f-300" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-65" decimals="-3" id="f-301" unitRef="usd">1789000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-66" decimals="-3" id="f-302" unitRef="usd">1789000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-67" decimals="-3" id="f-303" unitRef="usd">1789000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-69" decimals="-3" id="f-304" unitRef="usd">4574000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-66" decimals="-3" id="f-305" unitRef="usd">4574000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-70" decimals="-3" id="f-306" unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-67" decimals="-3" id="f-307" unitRef="usd">4580000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <brns:SharesCancelledDuringPeriodSharesDeferredShares
      contextRef="c-71"
      decimals="INF"
      id="f-308"
      unitRef="shares">570987</brns:SharesCancelledDuringPeriodSharesDeferredShares>
    <brns:SharesCancelledDuringPeriodValueDeferredShares contextRef="c-71" decimals="-3" id="f-309" unitRef="usd">8000</brns:SharesCancelledDuringPeriodValueDeferredShares>
    <brns:SharesCancelledDuringPeriodSharesDeferredShares
      contextRef="c-72"
      decimals="INF"
      id="f-310"
      unitRef="shares">27828231</brns:SharesCancelledDuringPeriodSharesDeferredShares>
    <brns:SharesCancelledDuringPeriodValueDeferredShares contextRef="c-72" decimals="-3" id="f-311" unitRef="usd">0</brns:SharesCancelledDuringPeriodValueDeferredShares>
    <brns:SharesCancelledDuringPeriodValueDeferredShares contextRef="c-65" decimals="-3" id="f-312" unitRef="usd">-8000</brns:SharesCancelledDuringPeriodValueDeferredShares>
    <brns:SharesCancelledDuringPeriodValueDeferredShares contextRef="c-66" decimals="-3" id="f-313" unitRef="usd">0</brns:SharesCancelledDuringPeriodValueDeferredShares>
    <brns:SharesCancelledDuringPeriodValueDeferredShares contextRef="c-67" decimals="-3" id="f-314" unitRef="usd">0</brns:SharesCancelledDuringPeriodValueDeferredShares>
    <us-gaap:ProfitLoss contextRef="c-73" decimals="-3" id="f-315" unitRef="usd">-18180000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-66" decimals="-3" id="f-316" unitRef="usd">-18180000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-70" decimals="-3" id="f-317" unitRef="usd">-43000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-67" decimals="-3" id="f-318" unitRef="usd">-18223000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="c-74"
      decimals="INF"
      id="f-319"
      unitRef="shares">38357025</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-3" id="f-320" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-75"
      decimals="INF"
      id="f-321"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-3" id="f-322" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-76"
      decimals="INF"
      id="f-323"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-77"
      decimals="INF"
      id="f-325"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-77" decimals="-3" id="f-326" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="-3" id="f-327" unitRef="usd">383523000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="-3" id="f-328" unitRef="usd">-121423000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-80" decimals="-3" id="f-329" unitRef="usd">-28886000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-81" decimals="-3" id="f-330" unitRef="usd">233301000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-82" decimals="-3" id="f-331" unitRef="usd">268000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-83" decimals="-3" id="f-332" unitRef="usd">233569000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-84" decimals="-3" id="f-333" unitRef="usd">1990000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-85" decimals="-3" id="f-334" unitRef="usd">1990000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-335" unitRef="usd">1990000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-86"
      decimals="INF"
      id="f-336"
      unitRef="shares">167034</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-86" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-84" decimals="-3" id="f-338" unitRef="usd">123000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-85" decimals="-3" id="f-339" unitRef="usd">123000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-3" id="f-340" unitRef="usd">123000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-87" decimals="-3" id="f-341" unitRef="usd">5597000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-85" decimals="-3" id="f-342" unitRef="usd">5597000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-88" decimals="-3" id="f-343" unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-344" unitRef="usd">5604000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-89" decimals="-3" id="f-345" unitRef="usd">-23802000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-85" decimals="-3" id="f-346" unitRef="usd">-23802000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-88" decimals="-3" id="f-347" unitRef="usd">-22000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-348" unitRef="usd">-23824000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="c-90"
      decimals="INF"
      id="f-349"
      unitRef="shares">38524059</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-90" decimals="-3" id="f-350" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-91"
      decimals="INF"
      id="f-351"
      unitRef="shares">63443</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-91" decimals="-3" id="f-352" unitRef="usd">86000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-92"
      decimals="INF"
      id="f-353"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-92" decimals="-3" id="f-354" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="c-93"
      decimals="INF"
      id="f-355"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-93" decimals="-3" id="f-356" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-94" decimals="-3" id="f-357" unitRef="usd">385636000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-95" decimals="-3" id="f-358" unitRef="usd">-145225000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-96" decimals="-3" id="f-359" unitRef="usd">-23289000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-97" decimals="-3" id="f-360" unitRef="usd">217209000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-98" decimals="-3" id="f-361" unitRef="usd">253000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-99" decimals="-3" id="f-362" unitRef="usd">217462000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">-32463000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-364" unitRef="usd">-42047000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">2810000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-15" decimals="-3" id="f-366" unitRef="usd">4212000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-367" unitRef="usd">2897000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-15" decimals="-3" id="f-368" unitRef="usd">2520000</us-gaap:DepreciationDepletionAndAmortization>
    <brns:NonCashLeaseExpenses contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">717000</brns:NonCashLeaseExpenses>
    <brns:NonCashLeaseExpenses contextRef="c-15" decimals="-3" id="f-370" unitRef="usd">595000</brns:NonCashLeaseExpenses>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">583000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-15" decimals="-3" id="f-372" unitRef="usd">-7122000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-373" unitRef="usd">78000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-3" id="f-374" unitRef="usd">309000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <brns:NonCashInterestExpenseOnConvertibleLoanNotes contextRef="c-1" decimals="-3" id="f-375" unitRef="usd">19000</brns:NonCashInterestExpenseOnConvertibleLoanNotes>
    <brns:NonCashInterestExpenseOnConvertibleLoanNotes contextRef="c-15" decimals="-3" id="f-376" unitRef="usd">14000</brns:NonCashInterestExpenseOnConvertibleLoanNotes>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">-44000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-378" unitRef="usd">-1652000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-379" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-15" decimals="-3" id="f-380" unitRef="usd">-5606000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-381" unitRef="usd">-262000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-15" decimals="-3" id="f-382" unitRef="usd">-3107000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">-352000</brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable>
    <brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable contextRef="c-15" decimals="-3" id="f-384" unitRef="usd">-1586000</brns:IncreaseDecreaseInResearchAndDevelopmentIncentivesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-385" unitRef="usd">967000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-15" decimals="-3" id="f-386" unitRef="usd">-1916000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-387" unitRef="usd">1140000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-15" decimals="-3" id="f-388" unitRef="usd">275000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">839000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c-15" decimals="-3" id="f-390" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-391" unitRef="usd">-819000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-15" decimals="-3" id="f-392" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-393" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-15" decimals="-3" id="f-394" unitRef="usd">-138000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-395" unitRef="usd">-23828000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-15" decimals="-3" id="f-396" unitRef="usd">-20131000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-397" unitRef="usd">500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-15" decimals="-3" id="f-398" unitRef="usd">5530000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-399" unitRef="usd">-500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-15" decimals="-3" id="f-400" unitRef="usd">-5530000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-401" unitRef="usd">861000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-15" decimals="-3" id="f-402" unitRef="usd">1880000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-403" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-15" decimals="-3" id="f-404" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="-3" id="f-405" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-15" decimals="-3" id="f-406" unitRef="usd">163000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">861000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-15" decimals="-3" id="f-408" unitRef="usd">1717000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-409" unitRef="usd">-849000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-15" decimals="-3" id="f-410" unitRef="usd">2589000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-411" unitRef="usd">-24316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-15" decimals="-3" id="f-412" unitRef="usd">-21355000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-413" unitRef="usd">142090000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-64" decimals="-3" id="f-414" unitRef="usd">194385000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-415" unitRef="usd">117774000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-99" decimals="-3" id="f-416" unitRef="usd">173030000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-417" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-15" decimals="-3" id="f-418" unitRef="usd">506000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <brns:AssetRetirementObligations contextRef="c-1" decimals="-3" id="f-419" unitRef="usd">0</brns:AssetRetirementObligations>
    <brns:AssetRetirementObligations contextRef="c-15" decimals="-3" id="f-420" unitRef="usd">282000</brns:AssetRetirementObligations>
    <brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent contextRef="c-1" decimals="-3" id="f-421" unitRef="usd">0</brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent>
    <brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent contextRef="c-15" decimals="-3" id="f-422" unitRef="usd">-47000</brns:ChangesToRightOfUseAssetResultingFromLeaseReassessmentEvent>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-423">Nature of Business and Basis of Presentation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Barinthus Biotherapeutics plc is a public limited company incorporated pursuant to the laws of England and Wales in March 2021. Barinthus Biotherapeutics plc and its direct and indirect subsidiaries, Barinthus Biotherapeutics (UK) Limited, Barinthus Australia Pty Limited, Vaccitech Oncology Limited (&#x201c;VOLT&#x201d;), Barinthus Biotherapeutics North America, Inc., Barinthus Biotherapeutics Switzerland GmbH and Barinthus Biotherapeutics S.R.L., are collectively referred to as the &#x201c;Company&#x201d; or &#x201c;Barinthus Bio.&#x201d; The Company is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases and autoimmunity. The Company is headquartered in Harwell, Oxfordshire, United Kingdom. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in an environment of rapid technological change and substantial competition from pharmaceutical and biotechnology companies. The Company is subject to risks common to companies in the biopharmaceutical industry in a similar stage of its life cycle including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its immunotherapeutic product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of any of its products that are approved, and protection of proprietary technology. There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. If the Company does not successfully commercialize any of its products or mitigate any of these other risks, it will be unable to generate revenue or achieve profitability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain notes or other information that are normally required by GAAP have been omitted if they substantially duplicate the disclosures contained in the Company&#x2019;s annual audited consolidated financial statements. Accordingly, the unaudited condensed consolidated financial statements should be read in connection with the Company&#x2019;s audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2023. The condensed consolidated balance sheet as of December&#160;31, 2023, was derived from the audited financial statements but does not contain all of the footnote disclosures from the annual financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company had cash, cash equivalents and restricted cash of $117.8 million and an accumulated deficit of $209.0 million, and the Company expects to incur losses for the foreseeable future. The Company expects that its cash, cash equivalents and restricted cash will be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. The Company expects to seek additional funding through equity financing, government or private-party grants, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or rights of the Company&#x2019;s stockholders. If the Company is unable to obtain sufficient capital, the Company will be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Condensed Consolidated Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Balance Sheets as of June&#160;30, 2024, and December&#160;31, 2023, the Condensed Consolidated Statements of Operations and Comprehensive Loss, Condensed Consolidated Statements of Changes in Stockholders&#x2019; Equity and the Condensed Consolidated Statements of Cash Flows for the three and six months ended June&#160;30, 2024 and 2023 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the Securities Exchange Commission (the &#x201c;Annual Report&#x201d;) on March 20, 2024. In our opinion, the unaudited condensed consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of our financial position as of June&#160;30, 2024, our results of operations for the three and six months ended June&#160;30, 2024, and 2023, and our cash flows for the six months ended June&#160;30, 2024, and 2023. The results of operations for the three and six months ended June&#160;30, 2024, are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2024, or any other interim periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-5" id="f-424" unitRef="usd">117800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-5" id="f-425" unitRef="usd">-209000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-426">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Annual Report, except as discussed below related to newly adopted accounting pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker ("CODM"), the Company&#x2019;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts and approves the Company's consolidated operating budget. The Company views its operations and manages its business as one operating segment, the research and development of vaccines and immunotherapies. The chief operating decision maker uses net loss to monitor budget versus actual results and decide how to use the Company's resources. As the Company operates in one operating segment, all required financial segment information can be found in these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our current operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-427">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the date of issuance of these unaudited condensed consolidated financial statements, the Company is not aware of any other specific event or circumstance that would require the Company to update its estimates, assumptions and judgments or revise the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information is obtained and are recognized in the unaudited condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker ("CODM"), the Company&#x2019;s Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The CODM approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts and approves the Company's consolidated operating budget. The Company views its operations and manages its business as one operating segment, the research and development of vaccines and immunotherapies. The chief operating decision maker uses net loss to monitor budget versus actual results and decide how to use the Company's resources. As the Company operates in one operating segment, all required financial segment information can be found in these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-429"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-430"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-431">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition period related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and nonpublic companies, the Company can adopt the new or revised standard at the time nonpublic companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reviewed all recently issued standards and have determined that such standards will not have a material impact on our condensed consolidated financial statements or do not otherwise apply to our current operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyDisclosureTextBlock contextRef="c-1" id="f-432">Foreign Currency Translation in General and Administrative Expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate, net foreign exchange gain or loss recognized in general and administrative expenses for the three and six months ended June&#160;30, 2024, was a loss of $0.1 million and gain of $1.1 million, respectively (three and six months ended June&#160;30, 2023: $4.2 million loss and $7.7 million loss, respectively).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-13" decimals="-5" id="f-433" unitRef="usd">-100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-5" id="f-434" unitRef="usd">1100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-14" decimals="-5" id="f-435" unitRef="usd">-4200000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-15" decimals="-5" id="f-436" unitRef="usd">-7700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-437">Net Loss Per Share&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended  June&#160;30, 2024, and 2023 (in thousands, except number of shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.950%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(32,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(42,047)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Barinthus Biotherapeutics plc shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(32,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(41,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average ordinary shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,041,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,407,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,907,296&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,211,625&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average ordinary shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,041,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,407,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,907,296&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,211,625&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to ordinary shareholders, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to ordinary shareholders, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. As of June&#160;30, 2024, 7,779,884 potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect (June&#160;30, 2023: 6,781,099).&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-438">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended  June&#160;30, 2024, and 2023 (in thousands, except number of shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.948%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.950%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(32,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(42,047)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Barinthus Biotherapeutics plc shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(23,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(32,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(41,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average ordinary shares outstanding, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,041,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,407,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,907,296&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,211,625&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average ordinary shares outstanding, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;39,041,111&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,407,672&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,907,296&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38,211,625&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to ordinary shareholders, basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to ordinary shareholders, diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.83)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c-13" decimals="-3" id="f-439" unitRef="usd">-16943000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-440" unitRef="usd">-23824000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-441" unitRef="usd">-32463000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-442" unitRef="usd">-42047000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-443" unitRef="usd">-12000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-444" unitRef="usd">-22000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-445" unitRef="usd">-43000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-446" unitRef="usd">-65000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-447" unitRef="usd">-16931000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-448" unitRef="usd">-23802000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-449" unitRef="usd">-32420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-450" unitRef="usd">-41982000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="0" id="f-451" unitRef="shares">39041111</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="0" id="f-452" unitRef="shares">38407672</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-453" unitRef="shares">38907296</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="0" id="f-454" unitRef="shares">38211625</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="0" id="f-455" unitRef="shares">39041111</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="0" id="f-456" unitRef="shares">38407672</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-457" unitRef="shares">38907296</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="0" id="f-458" unitRef="shares">38211625</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-459"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-460"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-461"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-462"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-463"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-464"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-465"
      unitRef="usdPerShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-466"
      unitRef="usdPerShare">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-467" unitRef="shares">7779884</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-15" decimals="0" id="f-468" unitRef="shares">6781099</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-469">Property and Equipment, Net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2024, the Company&#x2019;s additions to property and equipment, net were $0.5 million which primarily related to an increase in lab equipment in the Company's U.K. office (six months ended June&#160;30, 2023: $6.4 million, primarily related to an increase in leasehold improvements from the Company&#x2019;s U.S. office in Germantown, Maryland).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the three and six months ended June&#160;30, 2024 was $0.7 million and $1.3 million, respectively (June&#160;30, 2023: three and six months $0.5 million and $0.9 million, respectively).&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-1" decimals="-5" id="f-470" unitRef="usd">500000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-15" decimals="-5" id="f-471" unitRef="usd">6400000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-472" unitRef="usd">700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-473" unitRef="usd">1300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-14" decimals="-5" id="f-474" unitRef="usd">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-475" unitRef="usd">900000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-476">Intangible Assets, Net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross amount of amortizable intangible assets, consisting of acquired developed technology, was $31.6&#160;million and $31.6&#160;million as of June&#160;30, 2024 and December&#160;31 2023, respectively, and accumulated amortization was $8.1&#160;million and $6.5&#160;million as of June&#160;30, 2024 and December&#160;31, 2023, respectively. The amortization expense for the three and six months ended June&#160;30, 2024 was $0.8&#160;million and $1.6&#160;million, respectively (three and six months ended June&#160;30, 2023: $0.8&#160;million and $1.6&#160;million, respectively). The estimated annual amortization expense is $3.2&#160;million for the years 2024 through to 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In June 2024, the Company announced plans to prioritize its pipeline to focus on the development of VTP-300 for chronic Hepatitis B virus infection and VTP-1000 in celiac disease. Given this change in Company focus, management identified circumstances that could indicate that the carrying amount of the Company's intangible assets may not be recoverable. Therefore, the Company performed both a qualitative and quantitative assessment as of June&#160;30, 2024 and determined that the carrying amount of the Company's intangible assets are recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-100" decimals="-5" id="f-477" unitRef="usd">31600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-101" decimals="-5" id="f-478" unitRef="usd">31600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-100" decimals="-5" id="f-479" unitRef="usd">8100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-101" decimals="-5" id="f-480" unitRef="usd">6500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-5" id="f-481" unitRef="usd">800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-482" unitRef="usd">1600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-14" decimals="-5" id="f-483" unitRef="usd">800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-484" unitRef="usd">1600000</us-gaap:AmortizationOfIntangibleAssets>
    <brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSix contextRef="c-5" decimals="-5" id="f-485" unitRef="usd">3200000</brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSix>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-5" decimals="-5" id="f-486" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-5" decimals="-5" id="f-487" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSeven contextRef="c-5" decimals="-5" id="f-488" unitRef="usd">3200000</brns:FiniteLivedIntangibleAssetExpectedAmortizationYearSeven>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-5" decimals="-5" id="f-489" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <brns:FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear contextRef="c-5" decimals="-5" id="f-490" unitRef="usd">3200000</brns:FiniteLivedIntangibleAssetExpectedAmortizationCurrentYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-5" decimals="-5" id="f-491" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-5" decimals="-5" id="f-492" unitRef="usd">3200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock contextRef="c-1" id="f-494">Prepaid Expenses and Other Current Assets (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepayments and accrued income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value Added Tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.64pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:PrepaidExpenseAndOtherAssetsCurrentTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c-1" id="f-493">Prepaid Expenses and Other Current Assets (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Prepayments and accrued income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Value Added Tax receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.64pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-495" unitRef="usd">7813000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-496" unitRef="usd">5402000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-5" decimals="-3" id="f-497" unitRef="usd">1143000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-6" decimals="-3" id="f-498" unitRef="usd">3031000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-499" unitRef="usd">626000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-500" unitRef="usd">1474000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-501" unitRef="usd">9582000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-502" unitRef="usd">9907000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock contextRef="c-1" id="f-504">Accrued Expenses and Other Current Liabilities (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued manufacturing and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Included in Accrued other as of June 30, 2024 is a provision of $0.8 million for severance costs for the reduction in workforce following the Company&#x2019;s announcement in June 2024 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to prioritize its pipelin&lt;/span&gt;e. Of this expense, $0.7&#160;million is included in research and development expenses and $0.1&#160;million is included in general and administrative expenses in the statements of operations and comprehensive loss.</brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock>
    <brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-503">Accrued Expenses and Other Current Liabilities (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued manufacturing and clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:114%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Included in Accrued other as of June 30, 2024 is a provision of $0.8 million for severance costs for the reduction in workforce following the Company&#x2019;s announcement in June 2024 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to prioritize its pipelin&lt;/span&gt;e. Of this expense, $0.7&#160;million is included in research and development expenses and $0.1&#160;million is included in general and administrative expenses in the statements of operations and comprehensive loss.</brns:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <brns:AccruedManufacturingAndClinicalExpensesCurrent contextRef="c-5" decimals="-3" id="f-505" unitRef="usd">5124000</brns:AccruedManufacturingAndClinicalExpensesCurrent>
    <brns:AccruedManufacturingAndClinicalExpensesCurrent contextRef="c-6" decimals="-3" id="f-506" unitRef="usd">4003000</brns:AccruedManufacturingAndClinicalExpensesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c-5" decimals="-3" id="f-507" unitRef="usd">1232000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent contextRef="c-6" decimals="-3" id="f-508" unitRef="usd">2412000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-5" decimals="-3" id="f-509" unitRef="usd">985000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c-6" decimals="-3" id="f-510" unitRef="usd">789000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-511" unitRef="usd">1049000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-3" id="f-512" unitRef="usd">942000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-513" unitRef="usd">1888000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-514" unitRef="usd">1066000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-515" unitRef="usd">10278000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-516" unitRef="usd">9212000</brns:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:SeveranceCosts1 contextRef="c-1" decimals="-5" id="f-517" unitRef="usd">800000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-102" decimals="-5" id="f-518" unitRef="usd">700000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-103" decimals="-5" id="f-519" unitRef="usd">100000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherOperatingIncomeAndExpenseTextBlock contextRef="c-1" id="f-520">Grant Income&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) Funding Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2023, Barinthus Biotherapeutics (UK) Limited (the &#x201c;Company&#x201d;), the Chancellors, Masters and Scholars of the University of Oxford (&#x201c;Oxford,&#x201d; together with the Company, the &#x201c;Partners&#x201d;) and the Coalition for Epidemic Preparedness Innovations (&#x201c;CEPI&#x201d;) entered into a Funding Agreement (the &#x201c;Funding Agreement&#x201d;) pursuant to which CEPI will provide funding of up to $34.8 million to the Company to advance the development of VTP-500, the Company&#x2019;s vaccine candidate against Middle East Respiratory Syndrome (&#x201c;MERS,&#x201d; and such development activities, the &#x201c;Project&#x201d;). In December 2023, VTP-500 received PRIME (PRIority MEdicines) designation by the European Medicines Agency. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Funding Agreement, the Company has agreed to pay CEPI on a country-by-country basis increasing mid-single digit percentage royalties of net sales and net income with respect to future cash sales of VTP-500, less certain deductions, for a period starting on December 20, 2023 (&#x201c;Effective Date&#x201d;) and ending the later of: (i) the expiration of the last valid patent claim included in intellectual property developed under the Project covering VTP-500 in such country, (ii) the expiration of Regulatory Exclusivity (as defined in the Funding Agreement) for VTP-500 in such country, and (iii) the tenth (10th) anniversary of the first commercial sale of VTP-500 (the &#x201c;Royalty Term&#x201d;). The Company shall also pay CEPI a mid-double-digit percentage of net revenue earned on VTP-500 until CEPI has received payments from the Company under the Funding Agreement equaling the total amount of funding paid by CEPI to the Company and a low double-digit percentage of such net revenue thereafter. Sales for the benefit of end users in specified low and middle income countries (&#x201c;LMICs&#x201d;) and upper and middle income countries (&#x201c;UMICs&#x201d;) are excluded from the calculations of net sales and net revenue. Sales of the product for the benefit of end users in LMICs and UMICs are subject to tiered discounted pricing requirements under the Funding Agreement. The Company is further required to pay a low to mid-double-digit percentage of any proceeds earned on any priority review voucher related to VTP-500 during the Royalty Period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the six months period ended June&#160;30, 2024, $1.6 million proceeds have been received and $0.8 million income has been recognized in relation to this contract. This is presented as other operating income in the condensed consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Funding Agreement cash payments are restricted as to the use and management of the funds. The remaining unused amounts of the Funding Agreement cash payments of $0.8 million as of June&#160;30, 2024 are reflected in Cash, cash equivalents and restricted cash in the condensed consolidated balance sheets until expenditures contemplated in the Funding Agreement are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Deferred income&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred income primarily relates to payments received from CEPI in advance of the eligible research and development expenses being incurred and are disclosed as deferred income separately in the condensed consolidated balance sheets. Deferred income is released to the condensed consolidated statements of operations and comprehensive loss in the period in which such research and development activities are actually performed in a manner that satisfies the conditions of the Funding Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in deferred income during the three and six months ended June&#160;30, 2024 and 2023, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income recognized related to the Funding Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherOperatingIncomeAndExpenseTextBlock>
    <brns:FundingAmountMaximum contextRef="c-104" decimals="-5" id="f-521" unitRef="usd">34800000</brns:FundingAmountMaximum>
    <brns:RoyaltyPaymentTermMaximum contextRef="c-105" id="f-522">P10Y</brns:RoyaltyPaymentTermMaximum>
    <us-gaap:DeferredIncomeAddition contextRef="c-106" decimals="-5" id="f-523" unitRef="usd">1600000</us-gaap:DeferredIncomeAddition>
    <us-gaap:DeferredIncomeRevenueRecognized contextRef="c-106" decimals="-5" id="f-524" unitRef="usd">800000</us-gaap:DeferredIncomeRevenueRecognized>
    <us-gaap:RestrictedCashCurrent contextRef="c-107" decimals="-5" id="f-525" unitRef="usd">800000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DeferredIncomeTableTextBlock contextRef="c-1" id="f-526">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Changes in deferred income during the three and six months ended June&#160;30, 2024 and 2023, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income recognized related to the Funding Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredIncomeTableTextBlock>
    <us-gaap:DeferredIncome contextRef="c-41" decimals="-3" id="f-527" unitRef="usd">1434000</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c-83" decimals="-3" id="f-528" unitRef="usd">0</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c-6" decimals="-3" id="f-529" unitRef="usd">0</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c-64" decimals="-3" id="f-530" unitRef="usd">0</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncomeAddition contextRef="c-13" decimals="-3" id="f-531" unitRef="usd">0</us-gaap:DeferredIncomeAddition>
    <us-gaap:DeferredIncomeAddition contextRef="c-14" decimals="-3" id="f-532" unitRef="usd">0</us-gaap:DeferredIncomeAddition>
    <us-gaap:DeferredIncomeAddition contextRef="c-1" decimals="-3" id="f-533" unitRef="usd">1629000</us-gaap:DeferredIncomeAddition>
    <us-gaap:DeferredIncomeAddition contextRef="c-15" decimals="-3" id="f-534" unitRef="usd">0</us-gaap:DeferredIncomeAddition>
    <us-gaap:DeferredIncomeRevenueRecognized contextRef="c-13" decimals="-3" id="f-535" unitRef="usd">577000</us-gaap:DeferredIncomeRevenueRecognized>
    <us-gaap:DeferredIncomeRevenueRecognized contextRef="c-14" decimals="-3" id="f-536" unitRef="usd">0</us-gaap:DeferredIncomeRevenueRecognized>
    <us-gaap:DeferredIncomeRevenueRecognized contextRef="c-1" decimals="-3" id="f-537" unitRef="usd">782000</us-gaap:DeferredIncomeRevenueRecognized>
    <us-gaap:DeferredIncomeRevenueRecognized contextRef="c-15" decimals="-3" id="f-538" unitRef="usd">0</us-gaap:DeferredIncomeRevenueRecognized>
    <brns:DeferredIncomeForeignExchangeTranslationGainLoss contextRef="c-13" decimals="-3" id="f-539" unitRef="usd">18000</brns:DeferredIncomeForeignExchangeTranslationGainLoss>
    <brns:DeferredIncomeForeignExchangeTranslationGainLoss contextRef="c-14" decimals="-3" id="f-540" unitRef="usd">0</brns:DeferredIncomeForeignExchangeTranslationGainLoss>
    <brns:DeferredIncomeForeignExchangeTranslationGainLoss contextRef="c-1" decimals="-3" id="f-541" unitRef="usd">8000</brns:DeferredIncomeForeignExchangeTranslationGainLoss>
    <brns:DeferredIncomeForeignExchangeTranslationGainLoss contextRef="c-15" decimals="-3" id="f-542" unitRef="usd">0</brns:DeferredIncomeForeignExchangeTranslationGainLoss>
    <us-gaap:DeferredIncome contextRef="c-5" decimals="-3" id="f-543" unitRef="usd">839000</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c-99" decimals="-3" id="f-544" unitRef="usd">0</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c-5" decimals="-3" id="f-545" unitRef="usd">839000</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome contextRef="c-99" decimals="-3" id="f-546" unitRef="usd">0</us-gaap:DeferredIncome>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-547">Ordinary Shares&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All ordinary shares rank pari passu as a single class. The following is a summary of the rights and privileges of the holders of ordinary shares as of June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liquidation preference: in the event of the liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to holders of the ordinary shares shall be distributed amongst all holders of the ordinary shares in proportion to the number of shares held irrespective of the amount paid or credited as paid on any share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends: The Company may, subject to the provisions of the Companies Act 2006 and our Articles, by ordinary resolution from time to time declare dividends to be paid to shareholders not exceeding the amount recommended by the Company&#x2019;s board of directors. Subject to the provisions of the Companies Act 2006, in so far as, in the board of directors&#x2019; opinions, the Company&#x2019;s profits justify such payments, the board of directors may pay interim dividends on the Company&#x2019;s ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Voting Rights: Each holder of ordinary shares has the right to receive notice of, and to vote at, the Company&#x2019;s general meetings. Each holder of ordinary shares who is present (in person or by proxy) at a general meeting on a show of hands has one vote and, on a poll, every such holder who is present (in person or by proxy) has one vote in respect of each share of which they are the holder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Preemption rights: Pursuant to section 561 of the Companies Act 2006, shareholders are granted preemptive rights when new shares are issued for cash. However, it is possible for our Articles, or shareholders at a general meeting representing at least 75% of our ordinary shares present (in person or by proxy) and eligible to vote at that general meeting, to disapply these preemptive rights by passing a special resolution. Such a disapplication of preemption rights may be for a maximum period of up to five years from the date on which the shareholder resolution was passed. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, at least every five years) to remain effective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April&#160;21, 2021, our shareholders approved the disapplication of preemptive rights for a period of five years from the date of approval by way of a special resolution of our shareholders. This included the disapplication of preemption rights in relation to the allotment of our ordinary shares in connection with the IPO. This disapplication will need to be renewed upon expiration (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;6, 2023, we held a general meeting where our shareholders approved resolutions granting our board of directors or any duly authorized committee of the board of directors the authority to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company free from pre-emption rights. Pursuant to such approval, our board of directors was authorized to allot shares up to an aggregate nominal amount of &#xa3;1,928 free from statutory pre-emption rights. The granting of this authority and the corresponding disapplication of preemptive rights was in addition to all subsisting authorities. This disapplication will need to be renewed upon expiration (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, at least every five years) to remain effective, but may be sought more frequently for additional five-year terms (or any shorter period).&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <brns:CommonStockNumberOfVotesPerShare contextRef="c-5" decimals="INF" id="f-548" unitRef="vote">1</brns:CommonStockNumberOfVotesPerShare>
    <brns:CommonStockNumberOfVotesPerShare contextRef="c-5" decimals="INF" id="f-549" unitRef="vote">1</brns:CommonStockNumberOfVotesPerShare>
    <brns:PercentageOfSharesNecessaryToExercisePreemptiveRights contextRef="c-5" decimals="2" id="f-550" unitRef="number">0.75</brns:PercentageOfSharesNecessaryToExercisePreemptiveRights>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-1" id="f-551">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-108" id="f-552">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-109" id="f-553">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-109" id="f-554">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-109" id="f-555">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights contextRef="c-110" decimals="0" id="f-556" unitRef="gbp">1928</brns:MaximumAggregateNominalAmountOfSharesAuthorizedToBeAllottedFreeFromStatutoryPreEmptionRights>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-111" id="f-557">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:PeriodOfPreemptiveRightsToBeExercised contextRef="c-111" id="f-558">P5Y</brns:PeriodOfPreemptiveRightsToBeExercised>
    <brns:StockholdersEquityDeferredSharesDisclosureTextBlock contextRef="c-1" id="f-559">Deferred Shares&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All deferred shares rank pari passu as a single class. The deferred shares do not have rights to dividends or to any other right of participation in the profits of the Company. On a return of assets on liquidation, the deferred shares shall confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst the shareholders (subject to the rights of any new class of shares with preferred rights) the amount credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares of the amounts paid up or credited as paid up on such shares and the sum of &#xa3;1.0&#160;million in respect of each ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;29, 2023, all deferred B shares (nominal value of &#xa3;0.01 each) and deferred C shares (nominal value of &#xa3;0.00000736245954692556 each) previously in issue were transferred back to the Company and subsequently cancelled. These deferred shares had previously been issued to certain pre-IPO shareholders in connection with the implementation of certain stages of the Company&#x2019;s pre-IPO share capital reorganization. The Company received shareholder approval on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;April 21, 2021 (pursuant to the shareholder resolutions passed on that date) in order to effect the transfer back and cancellation of the deferred shares for nil consideration in accordance with sections 659 and 662 of the Companies Act 2006.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s deferred A shares with a nominal value of &#xa3;1.00 each remain in issue for the purposes of satisfying the minimum share capital requirements for a public limited company as prescribed by the Companies Act 2006.&lt;/span&gt;&lt;/div&gt;</brns:StockholdersEquityDeferredSharesDisclosureTextBlock>
    <brns:OrdinarySharesLiquidationPreference contextRef="c-8" decimals="-5" id="f-560" unitRef="gbp">1000000</brns:OrdinarySharesLiquidationPreference>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-112"
      decimals="INF"
      id="f-561"
      unitRef="gbpPerShare">0.01</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-113"
      decimals="INF"
      id="f-562"
      unitRef="gbpPerShare">0.00000736245954692556</brns:DeferredStockParOrStatedValuePerShare>
    <brns:DeferredStockParOrStatedValuePerShare
      contextRef="c-114"
      decimals="INF"
      id="f-563"
      unitRef="gbpPerShare">1.00</brns:DeferredStockParOrStatedValuePerShare>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-564">Fair Value&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash, cash equivalents and restricted cash, accounts receivable, accounts payable, certain accrued expenses, and contingent consideration. The carrying amounts of cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued expenses approximated their respective fair value due to the short-term nature and maturity of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company had a contingent consideration liability of $1.9&#160;million related to the acquisition of Avidea Technologies, Inc. The fair value of the contingent consideration is a Level 3 valuation with the significant unobservable inputs being the probability of success of achievement of the milestones and the expected date of the milestone achievement. Significant judgment is employed in determining the appropriateness of certain of these inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes changes to our financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in fair value recognized in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-115" decimals="-5" id="f-565" unitRef="usd">1900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-566">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes changes to our financial instruments carried at fair value and classified within Level 3 of the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Change in fair value recognized in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Foreign exchange translation recognized in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-116" decimals="-3" id="f-567" unitRef="usd">1867000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-117" decimals="-3" id="f-568" unitRef="usd">1710000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-118" decimals="-3" id="f-569" unitRef="usd">1823000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-119" decimals="-3" id="f-570" unitRef="usd">1711000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-120" decimals="-3" id="f-571" unitRef="usd">-18000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-121" decimals="-3" id="f-572" unitRef="usd">-354000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-122" decimals="-3" id="f-573" unitRef="usd">-78000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-123" decimals="-3" id="f-574" unitRef="usd">-316000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation contextRef="c-120" decimals="-3" id="f-575" unitRef="usd">3000</brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation>
    <brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation contextRef="c-121" decimals="-3" id="f-576" unitRef="usd">53000</brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation>
    <brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation contextRef="c-122" decimals="-3" id="f-577" unitRef="usd">-13000</brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation>
    <brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation contextRef="c-123" decimals="-3" id="f-578" unitRef="usd">90000</brns:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityForeignExchangeTranslation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-124" decimals="-3" id="f-579" unitRef="usd">1888000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-125" decimals="-3" id="f-580" unitRef="usd">2117000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-124" decimals="-3" id="f-581" unitRef="usd">1888000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-125" decimals="-3" id="f-582" unitRef="usd">2117000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="c-1" id="f-583">Goodwill&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified qualitative indicators of impairment due to a sustained decline in the price of the Company&#x2019;s American Depositary Shares, whereby the market capitalization continues to be below the value of the net assets of the Company, and the plans announced in June 2024 to prioritize its pipeline to focus on the development of VTP-300 for chronic Hepatitis B virus infection and VTP-1000 in celiac disease. Therefore, the Company performed both an interim qualitative and quantitative assessment as of June&#160;30, 2024 to determine whether it was more likely than not that the fair value of the reporting unit is less than its carrying amount. Based on this assessment, management determined it is not more likely than not that the fair value of the reporting unit is less than its carrying amount and hence no impairment loss has been recognized.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-13" decimals="-5" id="f-584" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-5" id="f-585" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-586">Share-Based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six month period ended June&#160;30, 2024, in accordance with the terms of the Annual Increase of the Barinthus Biotherapeutics plc Award Plan 2021 (the &#x201c;Plan&#x201d;), the total number of ordinary shares available for issuance under the Plan increased by 4% of the Company&#x2019;s issued and outstanding ordinary shares as of January 1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June&#160;30, 2024, the Company granted 1,951,377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;options to employees and directors with a weighted average grant date fair value of $2.71 and a weighted average exercise price of $3.41 per share (June&#160;30, 2023: granted 2,142,905 options, weighted average grant date fair value of $2.00 and a weighted average exercise price of $2.51 per share). For the six months ended June&#160;30, 2024, 229,430 options (June&#160;30, 2023: 217,860) were forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option issued to employees was estimated at the date of grant using the Black-Scholes model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, 7,779,884 options with a weighted average exercise price of $6.19 were outstanding. As of June&#160;30, 2024, there was $5.4&#160;million unrecognized compensation cost related to stock options, which is expected to be recognized over a weighted average period of 1.9 years. As of June&#160;30, 2023, 6,781,099 options with a weighted average exercise price of $9.51 were outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share based compensation expense is classified in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares contextRef="c-126" decimals="2" id="f-587" unitRef="number">0.04</brns:ShareBasedCompensationPercentageOfSharesAvailableForIssuanceAsPercentageOfIssuedAndOutstandingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-588" unitRef="shares">1951377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-589"
      unitRef="usdPerShare">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-590"
      unitRef="usdPerShare">3.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-15"
      decimals="INF"
      id="f-591"
      unitRef="shares">2142905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-15"
      decimals="2"
      id="f-592"
      unitRef="usdPerShare">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-15"
      decimals="2"
      id="f-593"
      unitRef="usdPerShare">2.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-594" unitRef="shares">229430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-15"
      decimals="INF"
      id="f-595"
      unitRef="shares">217860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-596">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option issued to employees was estimated at the date of grant using the Black-Scholes model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;108.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;97.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-127" decimals="3" id="f-597" unitRef="number">1.087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-128" decimals="3" id="f-598" unitRef="number">0.972</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-127" id="f-599">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-128" id="f-600">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-127" decimals="3" id="f-601" unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-128" decimals="3" id="f-602" unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-127"
      decimals="INF"
      id="f-603"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-128"
      decimals="INF"
      id="f-604"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-605" unitRef="shares">7779884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-606"
      unitRef="usdPerShare">6.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-5" decimals="-5" id="f-607" unitRef="usd">5400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-129" id="f-608">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-99"
      decimals="INF"
      id="f-609"
      unitRef="shares">6781099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-99"
      decimals="2"
      id="f-610"
      unitRef="usdPerShare">9.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-611">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share based compensation expense is classified in the unaudited condensed consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-130" decimals="-3" id="f-612" unitRef="usd">505000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-131" decimals="-3" id="f-613" unitRef="usd">1027000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-102" decimals="-3" id="f-614" unitRef="usd">1217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-3" id="f-615" unitRef="usd">2146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-3" id="f-616" unitRef="usd">690000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-134" decimals="-3" id="f-617" unitRef="usd">963000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-103" decimals="-3" id="f-618" unitRef="usd">1593000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-135" decimals="-3" id="f-619" unitRef="usd">2066000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-620" unitRef="usd">1195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-3" id="f-621" unitRef="usd">1990000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-622" unitRef="usd">2810000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-15" decimals="-3" id="f-623" unitRef="usd">4212000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-624">Commitments and Contingencies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to a number of licensing agreements, most of which are with related parties. These agreements serve to provide the Company with the right to develop and exploit the counterparties&#x2019; intellectual property for certain medical indications. As part of execution of these arrangements, the Company paid certain upfront fees, which have been expensed as incurred because the developing technology has not yet reached technical feasibility, the lack of alternative use, and the lack of proof of potential value. The agreements cover a variety of fields, including influenza, cancer, human papillomavirus infection, (&#x201c;HPV&#x201d;), hepatitis B virus (&#x201c;HBV&#x201d;) and MERS. The Company&#x2019;s obligations for future payments under these arrangements are dependent on its ability to develop promising drug candidates, the potential market for these candidates and potential competing products, and the payment mechanisms in place in countries where the Company retains the right to sell. Each agreement provides for specific milestone payments, typically triggered by achievement of certain testing phases in human candidates, and future royalties ranging from 1 to 5% for direct sales of a covered product to 3 to 7% of net payments received for allowable sublicenses of technology developed by the Company. The obligation to make these payments is contingent upon the Company&#x2019;s ability to develop candidates for submission for phased testing and approvals, and for the development of markets for the products developed by the Company. The Company has not made or accrued any material payments under these license agreements during the six month periods ended June&#160;30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain laboratory and office space under operating leases, which are described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Harwell Science and Innovation Campus, Oxfordshire&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;3, 2021, the Company entered into a lease agreement for the lease of approximately 31,000 square feet in Harwell, Oxfordshire which expires in September 2031. The property is the Company&#x2019;s corporate headquarters. As the Company&#x2019;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date, being the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The Company has provided the lessor with a refundable security deposit of $0.7&#160;million which is included in Other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Germantown, Maryland&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;14, 2022, the Company entered into a lease agreement for the lease of approximately 19,700 square feet in Germantown, Maryland. The site houses the Company&#x2019;s state-of-the-art wet laboratory in the United States of America. The lease expires on February 28, 2034, with the Company having a single right to extend for an additional five years on the same terms and conditions other than for the base rent. The Company had a rent-free period up to February 29, 2024, and was entitled to up to $3.5&#160;million for leasehold improvements to the premises desired by the Company. The Company has provided the lessor with a refundable security deposit of $0.2&#160;million which is included in Other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a right-of-use asset and a lease liability on the effective date of the lease term. The Company&#x2019;s right-of-use asset and lease liability are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.799%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;819&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;442&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;595&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;898&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual minimum lease payments under operating leases as of June&#160;30, 2024, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.893%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Remainder of 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the date of this Quarterly Report on Form 10-Q, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. However, from time to time, we could be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Regardless of the outcome, legal proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement contextRef="c-136" decimals="2" id="f-625" unitRef="number">0.01</brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement>
    <brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement contextRef="c-137" decimals="2" id="f-626" unitRef="number">0.05</brns:PercentageOfFutureRoyaltiesForDirectSalesOfCoveredProductLicenseAgreement>
    <brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement contextRef="c-136" decimals="2" id="f-627" unitRef="number">0.03</brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement>
    <brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement contextRef="c-137" decimals="2" id="f-628" unitRef="number">0.07</brns:PercentageOfNetPaymentsReceivedForAllowableSublicensesOfTechnologyDevelopedLicenseAgreement>
    <brns:NumberOfSquareFeetUnderLeaseAgreement contextRef="c-138" decimals="-3" id="f-629" unitRef="sqft">31000</brns:NumberOfSquareFeetUnderLeaseAgreement>
    <us-gaap:SecurityDeposit contextRef="c-139" decimals="-5" id="f-630" unitRef="usd">700000</us-gaap:SecurityDeposit>
    <brns:NumberOfSquareFeetUnderLeaseAgreement contextRef="c-140" decimals="-2" id="f-631" unitRef="sqft">19700</brns:NumberOfSquareFeetUnderLeaseAgreement>
    <brns:LesseeOperatingLeaseExtendedTerm contextRef="c-140" id="f-632">P5Y</brns:LesseeOperatingLeaseExtendedTerm>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-141" decimals="-5" id="f-633" unitRef="usd">3500000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:SecurityDeposit contextRef="c-141" decimals="-5" id="f-634" unitRef="usd">200000</us-gaap:SecurityDeposit>
    <brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock contextRef="c-1" id="f-635">The Company&#x2019;s right-of-use asset and lease liability are as follows (in thousands):&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, current&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Lease liability, non-current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.799%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;819&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;442&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</brns:LesseeOperatingLeaseRightOfUseAssetAndOtherInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-636" unitRef="usd">7286000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-637" unitRef="usd">7581000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-638" unitRef="usd">1916000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-639" unitRef="usd">1785000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-640" unitRef="usd">10654000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-641" unitRef="usd">11191000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-642" unitRef="usd">819000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-15" decimals="-3" id="f-643" unitRef="usd">442000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-644">P8Y8M15D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-99" id="f-645">P9Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-646" unitRef="number">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-99" decimals="3" id="f-647" unitRef="number">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-648">&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six months ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;151&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;303&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;316&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;595&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;358&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;717&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;898&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:ShortTermLeaseCost contextRef="c-13" decimals="-3" id="f-649" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-14" decimals="-3" id="f-650" unitRef="usd">151000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-651" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-15" decimals="-3" id="f-652" unitRef="usd">303000</us-gaap:ShortTermLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-3" id="f-653" unitRef="usd">358000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-14" decimals="-3" id="f-654" unitRef="usd">316000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-655" unitRef="usd">717000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-15" decimals="-3" id="f-656" unitRef="usd">595000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost contextRef="c-13" decimals="-3" id="f-657" unitRef="usd">358000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-14" decimals="-3" id="f-658" unitRef="usd">467000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-659" unitRef="usd">717000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-15" decimals="-3" id="f-660" unitRef="usd">898000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-661">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual minimum lease payments under operating leases as of June&#160;30, 2024, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.424%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.907%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.893%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Remainder of 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-5" decimals="-3" id="f-662" unitRef="usd">958000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-663" unitRef="usd">1928000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-664" unitRef="usd">1952000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-665" unitRef="usd">1977000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-666" unitRef="usd">2003000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <brns:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-5" decimals="-3" id="f-667" unitRef="usd">7979000</brns:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-668" unitRef="usd">16797000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-669" unitRef="usd">4227000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-670" unitRef="usd">12570000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-671">Related Party Transactions&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2024, the Company incurred expenses of $0.3 million and $0.5 million, respectively (three and six months ended June&#160;30, 2023: $0.3 million and $0.4 million, respectively) from Oxford University Innovation Limited which is a wholly owned subsidiary of the Company&#x2019;s shareholder, the University of Oxford. &lt;/span&gt;&lt;/div&gt;During the three and six months ended June&#160;30, 2024, the Company recognized license revenue of nil (three and six months ended June&#160;30, 2023: $0.3 million and $0.8 million, respectively), from Oxford University Innovation Limited.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-142" decimals="-5" id="f-672" unitRef="usd">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-143" decimals="-5" id="f-673" unitRef="usd">500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-144" decimals="-5" id="f-674" unitRef="usd">300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="c-145" decimals="-5" id="f-675" unitRef="usd">400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-146" decimals="-5" id="f-676" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-147" decimals="-5" id="f-677" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-148" decimals="-5" id="f-678" unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-149" decimals="-5" id="f-679" unitRef="usd">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-13" id="f-680">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-13" id="f-681">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-13" id="f-682">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-13" id="f-683">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#f-110"
          xlink:label="f-110"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-109"
          xlink:label="f-109"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-111"
          xlink:label="f-111"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-112"
          xlink:label="f-112"
          xlink:type="locator"/>
        <link:footnote id="fn-1" xlink:label="fn-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Includes <xhtml:span style="-sec-ix-hidden:f-213"><xhtml:span style="-sec-ix-hidden:f-214"><xhtml:span style="-sec-ix-hidden:f-215"><xhtml:span style="-sec-ix-hidden:f-216">license revenue</xhtml:span></xhtml:span></xhtml:span></xhtml:span> from related parties for the three and six months ended June&#160;30, 2024 of nil and for the three and six months ended June&#160;30, 2023 of $0.3 million and $0.8 million, respectively.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-110"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-109"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-111"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-112"
          xlink:to="fn-1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-337"
          xlink:label="f-337"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-261"
          xlink:label="f-261"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-289"
          xlink:label="f-289"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-311"
          xlink:label="f-311"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-300"
          xlink:label="f-300"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-356"
          xlink:label="f-356"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-235"
          xlink:label="f-235"
          xlink:type="locator"/>
        <link:footnote id="fn-2" xlink:label="fn-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Indicates amount less than one thousand</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-337"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-261"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-289"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-311"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-300"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-356"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-235"
          xlink:to="fn-2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#f-404"
          xlink:label="f-404"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#f-403"
          xlink:label="f-403"
          xlink:type="locator"/>
        <link:footnote id="fn-3" xlink:label="fn-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.75pt">Indicates amounts less than one thousand</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-404"
          xlink:to="fn-3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="f-403"
          xlink:to="fn-3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
